<SEC-DOCUMENT>0000912057-20-000122.txt : 20200619
<SEC-HEADER>0000912057-20-000122.hdr.sgml : 20200619
<ACCEPTANCE-DATETIME>20200410153845
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000912057-20-000122
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		27
FILED AS OF DATE:		20200410
<PUBLIC-REL-DATE>20200619
DATE AS OF CHANGE:		20200410

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Inventiva S.A.
		CENTRAL INDEX KEY:			0001756594
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-03119
		FILM NUMBER:		20786733

	BUSINESS ADDRESS:	
		STREET 1:		50 RUE DE DIJON
		CITY:			DAIX
		STATE:			I0
		ZIP:			21121
		BUSINESS PHONE:		33380447500

	MAIL ADDRESS:	
		STREET 1:		50 RUE DE DIJON
		CITY:			DAIX
		STATE:			I0
		ZIP:			21121
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>

<P style="font-family:arial;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>This draft registration statement has not been publicly filed with the United States Securities and Exchange<BR>
Commission and all information herein remains strictly confidential.<BR>
As confidentially submitted to the United States Securities and Exchange Commission on April&nbsp;10,&nbsp;2020.  </B></FONT></P>

<P ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> Registration No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> &nbsp;<BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> <div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>  </B></FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


  </I></FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>FORM F-1<BR>  </B></FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>REGISTRATION STATEMENT<BR>
UNDER<BR>
THE SECURITIES ACT OF&nbsp;1933  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


  </I></FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>Inventiva&nbsp;S.A.<BR>  </B></FONT><FONT  style="font-size:8pt;line-height:9pt;">(Exact name of registrant as specified in its charter) </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


  </I></FONT><FONT  style="font-size:8pt;line-height:9pt;">

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="31%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="31%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="31%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>France</B></FONT><FONT  style="font-size:8pt;line-height:9pt;"><BR>
(State or other jurisdiction of<BR>
incorporation or organization)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 2834</B></FONT><FONT  style="font-size:8pt;line-height:9pt;"><BR>
(Primary Standard Industrial<BR>
Classification Code Number)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> Not applicable</B></FONT><FONT  style="font-size:8pt;line-height:9pt;"><BR>
(I.R.S. Employer<BR>
Identification Number)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Inventiva&nbsp;S.A.<BR>
50 rue de Dijon<BR>
21121 Daix France<BR>
+33 3 80 44 75 00</B></FONT><FONT  style="font-size:8pt;line-height:9pt;"><BR>
(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><I>


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT  style="font-size:8pt;line-height:9pt;">

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Cogency Global&nbsp;Inc.<BR>
10 East 40th&nbsp;Street,<BR>
10th&nbsp;Floor<BR>
New York, New York 10016<BR>
+1&nbsp;212-947-7200</B></FONT><FONT  style="font-size:8pt;line-height:9pt;"><BR>
(Name, address, including zip code, and telephone number, including area code, of agent for service) </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT  style="font-size:8pt;line-height:9pt;">

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="24%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="24%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="24%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="24%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=7 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Copies to:</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><BR><FONT  style="font-size:8pt;line-height:9pt;"><B>Divakar Gupta<BR>
Richard Segal<BR>
Alison Haggerty<BR>
Cooley&nbsp;LLP<BR>
55 Hudson Yards<BR>
New York, New York 10001<BR>
+1&nbsp;212&nbsp;479 6000</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B><BR>&nbsp;</B></FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B><BR>
Arnaud Duhamel<BR>
Gide Loyrette Nouel A.A.R.P.I.<BR>
15 rue de Laborde<BR>
75008 Paris France<BR>
+33 1 40 75 00 00</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><BR><FONT  style="font-size:8pt;line-height:9pt;"><B> Deanna Kirkpatrick<BR>
Yasin Keshvargar<BR>
Davis&nbsp;Polk&nbsp;&amp;&nbsp;Wardwell&nbsp;LLP<BR>
450 Lexington Avenue<BR>
New York, New York 10017<BR>
+1&nbsp;212&nbsp;450-4000</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><BR><FONT  style="font-size:8pt;line-height:9pt;"><B> Jacques Naquet-Radiguet<BR>
Davis Polk&nbsp;&amp; Wardwell&nbsp;LLP<BR>
121 Avenue des Champs-&Eacute;lys&eacute;es<BR>
75008 Paris France<BR>
+33 1 56 59 36 00</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


  </I></FONT><FONT  style="font-size:8pt;line-height:9pt;">

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Approximate date of commencement of proposed sale to the public: As soon as practicable after this registration statement becomes effective.  </B></FONT></P>


<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act, check the
following box.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">If this Form is filed to register additional securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, please check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(c) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&nbsp;405 of the Securities Act of 1933. </FONT></P>


<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Emerging
growth company&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT> </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">If an emerging growth company that prepares its financial statements in accordance with U.S.&nbsp;GAAP, indicate by check mark if the registrant has elected not to use the
extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities
Act.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT  style="font-size:8pt;line-height:9pt;">

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>CALCULATION OF REGISTRATION FEE  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="65%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="96" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="96" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:3pt;text-indent:-3pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" style="font-family:arial;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Title of each class of securities<BR>
to be registered<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Proposed maximum<BR>
aggregate offering<BR>
price<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font></B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Amount of<BR>
registration fee</B></FONT><BR></TH>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" style="font-family:arial;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:3pt;text-indent:-3pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B> </B></FONT><FONT  style="font-size:8pt;line-height:9pt;">Ordinary shares, nominal value &euro;0.01 per share</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" style="font-family:arial;border-bottom:double #000000 2.25pt;"><p style="font-family:arial;margin-left:3pt;text-indent:-3pt;"> &nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Ordinary
shares may be represented by American Depositary Shares, or ADSs. Each ADS represents&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares. ADSs issuable upon
deposit of the ordinary shares registered hereby have been registered pursuant to a separate registration statement on Form&nbsp;F-6 (File No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;).
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Includes
additional ordinary shares (including in the form of ADSs) that the underwriters have the option to purchase.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Estimated
solely for the purpose of computing the amount of the registration fee pursuant to Rule&nbsp;457(o) under the Securities Act. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


  </I></FONT><FONT  style="font-size:8pt;line-height:9pt;">

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file&nbsp;a further
amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the
registration statement shall become effective on such date as the Securities and Exchange Commission acting pursuant to said Section&nbsp;8(a), may determine.</B></FONT></P>
 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT  style="font-size:8pt;line-height:9pt;">
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><div
style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=54986,FOLIO='blank',FILE='DISK116:[20ZBV1.20ZBV74901]BA74901A.;17',USER='VRIVERA',CD=';9-APR-2020;23:31' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT COLOR="#EB5A4E" SIZE=2>The information contained in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the
Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any jurisdiction where
the offer or sale is not permitted.</FONT></P>

<P ALIGN="RIGHT" style="font-family:arial;"><FONT COLOR="#EB5A4E" SIZE=2>Subject to completion, dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>PRELIMINARY PROSPECTUS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>(consisting of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares in the form of American Depositary Shares to be sold in the United States
and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares to
be sold outside of the United States) </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g778779.jpg" ALT="LOGO" WIDTH="184" HEIGHT="69">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
are offering&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares, nominal value &euro;0.01 per share, in a global offering. We are
offering&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares in the form
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
American Depositary Shares, or ADSs, in the United States, which we refer to as the U.S. offering. Each ADS represents the right to
receive&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares and the ADSs may be
evidenced by American Depositary Receipts, or ADRs. We are concurrently offering&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares outside the United States in an
offering exclusively addressed to "qualified
investors," as such term is defined in Regulation (EU) No.&nbsp;2017/1129, through the underwriters named in this prospectus, which we refer to as the European offering. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This
is our initial public offering of our ADSs, and no public market exists for our ADSs. We intend to apply to list our ADSs on the Nasdaq Global Market under the symbol "IVA." Our ordinary shares
are listed on Euronext Paris under the symbol "IVA." On&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, the closing price of our ordinary shares on Euronext Paris was
&euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share,
equivalent to a price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS, assuming an exchange rate of
&euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per U.S. dollar. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
are an "emerging growth company" as that term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, have elected to comply with certain reduced public company reporting
requirements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>Investing in our ordinary shares and ADSs involves a high degree of risk. See "Risk Factors" beginning on
page&nbsp;12.</B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:75%;margin-left:12%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="125pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="72pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="39pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Per ordinary share </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Per ADS </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Total </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Offering price</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Underwriting commission<SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds, before expenses, to Inventiva</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">(1)</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">See "Underwriting" for additional details regarding underwriter compensation. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>We have granted the underwriters an option to purchase up to an additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADSs from us in the U.S. offering at the
public offering price, for
30&nbsp;days after the date of this prospectus. We have also granted the underwriters an option to purchase up to an
additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares from us in the European offering, at
the offering price for 30&nbsp;days after the date of this prospectus. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
total number of ordinary shares (including ordinary shares in the form of ADSs) to be sold in the U.S. offering and the European offering (including upon exercise of the underwriters' option to
purchase additional ordinary shares and ADSs) is subject to reallocation between them. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B>Neither the U.S. Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the adequacy or accuracy of this
prospectus. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
underwriters expect to deliver the ADSs and ordinary shares to purchasers on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="23%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="23%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="47%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=4><B>Jefferies</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B> Stifel</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=4><B> Guggenheim Securities</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="48%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=3><B>KBC Securities</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=3>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=3><B>Roth Capital Partners</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:arial;"><font> </FONT> <FONT SIZE=2>
Prospectus dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 </FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=976468,FOLIO='blank',FILE='DISK116:[20ZBV1.20ZBV74901]BC74901A.;24',USER='VRIVERA',CD='10-APR-2020;01:22' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_bg74901_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="BG74901A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> TABLE OF CONTENTS  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<A NAME="BG74901_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="25pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Page </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#ca74901_prospectus_summary"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prospectus Summary</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#ca74901_prospectus_summary"><FONT SIZE=2>1</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#cg74901_risk_factors"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk Factors</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#cg74901_risk_factors"><FONT SIZE=2>12</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#co74901_special_note_regarding_forward-looking_statements"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Special Note Regarding Forward-Looking Statements</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#co74901_special_note_regarding_forward-looking_statements"><FONT SIZE=2>72</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#co74901_use_of_proceeds"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Use of Proceeds</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#co74901_use_of_proceeds"><FONT SIZE=2>74</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#co74901_dividend_policy"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dividend Policy</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#co74901_dividend_policy"><FONT SIZE=2>76</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#co74901_capitalization"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Capitalization</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#co74901_capitalization"><FONT SIZE=2>77</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#cq74901_dilution"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dilution</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#cq74901_dilution"><FONT SIZE=2>79</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#cq74901_selected_financial_data"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Selected Financial Data</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#cq74901_selected_financial_data"><FONT SIZE=2>81</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#cs74901_management_s_discussion_and_an__man03466"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Management's Discussion and Analysis of Financial Condition and Results of
Operations</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#cs74901_management_s_discussion_and_an__man03466"><FONT SIZE=2>83</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#cw74901_business"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Business</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#cw74901_business"><FONT SIZE=2>95</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#de74901_management"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Management</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#de74901_management"><FONT SIZE=2>136</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#di74901_certain_relationships___di702238"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Certain Relationships and Related Person Transactions</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#di74901_certain_relationships___di702238"><FONT SIZE=2>150</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#di74901_principal_shareholders"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Principal Shareholders</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#di74901_principal_shareholders"><FONT SIZE=2>153</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#dk74901_description_of_share_capital"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Description of Share Capital</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#dk74901_description_of_share_capital"><FONT SIZE=2>155</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#do74901_limitations_affecting___do702222"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Limitations Affecting Shareholders of a French Company</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#do74901_limitations_affecting___do702222"><FONT SIZE=2>177</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#do74901_description_of_american_depositary_shares"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Description of American Depositary Shares</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#do74901_description_of_american_depositary_shares"><FONT SIZE=2>179</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#dq74901_shares_and_adss_eligible_for_future_sale"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shares and ADSs Eligible for Future Sale</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#dq74901_shares_and_adss_eligible_for_future_sale"><FONT SIZE=2>188</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#dq74901_material_u.s._federal___dq702252"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Material U.S. Federal Income and French Tax Considerations</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#dq74901_material_u.s._federal___dq702252"><FONT SIZE=2>190</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#ds74901_enforcement_of_civil_liabilities"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Enforcement of Civil Liabilities</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#ds74901_enforcement_of_civil_liabilities"><FONT SIZE=2>199</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#ds74901_underwriting"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Underwriting</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#ds74901_underwriting"><FONT SIZE=2>200</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#du74901_expenses_relating_to_this_offering"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expenses Relating to this Offering</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#du74901_expenses_relating_to_this_offering"><FONT SIZE=2>208</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#du74901_legal_matters"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Legal Matters</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#du74901_legal_matters"><FONT SIZE=2>208</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#du74901_experts"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Experts</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#du74901_experts"><FONT SIZE=2>208</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#du74901_where_you_can_find_more_information"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Where You can Find More Information</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#du74901_where_you_can_find_more_information"><FONT SIZE=2>208</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#Index"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Index to Financial Statements</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#Index"><FONT SIZE=2>F-1</FONT></A></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>We
have not, and the underwriters have not, authorized any person to provide you with information different from that contained in this prospectus or any related free-writing prospectus that we
authorize to be distributed to you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. You should not assume that the
information contained in this prospectus is accurate as of any date other than the date on the front cover of this prospectus, regardless of the time of delivery of this prospectus or the sale of any
ordinary shares and ADSs. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>For investors outside the United States: Neither we nor any of the underwriters have done anything that would permit this offering or possession or distribution of this
prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform
themselves about, and observe any restrictions relating to, the offering of our ordinary shares and ADSs and the distribution of this prospectus outside the United States.</B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
are incorporated in France, and a majority of our outstanding securities are owned by non-U.S. residents. Under the rules of the Securities and Exchange Commission, or SEC, we are currently
eligible for treatment as a "foreign private issuer." As a foreign private issuer, we will not be required to file periodic reports and financial statements with the SEC as frequently or as promptly
as domestic registrants whose securities are registered under the Securities Exchange Act of 1934, as amended, or the Exchange Act. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>i</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=340978,FOLIO='i',FILE='DISK116:[20ZBV1.20ZBV74901]BG74901A.;12',USER='VRIVERA',CD=';9-APR-2020;23:31' -->
<A NAME="page_bg74901_1_2"> </A>

<P style="font-family:arial;"><FONT SIZE=2>Our
financial statements included in this prospectus are presented in euros and, unless otherwise specified, all monetary amounts are in euros. All references in this prospectus to "$," "US$,"
"U.S.$," "U.S. dollars," "dollars" and "USD" mean U.S. dollars and all references to "&euro;" and "euros," mean euros, unless otherwise noted. Throughout this prospectus, references to ADSs
mean ADSs or ordinary shares represented by such ADSs, as the case may be. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Through
and including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 (the 25th&nbsp;day after the date of this prospectus), all dealers that effect
transactions in these securities, whether or not participating in this
offering, may be required to deliver a prospectus. This is in addition to the dealers' obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or
subscriptions. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A NAME="bg74901_market,_industry_and_other_data"> </A>
<BR></FONT><FONT SIZE=2><B>  MARKET, INDUSTRY AND OTHER DATA    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Unless otherwise indicated, information contained in this prospectus concerning our industry and the markets in which we operate, including our general
expectations and market position, market opportunity and market size estimates, is based on information from independent industry analysts, third-party sources and management estimates. Management
estimates are derived from publicly-available information released by independent industry analysts and third-party sources, as well as data from our internal research, and are based on assumptions
made by us based on such data and our knowledge of such industry and market, which we believe to be reasonable. In addition, while we believe the market opportunity information included in this
prospectus is generally reliable and is based on reasonable assumptions, such data involves risks and uncertainties and is subject to change based on various factors, including those discussed under
the heading "Risk Factors." </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A NAME="bg74901_trademarks_and_service_marks"> </A>
<BR></FONT><FONT SIZE=2><B>  TRADEMARKS AND SERVICE MARKS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>"INVENTIVA," "PanNASH" and the Inventiva logo appearing in this prospectus are the property of Inventiva&nbsp;S.A. Solely for convenience, the trademarks,
service marks and trade names referred to in this prospectus are listed without the &reg; and &#153; symbols, but such references should not be construed as any indicator that their
respective owners will not assert, to the fullest extent under applicable law, their right thereto. All other trademarks, trade names and service marks appearing in this prospectus are the property of
their respective owners. We do not intend to use or display other companies' trademarks and trade names to imply any relationship with, or endorsement or sponsorship of us by, any other companies. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>ii</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=4,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=944987,FOLIO='ii',FILE='DISK116:[20ZBV1.20ZBV74901]BG74901A.;12',USER='VRIVERA',CD=';9-APR-2020;23:31' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_ca74901_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A NAME="ca74901_prospectus_summary"> </A>
<A NAME="toc_ca74901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROSPECTUS SUMMARY    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>The following summary highlights information contained elsewhere in this prospectus and does not contain all of the information you
should consider before investing in our ordinary shares (including ordinary shares in the form of ADSs). You should read the entire prospectus carefully, including "Risk Factors" and our financial
statements and the related notes appearing elsewhere in this prospectus. You should carefully consider, among other things, the matters discussed in the sections of this prospectus titled "Business"
and "Management's Discussion and Analysis of Financial Condition and Results of Operations" before making an investment decision. Unless otherwise indicated, "Inventiva," "the company," "our company,"
"we," "us" and "our" refer to Inventiva&nbsp;S.A.</I></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Overview  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic
steatohepatitis, or NASH, mucopolysaccharidoses, or MPS, and other diseases with significant unmet medical need. We have built a pipeline backed by a discovery engine with an extensive library of
proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and experience in the development of compounds that target nuclear receptors,
transcription factors and epigenetic modulation. Leveraging these assets and expertise, we are advancing two clinical candidates, lanifibranor and odiparcil, for the treatment of NASH and MPS,
respectively, as well as a deep pipeline of earlier stage programs in oncology and other diseases with significant unmet medical need.  </FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I> Lanifibranor for the Treatment of
NASH.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;We are developing our lead product candidate, lanifibranor, for the treatment of patients with NASH, a progressive, chronic liver disease
for which there are currently no approved therapies. NASH is believed to affect 12% of the United States population and is a leading cause of cirrhosis, liver transplantation and liver cancer.
Compared to the general population, patients with NASH have a ten-fold greater risk of liver-related mortality. NASH is characterized by a metabolic process known as steatosis, or the excessive
accumulation of fat in the liver, inflammation and ballooning of liver cells and progressive liver fibrosis that can ultimately lead to cirrhosis. Lanifibranor is an orally-available small molecule in
development for the treatment of NASH that acts to induce anti-fibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome
proliferator-activated receptor, or PPAR, isoforms. PPARs are well-characterized nuclear receptor proteins that regulate gene expression, and their relevance for the fibrotic, inflammatory, vascular
and metabolic processes that characterize NASH is well-established. While there are other PPAR agonists that target only one or two PPAR isoforms, lanifibranor is the only pan PPAR agonist in clinical
development. We believe that this pan PPAR approach provides for a combination of anti-fibrotic, anti-inflammatory and beneficial vascular and metabolic effects that cannot be obtained with single and
dual PPAR agonists. In September 2019, we completed enrollment in a Phase&nbsp;IIb clinical trial of lanifibranor in patients with NASH and plan to report data in June 2020. Lanifibranor has
received fast track designation from the U.S. Food and Drug Administration, or FDA, for the treatment of NASH.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I> Odiparcil for the Treatment of
MPS.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;Our second clinical-stage asset is odiparcil, which we are developing for the treatment of patients with MPS, a group of rare genetic
disorders characterized by an excessive accumulation of large sugar chains, known as glycosaminoglycans, or GAGs, in cells. Odiparcil is an orally-available small molecule designed to modify how GAGs
are synthesized. Odiparcil acts to facilitate the production of soluble GAGs that can be excreted in the urine, rather than accumulating in cells. The current standard of care for the treatment of
patients with MPS is enzyme replacement therapy, or ERT, which requires weekly infusions and is generally administered in an outpatient hospital setting. While ERT has been shown to be effective in
reducing GAG accumulation in certain tissue types, it has shown limited efficacy in reducing GAG accumulation in </FONT></DD></DL>
</UL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=5,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=836818,FOLIO='1',FILE='DISK116:[20ZBV1.20ZBV74901]CA74901A.;15',USER='VRIVERA',CD='10-APR-2020;00:14' -->
<A NAME="page_ca74901_1_2"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <UL>
<UL>

<P style="font-family:arial;"><FONT SIZE=2>poorly
vascularized tissues and organs, such as cartilage, or in tissues that are protected by a barrier, such as the eye. Unlike ERT, odiparcil is a small molecule that we have observed to be well
distributed in the body, even in certain tissues that are poorly vascularized or protected by a barrier. In December 2019, we announced positive results from a Phase&nbsp;IIa clinical trial of
odiparcil for the treatment of adult patients with the MPS VI subtype. In this trial, we observed that odiparcil, in combination with ERT, was associated with improvements in corneal clouding and
cardiac and respiratory function and exhibited a favorable tolerability profile. Signals of clinical activity were also detected in patients treated only with odiparcil. Because MPS is a progressive
disease, we believe there is benefit in treating pediatric patients with MPS, and we plan to commence a Phase Ib/II clinical trial of odiparcil in a pediatric population with MPS VI by
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. If the results of this pediatric trial are favorable, we plan to initiate Phase&nbsp;III clinical development of odiparcil as a
monotherapy and in combination with ERT for the
treatment of adult and pediatric patients with MPS&nbsp;VI. In addition, we plan to initiate an open label Phase&nbsp;IIa extension study
in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to investigate the long-term safety and
efficacy of odiparcil in patients 16&nbsp;years and above with MPS VI who completed the prior Phase&nbsp;IIa trial. We believe odiparcil's mechanism of action is relevant to a number of MPS
subtypes, and we also plan to initiate pivotal trials for the treatment of one or more of MPS subtypes&nbsp;I, II, IVa and VII. Odiparcil has received orphan drug designation from the FDA and
European Medicines Agency, or EMA, and rare pediatric disease designation from the FDA for the treatment of MPS VI.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I> Discovery
Engine.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;We have a scientific team of approximately 50 people with deep biology, medicinal and computational chemistry, pharmacokinetics and
pharmacology expertise, more than 75% of whom have worked together for more than 15&nbsp;years. We also own a library of approximately 240,000 pharmacologically relevant molecules, 60% of which are
proprietary, as well as a wholly-owned research and development facility. Using these assets and this expertise, we have built a discovery engine focused on small molecule compounds that target
nuclear receptors, transcription factors and epigenetic modulation. We are leveraging this discovery engine to identify and develop compounds addressing a wide range of indications. Our Hippo
signaling pathway program aims to disrupt the interaction between yes-associated protein, or YAP, and transcription enhancer associated domain transcription factors, or TEAD, an interaction that plays
a key role in oncogenic and fibrotic processes. In xenograft and orthotopic models of malignant pleural mesothelioma, or MPM, we observed that YAP-TEAD inhibition was associated with reduced tumor
growth and we are in the process of selecting development candidate for our Hippo program, which we anticipate entering pre-clinical development
in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for the treatment of non-small cell
lung cancer and mesothelioma. In addition, AbbVie is currently investigating ABBV-157, a ROR<FONT FACE="SYMBOL">g</FONT> inverse agonist that we and AbbVie jointly discovered, in a
Phase&nbsp;I clinical trial for the treatment of moderate to severe psoriasis under the terms of our multi-year drug discovery collaboration. We are also advancing a pre-clinical program for the
treatment of idiopathic pulmonary fibrosis, or IPF, and have validated a new target within the transforming growth factor beta, or TGF-<FONT FACE="SYMBOL">b</FONT>, signaling pathway. </FONT></DD></DL>
</UL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=6,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=498249,FOLIO='2',FILE='DISK116:[20ZBV1.20ZBV74901]CA74901A.;15',USER='VRIVERA',CD='10-APR-2020;00:14' -->
<A NAME="page_ca74901_1_3"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Our Pipeline  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have leveraged our assets and expertise to advance the development of multiple, novel and differentiated oral small molecule therapies. The following table
summarizes our key candidates and programs: </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g328266.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="391">
  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">*</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Lead
generation means identifying molecules in anticipation of selecting candidates. </FONT></DD></DL>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Lanifibranor for the Treatment of NASH  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Lanifibranor is an orally-available small molecule in development for the treatment of NASH that acts to induce anti-fibrotic, anti-inflammatory and beneficial
vascular and metabolic changes in the body by activating each of the three PPAR isoforms, known as PPAR<FONT FACE="SYMBOL">a</FONT>,
PPAR<FONT FACE="SYMBOL">d</FONT> and PPAR<FONT FACE="SYMBOL">g</FONT>. PPARs are ligand-activated transcription factors belonging to the nuclear hormone receptor family that
regulate the expression of genes. PPARs play essential roles in the regulation of cellular differentiation, development and tumorigenesis, and their relevance to different aspects of the fibrotic,
inflammatory, vascular and metabolic processes that characterize NASH is well-established. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Lanifibranor
is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPAR<FONT FACE="SYMBOL">a</FONT> and
PPAR<FONT FACE="SYMBOL">d</FONT>, and a partial activation of PPAR<FONT FACE="SYMBOL">g</FONT>. While there are other PPAR agonists that target only one or two PPAR isoforms,
lanifibranor is the only pan-PPAR agonist in clinical development. We believe that this pan-PPAR approach provides for a combination of anti-fibrotic, anti-inflammatory and beneficial vascular and
metabolic effects that cannot be obtained with single and dual PPAR agonists. In pre-clinical studies, we observed that the administration of lanifibranor improved insulin sensitivity and lipid
profile, reduced nonalcoholic fatty liver disease activity score, reversed liver fibrosis and reduced portal pressure. Further, in clinical trials in type&nbsp;2 diabetes conducted prior to our
founding, the administration of lanifibranor was associated with favorable anti-inflammatory effects, including increased levels of adiponectin, which inhibits the release of cytokines and other
pro-inflammatory proteins. Lanifibranor was also associated with favorable metabolic effects, including improvements in insulin sensitivity, reductions in levels of triglycerides, which are a type of
fat, and increases in high-density lipoprotein, or HDL, cholesterol levels. We believe lanifibranor's moderate and balanced pan-PPAR binding </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=7,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=590997,FOLIO='3',FILE='DISK116:[20ZBV1.20ZBV74901]CA74901A.;15',USER='VRIVERA',CD='10-APR-2020;00:14' -->
<A NAME="page_ca74901_1_4"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:arial;"><FONT SIZE=2>profile
also contributes to the favorable tolerability profile that has been observed in clinical trials and pre-clinical studies to date. As of March&nbsp;16, 2020, approximately 250 patients have
been treated for 24 or 48&nbsp;weeks in our Phase&nbsp;IIb clinical trials of lanifibranor, including our ongoing trial in patients with NASH and a completed trial in another indication. In
connection with these trials, lanifibranor has undergone a total of seven data and safety monitoring board, or DSMB, reviews, and the DSMBs have not recommended any changes to the trial protocols. In
addition, prior to inception of Inventiva, lanifibranor was administered to over 150 subjects in clinical trials in type&nbsp;2 diabetes and exhibited a favorable tolerability profile, including
with respect to key markers of liver, kidney, heart, muscle and bone function. By contrast, single and dual PPAR agonists, which generally target PPAR isoforms in a very potent and imbalanced manner,
have historically been associated with toxicity and adverse effects. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
September 2019, we completed enrollment in the NATIVE Phase&nbsp;IIb clinical trial of lanifibranor in patients with NASH and plan to report data in June 2020. If positive, we plan to advance
lanifibranor, alone or together with a collaborator, into pivotal Phase&nbsp;III clinical development. Lanifibranor has received fast track designation from the FDA for the treatment of NASH. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Odiparcil for the Treatment of MPS  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are developing odiparcil for the treatment of patients with several subtypes of MPS. Odiparcil is an orally-available small molecule that acts on the
underlying cause of the symptoms of MPS, which is the accumulation of GAGs in cells due to deficient lysosomal enzymes. By modifying how GAGs are synthesized, odiparcil facilitates the production of
soluble GAGs that can be excreted in the urine, rather than accumulating in cells. In pre-clinical studies, we have observed that odiparcil reduced accumulation of two specific GAGs, chondroitin
sulfate, or CS, and dermatan sulfate, or DS, in several organs and tissues. ERT is the current standard of care for the treatment of patients with MPS but requires weekly infusions and is generally
administered in an outpatient hospital setting. Furthermore, while ERT has been shown to be effective in reducing GAG accumulation in some tissue types, it has shown limited efficacy in reducing GAG
accumulation in tissues that are poorly vascularized or protected by a barrier. By contrast, we have observed, in pre-clinical studies, that odiparcil is well distributed in the body, including in
cartilage and the eye, which are tissues that are poorly penetrated by ERT and in which MPS symptoms often manifest. Because odiparcil has a different mechanism of action than ERT and reaches tissues
that are poorly penetrated by ERT, we believe odiparcil could be used as a combination therapy with ERT. Based on our pre-clinical data, we also believe odiparcil has potential as a stand-alone
therapy. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>MPS
is separated into subtypes, depending on the lysosomal enzyme that is deficient and the corresponding GAGs that accumulate. One or both of CS and DS, the GAGs on which odiparcil acts, accumulate
in patients with MPS I, II, IVa, VI and VII. To date, we have focused development of odiparcil on the treatment of patients with MPS VI, which is characterized by rounded and thickened facial
features, corneal clouding, hearing loss, dwarfism with deformity of the limbs, enlargement of the liver and spleen, cardiac valve disease and reduced pulmonary function, and an approximate life
expectancy of 20&nbsp;years for untreated patients with severe forms of the disease. In an MPS VI model using a mouse that was genetically modified to reflect human MPS pathology, we observed that
administration of odiparcil reduced GAG accumulation in organs and tissues and improved mobility. Prior to our founding, odiparcil was administered to over 1,800 subjects in clinical trials in an
unrelated indication and was reported to be well tolerated and exhibited a favorable safety profile at daily doses in excess of the therapeutic range. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
December 2019, we announced positive results from the iMProveS Phase&nbsp;IIa clinical trial of odiparcil, which enrolled twenty patients, aged 16&nbsp;years or older, with the MPS VI subtype.
Fifteen patients were randomized to receive baseline ERT in combination with one of two doses of odiparcil, 250 mg or 500 mg administered twice daily, or placebo. Five patients who were not receiving
ERT received 500 mg of odiparcil administered twice daily in an open label cohort. After 26&nbsp;weeks of treatment, we observed that odiparcil in combination with ERT was associated with
improvements in corneal clouding and cardiac and respiratory function and exhibited a favorable tolerability profile. Signals of clinical activity were also detected in patients treated only with
odiparcil. We observed improved mobility as assessed using the six minute walk </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=8,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=590074,FOLIO='4',FILE='DISK116:[20ZBV1.20ZBV74901]CA74901A.;15',USER='VRIVERA',CD='10-APR-2020;00:14' -->
<A NAME="page_ca74901_1_5"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:arial;"><FONT SIZE=2>test,
or 6MWT, in patients treated with ERT and the 250mg twice daily dose of odiparcil, as well as in patients in the open label cohort. We did not observe improved mobility using the 6MWT in
patients treated with ERT and the 500mg twice daily dose of odiparcil. Dose-dependent urinary GAGs clearance, used as an activity biomarker, was observed in the entire odiparcil-treated patient
population. A reduction in leukocyte GAGs was not observed and therefore was not confirmed as a biomarker for the decrease of GAG accumulation, while the analysis of skin GAG content remains ongoing.
The trial also met its safety primary endpoint with odiparcil exhibiting a favorable tolerability profile. Because MPS is a progressive disease, we believe there is benefit in treating pediatric
patients with MPS, and we plan to commence a Phase Ib/II clinical trial of odiparcil in a pediatric population with MPS VI by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. If
the results of this pediatric trial are favorable, we
plan to initiate Phase&nbsp;III clinical development of odiparcil as a monotherapy and in combination with ERT for the treatment of adult and pediatric patients with MPS VI. In addition, we plan to
initiate an open label Phase&nbsp;IIa extension study in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to investigate the long-term safety and efficacy of odiparcil in patients
16&nbsp;years and above with MPS VI who completed
the prior Phase&nbsp;IIa trial. Because odiparcil targets GAGs that are also present in other MPS subtypes, we believe that the data generated in the iMProveS trial may also support moving directly
to Phase&nbsp;III pivotal trials in other MPS subtypes that are characterized by the accumulation of CS or DS. Odiparcil has received orphan drug designation from the FDA and EMA and rare pediatric
disease designation from the FDA for the treatment of MPS VI. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our Strategy  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our goal is to rapidly deliver multiple, novel and differentiated oral small molecule therapies to patients suffering from NASH, MPS, cancer and other diseases
with significant unmet medical need. To achieve our goal, we are pursuing the following strategies:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Demonstrate clinical proof of concept for lanifibranor in the treatment of NASH. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Rapidly advance odiparcil to pivotal trials in the treatment of MPS VI. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Leverage the power of our discovery engine to identify and advance additional novel
programs in areas with high unmet medical need. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Selectively seek strategic collaborations to maximize the value of our assets. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Selected Risks Affecting Our Business  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Investing in our securities involves risk. You should carefully consider all the information in this prospectus prior to investing in our securities. These
risks are discussed more fully in the section titled "Risk Factors" immediately following this prospectus summary. These risks and uncertainties include, but are not limited to, the
following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We are a clinical-stage company with no approved products and no historical product
revenues, which makes it difficult to assess our future prospects and financial results. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We have incurred significant losses since our inception and anticipate that we will
continue to incur significant losses for the foreseeable future. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We will require substantial additional funding, which may not be available to us on
acceptable terms, or at all. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We cannot give any assurance that any product candidate, or any other compounds in
development, will successfully complete clinical trials, receive regulatory approval or be commercialized. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The regulatory approval processes of the FDA, the EMA and other comparable regulatory
authorities are lengthy, time consuming and inherently unpredictable. </FONT></DD></DL>
</UL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=9,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=497633,FOLIO='5',FILE='DISK116:[20ZBV1.20ZBV74901]CA74901A.;15',USER='VRIVERA',CD='10-APR-2020;00:14' -->
<A NAME="page_ca74901_1_6"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Results of earlier studies and trials as well as data from any interim analysis of
ongoing clinical trials may not be predictive of future trial results. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We face significant competition for our drug discovery and development efforts, and if we
do not compete effectively, our commercial opportunities will be reduced or eliminated. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Even if any of our product candidates are commercialized, they may not be accepted by
physicians, healthcare payors, patients or the medical community in general. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Our ability to compete may decline if we do not adequately protect our proprietary
rights. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We do not have composition of matter patent protection with respect to odiparcil. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Developments in patent law could have a negative impact on our business. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Our international operations subject us to various risks, and our failure to manage these
risks could adversely affect our results of operations. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Business and clinical trial interruptions resulting from public health emergencies,
including those related to the COVID-19 pandemic. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> If we are unable to establish marketing and sales capabilities or enter into agreements
with third parties to market and sell our product candidates, we may not be able to effectively market and sell any product candidates, if approved, or generate product revenues. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> After this offering, voting control with respect to our company will remain concentrated
in the hands of Fr&eacute;d&eacute;ric Cren, our Chief Executive Officer, Pierre Broqua, our Deputy Chief Executive Officer and Chief Scientific Officer, and our significant
shareholders and affiliates, who will continue to be able to exercise significant influence on us. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We are a French public limited company, and the rights of shareholders in companies
subject to French corporate law differ in material respects from the rights of shareholders of corporations incorporated in the United States. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Implications of Being an Emerging Growth Company  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We qualify as an "emerging growth company" as defined in the U.S. Jumpstart Our Business Startups Act of 2012, or the JOBS Act. As an emerging growth company,
we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions
include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the ability to present only two years of audited financial statements in addition to any
required interim financial statements and only two years of related Management's Discussion and Analysis of Financial Condition and Results of Operations in the registration statement for our initial
public offering of our ADSs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> not being required to comply with the auditor attestation requirements of
Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> to the extent that we no longer qualify as a foreign private issuer, (1)&nbsp;reduced
disclosure obligations regarding executive compensation in our periodic reports and proxy statements and (2)&nbsp;exemptions from the requirements of holding a non-binding advisory vote on executive
compensation, including golden parachute compensation. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>We
may take advantage of these provisions for up to five years from the initial public offering of our ADSs or such earlier time that we no longer qualify as an emerging growth company. We would cease
to be an emerging growth company upon the earliest to occur of the following: (1)&nbsp;if we have more than $1.07&nbsp;billion in total annual gross revenue, (2)&nbsp;if we have more than
$700&nbsp;million in market value of our capital stock held by non-affiliates or (3)&nbsp;if we issue more than $1.0&nbsp;billion of non-convertible debt over a </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=10,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=920703,FOLIO='6',FILE='DISK116:[20ZBV1.20ZBV74901]CA74901A.;15',USER='VRIVERA',CD='10-APR-2020;00:14' -->
<A NAME="page_ca74901_1_7"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:arial;"><FONT SIZE=2>three-year
period. We may choose to take advantage of some but not all of these reduced burdens. For example, we have presented only two years of audited financial statements and only two years of
related Management's Discussion and Analysis of Financial Condition and Results of Operations disclosure in this prospectus, and plan to take advantage of the exemption from auditor attestation on the
effectiveness of our internal control over financial reporting. To the extent that we take advantage of these reduced burdens, the information that we provide shareholders may be different than you
might obtain from other public companies in which you hold equity interests. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. Since International
Financial Reporting Standards make no distinction between public and private companies for purposes of compliance with new or revised accounting standards, the requirements for our compliance as a
private company and as a public company are the same. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Implications of Being a Foreign Private Issuer  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are also considered a "foreign private issuer" under U.S. securities laws. In our capacity as a foreign private issuer, we are exempt from certain rules
under the U.S. Securities Exchange Act of 1934, as amended, or the Exchange Act, that impose certain disclosure obligations and procedural requirements for proxy solicitations under Section&nbsp;14
of the Exchange Act. In addition, our officers, directors and principal shareholders are exempt from the reporting and "short-swing" profit recovery provisions of Section&nbsp;16 of the Exchange Act
and the rules under the Exchange Act with respect to their purchases and sales of our securities. Moreover, we are not required to file periodic reports and financial statements with the SEC as
frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. In addition, we are not required to comply with Regulation&nbsp;FD, which restricts the selective
disclosure of material information. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
may take advantage of these exemptions until such time as we are no longer a foreign private issuer. We will remain a foreign private issuer until such time that more than 50% of our outstanding
voting securities are held by U.S. residents and any of the following three circumstances applies: (1)&nbsp;the majority of our executive officers or directors are U.S. citizens or residents;
(2)&nbsp;more than 50% of our assets are located in the United States; or (3)&nbsp;our business is administered principally in the United States. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
have taken advantage of certain reduced reporting and other requirements in this prospectus. Accordingly, the information contained herein may be different from the information you receive from
other public companies in which you hold equity securities. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Corporate Information  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We were founded in 2011 and incorporated as a </FONT><FONT SIZE=2><I>soci&eacute;t&eacute; anonyme</I></FONT><FONT SIZE=2>, or&nbsp;S.A., in
2016. Our principal executive offices are located at 50 rue de Dijon, 21121 Daix, France. We are registered at the Dijon Trade and Companies Register (</FONT><FONT SIZE=2><I>Registre du commerce et
des soci&eacute;t&eacute;s</I></FONT><FONT SIZE=2>) under the number&nbsp;537&nbsp;530&nbsp;255. In February 2017, we completed the initial public offering of our
ordinary shares on Euronext Paris, raising &euro;48.5&nbsp;million in gross proceeds. Our telephone number at our principal executive offices is +33 3 80 44 75 00. Our agent for service
of process in the United States is Cogency Global&nbsp;Inc., 10 East 40th&nbsp;Street, 10th&nbsp;Floor, New York, New York 10016. Our website address is www.inventivapharma.com. The reference to
our website is an inactive textual reference only and information contained in, or that can be accessed through, our website is not part of this prospectus. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=11,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=573618,FOLIO='7',FILE='DISK116:[20ZBV1.20ZBV74901]CA74901A.;15',USER='VRIVERA',CD='10-APR-2020;00:14' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_cc74901_1_8"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A NAME="cc74901_the_offering"> </A>
<A NAME="toc_cc74901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  The Offering    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="32%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="64%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Global offering</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares offered by us, consisting
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares represented by American depositary shares, or ADSs, offered in the U.S. offering
and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares offered in the European offering. The total number of ordinary shares to be sold in the U.S. offering and European offering is subject to
reallocation between these offerings.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ADSs offered by us in the U.S.<BR>
offering</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADSs,
representing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares.</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ordinary shares offered by us in the European offering</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Option to purchase additional ADSs in the U.S. offering</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADSs,
representing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares.</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Option to purchase additional ordinary shares in the European offering</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ordinary shares (including ordinary shares underlying ADSs) to be outstanding after the global offering</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares
(&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares if the underwriters' option to purchase additional ordinary shares (which may be in the form of ADSs) is exercised in full).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>American Depositary Shares</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Each ADS represents&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares,
 nominal value &euro;0.01 per share. Purchasers of ADSs will have the rights of an ADS holder as provided in the deposit agreement among us, the depositary and all holders and beneficial owners of ADSs issued thereunder. To better understand the
terms of the ADSs, purchasers of ADSs should carefully read the section in this prospectus titled "Description of American Depositary Shares." We also encourage purchasers of ADSs to read the deposit agreement, which is filed as an exhibit to the
registration statement that includes this prospectus.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Depositary</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT
SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Use of proceeds</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We estimate that we will receive net proceeds from this global offering of approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(&euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)&nbsp;million, assuming an offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS in the U.S. offering and &euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share in
the European offering, based on the closing price of our ordinary shares on Euronext Paris (expressed in U.S. dollars, as applicable)
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, after deducting underwriting commissions and estimated offering
expenses payable by us. We intend to use the net proceeds from this offering to initiate and progress clinical trials and pre-clinical studies and for working capital and general corporate purposes. See "Use of Proceeds" for more
information.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dividend policy</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We do not expect to pay any dividends on our ordinary shares or ADSs in the foreseeable future.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<p style="font-family:arial;"><font  style="font-size:8pt;line-height:9pt;"></FONT><FONT SIZE=2>
</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=12,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=144772,FOLIO='8',FILE='DISK116:[20ZBV1.20ZBV74901]CC74901A.;9',USER='JFUSS',CD='10-APR-2020;08:07' -->
<A NAME="page_cc74901_1_9"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="32%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="64%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk factors</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>You should read the "Risk Factors" section of this prospectus for a discussion of factors to consider carefully before deciding to invest in
our ordinary shares or ADSs.</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proposed Nasdaq Global Market symbol for our ADSs</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>"IVA"</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Euronext Paris trading symbol for our ordinary shares</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>"IVA"</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>The
number of ordinary shares (including ordinary shares underlying ADSs) that will be outstanding after this offering is based on 26,846,112 ordinary shares outstanding as of December&nbsp;31, 2019
and excludes:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 274,800 ordinary shares issuable upon the exercise of founder's share warrants
(</FONT><FONT SIZE=2><I>bons de souscription de parts de cr&eacute;ateur d'entreprise)</I></FONT><FONT SIZE=2> and share warrants (</FONT><FONT SIZE=2><I>bons de souscription
d'actions)</I></FONT><FONT SIZE=2> outstanding as of December&nbsp;31, 2019 at a weighted average exercise price of &euro;6.06 per ordinary share ($6.79 per ordinary share based on the
exchange rate in effect as of December&nbsp;31, 2019); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 556,050 ordinary shares issuable upon the vesting of free shares
(</FONT><FONT SIZE=2><I>actions gratuites</I></FONT><FONT SIZE=2>) outstanding as of December&nbsp;31, 2019; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 15,879,556 ordinary shares reserved for future issuance under our share-based
compensation plans and other delegations of authority from our shareholders; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 3,778,338 ordinary shares issued at a purchase price of &euro;3.97 per share
in connection with a private placement, the settlement of which occurred on February&nbsp;11, 2020. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Except
as otherwise noted, the information in this prospectus assumes no exercise by the underwriters of their option to purchase ordinary shares or ADSs in this offering and no exercise of warrants
or vesting of free shares or other equity awards subsequent to December&nbsp;31, 2019. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=13,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=414332,FOLIO='9',FILE='DISK116:[20ZBV1.20ZBV74901]CC74901A.;9',USER='JFUSS',CD='10-APR-2020;08:07' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_ce74901_1_10"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A NAME="ce74901_summary_financial_data"> </A>
<A NAME="toc_ce74901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SUMMARY FINANCIAL DATA    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following summary statement of income (loss) data for the years ended December&nbsp;31, 2018 and 2019 and summary statement of financial position data as
of December&nbsp;31, 2019 have been derived from our audited financial statements included elsewhere in this prospectus. Our audited financial statements have been prepared in accordance with
International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Our
historical results are not necessarily indicative of the results that may be expected in the future. You should read this summary data together with our financial statements and related notes
beginning on page&nbsp;F-1 of this prospectus, as well as the sections of this prospectus titled "Selected financial data" and "Management's Discussion and Analysis of Financial Condition and
Results of Operations" and the other financial information included elsewhere in this prospectus. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Summary
Statement of Income (Loss) Data: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="161pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="161pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Year ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands, except share and<BR>
per share data)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Revenues</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
&euro;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3,197</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
&euro;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>6,998</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,182</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,293 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total revenues and other income</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 7,379</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>11,291</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating expenses:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development expenses</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(31,758</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(33,791</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Marketing&nbsp;&#151; Business development expenses</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(225</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(249</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative expenses</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(6,045</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(6,088</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other operating income (expense)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2,255</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(1,475</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total operating expenses</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> (40,282</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>(41,603</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Operating profit (loss)</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> (32,903</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>(30,312</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Financial income (loss)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(111</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>93</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Income tax</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net loss for the period</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>
<!-- -->
&euro;</B></FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>(33,014</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>
<!-- -->
&euro;</B></FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>(30,218</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Basic/diluted loss per share</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
&euro;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(1.61</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
&euro;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(1.28</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted average number of outstanding shares used for computing basic/ diluted loss per share</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>20,540,979</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>23,519,897</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=14,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=950059,FOLIO='10',FILE='DISK116:[20ZBV1.20ZBV74901]CE74901A.;8',USER='VRIVERA',CD=';9-APR-2020;23:31' -->
<A NAME="page_ce74901_1_11"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">


<P style="font-family:arial;"><FONT SIZE=2>Summary
Statement of Financial Position Data: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="143pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="150pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of December&nbsp;31, 2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Actual </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As adjusted<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)(2)</font> </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
&euro;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>35,840</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
&euro;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>56,960</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>15,568</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total shareholders' equity</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>41,392</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
as adjusted summary statement of financial position data reflects our issuance and sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADSs
and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares
in the global offering at an assumed offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS in the U.S. offering and
&euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share in the European offering, based on the
closing price of our ordinary shares on Euronext Paris (expressed in U.S. dollars, as applicable) on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, after deducting
underwriting commissions and estimated offering expenses
payable by us.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
as adjusted summary statement of financial position data is illustrative only and will change based on the actual offering price and other terms of
the offering determined at pricing. Each $1.00 (&euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) increase or decrease in the assumed offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS in the U.S. offering and
&euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share in the European offering would increase or decrease the as adjusted amount of each of cash and cash equivalents, total assets and total
shareholders' equity by approximately &euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the number of ADSs and ordinary shares offered by us, as set forth on the cover page of
this
prospectus, remains the same and after deducting underwriting commissions and estimated offering expenses payable by us. We may also increase or decrease the number of ordinary shares (including
ordinary shares in the form of ADSs) we are offering. Each increase or decrease of 1,000,000 ordinary shares (including ordinary shares in the form of ADSs) offered by us would increase or decrease
the as adjusted amount of each of cash and cash equivalents, total assets and total shareholders' equity by &euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the assumed
offering price
remains the same, and after deducting underwriting commissions and estimated offering expenses payable by us. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=15,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=59348,FOLIO='11',FILE='DISK116:[20ZBV1.20ZBV74901]CE74901A.;8',USER='VRIVERA',CD=';9-APR-2020;23:31' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_cg74901_1_12"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A NAME="cg74901_risk_factors"> </A>
<A NAME="toc_cg74901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  RISK FACTORS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>Investing in our ordinary shares or ADSs involves a high degree of risk. You should carefully consider the following risks and all other
information contained in this prospectus, including our financial statements and the related notes, before making an investment decision regarding our securities. The risks and uncertainties described
below are those significant risk factors, currently known and specific to us, that we believe are relevant to an investment in our securities. If any of these risks materialize, our business,
financial condition or results of operations could suffer, the price of our ordinary shares or ADSs could decline and you could lose part or all of your investment.</I></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risks related to our Financial Position and Need for Additional Capital  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We are a clinical-stage company with no approved products and no historical product revenues, which makes it
difficult to assess our future prospects and financial results.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are a clinical-stage biotechnology company and we have not yet generated any revenue from product sales. Pharmaceutical product development is a highly
speculative undertaking and involves a substantial degree of uncertainty. Our operations to date have been limited to developing our technology and undertaking clinical trials of our product
candidates lanifibranor and odiparcil, and pre-clinical and clinical studies of other compounds in development. Lanifibranor and odiparcil are in clinical development and have not been approved for
sale and we may never have any product approved for commercialization. We have not yet demonstrated an ability to overcome many of the risks and uncertainties frequently encountered by companies in
new and rapidly evolving fields, particularly in the pharmaceutical area. Consequently, the ability to predict our future operating results or business prospects is more limited than if we had a
longer operating history or approved products on the market. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
ability to generate revenue from product sales and achieve and maintain profitability depends on our ability, alone or with any future collaborators, to successfully complete the development of,
and obtain the regulatory approvals necessary to commercialize, lanifibranor, odiparcil and any additional product candidates that we may pursue in the future. Currently, lanifibranor and odiparcil
are our only product candidates in clinical development. Our prospects, including our ability to finance our operations and generate revenue from product sales, therefore will depend substantially on
the development and commercialization of lanifibranor and odiparcil, as other programs in our pre-clinical portfolio are still in earlier stages of development. Since our inception in 2011, the
majority of our revenue has been derived from our reliance on research collaborations unrelated to lanifibranor or odiparcil, and we do not anticipate generating revenue from product sales for the
next several years, if ever. Our ability to generate revenue from product sales depends heavily on our or any future collaborators' success in:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> timely and successful completion of clinical development of lanifibranor and odiparcil,
our current clinical-stage product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> obtaining and maintaining regulatory and marketing approvals for lanifibranor, odiparcil
and any future product candidates for which we successfully complete clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> launching and commercializing any product candidates for which we obtain regulatory and
marketing approval by establishing a sales force, marketing and distribution infrastructure or, alternatively, collaborating with a commercialization partner; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> obtaining coverage and adequate reimbursement from government and third-party payors for
our current or any future product candidates, if approved, both in the United States and internationally, and reaching acceptable agreements with foreign government and third-party payors on pricing
terms; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> developing, validating and maintaining a commercially viable, sustainable, scalable,
reproducible and transferable manufacturing process for lanifibranor, odiparcil or any future product candidates that are compliant with current good manufacturing practices, or cGMP; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=16,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=438442,FOLIO='12',FILE='DISK116:[20ZBV1.20ZBV74901]CG74901A.;11',USER='SCAVALI',CD='10-APR-2020;08:36' -->
<A NAME="page_cg74901_1_13"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> establishing and maintaining supply and manufacturing relationships with third parties
that can provide an adequate amount and quality of drugs and services to support our planned clinical development, as well as the market demand for lanifibranor, odiparcil and any future product
candidates, if approved; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> obtaining market acceptance, if and when approved, of lanifibranor, odiparcil or any
future product candidates as a viable treatment option by physicians, patients, third-party payors and others in the medical community; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> effectively addressing any competing technological and market developments; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> implementing additional internal systems and infrastructure, as needed; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> negotiating favorable terms in any collaboration, licensing or other arrangements into
which we may enter, and performing our obligations pursuant to such arrangements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> maintaining, protecting and expanding our portfolio of intellectual property rights,
including patents, trade secrets and know-how; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> avoiding and defending against third-party interference or infringement claims; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> attracting, hiring and retaining qualified personnel. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have incurred significant losses since our inception and anticipate that we will continue to incur
significant losses for the foreseeable future. We have never generated any revenue from product sales and may never achieve or maintain profitability.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have incurred significant operating losses since our inception in 2011. We incurred net losses of &euro;33.0&nbsp;million and
&euro;30.2&nbsp;million for the years ended December&nbsp;31, 2018 and 2019, respectively. We expect to continue to incur significant expenses and increasing operating losses for the
foreseeable future. We have devoted substantially all of our efforts to acquisition and pre-clinical and clinical development of our product candidates, as well as to building our intellectual
property portfolio, research programs, management team and infrastructure. It could be several years, if ever, before we or our collaborators have a commercialized product and our commercialized
products, if any, may not be profitable. The net losses we incur may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase significantly in
connection with our ongoing activities as we:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> continue the ongoing and planned clinical development of lanifibranor and odiparcil; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> initiate pre-clinical studies and clinical trials with respect to our other development
programs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> develop, maintain, expand and protect our intellectual property portfolio; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> manufacture, or have manufactured, clinical and commercial supplies of our product
candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> seek marketing approvals for our current and future product candidates that successfully
complete clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> establish a sales, marketing and distribution infrastructure to commercialize any product
candidate for which we may obtain marketing approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> hire additional administrative, clinical, regulatory and scientific personnel; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> incur additional costs associated with operating as a public company in the United States
following the completion of this offering. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>In
order to become and remain profitable, we will need to develop and eventually commercialize, on our own or with collaborators, one or more product candidates with significant market potential. This
will require us to be successful in a range of challenging activities, including completing clinical trials of our product candidates, developing commercial scale manufacturing processes, obtaining
marketing approval, </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=17,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=375080,FOLIO='13',FILE='DISK116:[20ZBV1.20ZBV74901]CG74901A.;11',USER='SCAVALI',CD='10-APR-2020;08:36' -->
<A NAME="page_cg74901_1_14"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>manufacturing,
marketing and selling any current and future product candidates for which we may obtain marketing approval, and satisfying any post-marketing requirements. We may never succeed in any
or all of these activities and, even if we do, we may never generate revenue from product sales or achieve profitability. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Because
of the numerous risks and uncertainties associated with pharmaceutical products and development, we are unable to accurately predict the timing or amount of increased expenses or when, or if,
we will be able to achieve profitability. If we are required by the U.S. Food and Drug Administration, or FDA, or other regulatory authorities such as the European Medicines Agency, or EMA, to perform
studies and trials in addition to those currently expected, or if there are any delays in the development or in the completion of any planned or future pre-clinical studies or clinical trials of our
current or future product candidates, our expenses could increase and profitability could be further delayed. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Even
if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our
company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company also could
cause you to lose all or part of your investment. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if this offering is successful, we will require substantial additional funding, which may not be
available to us on acceptable terms, or at all, and failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product candidate development efforts or other
operations.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our operations have consumed substantial amounts of cash since inception. We are currently conducting clinical trials for lanifibranor and odiparcil. We also
plan to conduct clinical trials for other compounds in development. Developing pharmaceutical product candidates, including conducting clinical trials, is expensive, lengthy and risky, and we expect
our research and development expenses to increase substantially in connection with our ongoing activities, particularly as we advance lanifibranor and odiparcil through later stages of clinical
development. We will require substantial additional future capital in order to complete clinical development and, if we are successful, to commercialize any of our current product candidates.
Accordingly, we will continue to require substantial additional capital to continue our clinical development activities and potentially engage in commercialization activities. Because successful
development of our product candidates is uncertain, we are unable to estimate the actual funds we will require to complete research and development and commercialize our product candidates. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
amount and timing of our future funding requirements will depend on many factors, including but not limited
to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the progress, costs, results of and timing of our ongoing and planned clinical trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to reach milestones under our existing collaboration arrangements or enter
into additional collaboration agreements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the willingness of the FDA, EMA and other comparable regulatory authorities to accept our
clinical trials and pre-clinical studies and other work as the basis for review and approval of product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the outcome, costs and timing of seeking and obtaining regulatory approvals from the FDA,
EMA and other comparable regulatory authorities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the need for additional or expanded pre-clinical studies and clinical trials beyond those
that we envision conducting with respect to our current and future product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the success of our current collaborators and any future collaborators, and the economic
and other terms of any licensing, collaboration or other similar arrangements into which we may enter; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>

<!-- ZEQ.=3,SEQ=18,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=592608,FOLIO='14',FILE='DISK116:[20ZBV1.20ZBV74901]CG74901A.;11',USER='SCAVALI',CD='10-APR-2020;08:36' -->
<A NAME="page_cg74901_1_15"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the number of product candidates and indications that we pursue; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the timing and costs associated with manufacturing our product candidates for clinical
trials and pre-clinical studies and, if approved, for commercial sale; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the timing and costs associated with establishing sales and marketing capabilities; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> market acceptance of any approved product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the costs of acquiring, licensing or investing in additional businesses, products,
product candidates and technologies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the cost to maintain, expand and defend the scope of our intellectual property portfolio,
including the amount and timing of any payments we may be required to make, or that we may receive, in connection with licensing, filing, prosecution, defense and enforcement of any patents or other
intellectual property rights; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our need and ability to hire additional management, development and scientific personnel;
and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our need to implement additional internal systems and infrastructure, including financial
and reporting systems. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>As
of December&nbsp;31, 2019, we had &euro;35.8&nbsp;million of cash and cash equivalents. We expect that the net proceeds from this offering, together with our existing cash and cash
equivalents, will enable us to fund our operating expenses and capital expenditure requirements at least through&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. This period
could be shortened if there are any significant increases
beyond our expectations in spending on development programs or more rapid progress of development programs than anticipated. Accordingly, we expect that we will need to raise substantial additional
funds in the future. Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and, if approved, commercialize
our product candidates. In addition, our ability to raise necessary financing could be impacted by the COVID-19 pandemic and its effects on market conditions. If we are unable to obtain funding on a
timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of any approved product or be unable to
expand our operations or otherwise capitalize on our business opportunities, as desired, which could impair our growth prospects. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Raising additional capital may cause dilution to our existing shareholders, restrict our operations or
require us to relinquish rights to our product candidates or technologies.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We may seek additional funding through a combination of equity offerings, debt financings, collaborations and/or licensing arrangements. To the extent that we
raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely
affect your rights as a holder of our ordinary shares or ADSs. The incurrence of additional indebtedness and/or the issuance of certain equity securities could result in increased fixed payment
obligations and could also result in certain additional restrictive covenants, such as limitations on our ability to incur additional debt and/or issue additional equity, limitations on our ability to
acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. In addition, issuance of additional equity securities,
or the possibility of such issuance, may cause the market price of our ordinary shares or ADSs to decline. In the event that we enter into collaborations and/or licensing arrangements in order to
raise capital, we may be required to accept unfavorable terms, including relinquishing or licensing to a third party on unfavorable terms our rights to technologies or product candidates that we
otherwise would seek to develop or commercialize ourselves or potentially reserve for future potential arrangements when we might be able to achieve more favorable terms. Additional funding may not be
available to us on acceptable terms, or at all. If we are unable to obtain funding on a timely basis, we may be required to significantly curtail one or more of programs or cease operations
altogether. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=19,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=581869,FOLIO='15',FILE='DISK116:[20ZBV1.20ZBV74901]CG74901A.;11',USER='SCAVALI',CD='10-APR-2020;08:36' -->
<A NAME="page_cg74901_1_16"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risks Related to Product Development, Regulatory Approval and Commercialization  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We are heavily dependent on the success of our product candidates lanifibranor and odiparcil. We cannot give
any assurance that any product candidate, or any other compounds in development, will successfully complete clinical trials, receive regulatory approval or be commercialized.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We do not have any drugs that have received regulatory approval and may never be able to develop marketable products. We expect that a substantial portion of
our efforts and expenses for the foreseeable future will be devoted to the clinical development of lanifibranor and odiparcil, and as a result, our business
currently depends heavily on the successful development, regulatory approval and commercialization of these product candidates. The development of lanifibranor and odiparcil has been and will continue
to be a time-consuming and costly process, and may leave us with insufficient resources to advance other programs. We cannot be certain that lanifibranor or odiparcil will receive regulatory approval
or be successfully commercialized, even if we receive regulatory approval. The research, testing, manufacturing, safety, efficacy, labeling, approval, sale, marketing and distribution of our product
candidates are, and will remain, subject to comprehensive regulation by the FDA in the United States, the European Union and EMA in Europe and regulatory authorities in other countries, with
regulations differing from country to country. We will not be permitted to market our drug candidates in the United States or Europe until we receive approval of a New Drug Application, or NDA, from
the FDA or a marketing authorization application, or MAA, from the European Commission (based on the positive opinion of the EMA), respectively. We have not submitted any marketing applications for
any of our product candidates. NDAs and MAAs must include extensive preclinical and clinical data and supporting information to establish the drug candidate's safety and effectiveness for each desired
indication. NDAs and MAAs must also include significant information regarding the chemistry, manufacturing and controls for the drug. Obtaining approval of a NDA or a MAA is a lengthy, expensive and
uncertain process, and we may not be successful in obtaining approval. We have received a fast track designation from the FDA for the development of lanifibranor for the treatment of NASH. While the
fast track designation for lanifibranor in NASH permits close and regular contact between us and the FDA, the FDA and the EMA review processes can take more than one year to complete and approval is
never guaranteed. If we submit a NDA to the FDA, the FDA must decide whether to accept or reject the submission for filing, before even reviewing the scientific basis. Regulators of other
jurisdictions, such as the EMA, have their own procedures for approval of drug candidates. Failure to obtain regulatory approval for lanifibranor or odiparcil in the United States, Europe or other
jurisdictions will prevent us from commercializing and marketing lanifibranor or odiparcil in such jurisdictions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Even
if we were to successfully obtain approval from the FDA, EMA and comparable foreign regulatory authorities for our product candidates, any approval might contain significant limitations related
to use restrictions for specified age groups, warnings, precautions or contraindications, or may be subject to burdensome post-approval study or risk management requirements. Furthermore, even if we
obtain regulatory approval for lanifibranor or odiparcil, we will still need to develop a commercial infrastructure, or otherwise develop relationships with collaborators to commercialize, establish a
commercially viable pricing structure and obtain coverage and adequate reimbursement from third-party payors, including and government healthcare programs. If we, or our collaborators, are unable to
successfully commercialize lanifibranor or odiparcil, we may not be able to generate sufficient revenue to continue our business. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Due to our limited resources and access to capital, we must and have in the past decided to prioritize
development of certain product candidates; these decisions may prove to have been wrong and may adversely affect our revenues.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Because we have limited resources and access to capital to fund our operations, we must decide which product candidates to pursue and the amount of resources
to allocate to each. As such, we are currently primarily focused on the development of lanifibranor and odiparcil, as well as on our collaboration with AbbVie. Our decisions concerning the allocation
of research, collaboration, management and financial resources toward particular compounds, product candidates or therapeutic areas may not lead to the </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=20,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=4160,FOLIO='16',FILE='DISK116:[20ZBV1.20ZBV74901]CG74901A.;11',USER='SCAVALI',CD='10-APR-2020;08:36' -->
<A NAME="page_cg74901_1_17"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>development
of viable commercial products and may divert resources away from better opportunities. For example, we previously committed resources to pursuing the development of lanifibranor for the
treatment of patients with systemic sclerosis, or SSC, through clinical trials. However, following the results of our Phase&nbsp;IIb clinical trial, we ceased development of lanifibranor in this
indication in February 2019. Similarly, our potential decisions to delay, terminate or collaborate with third parties in respect of certain product development programs may also prove not to be
optimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the market potential of our product candidates or misread trends in the pharmaceutical
industry, our business, financial condition and results of operations could be materially adversely affected. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The clinical and commercial success of lanifibranor and odiparcil, as well as our other compounds in
development, will depend on a number of factors, many of which are beyond our control, and we or our collaborators may be unable to complete the development or commercialization of our product
candidates or our other compounds in development.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The clinical and commercial success of lanifibranor and odiparcil, as well as our other compounds in development will depend on a number of factors, including
the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the timely completion of pre-clinical studies and clinical trials by us and our
collaborators; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our and our collaborators' ability to demonstrate the safety and efficacy of our product
candidates to the satisfaction of the relevant regulatory authorities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> whether we or our collaborators are required by the FDA or other regulatory authorities
to conduct additional pre-clinical studies or clinical trials, and the scope and nature of such studies or trials, prior to approval to market our products; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the timely receipt of necessary marketing approvals from the FDA and foreign regulatory
authorities, including pricing and reimbursement determinations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the ability to successfully commercialize our product candidates, if approved, for
marketing and sale by the FDA or foreign regulatory authorities, whether alone or in collaboration with others; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability and the ability of our third party manufacturing partners to manufacture
quantities of our product candidates at quality levels necessary to meet regulatory requirements and at a scale sufficient to meet anticipated demand at a cost that allows us to achieve profitability; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our and our collaborators' success in educating health care providers and patients about
the benefits, risks, administration and use of our product candidates, if approved; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> acceptance of our product candidates, if approved, as safe and effective by patients and
the healthcare community; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the achievement and maintenance of compliance with all regulatory requirements applicable
to our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the maintenance of an acceptable safety profile of our products following any approval; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the availability, perceived advantages, relative cost, relative safety, and relative
efficacy of alternative and competitive treatments; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our and our collaborators' ability to obtain and sustain coverage and an adequate level
of pricing or reimbursement for our products by third party payors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our and our collaborator's ability to enforce successfully the intellectual property
rights for our product candidates and against the products of potential competitors; and </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=21,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=149335,FOLIO='17',FILE='DISK116:[20ZBV1.20ZBV74901]CG74901A.;11',USER='SCAVALI',CD='10-APR-2020;08:36' -->
<A NAME="page_cg74901_1_18"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our and our collaborator's ability to avoid or succeed in third party claims, including
patent infringement claims, and patent interference, reexamination, post grant review, derivation, and opposition proceedings, and other proceedings at the USPTO and foreign patent offices. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Many
of these factors are beyond our control. Accordingly, we cannot assure you that we will ever be able to achieve profitability through the sale of, or royalties from, our product candidates. If we
or our collaborators are not successful in obtaining approval for and commercializing our product candidates, or are delayed in completing those efforts, our business and operations would be adversely
affected. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The regulatory approval processes of the FDA, the EMA and other comparable regulatory authorities are
lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The time required to obtain approval by the FDA, the EMA and other comparable regulatory authorities is unpredictable but typically takes many years following
the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and
amount of clinical data necessary to gain approval may change during the course of a product candidate's clinical development and may vary among jurisdictions. To date, substantially all of our
clinical development has been conducted outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to
certain conditions imposed by the FDA. Furthermore, while these clinical trials are subject to applicable local laws, FDA acceptance of the data will be dependent upon its determination that the
trials also comply with all applicable U.S. laws and regulations. There can be no assurance that the FDA will accept data from trials conducted outside of the United States. If the FDA does not accept
the data from any clinical trials that we or our collaborators conduct outside the United States, it would likely result in the need for additional clinical trials, which would be costly and
time-consuming and delay or permanently halt our ability to develop and market these or other product candidates in the United States. We have not obtained regulatory approval for any product
candidate and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
product candidates could fail to receive regulatory approval for many reasons, including the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the FDA, the EMA or other comparable regulatory authorities may disagree with the design
or implementation of our clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we may be unable to demonstrate to the satisfaction of the FDA, the EMA or other
comparable regulatory authorities that a product candidate is safe and effective for its proposed indication; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the results of clinical trials may not meet the level of statistical significance
required by the FDA, the EMA or other comparable regulatory authorities for approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we may be unable to demonstrate that a product candidate's clinical and other benefits
outweigh its safety risks; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the FDA, the EMA or other comparable regulatory authorities may disagree with our
interpretation of data from pre-clinical studies or clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the data collected from clinical trials of our product candidates may not be sufficient
to support the submission of a new drug application, or NDA, or other submission or to obtain regulatory approval in the United States, Europe or elsewhere; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the FDA, the EMA or other comparable regulatory authorities may fail to approve the
manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies or such processes or facilities may not pass a pre-approval inspection;
and </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>

<!-- ZEQ.=7,SEQ=22,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=941454,FOLIO='18',FILE='DISK116:[20ZBV1.20ZBV74901]CG74901A.;11',USER='SCAVALI',CD='10-APR-2020;08:36' -->
<A NAME="page_cg74901_1_19"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the approval policies or regulations of the FDA, the EMA or other comparable regulatory
authorities may change or differ from one another significantly in a manner rendering our clinical data insufficient for approval. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>This
lengthy approval process as well as the unpredictability of future clinical trial results may result in our or our collaborators' failure to obtain regulatory approval to market lanifibranor,
odiparcil and/or other future product candidates, which would harm our business, results of operations and prospects significantly. In addition, even if
we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may grant approval contingent on the performance of
costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that
product candidate. In certain jurisdictions, regulatory authorities may not approve the price we intend to charge for our products. Any of the foregoing scenarios could materially harm the commercial
prospects for our product candidates. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
have not previously submitted an NDA, an MAA, or any similar drug approval filing to the FDA, the EMA or any comparable regulatory authority for any product candidate, and we cannot be certain that
any of our product candidates will be successful in clinical trials or receive regulatory approval. Further, our product candidates may not receive regulatory approval even if they are successful in
clinical trials. Even if we successfully obtain regulatory approvals to market one or more of our product candidates, our revenues will be dependent, to a significant extent, upon the size of the
markets in the territories for which we gain regulatory approval and have commercial rights or share in revenues from the exercise of such rights. If the markets for patient subsets that we are
targeting are not as significant as we estimate, we may not generate significant revenues from sales of such products, if approved. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if we receive regulatory approval for any of our product candidates, we will be subject to ongoing
obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions
and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product may
be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase&nbsp;IV clinical trials, and surveillance to monitor the safety
and efficacy of the product candidate, and we may be required to include labeling that includes significant use or distribution restrictions or significant safety warnings, including boxed warnings. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
the FDA, EMA or any other comparable regulatory authority approves any of our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage,
advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing
information and reports, registration requirements and continued compliance with current good manufacturing practices, or cGMPs, and good clinical practices, or GCPs, for any clinical trials that we
conduct post-approval. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or
manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> restrictions on the marketing or manufacturing of the product, withdrawal of the product
from the market, or voluntary product recalls; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> fines, untitled or warning letters or holds on clinical trials; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=23,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=853276,FOLIO='19',FILE='DISK116:[20ZBV1.20ZBV74901]CG74901A.;11',USER='SCAVALI',CD='10-APR-2020;08:36' -->
<A NAME="page_cg74901_1_20"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> refusal by the FDA, the EMA or any other comparable regulatory authority to approve
pending applications or supplements to approved applications filed by us, or suspension or revocation of product approvals; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> product seizure or detention, or refusal to permit the import or export of products; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> injunctions or the imposition of civil or criminal penalties. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Moreover,
if any of our product candidates are approved, our product labeling, advertising and promotion will be subject to regulatory requirements and continuing regulatory review. The FDA strictly
regulates the promotional claims that may be made about drug products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product's approved
labeling. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Any
government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or
penalty described
above may inhibit our or our collaborators' ability to commercialize lanifibranor and odiparcil, and harm our business, financial condition and results of operations. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, the policies of the FDA, the EMA and other comparable regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory
approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory
compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Clinical development is a lengthy and expensive process with an uncertain outcome, and results of earlier
studies and trials as well as data from any interim analysis of ongoing clinical trials may not be predictive of future trial results. Clinical failure can occur at any stage of clinical development.  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical
trial process. Although product candidates may demonstrate promising results in early clinical (human) trials and pre-clinical (animal) studies, they may not prove to be effective in subsequent
clinical trials. For example, testing on animals may occur under different conditions than testing in humans and therefore the results of animal studies may not accurately predict human experience.
Likewise, early clinical studies may not be predictive of eventual safety or effectiveness results in larger-scale pivotal clinical trials. The results of pre-clinical studies and previous clinical
trials as well as data from any interim analysis of ongoing clinical trials of our product candidates, as well as studies and trials of other products with similar mechanisms of action to our product
candidates, may not be predictive of the results of ongoing or future clinical trials. There can be significant variability in safety and/or efficacy results between different trials of the same
product candidate due to numerous factors, including changes in trial protocols, differences in composition of the patient populations, adherence to the dosing regimen and other trial protocols and
the rate of dropout among clinical trial participants. For example, the completed Phase&nbsp;I and Phase&nbsp;II clinical trials for lanifibranor and odiparcil were conducted in patients with
type&nbsp;2 diabetes and thrombosis, respectively, which are different indications than we are currently pursuing. The results generated in trials for lanifibranor and odiparcil in these other
indications do not ensure that the current clinical trials for lanifibranor in NASH, for odiparcil in MPS or later clinical trials in these indications, will continue to demonstrate similar safety
and/or efficacy results. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, we did not control the pre-clinical and clinical development of lanifibranor and odiparcil prior to 2012 and we have relied on Abbott Laboratories, or Abbott, and Abbott's collaborators
to have conducted such research and development in accordance with the applicable protocol, legal, regulatory and scientific standards, having accurately reported the results of all clinical trials
conducted prior to our acquisition of lanifibranor and odiparcil, and having correctly collected and interpreted the data from these studies and </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=24,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=573800,FOLIO='20',FILE='DISK116:[20ZBV1.20ZBV74901]CG74901A.;11',USER='SCAVALI',CD='10-APR-2020;08:36' -->
<A NAME="page_cg74901_1_21"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>trials.
To the extent any of these has not occurred, expected development time and costs may be increased which could adversely affect any future revenue from lanifibranor and odiparcil. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Product
candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through pre-clinical studies and earlier clinical trials. In
addition to the safety and efficacy traits of any product candidate, clinical trial failures may result from a multitude of factors including flaws in trial design, dose selection, placebo effect and
patient enrollment criteria. A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles,
notwithstanding promising results in earlier trials, and it is possible that we will as well. Based upon negative or inconclusive results, we or our collaborators may decide, or regulators may require
us, to conduct additional clinical trials or pre-clinical studies. For example, we previously pursued the development of lanifibranor for the treatment of patients with SSC. However, following the
results of our Phase&nbsp;IIb clinical trial, we ceased development of lanifibranor in this indication in February 2019. In addition, data obtained from trials and studies are susceptible to varying
interpretations, and regulators may not interpret our data as favorably as we do, which may delay, limit or prevent regulatory approval. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may encounter substantial delays in our clinical trials or we may fail to demonstrate safety and efficacy
to the satisfaction of applicable regulatory authorities.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We may experience delays in our ongoing clinical trials and we do not know whether planned clinical trials will begin on time, need to be redesigned, enroll
patients on time or be completed on schedule, if at all. We have previously experienced such delays with the initiation of our Phase&nbsp;IIb clinical trial of lanifibranor in patients with NASH and
our Phase Ib/II clinical trial of odiparcil in a pediatric population with MPS VI, as well as delays in our plans to report data related to each of these trials. Clinical trials can be delayed for a
variety of reasons, including delays related to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> obtaining regulatory approval to commence a trial; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> reaching agreement on acceptable terms with prospective contract research organizations,
or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> obtaining Institutional Review Board, or IRB, or ethics committee approval at each site; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> obtaining regulatory concurrence on the design and parameters for the trial; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> obtaining approval for the designs of our clinical development programs for each country
targeted for trial enrollment; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> recruiting suitable patients to participate in a trial, which may be impacted by the
number of competing trials that are enrolling patients; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> having patients complete a trial or return for post-treatment follow-up; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> clinical sites deviating from trial protocol or dropping out of a trial; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> adding new clinical trial sites; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> manufacturing sufficient quantities of product candidate or obtaining sufficient
quantities of comparator drug for use in clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the availability of adequate financing and other resources; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> restrictions due to the recent COVID-19 pandemic. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>We
could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs or ethics committees of the institutions in which such trials are being conducted, by the data and safety
monitoring </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=25,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=748923,FOLIO='21',FILE='DISK116:[20ZBV1.20ZBV74901]CG74901A.;11',USER='SCAVALI',CD='10-APR-2020;08:36' -->
<A NAME="page_cg74901_1_22"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>board
for such trial or by the FDA, the EMA or other comparable regulatory authorities. A suspension or termination may be imposed due to a number of factors, including failure to conduct the clinical
trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, the EMA or other comparable regulatory authorities
resulting in the imposition of a clinical hold, safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative
actions, manufacturing issues or lack of adequate funding to continue the clinical trial. For example, it is possible that safety issues or adverse side effects could be observed in our trials for
lanifibranor in NASH or for odiparcil in MPS, which could result in a delay, suspension or termination of the ongoing trials of lanifibranor or odiparcil. If we experience delays in the completion of,
or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenues from any of these
product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize
our ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition and prospects significantly. In addition, many of the factors that
cause or lead to a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>If
lanifibranor or odiparcil or any other product candidate is found to be unsafe or lack efficacy, we will not be able to obtain regulatory approval for it and our business would be materially
harmed. For example, if the results of our ongoing trials for lanifibranor in NASH and/or odiparcil in MPS do not achieve the primary efficacy
endpoints or demonstrate unexpected safety findings, the prospects for approval of lanifibranor or odiparcil, as applicable, as well as the price of our ordinary shares or ADSs, would be materially
and adversely affected. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Moreover,
principal investigators for our clinical trials may serve as our scientific advisors or consultants from time to time and receive compensation in connection with such services. Under certain
circumstances, we may be required to report some of these relationships to the FDA or other regulatory authorities. The FDA or other regulatory authorities may conclude that a financial relationship
between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the trial results. The FDA or other regulatory authority may therefore question the
integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our
marketing applications by the FDA or other regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could
be made more difficult or rendered impossible by multiple factors outside our control, including difficulties in identifying NASH and MPS VI patients and significant competition for recruiting NASH
patients in clinical trials.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Identifying and qualifying patients to participate in our clinical trials is critical to our success. We may encounter delays in enrolling, or be unable to
enroll, a sufficient number of patients to complete any of our clinical trials, and even once enrolled we may be unable to retain a sufficient number of patients to complete any of our trials. In
particular, as a result of the inherent difficulties in diagnosing NASH and the significant competition for recruiting NASH patients in clinical trials, we have experienced delays in recruiting
patients with NASH for our ongoing trial of lanifibranor in that indication and we or our potential future collaborators may be unable to enroll the patients we need to complete clinical trials on a
timely basis, or at all. We previously announced that the receipt of data from our ongoing NATIVE Phase&nbsp;IIb clinical trial of lanifibranor for the treatment of patients with NASH has been
delayed until the first half of 2020 due to delays in patient enrollment. We have also experienced delays in recruiting patients with MPS VI for our ongoing trial of odiparcil in that indication. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=26,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=1009989,FOLIO='22',FILE='DISK116:[20ZBV1.20ZBV74901]CG74901A.;11',USER='SCAVALI',CD='10-APR-2020;08:36' -->
<A NAME="page_cg74901_1_23"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Additionally,
patient enrollment and retention in clinical trials depends on many factors, including the size of the patient population, the nature of the trial protocol, our ability to recruit
clinical trial investigators with the appropriate competencies and experience, the existing body of safety and efficacy data with respect to the study drug, the number and nature of competing
treatments and ongoing clinical trials of competing drugs for the same disease, the proximity of patients to clinical sites and the eligibility criteria for the trials, our ability to obtain and
maintain patient consents and the risk that patients enrolled in clinical trials will drop out of the trials before completion. Furthermore, any negative results we may report in clinical trials of
our product candidates, or results that we report that are less favorable or perceived to be less favorable than those reported with respect to
competitor product candidates, may make it difficult or impossible to recruit and retain patients in other clinical trials of those product candidates. Delays or failures in planned patient enrollment
or retention may result in increased costs, program delays or both, which could have a harmful effect on our ability to develop lanifibranor or odiparcil, or could render further development
impossible. In addition, we may rely on CROs and clinical trial sites to ensure proper and timely conduct of our future clinical trials and, while we intend to enter into agreements governing their
services, we will be limited in our ability to compel their actual performance. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We are developing certain of our product candidates in combination with other therapies, and safety or supply
issues with combination use products may delay or prevent development and approval of our therapeutic candidates.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are developing certain of our product candidates in combination with one or more approved or investigational therapies. For example, we are evaluating
odiparcil in combination with enzyme replacement therapy, or ERT, for the treatment of MPS. Even if any product candidate we develop were to receive marketing approval or be commercialized for use in
combination with other existing therapies, we would continue to be subject to the risks that the FDA, EMA or similar foreign regulatory authorities could revoke approval of the therapy used in
combination with our product or that safety, efficacy, manufacturing or supply issues could arise with any of those existing therapies. If the therapies we use in combination with our product
candidates are replaced as the standard of care for the indications we choose for any of our product candidates, the EMA, FDA or similar foreign regulatory authorities outside may require us to
conduct additional clinical trials. The occurrence of any of these risks could result in our own products, if approved, being removed from the market or being less successful commercially. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
also may evaluate our product candidates in combination with one or more therapies that have not yet been approved for marketing by the FDA, EMA or similar foreign regulatory authorities. We will
not be able to market and sell any product candidate we develop in combination with an unapproved therapy if that unapproved therapy does not ultimately obtain marketing approval. In addition,
unapproved therapies face the same risks described with respect to our product candidates currently in development, including the potential for serious adverse effects, delay in their clinical trials
and lack of FDA or EMA approval. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
the FDA, EMA or similar foreign regulatory authorities do not approve these other therapies or revoke their approval of, or if safety, efficacy, manufacturing, or supply issues arise with, the
therapies we choose to evaluate in combination with our product candidates, we may be unable to obtain approval of or market any such product candidate. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may not be successful in our efforts to discover and develop additional product candidates.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A key element of our strategy is to build a pipeline of product candidates and progress these product candidates through clinical development for the treatment
of a variety of diseases. Although our research
and development efforts to date have resulted in a pipeline of product candidates directed at various diseases, we may not be able to develop product candidates that are safe and effective. Even if we
are successful in continuing to build our pipeline, the potential product candidates that we identify may not be suitable for clinical development, including as a result of being shown to have harmful
side effects or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance. If we do not continue to successfully
develop and begin to commercialize product candidates, we will face difficulty in obtaining product revenues in future periods, which could result in significant harm to our financial position and
adversely affect the price of our ordinary shares or ADSs. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=27,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=992986,FOLIO='23',FILE='DISK116:[20ZBV1.20ZBV74901]CG74901A.;11',USER='SCAVALI',CD='10-APR-2020;08:36' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_ci74901_1_24"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have received Orphan Drug Designation from the FDA and the European Commission for odiparcil for the
treatment of MPS VI, and we may seek Orphan Drug Designation for our future product candidates, however we may be unable to maintain the benefits associated with Orphan Drug Designation, including the
potential for market exclusivity, which could limit the potential profitability of our drug candidates, if approved.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Regulatory authorities in some jurisdictions, including the United States and the European Union, may designate drugs for relatively small patient populations
as orphan drugs. Under the Orphan Drug Act of 1983, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a
patient population of fewer than 200,000 individuals in the United States, or if it affects more than 200,000, there is no reasonable expectation that sales of the drug in the United States will be
sufficient to offset the costs of developing and making the drug available in the United States. Generally, if a drug with an orphan drug designation subsequently receives the first marketing approval
for an indication for which it receives the designation, then the drug is eligible for a seven-year period of marketing exclusivity in the United States and a ten-year period of marketing exclusivity
in the European Union during which the competent authority may not approve another marketing application for the same drug for the same indication, except in limited circumstances, such as if a
subsequent application demonstrates that its product is
clinically superior. During an orphan drug's exclusivity period, however, competitors may receive approval for drugs with different active moieties for the same indication as the approved orphan drug,
or for drugs with the same active moiety as the approved orphan drug, but for different indications. Orphan drug exclusivity could block the approval of one of our products for seven years if a
competitor obtains approval for a drug with the same active moiety intended for the same indication before we do, unless we are able to demonstrate that grounds for withdrawal of the orphan drug
exclusivity exist or that our product is clinically superior. Further, if a designated orphan drug receives marketing approval for an indication broader than the rare disease or condition for which it
received orphan drug designation, it may not be entitled to exclusivity. A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the
indication for which it received orphan drug designation. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
have received orphan drug designation from the FDA and from the EMA for odiparcil for the treatment of MPS VI. We intend to pursue orphan drug designation for other future drug candidates as
applicable. Even if we obtain orphan drug designation for a drug candidate, we may not obtain orphan exclusivity, and any such exclusivity, if attained, may not effectively protect the drug from the
competition of different drugs for the same condition, which could be approved during the exclusivity period. Additionally, after an orphan drug is approved, the FDA could subsequently approve another
application for the same indication if the FDA concludes that the later drug is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusive marketing rights
in the United States also may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug
to meet the needs of patients with the rare disease or condition. The failure to obtain an orphan drug designation for any drug candidates we may develop, the inability to maintain that designation
for the duration of the applicable period, or the inability to obtain or maintain orphan drug exclusivity could reduce our ability to make sufficient sales of the applicable drug candidate to balance
our expenses incurred to develop it, which would have a negative impact on our operational results and financial condition. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, we may seek rare pediatric disease designation from the FDA for odiparcil for the treatment of MPS. The FDA defines a "rare pediatric disease" as a serious or life-threatening disease in
which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18&nbsp;years and the disease affects fewer than 200,000 individuals in the United States or
affects more than 200,000 in the United States and for which there is no reasonable expectation that the cost of developing and making in the United States a drug for such disease or condition will be
received from sales in the United States of such drug. Under the FDA's Rare Pediatric Disease Priority Review Voucher, or PRV, program, upon the approval of a NDA for the treatment of a rare pediatric
disease, the sponsor of such application would be </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=28,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=396313,FOLIO='24',FILE='DISK116:[20ZBV1.20ZBV74901]CI74901A.;15',USER='JFUSS',CD='10-APR-2020;10:41' -->
<A NAME="page_ci74901_1_25"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>eligible
for a Rare Pediatric Disease PRV that can be used to obtain priority review for a subsequent NDA. The PRV may be sold or transferred an unlimited number of times. Congress has extended the
PRV program until September&nbsp;30, 2020, with potential for PRVs to be granted until 2022. This program has been subject to criticism, including by the FDA, and it is possible that even if we
obtain approval for odiparcil for the treatment of MPS and qualify for such a PRV, the program may no longer be in effect at the time or the value of any such PRV may decrease such that we are may not
be able to realize the benefits of such PRV. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Fast Track Designation from the FDA may not actually lead to a faster development or regulatory review or
approval process.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The FDA has granted Fast Track Designation for lanifibranor for the treatment of patients with NASH. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>If
a product is intended for the treatment of a serious or life-threatening condition and the product demonstrates the potential to address unmet medical needs for this condition, the product sponsor
may apply for Fast Track Designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe our product candidate is eligible for this designation, we cannot
assure you that the FDA would decide to grant it. Even though we have received Fast Track Designation, we may not experience a faster development process, review or approval compared to conventional
FDA procedures. The FDA may withdraw Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development program. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Although the FDA has granted Rare Pediatric Disease Designation for odiparcil for the treatment of MPS VI, an
NDA for odiparcil, if approved, may not meet the eligibility criteria for a priority review voucher.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Rare Pediatric Disease Designation has been granted for odiparcil for MPS VI. In 2012, Congress authorized the FDA to award priority review vouchers to
sponsors of certain rare pediatric disease product applications. This provision is designed to encourage development of new drug and biological products for prevention and treatment of certain rare
pediatric diseases. Specifically, under this program, a sponsor who receives an approval for a drug or biologic for a "rare pediatric disease" may qualify for a voucher that can be redeemed to receive
a priority review of a subsequent marketing application for a different product. The sponsor of a rare pediatric disease drug product receiving a priority review voucher may transfer (including by
sale) the voucher to another sponsor. The voucher may be further transferred any number of times before the voucher is used, as long as the sponsor making the transfer has not yet submitted the
application. The FDA may also revoke any priority review voucher if the rare pediatric disease drug for which the voucher was awarded is not marketed in the U.S. within one year following the date of
approval. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Congress
has only authorized the Rare Pediatric Disease Priority Review Voucher program until September&nbsp;30, 2020. However, if a drug candidate receives Rare Pediatric Disease Designation before
October&nbsp;1, 2020, it is eligible to receive a voucher if it is approved before October&nbsp;1, 2022. However, odiparcil for MPS VI may not be approved by that date, or at all, and, therefore,
we may not be in a position to obtain a priority review voucher prior to expiration of the program, unless Congress further reauthorizes the program. Additionally, designation of a drug for a rare
pediatric disease does not guarantee that an NDA will meet the eligibility criteria for a rare pediatric disease priority review voucher at the time the application is approved. Finally, a Rare
Pediatric Disease Designation does not lead to faster development or regulatory review of the product, or increase the likelihood that it will receive marketing approval. We may or may not realize any
benefit even if we do receive a voucher. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The EMA, FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the
promotion of drugs for off-label uses. If we are found to have improperly promoted off-label use, we may become subject to significant liability.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The EMA, FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription drug products, such as our product
candidates, if approved. In particular, a product may not be promoted for uses that are not approved by the EMA, FDA or such other regulatory agencies as </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=29,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=615485,FOLIO='25',FILE='DISK116:[20ZBV1.20ZBV74901]CI74901A.;15',USER='JFUSS',CD='10-APR-2020;10:41' -->
<A NAME="page_ci74901_1_26"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>reflected
in the product's approved labeling. For example, if we receive marketing approval for lanifibranor for NASH and odiparcil for MPS, physicians, in their professional medical judgment, may
nevertheless prescribe either drug product to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label use, we may become subject to
significant liability under the U.S. federal Food, Drug, and Cosmetic Act, or FDCA, and other statutory authorities, such as laws prohibiting false claims for reimbursement. The federal government has
levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that
companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of our products, if
approved, we could become subject to significant liability, which would harm our reputation and negatively impact our financial condition. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if any of our product candidates are commercialized, they may not be accepted by physicians, healthcare
payors, patients or the medical community in general, and may also become subject to market conditions that could harm our business.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Even if we obtain regulatory approval for one or more of our product candidates, the product may not gain market acceptance or prevalent usage among
physicians, healthcare payors, patients and the medical community, which is critical to commercial success. Our current product candidates both treat diseases which may not frequently be identified by
physicians. For example, because various co-morbidities often confound the diagnosis of NASH and NASH diagnosis currently requires liver biopsy, many physicians may not be trained to identify or treat
NASH specifically, which could lead to limited prescribing of lanifibranor even if the product candidate obtains regulatory approval and is commercialized. Market acceptance of any product candidate
for which we receive approval depends on a number of factors, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the efficacy and safety as demonstrated in clinical trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the timing of market introduction of the product candidate as well as competitive
products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the clinical indications for which the product candidate is approved and physician and
medical community awareness of and familiarity with such indications; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> acceptance by physicians, the medical community and patients of the product candidate as
a safe and effective treatment; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> with respect to lanifibranor, the perception of PPAR agonists as a class of drugs; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the convenience of prescribing and initiating patients on the product candidate; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the potential and perceived advantages of such product candidate over alternative
treatments; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the cost of treatment in relation to alternative treatments, including any similar
generic treatments; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the availability of coverage and adequate reimbursement or pricing by third-party payors; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> relative convenience and ease of administration; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the prevalence and severity of adverse side effects; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the effectiveness of sales and marketing efforts. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>If
our product candidates are approved but fail to achieve an adequate level of acceptance by physicians, healthcare payors, patients and the medical community, we will not be able to generate
significant revenues, and we may not become or remain profitable. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=30,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=603284,FOLIO='26',FILE='DISK116:[20ZBV1.20ZBV74901]CI74901A.;15',USER='JFUSS',CD='10-APR-2020;10:41' -->
<A NAME="page_ci74901_1_27"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We currently have no marketing and sales organization. To the extent any of our product candidates for which
we maintain commercial rights is approved for marketing, if we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product
candidates, we may not be able to effectively market and sell any product candidates, or generate product revenues.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We currently do not have a marketing or sales organization for the marketing, sales and distribution of pharmaceutical products. In order to independently
commercialize any product candidates that receive marketing approval and for which we maintain commercial rights, we would have to build marketing, sales, distribution, managerial and other
non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. Factors that may inhibit our efforts to commercialize our
products on our own include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our inability to recruit, train and retain adequate numbers of effective sales and
marketing personnel; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the inability of sales personnel to obtain access to physicians, educate physicians about
patients for whom our product candidates may be appropriate treatment options and attain adequate numbers of physicians to prescribe any drugs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the inability of reimbursement professionals to negotiate arrangements for formulary
access, reimbursement, and other acceptance by payors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> restricted or closed distribution channels that make it difficult to distribute our
products to segments of the patient population; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the lack of complementary medicines to be offered by sales personnel, which may put us at
a competitive disadvantage relative to companies with more extensive product lines; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> unforeseen costs and expenses associated with creating an independent sales and marketing
organization. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>In
the event of successful development of lanifibranor, odiparcil or any other product candidates in those indications where we can do so in a capital efficient manner, we may elect to build a
targeted specialty sales force which will be expensive and time consuming. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact
the commercialization of these products. With respect to our product candidates for larger indications, we may collaborate with third parties that have direct sales forces and established distribution
systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into collaborations with third parties for
the commercialization of approved products, if any, on acceptable terms or at all, or if any such collaborator does not devote sufficient resources to the commercialization of our product or otherwise
fails in commercialization efforts, we may not be able to successfully commercialize any of our product candidates that receive regulatory approval. If we are not successful in commercializing our
product candidates, either on our own or through collaborations with one or more third parties, our future revenue will be materially and adversely impacted. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if we obtain and maintain approval for our current and future product candidates from the FDA, we may
nevertheless be unable to obtain approval for our product candidates outside of the United States, which would limit our market opportunities and could harm our business.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Approval of a product candidate in the United States by the FDA does not ensure approval of such product candidate by regulatory authorities in other countries
or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. If approved, sales of lanifibranor,
odiparcil and any future product candidate outside of the United States will be subject to foreign regulatory requirements governing clinical trials and marketing approval. Even if the FDA grants
marketing approval for a product candidate, comparable regulatory authorities of foreign countries also must approve the manufacturing and marketing of the product candidate in those countries.
Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and more onerous than, those in the United States, including additional
pre-clinical </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=31,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=776949,FOLIO='27',FILE='DISK116:[20ZBV1.20ZBV74901]CI74901A.;15',USER='JFUSS',CD='10-APR-2020;10:41' -->
<A NAME="page_ci74901_1_28"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>studies
or clinical trials. In many countries outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that country. In some cases, the
price that we intend to charge for any product candidates, if approved, is also subject to approval. Obtaining approval for lanifibranor, odiparcil or any future product candidate in the European
Union from the European Commission following the opinion of the EMA or in other foreign jurisdictions, if we choose to submit a marketing authorization application there, would be a lengthy and
expensive process. Even if a product candidate is approved, the FDA, the EMA or other foreign regulatory authorities, as the case may be, may limit the indications for which the drug may be marketed,
require extensive warnings on the drug labeling or require expensive and time-consuming additional clinical trials or reporting as conditions of approval. Obtaining foreign regulatory approvals and
compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of lanifibranor, odiparcil or any future
product candidate in certain countries. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Further,
clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Also, regulatory approval for lanifibranor, odiparcil or any future product
candidate may be withdrawn. If we fail to comply with the regulatory requirements, our target market will be reduced and our ability to realize the full market potential of lanifibranor, odiparcil or
any future product candidate will be negatively impacted, and our business, prospects, financial condition and results of operations could be harmed. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Coverage and reimbursement decisions by third-party payors may have an adverse effect on pricing and market
acceptance.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>There is significant uncertainty related to the third-party coverage and reimbursement of newly approved drugs. To the extent that we retain commercial rights
following clinical development, we would seek approval to market our product candidates in the United States, the European Union and other selected jurisdictions. Market acceptance and sales of our
product candidates, if approved, in both domestic and international markets will depend significantly on the availability of coverage and adequate reimbursement from third-party payors for any of our
product candidates and may be affected by existing and future healthcare reform measures. Government authorities and other third-party payors, such as private health insurers and health maintenance
organizations, decide which drugs they will cover and establish payment levels. We cannot be certain that coverage and adequate reimbursement will be available for any of our product candidates, if
approved. We cannot guarantee that we will be able to obtain price levels and reimbursement rates as high as those granted to other products that may be approved for the treatment of NASH or the
various form of MPS, particularly because these products may have a different therapeutic approach from those developed by us. Also, we cannot be certain that reimbursement policies will not reduce
the demand for any of our product candidates, if approved. If reimbursement is not available or is available on a limited basis for any of our product candidates, if approved, we or our collaborators
may not be able to successfully commercialize any such product candidate. Reimbursement by a third-party payor may depend upon a number of factors, including, without limitation, the third-party
payor's determination that use of a product is:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a covered benefit under its health plan; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> safe, effective and medically necessary; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> appropriate for the specific patient; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> cost-effective; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> neither experimental nor investigational. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Obtaining
coverage and reimbursement approval for a product from a government or other third-party payor is a time consuming and costly process that could require us to provide supporting scientific,
clinical and cost-effectiveness data for the use of our products to the payor. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement at a
satisfactory level. If </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=32,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=373544,FOLIO='28',FILE='DISK116:[20ZBV1.20ZBV74901]CI74901A.;15',USER='JFUSS',CD='10-APR-2020;10:41' -->
<A NAME="page_ci74901_1_29"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>reimbursement
of our future products, if any, is unavailable or limited in scope or amount, such as may result where alternative or generic treatments are available, we may be unable to achieve or
sustain profitability. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or MMA, changed the way Medicare covers and pays for pharmaceutical products. The legislation
established Medicare
Part&nbsp;D, which expanded Medicare coverage for outpatient prescription drug purchases by the elderly but provided authority for limiting the number of drugs that will be covered in any
therapeutic class. The MMA also introduced a new reimbursement methodology based on average sales prices for physician-administered drugs. Any negotiated prices for any of our product candidates, if
approved, covered by a Part&nbsp;D prescription drug plan will likely be lower than the prices we might otherwise obtain outside of the Medicare Part&nbsp;D prescription drug plan. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Moreover,
no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. While Medicare Part&nbsp;D
applies only to drug benefits for Medicare beneficiaries, private third-party payors often follow Medicare coverage policy and payment limitations in setting their own payment rates, but also have
their own methods and approval process apart from Medicare determinations. Any reduction in payment under Medicare Part&nbsp;D may result in a similar reduction in payments from non-governmental
payors. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
certain countries, particularly in the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental
authorities can take considerable time after the receipt of marketing approval for a product candidate. To obtain reimbursement or pricing approval in some countries, we may be required to conduct
additional clinical trials that compare the cost-effectiveness of our product candidates to other available therapies. If reimbursement of any of our product candidates, if approved, is unavailable or
limited in scope or amount in a particular country, or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability of our products in such country. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for
national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of healthcare and the pricing and reimbursement of
products in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant
health service providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product
candidates, restrict or regulate post-approval activities and affect our or our collaborators' ability to commercialize any products for which we obtain marketing approval. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Changes in healthcare law and implementing regulations, as well as changes in healthcare policy, may impact
our business in ways that we cannot currently predict, and may have a significant adverse effect on our business and results of operations.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes
regarding the healthcare system that could prevent or delay marketing approval of drug candidates, restrict or regulate post-approval activities, and affect our ability to profitably sell any drug
candidates for which we obtain marketing approval. Among policy makers and payors in the United States and elsewhere, including in the European Union, there is significant interest in promoting
changes in healthcare systems with the stated goals of containing healthcare costs, improving quality
and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=33,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=334637,FOLIO='29',FILE='DISK116:[20ZBV1.20ZBV74901]CI74901A.;15',USER='JFUSS',CD='10-APR-2020;10:41' -->
<A NAME="page_ci74901_1_30"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the Affordable Care Act, substantially changed the way
healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry. The Affordable Care Act, among other things: (1)&nbsp;increased the
minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and expanded rebate liability from fee-for-service Medicaid utilization to include the utilization of Medicaid
managed care organizations as well; (2)&nbsp;established a branded prescription drug fee that pharmaceutical manufacturers of branded prescription drugs must pay to the federal government;
(3)&nbsp;expanded the list of covered entities eligible to participate in the 340B drug pricing program by adding new entities to the program; (4)&nbsp;established a new Medicare Part&nbsp;D
coverage gap discount program, in which manufacturers must agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage
gap period, as a condition for the manufacturer's outpatient drugs to be covered under Medicare Part&nbsp;D; (5)&nbsp;extended manufacturers' Medicaid rebate liability to covered drugs dispensed
to individuals who are enrolled in Medicaid managed care organizations; (6)&nbsp;expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid
coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing
manufacturers' Medicaid rebate liability; (7)&nbsp;created a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and
biologics, including our product candidates, that are inhaled, infused, instilled, implanted or injected; (8)&nbsp;established a new Patient-Centered Outcomes Research Institute to oversee, identify
priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; (9)&nbsp;established a Center for Medicare and Medicaid Innovation at the Centers for
Medicare&nbsp;&amp; Medicaid Services (CMS) to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending; and
(10)&nbsp;created a licensure framework for follow-on biologic products. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>There
remain judicial and Congressional challenges to certain aspects of the Affordable Care Act, as well as recent efforts by the Trump administration to repeal or replace certain aspects of the
Affordable Care Act. Since January 2017, President Trump has signed Executive Orders and other directives designed to delay the implementation of certain provisions of the Affordable Care Act or
otherwise circumvent some of the requirements for health insurance mandated by the Affordable Care Act. Additionally, CMS issued a final rule in 2018 that gave states greater flexibility in setting
benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the Affordable Care Act for plans sold
through such marketplaces. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the Affordable Care Act. While Congress has not passed comprehensive
repeal legislation, several bills affecting the implementation of certain taxes under the Affordable Care Act have been signed into law. The Tax Cuts and Jobs Act includes a provision repealing,
effective January&nbsp;1, 2019, the tax-based shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part
of a year that is commonly referred to as the "individual mandate." Further, the 2020 federal spending package permanently eliminated, effective January&nbsp;1, 2020, the Affordable Care
Act-mandated "Cadillac" tax on high-cost employer-sponsored health coverage and medical device tax and, effective January&nbsp;1, 2021, also eliminates the health insurer tax. Moreover, the
Bipartisan Budget Act of 2018, or
the BBA, among other things, amended the Affordable Care Act, effective January&nbsp;1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the "donut hole." In
December 2018, CMS published a new final rule permitting further collections and payments to and from certain Affordable Care Act qualified health plans and health insurance issuers under the
Affordable Care Act risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. Congress may consider
additional legislation to repeal, or repeal and replace, other elements of the Affordable Care Act. On December&nbsp;14, 2018, a Texas U.S. District Court Judge ruled that the Affordable Care Act is
unconstitutional in its entirety because the "individual mandate" </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=34,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=110037,FOLIO='30',FILE='DISK116:[20ZBV1.20ZBV74901]CI74901A.;15',USER='JFUSS',CD='10-APR-2020;10:41' -->
<A NAME="page_ci74901_1_31"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>was
repealed by Congress as part of the Tax Act. Additionally, on December&nbsp;18, 2019, the U.S. Court of Appeals for the 5th&nbsp;Circuit upheld the District Court ruling that the individual
mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the Affortdable Care Act are invalid as well. On March&nbsp;2, 2020,
the United States Supreme Court granted the petitions for writs of certiorari to review this case, and has allotted one hour for oral arguments, which are expected to occur in the fall. We continue to
evaluate the Affordable Care Act and its possible repeal and replacement, as the extent to which any such changes may impact our business or financial condition remains uncertain. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Other
legislative changes have been proposed and adopted since the Affordable Care Act was enacted. These changes include aggregate reductions to Medicare payments to providers of up to 2% per fiscal
year pursuant to the Budget Control Act of 2011 and subsequent laws, which began in 2013 and, due to subsequent legislative amendments to the statute, including the BBA, will remain in effect through
2029 unless additional Congressional action is taken. New laws may result in additional reductions in Medicare and other healthcare funding, which may adversely affect customer demand and
affordability for our products and, accordingly, the results of our financial operations. Additional changes that may affect our business include the expansion of new programs such as Medicare payment
for performance initiatives for physicians under the Medicare Access and CHIP Reauthorization Act of 2015, or MACRA, which ended the use of the statutory formula and established a quality payment
program, also referred to as the Quality Payment Program. The Quality Payment Program has two tracks, one known as the merit based incentive payment system for providers in the fee-for service
Medicare program, and the advanced alternative payment model for providers in specific care models, such as accountable care organizations. In November 2019, CMS issued a final rule finalizing the
changes to the Quality Payment Program. At this time, it is unclear how the introduction of the Medicare quality payment program will impact overall physician reimbursement. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Also,
there has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries
and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient
programs, and reform government program reimbursement methodologies for drug products. At the federal level, the Trump administration's budget proposal for fiscal year 2021 includes a
$135&nbsp;billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to
lower-cost generic and biosimilar drugs. On March&nbsp;10, 2020, the Trump administration sent "principles" for drug pricing to Congress, calling for legislation that would, among other things, cap
Medicare Part&nbsp;D beneficiary out-of-pocket
pharmacy expenses, provide an option to cap Medicare Part&nbsp;D beneficiary monthly out-of-pocket expenses, and place limits on pharmaceutical price increases. Additionally, the Trump
administration previously released a "Blueprint" to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the
negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of drug products paid by consumers. The
U.S. Department of Health and Human Services has solicited feedback on some of these measures and has implemented others under its existing authority. For example, in May 2019, CMS issued a final rule
to allow Medicare Advantage Plans the option of using step therapy for Part&nbsp;B drugs beginning on January&nbsp;1, 2020. The final rule codified a CMS policy change that was effective
January&nbsp;1, 2019. Although a number of these and other proposals may require additional authorization to become effective, Congress and the Trump administration have each indicated that it will
continue to seek new legislative and/or administrative measures to control drug costs. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to
control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and
transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. For example, since 2016, Vermont requires certain manufacturers identified </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=35,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=332057,FOLIO='31',FILE='DISK116:[20ZBV1.20ZBV74901]CI74901A.;15',USER='JFUSS',CD='10-APR-2020;10:41' -->
<A NAME="page_ci74901_1_32"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>by
the state to justify their price increases. Additionally, on May&nbsp;30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, or the Right to
Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase&nbsp;I
clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA
permission under the FDA expanded access program. There is no obligation for a drug manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
expect that these and other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure
on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private
payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our drugs, once marketing
approval is obtained. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
the European Union, coverage and reimbursement status of any drug candidates for which we obtain regulatory approval are provided for by the national laws of EU Member States. The requirements may
differ across the EU Member States. Also at the national level, actions have been taken to enact transparency laws regarding payments between pharmaceutical companies and health care professionals. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We face significant competition for our drug discovery and development efforts, and if we do not compete
effectively, our commercial opportunities will be reduced or eliminated.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. Our drug discovery and
development efforts may target diseases and conditions that are already subject to existing therapies or that are being developed by our competitors, many of which have substantially greater
resources, larger research and development staffs and facilities, more experience in completing pre-clinical testing and clinical trials, and formulation, marketing and manufacturing capabilities than
we do. As a result of these resources, our competitors may develop drug products that render our products obsolete or noncompetitive by developing more effective drugs or by developing their products
more efficiently. Our ability to develop competitive products would be limited if our competitors succeeded in obtaining regulatory approvals for drug candidates more rapidly than we were able to or
in obtaining patent protection or other intellectual property rights that limited our drug development efforts. Any drug products resulting from our research and development efforts, or from our joint
efforts with collaborators or licensees, might not be able to compete successfully with our competitors' existing and future products, or obtain regulatory approval in the United States, European
Union or elsewhere. Further, we may be subject to additional competition from alternative forms of treatment, including generic or over-the-counter drugs. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Allergan&nbsp;plc,
Galmed Pharmaceuticals&nbsp;Ltd., Genfit S.A and Madrigal Pharmceuticals are investigating product candidates in Phase&nbsp;III clinical trials for the treatment of NASH,
while other companies have product candidates for the treatment of NASH that are in earlier stages of pre-clinical or clinical development. Intercept Pharmaceuticals,&nbsp;Inc. has announced that it
has filed for regulatory approval with the FDA and EMA for its NASH product candidate. Other companies, including Gilead Sciences,&nbsp;Inc. have product candidates for the treatment of NASH that
are in earlier stages of pre-clinical or clinical development. ERT is the standard of care for the treatment of MPS with current therapies being marketed by BioMarin Pharmaceuticals,&nbsp;Inc.,
Sanofi Genzyme, Shire&nbsp;Plc and Ultragenyx Pharmaceuticals,&nbsp;Inc. Additional ERTs, as well as gene therapy approaches to treating MPS, are in various stages of pre-clinical and clinical
development conducted by different companies, including Abeona Therapeutics&nbsp;Inc., ArmaGen,&nbsp;Inc., Eloxx Pharmaceuticals,&nbsp;Inc., Sanofi Genzyme, Esteve Pharmaceuticals,&nbsp;S.A.,
Lysogene&nbsp;S.A., Orchard Therapeutics&nbsp;plc, REGENXBIO&nbsp;Inc., Sangamo Therapeutics,&nbsp;Inc. and Takeda Pharmaceutical Company Limited. In the MPS&nbsp;VI subtype, the MeuSix
consortium is developing a gene therapy approach </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=36,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=584703,FOLIO='32',FILE='DISK116:[20ZBV1.20ZBV74901]CI74901A.;15',USER='JFUSS',CD='10-APR-2020;10:41' -->
<A NAME="page_ci74901_1_33"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>and
is conducting a multicenter Phase&nbsp;I/II clinical trial to investigate the safety and efficacy of its AAV-mediated gene therapy. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Mergers
and acquisitions in the pharmaceutical and biotechnology industries could result in even more resources being concentrated among a small number of our competitors. Competition may reduce the
number and types of patients available to us to participate in clinical trials, particularly with respect to NASH, because some patients
who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our product candidates may cause undesirable side effects or have other properties that could delay or
prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Results of our trials could reveal a high and unacceptable severity and prevalence of certain side effects. In such an event, our trials could be suspended or
terminated and the FDA, the EMA or comparable regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. The
drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm
our business, financial condition and prospects significantly. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>If
one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative
consequences could result, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> regulatory authorities may withdraw approvals of such product; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> regulatory authorities may require additional warnings on the label; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we may be required to create a medication guide outlining the risks of such side effects
for distribution to patients; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we could be sued and held liable for harm caused to patients; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our reputation may suffer. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Any
of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations
and prospects. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Clinical trials of our product candidates may not uncover all possible adverse effects that patients may
experience.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Clinical trials are conducted in representative samples of the potential patient population which may have significant variability. Clinical trials are by
design based on a limited number of subjects and of limited duration for exposure to the product used to determine whether, on a potentially statistically significant basis, the planned safety and
efficacy of any product candidate can be achieved. As with the results of any statistical sampling, we cannot be sure that all side effects of our product candidates may be uncovered, and it may be
the case that only with a significantly larger number of patients exposed to the product candidate for a longer duration, may a more complete safety profile be identified. Further, even larger
clinical trials may not identify rare serious adverse effects or the duration of such studies may not be sufficient to identify when those events may occur. There have been other products that have
been approved by the regulatory authorities but for which safety concerns have been uncovered following approval. Such safety concerns have led to labelling changes or withdrawal of products from the
market, and any of our product candidates may be subject to similar risks. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Although
to date we have not seen evidence of significant safety concerns with our product candidates currently in clinical trials, patients treated with our products, if approved, may experience
adverse reactions </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=37,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=323477,FOLIO='33',FILE='DISK116:[20ZBV1.20ZBV74901]CI74901A.;15',USER='JFUSS',CD='10-APR-2020;10:41' -->
<A NAME="page_ci74901_1_34"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>and
it is possible that the FDA or other regulatory authorities may ask for additional safety data as a condition of, or in connection with, our efforts to obtain approval of our product candidates.
If safety problems occur or are identified after our product candidates reach the market, we may, or regulatory authorities may require us to amend the labeling of our products, recall our products or
even withdraw approval for our products. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may not be able to conduct, or contract others to conduct, animal testing in the future, which could harm
our research and development activities.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Certain laws and regulations relating to drug development require us to test our product candidates on animals before initiating clinical trials involving
humans. Animal testing activities have been the subject of controversy and adverse publicity. Animal rights groups and other organizations and individuals have attempted to stop animal testing
activities by pressing for legislation and regulation in these areas and by disrupting these activities through protests and other means. To the extent the activities of these groups are successful,
our research and development activities may be interrupted or delayed. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The lack of a reliable non-invasive method for the diagnosis of NASH is likely to present a major challenge
to lanifibranor's market penetration, if ever commercialized.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Liver biopsy is the standard approach for the diagnosis of inflammation and fibrosis associated with NASH. However, the procedure-related morbidity and, in
rare cases, mortality, sample errors, costs, patient discomfort and thus lack of patient interest in undergoing the procedure limit its use. As such, only patients with a high risk of NASH, which
includes patients with metabolic syndrome and an indication of Non-Alcoholic Fatty Liver Disease, or NAFLD, are generally sent for liver biopsy. Because NASH tends to be asymptomatic until the disease
progresses, many individuals with NASH remain undiagnosed until the disease has reached its late stages, if at all. The lack of a reliable non-invasive method for the diagnosis of NASH is likely to
present a major challenge to lanifibranor's market penetration, as many practitioners and patients may not be aware that a patient suffers from NASH and requires treatment. As such, use of
lanifibranor might not be as wide-spread as our actual target market and this may limit the commercial potential of lanifibranor. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A
further challenge to lanifibranor's market penetration is that currently a liver biopsy is the standard approach for measuring improvement in NASH patients. Because it would be impractical to
subject all patients that take lanifibranor, when and if it approved, to regular and repeated liver biopsies, it will be difficult to demonstrate lanifibranor's effectiveness to practitioners and
patients unless and until a reliable non-invasive method for the diagnosis and monitoring of NASH becomes available, as to which there can be no assurance. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>While
other companies in the industry are currently working on advancing non-invasive diagnostic approaches, none of these has been clinically validated, and the timetable for commercial validation,
if at all, is uncertain. Moreover, such diagnostics may also be subject to regulation by FDA or other regulatory authorities as medical devices and may require premarket clearance or approval. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our business could be adversely affected by the effects of health epidemics, including the recent COVID-19
pandemic, in regions where we or third parties on which we rely have significant concentrations of clinical trial sites, manufacturing facilities or other business operations. The COVID-19 pandemic
could materially affect our operations, including at our headquarters in France and at our clinical trial sites, as well as the business or operations of our manufacturers, CROs or other third parties
with whom we conduct business.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our business could be adversely affected by health epidemics in regions where we have concentrations of clinical trial sites or other business operations, and
could cause significant disruption in the operations of third-party manufacturers and CROs upon whom we rely. For example, in December 2019, a novel strain of coronavirus, SARS-CoV-2, causing the
Coronavirus Disease 2019, or COVID-19, was reported to have surfaced in Wuhan, China. Since then, COVID-19 has spread to multiple countries, including France and </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>34</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=38,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=907652,FOLIO='34',FILE='DISK116:[20ZBV1.20ZBV74901]CI74901A.;15',USER='JFUSS',CD='10-APR-2020;10:41' -->
<A NAME="page_ci74901_1_35"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>several
other European countries. In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic, and the U.S. government imposed travel restrictions on travel between the
United States, Europe and certain other countries. We have implemented work-from-home policies for all employees. The effects of the executive order and our work-from-home policies may negatively
impact productivity, disrupt our business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other
limitations on our ability to conduct our business in the ordinary course. These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, operating
results and financial condition. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Quarantines,
shelter-in-place and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related to COVID-19
or other infectious diseases could impact our personnel and the personnel at third-party manufacturing facilities in the United States, the European Union and other countries. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
addition, our clinical trials may be affected by the COVID-19 pandemic. Clinical site initiation and patient enrollment may be delayed due to prioritization of hospital resources toward the
COVID-19 pandemic. For example, due to COVID-19, the recruitment and screening of new patients has been suspended at the University of Florida, where our Phase&nbsp;II NAFLD study is currently
ongoing. Some patients may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, our ability to recruit and retain
patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 and adversely impact our clinical trial operations. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
may also experience delays in receiving approval from local regulatory authorities to initiate our planned clinical trials and interruption in global shipping that may affect the transport of
clinical trial materials.
Furthermore, changes in local regulations as part of a response to the COVID-19 outbreak may require us to change the ways in which our clinical trials are conducted, which may result in unexpected
costs, or discontinue the clinical trials altogether especially in case of delays due to necessary interactions with local regulators, ethics committees and other important agencies and contractors
triggered by limitations in employee resources or forced furlough of government employees. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult
to assess or predict, a widespread pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our
liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
global pandemic of COVID-19 continues to rapidly evolve. The ultimate impact of the COVID-19 pandemic or a similar health epidemic is highly uncertain and subject to change. We do not yet know the
full extent of potential delays or impacts on our business, our clinical trials, healthcare systems or the global economy as a whole. However, these effects could have a material impact on our
operations, and we will continue to monitor the COVID-19 situation closely. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risks Related to Our Reliance on Third Parties  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may not be successful in establishing development and commercialization collaborations, which could
adversely affect, and potentially prohibit, our ability to develop our product candidates.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Developing pharmaceutical products, conducting clinical trials, obtaining regulatory approval, establishing manufacturing capabilities and marketing approved
products are expensive. Accordingly, we have sought and may in the future seek to enter into collaborations with companies that have more resources and experience. If we are unable to obtain a
collaborator for our product candidates, we may be unable to advance the development of our product candidates through late-stage clinical development and seek approval in any market. In situations
where we enter into a development and commercial collaboration </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>35</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=39,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=57372,FOLIO='35',FILE='DISK116:[20ZBV1.20ZBV74901]CI74901A.;15',USER='JFUSS',CD='10-APR-2020;10:41' -->
<A NAME="page_ci74901_1_36"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>arrangement
for a product candidate, we may also seek to establish additional collaborations for development and commercialization in territories outside of those addressed by the first collaboration
arrangement for such product candidate. In addition, we may have particular difficulties in finding collaborators for lanifibranor in light of the discontinuation of development of certain PPAR
agonists as a result of safety observations that may, or may be perceived to be, linked to the PPAR agonist class of drugs, which may result in delays in the commencement of any Phase&nbsp;III
clinical trial of lanifibranor for the treatment of NASH. If we are unable to enter into any development and commercial collaborations and/or sales and marketing arrangements on acceptable terms, or
at all, we may be unable to successfully develop and seek regulatory approval for our product candidates and/or effectively market and sell approved products, if any. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may not be successful in maintaining development and commercialization collaborations, and any
collaborator may not devote sufficient resources to the development or commercialization of our product candidates or may otherwise fail in development or commercialization efforts, which could
adversely affect our ability to develop certain of our product candidates and our financial condition and operating results.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The collaboration arrangements that we have established, and any collaboration arrangements that we may enter into in the future, may not ultimately be
successful, which could have a negative impact on our business, results of operations, financial condition and growth prospects. If we collaborate with a third party for development and
commercialization of a product candidate, we can expect to relinquish some or all of the control over the future success of that product candidate to the third party. For example, in our collaboration
with AbbVie, AbbVie is solely responsible for clinical development of any product candidates developed through the collaboration and is the owner of all intellectual property rights resulting from the
collaboration. It is possible that a collaborator may not devote sufficient resources to the development or commercialization of our product candidate or may otherwise fail in development or
commercialization efforts, in which event the development and commercialization of such product candidate could be delayed or terminated and our business could be substantially harmed. For example, we
previously entered into a collaboration with Boehringer Ingelheim, or BI, for the development of new treatments for idiopathic pulmonary fibrosis, which ended in November 2019 following BI's decision
to prioritize other products in its portfolio. In addition, the terms of any collaboration or other arrangement that we establish may not be favorable to us or may not be perceived as favorable, which
may negatively impact the trading price of our ordinary shares or ADSs. In some cases, we may be responsible for continuing development of a product candidate or research program under a collaboration
and the payment we receive from our collaborator may be insufficient to cover the cost of this development. Moreover, collaborations and sales and marketing arrangements are complex and time consuming
to negotiate, document and implement and they may require substantial resources to maintain. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
are subject to a number of additional risks associated with our dependence on collaborations with third parties, the occurrence of which could cause our collaboration arrangements to fail.
Conflicts may arise between us and collaborators, such as conflicts concerning the interpretation of clinical data, the achievement of milestones, the interpretation of financial provisions or the
ownership of intellectual property developed during the collaboration. If any such conflicts arise, a collaborator could act in its own self-interest, which may be adverse to our best interests. Any
such disagreement between us and a collaborator could result in one or more of the
following, each of which could delay or prevent the development or commercialization of our product candidates, and in turn prevent us from generating sufficient revenues to achieve or maintain
profitability:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> reductions in the payment of royalties or other payments we believe are due pursuant to
the applicable collaboration arrangement; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> actions taken by a collaborator inside or outside our collaboration which could
negatively impact our rights or benefits under our collaboration including termination of the collaboration for convenience by the collaborator; or </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>36</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>

<!-- ZEQ.=13,SEQ=40,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=757627,FOLIO='36',FILE='DISK116:[20ZBV1.20ZBV74901]CI74901A.;15',USER='JFUSS',CD='10-APR-2020;10:41' -->
<A NAME="page_ci74901_1_37"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> unwillingness on the part of a collaborator to keep us informed regarding the progress of
its development and commercialization activities or to permit public disclosure of the results of those activities. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>If
our collaborations on research and development candidates do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with
us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, the development of our
product candidates could be delayed and we may need additional resources to develop product candidates. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We rely on third parties to conduct our pre-clinical studies and clinical trials. If these third parties do
not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be
substantially harmed.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have relied upon and plan to continue to rely upon CROs to monitor and manage data for our pre-clinical and clinical programs. We rely on these parties for
execution of our pre-clinical studies and clinical trials, and we control only certain aspects of their activities. We and our CROs also rely upon clinical sites and investigators for the performance
of our clinical trials in accordance with the applicable protocols and applicable legal, regulatory and scientific standards. Nevertheless, we are responsible for ensuring that each of our studies and
trials is conducted in accordance with the applicable protocol and applicable legal and regulatory requirements and scientific standards, and our reliance on CROs as well as clinical sites and
investigators does not relieve us of our regulatory responsibilities. We, our CROs, as well as the clinical sites and investigators are required to comply with current GCPs, which are regulations and
guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area, or EEA, and comparable regulatory authorities for all of our products in clinical
development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, investigators and clinical sites. If we, any of our CROs or any of the clinical sites or
investigators fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, EMA or comparable regulatory authorities may require us to
perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that
any of our clinical trials comply with GCP regulations. We also cannot assure you that our CROs, as well as the clinical sites and investigators, will perform our clinical trials in accordance with
the applicable protocols as well as applicable legal and regulatory requirements and scientific standards, or report the results obtained in a timely and accurate manner. Furthermore, the operations
of our CROs may be constrained or disrupted by the recent COVID-19 pandemic. In addition to GCPs, our clinical trials must be conducted with product produced under cGMP regulations. While we have
agreements governing activities of our CROs, we have limited influence over the actual performance of our CROs as well as the performance of clinical sites and investigators. In addition, significant
portions of the clinical trials for our product candidates will be conducted outside of France, which will make it more difficult for us to monitor CROs as well as clinical sites and investigators and
perform visits of our clinical sites, and will force us to rely heavily on CROs to ensure the proper and timely conduct of our clinical trials in accordance with the applicable protocols and
compliance with applicable regulations, including GCPs. Failure to comply with applicable protocols and regulations in the conduct of the clinical trials for our product candidates may require us to
repeat clinical trials, which would delay the regulatory approval process. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Some
of our CROs have an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants
such termination, if we make a general assignment for the benefit of our creditors or if we are liquidated. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
any of our relationships with these CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. In addition, our CROs are not
our </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>37</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=14,SEQ=41,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=427927,FOLIO='37',FILE='DISK116:[20ZBV1.20ZBV74901]CI74901A.;15',USER='JFUSS',CD='10-APR-2020;10:41' -->
<A NAME="page_ci74901_1_38"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>employees,
and except for remedies available to us under our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to our pre-clinical and clinical
programs. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the clinical data they
obtain is compromised due to the failure (including by clinical sites or investigators) to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be
extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial
prospects for our product candidates would be harmed, our costs could increase substantially and our ability to generate revenues could be delayed significantly. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Switching
or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result,
delays may occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that
we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We rely completely on third parties to manufacture our pre-clinical and clinical drug supplies and we intend
to rely on third parties to produce commercial supplies of any approved product candidate. Manufacturers are subject to significant regulation with respect to manufacturing our products. The
manufacturing facilities on which we rely may not continue to meet regulatory requirements and may have limited capacity.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If, for any reason, we were to experience an unexpected loss of supply of our product candidates or placebo or comparator drug used in certain of our clinical
trials, whether as a result of manufacturing, supply or storage issues or otherwise, we could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any
pending or ongoing clinical trials. We do not currently have, nor do we plan to acquire, the infrastructure or capability internally to manufacture our pre-clinical and clinical drug supplies and we
lack the resources and the capability to manufacture any of our product candidates on a clinical or commercial scale. The facilities used by our contract manufacturers or other third-party
manufacturers to manufacture our product candidates are subject to the FDA's, EMA's and other comparable regulatory authorities' pre-approval inspections that will be conducted after we submit our NDA
to the FDA or the required approval documents to any other relevant regulatory authority. We do not control the implementation of the manufacturing process of, and are completely dependent on, our
contract manufacturers or other third-party manufacturers for compliance with the cGMPs for manufacture of both active drug substances and finished drug products. If our contract manufacturers or
other third-party manufacturers cannot successfully manufacture material that conforms to applicable specifications and the strict regulatory requirements of the FDA, EMA or others, we will not be
able to secure and/or maintain regulatory approvals for our products manufactured at these facilities. In addition, we have no control over the ability of our contract manufacturers or other
third-party manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA, EMA or other comparable regulatory authority finds deficiencies at these
facilities for the manufacture of our product candidates or if it withdraws any approval because of deficiencies at these facilities in the future, we may need to
find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Further, our
agreements with our contract and other third-party manufacturers generally limit these parties liability to us and we therefore may not be able to obtain reimbursement for losses or damages that we
incur as a result of actions by such parties. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
rely on our manufacturers to purchase from third-party suppliers the materials necessary to produce our product candidates for our clinical trials. There are a limited number of suppliers for raw
materials that we use to manufacture our drugs and there may be a need to assess alternate suppliers to prevent a possible disruption of the manufacture of the materials necessary to produce our
product candidates for our clinical trials, and if approved, for commercial sale. We do not have any control over the process or timing of the acquisition of these raw materials by our manufacturers.
Moreover, we currently do not have any agreements </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>38</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=15,SEQ=42,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=614043,FOLIO='38',FILE='DISK116:[20ZBV1.20ZBV74901]CI74901A.;15',USER='JFUSS',CD='10-APR-2020;10:41' -->
<A NAME="page_ci74901_1_39"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>for
the commercial production of these raw materials. Although we generally do not begin a clinical trial unless we believe we have access to a sufficient supply of a product candidate to complete the
clinical trial, any significant delay in the supply of a product candidate, or the raw material components thereof, for an ongoing clinical trial due to the need to replace a contract manufacturer or
other third-party manufacturer could considerably delay completion of our clinical trials, product testing and potential regulatory approval of our product candidates. If our manufacturers or we are
unable to purchase these raw materials after regulatory approval has been obtained for our product candidates, the commercial launch of our product candidates would be delayed or there would be a
shortage in supply, which would impair our ability to generate revenues from the sale of our product candidates. Additionally, if we receive regulatory approval for our product candidates, we may
experience unforeseen difficulties or challenges in the manufacture of our product candidates on a commercial scale compared to the manufacture for clinical purposes. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
expect to continue to depend on contract manufacturers or other third-party manufacturers for the foreseeable future. We currently obtain our supplies of finished drug product through individual
purchase orders. We have not entered into long-term agreements with our current contract manufacturers or with any alternate fill/finish suppliers. Although we intend to do so prior to any commercial
launch in order to ensure that we maintain adequate supplies of finished drug product, we may be unable to enter into such an agreement or do so on commercially reasonable terms, which could have a
material adverse impact upon our business. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We are dependent on single-source suppliers for some of the components and materials used in, and the
processes required to develop, our development candidates and investigational medicines.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We currently depend on single-source suppliers for some of the components and materials used in lanifibranor and odiparcil. We cannot ensure that these
suppliers will remain in business, have sufficient
capacity or supply to meet our needs, or that they will not be purchased by one of our competitors or another company that is not interested in continuing to work with us. Our use of single-source
suppliers of raw materials, components and finished goods exposes us to several risks, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> delays to the development timelines for our product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> interruption of supply resulting from modifications to or discontinuation of a supplier's
operations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> delays in product shipments resulting from uncorrected defects, reliability issues, or a
supplier's variation in a component; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a lack of long-term supply arrangements for key components with our suppliers; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> inability to obtain adequate supply in a timely manner, or to obtain adequate supply on
commercially reasonable terms; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> difficulty and cost associated with locating and qualifying alternative suppliers for our
components in a timely manner; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> production delays related to the evaluation and testing of components from alternative
suppliers, and corresponding regulatory qualifications; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> delay in delivery due to our suppliers' prioritizing other customer orders over ours; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> damage to our reputation caused by defective components produced by our suppliers; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> potential price increases; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> delays due to the recent COVID-19 pandemic. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>There
are, in general, relatively few alternative sources of supply for substitute components. These vendors may be unable or unwilling to meet our future demands for our clinical trials or commercial
sale. Establishing additional or replacement suppliers for these components, materials, and processes could take a substantial amount of time and it may be difficult to establish replacement suppliers
who meet regulatory </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>39</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=16,SEQ=43,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=919007,FOLIO='39',FILE='DISK116:[20ZBV1.20ZBV74901]CI74901A.;15',USER='JFUSS',CD='10-APR-2020;10:41' -->
<A NAME="page_ci74901_1_40"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>requirements.
Any disruption in supply from any single-source supplier could lead to supply delays or interruptions which would damage our business, financial condition, results of operations, and
prospects.If we have to switch to a replacement supplier, the manufacture and delivery of our product candidates could be interrupted for an extended period, which could adversely affect our business.
Establishing additional or replacement suppliers for any of the components used in our product candidates, if required, may not be accomplished quickly. If we are able to find a replacement supplier,
the replacement supplier would need to be qualified and may require additional regulatory authority approval, which could result in further delay. Any interruption or delay in the supply of components
or materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand for our investigational
medicines. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Manufacturing issues may arise that could increase product and regulatory approval costs or delay
commercialization of our products.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As the manufacturing processes are scaled up they may reveal manufacturing challenges or previously unknown impurities that could require resolution in order
to proceed with our planned clinical trials and obtain regulatory approval for the commercial marketing of our products. In the future, we may identify manufacturing issues or impurities that could
result in delays in the clinical program and regulatory approval for our products, increases in our operating expenses, or failure to obtain or maintain approval for our products. Our reliance on
third-party manufacturers entails risks, including the following: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the inability to meet our product specifications, including product formulation, and
quality requirements consistently; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a delay or inability to procure or expand sufficient manufacturing capacity; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> manufacturing and product quality issues, including those related to scale-up of
manufacturing; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> costs and validation of new equipment and facilities required for scale-up; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a failure to comply with cGMP and similar quality standards; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the inability to negotiate manufacturing agreements with third parties under commercially
reasonable terms; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> termination or nonrenewal of manufacturing agreements with third parties in a manner or
at a time that is costly or damaging to us; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the reliance on a limited number of sources, and in some cases, single sources for key
materials, such that if we are unable to secure a sufficient supply of these key materials, we will be unable to manufacture and sell our product candidates in a timely fashion, in sufficient
quantities or under acceptable terms; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the lack of qualified backup suppliers for those materials that are currently purchased
from a sole or single source supplier; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> operations of our third-party manufacturers or suppliers could be disrupted by conditions
unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> disruption of the distribution of chemical supplies between the U.K. and E.U. due to
Brexit; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> carrier disruptions or increased costs that are beyond our control; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the failure to deliver our products under specified storage conditions and in a timely
manner. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Any
of these events could lead to delays in any clinical study we may undertake, failure to obtain regulatory approval or impact our ability to successfully commercialize any product candidates. Some
of these events could be the basis for FDA or other regulatory authorities' action, including injunction, recall, seizure, or total or partial suspension of production. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>40</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=17,SEQ=44,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=68749,FOLIO='40',FILE='DISK116:[20ZBV1.20ZBV74901]CI74901A.;15',USER='JFUSS',CD='10-APR-2020;10:41' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_ck74901_1_41"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risks Related to Our Intellectual Property  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we are unable to obtain and maintain patent protection for our product candidates, or if the patent
protection obtained is not sufficiently broad in scope or is non-exclusive, our competitors could develop and commercialize products and technology similar or identical to our product candidates, and
our ability to successfully commercialize any product candidates we may develop may be adversely affected.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our commercial success depends on obtaining and maintaining proprietary rights to our product candidates and other compounds in development for the treatment
of NASH, MPS and other diseases, as well as successfully defending these rights against third party challenges. We will only be able to protect our product candidates and our other compounds in
development, and their uses from unauthorized use by third parties to the extent that valid and enforceable patents or effectively protected trade secrets, cover them. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
ability to obtain patent protection for our product candidates and other compounds in development is uncertain due to a number of factors,
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we may not have been the first to make the inventions covered by pending patent
applications or issued patents; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we may not have been the first to file patent applications for our product candidates or
the compositions we developed or for their uses; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> others may independently develop identical, similar or alternative products or
compositions and uses thereof; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our disclosures in patent applications may not be sufficient to meet the statutory
requirements for patentability; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> any or all of our pending patent applications may not result in issued patents; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we may choose not to seek or obtain patent protection in countries that may eventually
provide us a significant business opportunity; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> any patents issued to us may not provide a basis for commercially viable products, may
not provide any competitive advantages, or may be successfully challenged, narrowed, invalidated or circumvented by third parties; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our compositions and methods may not be patentable; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> others may design around our patent claims to produce competitive products which fall
outside of the scope of our patents; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> others may identify prior art or other bases which could invalidate our patents. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Even
if we have or obtain patents covering our product candidates or compositions, we may still be barred from making, using and selling our product candidates or technologies because of the patent
rights of others. Others may have filed, and in the future may file, patent applications covering compositions or products that are similar or identical to ours. If a patent owned by a third party
covers one of our product candidates or its use, this could materially affect our ability to develop the product candidate or sell the resulting product if approved. Because patent applications in the
United States are not published until 18&nbsp;months from their priority date, there may be currently pending applications unknown to us that may later result in issued patents that our product
candidates or compositions may infringe. Additionally, because the scope of claims in pending patent applications can change, there may be pending applications whose claims do not currently cover any
of our product candidates but
may be altered such that one or more of our product candidates are covered when the resulting patent issues. These patent applications may have priority over patent applications filed by us. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>41</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=45,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=305213,FOLIO='41',FILE='DISK116:[20ZBV1.20ZBV74901]CK74901A.;15',USER='SCAVALI',CD='10-APR-2020;08:42' -->
<A NAME="page_ck74901_1_42"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Moreover,
even if we are able to obtain patent protection, such patent protection may be insufficient to achieve our business objectives. For example, the coverage claimed in a patent application can
be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance, which could allow others develop products that are similar to, or better than, ours in a way
that is not covered by the claims of our patents. Furthermore, some of our owned and in-licensed patents and patent applications are, and may in the future be, co-owned with third parties. If we are
unable to obtain an exclusive license to any such third party co-owners' interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties,
including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such
patents against third parties, and such cooperation may not be provided to us. Therefore, even if patent applications we rely on issue as patents, they may not provide us with any meaningful
protection, prevent third parties from competing with us, or otherwise provide us with any competitive advantage. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Obtaining
and maintaining a patent portfolio entails significant expense and resources. Part of the expense includes periodic maintenance fees, renewal fees, annuity fees, various other governmental
fees on patents and/or applications due in several stages over the lifetime of patents and/or applications, as well as the cost associated with complying with numerous procedural provisions during the
patent application process. We may or may not choose to pursue or maintain protection for particular inventions. In addition, there are situations in which failure to make certain payments or
noncompliance with certain requirements in the patent process can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the
relevant jurisdiction. If we choose to forgo patent protection or allow a patent application or patent to lapse purposefully or inadvertently, our competitive position could suffer. Moreover, in
future collaborations, we may not have the right to control the preparation, filing or prosecution of patent applications, or to maintain the patents, covering technology subject to our collaboration
or license agreements with third parties. In addition, in future collaborations, our counterparty may have the right to enforce the patent rights subject to the applicable agreement without our
involvement or consent or to otherwise control the enforcement of such patent rights. Therefore, these patents and patent applications may not be prosecuted or enforced in a manner consistent with the
best interests of our business. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Legal
actions to enforce our patent rights can be expensive and may involve the diversion of significant management time. In addition, these legal actions could be unsuccessful and could also result
in the invalidation of our patents or a finding that they are unenforceable. We may or may not choose to pursue litigation or other actions against those that have infringed on our patents, or used
them without authorization, due to the associated expense and time commitment of monitoring these activities. If we fail to protect or to enforce our intellectual property rights successfully, our
competitive position could suffer, which could harm our results of operations. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We do not have composition of matter patent protection with respect to odiparcil.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We own certain patents and patent applications with claims directed to specific methods of using odiparcil and we expect to have marketing exclusivity from the
FDA and EMA for a period of seven and ten years, respectively, because odiparcil has orphan drug designation in these jurisdictions. However, composition of matter protection in the United States and
elsewhere covering odiparcil has expired. We may be limited in our ability to list our patents in the FDA's Orange Book if the use of our product, consistent with its FDA-approved label, would not
fall within the scope of our patent claims. Also, our competitors may be able to offer and sell products so long as these competitors do not infringe any other patents that we (or third parties) hold,
including patents with claims directed to the manufacture of odiparcil and/or method of use patents. In general, method of use patents are more difficult to enforce than composition of matter patents
because, for example, of the risks that the FDA may approve alternative uses of the subject compounds not covered by the method of use patents, and others may engage in off-label sale or use of the
subject compounds. Physicians are permitted to prescribe an approved product for uses that are not described in </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>42</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=46,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=1008498,FOLIO='42',FILE='DISK116:[20ZBV1.20ZBV74901]CK74901A.;15',USER='SCAVALI',CD='10-APR-2020;08:42' -->
<A NAME="page_ck74901_1_43"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>the
product's labeling. Although off-label prescriptions may infringe our method of use patents, the practice is common across medical specialties and such infringement is difficult to prevent or
prosecute. FDA approval of uses that are not covered by our patents would limit our ability to generate revenue from the sale of odiparcil, if approved for commercial sale. Off-label sales would limit
our ability to generate revenue from the sale of odiparcil, if approved for commercial sale. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Pharmaceutical patents and patent applications involve highly complex legal and factual questions, which, if
determined adversely to us, could negatively impact our patent position.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The patent positions of biotechnology and pharmaceutical companies can be highly uncertain and involve complex legal and factual questions. The interpretation
and breadth of claims allowed in some patents covering pharmaceutical compositions may be uncertain and difficult to determine, and are often affected materially by the facts and circumstances that
pertain to the patented compositions and the related patent claims. The standards of the United States Patent and Trademark Office, or USPTO, the European Patent Office, and other foreign counterparts
are sometimes uncertain and could change in the future. Consequently, the issuance and scope of patents cannot be predicted with certainty. Patents, if issued, may be challenged, invalidated or
circumvented. Certain U.S. patents and patent applications may also be subject to interference proceedings, and U.S. patents may be subject to reexamination proceedings, post-grant review and/or inter
partes review and derivation proceedings in the USPTO. European patents and other foreign patents may be subject also to opposition or comparable proceedings in the corresponding foreign patent
office, which could result in either
loss of the patent or denial of the patent application or loss or reduction in the scope of one or more of the claims of the patent or patent application. In addition, such interference,
reexamination, post-grant review, inter partes review and opposition proceedings may be costly. Accordingly, rights under any issued patents may not provide us with sufficient protection against
competitive products or processes. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, changes in or different interpretations of patent laws in the United States, Europe, and other jurisdictions may permit others to use our discoveries or to develop and commercialize our
technology and products without providing any compensation to us, or may limit the number of patents or claims we can obtain. The laws of some countries do not protect intellectual property rights to
the same extent as U.S. and European laws and those countries may lack adequate rules and procedures for defending our intellectual property rights. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>If
we fail to obtain and maintain patent protection and trade secret protection of our product candidates, we could lose our competitive advantage and competition we face would increase, reducing any
potential revenues and adversely affecting our ability to attain or maintain profitability. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Developments in patent law could have a negative impact on our business.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing
patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Changes in either the patent laws or
interpretation of the patent laws in the United States could increase the uncertainties and costs. Recent patent reform legislation in the United States and other countries, including the Leahy-Smith
America Invents Act (the Leahy-Smith Act), signed into law on September&nbsp;16, 2011, could increase those uncertainties and costs surrounding the prosecution of our patent applications and the
enforcement or defense of our issued patents. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are
prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. These include allowing third-party submission of prior art to
the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, inter partes review, and
derivation proceedings. After March 2013, under the Leahy-Smith Act, the United States transitioned to a first </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>43</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=47,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=242998,FOLIO='43',FILE='DISK116:[20ZBV1.20ZBV74901]CK74901A.;15',USER='SCAVALI',CD='10-APR-2020;08:42' -->
<A NAME="page_ck74901_1_44"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>inventor
to file system in which, assuming that the other statutory requirements are met, the first inventor to file&nbsp;a patent application will be entitled to the patent on an invention
regardless of whether a third party was the first to invent the claimed invention. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the
prosecution of our patent applications and the enforcement or defense of
our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in
certain situations. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could
change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we are unable to protect the confidentiality of our trade secrets, our business and competitive position
would be harmed.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In addition to patent protection, because we operate in the highly technical field of development of therapies, we rely in part on trade secret protection in
order to protect our proprietary technology and processes. However, trade secrets are difficult to protect. It is our policy to enter into confidentiality and intellectual property assignment
agreements with our employees, consultants, outside scientific collaborators, sponsored researchers, and other advisors. These agreements generally require that the other party keep confidential and
not disclose to third parties any confidential information developed by the party or made known to the party by us during the course of the party's relationship with us. These agreements also
generally provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. However, these agreements may not be honored and may not effectively
assign intellectual property rights to us. Adequate remedies may not exist in the event of unauthorized use or disclosure of our confidential information. The disclosure of our trade secrets would
impair our competitive position and may materially harm our business, financial condition and results of operations. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
addition to contractual measures, we try to protect the confidential nature of our proprietary information using physical and technological security measures. Such measures may not, for example, in
the case of misappropriation of a trade secret by an employee or third party with authorized access, provide adequate protection for our proprietary information. Our security measures may not prevent
an employee or consultant from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our
interests fully. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition,
courts outside the United States may be less willing to protect trade secrets, with protection varying across Europe and in other countries. Trade secrets may be independently developed by others in a
manner that could prevent legal recourse by us. If any of our confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any such information
was independently developed by a competitor, our competitive position could be harmed. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We will not seek to protect our intellectual property rights in all jurisdictions throughout the world and we
may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Filing, prosecuting and defending patents on our product candidates in all countries and jurisdictions throughout the world would be prohibitively expensive,
and our intellectual property rights in some countries could be less extensive than those in the United States and Europe, assuming that rights are obtained in the United States and Europe.
Furthermore, even if patents are granted based on our European patent applications, we may not choose to perfect or maintain our rights in all available European countries. In </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>44</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=48,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=709921,FOLIO='44',FILE='DISK116:[20ZBV1.20ZBV74901]CK74901A.;15',USER='SCAVALI',CD='10-APR-2020;08:42' -->
<A NAME="page_ck74901_1_45"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>addition,
the laws of some foreign countries do not protect intellectual property rights to the same extent as laws in the United States and Europe. Consequently, we may not be able to prevent third
parties from practicing our inventions in all countries, or from selling or importing products made using our inventions. The statutory deadlines for pursuing patent protection in individual foreign
jurisdictions are based on the priority dates of each of our patent applications. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Competitors
may use our technologies in jurisdictions where we do not pursue and obtain patent protection to develop their own products and further, may export otherwise infringing products to
territories where we have patent protection, but enforcement is not as strong as that in the United States and Europe. These products may compete with our products and our patents or other
intellectual property rights may not be effective or sufficient to prevent them from competing. Even if we pursue and obtain issued patents in particular jurisdictions, our patent claims or other
intellectual property rights may not be effective or sufficient to prevent third parties from so competing. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States and Europe. Many companies have encountered significant problems in
protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents
and other intellectual property protection, especially those relating to pharmaceuticals or biotechnologies. This could make it difficult for us to stop the infringement of our patents, if obtained,
or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties.
In addition, many countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no
benefit. Patent protection must ultimately be sought on a country-by-country basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek
patent protection in certain countries, and we will not have the benefit of patent protection in such countries. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Proceedings
to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at
risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any
lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. In addition, changes in the law and legal decisions by courts in the United States,
Europe and other jurisdictions may affect our ability to obtain adequate protection for our technology and the enforcement of intellectual property. Accordingly, our efforts to enforce our
intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be subject to claims by third parties asserting ownership or commercial rights to inventions we
develop or obligations to make compensatory payments to employees.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Third parties may in the future make claims challenging the inventorship or ownership of our intellectual property. We have written agreements with
collaborators that provide for the ownership of intellectual property arising from our collaborations. These agreements provide that we must negotiate certain commercial rights with collaborators with
respect to joint inventions or inventions made by our collaborators that arise from the results of the collaboration. In some instances, there may not be adequate written provisions to address clearly
the resolution of intellectual property rights that may arise from a collaboration. If we cannot successfully negotiate sufficient ownership and commercial rights to the inventions that result from
our use of a third-party collaborator's materials where required, or if disputes otherwise arise with respect to the intellectual property developed with the use of a collaborator's samples, we may be
limited in our ability to capitalize on the market potential of these inventions. In addition, we may face claims by third parties that our agreements with employees, contractors, or consultants
obligating them to assign intellectual property to us are ineffective, or in conflict with prior or competing contractual obligations of </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>45</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=49,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=441205,FOLIO='45',FILE='DISK116:[20ZBV1.20ZBV74901]CK74901A.;15',USER='SCAVALI',CD='10-APR-2020;08:42' -->
<A NAME="page_ck74901_1_46"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>assignment,
which could result in ownership disputes regarding intellectual property we have developed or will develop and interfere with our ability to capture the commercial value of such
inventions. Litigation may be necessary to resolve an ownership dispute, and if we are not successful, we may be precluded from using certain intellectual property, or may lose our exclusive rights in
that intellectual property. Either outcome could have an adverse impact on our business. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>While
it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may
be unsuccessful in executing or obtaining such an agreement with each party who, in fact, develops intellectual property that we regard as our own. In addition, such agreements may be breached or may
not be self-executing, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the
ownership of what we regard as our intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property
rights or personnel. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Third parties may assert that our employees or consultants have wrongfully used or disclosed confidential
information or misappropriated trade secrets.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We employ individuals who were previously employed at universities, pharmaceutical companies or biopharmaceutical companies, including our competitors or
potential competitors. Although we try to ensure that our employees and consultants do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that
we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of a
former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose
valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and
other employees. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


A dispute concerning the infringement or misappropriation of our proprietary rights or the proprietary rights
of others could be time consuming and costly, and an unfavorable outcome could harm our business.  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Our success will depend in part on our ability to operate without infringing the intellectual property and proprietary rights of third parties. We cannot
assure you that our business, products and methods do not or will not infringe the patents or other intellectual property rights of third parties. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>There
is significant litigation in the pharmaceutical industry regarding patent and other intellectual property rights. While we are not currently subject to any pending intellectual property
litigation, and are not aware of any such threatened litigation, we may be exposed to future litigation by third parties based on claims that our product candidates, technologies or activities
infringe the intellectual property rights of others. If our development activities are found to infringe any such intellectual property rights, we may have to pay significant damages or seek licenses
to such rights. For example, a patentee could prevent us from using the patented drugs or compositions. We may need to resort to litigation to enforce a patent issued to us, to protect our trade
secrets, or to determine the scope and validity of third-party proprietary rights. From time to time, we may hire scientific personnel or consultants formerly employed by other companies involved in
one or more areas similar to the activities conducted by us. Either we or these individuals may be subject to allegations of trade secret misappropriation or other similar claims as a result of prior
affiliations. Even if we are successful in these proceedings, we may incur substantial costs and divert management time and attention in pursuing these proceedings, which could have a material adverse
effect on us. If we are unable to avoid infringing the rights of others, we may be required to seek a license, defend an infringement action or challenge the validity of such rights in court, or
redesign our products. Patent and other intellectual property litigation is costly and time consuming. We may not have sufficient resources to bring these actions to a successful conclusion. Any
adverse ruling or perception of an adverse ruling in defending ourselves </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>46</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=50,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=443462,FOLIO='46',FILE='DISK116:[20ZBV1.20ZBV74901]CK74901A.;15',USER='SCAVALI',CD='10-APR-2020;08:42' -->
<A NAME="page_ck74901_1_47"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>against
these claims could have a material adverse impact on our cash position and the price of our ordinary shares or ADSs. Any legal action against us or our collaborators could lead
to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> payment of substantial damages for past use of the asserted intellectual property and
potentially treble damages, if we are found to have willfully infringed a party's patent rights; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> injunctive or other equitable relief that may effectively block our ability to further
develop, commercialize, and sell our product candidates; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> us or our collaborators having to enter into license arrangements that may not be
available on commercially acceptable terms, if at all, all of which could have a material adverse impact on our cash position and business and financial condition. As a result, we could be prevented
from commercializing current or future product candidates. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Any
of these risks coming to fruition could have a material adverse effect on our business, results of operations, financial condition and prospects. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Issued patents covering our product candidates could be found to be invalid or unenforceable if challenged in
court.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If we or one of our licensing partners initiated legal proceedings against a third party to enforce a patent covering our product candidate, the defendant
could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation, defendant counterclaims alleging invalidity and/or unenforceability are
commonplace. Grounds for a validity challenge include alleged failures to meet any of
several statutory requirements in most jurisdictions, including lack of novelty, obviousness or non-enablement. In the United States, grounds for unenforceability assertions include allegations that
someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may also raise similar claims before
administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review and equivalent proceedings in foreign
jurisdictions (e.g.,&nbsp;opposition proceedings). Such proceedings could result in revocation or amendment of our patents in such a way that they no longer cover our product candidates or
competitive products. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to validity, for example, we cannot be certain that there is no
invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at
least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection would have a material adverse impact on our business. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate
amount of time.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Given the amount of time required for the development, testing and regulatory review of new product candidates such as lanifibranor and odiparcil, patents
protecting such candidates might expire before or shortly after such candidates are commercialized. We expect to seek extensions of patent terms in the United States and, if available, in other
countries where we are prosecuting patents. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits extension of the term of one U.S. patent that includes at
least one claim covering the composition of matter of an FDA-approved drug, an FDA-approved method of treatment using the drug and/or a method of manufacturing the FDA-approved drug. The extended
patent term cannot exceed the shorter of five years beyond the non-extended expiration of the patent or 14&nbsp;years from the date of the FDA approval of the drug. However, the applicable
authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are
available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. Further, we may not elect to extend the most beneficial patent to us or the claims
underlying the patent that we choose </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>47</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=51,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=859962,FOLIO='47',FILE='DISK116:[20ZBV1.20ZBV74901]CK74901A.;15',USER='SCAVALI',CD='10-APR-2020;08:42' -->
<A NAME="page_ck74901_1_48"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>to
extend could be invalidated. If any of the foregoing occurs, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and
pre-clinical data and launch their drug earlier than might otherwise be the case. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Intellectual property rights do not address all potential threats to any competitive advantage we may have.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and
intellectual property rights may not adequately protect our business or permit us to maintain our competitive advantage. The following examples are illustrative:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Others may be able to make compounds that are the same as or similar to our current or
future product candidates but that are not covered by the claims of the patents that we own or have exclusively licensed. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We or any of our licensors or collaborators might not have been the first to make the
inventions covered by the issued patent or pending patent application that we own or have exclusively licensed. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We or any of our licensors or collaborators might not have been the first to file patent
applications covering certain of our inventions. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Others may independently develop similar or alternative technologies or duplicate any of
our technologies without infringing our intellectual property rights. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The prosecution of our pending patent applications may not result in granted patents. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Granted patents that we own or have exclusively licensed may not provide us with any
competitive advantages, or may be held invalid or unenforceable, as a result of legal challenges by our competitors. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Patent protection on our product candidates may expire before we are able to develop and
commercialize the product, or before we are able to recover our investment in the product. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Our competitors might conduct research and development activities in the United States
and other countries that provide a safe harbor from patent infringement claims for such activities, as well as in countries in which we do not have patent rights, and may then use the information
learned from such activities to develop competitive products for sale in markets where we intend to market our product candidates. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If our trademarks and trade names are not adequately protected, then we may not be able to build name
recognition in our markets of interest and our business may be adversely affected.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other
marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition by potential collaborators or customers in our markets of interest. For
example, we have not yet registered our company name as a trademark with the U.S. Patent and Trademark Office. Over the long term, if we are unable to establish name recognition based on our
trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. In addition, some of our trademarks may conflict with trademarks of others. In
the event of a conflict, a third party could bring claims against us that could cause us to incur substantial expenses or restrict our ability to use certain marks. Any of the foregoing could have an
adverse effect on our business. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>48</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=52,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=458105,FOLIO='48',FILE='DISK116:[20ZBV1.20ZBV74901]CK74901A.;15',USER='SCAVALI',CD='10-APR-2020;08:42' -->
<A NAME="page_ck74901_1_49"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risks Related to Our Organization, Structure and Operation  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our future success depends on our ability to retain the members of our management and to attract, retain and
motivate qualified personnel. If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our industry has experienced a high rate of turnover of management personnel in recent years. Our ability to compete in the highly competitive biotechnology
and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific and
medical personnel, especially our executive officers: Fr&eacute;d&eacute;ric Cren, our Chief Executive Officer, and Pierre Broqua, our Deputy Chief Executive Officer and Chief
Scientific Officer, whose services are critical to the successful implementation of our product candidate acquisition, development and regulatory strategies. We are not aware of any present intention
of any of these individuals to leave our company. Although we maintain "key man" insurance with respect to certain of our key employees, this insurance may be insufficient to compensate us for the
losses we may incur if we no longer have the services of such key employees. In order to induce valuable employees to continue their employment with us, we have provided founder's share warrants
(</FONT><FONT SIZE=2><I>bons de souscription de parts de cr&eacute;ateur d'entreprise)</I></FONT><FONT SIZE=2>, share warrants (</FONT><FONT SIZE=2><I>bons de souscription
d'actions)</I></FONT><FONT SIZE=2> and free shares </FONT><FONT SIZE=2><I>(actions gratuites)</I></FONT><FONT SIZE=2> that vest over time. The value to employees of such warrants and free shares that
vest over time is significantly affected by movements in our share price that are beyond our control, and may at any time be insufficient to counteract more lucrative offers from other companies. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Despite
our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us. The loss of the services of any of the members of
management or other key employees and our inability to find suitable replacements could harm our business, financial condition and prospects. Our success also depends on our ability to continue to
attract, retain and motivate highly skilled junior, mid-level, and senior managers as well as junior, mid-level, and senior scientific and medical personnel. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
may not be able to attract or retain qualified management and scientific personnel in the future due to the intense competition for a limited number of qualified personnel among biopharmaceutical,
biotechnology, pharmaceutical and other businesses. Many of the other pharmaceutical companies that we compete against for qualified personnel have greater financial and other resources, different
risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more
appealing to high quality candidates than what we have to offer. If we are unable to continue to attract and retain high quality personnel, the rate and success at which we can develop and
commercialize product candidates will be limited. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we fail to manage our growth effectively, our ability to develop and commercialize products could suffer.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We expect that if our drug discovery efforts continue to generate drug candidates, our clinical drug candidates continue to progress in development, and we
continue to build our development, medical and commercial organizations, we will require significant additional investment in personnel, management and resources. Our ability to achieve our research,
development and commercialization objectives depends on our ability to respond effectively to these demands and expand our internal organization, systems, controls and facilities to accommodate
additional anticipated growth. If we are unable to manage our growth effectively, our business could be harmed and our ability to execute our business strategy could suffer. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>49</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=53,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=443114,FOLIO='49',FILE='DISK116:[20ZBV1.20ZBV74901]CK74901A.;15',USER='SCAVALI',CD='10-APR-2020;08:42' -->
<A NAME="page_ck74901_1_50"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If product liability lawsuits are brought against us, we may incur substantial liabilities and may be
required to limit commercialization of any of our product candidates, if approved.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we
commercialize any products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or
sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a
breach of warranties. Physicians and patients may not comply with any warnings that identify known potential adverse effects and patients who should not use our products. Claims could also be asserted
under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to stop development or, if
approved, limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome,
liability claims may result in:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> delay or termination of clinical trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> injury to our reputation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> withdrawal of clinical trial participants; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> initiation of investigations by regulators; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> costs to defend the related litigation; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a diversion of management's time and our resources; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> substantial monetary awards to trial participants or patients; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> decreased demand for our product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> product recalls, withdrawals or labeling, marketing or promotional restrictions; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> loss of revenues from product sales; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the inability to commercialize any our product candidates, if approved. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Our
inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the development or
commercialization of our product candidates. We currently carry clinical trial liability insurance at levels which we believe are appropriate for our clinical trials. Although we maintain such
insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the
limits of our insurance coverage. Our insurance policies also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts
awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay
such amounts. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risks from the improper conduct of employees, agents, contractors, or collaborators could adversely affect
our reputation and our business, prospects, operating results, and financial condition.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We cannot ensure that our compliance controls, policies, and procedures will in every instance protect us from acts committed by our employees, agents,
contractors, or collaborators that would violate the laws or regulations of the jurisdictions in which we operate, including, without limitation, healthcare, employment, foreign corrupt practices,
environmental, competition, and patient privacy and other privacy laws and regulations. Such improper actions could subject us to civil or criminal investigations, and monetary and injunctive
penalties, and could adversely impact our ability to conduct business, operating results, and reputation. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>50</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=54,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=386033,FOLIO='50',FILE='DISK116:[20ZBV1.20ZBV74901]CK74901A.;15',USER='SCAVALI',CD='10-APR-2020;08:42' -->
<A NAME="page_ck74901_1_51"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
particular, our business activities may be subject to the Foreign Corrupt Practices Act, or FCPA, and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which
we operate, including the U.K. Bribery Act. The FCPA generally prohibits offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to a non-U.S.
government official in order to influence official action, or
otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and
maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S.
governments. Additionally, in many other countries, the health care providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government
entities; therefore, our dealings with these prescribers and purchasers are subject to regulation under the FCPA. Recently the Securities and Exchange Commission, or SEC, and Department of Justice
have increased their FCPA enforcement activities with respect to pharmaceutical companies. There is no certainty that all of our employees, agents, contractors, or collaborators, or those of our
affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in significant
administrative, civil and criminal fines and sanctions against us, our officers, or our employees, the closing down of our facilities, requirements to obtain export licenses, cessation of business
activities in sanctioned countries, exclusion from participation in federal healthcare programs including Medicare and Medicaid, implementation of compliance programs, integrity oversight and
reporting obligations, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries and could
materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results and financial condition. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We could be subject to liabilities under environmental, health and safety laws or regulations, or fines,
penalties or other sanctions, if we fail to comply with such laws or regulations or otherwise incur costs that could have a material adverse effect on the success of our business.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are subject to numerous French and U.S. federal, state, local and foreign environmental, health and safety laws, regulations, and permitting requirements,
including those governing laboratory procedures, decontamination activities and the handling, transportation, use, remediation, storage, treatment and disposal of hazardous materials and wastes. Our
operations involve the use of hazardous and flammable materials, including chemicals, radioactive isotopes and biological materials and produce hazardous waste products. We generally contract with
third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials or wastes either at our sites or at third party disposal
sites. In the event of such contamination or injury, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated
with civil or criminal fines and penalties. Although we maintain workers' compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use
of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws, regulations or permitting requirements. These current or future laws,
regulations and permitting requirements may impair our research, development or production efforts. Failure to comply with these laws, regulations and permitting requirements also may result in
substantial fines, penalties or other sanctions. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>51</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=55,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=1032171,FOLIO='51',FILE='DISK116:[20ZBV1.20ZBV74901]CK74901A.;15',USER='SCAVALI',CD='10-APR-2020;08:42' -->
<A NAME="page_ck74901_1_52"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Failure to comply with health and data protection laws and regulations could lead to government enforcement
actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We and any potential collaborators may be subject to federal, state, and foreign data protection laws and regulations (i.e.,&nbsp;laws and regulations that
address privacy and data security). In the United States, numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state
health information privacy laws, and federal and state consumer protection laws (e.g.,&nbsp;Section&nbsp;5 of the Federal Trade Commission Act), that govern the collection, use, disclosure and
protection of health-related and other personal information could apply to our operations or the operations of our collaborators. In addition, we may obtain health information from third parties
(including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under federal Health Insurance Portability and Accountability Act of
1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH. Depending on the facts and circumstances, we could be subject to civil,
criminal, and administrative penalties if we knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or
permitted by HIPAA. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Several
foreign jurisdictions, including the European Union, or the EU, its member states, the United Kingdom and Australia, among others, have adopted legislation and regulations that increase or
change the requirements governing the collection, use, disclosure and transfer of the personal information of individuals in these jurisdictions. In the United States, the state of California enacted
legislation, the California Consumer Protection Act, or CCPA, effective January&nbsp;1, 2020, that increases the requirements governing the collection, use, disclosure and transfer of the personal
information of individuals in the state of California. These laws and regulations are complex and change frequently, at times due to changes in political climate, and existing laws and regulations are
subject to different and conflicting interpretations, which adds to the complexity of processing personal data from these jurisdictions. These laws have the potential to increase costs of compliance,
risks of noncompliance and penalties for noncompliance. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Regulation (EU) 2016/679, known as the General Data Protection Regulation, or GDPR, as well as EU&nbsp;Member State implementing legislations, apply to the collection and processing of personal
data, including health-related information, by companies located in the EU, or in certain circumstances, by companies located outside of the EU and processing personal information of individuals
located in the EU. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>These
laws impose strict obligations on the ability to process personal data, including health-related information, in particular in relation to their collection, use, disclosure and transfer. These
include several requirements
relating to (1)&nbsp;obtaining, in some situations, the consent of the individuals to whom the personal data relates, (2)&nbsp;the information provided to the individuals about how their personal
information is used, (3)&nbsp;ensuring the security and confidentiality of the personal data, (4)&nbsp;the obligation to notify regulatory authorities and affected individuals of personal data
breaches, (5)&nbsp;extensive internal privacy governance obligations, and (6)&nbsp;obligations to honor rights of individuals in relation to their personal data (for example, the right to access,
correct and delete their data). The GDPR prohibits the transfer of personal data to countries outside of the European Economic Area, or EEA, such as the United States, which are not considered by the
European Commission to provide an adequate level of data protection. Switzerland has adopted similar restrictions. Although there are legal mechanisms to allow for the transfer of personal data from
the EEA and Switzerland to the United States, they are subject to legal challenges and uncertainty about compliance with EU data protection laws remains. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Also,
in certain countries, in particular France, the conduct of clinical trials is subject to compliance with specific provisions of the Act No.78-17 of 6&nbsp;January 1978 on Information
Technology, Data Files and Civil Liberties, as amended, and in particular Section&nbsp;3 of the Chapter&nbsp;III of the Title II relating to the processing of personal data in the health sector.
These provisions require, among others, the filing of compliance </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>52</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=56,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=425787,FOLIO='52',FILE='DISK116:[20ZBV1.20ZBV74901]CK74901A.;15',USER='SCAVALI',CD='10-APR-2020;08:42' -->
<A NAME="page_ck74901_1_53"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>undertakings
with "standard methodologies" adopted by the French Data Protection Authority (the CNIL), or, if not complying, obtaining a specific authorization from the CNIL. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Potential
pecuniary fines for noncompliant companies may be up to the greater of &euro;20&nbsp;million or 4% of annual global revenue. The GDPR has increased our responsibility and
liability in relation to personal data that we process, and we may be required to put in place additional potential mechanisms to ensure compliance with the new EU data protection rules. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Compliance
with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose
data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with these laws and regulations could result in government enforcement actions (which could include
civil, criminal and administrative penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects, employees
and other individuals about whom we or our potential collaborators obtain personal information, as well as the providers who share this information with us, may limit our ability to collect, use and
disclose the information. Claims that we have violated individuals' privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found
liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our current and future operations are subject to applicable fraud and abuse, transparency, government price
reporting, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any future drug candidates we may
develop and any drug candidates for which we obtain marketing approval. Our current and future arrangements with healthcare providers, physicians, third-party payors and customers may expose us to
broadly applicable fraud and abuse and other healthcare laws and regulations that may affect the business or financial arrangements and relationships through which we would market, sell and distribute
our products. Even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, federal and state healthcare laws and
regulations pertaining to fraud and abuse and patients' rights are and will be applicable to our business. The laws that may affect our ability to operate include, but are not limited
to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The federal Anti-Kickback Statute, which prohibits any person or entity from, among other
things, knowingly and willfully soliciting, receiving, offering or paying any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of
an individual for, or the purchase, order or recommendation of an item or service reimbursable, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. The
term "remuneration" has been broadly interpreted to include anything of value. The federal Anti-Kickback Statute has also been interpreted to apply to arrangements between pharmaceutical manufacturers
on the one hand and prescribers, purchasers, and formulary managers on the other hand. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from
prosecution. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Federal civil and criminal false claims laws, such as the False Claims Act, or FCA, which
can be enforced by private citizens through civil qui tam actions and civil monetary penalty laws, prohibit individuals or entities from, among other things, knowingly presenting, or causing to be
presented, false, fictitious or fraudulent claims for payment of federal funds, and knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent
claim to avoid, decrease or conceal an obligation to pay money to the federal government. For example, pharmaceutical companies have been prosecuted under the FCA in connection with their alleged
off-label promotion of drugs, purportedly concealing price concessions in the pricing information </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>53</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=57,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=15891,FOLIO='53',FILE='DISK116:[20ZBV1.20ZBV74901]CK74901A.;15',USER='SCAVALI',CD='10-APR-2020;08:42' -->
<A NAME="page_ck74901_1_54"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:arial;"><FONT SIZE=2>submitted
to the government for government price reporting purposes, and allegedly providing free product to customers with the expectation that the customers would bill federal health care programs
for the product. In addition, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. As a
result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes "any request or demand" for money or property presented to the U.S. government. In addition,
manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to "cause" the submission of false or fraudulent claims. </FONT></P>

</UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> HIPAA, among other things, imposes criminal liability for executing or attempting to
execute a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully
obstructing a criminal investigation of a healthcare offense, and creates federal criminal laws that prohibit knowingly and willfully falsifying, concealing or covering up a material fact or making
any materially false, fictitious or fraudulent statement or representation, or making or using any false writing or document knowing the same to contain any materially false, fictitious or fraudulent
statement or entry in connection with the delivery of or payment for healthcare benefits, items or services. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> HIPAA, as amended by HITECH, and their implementing regulations, which impose privacy,
security and breach reporting obligations with respect to individually identifiable health information upon entities subject to the law, such as health plans, healthcare clearinghouses and certain
healthcare providers, known as covered entities, and their respective business associates that perform services for them that involve individually identifiable health information. HITECH also created
new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil
actions for damages or injunctions in U.S. federal courts to enforce HIPAA laws and seek attorneys' fees and costs associated with pursuing federal civil actions. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Federal and state consumer protection and unfair competition laws, which broadly regulate
marketplace activities and activities that potentially harm consumers. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The federal transparency requirements under the Physician Payments Sunshine Act, created
under the Affordable Care Act, which requires, among other things, certain manufacturers of drugs, devices, biologics and medical supplies reimbursed under Medicare, Medicaid, or the Children's Health
Insurance Program to report to CMS information related to payments and other transfers of value provided to physicians, as defined by such law, and teaching hospitals and physician ownership and
investment interests, including such ownership and investment interests held by a physician's immediate family members. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> State and foreign law equivalents of each of the above federal laws, such as
anti-kickback and false claims laws, that may impose similar or more prohibitive restrictions, and may apply to items or services reimbursed by non-governmental third-party payors, including private
insurers. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> State and foreign laws that require pharmaceutical companies to implement compliance
programs, comply with the pharmaceutical industry's voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or to track and report gifts,
compensation and other remuneration provided to physicians and other health care providers, marketing expenditures and/or drug pricing, state and local laws that require the registration of
pharmaceutical sales representatives and other federal, state and foreign laws that govern the privacy and security of health information or personally identifiable information in certain
circumstances, including state health information privacy and data breach notification laws which govern the collection, use, disclosure, and protection of health-related and other personal
information, many of which differ from each other in significant ways and often are not pre-empted by HIPAA, thus requiring additional compliance efforts. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>54</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=14,SEQ=58,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=26005,FOLIO='54',FILE='DISK116:[20ZBV1.20ZBV74901]CK74901A.;15',USER='SCAVALI',CD='10-APR-2020;08:42' -->
<A NAME="page_ck74901_1_55"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
have entered into consulting and scientific advisory board arrangements with physicians and other healthcare providers, including some who could influence the use of our drug candidates, if
approved. Because of the complex and far-reaching nature of these laws, regulatory agencies may view these transactions as prohibited arrangements that must be restructured, or discontinued, or for
which we could be subject to other significant penalties. We could be adversely affected if regulatory agencies interpret our financial relationships with providers who may influence the ordering and
use of our drug candidates, if approved, to be in violation of applicable laws. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. Federal and state enforcement bodies have recently increased
their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry.
Responding to investigations can be time-and resource-consuming and can divert management's attention from the business. Any such investigation or settlement could increase our costs or otherwise have
an adverse effect on our business. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Ensuring
that our business arrangements with third parties comply with applicable healthcare laws and regulations will likely be costly. If our operations are found to be in violation of any of these
laws or any other current or future governmental laws and regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement,
imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future earnings, additional reporting
obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of
our operations, any of which could substantially disrupt our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in
compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We must maintain effective internal control over financial reporting, and if we are unable to do so, the
accuracy and timeliness of our financial reporting may be adversely affected, which could have a material adverse effect on our business, investor confidence and market price.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We must maintain effective internal control over financial reporting in order to accurately and timely report our results of operations and financial
condition. In addition, once we are a U.S. public company, the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, will require, among other things, that we assess the effectiveness of our
disclosure controls and procedures annually and the effectiveness of our internal control over financial reporting at the end of each fiscal year. We anticipate being first required to issue
management's annual report on internal control over financial reporting, pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act, in connection with issuing our financial statements as of and for the
year ending December&nbsp;31, 2021. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
rules governing the standards that must be met for our management to assess our internal control over financial reporting pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act are complex and
require significant documentation, testing and possible remediation. These stringent standards require that our audit committee be advised and regularly updated on management's review of internal
control over financial reporting. We plan to design, implement and test our internal control over financial reporting in order to comply with this obligation. This process will be time-consuming,
costly and complicated. In addition, our independent registered public accounting firm will be required to attest to the effectiveness of our internal controls over financial reporting beginning with
our annual report following the date on which we are no longer an "emerging growth company," which may be up to five fiscal years following the date of this offering. Our management may not be able to
effectively and timely implement controls and procedures that adequately respond to the increased regulatory compliance and reporting requirements that will be </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>55</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=15,SEQ=59,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=212125,FOLIO='55',FILE='DISK116:[20ZBV1.20ZBV74901]CK74901A.;15',USER='SCAVALI',CD='10-APR-2020;08:42' -->
<A NAME="page_ck74901_1_56"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>applicable
to us as a U.S. public company. If we fail to staff our accounting and finance function adequately or maintain internal control over financial reporting adequate to meet the demands that
will be placed upon us as a U.S. public company, including the requirements of the Sarbanes-Oxley Act, our business and reputation may be harmed and the price of our ordinary shares or ADSs may
decline. Furthermore, investor perceptions of us may be adversely affected, which could cause a decline in the market price of our ordinary shares or ADSs. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our information technology systems could face serious disruptions that could adversely affect our business.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The United States federal and various state and foreign governments have adopted or proposed requirements regarding the collection, distribution, use,
security, and storage of personally identifiable information and other data relating to individuals, and federal and state consumer protection laws are being applied to enforce regulations related to
the collection, use, and dissemination of data. Despite the implementation of security measures, our information technology and other internal infrastructure systems, including corporate firewalls,
servers, leased lines and connection to the Internet, face the risk of systemic failure that could disrupt our operations. If such an event were to occur and cause significant disruption in the
availability of our information technology and other internal infrastructure systems, or result in the unauthorized disclosure of or access to personally identifiable information or individually
identifiable health information (violating certain privacy laws such as GDPR), it could cause interruptions in our collaborations and delays in our research and development work. Some of the federal,
state and foreign government requirements include obligations of companies to notify individuals of security breaches involving particular personally identifiable information, which could result from
breaches experienced by us or by our vendors, contractors, or organizations with which we have formed strategic relationships. Even though we may have contractual protections with such vendors,
contractors, or other organizations, notifications and follow-up actions related to a security breach could impact our reputation, cause us to incur significant costs, including legal expenses, harm
customer confidence, hurt our expansion into new markets, cause us to incur remediation costs, or cause us to lose existing customers. The loss of product development or clinical trial data could
result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss
of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and our development programs and the development of our
product candidates could be delayed, and we could be subject to significant fines, penalties or liabilities for any noncompliance to certain privacy and security laws. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Business interruptions could delay us in the process of developing our product candidates.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Loss of our laboratory facilities through fire or other causes could have an adverse effect on our ability to continue to conduct our business. We currently
have insurance coverage to compensate us for such business interruptions; however, such coverage may prove insufficient to fully compensate us for the damage to our business resulting from any
significant property or casualty loss to our facilities. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may undertake strategic acquisitions in the future and any difficulties from integrating such acquisitions
could adversely affect our share price, operating results and results of operations.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We may acquire companies, businesses and products that complement or augment our existing business. We may not be able to integrate any acquired business
successfully or operate any acquired business profitably. Integrating any newly acquired business could be expensive and time-consuming. Integration efforts often take a significant amount of time,
place a significant strain on managerial, operational and financial resources, result in loss of key personnel and could prove to be more difficult or expensive than we predict. The diversion of our
management's attention and any delay or difficulties encountered in connection with any future acquisitions we may consummate could result in the disruption of our on-going business or inconsistencies
in standards and controls that could negatively affect our ability to maintain third-party relationships. Moreover, we may need to raise additional funds through public or private debt or </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>56</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=16,SEQ=60,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=397080,FOLIO='56',FILE='DISK116:[20ZBV1.20ZBV74901]CK74901A.;15',USER='SCAVALI',CD='10-APR-2020;08:42' -->
<A NAME="page_ck74901_1_57"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>equity
financing, or issue additional shares, to acquire any businesses or products, which may result in dilution for shareholders or the incurrence of indebtedness. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>As
part of our efforts to acquire companies, business or product candidates or to enter into other significant transactions, we conduct business, legal and financial due diligence with the goal of
identifying and evaluating material risks involved in the transaction. Despite our efforts, we ultimately may be unsuccessful in ascertaining or evaluating all such risks and, as a result, might not
realize the intended advantages of the transaction. If we fail to realize the expected benefits from acquisitions we may consummate in the future or have consummated in the past, whether as a result
of unidentified risks or liabilities, integration difficulties, regulatory setbacks, litigation with current or former employees and other events, our business, results of operations and financial
condition could be adversely affected. If we acquire product candidates, we will also need to make certain assumptions about, among other things, development costs, the likelihood of receiving
regulatory approval and the market for such product candidates. Our assumptions may prove to be incorrect, which could cause us to fail to realize the anticipated benefits of these transactions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, we will likely experience significant charges to earnings in connection with our efforts, if any, to consummate acquisitions. For transactions that are ultimately not consummated, these
charges may include fees and expenses for investment bankers, attorneys, accountants and other advisors in connection with our efforts. Even if our efforts are successful, we may incur, as part of a
transaction, substantial charges for closure costs associated with elimination of duplicate operations and facilities and acquired in-process research and development charges. In either case, the
incurrence of these charges could adversely affect our results of operations for particular periods. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our international operations subject us to various risks, and our failure to manage these risks could
adversely affect our results of operations.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We face significant operational risks as a result of doing business internationally, such as:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> fluctuations in foreign currency exchange rates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Differing payor reimbursement regimes, governmental payors or patient self-pay systems
and price controls; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> potentially adverse and/or unexpected tax consequences, including penalties due to the
failure of tax planning or due to the challenge by tax authorities on the basis of transfer pricing and liabilities imposed from inconsistent enforcement; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> potential changes to the accounting standards, which may influence our financial
situation and results; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> becoming subject to the different, complex and changing laws, regulations and court
systems of multiple jurisdictions and compliance with a wide variety of foreign laws, treaties and regulations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> reduced protection of, or significant difficulties in enforcing, intellectual property
rights in certain countries; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> difficulties in attracting and retaining qualified personnel; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> restrictions imposed by local labor practices and laws on our business and operations,
including unilateral cancellation or modification of contracts; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> rapid changes in global government, economic and political policies and conditions,
political or civil unrest or instability, terrorism or epidemics and other similar outbreaks or events, and potential failure in confidence of our suppliers or customers due to such changes or events;
and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> tariffs, trade protection measures, import or export licensing requirements, trade
embargoes and other trade barriers. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>57</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=17,SEQ=61,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=80637,FOLIO='57',FILE='DISK116:[20ZBV1.20ZBV74901]CK74901A.;15',USER='SCAVALI',CD='10-APR-2020;08:42' -->
<A NAME="page_ck74901_1_58"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we are unable to use tax loss carryforwards and/or tax credits to reduce future taxable income or benefit
from favorable tax legislation, our business, results of operations and financial condition may be adversely affected.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>At December&nbsp;31, 2019, we had cumulative carry forward tax losses of &euro;93.3&nbsp;million in France. These are available to carry forward
and offset against future taxable income for an indefinite period in France. If we are unable to use tax loss carryforwards to reduce future taxable income, our business, results of operations and
financial condition may be adversely affected. In France, the use of these carry forward tax losses is capped at &euro;1&nbsp;million annually, plus 50% of the fraction of profits
exceeding this limit. The unutilized balance of these tax losses can be carried forward to subsequent years and set-off under the same conditions without any time limits. However, it is possible that
future fiscal changes could limit our ability to utilize the balance of any tax loses, which could adversely affect our results. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
a company active in research and development in France, we have benefited from certain research and development incentives including, for example, the French research tax credit
(</FONT><FONT SIZE=2><I>credit d'imp&ocirc;t recherche</I></FONT><FONT SIZE=2>), or CIR. These tax credits can be used to offset French corporate income tax due. The excess portion beyond that
used to offset corporate income tax due is generally refunded in cash at the end of a three-year fiscal period; however, as long as we are considered a small or medium-sized entity
(</FONT><FONT SIZE=2><I>petite ou moyenne entreprise</I></FONT><FONT SIZE=2>) in France, the CIR tax credit is refundable in the fiscal year after it is generated, provided that we comply with
eligibility requirements. The research and development incentives are calculated based on the amount of eligible research and development expenditures. The French CIR tax credit amounted to
&euro;4.3&nbsp;million for the year ended December&nbsp;31, 2019. In addition, the French tax authorities have audited in the past, and may again audit in the future, research and
development programs in respect of which a tax credit has been claimed in order to assess whether it qualifies for the tax credit regime. The tax authorities may challenge our eligibility for, or our
calculation of, certain tax reductions and/or deductions in respect of our research and development activities and expenditures, and should the French tax authorities be successful, we may be liable
for additional corporate income tax, and penalties and interest related thereto, which could have a significant impact on our results of operations and future cash flows. For example, in August 2018,
we received a collection notice in the amount of &euro;1.9&nbsp;million, including penalties and late payment interest, related to our CIRs for the 2013, 2014 and 2015 taxable years.
Furthermore, if the French government decides to eliminate, or reduce the scope or the rate of, the research and development incentive benefit, either of which it could decide to do at any time, our
results of operations could be adversely affected. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be exposed to significant foreign exchange risk.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We incur portions of our expenses, and may in the future derive revenues, in currencies other than the euro, in particular, the U.S. dollar. As a result, we
are exposed to foreign currency exchange risk as our results of operations and cash flows are subject to fluctuations in foreign currency exchange rates. We currently do not engage in hedging
transactions to protect against uncertainty in future exchange rates between particular foreign currencies and the euro. Therefore, for example, an increase in the value of the euro against the U.S.
dollar could be expected to have a negative impact on our revenue and earnings growth as U.S. dollar revenue and earnings, if any, would be translated into euros at a reduced value. We cannot predict
the impact of
foreign currency fluctuations, and foreign currency fluctuations in the future may adversely affect our financial condition, results of operations and cash flows. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The requirements of being a U.S. public company may strain our resources and divert management's attention.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are required to comply with various corporate governance and financial reporting requirements under the Sarbanes-Oxley Act, the Securities and Exchange Act
of 1934, as amended, or the Exchange Act, and the rules and regulations adopted by the Securities and Exchange Commission and the Public Corporation Accounting Oversight Board. Further, compliance
with various regulatory reporting requires significant commitments of time from our management and our directors, which reduces the time available for the </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>58</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=18,SEQ=62,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=945072,FOLIO='58',FILE='DISK116:[20ZBV1.20ZBV74901]CK74901A.;15',USER='SCAVALI',CD='10-APR-2020;08:42' -->
<A NAME="page_ck74901_1_59"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>performance
of their other responsibilities. Our failure to track and comply with the various rules may materially adversely affect our reputation, ability to obtain the necessary certifications to
financial statements, lead to additional regulatory enforcement actions, and could adversely affect the value of our ordinary shares or ADSs. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risks Related to this Offering and Ownership of our Ordinary Shares and ADSs  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


There has been no prior active market for our ADSs and an active and liquid market for our ADSs may fail to
develop, which could harm the market price of our ADSs.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Prior to this offering, while our ordinary shares have been traded on Euronext Paris since February 2017, there has been no active public market for our
ordinary shares or ADSs in the United States. Although we anticipate our ADSs being approved for listing on Nasdaq an active trading market for our ADSs may never develop or be sustained following
this offering. The initial public offering price of our ADSs will be based and determined through negotiations between us and the underwriters. This initial public offering price may not be indicative
of the market price of our ordinary shares or ADSs after this offering. In the absence of an active
trading market for our ADSs, investors may not be able to sell their ADSs at or above the initial public offering price or at the time that they would like to sell. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The market price of our equity securities may be volatile, and purchasers of our ordinary shares or ADSs or
could incur substantial losses.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The market price for our ordinary shares and ADSs may be volatile. The stock market in general and the market for biopharmaceutical companies in particular
have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their ordinary
shares or ADSs at or above the price originally paid for the security. The market price for our ordinary shares and ADSs may be influenced by many factors, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> actual or anticipated fluctuations in our financial condition and operating results; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> actual or anticipated changes in our growth rate relative to our competitors; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> competition from existing products or new products that may emerge; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> announcements by us, our collaborators or our competitors of significant acquisitions,
strategic partnerships, joint ventures, collaborations, or capital commitments; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> failure to meet or exceed financial estimates and projections of the investment community
or that we provide to the public; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> issuance of new or updated research or reports by securities analysts; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> fluctuations in the valuation of companies perceived by investors to be comparable to us; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> share price and volume fluctuations attributable to inconsistent trading volume levels of
our shares; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> additions or departures of key management or scientific personnel; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> disputes or other developments related to proprietary rights, including patents,
litigation matters, and our ability to obtain patent protection for our technologies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> changes to coverage policies or reimbursement levels by commercial third-party payors and
government payors and any announcements relating to coverage policies or reimbursement levels; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> announcement or expectation of additional debt or equity financing efforts; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> sales of our ordinary shares or ADSs by us, our insiders or our other shareholders; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> general economic and market conditions. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>59</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=19,SEQ=63,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=328640,FOLIO='59',FILE='DISK116:[20ZBV1.20ZBV74901]CK74901A.;15',USER='SCAVALI',CD='10-APR-2020;08:42' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_cm74901_1_60"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>These and other market and industry factors may cause the market price and demand for our ordinary shares or ADSs to fluctuate substantially, regardless of our actual operating
performance, which may limit or prevent investors from readily selling their ordinary shares or ADSs and may otherwise negatively affect the liquidity of our capital shares. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we do not achieve our projected development and commercialization goals in the timeframes we announce and
expect, our business will be harmed and the price of our securities could decline as a result.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We sometimes estimate for planning purposes the timing of the accomplishment of various scientific, clinical, regulatory and other product development
objectives. These milestones may include our expectations regarding the commencement or completion of scientific studies, clinical trials, the submission of regulatory filings, or commercialization
objectives. From time to time, we may publicly announce the expected timing of some of these milestones, such as the completion of an ongoing clinical trial, the receipt of data from a clinical trial,
the initiation of other clinical programs, receipt of marketing approval, or a commercial launch of a
product. For example, in September 2018 we announced that our expectation regarding the timing of data from our ongoing Phase&nbsp;IIb clinical trial of lanifibranor for the treatment of patients
with NASH would be delayed until the first half of 2020 due to delays in patient enrollment. The achievement of many of these milestones may be outside of our control. All of these milestones are
based on a variety of assumptions which may cause the timing of achievement of the milestones to vary considerably from our estimates,
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our available capital resources or capital constraints we experience; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the rate of progress, costs and results of our clinical trials and research and
development activities, including the extent of scheduling conflicts with participating clinicians and collaborators, and our ability to identify and enroll patients who meet clinical trial
eligibility criteria; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our receipt of approvals by the EMA, FDA and other regulatory agencies and the timing
thereof; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> other actions, decisions or rules issued by regulators; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to access sufficient, reliable and affordable supplies of compounds and raw
materials used in the manufacture of our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the efforts of our collaborators with respect to the commercialization of our products;
and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the securing of, costs related to, and timing issues associated with, product
manufacturing as well as sales and marketing activities. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>If
we fail to achieve announced milestones in the timeframes we expect, the commercialization of our product candidates may be delayed, our business and results of operations may be harmed, and the
trading price of our ordinary shares and ADSs may decline as a result. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


After this offering, voting control with respect to our company will remain concentrated in the hands of
Fr&eacute;d&eacute;ric Cren, our Chief Executive Officer, Pierre Broqua, our Deputy Chief Executive Officer and Chief Scientific Officer, and our significant shareholders and
affiliates who will continue to be able to exercise significant influence on us.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In accordance with French law, double voting rights automatically attach to each ordinary share of companies listed on a regulated market (such as the Euronext
Paris, where our ordinary shares are listed) that is held of record in the name of the same shareholder for a period of at least two years, except as otherwise set forth in a company's bylaws. Our
bylaws do not exclude such double voting rights. However, under French law, ordinary bearer shares in the form of ADSs are not eligible for double voting rights. To our knowledge, among our
significant shareholders, double voting rights currently only attach to the 5,704,816 ordinary shares held by Fr&eacute;d&eacute;ric Cren, our Chief Executive Officer, and to the
3,882,500 ordinary shares held by Pierre Broqua, our Deputy Chief Executive Officer and Chief Scientific Officer, as of December&nbsp;31, </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>60</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=64,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=55539,FOLIO='60',FILE='DISK116:[20ZBV1.20ZBV74901]CM74901A.;13',USER='JFUSS',CD='10-APR-2020;08:10' -->
<A NAME="page_cm74901_1_61"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>2019.
Given the double voting rights per share attributed to ordinary shares held by Mr.&nbsp;Cren and Dr.&nbsp;Broqua, Mr.&nbsp;Cren and Dr.&nbsp;Broqua will together beneficially own
approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding ordinary shares (including ordinary shares underlying ADSs), but control approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the
voting rights of our outstanding share
capital immediately following the completion of this offering, assuming in each case no exercise of the underwriters' option to purchase additional ADSs and/or ordinary shares in this offering. As a
result, Mr.&nbsp;Cren and Dr.&nbsp;Broqua, if they act together, will have a significant influence over all matters that require approval by our shareholders, such as the election of directors and
approval of significant corporate transactions. Such corporate action might be taken even if other shareholders, including those who purchase ordinary shares or ADSs in this offering, oppose them.
This concentration of ownership might also have the effect of delaying or preventing a change of control of our company that other shareholders may view as beneficial. As members of our board of
directors, Mr.&nbsp;Cren and Dr.&nbsp;Broqua have a duty to act without self-interest, on a well-informed basis and to not make any decision against our corporate interest
(</FONT><FONT SIZE=2><I>int&eacute;r&ecirc;t social</I></FONT><FONT SIZE=2>) considering the interests of our shareholders, employees and other stakeholders as a whole. However, as
shareholders, Mr.&nbsp;Cren and Dr.&nbsp;Broqua are entitled to vote their shares in their own interests, which may not always be in the interests of our shareholders generally. In addition,
Mr.&nbsp;Cren and Dr.&nbsp;Broqua have the ability to control the management and major strategic investments of our company as a result of their positions as our Chief Executive Officer and Deputy
Chief Executive Officer and Chief Scientific Officer, respectively. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Further,
we anticipate that our executive officers, directors, current 5% or greater shareholders and affiliated entities, including BVF Partners&nbsp;L.P., New Enterprise Associates, Novo Holdings
A/S and Sofinnova Crossover I SLP, will together beneficially own approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding ordinary shares (including ordinary shares underlying ADSs) and approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the voting rights of our outstanding share capital immediately following the completion of this offering, assuming in each case no exercise of the underwriters' option to purchase
additional ADSs and/or ordinary shares in this offering. As a result, these shareholders, if they act together, will have control over all matters that require approval of our shareholders. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This
concentrated control will limit your ability to influence corporate matters for the foreseeable future and potentially in perpetuity, particularly because purchasers of ADSs or ordinary shares in
this offering, in the open market following the completion of this offering or in subsequent offerings will be unlikely to meet the requirements to have double voting rights attach to any ordinary
shares held by them. This concentrated control could also discourage a potential investor from acquiring our ADSs or ordinary shares and might harm the market price of our ADSs or ordinary shares. We
cannot predict whether the concentrated control of our shareholders who held our ordinary shares prior to the completion of this offering, including our executive officers, employees and directors and
their affiliates, will result in a lower or more volatile market price of our ADSs or ordinary shares or in adverse publicity or other adverse consequences. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have not elected to take advantage of the "controlled company" exemption to the corporate governance rules
for publicly-listed companies but may do so in the future.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Because Fr&eacute;d&eacute;ric Cren, our Chief Executive Officer, and Pierre Broqua, our Deputy Chief Executive Officer and Chief Scientific
Officer, may act in concert and collectively own in excess of 50% of the voting power of our outstanding share capital, we are eligible to elect the "controlled company" exemption to the corporate
governance rules for publicly-listed companies. We have not elected to do so. However, we may decide to become a controlled company in the future, and our status as a controlled company could cause
our ADSs or ordinary shares to be less attractive to certain investors or otherwise harm the trading price of our securities. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>61</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=65,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=624921,FOLIO='61',FILE='DISK116:[20ZBV1.20ZBV74901]CM74901A.;13',USER='JFUSS',CD='10-APR-2020;08:10' -->
<A NAME="page_cm74901_1_62"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Fluctuations in the exchange rate between the U.S. dollar and the euro may increase the risk of holding our
ordinary shares and ADSs.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our ordinary shares currently trade on Euronext Paris in euros, while our ADSs will trade on Nasdaq in U.S. dollars. Fluctuations in the exchange rate between
the U.S. dollar and the euro may result in temporary differences between the value of our ADSs and the value of our ordinary shares, which may result in heavy trading by investors seeking to exploit
such differences. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, as a result of fluctuations in the exchange rate between the U.S. dollar and the euro, the U.S. dollar equivalent of the proceeds that a holder of our ADSs would receive upon the sale in
France of any ordinary shares withdrawn from the depositary and the U.S. dollar equivalent of any cash dividends paid in euros on our ordinary shares represented by our ADSs could also decline. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have broad discretion in the use of the net proceeds from this offering and may not use them effectively.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our management will have broad discretion in the application of the net proceeds that we receive from this offering, including applications for working
capital, possible acquisitions and other general corporate purposes, and we may spend or invest these proceeds in a way with which our shareholders disagree. The failure by our management to apply
these funds effectively could harm our business and financial condition. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses
value. These investments may not yield a favorable return to our investors. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If securities or industry analysts do not publish research or publish inaccurate research or unfavorable
research about our business, the price of our ordinary shares and ADSs and trading volume could decline.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The trading market for our ordinary shares and ADSs depends in part on the research and reports that securities or industry analysts publish about us or our
business. If no or few securities or industry analysts cover our company, the trading price for our ordinary shares and ADSs would be negatively impacted. If one or more of the analysts who covers us
downgrades our ordinary shares and ADSs or publishes incorrect or unfavorable research about our business, the price of our ordinary shares and ADSs would likely decline. If one or more of these
analysts ceases coverage of our company or fails to publish reports on us regularly, or downgrades our ordinary shares and ADSs, demand for our ordinary shares and ADSs could decrease, which could
cause the price of our ordinary shares and ADSs or trading volume to decline. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have no present intention to pay dividends on our ordinary shares in the foreseeable future and,
consequently, your only opportunity to achieve a return on your investment during that time is if the price of our ordinary shares or ADSs, as applicable, appreciates.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have never declared or paid any cash dividends on our ordinary shares and we have no present intention to pay dividends in the foreseeable future. Any
recommendation by our board of directors to pay dividends will depend on many factors, including our financial condition (including losses carried-forward), results of operations, legal requirements
and other factors. Further, under French law, the determination of whether we have been sufficiently profitable to pay dividends is made on the basis of our statutory financial statements prepared and
presented in accordance with accounting standards applicable in France. In addition, payment of dividends may subject us to additional taxes under French law. Please see the section of this prospectus
titled "Description of Share Capital&nbsp;&#151; Key provisions of our bylaws and French law affecting our ordinary shares&nbsp;&#151; Rights, preferences and restrictions attaching
to ordinary shares (Articles&nbsp;11, 14, 28, 31 and 32 of the bylaws)" for further details on the limitations on our ability to declare and pay dividends and the taxes that may become payable by us
if we elect to pay a dividend. Therefore, we may be more restricted in our ability to declare dividends than companies not based in France. If the price of our ordinary shares or ADSs declines before
we pay dividends, you will incur a loss on your investment, without the likelihood that this loss will be offset in part or at all by potential future cash dividends. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>62</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=66,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=920236,FOLIO='62',FILE='DISK116:[20ZBV1.20ZBV74901]CM74901A.;13',USER='JFUSS',CD='10-APR-2020;08:10' -->
<A NAME="page_cm74901_1_63"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If you purchase our ADSs in the U.S. offering or ordinary shares in the European offering, you will
experience substantial and immediate dilution.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If you purchase our ADSs in the U.S. offering or ordinary shares in the European offering, you will experience substantial and immediate dilution of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS or &euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share in the net tangible book value
after giving effect to this offering at an assumed offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
ADS in the U.S. offering and &euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share in the European offering, based on the closing price of our ordinary shares on Euronext Paris (expressed
in U.S.
dollars, as applicable) on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, because the price that you pay will be substantially greater than the net tangible book value per ordinary share or per ADS,
as applicable, that you
acquire. This dilution is due in large part to the fact that our earlier investors paid substantially less than the offering price when they purchased their ordinary shares. You will experience
additional dilution upon exercise of any outstanding founder's share warrants (</FONT><FONT SIZE=2><I>bons de souscription de parts de cr&eacute;ateur d'entreprise)</I></FONT><FONT SIZE=2> and
share warrants (</FONT><FONT SIZE=2><I>bons de souscription d'actions)</I></FONT><FONT SIZE=2> or acquisition of any free shares </FONT><FONT SIZE=2><I>(actions gratuites)</I></FONT><FONT SIZE=2> under
our equity incentive plans, or if we otherwise issue additional shares below the public offering price. For a further description of the dilution that you will experience immediately after this
offering, see the section of this prospectus titled "Dilution." </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Future sales of ordinary shares or ADSs by existing shareholders could depress the market price of our
ordinary shares and ADSs.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If our existing shareholders sell, or indicate an intent to sell, substantial amounts of ordinary shares or ADSs in the public market after the 90-day
contractual lock-up and other legal restrictions on resale discussed in this prospectus lapse, the trading price of our ordinary shares and ADSs could decline significantly and could decline below the
offering price. Upon completion of this offering, we will have outstanding&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares,
approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of which are subject to the 90-day contractual lock-up
referred to above. The representatives of the underwriters may permit us, our directors and our executive officers to sell shares prior to the expiration of the lock-up agreements. See "Underwriting." </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>After
the lock-up agreements pertaining to this offering expire, and based on the number of ordinary shares outstanding upon completion of this offering,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional
shares will be
eligible for sale in the public market,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of which shares are held by directors and executive officers and will be subject to volume limitations under
Rule&nbsp;144 under the
Securities Act of 1933, as amended, or the Securities Act. In addition, the ordinary shares subject to outstanding founder's share warrants (</FONT><FONT SIZE=2><I>bons de souscription de parts de
cr&eacute;ateur d'entreprise)</I></FONT><FONT SIZE=2>, share warrants (</FONT><FONT SIZE=2><I>bons de souscription d'actions)</I></FONT><FONT SIZE=2> and free shares </FONT> <FONT SIZE=2><I>(actions gratuites)</I></FONT><FONT SIZE=2> issued under our
equity incentive plans and the shares reserved for future issuance under our equity incentive plans will become
eligible for sale in the public market in the future, subject to certain legal and contractual limitations. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Following
this offering, we intend to file one or more registration statements with the SEC covering ordinary shares available for future issuance under our equity incentive plans. Upon effectiveness
of such registration statements, any shares subsequently issued under such plans will be eligible for sale in the public market, except to the extent that they are restricted by the lock-up agreements
referred to above and subject to compliance with Rule&nbsp;144 in the case of our affiliates. Sales of a large number of the shares issued under these plans in the public market could have an
adverse effect on the market price of our ordinary shares and ADSs. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>See
the section of this prospectus titled "Shares and ADSs eligible for future sale" for a more detailed description of sales that may occur in the future. If these additional shares or ADSs are sold,
or if it is perceived that they will be sold, in the public market, the trading price of our ordinary shares and ADSs could decline substantially. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>63</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=67,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=896703,FOLIO='63',FILE='DISK116:[20ZBV1.20ZBV74901]CM74901A.;13',USER='JFUSS',CD='10-APR-2020;08:10' -->
<A NAME="page_cm74901_1_64"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The rights of shareholders in companies subject to French corporate law differ in material respects from the
rights of shareholders of corporations incorporated in the United States.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are a French public limited company (</FONT><FONT SIZE=2><I>soci&eacute;t&eacute; anonyme</I></FONT><FONT SIZE=2>). Our corporate affairs are
governed by our bylaws and by the laws governing companies incorporated in France. The rights of shareholders and the responsibilities of members of our board of directors are in many ways different
from the rights and obligations of shareholders in companies governed by the laws of U.S. jurisdictions. For example, in the performance of its duties, our board of directors is required by French law
to consider the interests of our company, its shareholders, its employees and other stakeholders, rather than solely our shareholders and/or creditors. It is possible that some of these parties will
have interests that are different from, or in addition to, your interests as a shareholder or holder of ADSs. Further, in accordance with French law, double voting rights automatically attach to each
ordinary share of companies listed on a regulated market (such as the Euronext Paris, where our ordinary shares are listed) that is held of record in the name (</FONT><FONT SIZE=2><I>action au
nominatif</I></FONT><FONT SIZE=2>) of the same shareholder for a period of at least two years, except as otherwise set forth in a company's bylaws. Our bylaws currently do not exclude such double
voting rights; however, the holders of two-thirds of our outstanding voting rights may vote to amend our bylaws to exclude such double voting rights at any extraordinary general meeting of our
shareholders. See "Management&nbsp;&#151; Corporate Governance Practices" and "Description of Share Capital." </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our bylaws and French corporate law contain provisions that may delay or discourage a takeover attempt.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Provisions contained in our bylaws and French corporate law could make it more difficult for a third-party to acquire us, even if doing so might be beneficial
to our shareholders. In addition, provisions of our bylaws impose various procedural and other requirements, which could make it more difficult for shareholders to effect certain corporate actions.
These provisions include the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> under French law, the owner of 90% of the share capital and voting rights of a public
company with registered seat in France and whose shares are listed on a regulated market in a Member State of the European Union or in a state party to the European Economic Area, or EEA, Agreement,
including France, has the right to force out minority shareholders following a tender offer made to all shareholders; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> under French law, a non-French resident must file&nbsp;a declaration for statistical
purposes with the Bank of France (</FONT><FONT SIZE=2><I>Banque de France</I></FONT><FONT SIZE=2>) within twenty working days following the date of certain direct foreign investments in us, including
any purchase of our ADSs. In particular, such filings are required in connection with investments exceeding &euro;&nbsp;15&nbsp;million that lead to the acquisition of at least
10% of our Company's share capital or voting rights or cross such 10% threshold; see the section of this prospectus titled "Limitations affecting shareholders of a French company"; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> under French law, certain investments in a French company relating to certain strategic
industries by individuals or entities are subject to prior authorization of the Ministry of Economy pursuant to Law n&deg;2019-486 (and as from April&nbsp;1st, 2020 pursuant to the decree
n&deg;2019-1590); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a merger (i.e.,&nbsp;in a French law context, a stock for stock exchange following
which our company would be dissolved into the acquiring entity and our shareholders would become shareholders of the acquiring entity) of our company into a company incorporated in the European Union
would require the approval of our board of directors as well as a two-thirds majority of the votes held (of the votes cast, as from our general shareholders' meeting convened to vote on the financial
statements for the year ended December&nbsp;31, 2019) by the shareholders present, represented by proxy or voting by mail at the relevant meeting; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a merger of our company into a company incorporated outside of the European Union would
require 100% of our shareholders to approve it; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>64</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=68,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=334500,FOLIO='64',FILE='DISK116:[20ZBV1.20ZBV74901]CM74901A.;13',USER='JFUSS',CD='10-APR-2020;08:10' -->
<A NAME="page_cm74901_1_65"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> under French law, a cash merger is treated as a share purchase and would require the
consent of each participating shareholder; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our shareholders have granted and may grant in the future our board of directors broad
authorizations to increase our share capital or to issue additional ordinary shares or other securities, such as warrants, to our shareholders, the public or qualified investors, including as a
possible defense following the launching of a tender offer for our shares; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our shareholders have preferential subscription rights on a pro rata basis on the
issuance by us of any additional securities for cash or a set-off of cash debts, which rights may only be waived by the extraordinary general meeting (by a two-thirds majority vote) of our
shareholders or on an individual basis by each shareholder; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our Chief Executive Officer and Deputy Chief Executive Officer have double voting rights
with respect to ordinary shares held by them, and their interests may not be aligned with those of our shareholders more generally with respect to a takeover attempt; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our board of directors has the right to appoint directors to fill a vacancy created by
the resignation or death of a director, for the remaining duration of such director's term of office and subject to the approval by the shareholders of such appointment at the next shareholders'
meeting, which prevents shareholders from having the sole right to fill vacancies on our board of directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our board of directors can be convened by our chairman, or our managing director, if any,
upon request made to the chairman or, when no board meeting has been held for more than three consecutive months, by directors representing at least one third of the total number of directors; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our board of directors meetings can only be regularly held if at least half of the
directors attend either physically or by way of videoconference or teleconference enabling the directors' identification and ensuring their effective participation in the board's decisions; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our shares are nominative or bearer, if the legislation so permits, according to the
shareholder's choice; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> approval of at least a majority of the votes held (of the votes cast, as from our general
shareholders' meeting convened to vote on the financial statements for the year ended December&nbsp;31, 2019) by shareholders present, represented by a proxy, or voting by mail at the relevant
ordinary shareholders' general meeting is required to remove directors with or without cause; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> advance notice is required for nominations to the board of directors or for proposing
matters to be acted upon at a shareholders' meeting, except that a vote to remove and replace a director can be proposed at any shareholders' meeting without notice; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our bylaws can be amended in accordance with applicable laws; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the crossing of certain thresholds has to be disclosed and can impose certain
obligations; see "Description of Share Capital&nbsp;&#151; Key provision of our bylaws and French law affecting our ordinary shares&nbsp;&#151; Declaration of crossing of ownership
thresholds (Article&nbsp;11 of the bylaws)"; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> transfers of shares shall comply with applicable insider trading laws and regulations
and, in particular, with the Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16&nbsp;April 2014 on market abuse, or Market Abuse Regulation; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> pursuant to French law, our bylaws, including the sections relating to the number of
directors and election and removal of a director from office, may only be modified by a resolution adopted by at least a two-third majority of the votes held (of the votes cast, as from our general
shareholders' meeting convened to vote on the financial statements for the year ended December&nbsp;31, 2019) of our shareholders present, represented by a proxy or voting by mail at the meeting. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>65</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=69,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=492815,FOLIO='65',FILE='DISK116:[20ZBV1.20ZBV74901]CM74901A.;13',USER='JFUSS',CD='10-APR-2020;08:10' -->
<A NAME="page_cm74901_1_66"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Holders of our ADSs are not treated as shareholders of our company.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>By participating in the U.S. offering you will become a holder of ADSs with underlying shares in a French public limited company
(</FONT><FONT SIZE=2><I>soci&eacute;t&eacute; anonyme</I></FONT><FONT SIZE=2>). Holders of our ADSs are not treated as shareholders of our company, unless they withdraw the ordinary
shares underlying our ADSs. The depositary, or its nominee, is the holder of the ordinary shares underlying our ADSs. Holders of ADSs therefore do not have any rights as shareholders of our company,
other than the rights that they have pursuant to the deposit agreement. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


You may not be able to exercise your right to vote the ordinary shares underlying your ADSs.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Holders of ADSs may exercise voting rights with respect to the ordinary shares represented by the ADSs only in accordance with the provisions of the deposit
agreement. The deposit agreement provides that, upon receipt of notice of any meeting of holders of our ordinary shares, the depositary will fix a record date for the determination of ADS holders who
shall be entitled to give instructions for the exercise of voting rights. Upon timely receipt of notice from us, if we so request, the depositary shall distribute to the holders as of the record date
(1)&nbsp;the notice of the meeting or solicitation of consent or proxy sent by us and (2)&nbsp;a statement as to the manner in which instructions may be given by the holders. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Holders
of ADSs may instruct the depositary of their ADSs to vote the ordinary shares underlying their ADSs. Otherwise, ADS holders will not be able to exercise their right to vote, unless they
withdraw the ordinary shares underlying the ADSs they hold. However, ADS holders may not know about the meeting far enough in advance to withdraw those ordinary shares. If we ask for instructions from
holders of ADSs, the depositary, upon timely notice from us, will notify them of the upcoming vote and arrange to deliver our voting materials to them. We cannot guarantee ADS holders that they will
receive the voting materials in time to ensure that they can instruct the depositary to vote their ordinary shares or to withdraw their ordinary shares so that they can vote them themselves. If the
depositary does not receive timely voting instructions from a holder of ADSs, it may give a proxy to a person designated by us to vote the ordinary shares underlying such holder's ADSs. In addition,
the depositary and its
agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions. This means that ADS holders may not be able to exercise their right to
vote, and there may be nothing they can do if the ordinary shares underlying their ADSs are not voted as they requested. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The right as a holder of ADSs to participate in any future preferential subscription rights or to elect to
receive dividends in shares may be limited, which may cause dilution to the holdings of purchasers of ADSs in the U.S. offering.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>According to French law, if we issue additional securities for cash, current shareholders will have preferential subscription rights for these securities on a
pro rata basis unless they waive those rights at an extraordinary meeting of our shareholders (by a two-thirds majority vote) or individually by each shareholder. However, our ADS holders in the
United States will not be entitled to exercise or sell such rights unless we register the rights and the securities to which the rights relate under the Securities Act or an exemption from the
registration requirements is available. In addition, the deposit agreement provides that the depositary will not make rights available to purchasers of ADSs in the U.S. offering unless the
distribution to ADS holders of both the rights and any related securities are either registered under the Securities Act or exempted from registration under the Securities Act. Further, if we offer
holders of our ordinary shares the option to receive dividends in either cash or shares, under the deposit agreement the depositary may require satisfactory assurances from us that extending the offer
to holders of ADSs does not require registration of any securities under the Securities Act before making the option available to holders of ADSs. We are under no obligation to file&nbsp;a
registration statement with respect to any such rights or securities or to endeavor to cause such a registration statement to be declared effective. Moreover, we may not be able to establish an
exemption from registration under the Securities Act. Accordingly, ADS holders may be unable to participate in our rights offerings or to elect to receive dividends in shares and may experience
dilution in their holdings. In addition, if the depositary is unable to sell rights that are not exercised or not distributed or if </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>66</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=70,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=155880,FOLIO='66',FILE='DISK116:[20ZBV1.20ZBV74901]CM74901A.;13',USER='JFUSS',CD='10-APR-2020;08:10' -->
<A NAME="page_cm74901_1_67"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>the
sale is not lawful or reasonably practicable, it will allow the rights to lapse, in which case you will receive no value for these rights. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Holders of ADSs may be subject to limitations on the transfer of their ADSs and the withdrawal of the
underlying ordinary shares.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>ADSs are transferable on the books of the depositary. However, the depositary may close its books at any time or from time to time when it deems expedient in
connection with the performance of its duties. The depositary may refuse to deliver, transfer or register transfers of ADSs generally when our books or the books
of the depositary are closed, or at any time if we or the depositary think it is advisable to do so because of any requirement of law, government or governmental body, or under any provision of the
deposit agreement, or for any other reason, subject to the right of ADS holders to cancel their ADSs and withdraw the underlying ordinary shares. Temporary delays in the cancellation of your ADSs and
withdrawal of the underlying ordinary shares may arise because the depositary has closed its transfer books or we have closed our transfer books, the transfer of ordinary shares is blocked to permit
voting at a shareholders' meeting or we are paying a dividend on our ordinary shares. In addition, ADS holders may not be able to cancel their ADSs and withdraw the underlying ordinary shares when
they owe money for fees, taxes and similar charges and when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal
of ordinary shares or other deposited securities. See "Description of American Depositary Shares&nbsp;&#151; Your right to receive the ordinary shares underlying your ADSs." </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


ADS holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement,
which could result in less favorable outcomes to the plaintiff(s) in any such action.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The deposit agreement governing our ADSs provides that holders and beneficial owners of ADSs irrevocably waive the right to a trial by jury in any legal
proceeding arising out of or relating to the deposit agreement or the ADSs, including in respect of claims under federal securities laws, against us or the depositary to the fullest extent permitted
by applicable law. If this jury trial waiver provision is prohibited by applicable law, an action could nevertheless proceed under the terms of the deposit agreement with a jury trial. To our
knowledge, the enforceability of a jury trial waiver under the federal securities laws has not been finally adjudicated by a federal court. However, we believe that a jury trial waiver provision is
generally enforceable under the laws of the State of New York, which govern the deposit agreement, by a court of the State of New York or a federal court, which have non-exclusive jurisdiction over
matters arising under the deposit agreement, applying such law. In determining whether to enforce a jury trial waiver provision, New York courts and federal courts will consider whether the visibility
of the jury trial waiver provision within the agreement is sufficiently prominent such that a party has knowingly waived any right to trial by jury. We believe that this is the case with respect to
the deposit agreement and the ADSs. In addition, New York courts will not enforce a jury trial waiver provision in order to bar a viable setoff or counterclaim sounding in fraud or one which is based
upon a creditor's negligence in failing to liquidate collateral upon a guarantor's demand, or in the case of an intentional tort claim (as opposed to a contract dispute), none of which we believe are
applicable in the case of the deposit agreement or the ADSs. No condition, stipulation or provision of the deposit agreement or ADSs serves as a waiver by any holder or beneficial owner of ADSs or by
us or the depositary of compliance with any provision of the federal securities laws. If you or any other holder or beneficial owner of ADSs brings a claim against us or the depositary in connection
with such matters, you or such other holder or beneficial owner may not be entitled to a jury trial with respect to such claims, which may have the effect of limiting and discouraging lawsuits against
us and/or the depositary. If a lawsuit is brought against us and/or the depositary under the deposit agreement, it may be heard only by a judge or justice of the applicable trial court, which would be
conducted according to different civil procedures and may result in different outcomes than a trial by jury would have had, including results that could be less favorable to the plaintiff(s) in any
such action, depending on, among other things, the nature of the claims, the judge or justice hearing such claims, and the venue of the hearing. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>67</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=71,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=943442,FOLIO='67',FILE='DISK116:[20ZBV1.20ZBV74901]CM74901A.;13',USER='JFUSS',CD='10-APR-2020;08:10' -->
<A NAME="page_cm74901_1_68"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We are an "emerging growth company" under the JOBS Act and will be able to avail ourselves of reduced
disclosure requirements applicable to emerging growth companies, which could make our ordinary shares or ADSs less attractive to investors.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are an "emerging growth company," as defined in the U.S. Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we intend to take advantage of
certain exemptions from various reporting requirements that are applicable to other public companies that are not "emerging growth companies," including not being required to comply with the auditor
attestation requirements of Section&nbsp;404(b) of the Sarbanes-Oxley Act, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder
approval of any golden parachute payments not previously approved. In addition, Section&nbsp;107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended
transition period provided in Section&nbsp;7(a)(2)(B) of the U.S. Securities Act of 1933, as amended, or the Securities Act, for complying with new or revised accounting standards. We will not take
advantage of the extended transition period provided under Section&nbsp;7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. Since IFRS makes no distinction
between public and private companies for purposes of compliance with new or revised accounting standards, the requirements for our compliance as a private company and as a public company are the same. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
cannot predict if investors will find our ordinary shares or ADSs less attractive because we may rely on these exemptions. If some investors find our ordinary shares or ADSs less attractive as a
result, there may be a less active trading market for our ordinary shares or ADSs and the price of our ordinary shares or ADSs may be more volatile. We may take advantage of these reporting exemptions
until we are no longer an emerging growth company. We will remain an emerging growth company until the earliest of (1)&nbsp;the last day of the fiscal year in which we have total annual gross
revenue of $1.07&nbsp;billion or more; (2)&nbsp;the last day of our fiscal year following the fifth anniversary of the date of the completion of this offering; (3)&nbsp;the date on which we have
issued more than $1.0&nbsp;billion in nonconvertible debt during the previous three years; and (4)&nbsp;the date on which we are deemed to be a large accelerated filer under the rules of the SEC. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


As a foreign private issuer, we are exempt from a number of rules under the U.S. securities laws and are
permitted to file less information with the SEC than a U.S. company. This may limit the information available to holders of ordinary shares or ADSs.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are a foreign private issuer, as defined in the SEC's rules and regulations and, consequently, we are not subject to all of the disclosure requirements
applicable to public companies organized
within the United States. For example, we are exempt from certain rules under the Exchange Act that regulate disclosure obligations and procedural requirements related to the solicitation of proxies,
consents or authorizations applicable to a security registered under the Exchange Act, including the U.S. proxy rules under Section&nbsp;14 of the Exchange Act. In addition, our officers and
directors are exempt from the reporting and "short-swing" profit recovery provisions of Section&nbsp;16 of the Exchange Act and related rules with respect to their purchases and sales of our
securities. Moreover, while we currently make annual and semi-annual filings with respect to our listing on Euronext Paris and expect to file financial reports on an annual and semi-annual basis, we
will not be required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. domestic issuers and will not be required to file quarterly reports on
Form&nbsp;10-Q or current reports on Form&nbsp;8-K under the Exchange Act. Accordingly, there will be less publicly available information concerning our company than there would be if we were not
a foreign private issuer. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


As a foreign private issuer, we are permitted and we expect to follow certain home country practices in
relation to corporate governance matters that differ significantly from Nasdaq's corporate governance standards. These practices may afford less protection to shareholders than they would enjoy if we
complied fully with the corporate governance standards of the Nasdaq Global Market.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As a foreign private issuer listed on the Nasdaq Global Market, we will be subject to Nasdaq's corporate governance standards. However, Nasdaq rules provide
that foreign private issuers are permitted to follow </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>68</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=72,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=1031243,FOLIO='68',FILE='DISK116:[20ZBV1.20ZBV74901]CM74901A.;13',USER='JFUSS',CD='10-APR-2020;08:10' -->
<A NAME="page_cm74901_1_69"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>home
country corporate governance practices in lieu of Nasdaq's corporate governance standards as long as notification is provided to Nasdaq of the intention to take advantage of such exemptions. We
intend to rely on exemptions for foreign private issuers and follow French corporate governance practices in lieu of Nasdaq's corporate governance standards, to the extent possible. Certain corporate
governance practices in France, which is our home country, may differ significantly from Nasdaq corporate governance standards. For example, as a French company, neither the corporate laws of France
nor our bylaws require a majority of our directors to be independent and we can include non-independent directors as members of our remuneration committee, and our independent directors are not
required to hold regularly scheduled meetings at which only independent directors are present. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
are also exempt from provisions set forth in Nasdaq rules which require an issuer to provide in its bylaws for a generally applicable quorum, and that such quorum may not be less than one-third of
the outstanding voting stock. Consistent with French law, our bylaws provide that, at the first meeting convened, a quorum requires the presence of shareholders having at least (1)&nbsp;20% of the
shares entitled to vote in the case of an ordinary shareholders' general meeting or at an extraordinary shareholders' general meeting where shareholders are voting on a capital increase by
capitalization of reserves, profits or share premium (in case of lack of quorum, no quorum is required at the second meeting convened), or (2)&nbsp;25% of the shares entitled to vote in the case of
any other
extraordinary shareholders' general meeting (in case of lack of quorum, it is decreased to at least 20% of the shares entitled to vote at the second meeting convened). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
a foreign private issuer, we are required to comply with Rule&nbsp;10A-3 of the Exchange Act, relating to audit committee composition and responsibilities. Under French law, the audit committee
may only have an advisory role and appointment of our statutory auditors, in particular, must be decided by the shareholders at our annual meeting. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Therefore,
our shareholders may be afforded less protection than they otherwise would have under Nasdaq's corporate governance standards applicable to U.S. domestic issuers. For an overview of our
corporate governance practices, see "Management&nbsp;&#151; Corporate Governance Practices." </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may lose our foreign private issuer status in the future, which could result in significant additional
cost and expense.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>While we currently qualify as a foreign private issuer, the determination of foreign private issuer status is made annually on the last business day of an
issuer's most recently completed second fiscal quarter and, accordingly, the next determination will be made with respect to us on June&nbsp;30, 2020. In the future, we would lose our foreign
private issuer status if we fail to meet the requirements necessary to maintain our foreign private issuer status as of the relevant determination date. We will remain a foreign private issuer until
such time that more than 50% of our outstanding voting securities are held by U.S. residents and any of the following three circumstances applies: (1)&nbsp;the majority of our executive officers or
directors are U.S. citizens or residents; (2)&nbsp;more than 50% of our assets are located in the United States; or (3)&nbsp;our business is administered principally in the United States. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
regulatory and compliance costs to us under U.S. securities laws as a U.S. domestic issuer may be significantly more than costs we incur as a foreign private issuer. If we are not a foreign
private issuer, we will be required to file periodic reports and registration statements on U.S. domestic issuer forms with the SEC, which are more detailed and extensive in certain respects than the
forms available to a foreign private issuer. We would be required under current SEC rules to prepare our financial statements in accordance with U.S.&nbsp;GAAP, rather than IFRS, and modify certain
of our policies to comply with corporate governance practices associated with U.S. domestic issuers. Such conversion of our financial statements to U.S.&nbsp;GAAP would involve significant time and
cost. In addition, we may lose our ability to rely upon exemptions from certain corporate governance requirements on U.S. stock exchanges that are available to foreign private issuers such as the ones
described herein and exemptions from procedural requirements related to the solicitation of proxies. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>69</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=73,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=329627,FOLIO='69',FILE='DISK116:[20ZBV1.20ZBV74901]CM74901A.;13',USER='JFUSS',CD='10-APR-2020;08:10' -->
<A NAME="page_cm74901_1_70"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


U.S. investors may have difficulty enforcing civil liabilities against our company and directors and senior
management and the experts named in this prospectus.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Certain members of our board of directors and senior management and certain experts named in this prospectus are non-residents of the United States, and all or
a substantial portion of our assets and the assets of such persons are located outside the United States. As a result, it may not be possible to serve process on such persons or us in the United
States or to enforce judgments obtained in U.S. courts against them or us based on civil liability provisions of the securities laws of the United States. Additionally, it may be difficult to assert
U.S. securities law claims in actions originally instituted outside of the United States. Foreign courts may refuse to hear a U.S. securities law claim because foreign courts may not be the most
appropriate forums in which to bring such a claim. Even if a foreign court agrees to hear a claim, it may determine that the law of the jurisdiction in which the foreign court resides, and not U.S.
law, is applicable to the claim. Further, if U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact, which can be a time-consuming and costly process, and
certain matters of procedure would still be governed by the law of the jurisdiction in which the foreign court resides. In particular, there is some doubt as to whether French courts would recognize
and enforce certain civil liabilities under U.S. securities laws in original actions or judgments of U.S. courts based upon these civil liability provisions. In addition, awards of punitive damages in
actions brought in the United States or elsewhere may be unenforceable in France. An award for monetary damages under the U.S. securities laws would be considered punitive if it does not seek to
compensate the claimant for loss or damage suffered but is intended to punish the defendant. French law provides that a shareholder, or a group of shareholders, may initiate a legal action to seek
indemnification from the directors of a corporation in the corporation's interest if it fails to bring such legal action itself. If so, any damages awarded by the court are paid to the corporation and
any legal fees relating to such action may be borne by the relevant shareholder or the group of shareholders. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
enforceability of any judgment in France will depend on the particular facts of the case as well as the laws and treaties in effect at the time. The United States and France do not currently have
a treaty providing for recognition and enforcement of judgments (other than arbitration awards) in civil and commercial matters. See "Enforcement of civil liabilities." </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


After the completion of this offering, we may be at an increased risk of securities class action litigation.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Historically, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk
is especially relevant for us because biotechnology and biopharmaceutical companies have experienced significant share price volatility in recent years. If we were to be sued, it could result in
substantial costs and a diversion of management's attention and resources, which could harm our business. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


U.S. holders of our ADSs may suffer adverse tax consequences if we are characterized as a passive foreign
investment company.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Generally, if, for any taxable year, at least 75% of our gross income is passive income, or at least 50% of the value of our assets is attributable to assets
that produce passive income or are held for the production of passive income, we would be characterized as a passive foreign investment company, or PFIC, for U.S. federal income tax purposes. For
purposes of these tests, passive income includes dividends, interest, and gains from the sale or exchange of investment property and rents and royalties other than rents and royalties which are
received from unrelated parties in connection with the active conduct of a trade or business. Assets that produce or are held for the production of passive income may include cash, even if held as
working capital or raised in a public offering, marketable securities, and other assets that may produce passive income. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
status as a PFIC will depend on the composition of our income and the composition and value of our assets (which, may be determined in large part by reference to the market value of our ordinary
shares and </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>70</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=74,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=920251,FOLIO='70',FILE='DISK116:[20ZBV1.20ZBV74901]CM74901A.;13',USER='JFUSS',CD='10-APR-2020;08:10' -->
<A NAME="page_cm74901_1_71"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>ADSs,
which may be volatile) from time to time. Our status may also depend, in part, on how quickly we utilize the cash proceeds from this offering in our business. With respect to the taxable year
ended December&nbsp;31, 2019, we believe that we were a PFIC and it is possible that we will be classified as a PFIC for the current year. However, our status as a PFIC is a fact-intensive
determination made on an annual basis and we cannot provide any assurances regarding our PFIC status for the past, current or future taxable years. If we are characterized as a PFIC, our U.S. holders
may suffer adverse tax consequences, including having gains realized on the sale of our ADSs treated as ordinary income, rather than as capital gain and the loss of the preferential rate applicable to
dividends received on our ADSs by individuals who are U.S. holders, and having interest charges apply to distributions by us and the proceeds of sales of the ADSs. A U.S. shareholder of a PFIC
generally may mitigate these adverse U.S. federal income tax consequences by making a "qualified electing fund," or QEF, election, or, to a lesser extent, a "mark to market" election. If we determine
that we are a PFIC for any taxable year, we will use commercially reasonable efforts to, and currently expect to, provide the necessary information for U.S. holders to make a QEF election. See
"Material U.S. Federal Income and French Tax Considerations&nbsp;&#151; Material U.S. Federal Income Tax Considerations for U.S. Holders&nbsp;&#151; Passive Foreign Investment
Company Considerations". </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>71</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=75,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=570042,FOLIO='71',FILE='DISK116:[20ZBV1.20ZBV74901]CM74901A.;13',USER='JFUSS',CD='10-APR-2020;08:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_co74901_1_72"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A NAME="co74901_special_note_regarding_forward-looking_statements"> </A>
<A NAME="toc_co74901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This prospectus, particularly the sections of this prospectus titled "Prospectus summary," "Risk Factors," "Management's Discussion and Analysis of Financial
Condition and Results of Operations" and "Business," contains forward-looking statements. All statements other than present and historical facts and conditions contained in this prospectus, including
statements regarding our future results of operations and financial position, business strategy, plans and our objectives for future operations, are forward-looking statements. When used in this
prospectus, the words "anticipate," "believe," "can," "could," "estimate," "expect," "intend," "is designed to," "may," "might," "plan," "potential," "predict," "objective," "should," or the negative
of these and similar expressions identify forward-looking statements. Forward-looking statements include, but are not limited to, statements
about:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our plans to develop and commercialize our product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the timing of initiation of our planned clinical trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the timing of the availability of data from our clinical trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the timing of any planned investigational new drug application or new drug application; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our plans to research, develop and commercialize our current and future product
candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to successfully collaborate with existing collaborators or enter into new
collaborations, and to fulfill our obligations under any such collaboration agreements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the clinical utility, potential benefits and market acceptance of our product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our commercialization, marketing and manufacturing capabilities and strategy; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to identify additional products or product candidates with significant
commercial potential; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our expectations related to the sufficiency of our capital resources and our use of
proceeds from this offering; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> developments and projections relating to our competitors and our industry; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the impact of government laws and regulations; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the potential effects of the recent COVID-19 pandemic on our business and, operations and
clinical development timelines and plans; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our intellectual property position; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our estimate regarding future revenue, expenses, capital requirements and need for
additional financing. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>You
should refer to the section of this prospectus titled "Risk Factors" for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by
our forward-looking
statements. As a result of these factors, we cannot assure you that the forward-looking statements in this prospectus will prove to be accurate. Furthermore, if our forward-looking statements prove to
be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by
us or any other person that we will achieve our objectives and plans in any specified time frame or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a
result of new information, future events or otherwise, except as required by law. The Private Securities Litigation Reform Act of 1995 and Section&nbsp;27A of the Securities Act do not protect any
forward-looking statements that we make in connection with this offering. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>72</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=76,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=9265,FOLIO='72',FILE='DISK116:[20ZBV1.20ZBV74901]CO74901A.;12',USER='JFUSS',CD='10-APR-2020;08:13' -->
<A NAME="page_co74901_1_73"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of
this prospectus, and while we believe such information forms&nbsp;a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to
indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to
unduly rely upon these statements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>You
should read this prospectus and the documents that we reference in this prospectus and have filed with the SEC as exhibits to the registration statement of which this prospectus is a part with the
understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect. We qualify all of our forward-looking
statements by these cautionary statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>73</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=77,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=548247,FOLIO='73',FILE='DISK116:[20ZBV1.20ZBV74901]CO74901A.;12',USER='JFUSS',CD='10-APR-2020;08:13' -->
<A NAME="page_co74901_1_74"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A NAME="co74901_use_of_proceeds"> </A>
<A NAME="toc_co74901_2"> </A>
<BR></FONT><FONT SIZE=2><B>  USE OF PROCEEDS    <BR>    </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We estimate that we will receive net proceeds from this global offering of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
(&euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) million, assuming
an offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS in the U.S. offering and &euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
ordinary share in the European offering, based on the closing price of our ordinary shares
on Euronext Paris (expressed in U.S. dollars, as applicable)
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;, 2020, after deducting underwriting commissions and estimated offering expenses payable by us. If the underwriters
exercise in full their option to purchase additional ADSs
and/or ordinary shares in this global offering, we estimate that we will receive net proceeds from the offering of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
(&euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) million, based on
the same assumptions stated above. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Each
$1.00 (&euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) increase or decrease in the assumed offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS in the U.S. offering and &euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary
share in the European offering would increase or decrease our net proceeds from the offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
(&euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) million, assuming the number of ADSs and ordinary
shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting underwriting commissions and estimated offering expenses payable by us. We may also
increase or decrease the number of ordinary shares (including in the form of ADSs) that we are offering. Each increase or decrease of 1,000,000 ordinary shares (including ordinary shares in the form
of ADSs) offered by us would increase or decrease the net proceeds to us by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
(&euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) million, assuming that the assumed offering price remains
the same and after deducting underwriting commissions and estimated offering expenses payable by us. The actual net proceeds payable to us will adjust based on the actual number of ADSs and ordinary
shares, respectively, offered by us, the actual offering price and other terms of the offering determined at pricing. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
currently expect to use the net proceeds from this offering, together with our existing cash and cash equivalents, as
follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to complete preparations for and initiate a
Phase&nbsp;III clinical trial of lanifibranor for the treatment of patients with NASH; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to complete our planned Phase Ib/II
clinical trial of odiparcil in a pediatric population with MPS VI, initiate our planned label Phase&nbsp;IIa extension study of odiparcil in patients 16 years and above with MPS VI and initiate
Phase&nbsp;III clinical development of odiparcil as a monotherapy and in combination with ERT for the treatment of adult and pediatric patients with MPS&nbsp;VI; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to advance development of our Hippo
pathway
signaling program and other pre-clinical programs; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the balance for working capital and general corporate purposes. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>This
expected use of the net proceeds from the offering represents our intentions based upon our current plans, business conditions and clinical trials to date. As of the date of this prospectus, we
cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion of the offering or the amounts that we will actually spend on the uses set forth above. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Based
on our planned use of the net proceeds of this offering, and our current cash and cash equivalents, we estimate that such funds will be sufficient to enable us
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;. We have based
this estimate on assumptions that may prove to be incorrect, and we could use our available capital resources sooner than we currently expect. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
management will have significant flexibility in applying the net proceeds of this offering. The timing and amount of our actual expenditures will be based on many factors, including the progress,
cost and results of product development and clinical research and trials, the expenses we incur in our sales and </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>74</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=78,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=967325,FOLIO='74',FILE='DISK116:[20ZBV1.20ZBV74901]CO74901A.;12',USER='JFUSS',CD='10-APR-2020;08:13' -->
<A NAME="page_co74901_1_75"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>marketing
efforts, the scope of research and development efforts and other factors described under "Risk Factors" elsewhere in this prospectus, as well as the amount of cash used in our operations. We
may find it necessary or advisable to use the net proceeds from this offering for other purposes, and our management will have broad discretion in the application of the net proceeds. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Pending
our use of the net proceeds from the offering, we intend to invest the net proceeds in a variety of capital preservation investments, including short-term, investment-grade, interest-bearing
instruments. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>75</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=79,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=1005059,FOLIO='75',FILE='DISK116:[20ZBV1.20ZBV74901]CO74901A.;12',USER='JFUSS',CD='10-APR-2020;08:13' -->
<A NAME="page_co74901_1_76"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A NAME="co74901_dividend_policy"> </A>
<A NAME="toc_co74901_3"> </A>
<BR></FONT><FONT SIZE=2><B>  DIVIDEND POLICY    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have never declared or paid any dividends on our ordinary shares. We do not anticipate paying cash dividends on our ordinary shares or ADSs in the
foreseeable future and intend to retain all available funds and any future earnings for use in the operation and expansion of our business, given our state of development. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Subject
to the requirements of French law and our bylaws, dividends may only be distributed from our distributable profits, plus any amounts held in our available reserves which are reserves other
than legal and statutory and revaluation surplus. See the section of this prospectus titled "Description of Share Capital&nbsp;&#151; Key provisions of our bylaws and French law affecting our
ordinary shares&nbsp;&#151; Rights, preferences and restrictions attaching to ordinary shares (Articles&nbsp;11, 14, 28, 31 and 32 of the bylaws)" for further details on the limitations on
our ability to declare and pay dividends. Dividend distributions, if any in the future, will be made in euros and converted into U.S. dollars with respect to the ADSs, as provided in the deposit
agreement. See "Description of American Depositary Shares&nbsp;&#151; Dividends and other distributions." </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>76</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=80,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=1040356,FOLIO='76',FILE='DISK116:[20ZBV1.20ZBV74901]CO74901A.;12',USER='JFUSS',CD='10-APR-2020;08:13' -->
<A NAME="page_co74901_1_77"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A NAME="co74901_capitalization"> </A>
<A NAME="toc_co74901_4"> </A>
<BR></FONT><FONT SIZE=2><B>  CAPITALIZATION    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following table sets forth our cash and cash equivalents and capitalization as of December&nbsp;31,
2019:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> on an actual basis; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> on an as adjusted basis to reflect the issuance and sale
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADSs and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares in the global offering at an assumed offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS in the U.S. offering and &euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share in the
European offering, based on the closing price of our ordinary shares on Euronext Paris (expressed in U.S. dollars, as applicable)
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, after deducting underwriting commissions and
estimated offering expenses payable by us. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Our
cash and cash equivalents and capitalization following the completion of this offering will depend on the actual offering price and other terms of this offering determined at pricing. The table
should be read in conjunction with the information contained in "Use of Proceeds," "Selected Financial Data" and "Management's Discussion and Analysis of Financial Condition and Results of
Operations," as well as our financial statements and the related notes included elsewhere in this prospectus. </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="140pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="136pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of December&nbsp;31, 2019<BR>
(in thousands, except share<BR>
and per share information) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Actual </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As adjusted(1) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>

<!-- -->
&euro;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>35,840</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
&euro;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Long-term debt, net of current portion</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shareholders' equity:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ordinary shares, nominal value &euro;0.01 per share: 26,846,112 shares issued and outstanding,
actual;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, as adjusted</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>268</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Premiums related to share capital</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>86,012</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Reserves</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(14,670</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss for the period</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(30,218</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total shareholders' equity</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>41,392</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total capitalization</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
&euro;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>41,394</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
&euro;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Each
$1.00 (&euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) increase or decrease in the assumed offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS in the U.S. offering and
&euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share in the European offering, based on the closing price of our ordinary shares on Euronext Paris (expressed in U.S. dollars, as
applicable) on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;, 2020, would increase or decrease each of cash and cash equivalents, total shareholders' equity and total capitalization by approximately
&euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the number of ADSs and ordinary shares offered by us, as set forth on the cover page of this prospectus, remains the same and
after
deducting underwriting commissions and estimated offering expenses payable by us. We may also increase or decrease the number of ordinary shares (including ordinary shares in the form of ADSs) we are
offering. Each increase or decrease of 1,000,000 ordinary shares (including ordinary shares in the form of ADSs) offered by us would increase or decrease each of total shareholders' equity and total
capitalization by approximately &euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the assumed offering price remains the same, and after deducting underwriting commissions and
estimated
offering expenses payable by us. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>77</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=81,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=992235,FOLIO='77',FILE='DISK116:[20ZBV1.20ZBV74901]CO74901A.;12',USER='JFUSS',CD='10-APR-2020;08:13' -->
<A NAME="page_co74901_1_78"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The number of ordinary shares (including ordinary shares in the form of ADSs) that will be outstanding after the global offering is based on 26,846,112 ordinary
shares outstanding as of December&nbsp;31, 2019 and excludes:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 274,800 ordinary shares issuable upon the exercise of founder's share warrants
(</FONT><FONT SIZE=2><I>bons de souscription de parts de cr&eacute;ateur d'entreprise</I></FONT><FONT SIZE=2>) and share warrants (</FONT><FONT SIZE=2><I>bons de souscription
d'actions</I></FONT><FONT SIZE=2>) outstanding as of December&nbsp;31, 2019 at a weighted average exercise price of &euro;6.06 per ordinary share ($6.79 per ordinary share based on the
exchange rate in effect as of December&nbsp;31, 2019); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 556,050 ordinary shares issuable upon the vesting of free shares
(</FONT><FONT SIZE=2><I>actions gratuites</I></FONT><FONT SIZE=2>) outstanding as of December&nbsp;31, 2019; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 15,879,556 ordinary shares reserved for future issuance under our share-based
compensation plans and other delegations of authority from our shareholders; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 3,778,338 ordinary shares issued at a purchase price of &euro;3.97 per share
in connection with a private placement, the settlement of which occurred on February&nbsp;11, 2020. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>78</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=82,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=728733,FOLIO='78',FILE='DISK116:[20ZBV1.20ZBV74901]CO74901A.;12',USER='JFUSS',CD='10-APR-2020;08:13' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_cq74901_1_79"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A NAME="cq74901_dilution"> </A>
<A NAME="toc_cq74901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  DILUTION    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If you invest in our ordinary shares or ADSs in the global offering, your ownership interest will be diluted to the extent of the difference between the
offering price per ordinary share/ADS paid by purchasers in this offering and the as adjusted net tangible book value per ordinary share/ADS, as applicable, after completion of the global offering.
Our net tangible book value as of December&nbsp;31, 2019 was &euro;40.2 ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million), or &euro;1.50 per ordinary share (equivalent to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS),
based on the exchange rate in effect as of December&nbsp;31, 2019. Net tangible book value per ordinary share is determined by dividing (1)&nbsp;our total assets less our intangible assets and our
total liabilities by (2)&nbsp;the number of ordinary shares outstanding as of December&nbsp;31, 2019, or 26,846,112 ordinary shares. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>After
giving effect to our sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADSs
and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares in the global offering at an assumed offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS in the U.S. offering and
&euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share in the European offering, based on the closing price of our ordinary shares on Euronext Paris (expressed in U.S. dollars, as
applicable) on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, and
after deducting underwriting commissions and estimated offering expenses payable by us, our as adjusted net tangible book value at December&nbsp;31, 2019 (based on the exchange rate in effect as of
December&nbsp;31, 2019) would have been approximately &euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million), or &euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share
(equivalent to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS). This represents an immediate increase in net tangible book value of
&euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share (equivalent to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
ADS) to existing shareholders and an immediate dilution in net tangible book value of &euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share (equivalent to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS) to new investors. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
following table illustrates this dilution to new investors on a per ordinary share basis: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="18pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="39pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Assumed offering price per ordinary share</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
&euro;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Historical net tangible book value per ordinary share as of December&nbsp;31, 2019</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
&euro;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1.50</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Increase in net tangible book value per ordinary share attributable to new investors participating in the global offering</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>As adjusted net tangible book value per ordinary share after the global offering</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dilution per ordinary share to new investors participating in the global offering</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
&euro;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>The
dilution information discussed above is illustrative only and will change based on the actual offering price and other terms of the global offering determined at pricing. Each $1.00
(&euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) increase or decrease in the assumed offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
ADS in the U.S. offering and &euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share in the
European offering, based on the closing price of our ordinary shares on Euronext Paris (expressed in U.S. dollars, as applicable)
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, would increase or decrease our as adjusted
net tangible book value by approximately &euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million), or approximately &euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share
(equivalent to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS), and the dilution to new investors participating in the global offering would be approximately
&euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share (equivalent
to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS), assuming that the number of ADSs and ordinary shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after
deducting underwriting
commissions and estimated offering expenses payable by us. We may also increase or decrease the number of ordinary shares and ADSs we are offering. An increase in the aggregate number of ordinary
shares (including in the form of ADSs) offered by us of 1,000,000 ordinary shares would increase the as adjusted net tangible book value by approximately
&euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million), or
&euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share (equivalent to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS), and the dilution to
new investors participating in the global offering would be &euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share (equivalent to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS), assuming that the assumed offering price </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>79</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=83,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=996361,FOLIO='79',FILE='DISK116:[20ZBV1.20ZBV74901]CQ74901A.;15',USER='JFUSS',CD='10-APR-2020;12:44' -->
<A NAME="page_cq74901_1_80"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>remains
the same, and after deducting underwriting commissions and estimated offering expenses payable by us. Similarly, a decrease in the aggregate number of ordinary shares (including in the form of
ADSs) offered by us of 1,000,000 ordinary shares would decrease the as adjusted net tangible book value by approximately &euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million), or &euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share (equivalent to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS), and the dilution to new investors participating in the global
offering would be &euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share (equivalent to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS),
assuming that the assumed offering price remains the same, and after deducting
underwriting commissions and estimated offering expenses payable by us. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
the underwriters exercise their option to purchase additional ordinary shares (including in the form of ADSs) in full, the as adjusted net tangible book value per ordinary share after the offering
would be &euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(equivalent to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS), the increase in the as
adjusted net tangible book value to existing shareholders would be
&euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share (equivalent to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS), and the dilution to
new investors participating in the global offering would be
&euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share (equivalent to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
following table sets forth, as of December&nbsp;31, 2019, on the as adjusted basis described above, consideration paid to us in cash for ordinary shares (including in the form of ADSs) purchased
from us by our existing shareholders and by new investors participating in the global offering, based on an assumed offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS in the U.S.
offering and
&euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share in the European offering, the closing price
of our ordinary shares on Euronext Paris (expressed in U.S. dollars, as applicable)
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, and before deducting underwriting commissions and estimated
offering expenses payable by
us: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="45pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="37pt" style="font-family:arial;"></TD>
<TD WIDTH="18pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="37pt" style="font-family:arial;"></TD>
<TD WIDTH="18pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Ordinary shares<BR>
purchased<BR>
from Us </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Total consideration </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Average<BR>
price per<BR>
ordinary<BR>
share/ADS </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Number </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Percent </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Amount </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Percent </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Existing shareholders</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
&euro;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
&euro;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>New investors</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>100.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
&euro;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>100.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
&euro;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>The
tables and calculations above are based on the number of ordinary shares (including ordinary shares in the form of ADSs) that will be outstanding after this offering, which is based on 26,846,112
ordinary shares outstanding as of December&nbsp;31, 2019 and exclude:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 274,800 ordinary shares issuable upon the exercise of founder's share warrants
(</FONT><FONT SIZE=2><I>bons de souscription de parts de cr&eacute;ateur d'entreprise)</I></FONT><FONT SIZE=2> and share warrants (</FONT><FONT SIZE=2><I>bons de souscription
d'actions)</I></FONT><FONT SIZE=2> outstanding as of December&nbsp;31, 2019 at a weighted average exercise price of &euro;6.06 per ordinary share ($6.79 per ordinary share based on the
exchange rate in effect as of December&nbsp;31, 2019); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 556,050 ordinary shares issuable upon the vesting of free shares
(</FONT><FONT SIZE=2><I>actions gratuites</I></FONT><FONT SIZE=2>) outstanding as of December&nbsp;31, 2019; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 15,879,556 ordinary shares reserved for future issuance under our share-based
compensation plans and other delegations of authority from our shareholders; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 3,778,338 ordinary shares issued at a purchase price of &euro;3.97 per share
in connection with a private placement, the settlement of which occurred on February&nbsp;11, 2020. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>80</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=84,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=613935,FOLIO='80',FILE='DISK116:[20ZBV1.20ZBV74901]CQ74901A.;15',USER='JFUSS',CD='10-APR-2020;12:44' -->
<A NAME="page_cq74901_1_81"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A NAME="cq74901_selected_financial_data"> </A>
<A NAME="toc_cq74901_2"> </A>
<BR></FONT><FONT SIZE=2><B>  SELECTED FINANCIAL DATA    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following selected statement of income (loss) data for the years ended December&nbsp;31, 2018 and 2019 and selected statement of financial position data
as of December&nbsp;31, 2018 and 2019 have been derived from our audited financial statements included elsewhere in this prospectus. Our audited financial statements have been prepared in accordance
with International Financial Reporting Standards, or IFRS as issued by the International Accounting Standards Board. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
historical results are not necessarily indicative of the results that may be expected in the future. You should read this selected data together with our financial statements and related notes
beginning on page&nbsp;F-1 of this prospectus, as well as the sections of this prospectus titled "Management's Discussion and Analysis of Financial Condition and Results of Operations" and the other
financial information included elsewhere in this prospectus. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Selected
Statement of Income (Loss) Data: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="73pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="73pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Year ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands, except share and<BR>
per share data)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Revenues</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
&euro;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3,197</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
&euro;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>6,998</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,182</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,293 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total revenues and other income</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 7,379</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>11,291</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating expenses:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development expenses</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(31,758</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(33,791</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Marketing&nbsp;&#151; Business development expenses</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(225</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(249</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative expenses</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(6,045</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(6,088</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other operating income (expense)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2,255</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(1,475</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total operating expenses</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> (40,282</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>(41,603</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Operating profit (loss)</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> (32,903</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>(30,312</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Financial income (loss)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(111</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>93</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Income tax</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net loss for the period</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>
<!-- -->
&euro;</B></FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>(33,014</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>
<!-- -->
&euro;</B></FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>(30,218</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Basic/diluted loss per share</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
&euro;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(1.61</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
&euro;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(1.28</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted average number of outstanding shares used for computing basic/diluted loss per share</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>20,540,979</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>23,519,897</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>81</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=85,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=1035621,FOLIO='81',FILE='DISK116:[20ZBV1.20ZBV74901]CQ74901A.;15',USER='JFUSS',CD='10-APR-2020;12:44' -->
<A NAME="page_cq74901_1_82"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Selected
Statement of Financial Position Data: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="56pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="56pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
&euro;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>56,692</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
&euro;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>35,840</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>79,812</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>56,960</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>18,216</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>15,568</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total shareholders' equity</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>61,596</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>41,392</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>82</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=86,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=1004116,FOLIO='82',FILE='DISK116:[20ZBV1.20ZBV74901]CQ74901A.;15',USER='JFUSS',CD='10-APR-2020;12:44' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_cs74901_1_83"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A NAME="cs74901_management_s_discussion_and_an__man03466"> </A>
<A NAME="toc_cs74901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION<BR>  AND RESULTS OF OPERATIONS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>You should read the following discussion of our financial condition and results of operations in conjunction with the "Selected
financial data" and our financial statements and the related notes thereto included elsewhere in this prospectus. In addition to historical information, the following discussion and analysis contains
forward-looking statements that reflect our plans, estimates and beliefs. Our actual results and the timing of events could differ materially from those anticipated in the forward-looking statements.
Factors that could cause or contribute to these differences include those discussed below and elsewhere in this prospectus, particularly in sections titled "Risk Factors" and "Special Note Regarding
Forward-Looking Statements." The audited financial statements as of and for the years ended December&nbsp;31, 2019 and 2018 were prepared in accordance with International Financial Reporting
Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB.</I></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Overview  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic
steatohepatitis, or NASH, mucopolysaccharidoses, or MPS, as well as other diseases with significant unmet medical need. We have built a pipeline backed by a discovery engine with an extensive library
of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and experience in the development of compounds that target nuclear receptors,
transcription factors and epigenetic modulation. Leveraging these assets and expertise, we are advancing two clinical candidates, lanifibranor and odiparcil for the treatment of NASH and MPS,
respectively, as well as a deep pipeline of earlier stage programs in oncology and other diseases with significant unmet medical need. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
began our operations in 2012 following the purchase of assets from Abbott Laboratories, or Abbott. Our operations have focused on organizing and staffing our company, business planning, raising
capital, entering into collaboration agreements and conducting pre-clinical and clinical development of our product candidates. We do not have any products approved for sale and have not generated any
revenue from product sales. We received a net aggregate of &euro;96.0&nbsp;million in payments from Abbott pursuant to agreements entered into in connection with our formation, and raised
&euro;44.6&nbsp;million in net proceeds from the initial public offering of our ordinary shares on Euronext Paris in February 2017, followed by &euro;32.4&nbsp;million in net
proceeds from a private placement of our ordinary shares in April 2018, &euro;8.6&nbsp;million in net proceeds from two capital increases for categories of investors in September and
October 2019 and &euro;14.6&nbsp;million in net proceeds from a capital increase for categories of investors in February 2020. We also received payments under our collaboration agreements
with AbbVie,&nbsp;Inc. or AbbVie, and Boehringer Ingelheim International&nbsp;GmbH, or BI, research tax credits, subsidies and bank borrowings. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
have incurred significant operating losses in recent periods. Our net loss was &euro;33.0&nbsp;million and &euro;30.2&nbsp;million for the year ended December&nbsp;31,
2018 and 2019, respectively. As of December&nbsp;31, 2019, we had cash and cash equivalents of &euro;35.8&nbsp;million. We expect to incur significant expenses and substantial operating
losses over the next several years as we advance clinical development and prepare for potential commercialization of lanifibranor and odiparcil and continue our pre-clinical and research and
development efforts. Our net losses may fluctuate significantly from quarter to quarter and year to year, depending on the timing of our clinical trials, the receipt of milestone and other payments,
if any, under our collaboration with AbbVie and our expenditures on other research and development activities. We anticipate that our expenses will increase substantially in connection with our
ongoing activities, as we:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> initiate additional clinical trials of lanifibranor and odiparcil in the United States
and Europe; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> continue the research and development of our pre-clinical programs, including planned and
future clinical trials; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>83</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=87,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=1031158,FOLIO='83',FILE='DISK116:[20ZBV1.20ZBV74901]CS74901A.;12',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_cs74901_1_84"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> seek to discover and develop additional product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> seek regulatory approvals for any product candidates that successfully complete clinical
trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> scale up our manufacturing capabilities to support the launch and commercialization of
our product candidates, if approved; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> establish a sales and marketing infrastructure for the commercialization of our product
candidates, if approved; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> maintain, expand and protect our intellectual property portfolio; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> hire additional clinical, quality control and scientific personnel; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> add operational, financial and management information systems and personnel, including
personnel to support our product development and commercialization efforts and our operations as a public company in the United States. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Financial Operations Overview  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Revenue  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our revenue consists primarily of up-front and milestone payments, as well as service fees, received under our collaboration with AbbVie and prior
collaboration with BI. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under
our collaboration with AbbVie, we developed inverse agonists of the nuclear receptor ROR<FONT FACE="SYMBOL">g</FONT> for the treatment of moderate to severe psoriasis. We completed
performance of our obligations under our initial agreement with AbbVie with respect to our ROR<FONT FACE="SYMBOL">g</FONT> program in August 2018, following a one-year extension, and with
respect to all other programs in March 2019. Since April 2019, we no longer provide research services under our AbbVie collaboration, but remain eligible to receive up to an aggregate of
&euro;35&nbsp;million in future milestone payments, as well as tiered royalties on product sales from the mid-single to low-double (below teens) digits. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Our
collaboration with BI, was focused on the identification of new treatments for idiopathic pulmonary fibrosis and other fibrotic diseases and was ended in November 2019 following the BI's decision
to prioritize other products in its portfolio. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To
date, we have not generated any revenue from the sale of products and do not expect to do so for several years at a minimum. Our ability to generate product revenue and to become profitable will
depend upon our ability to successfully develop and commercialize lanifibranor and odiparcil and our other programs. Because of the numerous risks and uncertainties associated with product development
and regulatory approval, we are unable to predict the amount or timing of product revenue. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Other Income  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our other income consists primarily of research tax credits. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Research
tax credits (</FONT><FONT SIZE=2><I>cr&eacute;dit d'imp&ocirc;t recherche</I></FONT><FONT SIZE=2>), or CIR, are granted by the French tax authorities to encourage technical
and scientific research by French companies. Companies demonstrating that they have expenses that meet the required criteria, including research expenses located in France or certain other European
countries, receive a tax credit that can be used against the payment of the corporate tax due the fiscal year in which the expenses were incurred and during the next three fiscal years. Companies may
receive cash reimbursement for any excess portion. We requested the reimbursement of the CIR for 2018 in 2019 (paid in January 2020) and expect to request the reimbursement of the CIR for 2019 in
2020, in each case under the community tax rules for small and medium sized entities and in compliance with the current regulations. CIRs are subject to audit by the French tax authorities. In August
2018, we received a collection notice in the amount of &euro;1.9&nbsp;million, including penalties and late payment interest, related to our </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>84</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=88,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=777443,FOLIO='84',FILE='DISK116:[20ZBV1.20ZBV74901]CS74901A.;12',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_cs74901_1_85"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>CIRs
for the 2013, 2014 and 2015 taxable years, which we continue to dispute as of the date of this prospectus. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Research and Development Expenses  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Research and development expenses consist primarily of costs incurred in connection with the development of our product candidates and pre-clinical programs.
We expense research and development costs as incurred. These expenses include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> personnel expenses, including salaries, benefits and share-based compensation expense,
for employees engaged in research and development activities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> costs of funding research performed by third parties, including pursuant to agreements
with contract research organizations, or CROs, as well as investigative sites and consultants that conduct our pre-clinical studies and clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> expenses incurred under agreements with contract manufacturing organizations, or CMOs,
including manufacturing scale-up expenses and the cost of acquiring and manufacturing pre-clinical study and clinical trial materials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> expenses for regulatory activities, including filing fees paid to regulatory agencies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> depreciation and amortization; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> allocated expenses for facility costs, including rent, utilities and maintenance. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Following
the application of IFRS&nbsp;16 </FONT><FONT SIZE=2><I>Leases</I></FONT><FONT SIZE=2> as of January&nbsp;1, 2019, only rent that is exempt from IFRS&nbsp;16 is recognized as expense. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
typically use our employee, consultant and infrastructure resources across our development programs. We track certain outsourced development costs by product candidate, but we do not allocate all
personnel costs or other internal costs to specific product candidates. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
expect our research and development expenses will increase for the foreseeable future as we seek to advance development of our product candidates. Further, product candidates in later stages of
clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the
increased size and duration of later-stage clinical trials. The successful development of our product candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature,
timing and costs of the efforts that will be necessary to complete the remainder of the development of lanifibranor or odiparcil, and we may never succeed in obtaining regulatory approval for
lanifibranor, odiparcil or any future product candidates we may develop. We are also unable to predict when, if ever, material net cash inflows may commence from sales of lanifibranor, odiparcil or
any future product candidates we may develop due to the numerous risks and uncertainties associated with clinical development, including risks and uncertainties related to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the number of clinical sites included in the trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the length of time required to enroll suitable patients; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the number of patients that ultimately participate in the trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the number of doses patients receive; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the duration of patient follow-up; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the results of our clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the establishment of commercial manufacturing capabilities; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the receipt of marketing approvals; and </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>85</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=89,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=827240,FOLIO='85',FILE='DISK116:[20ZBV1.20ZBV74901]CS74901A.;12',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_cs74901_1_86"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the commercialization of product candidates. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


General and Administrative Expenses  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>General and administrative expenses include personnel costs, including salaries, benefits and share-based compensation expense, for personnel other than
employees engaged in research and development and marketing and business development activities. General and administrative expenses also include fees for professional services, mainly related to
audit and legal services; consulting costs; communications and travel costs; allocated expenses for facility costs, including rent, utilities and maintenance; directors' attendance fees; and insurance
costs. Following the application of IFRS&nbsp;16 </FONT><FONT SIZE=2><I>Leases</I></FONT><FONT SIZE=2> as of January&nbsp;1, 2019, only rent that is exempt from IFRS&nbsp;16 is recognized as an
expense. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
anticipate that our general and administrative expenses will increase in the future as we grow our support functions for the expected increase in our research and development activities and the
potential commercialization of our product candidates. We also anticipate increased expenses associated with being a public company in the United States, including costs related to audit, legal,
regulatory and tax-related services associated with maintaining compliance with U.S. exchange listing and SEC requirements, director and officer insurance premiums, and investor relations costs. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Marketing&nbsp;&#151; Business Development Expenses  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Marketing&nbsp;&#151; business development expenses consists primarily of personnel costs, including salaries, benefits and share-based compensation
expense, for our business development team. We anticipate that our sales and marketing expenses will increase in the future as we prepare for the potential launch and commercialization of our product
candidates, if approved. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Other Operating Income (Expenses)  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For the year ended December&nbsp;31, 2019, our other operating income (expenses) consisted primarily of restructuring costs incurred in connection with the
implementation of our redundancy plan pursuant to an agreement signed on June&nbsp;11, 2019. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For
the year ended December&nbsp;31, 2018, our other operating income (expenses) consisted of transaction costs incurred in connection with a contemplated financing transaction. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
December 2016, we received a proposed payroll tax adjustment from the French tax authorities with respect to the 2013 taxable year. The proposed adjustment related to the classification of the
subsidy granted to us, subject to conditions, in 2012 by Abbott in connection with our asset purchase. In July 2017, the proposed payroll tax adjustment was extended to the 2014 and 2015 taxable years
and amounted to a total of &euro;1.9&nbsp;million, in the aggregate, including penalties and late payment interest. Under the terms of our asset purchase agreement with Abbott, Abbott is
required to indemnify us in an amount up to &euro;2.0&nbsp;million for any amount claimed by the French tax authorities in relation to the tax treatment of the subsidy granted to us with
respect to the 2012 through 2017 taxable years. While we continue to dispute the payroll tax adjustment with the French tax authorities, we accrued expense in the amount of the total proposed payroll
tax adjustment related to the 2013 to 2015 taxable years as of December&nbsp;31, 2016 and offsetting income in an equal amount as a result of Abbott's indemnity obligation as of December&nbsp;31,
2016. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
2019, our payroll taxes for the 2016, 2017 and 2018 taxable years were audited by the French tax authorities and we received a proposed tax adjustment of &euro;1.7&nbsp;million
(including penalties and late payment interest) in December 2019. This proposed tax adjustment gives rise to a potential risk of &euro;0.5&nbsp;million (including penalties and late
payment interest) for the 2018 taxable year, which we are challenging. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>86</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=90,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=158931,FOLIO='86',FILE='DISK116:[20ZBV1.20ZBV74901]CS74901A.;12',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_cs74901_1_87"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Net Financial Income (Expense)  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Net financial income (expense) relates primarily to interest and other expense for loans and other financial debts, offset by income received from cash and
cash equivalents, as well as foreign exchange gains and losses. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Income Tax  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Income tax income reflects our current income tax, as well as our deferred tax income (expense). </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
2018 and 2019, we have faced tax losses. As the recoverability of our tax losses is not considered probable in subsequent periods due to the uncertainties inherent in our business, no deferred tax
assets were recognized in the financial statements as of December&nbsp;31, 2018 or December&nbsp;31, 2019. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Results of Operations  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Comparison of the years ended December&nbsp;31, 2018 and 2019  </I></B></FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Revenue  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We generated revenue of &euro;7.0&nbsp;million in the year ended December&nbsp;31, 2019, an increase of &euro;3.8&nbsp;million
compared to revenue of &euro;3.2&nbsp;million generated for the year ended December&nbsp;31, 2018. The increase was primarily related to the &euro;3.5&nbsp;million
milestone payment from AbbVie in December 2019 following the enrollment of the first patient with psoriasis in the ongoing clinical trial of ABBV-157 and the reversal of all contract liabilities
recognized as of December&nbsp;31, 2018 in application of </FONT><FONT SIZE=2><I>IFRS&nbsp;15&nbsp;&#151; Revenue from Contracts with Customers</I></FONT><FONT SIZE=2> in an amount of
&euro;2.1&nbsp;million following BI's decision to end our collaboration. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This
increase was partially offset by a &euro;1.8&nbsp;million decrease in recurring revenue received from our collaboration agreements with AbbVie and BI and our service agreement with
Enyo Pharma following the completion of our services rendered under each agreement in 2019. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Other Income  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We generated other income of &euro;4.3&nbsp;million in the year ended December&nbsp;31, 2019, compared to other income of
&euro;4.2&nbsp;million generated in the year ended December&nbsp;31, 2018, with an increase of 3%. Other Income consisted of research tax credits in the year ended December&nbsp;31,
2019 and 2018, respectively. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Research and Development Expenses  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our research and development expenses were &euro;33.8&nbsp;million in the year ended December&nbsp;31, 2019, an increase of 6% compared to
research and development expenses of &euro;31.8&nbsp;million in the year ended December&nbsp;31, 2018. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
components of our research and development expenses were as follows for the periods presented: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="47pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Year ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands of &euro;)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>% change </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research, pre-clinical study and clinical trial expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>17,351</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>19,353</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>12</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Personnel costs, other than share-based compensation</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>7,109</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>7,208</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Share-based compensation expense</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>516</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>868</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>68</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,782</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,362</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> (6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total research and development expenses</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 31,758</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>33,791</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>6</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>%</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>87</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=91,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=55995,FOLIO='87',FILE='DISK116:[20ZBV1.20ZBV74901]CS74901A.;12',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_cs74901_1_88"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
increase in our research and development expenses was primarily the result of a &euro;2.0&nbsp;million, or 12%, increase in research, pre-clinical study and clinical trial expenses,
which are broken down by product candidate for the year ended December&nbsp;31, 2018 and 2019 in the following table: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="47pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Year ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands of &euro;)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>% change </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Lanifibranor</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>11,865</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>13,209</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>11</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Odiparcil</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3,285</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4,965</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>51</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>YAP/TEAD</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,386</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,094</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> (21</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Other</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>815</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>92</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> (89</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total Research, pre-clinical study and clinical trial expenses</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 17,351</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>19,353</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>12</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>%</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>The
increase in research, pre-clinical study and clinical trial expenses is primarily related to lanifibranor and odiparcil. Research, pre-clinical study and clinical trial expenses of lanifibranor
increased by &euro;1.3&nbsp;million, or 11%, primarily due to the continuation of the NATIVE Phase&nbsp;IIb study, of which the results are expected in June 2020. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Research,
pre-clinical study and clinical trial expenses of odiparcil increased by &euro;1.7&nbsp;million, or 51%, primarily due to the continuation of the iMProveS Phase&nbsp;IIa
study, of which the results were published at the end of 2019. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>These
increases were partially offset by a &euro;0.7&nbsp;million decrease in other research, pre-clinical study and clinical trial expenses and a &euro;0.3&nbsp;million
decrease in expenses incurred in connection with our YAP/TEAD program. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


General and Administrative Expenses  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our general and administrative expenses were &euro;6.1&nbsp;million in the year ended December&nbsp;31, 2019, an increase of 1% compared to
general and administrative expenses of &euro;6.0&nbsp;million in the year ended December&nbsp;31, 2018. The increase in general and administrative expenses primarily related to an
increase in share-based compensation expenses, partially offset by the decrease in fees for the legal and financial departments, resulting from the expansion of the legal team. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Marketing&nbsp;&#151; Business Development Expenses  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our marketing&nbsp;&#151; business development expenses remained consistent in an amount of &euro;0.2&nbsp;million in the years ended
December&nbsp;31, 2019 and 2018. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Other Operating Income (Expenses)  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In the year ended December&nbsp;31, 2018, we had net other operating expense of &euro;2.3&nbsp;million related to the transaction costs incurred
in connection with a contemplated financing transaction. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
the year ended December&nbsp;31, 2019, we had net other operating expense of &euro;1.5&nbsp;million primarily related to the restructuring costs of
&euro;1.1&nbsp;million incurred in connection with the implementation of our redundancy plan, residual transaction costs of &euro;0.3&nbsp;million and the additional late
payment interest of &euro;0.1&nbsp;million related to the payroll tax adjustment. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Net Financial Income (Expense)  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our net financial income was &euro;0.1&nbsp;million in the year ended December&nbsp;31, 2019 compared to a net financial expense of
&euro;0.1&nbsp;million in the year ended December&nbsp;31, 2018. The change was primarily attributable to increased income on cash equivalents due to more favorable bond market
conditions. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>88</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=92,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=174121,FOLIO='88',FILE='DISK116:[20ZBV1.20ZBV74901]CS74901A.;12',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_cu74901_1_89"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Liquidity and Capital Resources  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>From our inception through December&nbsp;31, 2019, we have received a net aggregate of &euro;96.0&nbsp;million in payments from Abbott pursuant
to agreements entered into in connection with our formation, raised &euro;44.6&nbsp;million in net proceeds from the initial public offering of our ordinary shares on Euronext Paris in
February 2017, &euro;32.4&nbsp;million in net proceeds from a private placement of our ordinary shares in April 2018, &euro;8.6&nbsp;million in net proceeds from two capital
increases reserved to categories of investors in September and October 2019 and &euro;14.6&nbsp;million in net proceeds from a capital increase reserved to categories of investors in
February 2020. In addition, we have received an aggregate of &euro;9.0&nbsp;million and &euro;3.0&nbsp;million in upfront and milestone payments under our collaboration
agreements with AbbVie and BI, respectively. We have also received an aggregate of &euro;16.5&nbsp;million of CIR reimbursements, as well as an aggregate of
&euro;1.1&nbsp;million and &euro;0.4&nbsp;million of non-refundable subsidies from Bpifrance and France's national research agency, respectively. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>As
of December&nbsp;31, 2018 and 2019, we had cash and cash equivalents of &euro;56.7&nbsp;million and &euro;35.8&nbsp;million, respectively. The following table shows a
summary of our cash flows for the periods indicated: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Year ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands of &euro;)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash used in operating activities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(34,207</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(28,404</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash used in investing activities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(420</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(826</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash provided by (used in) financing activities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>32,268</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>8,378 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net decrease in cash and cash equivalents</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> (2,358</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>(20,852</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Operating Activities  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>During the year ended December&nbsp;31, 2018, we used &euro;34.2&nbsp;million of cash in operating activities. Cash used in operating activities
mainly reflected our net loss of &euro;33.0&nbsp;million and non-cash income of &euro;2.2&nbsp;million, principally related to the right to receive our CIR reimbursement of
&euro;4.2&nbsp;million for 2018. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>During
the year ended December&nbsp;31, 2019, we used &euro;28.4&nbsp;million of cash in operating activities. Cash used in operating activities reflected our net loss of
&euro;30.2&nbsp;million and non-cash income of &euro;1.3&nbsp;million, principally related to the right to receive our CIR reimbursement of
&euro;4.3&nbsp;million for 2019, partially offset by &euro;3.6&nbsp;million of the 2017 CIR received in 2019. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Investing Activities  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>During the year ended December&nbsp;31, 2018, we used &euro;0.4&nbsp;million of cash in investing activities. Cash used in investing activities
reflected the acquisitions of property, plant and equipment totaling &euro;0.5&nbsp;million, primarily research equipment and software, partially offset by changes in long-term deposit of
&euro;0.1&nbsp;million. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>During
the year ended December&nbsp;31, 2019, we used &euro;0.8&nbsp;million of cash in investing activities. Cash used in investing activities reflected mainly the deposit of
&euro;0.7&nbsp;million pledged in February 2019 in connection with the surety provided to the French tax authorities related to the payroll tax audit. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Financing Activities  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>During the year ended December&nbsp;31, 2018, financing activities provided &euro;32.3&nbsp;million of cash, primarily consisting of the net
proceeds from a private placement of our ordinary shares in April 2018. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>During
the year ended December&nbsp;31, 2019, financing activities provided &euro;8.4&nbsp;million of cash, primarily consisting of the net proceeds from the two capital increases
carried out in September and October 2019. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>89</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=93,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=660809,FOLIO='89',FILE='DISK116:[20ZBV1.20ZBV74901]CU74901A.;18',USER='JFUSS',CD='10-APR-2020;08:21' -->
<A NAME="page_cu74901_1_90"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Operating Capital Requirements  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development of, continue or initiate
clinical trials of, and seek marketing approval for, our product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant
commercialization expenses related to program sales, marketing, manufacturing and distribution to the extent that such sales, marketing and distribution are not the responsibility of collaborators.
Furthermore, following the completion of this offering, we expect to incur additional costs associated with operating as a public company in the United States. Accordingly, we will need to obtain
substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our
research and development programs or future commercialization efforts. We believe that the net proceeds of this offering, together with our existing cash and cash equivalents at December&nbsp;31,
2019, will enable us to fund our operating expenses and capital expenditure requirements for at least&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We
have based this estimate on assumptions that may prove to be wrong, and we
could use our capital resources sooner than we currently expect. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
future capital requirements will depend on many factors, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the scope, progress, results and costs of product discovery, pre-clinical studies and
clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the scope, prioritization and number of our research and development programs; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the costs, timing and outcome of regulatory review of our product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to establish and maintain collaborations on favorable terms; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the costs of preparing, filing and prosecuting patent applications, maintaining and
enforcing our intellectual property rights and defending intellectual property-related claims; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the extent to which we acquire or in-license other product candidates and technologies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the costs of securing manufacturing arrangements for commercial production; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the costs of establishing or contracting for sales and marketing capabilities if we
obtain regulatory approvals to market our product candidates. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Identifying
potential product candidates and conducting pre-clinical studies and clinical trials is a time-consuming, expensive and uncertain process that takes many years to complete, and we may
never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our
commercial revenues, if any, will be derived from sales of product candidates that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to
rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Until
such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic
alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms
of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include covenants
limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>If
we raise funds through additional collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue
streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>90</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=94,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=553128,FOLIO='90',FILE='DISK116:[20ZBV1.20ZBV74901]CU74901A.;18',USER='JFUSS',CD='10-APR-2020;08:21' -->
<A NAME="page_cu74901_1_91"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>unable
to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or
grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Contractual Obligations  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following table discloses aggregate information about our material contractual obligations and the periods in which payments are due as of
December&nbsp;31, 2019. Future events could cause actual payments and timing of payments to differ from the contractual cash flows set forth below. </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="36pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="36pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="49pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="34pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Less than<BR>
1&nbsp;year </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>1 to<BR>
3&nbsp;years </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>3 to<BR>
5&nbsp;years </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>More than<BR>
5&nbsp;years </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Total </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(in thousands)</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bank borrowings<SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&euro;74</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&euro;&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&euro;&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&euro;&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&euro;74</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other loans and similar borrowings<SUP>(2)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lease liabilities<SUP>(3)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>35</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>37 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&euro;112</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&euro;2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&euro;&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&euro;&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&euro;114</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">As
of December&nbsp;31, 2019, our bank loans consisted of (1)&nbsp;a loan from Cr&eacute;dit Agricole in the outstanding principal amount
of &euro;19,590, which bears interest at a fixed annual rate of 1.32% and is repayable in regular installments over a 60-month term, (2)&nbsp;a loan from CIC Lyonnaise de Banque in the
outstanding principal amount of &euro;15,374, which bears interest at a fixed annual rate of 1.50% and is repayable in regular installments over a 60-month term and (iii)&nbsp;a loan from
Soci&eacute;t&eacute; G&eacute;n&eacute;rale in the outstanding principal amount of &euro;38,832, which bears interest at a fixed annual rate of 0.90% and is
repayable in regular installments over a 60-month term.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Other
loans and similar borrowings correspond to current bank overdraft facilities.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Lease
liabilities were accounted for according to the new lease standard IFRS&nbsp;16 and represent the present value of the remaining lease payments </FONT></DD></DL>


<P style="font-family:arial;"><FONT SIZE=2>The amounts of contractual obligations set forth in the table above are associated with contracts that are enforceable and legally binding and that specify all
significant terms, fixed or minimum services to be used, fixed, minimum or variable price provisions, and the approximate timing of the actions under the contracts. The table does not include
obligations under agreements that we can cancel without a significant penalty. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Critical Accounting Policies and Estimates  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our financial statements are prepared in accordance with IFRS as issued by the IASB. Some of the accounting methods and policies used in preparing our
financial statements under IFRS are based on complex and subjective assessments by our management or on estimates based on past experience and assumptions deemed realistic and reasonable based on the
circumstances concerned. The actual value of our assets, liabilities and shareholders' equity and of our earnings could differ from the value derived from these estimates if conditions change and
these changes had an impact on the assumptions adopted. We believe that the most significant management judgments and assumptions in the preparation of our financial statements as of and for the year
ended December&nbsp;31, 2019 and 2018 are described below. See Note&nbsp;3 to our financial statements for a description of our other significant accounting policies. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Revenue  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Allocation of Transaction Price to Performance Obligations</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&#151;&nbsp;&nbsp;A contract's transaction price is allocated to each distinct performance
obligation and recognized as revenue when, or as, the performance obligation is satisfied. To determine the proper revenue recognition method, we evaluate whether the contract should be accounted for
as more than one performance obligation. This evaluation requires significant judgment; some of our contracts have a single performance obligation as the promise to transfer the individual goods or
services is not separately identifiable from other promises in the contracts and, therefore, not distinct. For </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>91</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=95,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=816409,FOLIO='91',FILE='DISK116:[20ZBV1.20ZBV74901]CU74901A.;18',USER='JFUSS',CD='10-APR-2020;08:21' -->
<A NAME="page_cu74901_1_92"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>contracts
with multiple performance obligations, we allocate the contract's transaction price to each performance obligation using our best estimate of the standalone selling price of each distinct
good or service in the contract. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Variable Consideration</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&#151;&nbsp;&nbsp;Due to the nature of the work required to be performed on many of our performance obligations, the estimation of
total revenue and cost at completion is complex, subject to many
variables and requires significant judgment. It is common for our collaboration agreements to contain variable consideration that can increase the transaction price. Variability in the transaction
price arises primarily due to milestone payments obtained following the achievement of specific milestones (e.g.,&nbsp;scientific results or regulatory or commercial approvals). We include the
related amounts in the transaction price as soon as their receipt is highly probable. The effect of the increase of the transaction price due to milestones payments is recognized as an adjustment to
revenue on a cumulative catch-up basis. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Revenue Recognized Over Time and Input Method</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&#151;&nbsp;&nbsp;Our performance obligations are satisfied over time as work progresses or at a point in
time. For our collaboration agreements, because services are rendered over time, revenue is recognized based on the extent of progress towards completion of the performance obligation, using an input
measure of progress as it best depicts the transfer of control to the customer. Under our input measure of progress, the extent of progress towards completion is measured based on the ratio of days
expended to date to the total estimated days at completion of the performance obligation. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Provision for Tax Audit  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We calculate our provision for tax audit based on an estimate of the related risk. The provision represents the best estimate of the amount required to settle
any amounts owed to the relevant tax authorities at the end of the reporting period. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Research Tax Credit  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The amount of the research tax credit for which we are eligible depends on internal and external research and development expenditures. The calculation of
eligible expenditures requires management to make judgments and estimates. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Share-Based Compensation  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have granted share-based compensation to certain employees, as well as to members of our board of directors and certain other parties in the form of
founder's share warrants (</FONT><FONT SIZE=2><I>bons de souscription de parts de cr&eacute;ateur d'entreprise</I></FONT><FONT SIZE=2>) share warrants (</FONT><FONT SIZE=2><I>bons de
souscription d'actions</I></FONT><FONT SIZE=2>) and bonus share awards (</FONT><FONT SIZE=2><I>actions gratuites</I></FONT><FONT SIZE=2>). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
account for share-based compensation in accordance with the authoritative guidance on share-based compensation, IFRS&nbsp;2 </FONT><FONT SIZE=2><I>Share-based payment</I></FONT><FONT SIZE=2>, or
IFRS&nbsp;2. Under the fair value recognition provisions of IFRS&nbsp;2, share-based compensation is measured at the grant date based on the fair value of the award and is recognized as expense,
net of estimated forfeitures, over the requisite service period, which is generally the vesting period of the respective award. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Determining
the fair value of share-based awards at the grant date requires judgment. We use the Black-Scholes option-pricing model to determine the fair value of share-based awards. The determination
of the grant date fair value of share-based awards using an option-pricing model is affected by assumptions regarding a number of complex and subjective variables. These variables include the fair
value of our ordinary shares on the date of grant, the expected term of the awards, our share price volatility, risk-free interest rates and expected dividends. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>For
the years ended December&nbsp;31, 2018 and 2019, we recorded share-based compensation expenses of &euro;0.8&nbsp;million and &euro;1.4&nbsp;million, respectively. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>92</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=96,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=88339,FOLIO='92',FILE='DISK116:[20ZBV1.20ZBV74901]CU74901A.;18',USER='JFUSS',CD='10-APR-2020;08:21' -->
<A NAME="page_cu74901_1_93"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


New Accounting Standards  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We adopted IFRS&nbsp;16&nbsp;&#151; Leases, effective from January&nbsp;1 2019. In accordance with this standard, we recognized </FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an asset, representing our right to use the leased asset during the lease term
(right-of-use asset); and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a liability, representing the value of the outstanding lease payments (lease liability). </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>In
accordance with IFRS&nbsp;16, as we used the simplified retrospective method, our comparative data have not been restated. However, the impact being less than &euro;0.1&nbsp;million
on our income statement for the year ended December&nbsp;31,2019, the comparability of our result of operations between 2018 and 2019 is not materially impacted. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>See
Note&nbsp;2.1. to our financial statements for further details on IFRS&nbsp;16 first-time adoption impacts. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Off-Balance Sheet Arrangements  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>During the periods presented, we did not and do not currently have any off-balance sheet arrangements as defined under Securities and Exchange Commission
rules, such as relationships with other entities or financial partnerships, which are often referred to as structured finance or special purpose entities, established for the purpose of facilitating
financing transactions that are not required to be reflected on our statement of financial position. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Quantitative and Qualitative Disclosures About Market Risk  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Foreign Currency Exchange Risk  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We use the euro as our functional currency for our financial communications. However, a portion of our operating expenses is denominated in foreign currencies
as a result of our studies and clinical trials performed in the United States, United Kingdom, Switzerland, Australia, Canada and Sweden. During 2019, these expenses in foreign currencies totaled
approximately &euro;3.8&nbsp;million based on the exchange rates in effect at the date of each transaction, or approximately 9% of our operating expenses, compared to approximately
&euro;2.3&nbsp;million, or 6%, during 2018. As a result, we are exposed to foreign exchange risk inherent in operating expenses incurred. Due to the relatively low level of these
expenditures, the exposure to foreign exchange risk is unlikely to have a material adverse impact on our results of operations or financial position. In addition, we currently have revenues only in
euros. As we advance our clinical development in the United States and potentially commercialize our product candidates in that market, we expect to face greater exposure to exchange rate risk and
would then consider using exchange rate hedging techniques at that time. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Interest Rate Risk  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We believe we have very low exposure to interest rate risk. Such exposure primarily involves our money market funds and time deposit accounts. Changes in
interest rates have a direct impact on the rate of return on these investments and the cash flows generated. The repayment flows of the conditional advances from BPI France are not subject to interest
rate risk. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Credit Risk  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We believe that the credit risk related to our cash and cash equivalents is not significant in light of the quality of the financial institutions at which such
funds are held. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


JOBS Act Exemptions and Foreign Private Issuer Status  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We qualify as an "emerging growth company" as defined in the U.S. Jumpstart Our Business Startups Act of 2012. An emerging growth company may take advantage of
specified reduced reporting and other burdens that are otherwise applicable generally to public companies in the United States. This includes an exemption from the auditor attestation requirement in
the assessment of our internal control over financial </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>93</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=97,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=361492,FOLIO='93',FILE='DISK116:[20ZBV1.20ZBV74901]CU74901A.;18',USER='JFUSS',CD='10-APR-2020;08:21' -->
<A NAME="page_cu74901_1_94"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>reporting
pursuant to the Sarbanes-Oxley Act of 2002. We may take advantage of this exemption until such time as we are no longer an emerging growth company. We would cease to be an emerging growth
company upon the earliest to occur of the following: (1)&nbsp;the last day of the fiscal year in which we have total annual gross revenue of $1.07&nbsp;billion or more; (2)&nbsp;the last day of
our fiscal year following the fifth anniversary of the date of the completion of this offering; (3)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in nonconvertible debt during
the previous three years; and (4)&nbsp;the date on which we are deemed to be a large accelerated filer under the rules of the SEC. We may choose to take advantage of some but not all of these
reduced burdens. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
will not take advantage of the extended transition period provided under Section&nbsp;7(a)(2)(B) of the U.S. Securities Act of 1933, as amended, for complying with new or revised accounting
standards. Since IFRS makes no distinction between public and private companies for purposes of compliance with new or revised accounting standards, the requirements for our compliance as a private
company and as a public company are the same. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Upon
consummation of this offering, we will report under the U.S. Securities Exchange Act of 1934, as amended, or the Exchange Act, as a non-U.S. company with foreign private issuer status. Even after
we no longer qualify as an emerging growth company, as long as we qualify as a foreign private issuer under the Exchange Act, we will be exempt from certain provisions of the Exchange Act that are
applicable to U.S. domestic public companies, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the sections of the Exchange Act regulating the solicitation of proxies, consents or
authorizations in respect of a security registered under the Exchange Act; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the sections of the Exchange Act requiring insiders to file public reports of their stock
ownership and trading activities and liability for insiders who profit from trades made in a short period of time; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the rules under the Exchange Act requiring the filing with the SEC of quarterly reports
on Form&nbsp;10-Q containing unaudited financial and other specified information, or current reports on Form&nbsp;8-K, upon the occurrence of specified significant events; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Regulation&nbsp;FD, which regulates selective disclosures of material information by
issuers. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>94</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=98,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=1020220,FOLIO='94',FILE='DISK116:[20ZBV1.20ZBV74901]CU74901A.;18',USER='JFUSS',CD='10-APR-2020;08:21' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_cw74901_1_95"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A NAME="cw74901_business"> </A>
<A NAME="toc_cw74901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  BUSINESS    <BR>    </B></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Overview  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic
steatohepatitis, or NASH, mucopolysaccharidoses, or MPS, and other diseases with significant unmet medical need. We have built a pipeline backed by a discovery engine with an extensive library of
proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and experience in the development of compounds that target nuclear receptors,
transcription factors and epigenetic modulation. Leveraging these assets and expertise, we are advancing two clinical candidates, lanifibranor and odiparcil for the treatment of NASH and MPS,
respectively, as well as a deep pipeline of earlier stage programs in oncology and other diseases with significant unmet medical need.  </FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I> Lanifibranor for the Treatment of
NASH.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;We are developing our lead product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a
progressive, chronic liver disease for which there are currently no approved therapies. NASH is believed to affect 12% of the United States population and is a leading cause of cirrhosis, liver
transplantation and liver cancer. Compared to the general population, patients with NASH have a ten-fold greater risk of liver-related mortality. NASH is characterized by a metabolic process known as
steatosis, or the excessive accumulation of fat in the liver, inflammation and ballooning of liver cells and progressive liver fibrosis that can ultimately lead to cirrhosis. Lanifibranor is an
orally-available small molecule in development for the treatment of NASH that acts to induce anti-fibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating
all three peroxisome proliferator-activated receptor, or PPAR, isoforms. PPARs are well-characterized nuclear receptor proteins that regulate gene expression, and their relevance for the fibrotic,
inflammatory, vascular and metabolic processes that characterize NASH is well-established. While there are other PPAR agonists that target only one or two PPAR isoforms, lanifibranor is the only pan
PPAR agonist in clinical development. We believe that this pan PPAR approach provides for a combination of anti-fibrotic, anti-inflammatory and beneficial vascular and metabolic effects that cannot be
obtained with single and dual PPAR agonists. In September 2019, we completed enrollment in a Phase&nbsp;IIb clinical trial of lanifibranor in patients with NASH and plan to report data in June 2020.
Lanifibranor has received fast track designation from the U.S. Food and Drug Administration, or FDA, for the treatment of NASH.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I> Odiparcil for the Treatment of
MPS.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;Our second clinical-stage asset is odiparcil, which we are developing for the treatment of patients with MPS, a group of rare genetic
disorders characterized by an excessive accumulation of large sugar chains, known as glycosaminoglycans, or GAGs, in cells. Odiparcil is an orally-available small molecule designed to modify how GAGs
are synthesized. Odiparcil acts to facilitate the production of soluble GAGs that can be excreted in the urine, rather than accumulating in cells. The current standard of care for the treatment of
patients with MPS is enzyme replacement therapy, or ERT, which requires weekly infusions and is generally administered in an outpatient hospital setting. While ERT has been shown to be effective in
reducing GAG accumulation in certain tissue types, it has shown limited efficacy in reducing GAG accumulation in poorly vascularized tissues and organs, such as cartilage, or in tissues that are
protected by a barrier, such as the eye. Unlike ERT, odiparcil is a small molecule that we have observed to be well distributed in the body, even in certain tissues that are poorly vascularized or
protected by a barrier. In December 2019, we announced positive results from a Phase&nbsp;IIa clinical trial of odiparcil for the treatment of adult patients with the MPS VI subtype. In this trial,
we observed that odiparcil, in combination with enzyme replacement therapy, or ERT, was associated with improvements in corneal clouding and cardiac and respiratory function and exhibited a favorable
tolerability profile. Signals of clinical activity were also detected in patients treated only with odiparcil. Because MPS is a progressive disease, we believe there is benefit in treating pediatric
patients with MPS, and we plan </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>95</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=99,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=72016,FOLIO='95',FILE='DISK116:[20ZBV1.20ZBV74901]CW74901A.;29',USER='SCAVALI',CD='10-APR-2020;08:06' -->
<A NAME="page_cw74901_1_96"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:arial;"><FONT SIZE=2>to
commence a Phase Ib/II clinical trial of odiparcil in a pediatric population with MPS VI by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. If the
results of this pediatric trial are favorable, we plan to initiate
Phase&nbsp;III clinical development of odiparcil as a monotherapy and in combination with ERT for the treatment of adult and pediatric patients with MPS VI. In addition, we plan to initiate an open
label Phase&nbsp;IIa extension study in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to investigate the long-term safety and efficacy of odiparcil in patients 16&nbsp;years and
above with MPS VI who completed the prior
Phase&nbsp;IIa trial. We believe odiparcil's mechanism of action is relevant to a number of MPS subtypes, and we also plan to initiate pivotal trials for the treatment of one or more of MPS
subtypes&nbsp;I, II, IVa and VII. Odiparcil has received orphan drug designation from the FDA and European Medicines Agency, or EMA, and rare pediatric disease designation from the FDA for the
treatment of MPS VI.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I> Discovery
Engine.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;We have a scientific team of approximately 50 people with deep biology, medicinal and computational chemistry, pharmacokinetics and
pharmacology expertise, more than 75% of whom have worked together for more than 15&nbsp;years. We also own a library of approximately 240,000 pharmacologically relevant molecules, 60% of which are
proprietary, as well as a wholly-owned research and development facility. Using these assets and this expertise, we have built a discovery engine focused on small molecule compounds that target
nuclear receptors, transcription factors and epigenetic modulation. We are leveraging this discovery engine to identify and develop compounds addressing a wide range of indications. Our Hippo
signaling pathway program aims to disrupt the interaction between yes-associated protein, or YAP, and transcription enhancer associated domain transcription factors, or TEAD, an interaction that plays
a key role in oncogenic and fibrotic processes. In xenograft and orthotopic models of malignant pleural mesothelioma, or MPM, we observed that YAP-TEAD inhibition was associated with reduced tumor
growth and we are in the process of selecting development candidate for our Hippo program, which we anticipate entering pre-clinical development
in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for the treatment of non-small cell
lung cancer and mesothelioma. In addition, AbbVie is currently investigating ABBV-157, a ROR<FONT FACE="SYMBOL">g</FONT> inverse agonist that we and AbbVie jointly discovered, in a
Phase&nbsp;I clinical trial for the treatment of moderate to severe psoriasis under the terms of our multi-year drug discovery collaboration. We are also advancing a pre-clinical program for the
treatment of idiopathic pulmonary fibrosis, or IPF, and have validated a new target within the transforming growth factor beta, or TGF-<FONT FACE="SYMBOL">b</FONT>, signaling pathway. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Lanifibranor for the Treatment of NASH  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are developing lanifibranor for the treatment of patients with NASH. NASH is a progressive chronic liver disease, often resulting in liver failure and
death, for which there are currently no
approved therapies. NASH is believed to affect 12% of the United States population. In 2020, NASH is expected to become a leading cause of liver transplantation in the United States. Additionally,
NASH is now considered to be the leading, and a rapidly increasing, cause of hepatocellular carcinoma, or primary liver cancer, of which up to 40% of cases in NASH patients develop prior to developing
cirrhosis. More than 20% of patients with NASH progress to cirrhosis within a decade of diagnosis and, compared to the general population, have a ten-fold greater risk of liver-related mortality. NASH
is characterized by (i)&nbsp;a metabolic process known as steatosis, or the excessive accumulation of fat in the liver, (ii)&nbsp;inflammation and ballooning of liver cells and
(iii)&nbsp;progressive liver fibrosis that can ultimately lead to cirrhosis. NASH is increasingly viewed as the expression in the liver of metabolic syndrome and is frequently accompanied by
obesity, insulin resistance and type&nbsp;2 diabetes. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Lanifibranor
is an orally available small molecule in development for the treatment of NASH that acts to induce anti-fibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the
body by activating each of the three PPAR isoforms, known as PPAR<FONT FACE="SYMBOL">a</FONT>, PPAR<FONT FACE="SYMBOL">d</FONT> and PPAR<FONT FACE="SYMBOL">g</FONT>.
PPARs are ligand-activated transcription factors belonging to the nuclear hormone receptor family that regulate the expression of genes. PPARs play essential roles in the regulation of cellular
differentiation, development and </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>96</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=100,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=563602,FOLIO='96',FILE='DISK116:[20ZBV1.20ZBV74901]CW74901A.;29',USER='SCAVALI',CD='10-APR-2020;08:06' -->
<A NAME="page_cw74901_1_97"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>tumorigenesis.
The relevance of each isoform to different aspects of fibrotic, inflammatory, vascular and metabolic processes is
well-established:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> activation of PPAR<FONT FACE="SYMBOL">g</FONT> is associated with
anti-fibrotic benefits; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> activation of each of PPAR<FONT FACE="SYMBOL">a</FONT>,
PPAR<FONT FACE="SYMBOL">d</FONT> and PPAR<FONT FACE="SYMBOL">g</FONT> is known to have anti-inflammatory effects; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> activation of each of PPAR<FONT FACE="SYMBOL">a</FONT> and
PPAR<FONT FACE="SYMBOL">g</FONT> is associated with beneficial vascular effects; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> activation of each of PPAR<FONT FACE="SYMBOL">a</FONT>,
PPAR<FONT FACE="SYMBOL">d</FONT> and PPAR<FONT FACE="SYMBOL">g</FONT> is known to result in positive metabolic effects. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Lanifibranor
is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPAR<FONT FACE="SYMBOL">a</FONT> and
PPAR<FONT FACE="SYMBOL">d</FONT>, and a partial activation of PPAR<FONT FACE="SYMBOL">g</FONT>. While there are other PPAR agonists that target only one or two PPAR isoforms,
lanifibranor is the only pan-PPAR agonist in clinical development. We believe that this pan-PPAR approach provides for a combination of anti-fibrotic, anti-inflammatory and beneficial vascular and
metabolic effects that cannot be obtained with single and dual PPAR agonists. In pre-clinical studies, we observed that the administration of lanifibranor improved insulin sensitivity and lipid
profile, reduced nonalcoholic fatty liver disease activity score, or NAS score, reversed liver fibrosis and reduced portal pressure. Further, in clinical trials in type&nbsp;2 diabetes conducted
prior to our founding, the administration of lanifibranor was associated with favorable anti-inflammatory effects, including increased levels of adiponectin, which inhibits the release of cytokines
and other pro-inflammatory proteins. Lanifibranor was also associated with favorable metabolic effects, including improvements in insulin sensitivity, reductions in levels of triglycerides, which are
a type of fat, and increases in high-density lipoprotein, or HDL, cholesterol levels. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
believe lanifibranor's moderate and balanced pan-PPAR binding profile also contributes to the favorable tolerability profile that has been observed in clinical trials and pre-clinical studies to
date. As of March&nbsp;16, 2020, approximately 250 patients have been treated for 24 or 48&nbsp;weeks in our ongoing and completed Phase&nbsp;IIb clinical trials of lanifibranor. In connection
with these trials, lanifibranor has undergone a total of seven data and safety monitoring board, or DSMB, reviews, and the DSMBs have not recommended any changes to the trial protocols. In addition,
prior to our founding, lanifibranor was administered to over 150 subjects in clinical trials in type&nbsp;2 diabetes and exhibited a favorable tolerability profile, including with respect to key
markers of liver, kidney, heart, muscle and bone function. By contrast, single and dual PPAR agonists, which generally target PPAR isoforms in a very potent and imbalanced manner, have historically
been associated with toxicity and adverse effects. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
September 2019, we completed enrollment in the NATIVE Phase&nbsp;IIb clinical trial of lanifibranor in patients with NASH and plan to report data in June 2020. If positive, we plan to advance
lanifibranor, alone or together with a collaborator, into pivotal Phase&nbsp;III clinical development. Lanifibranor has received fast track designation from the FDA for the treatment of NASH. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Odiparcil for the Treatment of MPS  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are developing odiparcil for the treatment of patients with several subtypes of MPS. Odiparcil is an orally-available small molecule that acts on the
underlying cause of the symptoms of MPS, which is the accumulation of GAGs in cells due to deficient lysosomal enzymes. By modifying how GAGs are synthesized, odiparcil facilitates the production of
soluble GAGs that can be excreted in the urine, rather than accumulating in cells. In pre-clinical studies, we observed that odiparcil reduced accumulation of two specific GAGs, chondroitin sulfate,
or CS, and dermatan sulfate, or DS, in several organs and tissues. ERT is the current standard of care for the treatment of patients with MPS but requires weekly infusions and is generally
administered in an outpatient hospital setting. Furthermore, while ERT has been shown to be effective in reducing GAG accumulation in some tissue types, it has shown limited efficacy in reducing GAG
accumulation in tissues that are poorly vascularized or protected by a barrier. By contrast, we have observed, in pre-clinical studies, that odiparcil is well distributed in the body, including in
cartilage and the eye, which are tissues that are poorly penetrated by ERT. Because odiparcil has a different mechanism of action than ERT and reaches tissues that are poorly penetrated by ERT and in
which MPS symptoms often </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>97</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=101,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=589191,FOLIO='97',FILE='DISK116:[20ZBV1.20ZBV74901]CW74901A.;29',USER='SCAVALI',CD='10-APR-2020;08:06' -->
<A NAME="page_cw74901_1_98"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>manifest,
we believe odiparcil could be used as a combination therapy with ERT. Based on our pre-clinical data, we also believe odiparcil has potential as a stand-alone therapy. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>MPS
is separated into subtypes, depending on the lysosomal enzyme that is deficient and the corresponding GAGs that accumulate. One or both of CS and DS, the GAGs on which odiparcil acts, accumulate
in patients with MPS I, II, IVa, VI and VII. To date, we have focused development of odiparcil on the treatment of patients with MPS VI, which is characterized by rounded and thickened facial
features, corneal clouding, hearing loss, dwarfism with deformity of the limbs, enlargement of the liver and spleen, cardiac valve disease and reduced pulmonary function, and an approximate life
expectancy of 20&nbsp;years for untreated patients with severe forms of the disease. In an MPS VI model using a mouse that was genetically modified to reflect human MPS pathology, we observed that
administration of odiparcil reduced GAG accumulation in organs and tissues and improved mobility. Prior to our founding, odiparcil was administered to over 1,800 subjects in clinical trials in an
unrelated indication and was reported to be well tolerated and exhibited a favorable safety profile at daily doses in excess of the therapeutic range. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
December 2019, we announced positive results from the iMProveS Phase&nbsp;IIa clinical trial of odiparcil, which enrolled twenty patients, aged 16&nbsp;years or older, with advanced MPS VI
subtype disease. Fifteen patients were randomized to receive baseline ERT in combination with one of two doses of odiparcil, 250&nbsp;mg or 500&nbsp;mg administered twice daily, or placebo. Five
patients who were not receiving ERT received 500&nbsp;mg of odiparcil administered twice daily in an open label cohort. After 26&nbsp;weeks of treatment, we observed that odiparcil in combination
with ERT was associated with improvements in corneal clouding and cardiac and respiratory function
and exhibited a favorable tolerability profile. Signals of clinical activity were also detected in patients treated only with odiparcil. We observed improved mobility as assessed using the six minute
walk test, or 6MWT, in patients treated with ERT and the 250mg twice daily dose of odiparcil, as well as in patients in the open label cohort. We did not observe improved mobility using the 6MWT in
patients treated with ERT and the 500mg twice daily dose of odiparcil. Dose-dependent urinary GAGs clearance, used as an activity biomarker, was observed in the entire odiparcil-treated patient
population. A reduction in leukocyte GAGs was not observed and therefore was not confirmed as a biomarker for the decrease of GAG accumulation, while the analysis of skin GAG content remains ongoing.
The trial also met its safety primary endpoint with odiparcil exhibiting a favorable tolerability profile. Because MPS is a progressive disease, we believe there is benefit in treating pediatric
patients with MPS, and we plan to commence a Phase Ib/II clinical trial of odiparcil in a pediatric population with MPS VI
by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. If the results of this pediatric trial are favorable, we
plan to initiate Phase&nbsp;III clinical development of odiparcil as a monotherapy and in combination with ERT for the treatment of adult and pediatric patients with MPS&nbsp;VI. In addition, we
plan to initiate an open label Phase&nbsp;IIa extension study in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to investigate the long-term safety and efficacy of odiparcil in
patients 16&nbsp;years and above with MPS VI who
completed the iMProveS trial. Because odiparcil targets GAGs that are also present in other MPS subtypes, we believe that the data generated in the iMProveS trial may also support moving directly to
Phase&nbsp;III pivotal trials in other MPS subtypes that are characterized by the accumulation of CS or DS. Odiparcil has received orphan drug designation from the FDA and EMA and rare pediatric
disease designation from the FDA for the treatment of MPS VI. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Our Discovery Engine  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Fr&eacute;d&eacute;ric Cren, our Chief Executive Officer, and Pierre Broqua, our Deputy Chief Executive Officer and Chief Scientific Officer,
co-founded Inventiva through the acquisition of assets, including a research and development facility, from the Fournier division of Abbott Laboratories, or Abbott. Mr.&nbsp;Cren and
Dr.&nbsp;Broqua previously led Fournier's research and development activities. In connection with our founding, Mr.&nbsp;Cren and Dr.&nbsp;Broqua recruited a team, which they previously led at
Fournier, that possesses deep biology, medicinal and computational chemistry, pharmacokinetics and pharmacology expertise, covering the drug discovery process from target validation to investigational
new drug application, or IND, enabling studies. More than 75% of the members of this team have worked with our co-founders and each other for more than 15&nbsp;years. Our research and development
capabilities, including a wholly-owned, 129,000 square foot research and </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>98</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=102,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=988871,FOLIO='98',FILE='DISK116:[20ZBV1.20ZBV74901]CW74901A.;29',USER='SCAVALI',CD='10-APR-2020;08:06' -->
<A NAME="page_cw74901_1_99"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>development
facility, are of a scale and quality that we believe ordinarily are only possessed by large pharmaceutical companies. We also own a library of approximately 240,000 pharmacologically
relevant molecules, 60% of which are proprietary. We believe these assets differentiate us from many other biotechnology companies at a similar stage of development, which in-license intellectual
property and outsource research and development capabilities. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Using
our assets and expertise, we have built a discovery engine focused on oral small molecule compounds that target nuclear receptors, transcription factors and epigenetic modulation. Our assets and
expertise have enabled us to efficiently identify and advance multiple, novel and differentiated programs in areas with high unmet medical need, including lanifibranor for the treatment of NASH and
odiparcil for the treatment of MPS. We are also leveraging our discovery engine to advance the development of our Hippo program, which aims to disrupt the YAP-TEAD interaction, an interaction that
plays a key role in oncogenic and fibrotic processes. In xenograft and orthotopic models of MPM, we observed that YAP-TEAD inhibition was associated with reduced tumor growth and we are in the process
of selecting development candidate for our Hippo program, which we anticipate entering pre-clinical development in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for the
treatment of non-small cell lung cancer and mesothelioma. We
are also advancing a pre-clinical program for the treatment of IPF, and have validated a new target within the TGF-<FONT FACE="SYMBOL">b</FONT> signaling pathway.
TGF-<FONT FACE="SYMBOL">b</FONT> is a cytokine that is a key driver of fibrosis and acts by activating fibroblasts into myofibroblasts, which in turn drives the production of fibrotic
connecting tissues. We are progressing this program into lead generation in anticipation of selecting a development candidate. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Validating Collaboration  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our assets and expertise also form the basis of a multi-year drug discovery collaboration that we have entered into with AbbVie. Together with AbbVie, we have
discovered new, potent, selective orally-available inverse agonists of the nuclear receptor ROR<FONT FACE="SYMBOL">g</FONT> that may potentially be useful in the treatment of autoimmune
diseases. AbbVie is currently investigating ABBV-157, a drug candidate resulting from our collaboration, in a second Phase&nbsp;I clinical trial for the treatment of moderate to severe psoriasis.
AbbVie is solely responsible for funding and conducting the clinical development of programs identified through our collaborations. We are eligible to receive up to &euro;35&nbsp;million
in pre-clinical, clinical and commercial milestone payments and royalties on sales of any approved products and, in December 2019, we received a &euro;3.5&nbsp;million payment as a result
of the enrollment of the first patient with psoriasis in the trial. We believe that this collaboration validates our approach and the potential of our discovery engine. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our Strategy  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our goal is to rapidly deliver multiple, novel and differentiated oral small molecule therapies to patients suffering from NASH, MPS, cancer and other diseases
with significant unmet medical need. To achieve our goal, we are pursuing the following strategies: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I> Demonstrate Clinical Proof of
Concept for Lanifibranor in the Treatment of NASH.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;We are currently investigating lanifibranor for the treatment of patients with NASH in the
randomized, double-blind, placebo-controlled NATIVE Phase&nbsp;IIb clinical trial. In September 2019, we completed enrollment in the NATIVE trial and plan to report data in June 2020. If positive,
we plan to advance lanifibranor, alone or together with a collaborator, into pivotal Phase&nbsp;III clinical development. We are also supporting a Phase&nbsp;II investigator-initiated clinical
trial studying lanifibranor for the treatment of nonalcoholic fatty liver disease, or NAFLD, the most common liver disorder in developed countries and a precursor to NASH. If positive, we expect that
these data would support our registrational filings for lanifibranor for the treatment of NASH. Lanifibranor has received fast track designation from the FDA for the treatment of NASH. Based on the
broad anti-fibrotic and anti-inflammatory properties, as well as beneficial vascular and metabolic effects, of lanifibranor observed in pre-clinical and clinical development to date, we may also
pursue development of lanifibranor for the treatment of NASH patients with stage four fibrosis, which is severe fibrosis with liver cirrhosis. Given our belief that NASH is underdiagnosed and poorly
understood by the medical community, we have </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>99</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=103,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=402120,FOLIO='99',FILE='DISK116:[20ZBV1.20ZBV74901]CW74901A.;29',USER='SCAVALI',CD='10-APR-2020;08:06' -->
<A NAME="page_cw74901_1_100"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:arial;"><FONT SIZE=2>founded
and sponsored the development of the panNASH Initiative, which is a working group of international independent NASH experts that aims to increase the visibility and contribute to a better
understanding of NASH, including improving diagnosis and establishing best practices for the treatment of the disease.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I> Rapidly Advance Odiparcil to
Pivotal Trials.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;In December 2019, we announced positive results from a Phase&nbsp;IIa clinical trial of odiparcil for the treatment of adult
patients with the MPS VI subtype. In this trial, we observed that odiparcil, in combination with ERT, was associated with improvements in corneal clouding and cardiac and respiratory function and
exhibited a favorable tolerability profile. Signals of clinical activity were also detected in patients treated only with odiparcil. Because MPS is a progressive disease, we believe there is benefit
in treating pediatric patients with MPS, and we plan to commence a Phase Ib/II clinical trial of odiparcil in a pediatric population with MPS VI
by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. If the results of this pediatric
trial are favorable, we plan to initiate Phase&nbsp;III clinical development of odiparcil as a monotherapy and in combination with ERT for the treatment of adult and pediatric patients with MPS VI.
In addition, we plan to initiate an open label Phase&nbsp;IIa extension study in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to investigate the
long-term safety and efficacy of odiparcil in patients 16&nbsp;years and above
with MPS VI who completed the prior Phase&nbsp;IIa trial. We believe odiparcil's mechanism of action is relevant to a number of MPS subtypes, and we also plan to initiate pivotal trials for the
treatment of one or more of MPS subtypes&nbsp;I, II, IVa and VII. Odiparcil has received orphan drug designation from the FDA and EMA and rare pediatric disease designation from the FDA for the
treatment of MPS VI.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I> Leverage the Power of Our
Discovery Engine to Identify and Advance Additional Novel Programs in Areas with High Unmet Medical Need.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;We plan to leverage our library of
approximately 240,000 pharmacologically relevant molecules, our advanced research and development facilities and our medicinal, computational chemistry, pharmacokinetics and pharmacology expertise to
identify and develop new compounds. For example, we are in the process of selecting development candidate for our Hippo program, which we anticipate entering pre-clinical development in
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for the treatment of non-small cell lung cancer and mesothelioma.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I> Selectively Seek Strategic
Collaborations to Maximize the Value of Our Assets.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;Our differentiated product candidates and robust discovery engine may enable us to address a
wide variety of indications. We plan to selectively form research, development and commercial strategic collaborations around product candidates or disease areas that we believe could benefit from the
resources of either larger biopharmaceutical companies or those specialized in a particular area of relevance. For example, our collaboration with AbbVie has been based on leveraging our scientific
and therapeutic expertise in fibrosis and AbbVie's expertise in the areas of psoriasis. In addition, assuming positive Phase&nbsp;IIb trial results for lanifibranor for the treatment of patients
with NASH, we plan to explore a strategic collaboration for pivotal development given the size and scope of this indication. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>100</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=104,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=1005267,FOLIO='100',FILE='DISK116:[20ZBV1.20ZBV74901]CW74901A.;29',USER='SCAVALI',CD='10-APR-2020;08:06' -->
<A NAME="page_cw74901_1_101"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our Pipeline  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have leveraged our assets and expertise to advance the development of multiple, novel and differentiated oral small molecule therapies. The following table
summarizes our key candidates and programs: </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g328266.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="391">
  </B></FONT></P>


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">*</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Lead
generation means identifying molecules in anticipation of selecting candidates. </FONT></DD></DL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Lanifibranor for the Treatment of NASH  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>NASH is a progressive chronic liver disease, often resulting in liver failure and death, that affects millions of patients and for which there are currently no
approved therapies. NASH is characterized by a metabolic process known as steatosis, or the excessive accumulation of fat in the liver, inflammation and ballooning of liver cells and progressive liver
fibrosis that can ultimately lead to cirrhosis. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
lead product candidate, lanifibranor, is an orally-available small molecule in development for the treatment of NASH that acts to induce anti-fibrotic, anti-inflammatory and beneficial vascular
and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor, or PPAR, isoforms. While there are other PPAR agonists that target only one or two PPAR isoforms,
lanifibranor is the only pan-PPAR agonist in clinical development. We believe that this pan-PPAR approach provides for a combination of anti-fibrotic, anti-inflammatory and beneficial vascular and
metabolic effects that cannot be obtained with single and dual PPAR agonists. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
pre-clinical studies, we observed that the administration of lanifibranor improved insulin sensitivity and lipid profile, reduced NAS score, slowed, blocked and reversed liver fibrosis and reduced
portal pressure. Further, in clinical trials in patients with type&nbsp;2 diabetes conducted prior to our founding, Abbott observed improvements in key metabolic parameters associated with NASH
following treatment with lanifibranor. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
September 2019, we completed enrollment in the NATIVE Phase&nbsp;IIb clinical trial of lanifibranor in patients with NASH and plan to report data in June 2020. If positive, we plan to advance
lanifibranor, alone or together with a collaborator, into pivotal Phase&nbsp;III clinical development. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>101</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=105,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=34981,FOLIO='101',FILE='DISK116:[20ZBV1.20ZBV74901]CW74901A.;29',USER='SCAVALI',CD='10-APR-2020;08:06' -->
<A NAME="page_cw74901_1_102"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Disease Overview and Opportunity  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>NASH is a common and progressive chronic liver disease that is an advanced progression of nonalcoholic fatty liver disease, or NAFLD. NASH has five main
components. The first component is metabolic. NASH is increasingly understood as the expression in the liver of metabolic syndrome and is frequently associated with obesity, insulin resistance and
type&nbsp;2 diabetes. Second, NASH is characterized by excessive fat accumulation in the liver, known as steatosis, that is not caused by excessive use of alcohol. Steatosis is a metabolic
dysfunction that occurs when the liver cells import more fatty acids than they can metabolize, leading to lipogenesis, or the creation of fat. Third, in NASH patients, steatosis induces chronic
inflammation and the death of liver cells, observed histologically as ballooning of necrotic cells. Fourth, inflammation and ballooning may lead to progressive fibrosis in the liver, and ultimately
cirrhosis, as the body responds to the liver's injured state by producing stellate cells, fibroblasts and accompanying proteins, such as collagen and fibronectin. Fifth, advanced fibrosis of the liver
is characterized in part by increased vascular resistance and portal hypertension, or high blood pressure in the system of veins running from the intestinal system to the liver. NASH is diagnosed by
means of a liver biopsy that confirms the presence of steatosis, inflammation, ballooning and fibrosis. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
overall NASH prevalence in the adult population of the United States is believed to be approximately 12%. Given the prevalence of the underlying risk factors for the disease, including
type&nbsp;2 diabetes and obesity, as well as the need for a biopsy to diagnose NASH, we also believe that the disease may be underdiagnosed. In 2020, NASH is expected to become a leading cause of
liver transplantation in the United States. Additionally, NASH is now considered to be the leading, and a rapidly increasing, cause of hepatocellular carcinoma, or primary liver cancer, of which up to
40% of cases in NASH patients develop prior to developing cirrhosis. More than 20% of patients with NASH progress to cirrhosis within a decade of diagnosis and, compared to the general population,
have a ten-fold greater risk of liver-related mortality. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>There
are currently no approved therapies for the treatment of NASH. Various therapeutics, including insulin sensitizers and vitamin E, are used off-label. Lifestyle changes, including modification of
diet and exercise to reduce body weight, as well as treatment of concomitant diabetes and dyslipidemia, are commonly accepted as the standard of care, but have not conclusively been shown to prevent
disease progression. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Background: PPAR Activation and NASH  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>PPARs are ligand-activated transcription factors belonging to the nuclear hormone receptor family that regulate the expression of genes. PPARs play essential
roles in the regulation of cellular differentiation, development and tumorigenesis. There are three PPAR isoforms, known as PPAR<FONT FACE="SYMBOL">a</FONT>,
PPAR<FONT FACE="SYMBOL">d</FONT> and PPAR<FONT FACE="SYMBOL">g</FONT>. As shown in the diagram below, PPAR activation has been established to play a role in regulating each of
the components of NASH: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I> Metabolism:</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;Activation of PPAR<FONT FACE="SYMBOL">a</FONT> and
PPAR<FONT FACE="SYMBOL">d</FONT> have been demonstrated to reduce triglyceride levels and increase HDL cholesterol levels, while activation of PPAR<FONT FACE="SYMBOL">g</FONT>
has been demonstrated to increase insulin sensitization, all of which are key metabolic markers in patients with NASH.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I> Steatosis:</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;Activation of PPAR<FONT FACE="SYMBOL">a</FONT> and
PPAR<FONT FACE="SYMBOL">g</FONT> address key elements of steatosis by enhancing fatty acid metabolism and ultimately decreasing lipogenesis.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I> Inflammation and
Ballooning:</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;Activation of PPAR<FONT FACE="SYMBOL">a</FONT>, PPAR<FONT FACE="SYMBOL">d</FONT> and
PPAR<FONT FACE="SYMBOL">g</FONT> have been associated with statistically significant reductions in inflammation and ballooning.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I> Fibrosis:</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;Activation of PPAR<FONT FACE="SYMBOL">g</FONT> is associated with anti-fibrotic
effects across the process of fibrosis, from the production of stellate cells to the production of fibrotic proteins such as collagen and fibronectin.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I> Vascular
Processes:</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;Activation of PPAR<FONT FACE="SYMBOL">a</FONT> and PPAR<FONT FACE="SYMBOL">g</FONT> have been shown to decrease
liver sinusoisal endothelial cell capillarisation and improve endothelial function, leading to decrease hepatic vascular resistance and portal pressure, and in turn reduced hypertension. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>102</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=106,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=185668,FOLIO='102',FILE='DISK116:[20ZBV1.20ZBV74901]CW74901A.;29',USER='SCAVALI',CD='10-APR-2020;08:06' -->
<A NAME="page_cw74901_1_103"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>
</UL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g669759.jpg" ALT="GRAPHIC" WIDTH="618" HEIGHT="423">
  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>PPAR
agonists act to induce anti-fibrotic, anti-inflammatory and positive vascular and metabolic effects by activating one or more PPAR isoforms, as well as by repressing or recruiting co-regulators
of these isoforms, which are proteins that interact with the transcription machinery of cells to enhance or inhibit the transcription of genes. Depending on their chemical structure, PPAR agonists can
activate different PPAR isoforms, and can activate each isoform more or less potently, depending on the manner in which the agonist binds to the isoform and the nature and number of co-regulators that
the agonist represses or recruits. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
interaction of PPAR agonists and PPAR isoforms is complex, and creating therapeutic chemical compounds that induce the desired clinical effects is challenging. A PPAR agonist intended to induce a
specific anti-fibrotic, anti-inflammatory, vascular or metabolic effect by activating an isoform may not activate the isoform with sufficient potency to induce the desired effect, may activate the
isoform with excessive potency, leading to unintended harmful consequences, or may co-activate additional isoforms, leading to additional effects, which may or may not be beneficial. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Single
and dual PPAR agonists have been associated with toxicity and adverse effects, including adverse effects on the heart, kidney, skeletal muscle and bladder, as well as on body weight, water
retention and bone mineral density. We believe this is because single and dual PPAR agonists have historically activated PPAR isoforms with excessive potency or in an imbalanced manner, leading to
over-activation of certain isoforms in the attempt to activate other isoforms, or an under-activation of other isoforms that could counterbalance the effects of the activated isoforms. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Lanifibranor as a Differentiated PPAR Agonist  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Lanifibranor is a pan-PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of
PPAR<FONT FACE="SYMBOL">a</FONT> and PPAR<FONT FACE="SYMBOL">d</FONT>, and a partial activation of PPAR<FONT FACE="SYMBOL">g</FONT>. While there are other PPAR
agonists that target only one or two PPAR isoforms, lanifibranor is the only pan-PPAR agonist in clinical development. We believe that this pan-PPAR approach provides for a combination of
anti-fibrotic, anti-inflammatory and beneficial vascular and metabolic effects that cannot be obtained with </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>103</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=107,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=190861,FOLIO='103',FILE='DISK116:[20ZBV1.20ZBV74901]CW74901A.;29',USER='SCAVALI',CD='10-APR-2020;08:06' -->
<A NAME="page_cw74901_1_104"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>single
and dual PPAR agonists. We believe lanifibranor's moderate and balanced pan-PPAR binding profile also contributes to the favorable safety and tolerability profile that has been observed in
clinical trials and pre-clinical studies to date. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
tested the response of each of the three PPAR isoforms to activation by lanifibranor at increasing doses. As shown in the first chart below, we observed that the response curve of each PPAR isoform
to lanifibranor was similar and dose-dependent. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
also measured the binding affinity of lanifibranor to each of the three PPAR isoforms by using EC50, a commonly accepted measure of the potency of binding affinity that represents higher potencies
with smaller numbers, and compared that to the documented binding affinity of other PPAR agonists. As shown in the second chart below, we observed that lanifibranor is the only PPAR agonist that
activates all three PPAR isoforms. In addition, we observed that lanifibranor exhibited a more balanced activation of PPAR isoforms in comparison to other PPAR agonists, while also acting with
moderate potency. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g89970.jpg" ALT="GRAPHIC" WIDTH="679" HEIGHT="226">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Pre-clinical
and clinical data have shown that lanifibranor is associated with a favorable safety and tolerability profile, which we believe is the result of its moderate and balanced binding profile.
We have examined the physical binding of lanifibranor to PPAR<FONT FACE="SYMBOL">g</FONT> and observed that lanifibranor binds differently to PPAR<FONT FACE="SYMBOL">g</FONT>
than other PPAR agonists, such as rosiglitazone, and recruits a more selective set of co-regulators, which suggests that lanifibranor will be less likely to induce an over-activation of the
PPAR<FONT FACE="SYMBOL">g</FONT> isoform. Further, studies conducted by others have shown that activation of certain PPAR isoforms can mitigate safety and tolerability issues that are
associated with activation of other PPAR isoforms. For example, administration of PPAR<FONT FACE="SYMBOL">g</FONT> agonists is associated with increased body weight and water retention in
patients with diabetes and decreased bone mineral density in rodent models; however, co-administration of both a PPAR<FONT FACE="SYMBOL">a</FONT> agonist and a
PPAR<FONT FACE="SYMBOL">g</FONT> agonist was observed to mitigate these adverse effects. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
shown in the chart below, in a 12-month toxicological study performed in non-human primates and two-year carcinogenicity studies in rats and mice, lanifibranor was not observed to be associated
with toxicity or adverse effects on the heart, kidney, skeletal muscle or bladder. By contrast, single and dual PPAR agonists have been associated with toxicity and adverse effects on these organs. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>104</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>

<!-- ZEQ.=10,SEQ=108,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=894063,FOLIO='104',FILE='DISK116:[20ZBV1.20ZBV74901]CW74901A.;29',USER='SCAVALI',CD='10-APR-2020;08:06' -->
<A NAME="page_cw74901_1_105"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g175228.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="250">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Furthermore,
as shown in the figure below, in pre-clinical studies, it was observed that lanifibranor was the only PPAR agonist tested that was not associated with statistically significant increases
in fluid retention, as evidenced by plasma volume expansion and heart weight increase, following nine weeks of administration at doses up to ten times greater than the therapeutic dose. By contrast,
these adverse effects were observed to be associated with the PPAR<FONT FACE="SYMBOL">g</FONT> agonist rosiglitazone as well as with the dual
PPAR<FONT FACE="SYMBOL">a</FONT>/<FONT FACE="SYMBOL">g</FONT> agonists tesaglitazar and muraglitazar. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g760827.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="214">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
this prospectus, statistically significant results are noted with asterisks. A result is considered to be statistically significant when the probability of the result occurring by random chance,
rather than from the efficacy of the treatment, is sufficiently low. The conventional method for measuring the statistical significance of a result is known as the "p-value," which represents the
probability that random chance caused the result (e.g.,&nbsp;a p-value&nbsp;= 0.001 means that there is a 0.1% or less probability that the difference between the control group and the treatment
group is purely due to random chance). In this prospectus, a p-value less than 0.05 is denoted by a single asterisk, a p-value less than 0.01 is denoted by two asterisks, a p-value less than 0.001 is
denoted by three asterisks and a p-value less than 0.0001 is denoted by four asterisks. Generally, a p-value less than 0.05 is considered statistically significant, and may be supportive of a finding
of efficacy by regulatory authorities. However, regulatory authorities, including the FDA and EMA, do not rely on strict statistical significance thresholds as criteria for marketing approval and
maintain the flexibility to evaluate the overall risks and benefits of a treatment. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under
Abbott's prior ownership, lanifibranor was also advanced through completion of Phase&nbsp;I clinical trials in which lanifibranor was administered to 125 healthy volunteers, and
Phase&nbsp;IIa clinical trials in which lanifibranor was administered to 47 patients with type&nbsp;2 diabetes over a period of four weeks. In these trials, lanifibranor exhibited a favorable
tolerability profile, including with respect to key markers of liver, kidney, heart, muscle and bone function. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>105</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=109,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=719193,FOLIO='105',FILE='DISK116:[20ZBV1.20ZBV74901]CW74901A.;29',USER='SCAVALI',CD='10-APR-2020;08:06' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_cy74901_1_106"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As of March&nbsp;16, 2020, approximately 250 patients have been treated for 24 or 48&nbsp;weeks in our ongoing and completed Phase&nbsp;IIb clinical trials of
lanifibranor. In connection with these trials, lanifibranor has undergone a total of seven DSMB reviews, and the DSMBs have not recommended any changes to the trial protocols. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>As
a result of the toxicity and adverse effects associated with single and dual PPAR agonists, FDA regulations regarding the PPAR class of compounds require two-year carcinogenicity and one-year </FONT> <FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2>
toxicity studies to be performed prior to a product candidate entering clinical trials longer than six months. In accordance with these
requirements, we conducted three long-term toxicological studies of lanifibranor in 2015. We first evaluated lanifibranor in a 12-month primate toxicological study, in which the administration of the
product candidate was not associated, at any dose-level tested, with adverse effects. Lanifibranor was also evaluated in two 2-year carcinogenicity studies in rats and mice designed to identify any
potential carcinogenic risk. In these two studies, lanifibranor was not associated with any carcinogenic effect relevant to humans up to the highest dose tested. Following its review of the two-year
carcinogenicity studies, the FDA has lifted the clinical hold in place on the PPAR target class with respect to lanifibranor. This decision enables us to conduct clinical trials longer than six months
evaluating lanifibranor for the treatment of NASH. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Pre-Clinical Development in NASH  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In pre-clinical studies, we evaluated the effect of lanifibranor on the components of NASH, including studies that address effects linked to metabolic
functions, including steatosis, to inflammation and ballooning, to the process of fibrosis and to vascular functions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
induced liver inflammation, steatosis and fibrotic gene expression in the liver in mice through a methionine choline deficient, or MCD, diet, which is a model commonly used in studies related to
NASH. We then administered a vehicle that served as a negative control, as well as lanifibranor at 10mg/kg and 30mg/kg. After three weeks of treatment, we observed statistically significant dose
dependent decreases in both steatosis and inflammation in those mice administered lanifibranor as shown in the figure below. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="48%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Lanifibranor effect on steatosis in the MCD<BR>
model</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> Lanifibranor effect on inflammation in the MCD<BR>
model</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2><B>
<IMG SRC="g114393.jpg" ALT="GRAPHIC" WIDTH="264" HEIGHT="196">
 </B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2><B>
<IMG SRC="g253994.jpg" ALT="GRAPHIC" WIDTH="250" HEIGHT="193">
 </B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>We
also administered lanifibranor in doses of 10mg/kg and 30mg/kg in a foz/foz mouse model. The rationale for using foz/foz mice in NASH research is that these mice spontaneously develop significant
liver steatosis, with appreciable fibrosis, when fed a high fat, atherogenic diet, or HFD. As shown in the left figure below, we observed that the administration of lanifibranor was associated with
statistically significant reductions in ballooning of the liver, and as shown in the right figure below, lanifibranor was associated with </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>106</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=110,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=1047972,FOLIO='106',FILE='DISK116:[20ZBV1.20ZBV74901]CY74901A.;21',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_cy74901_1_107"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>statistically
significant improvements in NAS score, a commonly accepted, semi-quantitative evaluation of biopsy results that assesses the severity of steatosis, inflammation and ballooning in the
liver. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="48%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Lanifibranor effect on ballooning in the foz/foz model</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> anifibranor effect on NAS score in the foz/foz model</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2><B>
<IMG SRC="g209163.jpg" ALT="GRAPHIC" WIDTH="256" HEIGHT="249">
 </B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2><B>
<IMG SRC="g852740.jpg" ALT="GRAPHIC" WIDTH="261" HEIGHT="219">
 </B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>We
also conducted pre-clinical studies of lanifibranor's anti-fibrotic activity in the liver. In a mouse model, we administered CCI4, an organic solvent that induces a strong liver inflammatory
response producing fibrosis, as well as corn oil, which served as a negative control. We measured the expression of collagen at each site of administration. We concurrently administered lanifibranor
at doses of 3mg/kg, 10mg/kg and 30mg/kg. As shown in the left figure below, we observed that the concurrent administration of lanifibranor with CCI4 was associated with statistically significant,
dose-dependent decreases in collagen production at the site of administration, suggesting that lanifibranor inhibited the progression of fibrotic processes. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Using
the same model, we also administered CCI4 and corn oil three weeks prior to the administration of lanifibranor at doses of 15mg/kg and 30mg/kg. As shown in the right figure below, we observed
that the administration of lanifibranor after the onset of fibrosis was associated with statistically significant decreases in collagen production, suggesting that the fibrotic process was reversed. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="48%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Lanifibranor effect on liver fibrosis induction</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> Lanifibranor effect on established liver fibrosis</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2><B>
<IMG SRC="g343056.jpg" ALT="GRAPHIC" WIDTH="265" HEIGHT="126">
 </B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2><B>
<IMG SRC="g374512.jpg" ALT="GRAPHIC" WIDTH="252" HEIGHT="111">
 </B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>In
other pre-clinical studies, we also evaluated the effect of lanifibranor on key metabolic parameters associated with NASH. In a diet-induced obesity and insulin resistance model, we observed that
administration of lanifibranor was associated with significant improvements in body weight, adiposity index, non-fasting glucose levels and insulin levels. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
also investigated the effect of two weeks of treatment with lanifibranor on cirrhotic rats and observed an amelioration of fibrosis and portal hypertension. As shown in the graphic below,
administration of lanifibranor was associated with a reduction in portal pressure, or PP, and an increase in portal blood flow, or PBF, which we believe are a result of improvement in the intrahepatic
vascular resistance. Increased PBF was associated with liver function improvement as evidenced by decreased aspartate aminotransferase, or </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>107</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=111,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=813242,FOLIO='107',FILE='DISK116:[20ZBV1.20ZBV74901]CY74901A.;21',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_cy74901_1_108"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>AST,
which is an enzyme released when the liver is damaged. In addition, in the lanifibranor treated group there were significantly fewer rats that presented with ascites, which is an accumulation of
fluid in the abdomen often caused by high blood pressure in the liver. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g841242.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="148">
  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Earlier Trials in Type&nbsp;2 diabetes&nbsp;&#151; Supportive Evidence for relevance of
Lanifibranor in NASH  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Prior to our founding, Abbott advanced lanifibranor through completion of Phase&nbsp;IIa clinical trials in which lanifibranor was administered to 56
patients with type&nbsp;2 diabetes over a period of four weeks. In these trials, it was observed that treatment with lanifibranor was associated with improvements in metabolic biomarkers relevant to
NASH, including insulin resistance and dyslipidemia markers, and also exhibited a favorable tolerability profile. While the results of these clinical trials were also supportive of continued clinical
development in type&nbsp;2 diabetes, we determined that the number of drugs available and in development for the treatment of type&nbsp;2 diabetes, as well as other competitive factors, made it
impractical for us to continue Abbott's development of lanifibranor for the treatment of type&nbsp;2 diabetes. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
shown in the figures below, administration of lanifibranor at all doses tested (400mg, 800mg and 1,400mg) was associated with increased levels of adiponectin, a fat-derived plasma protein with
anti-inflammatory functions, increased levels of HDL cholesterol and decreased levels of triglycerides. Moreover, at the 800mg and 1,400mg doses, the changes in all three parameters were statistically
significant as compared to the placebo. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g424598.jpg" ALT="GRAPHIC" WIDTH="651" HEIGHT="154">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Based
on the metabolic properties of lanifibranor observed in these clinical trials and their relevance to metabolic biomarkers associated with NASH, we believe lanifibranor can be relevant in
treating patients with NASH. We believe these trials will provide additional supporting clinical data for our discussions with regulatory authorities regarding the potential approval of lanifibranor
for the treatment of NASH. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Ongoing Clinical Development  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are currently investigating lanifibranor in the Phase&nbsp;IIb randomized, double-blind, placebo-controlled NATIVE clinical trial for the treatment of
patients with NASH. In September 2019, we completed enrollment of 247 patients (in excess of the original target of 225 patients) in the NATIVE trial at more than 70 sites in Europe, the United
States, Canada, Australia and Mauritius. We focused on recruiting patients with severe disease: approximately 73% of patients have a NAS score of six or higher, approximately
76% of patients have stage two or three fibrosis, indicating moderate to advanced fibrosis without cirrhosis, and approximately 40% of patients have type&nbsp;2 diabetes. The goal of the trial is to
assess improvement in liver inflammation and ballooning, which are two of the markers of the resolution of NASH. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>108</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=112,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=612325,FOLIO='108',FILE='DISK116:[20ZBV1.20ZBV74901]CY74901A.;21',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_cy74901_1_109"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To
be considered for inclusion, patients must have a diagnosis of NASH confirmed by liver biopsy and must have a cumulative score of inflammation and ballooning of three or four out of four,
indicating the presence of moderate to severe inflammation and ballooning; a steatosis score greater than or equal to one, indicating the presence of moderate to severe steatosis; and a fibrosis score
less than four, indicating the absence of cirrhosis. The scoring of each of these parameters was performed in a centralized laboratory following liver biopsy and using the steatosis, activity and
fibrosis, or SAF, score, which is a commonly accepted, semi-quantitative evaluation of liver biopsy results. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Patients
will be randomized in a 1:1:1 ratio to receive either lanifibranor at a dose of 800mg or 1,200mg once daily or placebo for a period of 24&nbsp;weeks. The primary endpoint of the trial is a
reduction in the combined inflammation and ballooning score of two points compared to baseline, without worsening fibrosis. Secondary endpoints include NASH resolution, improvements in each of the
steatosis, inflammation, ballooning and fibrosis scores from baseline as measured using the SAF score, improvements in various other fibrosis measures, improvements in several metabolic markers,
improvements in steatosis, inflammation and ballooning as measured using the NAS score, and safety. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
June 2018, October 2018, February 2019 and September 2019, we announced that the DSMB for the trial recommended that the trial continue without any changes to the protocol. As of March&nbsp;16,
2020, 228&nbsp;patients had completed the trial and 19 had withdrawn from the trial. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
expect to report data from the NATIVE clinical trial in June 2020, and, if positive, we plan to advance lanifibranor, alone or together with a collaborator, into pivotal Phase&nbsp;III clinical
development. We may also pursue development of lanifibranor for the treatment of NASH patients with stage four fibrosis, indicating severe fibrosis with cirrhosis. Clinical development in the United
States will be conducted pursuant to an IND accepted by the FDA in August 2018. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


NAFLD in Type&nbsp;2 Diabetes Patients  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In collaboration with Dr.&nbsp;Kenneth Cusi, Chief of the Division of Endocrinology, Diabetes&nbsp;&amp; Metabolism in the Department of Medicine at the
University of Florida, Gainesville, we are supporting a Phase&nbsp;II investigator-initiated clinical trial of lanifibranor for the treatment of NAFLD. The trial is expected to enroll 64 NAFLD
patients, each of whom has also been diagnosed with type&nbsp;2 diabetes, who will be treated for a 24-week period with a single daily dose of 800mg of lanifibranor, and ten subjects in a healthy,
non-obese control group. The trial's overall objective is to measure the metabolic effects of lanifibranor and its potential efficacy on liver triglycerides in type&nbsp;2 diabetes patients with
NAFLD. The primary endpoint is the change in liver triglycerides as assessed by proton magnetic resonance spectroscopy. Secondary endpoints include changes in liver fibrosis, evidence of metabolic
improvements in insulin resistance, de novo lipogenesis, free fatty acids and lipids, as well as safety. The trial is being conducted pursuant to an IND accepted by the FDA in May 2018 and results
from this trial are expected in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We believe this trial will provide
additional supporting clinical data for our discussions with regulatory authorities regarding the potential approval
of lanifibranor for the treatment of NASH. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


The PanNASH Initiative  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We believe that NASH is currently poorly understood and underdiagnosed. As we advance lanifibranor toward pivotal development, we are endeavoring to increase
awareness and disseminate knowledge related to NASH among the scientific and clinical community, patients and other key stakeholders within the healthcare system. To this end, we have founded and
sponsored the development of the PanNASH Initiative. The PanNASH Initiative is a working group consisting of a committee of international independent experts that aims to increase the visibility and
contribute to a better understanding of NASH, including improving diagnosis and establishing best practices for the treatment of the disease. The committee includes European and American medical
experts in areas related to NASH, such as hepatology, diabetes and cardiology, along with scientific experts focused on promoting a better understanding of the pathophysiological mechanisms involved
in NASH. The PanNASH Initiative intends to develop and disseminate new findings about NASH through publications, conferences and training sessions. It focuses </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>109</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=113,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=879271,FOLIO='109',FILE='DISK116:[20ZBV1.20ZBV74901]CY74901A.;21',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_cy74901_1_110"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>on
risk factors for the development of the disease, the identification of patients at risk, clinical markers and associated health risks, as well as the development of new treatments. Specifically,
the PanNASH Initiative is working to increase knowledge of the underlying pathological mechanisms of NASH ranging from metabolic disorders to fibrosis, with a focus on the modulating role in the
disease played by PPARs. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Odiparcil for the Treatment of MPS  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are developing odiparcil for the treatment of several subtypes of MPS, a group of rare, progressive genetic disorders that manifest early in life. Odiparcil
is designed to act on the underlying cause of the symptoms of MPS, which is the accumulation of GAGs in the lysosomes of cells. GAGs are important for the modulation of cell-to-cell signaling and the
maintenance of tissue structure and function. Lysosomes are enclosed sacs of enzymes that break down large molecules, including GAGs, so that they can be passed to other parts of the cell or excreted.
Due to genetic mutations, lysosomes in patients with MPS contain deficient versions of the enzymes necessary to break down GAGs. As a result, GAGs accumulate within the lysosomes, causing them to
swell and interfere with the ordinary functioning of cells, leading to the symptoms associated with MPS. MPS is categorized by subtypes, depending on the enzyme that is deficient and the corresponding
GAGs that accumulate. By modifying how GAGs are synthesized, odiparcil facilitates the production of soluble GAGs that can be excreted in the urine, rather than accumulating in cells. Specifically,
odiparcil acts on chondroitin sulfate, or CS, and dermatan sulfate, or DS, either or both of which accumulate in patients with MPS I, II, IVa, VI and VII. Prior to our founding, Abbott, in
collaboration with GlaxoSmithKline, investigated odiparcil for the treatment of thrombosis because odiparcil's mechanism of action, which involves the synthesis of soluble GAGs, is also believed to
have an anti-thrombotic effect. After acquiring odiparcil from Abbott, we determined that the mechanism of action of odiparcil is also relevant for the treatment of patients with certain subtypes of
MPS, and we decided to develop odiparcil for this indication. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Disease Overview and Opportunity  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>There are four types of GAGs that accumulate in MPS patients, which are DS and CS, as well as heparan sulfate, or HS, and keratan sulfate, or KS. The
manifestations of the disease depend on the type of GAGs that accumulate, with MPS being categorized into numerous subtypes, depending on the lysosomal enzyme that is deficient. Because odiparcil acts
on CS and DS, we believe odiparcil's mechanism of action could be effective in patients with MPS I, II, IVa, VI and VII, which, as shown in the figure below, are the MPS subtypes in which one or both
of CS and DS accumulate. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>110</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=114,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=257087,FOLIO='110',FILE='DISK116:[20ZBV1.20ZBV74901]CY74901A.;21',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_cy74901_1_111"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
following table summarizes the various MPS subtypes: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="58pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="81pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="143pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="47pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="14pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="14pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="16pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="14pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Type </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Name </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Deficient lysosomal enzyme </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Incidence </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Key disease features </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>DS </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>CS </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>HS </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>KS </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">MPS I-H</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Hurler syndrome</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Alpha-L-iduronidase</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1/100,000</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Corneal clouding, skeletal abnormalities, organ enlargement, heart and lung disease, mental retardation, hearing loss, death in childhood</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&uuml;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&uuml;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">MPS I-S</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Scheie syndrome</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Alpha-L-iduronidase</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1/100,000</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Corneal clouding, stiff joints, heart disease</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&uuml;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">MPS I-H/S</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Hurler-Scheie syndrome</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Alpha-L-iduronidase</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1/100,000</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Intermediate between MPS I-H and MPS I-S</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&uuml;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&uuml;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">MPS II (Types&nbsp;A&nbsp;&amp; B)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Hunter syndrome</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Iduronate sulphatase</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1/100,000</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Corneal clouding, hearing loss, skeletal abnormalities, stiff joints, organ enlargement, heart disease, mental retardation (type&nbsp;B), death in childhood (type&nbsp;B)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&uuml;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&uuml;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">MPS III</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Sanfilippo syndrome</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Heparan </FONT><FONT  style="font-size:8pt;line-height:9pt;"><I>N</I></FONT><FONT  style="font-size:8pt;line-height:9pt;">-sulphatase;<BR></FONT> <FONT  style="font-size:8pt;line-height:9pt;"><BR>
alpha-N-aceytylglucosaminidase;<BR></FONT> <FONT  style="font-size:8pt;line-height:9pt;"><BR>
Acetyl-CoA and alpha-<BR>
glucosaminide acyltransferase;<BR></FONT>
<BR>
<FONT  style="font-size:8pt;line-height:9pt;"><I>N-</I></FONT><FONT  style="font-size:8pt;line-height:9pt;">acetylglucosamine -6-sulphatase<BR></FONT>
</TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1/25,000 to 75,000</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Profound mental deterioration, hyperactivity and mild somatic manifestations</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&uuml;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">MPS IV Type&nbsp;A</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Morquio syndrome</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Galactose 6-sulphatase</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1/40,000 to 200,000</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Skeletal abnormalities, loose ligaments, degenerative joint disease, corneal clouding, heart disease, death in childhood or young adulthood</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&uuml;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&uuml;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">MPS IV Type&nbsp;B</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Morquio syndrome</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Beta-galactosidase</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1/40,000 to 200,000</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Similar to MPS IV Type&nbsp;A</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&uuml;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">MPS VI</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Maroteaux-Lamy syndrome</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Arylsulphatase B</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1/240,000 to 400,000</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Similar to MPS I (excluding mental retardation), death in childhood or young adulthood</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&uuml;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&uuml;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">MPS VII</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Sly syndrome</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Beta-glucuronidase</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Very rare</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Similar to MPS I</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&uuml;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&uuml;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&uuml;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>We
have focused our pre-clinical and clinical development to date on the treatment of MPS VI, primarily because both DS and CS, and no other types of GAGs, accumulate in this subtype. Patients with
MPS VI, also known as Maroteaux-Lamy syndrome, have rounded and thickened facial features, corneal clouding, hearing loss, dwarfism with deformity of the limbs, enlargement of the liver and spleen,
cardiac valve disease and reduced pulmonary function, with no mental retardation. As with other MPS subtypes, the time of onset, rate of progression and extent of the disease may vary between the
affected individuals. The life expectancy of MPS VI patients, if untreated, is approximately 20&nbsp;years for patients with the severe forms of the disease. Common causes of death for MPS VI
patients are heart disease and airway obstruction. The incidence of MPS VI is estimated to be approximately 1 in 240,000 to 400,000 live births, with variations between countries on account of
consanguinity. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Existing
therapeutic options for MPS patients aim to improve quality of life, slow disease progression or minimize irreversible damage to tissues and organs. The current standard of care for the
treatment of </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>111</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=115,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=412013,FOLIO='111',FILE='DISK116:[20ZBV1.20ZBV74901]CY74901A.;21',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_cy74901_1_112"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>patients
with MPS is ERT, which requires weekly infusions and is generally administered in an outpatient hospital setting. While ERT has been shown to be effective in reducing GAG accumulation in
certain tissue types, it has shown limited efficacy in reducing GAG accumulation in poorly vascularized tissues and organs, such as cartilage, or in tissues that are protected by a barrier, such as
the eye. The manifestations of MPS associated with GAG accumulation in these tissues and organs include hearing loss, corneal clouding, joint stiffness, spinal cord compression and heart and lung
diseases. ERT has increased the lifespan of many MPS patients, but these increases are accompanied by unmet medical needs in the tissues in which ERT shows limited efficacy. Hematopoietic stem cell
transplantation, or HSCT is also used in rare cases for patients with severe symptoms. HSCT resolves additional symptoms not addressed by ERT, but compatible donors are difficult to find. The
procedure is also associated with high rates of morbidity and mortality, and efficacy has been reported to be limited to certain patients and certain MPS subtypes. For MPS patients in which prominent
musculoskeletal involvement is seen, frequent orthopedic surgeries may also be required to correct the deformities and increase the quality of life of patients. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Our Solution  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Odiparcil, an orally-available small molecule, acts to decrease the lysosomal accumulation of CS and DS in patients with certain MPS subtypes. In normal GAG
synthesis, galactosyl transferase 1, or GT1, an enzyme, catalyzes the attachment of protein bound D-xylose to a sugar chain to form an insoluble proteoglycan. These insoluble GAGs have a variety of
functions in normal physiology, including modulation of cell-to-cell signaling and maintenance of tissue structure and function. As shown in the graphic below, in healthy cells, GAGs are processed by
the lysosomes, broken down into small parts, and then excreted in the urine, in a process that maintains balance between incoming and outgoing molecules. Because lysosomes in patients with MPS contain
deficient versions of the enzymes necessary to break down GAGs, these molecules accumulate within the lysosomes, leading to the symptoms associated with MPS. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g784446.jpg" ALT="GRAPHIC" WIDTH="390" HEIGHT="324">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>112</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=116,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=200883,FOLIO='112',FILE='DISK116:[20ZBV1.20ZBV74901]CY74901A.;21',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_da74901_1_113"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Odiparcil acts to modify how DS and CS are synthesized, thereby facilitating the production of soluble DS and CS GAGs, which can be excreted in the urine, rather than
accumulating in cells. Odiparcil acts to circumvent the normal process of GAG synthesis by introducing a higher affinity, non-protein bound substrate for GT1 to react with. As shown in the figure
below, we have observed in pre-clinical studies that in the presence of both odiparcil and D-xylose, the ratio at which GT1 reacts with odiparcil in comparison to D-xylose is approximately 2000 to 1.
When GT1 reacts with odiparcil, chains of DS and CS are built on odiparcil, rather than on protein-bound D-xylose. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g394328.jpg" ALT="GRAPHIC" WIDTH="658" HEIGHT="93">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>These
odiparcil-based chains are soluble, which means they can be directly excreted by the body and bypass the lysosomal degradation pathway. With fewer proteoglycans entering the lysosomes, GAG
accumulation is decreased, restoring the balance of the synthesis and degradation of GAGs. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g252607.jpg" ALT="GRAPHIC" WIDTH="538" HEIGHT="271">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
believe odiparcil's mechanism of action is relevant to a number of tissues in which GAGs accumulate that are addressed with limited efficacy by the current standard of care, which is ERT. Unlike
ERT, odiparcil is a small molecule that we have observed to be well distributed in the body, even in certain tissues that are poorly vascularized or protected by a barrier. As shown in the figure
below, pre-clinical studies conducted by others using cat models have measured the presence of rhASB, which is the enzyme used in ERT for patients with MPS VI, in certain tissues and organs. While
these studies observed the presence of rhASB in well-vascularized tissue, such as the heart muscle, they did not observe the presence of rhASB in the cornea or cartilage. By contrast, in pre-clinical
studies in rodent models, we observed meaningful concentrations of odiparcil in not only heart muscle tissue, but also bone, corneal tissue and cartilage. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>113</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=117,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=529715,FOLIO='113',FILE='DISK116:[20ZBV1.20ZBV74901]DA74901A.;16',USER='SCAVALI',CD='10-APR-2020;08:12' -->
<A NAME="page_da74901_1_114"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
following table summarizes the observed distribution of odiparcil and rhASB in certain tissues and organs: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="18%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="18%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="18%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="18%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="18%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Heart </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Bone </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Cornea </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Cartilage </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g938129.jpg" ALT="GRAPHIC" WIDTH="88" HEIGHT="108">
 </B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g1002373.jpg" ALT="GRAPHIC" WIDTH="87" HEIGHT="108">
 </B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g152837.jpg" ALT="GRAPHIC" WIDTH="114" HEIGHT="108">
 </B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g1004457.jpg" ALT="GRAPHIC" WIDTH="70" HEIGHT="108">
 </B></FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Odiparcil (rodent model)</B></FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>X</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>X</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>X</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>X</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>rhASB (cat model)</B></FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>X</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>Not tested</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>Not detected</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>Not detected</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>Because
odiparcil has a different mechanism of action than ERT and reaches tissues that are poorly penetrated by ERT, we believe odiparcil could be used as a combination therapy with ERT. Based on our
pre-clinical data, we also believe odiparcil has potential as a stand-alone therapy. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
December 2019, we announced positive results from a Phase&nbsp;IIa clinical trial of odiparcil for the treatment of adult patients with the MPS VI subtype. Because MPS is a progressive disease,
we believe there is benefit in treating pediatric patients with MPS, and we plan to commence a Phase Ib/II clinical trial of odiparcil in a pediatric population with MPS VI
by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. If the
results of this pediatric trial are favorable, we plan to initiate Phase&nbsp;III clinical development of odiparcil as a monotherapy and in combination with ERT for the treatment of adult and
pediatric patients with MPS VI. In addition, we plan to initiate an open label Phase&nbsp;IIa extension study in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to investigate the long-term safety and efficacy
of odiparcil in
patients 16&nbsp;years and above with MPS VI who completed the prior Phase&nbsp;IIa trial. We believe odiparcil's mechanism of action is relevant to a number of MPS subtypes, and we also plan to
initiate pivotal trials for the treatment of one or more of MPS subtypes&nbsp;I, II, IVa and VII. Odiparcil has received orphan drug designation from the FDA and EMA and rare pediatric disease
designation from the FDA for the treatment of MPS VI. We hold unencumbered rights to odiparcil's development and commercialization. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Pre-Clinical Development  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In pre-clinical studies of fibroblasts from healthy donors and MPS VI patients, we observed that administration of odiparcil was associated with a decrease in
CS intracellular content, while increasing the extra-cellular level of GAGs, as shown in the figure below. At 10&micro;M concentration, odiparcil was associated with a decrease in
intracellular CS content below the basal level observed in control fibroblasts from a healthy donor. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g877878.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="159">
  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
also observed </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> evidence of reduced GAG accumulation following administration of odiparcil in a drug-induced model of MPS. As shown in the first
figure below, in an MPS VI model using mice that were </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>114</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=118,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=583953,FOLIO='114',FILE='DISK116:[20ZBV1.20ZBV74901]DA74901A.;16',USER='SCAVALI',CD='10-APR-2020;08:12' -->
<A NAME="page_da74901_1_115"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>fed
a standard diet and were genetically modified to reflect human MPS pathology, or MPS VI mice, we observed that the concentration of GAGs in the liver was elevated in comparison to wild-type, or
WT, mice. However, in MPS VI mice that were also administered odiparcil at a dose of 4.5g/kg, referred to as MPS&nbsp;VI&nbsp;+&nbsp;odiparcil mice, the concentration of GAGs in the liver was
reduced (p&#60;0.001). As shown in the second figure below, we also tested the intra-cellular accumulation of GAG granules among the WT mice, MPS VI mice and MPS
VI&nbsp;+&nbsp;odiparcil mice. We observed that, while the rate of GAG granule accumulation was substantially greater in the MPS VI mice than in the WT mice, treating MPS VI mice with odiparcil
was associated with a decrease in the accumulation of large numbers of GAG granules. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g501832.jpg" ALT="GRAPHIC" WIDTH="579" HEIGHT="196">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
this same MPS VI mouse model, we also observed that odiparcil was active in tissues of the eyes, which is an area in which ERT has been observed to have limited efficacy. As shown in
Figures&nbsp;A and B below, we observed that corneal thickness and the number of cell layers in the corneal epithelium were decreased in MPS VI mice in comparison to WT mice. However, we also
observed that administration of odiparcil had a statistically significant effect (p&#60;0.0001) on the recovery of thickness in the corneal epithelium and in the layer of epithelial cells.
As shown in Figure&nbsp;C below, we also tested the accumulation of GAGs in the corneal stroma, which is a layer of the cornea in which GAGs are known to accumulate in MPS patients. We scored the
accumulation of the GAGs using a vacuolation scoring system, which is a semi-quantitative score applied to histological observations, with scores of 0, 1, 2 and 3 representing no, mild, moderate or
severe accumulations of GAGs, respectively. The mean score applied to the observations of GAG accumulation in WT mice was zero, representing no GAG accumulation. In MPS VI mice, the mean score applied
to the observations was 2.9, representing severe GAG accumulation. By contrast, in MPS VI&nbsp;+&nbsp;odiparcil mice, the mean score applied to the observations was 0.5, representing a mild GAG
accumulation and a decrease from the score in untreated MPS VI mice. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="31%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="31%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="31%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2><B>A. Odiparcil effect on corneal epithelium thickness</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>B. Odiparcil effect on number of corneal epithelium cell layers</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>C. Odiparcil effect on GAG storage in corneal stroma</B></FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=5 ALIGN="CENTER" VALIGN="TOP" style="font-family:arial;"><BR><FONT SIZE=2><B>
<IMG SRC="g146425.jpg" ALT="GRAPHIC" WIDTH="682" HEIGHT="157">
 </B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>In
this same MPS VI mouse model, we also observed that odiparcil was active in cartilage tissues, which is another area in which ERT has been observed to have limited efficacy. As shown in
Figures&nbsp;A and B below, we observed that trachea and knee cartilage thickness were increased in MPS VI mice in comparison to WT </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>115</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=119,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=1016452,FOLIO='115',FILE='DISK116:[20ZBV1.20ZBV74901]DA74901A.;16',USER='SCAVALI',CD='10-APR-2020;08:12' -->
<A NAME="page_da74901_1_116"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>mice.
However, we also observed that treatment of MPS VI mice with odiparcil was associated with a decrease in thickness in these tissues. In addition, as shown in Figure&nbsp;C below, we observed
statistically significant improvements in mobility, characterized by the amount of time required to descend a vertical pole, in the MPS VI&nbsp;+&nbsp;odiparcil mice in comparison to MPS VI mice. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="31%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="31%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="31%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2><B>A. Odiparcil effect on trachea cartilage thickness</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>B. Odiparcil effect on knee cartilage thickness</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>C. Odiparcil effect on animal mobility</B></FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=5 ALIGN="CENTER" VALIGN="TOP" style="font-family:arial;"><BR><FONT SIZE=2><B>
<IMG SRC="g554321.jpg" ALT="GRAPHIC" WIDTH="663" HEIGHT="172">
 </B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Earlier Clinical Development in Thrombosis&nbsp;&#151; Supportive Evidence of Safety and
Tolerability of Odiparcil  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>During their development of odiparcil as an anti-thrombotic therapy, Abbott and GlaxoSmithKline, advanced odiparcil through the completion of 29 Phase&nbsp;I
and Phase&nbsp;II clinical trials, in which odiparcil was administered to over 1,800 subjects. In these trials, odiparcil displayed a favorable tolerability profile at daily doses in excess of the
therapeutic range. Low toxicity was also observed in </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> toxicology studies of up to 36&nbsp;weeks. We believe these trials will provide additional
supporting clinical data for our discussions with regulatory authorities regarding the potential approval of odiparcil for the treatment of MPS. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Clinical Results and Planned Clinical Development  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In December 2019, we announced positive results from the iMProveS Phase&nbsp;IIa clinical trial of odiparcil, which enrolled twenty patients, aged
16&nbsp;years or older, with advanced MPS VI subtype disease. Fifteen patients were randomized to receive baseline ERT in combination with one of two doses of odiparcil, 250&nbsp;mg or
500&nbsp;mg administered twice daily, or placebo. Five patients who were not receiving ERT received 500&nbsp;mg of odiparcil administered twice daily in an open label cohort. Thirteen patients
completed the trial: four patients who received placebo in addition to ERT and nine patients equally distributed in each of the three odiparcil groups. The trial was conducted at four sites in Europe.
The primary endpoint of the trial was safety, as assessed by clinical and biological standard tests. Secondary endpoints included changes from baseline in leukocyte, skin and urinary GAG content,
improvements of activity and mobility, evaluation of cardiovascular, lung and respiratory function and vision and hearing impairments. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>After
26&nbsp;weeks of treatment, we observed that odiparcil in combination with ERT was associated with improvements in corneal clouding and cardiac and respiratory function and exhibited a
favorable tolerability profile. Signals of clinical activity were also detected in patients treated only with odiparcil. We observed improved mobility as assessed using the 6MWT in patients treated
with ERT and the 250mg twice daily dose of odiparcil, as well as in patients in the open label cohort. We did not observe improved mobility using the 6MWT in patients treated with ERT and the 500mg
twice daily dose of odiparcil. Dose-dependent urinary GAGs clearance, used as an activity biomarker, was observed in the entire odiparcil-treated patient population. A reduction in leukocyte GAGs was
not observed and therefore was not confirmed as a biomarker for the decrease of GAG accumulation, while the analysis of skin GAG content remains ongoing. The trial also met its safety primary
endpoint with odiparcil exhibiting a favorable tolerability profile, consistent with the tolerability profile observed with odiparcil as a monotherapy in prior clinical trials. The majority of the
adverse events reported were mild or moderate in severity. The most common adverse reactions in odiparcil groups were a laboratory interference false positive and skin reactions, among which three
were reported as serious adverse events, or SAEs, that were determined by the investigator to be </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>116</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=120,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=431468,FOLIO='116',FILE='DISK116:[20ZBV1.20ZBV74901]DA74901A.;16',USER='SCAVALI',CD='10-APR-2020;08:12' -->
<A NAME="page_da74901_1_117"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>associated
with the treatment occurred in patients treated with odiparcil. Two of these SAEs were abnormal laboratory results that were subsequently deemed to be false positives. The third SAE was
exanthema, a skin reaction consistent with the types of reaction frequently observed in patients with MPS VI treated with ERT. One death occurred in the placebo group. We observed that the
pharmacokinetic profile of odiparcil in this patient cohort was consistent with that observed in previous trials of odiparcil, suggesting that the introduction of ERT did not alter odiparcil's
pharmacokinetics. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Because
MPS is a progressive disease, we believe there is benefit in treating pediatric patients with MPS, and we plan to commence the SAFEty, pharmacoKInetics and pharmacoDynamics, Dose escalating
Study, or SAFE-KIDDS trial, which is a three-part Phase Ib/II clinical trial of odiparcil in a pediatric population with MPS VI,
by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We plan to sequentially enroll twenty four children
with MPS VI treated with ERT. The first phase of the trial will be a pharmacokinetics and pharmacodynamics assessment of three doses of odiparcil tested each for one week. The second phase will be a
double-blind, placebo controlled study with patients randomized to receive one of two doses of odiparcil or placebo for six months in order to assess safety and efficacy. Patients will be randomized
according to age. The third phase will be an open label extension study open to all patients who complete the second phase of the trial. Patients participating in the open label extension study who
received odiparcil in the second phase of the trial will continue to receive the same dose of odiparcil administered in the second phase of the trial, while patients who received placebo in the second
phase of the trial will be randomized to receive one of two doses of odiparcil. We expect to report initial data from this trial in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and to continue the third
phase of the trial under
such time as odiparcil is approved or its development is discontinued. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
the results of the SAFE-KIDDS trial are favorable, we plan to initiate Phase&nbsp;III clinical development of odiparcil as a monotherapy and in combination with ERT for the treatment of adult and
pediatric patients with MPS VI. In addition, we plan to initiate an open label Phase&nbsp;IIa extension study in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to investigate the long-term safety and efficacy
of odiparcil in
patients 16&nbsp;years and above with MPS VI who completed the iMProveS trial. This study will be designed to last two years, with a possibility of extension, and the 13 patients who completed the
26&nbsp;week iMProveS trial will be invited to participate. The primary endpoint of this extension study would be safety and secondary endpoints will include assessments of mobility, respiratory
function, cardiology, vision, audiology, pain and quality of life. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Because
odiparcil targets GAGs that are also present in other MPS subtypes, we believe that the data generated in the iMProveS and SAFE-KIDDS trials may also support moving directly to
Phase&nbsp;III pivotal trials in one or more of MPS subtypes&nbsp;I, II, IVa and VII if warranted by the results of our Phase&nbsp;IIa clinical trial and other pre-clinical studies we are
conducting. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Hippo Signaling Pathway Program in Oncology and Fibrosis  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Leveraging our assets and expertise, we have investigated the Hippo signaling pathway, which is implicated in the processes of cell differentiation and
proliferation, tissue growth and organ size. Dysregulation along the Hippo signaling pathway has been implicated in a variety of different types of cancer, particularly malignant mesothelioma, as well
as lung cancer, triple negative breast cancer, hepatocellular carcinoma and hepatoblastoma, as well as fibrotic disease. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
primary oncology program aims to disrupt the interaction between YAP and TEAD, which is an interaction that occurs along the Hippo signaling pathway and plays a key role in the oncogenic process.
In pre-clinical studies, we observed that our compounds prevented the formation of the YAP-TEAD transcriptional complex, reduced the expression of YAP-TEAD target genes and displayed
anti-proliferative effects in cancer cell lines controlled by the Hippo signaling pathway. Further, in xenograft models, we observed that our compounds inhibited gene expression and cell proliferation
in cell lines sensitive to YAP, and were associated with tumor regression, both as a monotherapy and in combination with approved cancer therapies. In addition, in xenograft and orthotopic models of
malignant pleural mesothelioma, or MPM, we observed that YAP-TEAD inhibition was associated with reduced tumor growth. Based on these findings, we </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>117</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=121,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=942275,FOLIO='117',FILE='DISK116:[20ZBV1.20ZBV74901]DA74901A.;16',USER='SCAVALI',CD='10-APR-2020;08:12' -->
<A NAME="page_da74901_1_118"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>plan
to expand our YAP-TEAD program to other cancer indications and explore the potential of our YAP-TEAD inhibitor as a monotherapy and in combination with other approve anti-cancer agents. We are in
the process of selecting development candidate for our Hippo program, which we anticipate entering pre-clinical development in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for
the treatment of non-small cell lung cancer and
mesothelioma. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Hippo signaling pathway has also been implicated in the fibrotic process, particularly stiffness-induced fibrosis, which plays a key role in a number of diseases, including NASH and IPF. In </FONT> <FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2>
studies, we have observed that our Hippo compounds exhibit anti-fibrotic properties, and we therefore may consider expanding our Hippo program to
fibrotic disease. We also plan to explore additional targets along the Hippo signaling pathway that are implicated in either fibrosis or oncology. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


ROR<FONT FACE="SYMBOL">g</FONT> Program with AbbVie  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We worked with AbbVie to identify orally-available inverse agonists of the nuclear receptor ROR<FONT FACE="SYMBOL">g</FONT> for the treatment of
moderate to severe psoriasis, a common skin condition that affects two to four percent of the population in western countries. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>T-lymphocytes
producing IL-17, known as Th17 cells, have been shown to play a key role in autoimmunity. The development and maintenance of Th17 cells is dependent on IL-23. Elevated levels of IL-23
and Th17-related cytokines have been observed in cutaneous lesions and in the serum of psoriatic patients, which supports the targeting of Th17 for the treatment of patients with psoriasis.
ROR<FONT FACE="SYMBOL">g</FONT> is believed to be the master regulator of Th17 as it controls differentiation of na&iuml;ve T-cells into Th17 cells, the regulation of the IL-23
receptor and the production of Th17 pro-inflammatory cytokines. Pharmacological inhibition of ROR<FONT FACE="SYMBOL">g</FONT> by small molecules has been observed to suppress Th17 cell
differentiation as well as IL-17 production, block cutaneous inflammation in animal models of psoriasis and inhibit Th17 signature gene expression by cells isolated from psoriatic patient samples.
ROR<FONT FACE="SYMBOL">g</FONT> is therefore a validated drug target for the treatment of psoriasis, and potentially other cutaneous inflammatory disorders. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Together
with AbbVie, we have discovered new, potent, selective and orally-available ROR<FONT FACE="SYMBOL">g</FONT> inverse agonists. We believe that these compounds may suppress a larger
set of inflammatory cytokines than the currently available biologics for the treatment of psoriasis, thereby resulting in meaningful clinical activity. AbbVie is currently investigating a candidate
developed through our collaboration, ABBV-157, in a Phase&nbsp;I clinical trial. This trial is comprised of two substudies evaluating a total of 60 healthy volunteers and patients with moderate to
severe psoriasis. AbbVie first evaluated ABBV-157 healthy volunteers and thereafter in a double-blind, randomized, placebo-controlled substudy in patients with moderate or severe chronic plaque
psoriasis. The primary completion date of the trial is expected in September 2020. In December 2019, we received a &euro;3.5&nbsp;million payment from AbbVie as a result of the enrollment
of the first patient with psoriasis in the trial. AbbVie is solely responsible for clinical development of product candidates developed through the collaboration and is the owner of all intellectual
property rights resulting from the collaboration. See "&nbsp;&#151; Research and development agreement with AbbVie" below. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


TGF-<FONT FACE="SYMBOL">b</FONT> Program  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are advancing a pre-clinical program for the treatment of IPF, and have validated a new target within the TGF-<FONT FACE="SYMBOL">b</FONT>,
signaling pathway. TGF-<FONT FACE="SYMBOL">b</FONT> is a cytokine that is a key driver of fibrosis and acts by
activating fibroblasts into myofibroblasts, which in turn drives the production of fibrotic tissues. This new target has been validated and we are generating leads for a development candidate. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Sales and Marketing  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We currently have worldwide development and commercialization rights with respect to lanifibranor and odiparcil. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>118</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=122,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=645710,FOLIO='118',FILE='DISK116:[20ZBV1.20ZBV74901]DA74901A.;16',USER='SCAVALI',CD='10-APR-2020;08:12' -->
<A NAME="page_da74901_1_119"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
have not yet established a sales, marketing or product distribution infrastructure but plan to independently develop and commercialize those product candidates in those indications where we can do
so in a capital efficient manner, with a focus on retaining rights to orphan indications in jurisdictions with a significant market opportunity. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Research and Development Agreement with AbbVie  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In August 2012, we entered into a research services agreement with AbbVie, which we refer to as the AbbVie Agreement, which included a collaboration to
identify orally-available inverse agonists of the nuclear receptor ROR<FONT FACE="SYMBOL">g</FONT> for the treatment of moderate to severe psoriasis and other auto-immune diseases. AbbVie
is currently investigating ABBV-157, a clinical candidate developed through our collaboration, in a Phase&nbsp;I clinical trial. AbbVie is responsible, at its sole cost and discretion, for all
further development and commercialization activities related to the ROR<FONT FACE="SYMBOL">g</FONT> program. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under
the AbbVie Agreement, we received research funding, and we are eligible to receive development, regulatory and commercial milestone payments as well as royalty payments. As of
December&nbsp;31, 2019, we have received an aggregate of &euro;16.3&nbsp;million in research funding and &euro;9.0&nbsp;million in milestone payments. We may receive up to
an aggregate of &euro;38.5&nbsp;million in milestone payments related to the psoriasis program, &euro;2.0&nbsp;million in milestone payments for each subsequent drug approval
application or extension in a new indication, and tiered royalties from the mid-single to low-double
(below teens) digits. Royalties are subject to specified reductions in the event AbbVie is required to obtain licenses to avoid infringing a third party's intellectual property, a generic competitor
to the product is introduced, or the product is exploited in a country without certain intellectual property coverage. Royalties are payable, on a product-by-product and country-by-country basis,
until the occurrence of certain specified patent expirations or loss of exclusivity. A separate, additional low-single digit royalty is payable after the expiration of the initial royalty term until
other specified patent expirations occur. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
are restricted from researching, developing, or commercializing any product directed to any target on which we collaborated with AbbVie for a certain period after the expiration of that
collaboration or occurrence of certain events in related patent prosecution. We are also subject to exclusivity obligations, which vary depending on the stage of development, with respect to research,
development or commercialization of small molecule ROR<FONT FACE="SYMBOL">g</FONT> inverse agonists. Under certain circumstances, we will have relief from our exclusivity obligations and
will be provided with access to all pre-clinical data related to the ROR<FONT FACE="SYMBOL">g</FONT> program, as well as a royalty free license to any assays or models developed by the
parties under the ROR<FONT FACE="SYMBOL">g</FONT> program. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>AbbVie
is the exclusive owner of all intellectual property rights resulting from the collaboration. We grant AbbVie a perpetual non-exclusive license to use our relevant intellectual property solely
as necessary to exploit such products derived from the collaboration. We are obliged to assist AbbVie in the preparation, filing, or prosecution of patents covering the intellectual property developed
from the agreement. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
research term of the AbbVie Agreement with respect to the ROR<FONT FACE="SYMBOL">g</FONT> program was initially five years, and was extended in August 2017. We are no longer providing
research services under the AbbVie Agreement with respect to the ROR<FONT FACE="SYMBOL">g</FONT> program. AbbVie may terminate the agreement for uncured material breach, and it may
terminate any element of the collaboration without cause upon 30&nbsp;days' prior written notice to us. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Competition  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The commercialization of new drugs is competitive, and we may face worldwide competition from major pharmaceutical companies, specialty pharmaceutical
companies, biotechnology companies and ultimately generic companies. Our competitors may develop or market therapies that are more effective, safer or less costly than any that we are commercializing,
or may obtain regulatory or reimbursement approval for their therapies more rapidly than we may obtain approval for ours. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>119</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=123,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=268823,FOLIO='119',FILE='DISK116:[20ZBV1.20ZBV74901]DA74901A.;16',USER='SCAVALI',CD='10-APR-2020;08:12' -->
<A NAME="page_da74901_1_120"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Though
there are no currently approved therapies for the treatment of NASH and we believe that lanifibranor is the only pan-PPAR agonist in clinical development for this indication, we cannot assure
you that any of our products that we successfully develop will be clinically superior or scientifically preferable to products developed or introduced by our competitors. Genfit&nbsp;S.A. is
currently advancing a dual PPAR agonist through Phase&nbsp;III clinical trials for the treatment of NASH, while Allergan&nbsp;plc, Galmed Pharmaceuticals&nbsp;Ltd. and Madrigal
Pharmaceuticals,&nbsp;Inc. each are investigating product candidates with different mechanisms of action in Phase&nbsp;III clinical trials for the treatment of NASH. Intercept
Pharmaceuticals,&nbsp;Inc. has announced that it has filed for regulatory approval with the FDA and EMA. Other companies, including Gilead Sciences,&nbsp;Inc. have product candidates for the
treatment of NASH that are in earlier stages of pre-clinical or clinical development. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>ERT
is the standard of care for the treatment of MPS with current therapies being marketed by BioMarin Pharmaceuticals,&nbsp;Inc., Sanofi Genzyme, Shire&nbsp;Plc and Ultragenyx
Pharmaceuticals,&nbsp;Inc. Additional ERTs, as well as gene therapy approaches to treating MPS, are in various stages of pre-clinical and clinical development conducted by different companies,
including Abeona Therapeutics&nbsp;Inc., ArmaGen,&nbsp;Inc., Eloxx Pharmaceuticals,&nbsp;Inc., Sanofi Genzyme, Esteve Pharmaceuticals,&nbsp;S.A., Lysogene&nbsp;S.A., Orchard
Therapeutics&nbsp;plc, REGENXBIO&nbsp;Inc., Sangamo Therapeutics,&nbsp;Inc. and Takeda Pharmaceutical Copmany Limited. In the MPS VI subtype, the MeuSix consortium is developing a gene therapy
approach and is conducting a multicenter Phase&nbsp;I/II clinical trial to investigate the safety and efficacy of its AAV-mediated gene therapy. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Although
we believe our product candidates possess attractive attributes, we cannot ensure that our product candidates will achieve regulatory or market acceptance. If our product candidates fail to
gain regulatory approvals and acceptance in their intended markets, we may not generate meaningful revenues or achieve profitability. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Intellectual Property  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our success will significantly depend upon our ability to obtain and maintain patent and other intellectual property and proprietary protection for our drug
candidates in the United States and internationally, including composition-of-matter, dosage and formulation patents, as well as patent and other intellectual property and proprietary protection for
our novel biological discoveries and other important technology inventions and know-how. In addition to patents, we rely upon unpatented trade secrets, know-how, and continuing technological
innovation to develop and maintain our competitive position. We protect our proprietary information, in part, using confidentiality agreements with our commercial partners, collaborators, employees
and consultants and invention assignment agreements with our employees. We also have confidentiality agreements or invention assignment agreements with our commercial partners and selected
consultants. Despite these measures, any of our intellectual property and proprietary rights could be challenged, invalidated, circumvented, infringed or
misappropriated, or such intellectual property and proprietary rights may not be sufficient to permit us to take advantage of current market trends or otherwise to provide competitive advantages. In
addition, such confidentiality agreements and invention assignment agreements can be breached and we may not have adequate remedies for any such breach. For more information, please see "Risk
factors&nbsp;&#151; Risks Relating to Intellectual Property." </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
of February&nbsp;29, 2020, with respect to lanifibranor, we own four issued United States patents, one United States patent application, and approximately 102 patents and patent applications in
other jurisdictions. As of February&nbsp;29, 2020, with respect to odiparcil, we own two issued United States patents, and approximately 85 patent and patent applications in other jurisdictions. We
cannot predict whether the patent applications we pursue will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide any proprietary protection from
competitors. The patent portfolios for our lead product candidates as of February&nbsp;29, 2020 are summarized below. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>120</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=124,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=247611,FOLIO='120',FILE='DISK116:[20ZBV1.20ZBV74901]DA74901A.;16',USER='SCAVALI',CD='10-APR-2020;08:12' -->
<A NAME="page_da74901_1_121"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we are seeking patent protection for our product
candidates, the patent term is 20&nbsp;years from the earliest date if filing a non-provisional patent application. In the United States, the term of a patent may be lengthened by a patent term
adjustment, which provides for term extension in the case of administrative delays at the United States Patent and Trademark Office in granting a patent, or may be shortened if a patent is terminally
disclaimed over another patent with an earlier expiration date. Furthermore, in the United States, the term of a patent covering an FDA approved drug may be eligible for a patent term extension under
the Hatch-Waxman Amendments as compensation for the loss of patent term during the FDA regulatory review process. The period of extension may be up to five years beyond the expiration of the patent
but cannot extend the remaining term of a patent beyond a total of 14&nbsp;years from the date of product approval. Only one patent among those eligible for an extension may be extended. In the
future, if any of our product candidates receives FDA approval, we expect to apply for a patent term extension, if available, to extend the term of the patent covering such approved product candidate.
We also expect to seek patent term extensions in any jurisdictions where they are available, however, there is no guarantee that the applicable authorities, including the FDA, will agree with our
assessment of whether such an extension should be granted, and even if granted, the length of such an extension. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Lanifibranor  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>With respect to lanifibranor patent rights, as of February&nbsp;29, 2020, we own four United States patents, which are due to expire between December 2026
and June 2035 excluding any additional term for patent term extension. Outside the United States, we own approximately 85 patents issued in approximately 55 jurisdictions, including Australia, Canada,
China, a number of European countries, Japan, Korea, Israel and
Russia; and approximately 17 patent applications pending in approximately 10 jurisdictions including Brazil and Tunisia. The foregoing patents and patent applications cover a form of and methods of
making and using lanifibranor or its analogs </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Odiparcil  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>With respect to odiparcil, as of February&nbsp;29, 2020, we own two issued United States patents, which are due to expire in October 2034, excluding any
additional term for patent term extension. Outside the United States, we own approximately 75 patents issued in approximately 43 jurisdictions, including a number of European countries; and
approximately 10 patent applications pending in approximately 10 jurisdictions, including Brazil, Canada, China, Israel and Korea. The foregoing patents and patent applications cover methods of using
odiparcil. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Manufacturing  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We rely on contract manufacturing organizations, or CMOs, to produce our drug candidates in accordance with the FDA's current Good Manufacturing Practices, or
cGMP, regulations for use in our clinical trials. The manufacture of pharmaceuticals is subject to extensive cGMP regulations, which impose various procedural and documentation requirements and govern
all areas of record keeping, production processes and controls, personnel and quality control. Our small molecule drug candidates, lanifibranor and odiparcil, are manufactured using common chemical
engineering and synthetic processes from commercially available raw materials. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To
meet our projected needs for clinical supplies to support our activities through regulatory approval and commercial manufacturing, the CMOs with whom we currently work will need to increase the
scale of production or we will need to secure alternate suppliers. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
we are unable to obtain sufficient quantities of drug candidates or receive raw materials in a timely manner, we could be required to delay our ongoing clinical trials and seek alternative
manufacturers, which would be costly and time-consuming. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>121</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=125,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=920346,FOLIO='121',FILE='DISK116:[20ZBV1.20ZBV74901]DA74901A.;16',USER='SCAVALI',CD='10-APR-2020;08:12' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_dc74901_1_122"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Government Regulation and Approval  </B></FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


United States&nbsp;&#151; FDA Process  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In the United States, the FDA regulates drugs. The Federal Food, Drug, and Cosmetic Act, or FDCA, and other federal and state statutes and regulations, govern,
among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing,
distribution, post-approval monitoring and reporting, sampling, and import and export of drugs. To obtain regulatory approvals in the United States and in foreign countries, and subsequently comply
with applicable statutes and regulations, we will need to spend substantial time and financial resources. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Approval Process  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The FDA must approve any new drug or a drug with certain changes to a previously approved drug before a manufacturer can market it in the United States. If a
company does not comply with applicable United States requirements it may be subject to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending applications, warning
or untitled letters, clinical holds, drug recalls, drug seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, and criminal prosecution. The steps we
must complete before we can market a drug include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> completion of pre-clinical laboratory tests, animal studies, and formulation studies, all
performed in accordance with the FDA's good laboratory practice, or GLP, regulations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> submission to the FDA of an IND application for human clinical testing, which must become
effective before human clinical studies start. The sponsor must update the IND annually; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> approval of the study by an independent institutional review board, or IRB, or ethics
committee representing each clinical site before each clinical study begins; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> performance of adequate and well-controlled human clinical studies to establish the
safety and efficacy of the drug for each indication to the FDA's satisfaction; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> submission to the FDA of an NDA; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> potential review of the drug application by an FDA advisory committee, where appropriate
and if applicable; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> satisfactory completion of an FDA inspection of the manufacturing facility or facilities
to assess compliance with current good manufacturing practices, cGMP, or regulations; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> FDA review and approval of the NDA. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>It
generally takes companies many years to satisfy the FDA approval requirements, but this varies substantially based upon the type, complexity, and novelty of the drug or disease. Pre-clinical tests
include laboratory evaluation of a drug's chemistry, formulation, and toxicity, as well as animal trials to assess the characteristics and potential safety and efficacy of the drug. The conduct of the
pre-clinical tests must comply with federal regulations and requirements, including GLP. The company submits the results of the pre-clinical testing to the FDA as part of an IND along with other
information, including information about the product drug's chemistry, manufacturing and controls, and a proposed clinical study protocol. Long term pre-clinical tests, such as animal tests of
reproductive toxicity and carcinogenicity, may continue after submitting the initial IND. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
FDA requires a 30-day waiting period after the submission of each IND before the company can begin clinical testing in humans. The FDA may, within the 30-day time period, raise concerns or
questions relating to one or more proposed clinical studies and place the study on a clinical hold. In such a case, the company and the FDA must resolve any outstanding concerns before the company
begins the clinical study. Accordingly, the submission of an IND may or may not be sufficient for the FDA to permit the sponsor to start a clinical study. The company must also make a separate
submission to an existing IND for each successive clinical study conducted during drug development. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>122</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>

<!-- ZEQ.=1,SEQ=126,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=392371,FOLIO='122',FILE='DISK116:[20ZBV1.20ZBV74901]DC74901A.;10',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dc74901_1_123"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Clinical Studies  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Clinical studies involve administering the investigational new drug to healthy volunteers or patients under the supervision of a qualified investigator. The
company must conduct clinical studies:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> in compliance with federal regulations; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> in compliance with good clinical practice, or GCP, an international standard meant to
protect the rights and health of patients and to define the roles of clinical study sponsors, administrators, and monitors; as well as </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> under protocols detailing the objectives of the trial, the safety monitoring parameters,
and the effectiveness criteria. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>The
company must submit each protocol involving testing on United States patients and subsequent protocol amendments to the FDA as part of the IND. The FDA may order the temporary, or permanent,
discontinuation of a clinical study at any time, or impose other sanctions, if it believes that the sponsor is not conducting the clinical study in accordance with FDA requirements or presents an
unacceptable risk to the clinical study patients. The sponsor must also submit the study protocol and informed consent information for patients in clinical studies to an institutional review board for
approval. An IRB may halt the clinical study, either temporarily or permanently, for failure to comply with the IRB's requirements, or may impose other conditions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Companies
generally divide the clinical investigation of a drug into three or four phases. While companies usually conduct these phases sequentially, they are sometimes overlapped or combined. </FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>  Phase&nbsp;I.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;The
company evaluates the drug in healthy human subjects or patients with the target disease or condition. These studies typically evaluate the safety, dosage tolerance, metabolism and pharmacologic
actions of the investigational new drug in humans, the side effects associated with increasing doses, and, if possible, gain early evidence on effectiveness.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I> Phase&nbsp;II.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;The company administers the drug to a limited patient population to evaluate dosage tolerance and optimal
dosage, identify
possible adverse side effects and safety risks, and preliminarily evaluate efficacy.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I> Phase&nbsp;III.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;The company administers the drug to an expanded patient population, generally at geographically dispersed
clinical study sites,
to generate enough data to statistically evaluate dosage, clinical effectiveness and safety, to establish the overall benefit-risk relationship of the investigational drug, and to provide an adequate
basis for product approval.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>  Phase&nbsp;IV.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;In
some cases, the FDA may condition approval of an NDA for a drug on the company's agreement to conduct additional clinical studies after approval. In other cases, a sponsor may voluntarily conduct
additional clinical studies after approval to gain more information about the drug. We typically refer to such post-approval studies as Phase&nbsp;4 clinical studies. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>A
pivotal study is a clinical study that adequately meets regulatory agency requirements to evaluate a drug's efficacy and safety to justify the approval of the drug. Generally, pivotal studies are
Phase&nbsp;III studies, but the FDA may accept results from Phase&nbsp;II studies if the study design provides a well-controlled and reliable assessment of clinical benefit, particularly in
situations in which there is an unmet medical need and the results are sufficiently robust. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
FDA, the IRB, or the clinical study sponsor may suspend or terminate a clinical study at any time on various grounds, including a finding that the research subjects are being exposed to an
unacceptable health risk. Additionally, an independent group of qualified experts organized by the clinical study sponsor, known as a data and safety monitoring board, may oversee some clinical
studies. This group provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>123</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=127,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=435157,FOLIO='123',FILE='DISK116:[20ZBV1.20ZBV74901]DC74901A.;10',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dc74901_1_124"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Submission of an NDA  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>After we complete the required clinical testing, we can prepare and submit an NDA to the FDA, who must approve the NDA before we can start marketing the drug
in the United States. An NDA must include all relevant data available from pertinent pre-clinical and clinical studies, including negative or ambiguous results as well as positive findings, together
with detailed information relating to the drug's chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from company-sponsored clinical studies on a drug, or from
a number of alternative sources, including studies initiated by investigators. To support marketing authorization, the data we submit must be sufficient in quality and quantity to establish the safety
and effectiveness of the investigational drug to the FDA's satisfaction. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
cost of preparing and submitting an NDA is substantial. The submission of most NDAs is additionally subject to a substantial application user fee, and the manufacturer and/or sponsor under an
approved new drug application are also subject to annual program user fees. The FDA typically increases these fees annually. Orphan drug designation entitles a party to financial incentives such as
opportunities for grant funding towards clinical study costs, tax advantages, and user-fee waivers. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
FDA has 60&nbsp;days from its receipt of an NDA to determine whether it will accept the application for filing based on the agency's threshold determination that the application is sufficiently
complete to permit substantive review. Once the FDA accepts the filing, the FDA begins an in-depth review. The FDA has agreed to certain performance goals in the review of NDAs. Under the Prescription
Drug User Fee Act, the FDA has a goal of responding to standard review NDAs within ten months after the 60-day filing review period, but this timeframe is often extended. The FDA reviews most
applications for standard review drugs within twelve months and most applications for priority review drugs within six to eight months. Priority review can be applied to drugs that the FDA determines
offer major advances in treatment, or provide a treatment where no adequate therapy exists. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
FDA may also refer applications for novel drugs that present difficult questions of safety or efficacy, to an advisory committee. This is typically a panel that includes clinicians and other
experts that will review, evaluate, and recommend whether the FDA should approve the application. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such
recommendations. Before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP, and will inspect the facility or the facilities at which the drug is
manufactured. The FDA will not approve the drug unless compliance with cGMP is satisfactory and the NDA contains data that provide evidence that the drug is safe and effective in the indication
studied. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


The FDA's Decision on an NDA  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>After the FDA evaluates the NDA and the manufacturing facilities, it issues either an approval letter or a complete response letter. A complete response letter
indicates that the FDA has completed its review of the application, and the agency has determined that it will not approve the application in its present form. A complete response letter generally
outlines the deficiencies in the submission and may require substantial additional clinical data and/or other significant, expensive, and time-consuming requirements related to clinical studies,
pre-clinical studies and/or manufacturing. The FDA has committed to reviewing resubmissions of the NDA addressing such deficiencies in two or six months, depending on the type of information included.
Even if we submit such data the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. Also, the government may establish additional requirements, including those resulting
from new legislation, or the FDA's policies may change, which could delay or prevent regulatory approval of our drugs under development. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>An
approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. As a condition of NDA approval, the FDA may require a risk evaluation and
mitigation strategy, or REMS, to help ensure that the benefits of the drug outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals, special
training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>124</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=128,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=261715,FOLIO='124',FILE='DISK116:[20ZBV1.20ZBV74901]DC74901A.;10',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dc74901_1_125"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>and
the use of patient registries. The requirement for REMS can materially affect the potential market and profitability of the drug. Moreover, the FDA may condition approval on substantial
post-approval testing and surveillance to monitor the drug's safety or efficacy. Once granted, the FDA may withdraw drug approvals if the company fails to comply with regulatory standards or
identifies problems following initial marketing. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Changes
to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of a
new NDA or NDA supplement before we can implement the change. An NDA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the
same procedures and actions in reviewing NDA supplements as it does in reviewing new NDAs. As with new NDAs, the FDA often significantly extends the review process with requests for additional
information or clarification. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Post-approval Requirements  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The FDA regulates drugs that are manufactured or distributed pursuant to FDA approvals and has specific requirements pertaining to recordkeeping, periodic
reporting, drug sampling and distribution, advertising and promotion and reporting of adverse experiences with the drug. After approval, the FDA must provide review and approval for most changes to
the approved drug, such as adding new indications or other labeling claims. There also are continuing, annual user fee requirements for any marketed drugs and the establishments who manufacture our
drugs, as well as new application fees for supplemental applications with clinical data. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
some cases, the FDA may condition approval of an NDA for a drug on the sponsor's agreement to conduct additional clinical studies after approval. In other cases, a sponsor may voluntarily conduct
additional clinical studies after approval to gain more information about the drug. Such post-approval studies are typically referred to as Phase&nbsp;IV clinical studies. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Drug
manufacturers are subject to periodic unannounced inspections by the FDA and state agencies for compliance with cGMP requirements. There are strict regulations regarding changes to the
manufacturing process, and, depending on the significance of the change, it may require prior FDA approval before we can implement it. FDA regulations also require investigation and correction of any
deviations from cGMP and impose reporting and documentation requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time,
money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
FDA may withdraw approval if a company does not comply with regulatory requirements and maintain standards or if problems occur after the drug reaches the market. If a company or the FDA discovers
previously unknown problems with a drug, including adverse events of unanticipated severity or frequency, issues with manufacturing processes, or the company's failure to comply with regulatory
requirements, the FDA may revise the approved labeling to add new safety information; impose post-marketing studies or other clinical studies to assess new safety risks; or impose distribution or
other restrictions under a REMS program. Other potential consequences may include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> restrictions on the marketing or manufacturing of the drug, complete withdrawal of the
drug from the market or drug recalls; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> fines, warning letters or holds on post-approval clinical studies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the FDA refusing to approve pending NDAs or supplements to approved NDAs, or suspending
or revoking of drug license approvals; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> drug seizure or detention, or refusal to permit the import or export of drugs; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> injunctions or the imposition of civil or criminal penalties. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>125</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=129,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=257035,FOLIO='125',FILE='DISK116:[20ZBV1.20ZBV74901]DC74901A.;10',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dc74901_1_126"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
FDA strictly regulates marketing, labeling, advertising, and promotion of drugs that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the
provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. We could be subject to significant administrative,
civil and criminal liability if we violated any of these laws and regulations. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Rare Pediatric Disease Priority Review Voucher Program  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>FDA awards priority review vouchers to sponsors of designated rare pediatric disease product applications as an incentive to encourage development of new drug
and biological products for prevention and treatment of rare pediatric diseases. Specifically, under this program, a sponsor who receives an approval for a drug or biologic for a "rare pediatric
disease" may qualify for a voucher that can be redeemed to receive a priority review of a subsequent marketing application for a different product. The sponsor of a rare pediatric disease drug
product receiving a priority review voucher may transfer (including by sale) the voucher to another sponsor. The voucher may be further transferred any number of times before the voucher is used, as
long as the sponsor making the transfer has not yet submitted the application. The FDA may also revoke any priority review voucher if the rare pediatric disease drug for which the voucher was awarded
is not marketed in the U.S. within one year following the date of approval. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For
the purposes of this program, a "rare pediatric disease" is a (a)&nbsp;serious or life-threatening disease in which the serious or life-threatening manifestations primarily affect individuals
aged from birth to 18&nbsp;years, including age groups often called neonates, infants, children, and adolescents; and (b)&nbsp;rare disease or conditions within the meaning of the Orphan Drug Act.
A sponsor may choose to request Rare Pediatric Disease Designation, but the designation process is entirely voluntary; requesting designation is not a prerequisite to requesting or receiving a
priority review voucher. In addition, sponsors who choose not to submit a Rare Pediatric Disease Designation request may nonetheless receive a priority review voucher if they request such a voucher in
their original marketing application and meet all of the eligibility criteria. Absent any extension, Congress has only authorized the Rare Pediatric Disease Priority Review Voucher program until
September&nbsp;30, 2020. However, if a drug candidate receives Rare Pediatric Disease Designation before October&nbsp;1, 2020, it is eligible to receive a voucher if it is approved before
October&nbsp;1, 2022. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Orphan Drug Designation  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition that affects fewer than 200,000 individuals in the United
States, or if it affects more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and making the drug for this type of disease or condition
will be recovered from sales in the United States. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Orphan
drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical study costs, tax advantages, and user-fee waivers. In addition, if a drug
receives FDA approval for the indication for which it has orphan drug designation, the drug may be entitled to orphan drug exclusivity, which means the FDA may not approve any other application to
market the same drug for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the drug with orphan exclusivity. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Pediatric Information  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under the Pediatric Research Equity Act, or PREA, NDAs or supplements to NDAs must contain data to assess the safety and effectiveness of the drug for the
claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the drug is safe and effective. The FDA may grant full
or partial waivers, or deferrals, for submission of data. Unless otherwise required by regulation, PREA does not apply to any drug for an indication for which the FDA has granted an orphan drug
designation. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>126</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=130,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=894465,FOLIO='126',FILE='DISK116:[20ZBV1.20ZBV74901]DC74901A.;10',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dc74901_1_127"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Healthcare Reform  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In the United States and foreign jurisdictions, the legislative landscape continues to evolve. There have been a number of legislative and regulatory changes
to the healthcare system that could affect our current and future results of operations. In particular, there have been and continue to be a number of initiatives at the federal and state levels that
seek to reform the way in which healthcare is funded and reduce healthcare costs. In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education
Reconciliation Act of 2009, or collectively, the Affordable Care Act, was enacted, which includes measures that have significantly changed health care financing by both governmental and private
insurers. The provisions of Affordable Care Act of importance to the pharmaceutical and biotechnology industry are, among others, the
following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an annual, nondeductible fee on any entity that manufactures or imports certain branded
prescription drugs agents, apportioned among these entities according to their market share in certain government healthcare programs; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an increase in the rebates a manufacturer must pay under the Medicaid Drug Rebate Program
to 23.1% and 13% of the average manufacturer price for branded and generic drugs, respectively; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a new Medicare Part&nbsp;D coverage gap discount program, in which manufacturers must
agree to offer 70% point-of-sale discounts to negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer's outpatient
drugs to be covered under Medicare Part&nbsp;D; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> extension of manufacturers' Medicaid rebate liability to covered drugs dispensed to
individuals who are enrolled in Medicaid managed care organizations, unless the drug is subject to discounts under the 340B drug discount program; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> expansion of eligibility criteria for Medicaid programs by, among other things, allowing
states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for certain individuals with income at or below 133% of the Federal Poverty Level,
thereby potentially increasing manufacturers' Medicaid rebate liability; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> expansion of the entities eligible for discounts under the Public Health Service
pharmaceutical pricing program; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> expansion of healthcare fraud and abuse laws, including the federal civil False Claims
Act and the federal Anti-Kickback Statute, new government investigative powers and enhanced penalties for noncompliance; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> new requirements under the federal Physician Payments Sunshine Act for drug manufacturers
to report information related to payments and other transfers of value made to physicians, as defined by such law, and teaching hospitals as well as ownership or investment interests held by
physicians and their immediate family members; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a new requirement to annually report certain drug samples that manufacturers and
distributors provide to licensed practitioners, or to pharmacies of hospitals or other healthcare entities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> establishment of a Center for Medicare and Medicaid Innovation at the Centers for
Medicare&nbsp;&amp; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> establishment of a new Patient-Centered Outcomes Research Institute to oversee, identify
priorities in, and conduct comparative clinical effectiveness research. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>There
remain judicial and Congressional challenges to certain aspects of the Affordable Care Act, as well as efforts by the Trump administration to repeal or repeal and replace certain aspects of the
Affordable Care Act. Since January 2017, President Trump has signed two Executive Orders and other directives designed to </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>127</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=131,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=190613,FOLIO='127',FILE='DISK116:[20ZBV1.20ZBV74901]DC74901A.;10',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dc74901_1_128"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>delay
the implementation of certain provisions of the Affordable Care Act or otherwise circumvent some of the requirements for health insurance mandated by the Affordable Care Act. Concurrently,
Congress has considered legislation that would repeal or repeal and replace all or part of the Affordable Care Act. While Congress has not passed comprehensive repeal legislation, several bills
affecting the implementation of certain taxes under the Affordable Care Act have been signed into law. The Tax Cuts and Jobs Act of 2017 includes a provision repealing, effective January&nbsp;1,
2019, the tax-based shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly
referred to as the "individual mandate." Additionally, the 2020 federal spending package permanently eliminated, effective January&nbsp;1, 2020, the Affordable Care Act's mandated "Cadillac" tax on
high-cost employer-sponsored health coverage and medical device tax and, effective January&nbsp;1, 2021, also eliminates the health insurer tax..
Further, the Bipartisan Budget Act of 2018, among other things, amended the Affordable Care Act, effective January&nbsp;1, 2019, to close the coverage gap in most Medicare drug plans, commonly
referred to as the "donut hole." In December 2018, CMS published a new final rule permitting further collections and payments to and from certain the Affordable Care Act qualified health plans and
health insurance issuers under the Affordable Care Act risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk
adjustment. On December&nbsp;14, 2018, a Texas U.S. District Court Judge ruled that the Affordable Care Act is unconstitutional in its entirety because the "individual mandate" was repealed by
Congress as part of the Tax Cuts and Jobs Act of 2017. Additionally, on December&nbsp;18, 2019, the U.S. Court of Appeals for the 5th&nbsp;Circuit upheld the District Court ruling that the
individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the Affordable Care Act are invalid as well. On
March&nbsp;2, 2020, the United States Supreme Court granted the petitions for writs of certiorari to review this case, and has allotted one hour for oral arguments, which are expected to occur in
the fall. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, other health reform measures have been proposed and adopted in the United States since the Affordable Care Act was enacted. For example, as a result of the Budget Control Act of 2011, as
amended, providers are subject to Medicare payment reductions of 2% per fiscal year through 2029 unless additional Congressional action is taken. Further, the American Taxpayer Relief Act of 2012
reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments from providers from three to five years. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Further,
there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several recent Congressional inquiries and
proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs,
reduce the cost of drugs under Medicare, and reform government program reimbursement methodologies for drugs. At the federal level, the Trump administration's budget proposal for fiscal year 2021
includes a $135&nbsp;billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access
to lower-cost generic and biosimilar drugs. On March&nbsp;10, 2020, the Trump administration sent "principles" for drug pricing to Congress, calling for legislation that would, among other things,
cap Medicare Part&nbsp;D beneficiary out-of-pocket pharmacy expenses, provide an option to cap Medicare Part&nbsp;D beneficiary monthly out-of-pocket expenses, and place limits on pharmaceutical
price increases. Additionally, the Trump administration previously released a "Blueprint" to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase
manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs
of drug products paid by consumers. The United States Department of Health and Human Services, or HHS, has solicited feedback on some of these measures and has implemented others under its existing
authority. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage Plans the option of using step therapy for Part&nbsp;B drugs beginning on January&nbsp;1, 2020. The final
rule codified a CMS policy change that was effective January&nbsp;1, 2019. Although a number of these and other proposed measures may </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>128</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=132,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=839830,FOLIO='128',FILE='DISK116:[20ZBV1.20ZBV74901]DC74901A.;10',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dc74901_1_129"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>require
additional authorization to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control
drug costs. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or
patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from
other countries and bulk purchasing. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Additionally,
on May&nbsp;30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, or the Right to Try Act, was signed into law. The law, among
other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase&nbsp;I clinical trial and that are undergoing
investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA's expanded
access program. There is no obligation for a drug manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


European Union-EMA Process  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In the European Union, our product candidates may also be subject to extensive regulatory requirements. As in the United States, medicinal products can only be
marketed if a marketing authorization, or MA, from the competent regulatory agencies has been obtained. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Similar
to the United States, the various phases of pre-clinical and clinical research in the European Union are subject to significant regulatory controls. Clinical trials of medicinal products in
the European Union must be conducted in accordance with European Union and national regulations and the International Conference on Harmonization, or ICH, guidelines on GCP. Although the EU Clinical
Trials Directive&nbsp;2001/20/EC has sought to harmonize the European Union clinical trials regulatory framework, setting out common rules for the control and authorization of clinical trials in the
European Union, the EU Member States have transposed and applied the provisions of the Directive differently. This has led to significant variations in the Member State regimes. To improve the current
system, Regulation (EU) No&nbsp;536/2014 on clinical trials on medicinal products for human use, which repealed Directive&nbsp;2001/20/EC, was adopted on April&nbsp;16, 2014 and published in the
European Official Journal on May&nbsp;27, 2014. The Regulation aims at harmonizing and streamlining the clinical trials authorization process, simplifying adverse event reporting procedures,
improving the supervision of clinical trials, and increasing their transparency. Although the Regulation entered into force on June&nbsp;16, 2014, it will not be applicable until six months after
the full functionality of the IT portal and database envisaged in the Regulation is confirmed (after the publication of the notice referred to in Article&nbsp;83(2)). This is not expected to occur
until 2019. Until then the Clinical Trials Directive 2001/20/EC will still apply. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under
the current regime, before a clinical trial can be initiated it must be approved in each of the EU Member States where the trial is to be conducted by two distinct bodies: the National Competent
Authority, or NCA, and one or more Ethics Committees, or ECs. Under the current regime all suspected unexpected serious adverse reactions, or SUSARs, to the investigated drug that occur during the
clinical trial have to be reported to the NCA and ECs of the Member State where they occurred. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


European Union Marketing Authorizations  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In the European Economic Area, or EEA, medicinal products can only be commercialized after obtaining a marketing authorization or MA, from the competent
regulatory authorities. There are different types of marketing authorizations including: </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Centralized Procedure  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A centralized MA is issued by the European Commission through the centralized procedure, based on the opinion of the CHMP and is valid in all EU Member States
and throughout the entire territory of the EEA. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
centralized procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, and medicinal products containing a new active substance
indicated </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>129</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=133,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=551603,FOLIO='129',FILE='DISK116:[20ZBV1.20ZBV74901]DC74901A.;10',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dc74901_1_130"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>for
the treatment of acquired immune deficiency syndrome, or AIDS, cancer, neurodegenerative disorders, diabetes, autoimmune and viral diseases. The centralized procedure is optional for products
containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public
health in the European Union. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>National
MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope
of the centralized procedure. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>When
a medicinal product does not fall within the mandatory scope of the Centralized Procedure, the applicant may use the decentralized procedure or the mutual recognition procedure in order to obtain
a marketing authorization in one or more countries in the European Union. In these cases, the competent authorities of the Member States will issue the MA. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Decentralized Procedure  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If the product has not received a national MA in any Member State at the time of application, it can be approved simultaneously in various Member States
through the decentralized procedure. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under
the decentralized procedure, an identical dossier is submitted to the competent authorities of each of the Member States in which the MA is sought, one of which is selected by the applicant as
the Reference Member State, or RMS. The competent authority of the RMS prepares a draft assessment report, a draft summary of the product characteristics, or SPC, and a draft of the labeling and
package leaflet, which are sent to the other Member States (referred to as the Concerned Member States, or CMSs) for their approval. If the CMSs raise no objections, based on a potential serious risk
to public health, to the assessment, SPC, labeling, or packaging proposed by the RMS, the product is subsequently granted a national MA in all the Member States (i.e.&nbsp;in the RMS and the CMSs). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under
the above described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the product on the
basis of scientific criteria concerning its quality, safety and efficacy. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
European Commission may also grant a so-called "conditional marketing authorization" prior to obtaining the comprehensive clinical data required for an application for a full MA. Such conditional
marketing authorizations may be granted for product candidates (including medicines designated as orphan medicinal products), if (1)&nbsp;the risk-benefit balance of the product candidate is
positive, (2)&nbsp;it is likely that the applicant will be in a position to provide the required comprehensive clinical trial data, (3)&nbsp;the product fulfills an unmet medical need and
(4)&nbsp;the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required.
A conditional marketing authorization may contain specific obligations to be fulfilled by the MA holder, including obligations with respect to the completion of ongoing or new studies, and with
respect to the collection of pharmacovigilance data. Conditional marketing authorizations are valid for one year, and may be renewed annually, if the risk-benefit balance remains positive, and after
an assessment of the need for additional or modified conditions and/or specific obligations. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Orphan Drug Designation  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In the European Union, Regulation (EC) No 141/2000, as amended, states that a drug will be designated as an orphan drug if its sponsor can establish
(Article&nbsp;3):</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> that it is intended for the diagnosis, prevention or treatment of a life-threatening or
chronically debilitating condition affecting not more than five in ten thousand persons in the European Union when the application is made, or that it is intended for the diagnosis, prevention or
treatment of a life-threatening, seriously debilitating or serious and chronic condition in the European Union and that without incentives it is unlikely that the marketing of the drug in the European
Union would generate sufficient return to justify the necessary investment; and that there exists no satisfactory </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>130</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=134,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=349299,FOLIO='130',FILE='DISK116:[20ZBV1.20ZBV74901]DC74901A.;10',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dc74901_1_131"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:arial;"><FONT SIZE=2>method
of diagnosis, prevention or treatment of the condition in question that has been authorized in the European Union or, if such method exists, that the drug will be of significant benefit to
those affected by that condition pursuant to Regulation (EC) No.&nbsp;847/2000 of April&nbsp;27, 2000 laying down the provisions for implementation of the criteria for designation of a medicinal
product as an orphan medicinal product and definitions of the concepts "similar medicinal product" and "clinical superiority." A sponsor applying for designation of a medicinal product as an orphan
medicinal product shall apply for designation at any stage of the development of the medicinal product. </FONT></P>

</UL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>If
a centralized procedure MA in respect of an orphan drug is granted pursuant to Regulation (EC)&nbsp;No&nbsp;726/2004, regulatory authorities will not, for a period of usually ten years, accept
another application for a MA, or grant a MA or accept an application to extend an existing MA, for the same therapeutic indication, in respect of a similar drug. This period may however be reduced to
six years if, at the end of the fifth year, it is established, in respect of the drug concerned, that the criteria for orphan drug designation are no longer met, in other words, when it is shown on
the basis of available evidence that the product is sufficiently profitable not to justify maintenance of market exclusivity. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Pursuant
to Regulation (EC) No 1901/2006, all applications for marketing authorization for new medicines must include the results of studies as described in a pediatric investigation plan, or PIP,
agreed between regulatory authorities and the applicant, unless the medicine is exempt because of a deferral or waiver (e.g.,&nbsp;because the relevant disease or condition occurs only in adults).
Before the EMA is able to begin its assessment of a centralized procedure MA application, it will validate that the applicant has complied with the agreed pediatric investigation plan. The applicant
and the EMA may, where such a step is adequately justified, agree to modify a pediatric investigation plan to assist validation. Modifications are not always possible; may take longer to agree than
the period of validation permits; and may still require the applicant to withdraw its marketing authorization application, or MAA, and to conduct additional non-clinical and clinical studies. Products
that are granted a MA on the basis of the pediatric clinical trials conducted in accordance with the PIP are eligible for a six month extension of the protection under a supplementary protection
certificate (if any is in effect at the time of approval) or, in the case of orphan medicinal products, a two-year extension of the orphan market exclusivity. This pediatric reward is subject to
specific conditions and is not automatically available when data in compliance with the PIP are developed and submitted. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
exclusivity period may increase to 12&nbsp;years if, among other things, the MAA includes the results of studies from an agreed pediatric investigation plan. Notwithstanding the foregoing, a MA
may be granted for the same therapeutic indication to a similar drug if:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the holder of the MA for the original orphan drug has given its consent to the second
applicant; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the holder of the MA for the original orphan drug is unable to supply sufficient
quantities of the drug; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the second applicant can establish in the application that the second drug, although
similar to the orphan drug already authorized, is safer, more effective or otherwise clinically superior. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Pursuant
to Regulation (EC) No.&nbsp;847/2000 of April&nbsp;27, 2000 laying down the provisions for implementation of the criteria for designation of a medicinal product as an orphan medicinal
product and definitions of the concepts "similar medicinal product" and "clinical superiority," a sponsor applying for designation of a medicinal product as an orphan medicinal product shall apply for
designation at any stage of the development of the medicinal product. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
abovementioned Regulation (EC) No.&nbsp;141/2000 provides for other incentives regarding orphan medicinal products. It notably provides for a protocol assistance. The sponsor of an orphan
medicinal product may indeed, prior to the submission of an application for marketing authorization, request advice from EMA on the conduct of the various tests and trials necessary to demonstrate the
quality, safety and </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>131</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=135,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=547892,FOLIO='131',FILE='DISK116:[20ZBV1.20ZBV74901]DC74901A.;10',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dc74901_1_132"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>efficacy
of the medicinal product. Besides, EMA shall draw up a procedure on the development of orphan medicinal products, covering regulatory assistance for the definition of the content of the
application for authorization. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Regulation
(EC) No.&nbsp;141/2000 also provides that medicinal products designated as orphan medicinal products under the provisions of this Regulation shall be eligible for incentives made
available by the European Union and by the Member States to support research into, and the development and availability of, orphan medicinal products and in particular aid for research for small- and
medium-sized undertakings provided for in framework programs for research and technological development. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Other International Markets-Drug Approval Process  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In some international markets (such as China or Japan), although data generated in United States or European Union trials may be submitted in support of a
marketing authorization application, regulators may require additional clinical studies conducted in the host territory, or studying people of the ethnicity of the host territory, prior to the filing
or approval of marketing applications within the country. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Pricing and Reimbursement  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Significant uncertainty exists as to the coverage and reimbursement status of any drugs for which we may obtain regulatory approval. In the United States and
markets in other countries, sales of any drugs for which we receive regulatory approval for commercial sale will depend in part on the availability of coverage and reimbursement from third-party
payors. Third-party payors include government authorities, managed care plans, private health insurers and other organizations. The process for determining whether a payor will provide coverage for a
drug may be separate from the process for setting the reimbursement rate that the payor will pay
for the drug. Third-party payors may limit coverage to specific drugs on an approved list, or formulary, which might not include all of the FDA-approved drugs for a particular indication. Moreover, a
payor's decision to provide coverage for a drug does not imply that an adequate reimbursement rate will be approved. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Additionally,
no uniform policy for coverage and reimbursement exists in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own
reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. Therefore, coverage and reimbursement for drugs can differ significantly from payor to
payor. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in drug development. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Third-party
payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of drugs and services, in addition to their safety and efficacy. To obtain coverage
and reimbursement for any drug that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies to demonstrate the medical necessity and cost-effectiveness of our drug. These
studies will be in addition to the studies required to obtain regulatory approvals. If third-party payors do not consider a drug to be cost-effective compared to other available therapies, they may
not cover the drug after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its drugs at a profit. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
United States government, state legislatures and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid health care
costs, including price controls, restrictions on reimbursement and requirements for substitution of generic drugs for branded prescription drugs. By way of example, the Affordable Care Act contains
provisions that may reduce the profitability of drugs, including, for example, increased rebates for drugs sold to Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans,
mandatory discounts for certain Medicare Part&nbsp;D beneficiaries and annual fees based on pharmaceutical companies' share of sales to federal health care programs. Adoption of government controls
and measures, and tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for our drugs. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>132</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=136,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=816233,FOLIO='132',FILE='DISK116:[20ZBV1.20ZBV74901]DC74901A.;10',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dc74901_1_133"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
the European Community, governments influence the price of drugs through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of
those drugs to consumers. Some jurisdictions operate positive and negative list systems under which drugs may only be marketed once a reimbursement price has been agreed to by the government. To
obtain reimbursement or pricing approval, some of these countries may require the completion of clinical studies that compare the cost effectiveness of a particular drug candidate to currently
available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs in general,
particularly prescription drugs, has become very intense. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country. The
marketability of any drugs for
which we receive regulatory approval for commercial sale may suffer if third-party payors fail to provide coverage and adequate reimbursement. In addition, the focus on cost containment measures in
the United States and other countries has increased and we expect will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change at
any time. Even if we attain favorable coverage and reimbursement status for one or more drugs for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be
implemented in the future. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Other Healthcare Laws Impacting Sales, Marketing, and Other Company Activities  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Numerous regulatory authorities in addition to the FDA, including, in the United States, the CMS, other divisions of HHS, the United States Department of
Justice, and similar foreign, state, and local government authorities, regulate and enforce laws and regulations applicable to sales, promotion and other activities of pharmaceutical manufacturers.
These laws and regulations may impact, among other things, our clinical research programs, proposed sales and marketing and education activities, and financial and business relationships with future
prescribers of our product candidates, once approved. These laws and regulations include. federal, state and foreign anti-kickback, false claims, and data privacy and security laws, which are
described below, among other legal requirements that may affect our current and future operations. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
FDA regulates all advertising and promotion activities for drugs under its jurisdiction both prior to and after approval. Only those claims relating to safety and efficacy that the FDA has
approved may be used in labeling. Physicians may prescribe legally available drugs for uses that are not described in the drug's labeling and that differ from those we tested and the FDA approved.
Such off-label uses are common across medical specialties, and often reflect a physician's belief that the off-label use is the best treatment for the patients. The FDA does not regulate the behavior
of physicians in their choice of treatments, but FDA regulations do impose stringent restrictions on manufacturers' communications regarding off-label uses. Promotion of off-label uses of drugs can
also implicate the false claims laws described below. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Anti-kickback
laws including, without limitation, the federal Anti-Kickback Statute that applies to items and services reimbursable under governmental healthcare programs such as Medicare and
Medicaid, make it illegal for a person or entity to, among other things, knowingly and willfully solicit, receive, offer or pay remuneration, directly or indirectly, to induce, or in return for,
purchasing, leasing, ordering, or arranging for or recommending the purchase, lease, or order of any good, facility, item, or service reimbursable, in whole or in part, under a federal healthcare
program. Due to the breadth of the statutory provisions, limited statutory exceptions and regulatory safe harbors, and the scarcity of guidance in the form of regulations, agency advisory opinions,
sub-regulatory guidance and judicial decisions addressing industry practices, it is possible that our practices might be challenged under anti-kickback or similar laws. Moreover, recent healthcare
reform legislation has strengthened these laws. For example, Affordable Care Act among other things, amends the intent requirement of the federal Anti-Kickback Statute and criminal healthcare fraud
statute to clarify that a person or entity does not need to have actual knowledge of these statutes or specific intent to violate them in order to have committed a crime. In addition, Affordable Care
Act clarifies that the government may assert that a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for
purposes of the federal civil False Claims Act. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>133</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=137,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=742751,FOLIO='133',FILE='DISK116:[20ZBV1.20ZBV74901]DC74901A.;10',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dc74901_1_134"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>False
claims laws, including, without limitation, the federal civil False Claims Act, and civil monetary penalties laws, prohibit, among other things, any individual or entity from knowingly and
willingly presenting, or causing to be presented for payment, to the federal government (including Medicare and Medicaid) claims for reimbursement for, among other things, drugs or services that are
false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services. Our activities relating to the sales and marketing of our drugs may be
subject to scrutiny under these laws. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, prohibits, among other things, executing or attempting to execute a scheme to defraud any healthcare benefit program,
including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and
creates federal criminal laws that prohibit knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or
representation, or making or using any false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry in connection with the delivery of or
payment for healthcare benefits, items or services. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>HIPAA,
as amended by the Health Information Technology for Economic and Clinical Health Act, and their implementing regulations, governs the conduct of certain electronic healthcare transactions and
imposes requirements with respect to safeguarding the security and privacy of protected health information on health plans, healthcare clearinghouses, and certain healthcare providers, known as
covered entities, and individual and entities who provide services involving protected health information to such covered entities, known as business associates. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics, and medical supplies to report annually to CMS information related to payments and other
transfers of value to physicians, as defined by such law, and teaching hospitals, and ownership and investment interests held by physicians and their immediate family members. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, we may be subject to state and foreign law equivalents of each of the above federal laws, such as anti-kickback, self-referral, and false claims laws which may apply to our business
practices, including but not limited to, research, distribution, sales and marketing arrangements as well as submitting claims involving healthcare items or services reimbursed by any third-party
payor, including commercial insurers; state laws that require pharmaceutical manufacturers to comply with the industry's voluntary compliance guidelines and the applicable compliance guidance
promulgated by the federal government that otherwise restricts payments that may be made to healthcare providers; state laws that require pharmaceutical manufacturers to file reports with states
regarding marketing information, such as the tracking and reporting of gifts, compensation and other remuneration and items of value provided to healthcare professionals and entities; state and local
laws requiring the registration of pharmaceutical sales representatives; and state laws governing the privacy and security of
health information in certain circumstances, many of which differ from each other in significant ways, thus complicating compliance efforts. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Violations
of these laws may result in significant criminal, civil and administrative sanctions, including fines and civil monetary penalties, the possibility of exclusion from federal healthcare
programs (including Medicare and Medicaid), disgorgement, contractual damages, reputational harm and the imposition of corporate integrity agreements or other similar agreements with governmental
entities, which may impose, among other things, rigorous operational and monitoring requirements on companies. Similar sanctions and penalties, as well as individual imprisonment, also can be imposed
upon executive officers and employees, including criminal sanctions against executive officers under the so-called "responsible corporate officer" doctrine, even in situations where the executive
officer did not intend to violate the law and was unaware of any wrongdoing. Given the significant penalties and fines that can be imposed on companies and individuals if convicted, allegations of
such violations often result in settlements, which can include significant civil sanctions and additional corporate integrity obligations, even if the company or individual being investigated admits
no wrongdoing. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>134</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=138,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=100174,FOLIO='134',FILE='DISK116:[20ZBV1.20ZBV74901]DC74901A.;10',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dc74901_1_135"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Similar
restrictions are imposed on the promotion and marketing of drugs in the European Union and other countries. Even in those countries where we may not be directly responsible for the promotion
and marketing of our drugs, if our potential international distribution partners engage in inappropriate activity it can have adverse implications for us. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Employees  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As of December&nbsp;31, 2019, we had 88 employees, 84 of whom were full-time employees and four of whom were part-time employees. As of December&nbsp;31,
2019, 67 of our employees were engaged in research and development activities and 21 of our employees were engaged in business development, finance, information systems, facilities, human resources or
administrative support. As of December&nbsp;31, 2019, 87 of our employees were located in France. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
French employees are represented by collective bargaining agreements of the pharmaceutical industry. We believe that we maintain good relations with our employees. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Facilities  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our corporate headquarters is located in Daix, France, where we occupy approximately 129,000 square feet of space that we own. We believe our existing
facilities meet our current needs. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Legal Proceedings  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to
any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because
of defense and settlement costs, diversion of management resources and other factors. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>135</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=14,SEQ=139,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=825294,FOLIO='135',FILE='DISK116:[20ZBV1.20ZBV74901]DC74901A.;10',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_de74901_1_136"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A NAME="de74901_management"> </A>
<A NAME="toc_de74901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  MANAGEMENT    <BR>    </B></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Executive Officers and Directors  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following table sets forth information concerning our executive officers and directors as of March&nbsp;31, 2020: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="20pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="322pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Age </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Position(s) </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2><B><I>Executive Officers</I></B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>Fr&eacute;d&eacute;ric Cren</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>54</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Chief Executive Officer and Chairman of the Board of Directors</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>Pierre Broqua</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>58</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Deputy Chief Executive Officer, Chief Scientific Officer and Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>Jean Volatier</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>55</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Chief Financial Officer</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>Marie-Paule Richard</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>66</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Chief Medical Officer</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2><B><I>Non-Employee Directors</I></B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>Chris Buyse<SUP>(1)(2)(3)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>55</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>Lucy Lu<SUP>(1)(4)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>45</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>Heinz Maeusli<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>57</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>Nawal Ouzren</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>41</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>Annick Schwebig<SUP>(1)(2)(5)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>69</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Director</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Member
of the audit committee.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Member
of the compensation and appointments committee.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">As
representative of Pienter-Jan BVBA, the legal entity that holds this board seat.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(4)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">As
representative of Sofinnova Partners, the legal entity that holds this board seat.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(5)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">As
representative of Cell+, the legal entity that holds this board seat. </FONT></DD></DL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Executive officers  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I>Fr&eacute;d&eacute;ric Cren</I></B></FONT><FONT SIZE=2> has served as our Chief Executive Officer since co-founding Inventiva
in 2011, and as the chairman of our board of directors since May 2016. Previously, he served as the General Manager, Research of Abbott Laboratories, a pharmaceutical company, from 2010 until 2012.
Prior to Abbott, Mr.&nbsp;Cren held a number of roles at Solvay Pharmaceuticals, a pharmaceutical company, and at Laboratoires Fournier&nbsp;SA, a pharmaceutical company, prior to its acquisition
by Solvay in 2005. Positions at Laboratories Fournier included: Vice-President Strategic Marketing and Vice-President U.S. Operations, as well as serving as a member of the Executive Committee.
Positions at Solvay included: Head of Business Strategy and Portfolio and Senior
Vice-President of the Research Division, as well as serving as a member of the Executive Committee. Mr.&nbsp;Cren began his career with Boston Consulting Group, where he worked from 1993 to 2002. He
received a master's degree in business administration from INSEAD, a master's degree in international relations from Johns Hopkins University and a bachelor's degree in economics from Paris IX
Dauphine University. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I>Pierre Broqua</I></B></FONT><FONT SIZE=2> has served as our Chief Scientific Officer since co-founding Inventiva in 2011, and as our Deputy Chief Executive Officer and a member of
our board of directors since May 2016. Previously, Dr.&nbsp;Broqua served as a Head of Research for Abbott Laboratories from 2010 until 2012 and as Head of Neuroscience for Solvay Pharmaceuticals
from 2007 to 2010. Prior to Solvay, Dr.&nbsp;Broqua was the Director of Research Project for Laboratoires Fournier&nbsp;SA from 2002 to 2005. He has a doctor of philosophy degree </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>136</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=140,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=456659,FOLIO='136',FILE='DISK116:[20ZBV1.20ZBV74901]DE74901A.;34',USER='SCAVALI',CD='10-APR-2020;08:18' -->
<A NAME="page_de74901_1_137"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>in
pharmacology from the University of Paris Descartes and a master's degree in chemistry and biochemistry from Universit&eacute; Pierre et Marie Curie, Paris. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I>Jean Volatier</I></B></FONT><FONT SIZE=2> has served as our Chief Financial Officer since August 2012. Previously, Mr.&nbsp;Volatier was a senior consultant for I Care
Environnement, a consulting company, from January 2011 to October 2011, the interim Chief Financial Officer of the NAOS Group, a skin care company, from April 2010 to November 2010, the Chief
Financial Officer of the Soufflet Group, an agro-industry company, from 2006 to 2008, the Financial Director&nbsp;&#151; International Operations of Laboratories Fournier, from 1999 to 2006
and the Head of Controlling for URGO Soins&nbsp;&amp; Sant&eacute; Laboratories, a pharmaceutical company, from 1996 to 1999. Mr.&nbsp;Volatier began his career at PriceWaterhouseCoopers,
where he worked from 1989 to 1996. He holds a master's degree in management from Paris IX Dauphine University, PSL University, an executive specialized master's degree in corporate social
responsibility from MINES-ParisTech, PSL University, and the </FONT><FONT SIZE=2><I>dipl&ocirc;me d'&eacute;tudes sup&eacute;rieures comptables et
financi&egrave;res</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I>Marie-Paule Richard</I></B></FONT><FONT SIZE=2> has served as our Chief Medical Officer since October 2018. From 2014 to 2018, Dr.&nbsp;Richard was the Chief Medical Officer of
TiGenix&nbsp;S.A., a Belgian biotechnology company that was acquired by Takeda Pharmaceutical Company&nbsp;Ltd. Dr.&nbsp;Richard also served as the Chief Medical Officer for
AiCuris&nbsp;GmbH&nbsp;&amp;&nbsp;Co., a pharmaceutical company, from 2010 to 2012, the Vice President of Clinical Development for Sanofi Pasteur, the vaccines division of the pharmaceutical company
Sanofi&nbsp;S.A., from 2001 to 2007, the Global Senior Group Director for GlaxoSmithKline&nbsp;plc, a pharmaceutical company, from 2000 to 2001 and the Clinical Development Director for Aventis
Pharma&nbsp;S.A. from 1993 to 2000. Dr.&nbsp;Richard received a doctor of medicine degree from the Medical School of Nancy University. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Non-Employee Directors  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I>Chris Buyse</I></B></FONT><FONT SIZE=2> has served as a member of our board of directors since February 2017. Chris Buyse is currently the
managing partner of Fund+, which is a life sciences investment fund that he co-founded in 2015. Previously, Mr.&nbsp;Buyse was Chief Financial Officer at ThromboGenics&nbsp;NV, a public
biotechnology company, from 2006 to 2014. He was previously Chief Financial Officer of CropDesign N.V, a Belgian biotechnology company. Before this, he was Finance Director of WorldCom/MCI
Belgium-Luxembourg, a telecommunications company, was Chief Financial Officer and interim Chief Executive Officer of Keyware Technologies&nbsp;N.V., an IT company, and held several financial
positions at Suez Lyonnaise des Eaux and Unilever. He is currently serving as an independent director of Celyad&nbsp;SA, a public biotechnology company, as well as Bioxodes&nbsp;SA, a
biotechnology company. Mr.&nbsp;Buyse holds a master's degree in applied economic sciences from the University of Antwerp and a master's degree in business administration from the Vlerick School of
Management in Ghent. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I>Lucy Lu</I></B></FONT><FONT SIZE=2> has served as a member of our board of directors since May 2018. She has been the President and Chief Executive Officer of Avenue
Therapeutics,&nbsp;Inc., a public biotechnology company, since its inception in 2015. Previously, she was Executive Vice President and Chief Financial Officer of Fortress Biotech,&nbsp;Inc. from
2012 to 2017. Before working in the biotechnology industry, Dr.&nbsp;Lu worked in healthcare-related equity research and investment banking, including as Senior Biotechnology Analyst at
Citigroup&nbsp;Inc. from 2007 to 2012. She currently serves as a board member of Veru&nbsp;Inc., a public biopharmaceutical company. Dr.&nbsp;Lu holds a doctor of medicine degree from the New
York University School of Medicine and a master's degree in business administration from the Leonard N. Stern School of Business at New York University. She also received a bachelor's degree from the
University of Tennesee's College of Arts and Sciences. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I>Heinz Maeusli</I></B></FONT><FONT SIZE=2> has served as a member of our board of directors since May 2019. Since November 2019, Mr.&nbsp;Maeusli has served on the board of
directors of Progenics Pharmaceuticals, a biopharmaceutical company, where he is the chairman of the audit committee. Prior to joining our board, he served as the Chief Financial Officer of Advanced
Accelerator Applications&nbsp;(AAA), a pharmaceutical group specializing in the field of nuclear medicine, from 2003 to July 2018, where he was involved with the sale of AAA to </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>137</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=141,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=581592,FOLIO='137',FILE='DISK116:[20ZBV1.20ZBV74901]DE74901A.;34',USER='SCAVALI',CD='10-APR-2020;08:18' -->
<A NAME="page_de74901_1_138"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Novartis,
a global healthcare company, in January 2018. Mr.&nbsp;Maeusli has an MBA from Columbia University in New York and a degree in Economics from the University of St.&nbsp;Gallen. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><I>Nawal Ouzren</I></B></FONT><FONT SIZE=2> has served as a member of our board of directors since May 2019. Since 2017, Ms.&nbsp;Ouzren has served as the Chief Executive Officer and
a member of the Board of Directors of Sensorion, a biopharmaceutical company. Prior to Sensorion, she served as the head of the Global Genetic Diseases Franchise at Shire&nbsp;plc, a
biopharmaceutical company, from June 2016 to April 2017. Prior to Shire, Ms.&nbsp;Ouzren held various positions at Baxalta from 2014 to June 2016 when Baxalta was acquired by Shire.
Ms.&nbsp;Ouzren holds a Master's degree in Chemical Engineering from the Technical University of Berlin, Germany and a Master of Science in Chemical Engineering from the Universit&eacute; de
Technologie de Compi&egrave;gne, France. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I>Annick Schwebig</I></B></FONT><FONT SIZE=2> has served as a member of our board of directors since February 2017. In 2000, she founded Actelion Pharmaceuticals France SAS, a
pharmaceuticals company specializing in developing drugs for orphan diseases, and was its Chairman and Chief Executive Officer from 2000 to 2015. Ms.&nbsp;Schwebig has held senior positions in the
pharmaceutical industry, including Vice President Medical Affairs France and Vice President Research and Development Europe at Bristol-Myers Squibb, a global biopharmaceutical company, from 1983 to
2000. Ms.&nbsp;Schwebig has been a member of the board of directors of Cellectis&nbsp;SA, a biotechnology company, since 2011. Ms.&nbsp;Schwebig is a graduate of the Paris Faculty of Medicine. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Family Relationships  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>There are no family relationships among any of our executive officers or directors. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Board Composition  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our board of directors currently consists of seven members, less than a majority of whom are citizens or residents of the United States. Under French law and
our bylaws, our board of directors must be comprised of between three and 18 members, without prejudice to the derogation established by law in the event of merger. The number of directors of each
gender may not be less than 40%. Any appointment made in violation of this limit that is not remedied within six months of this appointment will be null and void. Within these limits, the number of
directors is determined by our shareholders. Directors are appointed, reappointed to their position, or removed by our ordinary general meeting, and in particular, any appointment which remedies a
violation of the 40% limit must be ratified by our shareholders at the next ordinary general meeting. Their term of office, in accordance with our bylaws, is three years. Directors chosen or appointed
to fill a vacancy must be elected by our board of directors for the remaining duration of the current term of the vacant director. The appointment must then be ratified at the next shareholders'
general meeting. In the event the board of directors would be comprised of less than three directors as a result of a vacancy, the remaining directors shall immediately convene a shareholders' general
meeting to elect one or several new directors so there are at least three directors serving on the board of directors, in accordance with French law. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
following table sets forth the names of our directors, the years of their initial appointment as directors of the board and the expiration dates of their current term. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>138</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=142,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=759212,FOLIO='138',FILE='DISK116:[20ZBV1.20ZBV74901]DE74901A.;34',USER='SCAVALI',CD='10-APR-2020;08:18' -->
<A NAME="page_de74901_1_139"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="174pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="63pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="69pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Current position(s) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Year of initial<BR>
appointment </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Term<BR>
expiration year </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fr&eacute;d&eacute;ric Cren</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Chief Executive Officer; Chairman of the Board of Directors</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2011</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pierre Broqua</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Deputy Chief Executive Officer; Chief Scientific Officer; Director</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2011</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><SUP>(2)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pienter-Jan BVBA represented by Chris Buyse</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>Director</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2017</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2022</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Sofinnova Partners represented by Lucy Lu</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>Director</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2018</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2021</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Heinz Maeusli</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nawal Ouzren</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CELL+ represented by Annick Schwebig</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>Director</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2017</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2022</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Mr.&nbsp;Cren
served as our President until our transformation into a </FONT><FONT  style="font-size:8pt;line-height:9pt;"><I>soci&eacute;t&eacute;
anonyme</I></FONT><FONT  style="font-size:8pt;line-height:9pt;"> pursuant to the shareholders' meeting dated May&nbsp;31, 2016 and has served as our Chief Executive Officer and Chairman of the Board of Directors since then.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Dr.&nbsp;Broqua
was appointed Deputy Chief Executive Officer and Director following our transformation into a </FONT> <FONT  style="font-size:8pt;line-height:9pt;"><I>soci&eacute;t&eacute; anonyme</I></FONT><FONT  style="font-size:8pt;line-height:9pt;"> pursuant to the shareholders' meeting dated May&nbsp;31, 2016.
</FONT></DD></DL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Director Independence  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As a foreign private issuer, under the listing requirements and rules of the Nasdaq Global Market, we are not required to have independent directors on our
board of directors, except to the extent that our audit committee is required to consist of independent directors, subject to certain phase-in schedules. Nevertheless, our board of directors has
undertaken a review of the independence of the directors and considered whether any director has a material relationship with us that could compromise his or her ability to exercise independent
judgment in carrying out his or her responsibilities. Based upon information requested from, and provided by, each director concerning such director's background, employment and affiliations,
including family relationships, our board of directors has determined that all of our directors, except for Fr&eacute;d&eacute;ric Cren and Pierre Broqua, qualify as "independent
directors" as defined under applicable rules of the Nasdaq Global Market and the independence requirements contemplated by the Exchange Act. In making these determinations, our board of directors
considered the current and prior relationships that each non-employee director has had with our company and all other facts and circumstances that our board of directors deemed relevant in determining
their independence, including the beneficial ownership of our ordinary shares by each non-employee director and his or her affiliated entities (if any). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Furthermore,
our board has determined that, under the criteria of the MiddleNext Code, five of our directors are "independent directors." The MiddleNext Code sets out the five following criteria
justifying the independence of directors, characterized by the absence of any significant financial, contractual or family relationship likely to affect their independence of
judgment:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> they must not be a salaried employee or corporate officer of us or our group and must not
have held such a position within the last five years; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> they must not be in a significant business relationship with us or our group
(e.g.,&nbsp;client, supplier, competitor, provider, creditor, banker, etc.) within the last two years; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> they must not be a reference shareholder or hold a significant number of voting rights
(i.e.&nbsp;less than 10% of the share capital); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> they must not have close relationships or family ties with any of our corporate officer
or reference shareholder; and </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>139</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=143,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=417445,FOLIO='139',FILE='DISK116:[20ZBV1.20ZBV74901]DE74901A.;34',USER='SCAVALI',CD='10-APR-2020;08:18' -->
<A NAME="page_de74901_1_140"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> they must not have been our auditor within the last six years. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Based
on these criteria, our board of directors has determined that Pienter-Jan BVBA represented by Chris Buyse, CELL+ represented by Annick Schwebig, Sofinnova Partners represented by Lucy Lu, Nawal
Ouzren and Heinz Maeusli are "independent directors" under the independence criteria of the MiddleNext Code. In making such determination, our board of directors considered the relationships that each
non-employee director has with us and all other facts and circumstances the board of directors deemed relevant in determining the director's independence, including the number of ordinary shares
beneficially owned by the director and his or her affiliated entities, if any. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Role of the Board in Risk Oversight  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our board of directors is primarily responsible for the oversight of our risk management activities and has delegated to the audit committee the responsibility
to assist our board in this task. The audit committee also monitors our system of disclosure controls and procedures and internal control over financial reporting and reviews contingent financial
liabilities. The audit committee, among other things, examines our balance sheet commitments and risks and the relevance of risk monitoring procedures. While our board oversees our risk management,
our management is responsible for day-to-day risk management processes. Our board of directors expects our management to consider risk and risk management in each business decision, to proactively
develop and monitor risk management strategies and processes for day-to-day activities and to effectively implement risk management strategies adopted by the board of directors. We believe this
division of responsibilities is the most effective approach for addressing the risks we face. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Corporate Governance Practices  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As a French </FONT><FONT SIZE=2><I>soci&eacute;t&eacute; anonyme</I></FONT><FONT SIZE=2> listed on the regulated market of Euronext Paris, we
are subject to various corporate governance requirements under French law. In addition, as a foreign private issuer listed on the Nasdaq Global Market, we will be subject to Nasdaq corporate
governance listing standards. However, the corporate governance standards provide that foreign private issuers are permitted to follow home country corporate governance practices in lieu of Nasdaq
rules, with certain exceptions. We intend to rely on these exemptions for foreign private issuers and follow French corporate governance practices in lieu of the Nasdaq corporate governance rules,
which would otherwise require that (1)&nbsp;a majority of our board of directors consist of independent directors; (2)&nbsp;we establish a nominating and corporate governance committee; and
(3)&nbsp;our compensation committee be composed entirely of independent directors. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
a foreign private issuer, we are required to comply with Rule&nbsp;10A-3 of the Exchange Act, relating to audit committee composition and responsibilities. Rule&nbsp;10A-3 provides that the
audit committee must have direct responsibility for the nomination, compensation and choice of our auditors, as well as control over the performance of their duties, management of complaints made, and
selection of consultants. However, if the laws of a foreign private issuer's home country require that any such matter be approved by the board of directors or the shareholders, the audit committee's
responsibilities or powers with respect to such matter may instead be advisory. Under French law, the audit committee may only have an advisory role and appointment of our statutory auditors, in
particular, must be decided by the shareholders at our annual meeting. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, Nasdaq rules require that a listed company specify that the quorum for any meeting of the holders of ordinary shares be at least 33<SUP>1</SUP>/<SMALL>3</SMALL>% of the outstanding shares of the
company's voting stock. Consistent with French law, our bylaws provide that a quorum requires the presence of shareholders having at least (1)&nbsp;20% of the shares entitled to vote in the case of
an ordinary shareholders' general meeting or at an extraordinary shareholders'
general meeting where shareholders are voting on a capital increase by capitalization of reserves, profits or share premium, or (2)&nbsp;25% of the shares entitled to vote in the case of any other
extraordinary shareholders' general meeting. If a quorum is not present, the meeting is adjourned. There is no quorum requirement when an ordinary general meeting is reconvened, but the reconvened </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>140</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=144,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=645638,FOLIO='140',FILE='DISK116:[20ZBV1.20ZBV74901]DE74901A.;34',USER='SCAVALI',CD='10-APR-2020;08:18' -->
<A NAME="page_de74901_1_141"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>meeting
may consider only questions which were on the agenda of the adjourned meeting. When an extraordinary general meeting is reconvened, the quorum required is 20% of the shares entitled to vote,
except where the reconvened meeting is considering capital increases through capitalization of reserves, profits or share premium. For these matters, no quorum is required at the reconvened meeting.
If a quorum is not present at a reconvened meeting requiring a quorum, then the meeting may be adjourned for a maximum of two months. See "Description of Share Capital&nbsp;&#151; Key
provisions of our bylaws and French law affecting our ordinary shares&nbsp;&#151; Rights, preferences and restrictions attaching to ordinary shares (Articles&nbsp;11, 14, 28, 31 and 32 of
the bylaws)." </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Board Committees  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The board of directors has established an audit committee and a compensation and appointments committee, which operate pursuant to rules of procedure adopted
by our board of directors. The composition and functioning of all of our committees will comply with all applicable requirements of the French Commercial Code, the Nasdaq Global Market and SEC rules
and regulations. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
accordance with French law, committees of our board of directors only have an advisory role and can only make recommendations to our board of directors. As a result, decisions will be made by our
board of directors taking into account non-binding recommendations of the relevant board committee. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Audit Committee.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our audit committee assists our board of directors in its oversight of our corporate accounting and financial reporting and submits the selection
of our statutory auditors, their remuneration and independence for approval. Chris Buyse as representative of Pienter-Jan BVBA, Annick Schwebig as representative of CELL+, Lucy Lu as representative of
Sofinnova Partners and Heinz Maeusli currently serve on our audit committee. Chris Buyse as representative of Pienter-Jan BVBA is the chairperson of our audit committee. Our board has determined that
each of Chris Buyse as representative of Pienter-Jan BVBA, Annick Schwebig as representative of CELL+, Lucy Lu as representative of Sofinnova Partners and Heinz Maeusli are independent within the
meaning of the applicable listing rules and the independence requirements contemplated by Rule&nbsp;10A-3 under the Exchange Act.
Our board of directors has determined that Chris Buyse as representative of Pienter-Jan BVBA is an "audit committee financial expert" as defined by SEC rules and regulations and that each of the
members of the audit committee qualifies as financially sophisticated under the applicable exchange listing rules. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
principal responsibility of our audit committee is to monitor the existence and efficacy of the company's financial audit and risk control procedures on an ongoing basis. Our board of directors
has specifically assigned the following duties to the audit committee: </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Financial statements and financial information:  </I></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> examining our annual and interim financial statements; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> validating the relevance of our accounting methods, choices and policies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> verifying the relevance of the financial information published by us; </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Internal control:  </I></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> assuring that internal control procedures are implemented and followed, with the
assistance of internal quality audits; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> examining and approving the schedule of work for internal and external audits; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> reviewing any subject capable of having a meaningful financial and accounting impact on
us; </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Risk management:  </I></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> examining the state of significant disputes and off-balance-sheet commitments and risks,
the adequacy of risk monitoring procedures and the relevance of any regulated agreements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> directing the selection of statutory auditors, their compensation and ensuring their
independence; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>141</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=145,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=583948,FOLIO='141',FILE='DISK116:[20ZBV1.20ZBV74901]DE74901A.;34',USER='SCAVALI',CD='10-APR-2020;08:18' -->
<A NAME="page_de74901_1_142"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> helping to ensure the correct performance of the statutory auditors; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> establishing the rules for the use of statutory auditors for work other than auditing
accounts and verifying the correct execution thereof. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Compensation and Appointments Committee.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Annick Schwebig as representative of CELL+ and Chris Buyse as representative of Pienter-Jan BVBA currently serve on our
compensation and appointments committee. Annick Schwebig as representative of CELL+ is the chairperson of our compensation and appointments committee. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Our
board of directors has specifically assigned the following duties to the compensation and appointments
committee:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> formulating recommendations and proposals concerning (1)&nbsp;the various components to
compensation, pension and health insurance plans for officers and directors, (2)&nbsp;the procedures for establishing the variable portion of their compensation; (3)&nbsp;a general policy for
awarding shares pursuant to our equity incentive plans (including dilutive instruments); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> examining the amount of compensation and the system for distributing them between the
directors taking into account their dedication and the tasks performed within the board of directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> advising and assisting the board of directors as necessary in the selection of senior
executives and the establishment of their compensation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> assessing any increases in capital reserved to employees; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> assisting the board of directors when selecting new members; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> ensuring the implementation of structures and procedures to allow the application of good
governance practices within the company; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> preventing conflicts of interest within the board of directors; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> implementing the board of director's evaluation procedure. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Code of Business Conduct and Ethics  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Effective upon the effectiveness of the registration statement of which this prospectus is a part, we will adopt a Code of Business Conduct and Ethics, or the
Code of Conduct, applicable to all of our employees, executive officers and directors. The Code of Conduct will be available on our website at www.inventivapharma.com. The audit committee of our board
of directors is responsible for overseeing the Code of Conduct and must approve any waivers of the Code of Conduct for employees, executive officers and directors. We expect that any amendments to the
Code of Conduct, or any waivers of its requirements, will be disclosed on our website. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Compensation of Directors and Executive Officers  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The aggregate compensation paid and benefits in kind granted by us to our current executive officers and directors, including share-based compensation, for the
year ended December&nbsp;31, 2019 was &euro;1.7&nbsp;million. For the year ended December&nbsp;31, 2019, we did not allocate any amounts to be set aside or accrued to provide pension,
retirement or similar benefits to our directors or our executive officers. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Non-Employee Director Compensation  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our ordinary general meeting of shareholders held on May&nbsp;28, 2018 set the total annual attendance fees (ex-</FONT><FONT SIZE=2><I>jetons de
pr&eacute;sence</I></FONT><FONT SIZE=2>) to be distributed among non-employee directors at &euro;250,000 for each of the years ended December&nbsp;31, 2018 and 2019. The following
table sets forth information regarding the compensation earned by our non-employee directors for service on our board of directors during the year ended December&nbsp;31, 2019. Mr.&nbsp;Cren, who
is our Chief Executive Officer, and Dr.&nbsp;Broqua, who is our Deputy </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>142</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=146,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=72865,FOLIO='142',FILE='DISK116:[20ZBV1.20ZBV74901]DE74901A.;34',USER='SCAVALI',CD='10-APR-2020;08:18' -->
<A NAME="page_de74901_1_143"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Chief
Executive Officer and Chief Scientific Officer, are directors but do not receive any additional compensation for their services as directors. </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="129pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="149pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="119pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Name


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Gross Fees<BR>
Earned (&euro;)<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font> </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Warrants (&euro;)<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font> </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Total (&euro;) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pienter-Jan BVBA</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>54,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>54,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jean-Louis Junien<SUP>(4)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>16,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>16,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Sofinnova Partners<SUP>(3)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>31,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>31,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nanna L&uuml;neborg<SUP>(4)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chris Newton<SUP>(4)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>19,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>19,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CELL+</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>43,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>43,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nawal Ouzren<SUP>(5)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>20,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>20,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Heinz Maeusli<SUP>(5)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>23,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>23,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Includes
out-of-pocket expenses paid by us.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">This
column represents the full grant date fair value of share warrants (</FONT><FONT  style="font-size:8pt;line-height:9pt;"><I>bons de souscription d'actions</I></FONT><FONT  style="font-size:8pt;line-height:9pt;">)
granted during the year as measured pursuant to the Black-Scholes option-pricing model.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Sofinnova
Partners, represented by Lucy Lu, was appointed member of the board of directors by the ordinary and extraordinary general meeting held on
May&nbsp;28, 2018.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(4)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
Annual General Meeting held on May&nbsp;27, 2019 to approve the financial statements for the year ended December&nbsp;31, 2018 noted the expiry
of the directorships of Chris Newton, Nanna L&uuml;neborg and Jean-Louis Junien.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(5)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
Annual General Meeting held on May&nbsp;27, 2019 decided to appoint Heinz Maeusli and Nawal Ouzren as directors. </FONT></DD></DL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Executive Director Compensation  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following table sets forth information regarding compensation earned by Fr&eacute;d&eacute;ric Cren, our Chairman of the Board and Chief
Executive Officer, and by Pierre Broqua, our Deputy Chief Executive Officer, Chief Scientific Officer and Director, during the year ended December&nbsp;31, 2019. </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="125pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="125pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="35pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="65pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="34pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Name and principal position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Salary (&euro;) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Bonus (&euro;) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Equity<BR>
awards<BR>
(&euro;) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>All Other<BR>
compensation<BR>
(&euro;) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Paid<BR>
leave<BR>
(&euro;) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Incentive<BR>
payments<BR>
(&euro;) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Total<BR>
(&euro;) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Fr&eacute;d&eacute;ric Cren</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>242,528</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><SUP>(1)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>97,011</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><SUP>(2)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>24,003</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><SUP>(3)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>9,541</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>500</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>373,583</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Chief Executive Officer and Chairman of the Board</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><FONT SIZE=2>Pierre Broqua</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>173,945</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><SUP>(1)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>60,880</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><SUP>(2)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>22,863</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><SUP>(3)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,222</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>500</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>262,410</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Deputy Chief Executive Officer, Chief Scientific Officer and Director</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2><SUP>(1)</SUP></FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>Reflects
gross compensation before taxes.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2><SUP>(2)</SUP></FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>For
fiscal year 2019, variable compensation has been determined based on the achievement of targets set at the beginning of the year by the Board of
Directors in view of Compensation and Appointments Committee recommendations. The performance criteria, which are qualitative in nature, are related to product development, clinical studies results,
regulatory approval for certain products, as well as the marketing strategy and financial visibility.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2><SUP>(3)</SUP></FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>Represents
housing, car allowances and social guarantees for company managers and executives (GSC). </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>Following the entry in force of the Sapin 2 Law (French law no.&nbsp;2016-1691 of December&nbsp;9, 2016), the payment of the elements of variable
compensation and, as appropriate, exceptional compensation attributed for a financial year to the Chairman of the Board, the Chief Executive Officer and the Deputy Chief Executive Officer, is
conditional on approval by the next ordinary general meeting of their elements of </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>143</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=147,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=1003255,FOLIO='143',FILE='DISK116:[20ZBV1.20ZBV74901]DE74901A.;34',USER='SCAVALI',CD='10-APR-2020;08:18' -->
<A NAME="page_de74901_1_144"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>compensation,
paid or attributed during the said financial year (</FONT><FONT SIZE=2><I>ex post vote</I></FONT><FONT SIZE=2>). The payments of the above variable compensations were approved by the
ordinary and extraordinary shareholder meeting held on May&nbsp;27, 2019. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Limitations on Liability and Indemnification Matters  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under French law, provisions of bylaws that limit the liability of directors are ineffective. However, French law allows </FONT> <FONT SIZE=2><I>soci&eacute;t&eacute;s anonymes</I></FONT><FONT SIZE=2> to contract for and maintain
liability insurance against civil liabilities incurred by any of their
directors and officers involved in a third-party action, provided that they acted in good faith and within their capacities as directors or officers of the company. Criminal liability cannot be
indemnified under French law, whether directly by the company or through liability insurance. We have liability insurance for our directors and officers, including insurance against liability under
the Securities Act. Certain of our non-employee directors may also, through their relationships with their employers or partnerships, be insured against certain liabilities in their capacity as
members of our board of directors. These arrangements may discourage shareholders from bringing a lawsuit against our directors and executive officers for breach of their duty. These provisions also
may have the effect of reducing the likelihood of derivative litigation against directors and executive officers, even though such an action, if successful, might otherwise benefit us and our
shareholders. Furthermore, a shareholder's investment may be adversely affected to the extent we pay any costs of settlement and damage awards against directors and officers pursuant to any insurance
arranagements. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Equity Incentives  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We believe our ability to grant equity incentives is a valuable and necessary compensation tool that allows us to attract and retain the best available
personnel for positions of substantial responsibility, provides additional incentives to employees and promotes the success of our business. Due to French corporate law and tax considerations, we have
historically granted or may grant in the future several different equity incentive instruments to our directors, executive officers, employees and other service providers,
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> founder's share warrants (</FONT><FONT SIZE=2><I>bons de souscription de parts de
cr&eacute;ateurs d'entreprise</I></FONT><FONT SIZE=2>, or BSPCE), which are granted to our officers and employees; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> share warrants (</FONT><FONT SIZE=2><I>bons de souscription
d'actions</I></FONT><FONT SIZE=2>, or BSA), which have historically only been granted to non-employee directors and a consultant of the company; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> restricted, or free, shares (</FONT><FONT SIZE=2><I>actions
gratuites</I></FONT><FONT SIZE=2>, or AGA); and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> stock options (</FONT><FONT SIZE=2><I>options de souscription et/ou d'achats
d'actions</I></FONT><FONT SIZE=2>). </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Our
board of directors' authority to grant these equity incentive instruments and the aggregate amount authorized to be granted under these instruments must be approved by a two-thirds majority of the
votes held by our shareholders present, represented or voting by authorized means, at the relevant extraordinary shareholders' meeting. Once approved by our shareholders, our board of directors can
grant founder's share warrants (</FONT><FONT SIZE=2><I>bons de souscription de parts de cr&eacute;ateur d'entreprise</I></FONT><FONT SIZE=2>) and share warrants (</FONT><FONT SIZE=2><I>bons de
souscription d'actions</I></FONT><FONT SIZE=2>) for up to 18&nbsp;months, and free shares (</FONT><FONT SIZE=2><I>actions gratuites</I></FONT><FONT SIZE=2>) and stock options
(</FONT><FONT SIZE=2><I>options de souscription et/ou d'achats d'actions</I></FONT><FONT SIZE=2>) for up to 38&nbsp;months from the date of the applicable shareholders' approval. The authority of our
board of directors to grant equity incentives may be extended or increased only by extraordinary shareholders' meetings. As a result, we typically request that our shareholders authorize new pools of
equity incentive instruments at every annual shareholders' meeting. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>144</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=148,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=868286,FOLIO='144',FILE='DISK116:[20ZBV1.20ZBV74901]DE74901A.;34',USER='SCAVALI',CD='10-APR-2020;08:18' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_dg74901_1_145"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have ten share-based compensation plans in force for our executive officers, non-employee directors and employees, the BSPCE 2013-1 Plans dated 2013, the AGA 2018-2, 2018-3
Plans dated 2018, the AGA&nbsp;2019-1 and 2019-2 dated 2019 respectively and the BSA 2017, 2018, 2019, 2019 bis and 2019 ter Plans dated 2017, 2018, 2019 and 2020 respectively. In general, founder's
share warrants (</FONT><FONT SIZE=2><I>bons de souscription de parts de cr&eacute;ateur d'entreprise</I></FONT><FONT SIZE=2>) and share warrants (</FONT><FONT SIZE=2><I>bons de souscription
d'actions</I></FONT><FONT SIZE=2>) no longer continue to vest following termination of the employment, office or service of the holder and all vested shares must be exercised within post-termination
exercise periods set forth in the grant documents. In the event of certain changes in our share capital structure, such as a consolidation or share split or dividend, French law and applicable grant
documentation provides for appropriate adjustments of the numbers of shares issuable and/or the exercise price of the outstanding warrants. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
of March&nbsp;31, 2020, free shares (</FONT><FONT SIZE=2><I>actions gratuites</I></FONT><FONT SIZE=2>) were outstanding that can be settled for an aggregate of 484,350 ordinary shares. As of
March&nbsp;31, 2020, founder's share warrants (</FONT><FONT SIZE=2><I>bons de souscription de parts de cr&eacute;ateur d'entreprise</I></FONT><FONT SIZE=2>) and share warrants
(</FONT><FONT SIZE=2><I>bons de souscription d'actions</I></FONT><FONT SIZE=2>) allowing for the purchase of an aggregate of 274,800 ordinary shares at a weighted average exercise price of
&euro;6.06 per share ($6.68 per ordinary share based on the exchange rate in effect as of March&nbsp;31, 2020) were outstanding. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Founder's Share Warrants (bons de souscription de parts de cr&eacute;ateur d'entreprise)  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Founder's share warrants (</FONT><FONT SIZE=2><I>bons de souscription de parts de cr&eacute;ateur d'entreprise</I></FONT><FONT SIZE=2>) have
traditionally been granted to certain of our employees who were French tax residents because the warrants carry favorable tax and social security treatment for French tax residents. Similar to
options, founder's share warrants (</FONT><FONT SIZE=2><I>bons de souscription de parts de cr&eacute;ateur d'entreprise</I></FONT><FONT SIZE=2>) entitle a holder to exercise the warrant for the
underlying vested shares at an exercise price per share determined by our board of directors and at least equal to the fair market value of an ordinary share on the date of grant. However, unlike
options, the exercise price per share is fixed as of the date of implementation of the plans pursuant to which the warrants may be granted, rather than as of the date of grant of the individual
warrants. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
have one founder's share warrants in force (</FONT><FONT SIZE=2><I>bons de souscription de parts de cr&eacute;ateur d'entreprise</I></FONT><FONT SIZE=2>): </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="107pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Plan title

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>BSPCE 2013-1<BR>
(2013) plan </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Meeting date</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>November&nbsp;25, 2013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dates of allocation</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>December&nbsp;13, 2013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total number of BSPCEs authorized</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>15,013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><SUP>(1)</SUP></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total number of BSPCEs granted</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>9,027</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><SUP>(2)</SUP></FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Start date for the exercise of the BSPCEs</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><SUP>(3)</SUP></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>BSPCE expiration date</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>December&nbsp;31, 2023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>BSPCE exercise price</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&euro;58.50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><SUP>(4)</SUP></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Number of shares subscribed as of March&nbsp;31, 2020</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>621,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total number of BSPCEs granted but not exercised as of March&nbsp;31, 2020</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>88</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total number of shares available for subscription as of March&nbsp;31, 2020</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>8,800</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Maximum number of new shares that can be issued</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>8,800</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Represents
the aggregate number of warrants authorized under the BSPCE 2013-1 plans.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Of
which (1)&nbsp;2,729 BSCPCEs need to be excluded following cancellation or lapse for the BSPCE 2013-1 (2013) plan.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Subject
to cases of lapsing, the vested BSPCE 2013-1 share warrants may be exercised in all or in part at the (1)&nbsp;election of each holder,
(1)&nbsp;within three days as from the notification by the Company that an agreement has been entered into between one or more shareholders and another party resulting in the change of control of
the Company within the meaning of Article&nbsp;L. 233-3-I of the French Commercial Code, as a result of transfer of the Company's shares or merger by absorption of the Company, or (2)&nbsp;within
ten days following the end of a period of 30 calendar days beginning on the date on which the </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>145</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=149,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=595727,FOLIO='145',FILE='DISK116:[20ZBV1.20ZBV74901]DG74901A.;25',USER='SCAVALI',CD='10-APR-2020;08:24' -->
<A NAME="page_dg74901_1_146"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">price
of the Company's shares (including ordinary shares in the form of ADSs) is fixed as part of an initial public offering by the Company, and the admission of the Company's shares to a regulated or
unregulated market, in France, the EU or a stock exchange outside the EU, or (3)&nbsp;in the event of the Company's shares being admitted to trading on a regulated or unregulated market, in France,
EU or foreign exchange: (x)&nbsp;if the listing takes place between December&nbsp;5 and 31 of a year&nbsp;"N", during a period from January&nbsp;5 to 20 of each calendar year as from the
second year following the year&nbsp;"N" in which the listing occurred; (y)&nbsp;if the listing takes place during a period other than the period referred to above: during a period from
January&nbsp;5 to 20 of each calendar year from the date immediately following the calendar year in which the listing took place. Notwithstanding the foregoing, in case of notification by the
Company to the holders of BSPCE&nbsp;2013-1 that the shareholders holding more than half of the capital and voting rights have accepted a purchase offer from one or more shareholders or third
parties, acting alone or jointly, for all of the shares issued by the Company, the holders shall exercise all of their BSPCE&nbsp;2013-1 within 20&nbsp;days from such notification. </FONT></P>

</UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(4)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Price
for the subscription of 100 new ordinary shares. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>Our shareholders, or pursuant to delegations granted by our shareholders, our board of directors, determines the recipients of the warrants, the dates of grant,
the number and exercise price of the founder's share warrants (</FONT><FONT SIZE=2><I>bons de souscription de parts de cr&eacute;ateur d'entreprise</I></FONT><FONT SIZE=2>) to be granted, the
number of shares issuable upon exercise and certain other terms and conditions of the founder's share warrants (</FONT><FONT SIZE=2><I>bons de souscription de parts de cr&eacute;ateur
d'entreprise</I></FONT><FONT SIZE=2>), including the period of their exercisability and their vesting schedule. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Share Warrants (bons de souscription d'actions)  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Share warrants (</FONT><FONT SIZE=2><I>bons de souscription d'actions</I></FONT><FONT SIZE=2>) have historically been granted to our non-employee directors and
consultants that regularly work in partnership with the Company. Similar to options, share warrants (</FONT><FONT SIZE=2><I>bons de souscription d'actions</I></FONT><FONT SIZE=2>) entitle a holder to
exercise the warrant for the underlying vested shares at an exercise price per share determined by our board of directors and at least equal to the fair market value of an ordinary share on the date
of grant. However, unlike options, the exercise price per share is fixed as of the date of implementation of the plans pursuant to which the warrants may be granted, rather than as of the date of
grant of the individual warrants. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
of March&nbsp;31, 2020, we have issued three types of share warrants (</FONT><FONT SIZE=2><I>bons de souscription d'actions</I></FONT><FONT SIZE=2>) as follows: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="70pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="98pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="74pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="74pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="74pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Plan title

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>BSA<BR>
2017 plan </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>BSA<BR>
2018 plan </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>BSA<BR>
2019 plan </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>BSA<BR>
2019 bis plan </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>BSA<BR>
2019 ter plan </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Meeting date</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>May&nbsp;29, 2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>May&nbsp;28, 2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>May&nbsp;27, 2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Decision of issuance by the Board of Directors</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>May&nbsp;29, 2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>December&nbsp;14, 2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>June&nbsp;28, 2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>March&nbsp;9, 2020</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>March&nbsp;9, 2020</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total number of BSAs authorized (General meeting)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>600,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>600,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>600,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total number of BSAs authorized (Board of Directors)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>195,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>126,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><SUP>(2)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>36,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total number of BSA subscribed</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>195,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>126,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>0</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>0</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Start date for the exercise of the BSAs</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><SUP>(1)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><SUP>(3)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><SUP>(4)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><SUP>(5)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><SUP>(6)</SUP></FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>BSA expiration date</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>May&nbsp;29, 2027</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>December&nbsp;14, 2028</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>June&nbsp;28, 2029</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>March&nbsp;9, 2030</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>March&nbsp;9, 2030</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>BSA exercise price per share</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&euro;6.675</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&euro;6.067</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&euro;2.20</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&euro;3.68</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&euro;3.68</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Number of shares subscribed as of March&nbsp;31, 2020</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>0</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>0</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>0</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>0</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>0</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total number of shares available for subscription as of March&nbsp;31, 2020</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>120,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>38,667</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>0</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>0</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Maximum number of new shares that can be issued</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>140,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>116,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>0</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>0</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">BSA
2017 share warrants will vest in three tranches at the end of the following vesting periods: (1)&nbsp;one third on May&nbsp;29, 2018,
(2)&nbsp;one third on May&nbsp;29, 2019 and (3)&nbsp;the balance on May&nbsp;29, 2020. By decision of the Board of Directors on </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>146</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=150,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=495879,FOLIO='146',FILE='DISK116:[20ZBV1.20ZBV74901]DG74901A.;25',USER='SCAVALI',CD='10-APR-2020;08:24' -->
<A NAME="page_dg74901_1_147"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">April&nbsp;9,
2019, the final allotment of the second tier of BSA 2017 warrants, initially set for May&nbsp;29, 2019, has been brought forward to May&nbsp;27, 2019 to enable Chris Newton and
Jean-Louis Junien to benefit as a result of their presence on the Board for virtually all of the year. Furthermore, for these two members of the Board of Directors, there will be no final allotment of
the last tier as the 55,000 BSA 2017 warrants have lapsed.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Of
which 10,000 BSA 2018 need to be excluded following cancellation or lapse.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">BSA
2018 share warrants can only be exercised under the following conditions: (a)&nbsp;for David Nikodem, in tranches of one third at the end of the
following vesting periods: (1)&nbsp;one third as of September&nbsp;1, 2019, (2)&nbsp;one third as of September&nbsp;1, 2020 and (3)&nbsp;the balance as of September&nbsp;1, 2021;
(b)&nbsp;for JPG Healthcare&nbsp;LLC, in full as of November&nbsp;8, 2019; and (c)&nbsp;for ISLS Consulting, in tranches of one third at the end of the following vesting periods:
(1)&nbsp;26,667 as of December&nbsp;14, 2019, (2)&nbsp;26,667 as of December&nbsp;14, 2020 and (3)&nbsp;26,666 as of December&nbsp;14, 2021, it being specified that in each case, BSA 2018
vesting periods will lapse if the service agreement between the Company and the beneficiary or the company for which the beneficiary acts, is terminated before the date of the first vesting period or
in the event of the death of the beneficiary.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(4)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">BSA
2019 share warrants are only exercisable subject to a consultancy agreement still being in effect at June&nbsp;28, 2020, and no notice of
termination having been given by David Nikodem and/or Sapidus Consulting Group&nbsp;LLC or the Company.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(5)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">BSA
2019 bis share warrants may be subscribed until July&nbsp;13, 2020. If subscribed, they will only be exercisable subject to a consultancy
agreement still being in effect at March&nbsp;9, 2021, and no notice of termination having been given by Mr.&nbsp;Jeremy Goldberg and/or JPG Healthcare&nbsp;LLC or the Company.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(6)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">BSA
2019 ter share warrants may be subscribed until July&nbsp;13, 2020. If subscribed, they will only be exercisable in three tranches at the end of
the following periods: (1)&nbsp;one third on March&nbsp;9, 2021, (2)&nbsp;one third on March&nbsp;9, 2022 and (3)&nbsp;the balance on March&nbsp;9, 2023, subject to, for each of these
dates, that a consultancy agreement still being in effect and no notice of termination having been given by David Nikodem and/or Sapidus Consulting Group&nbsp;LLC or the Company. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>Our shareholders, or pursuant to delegations granted by our shareholders, our board of directors, determines the recipients of the warrants, the dates of grant,
the number and exercise price of the share warrants (</FONT><FONT SIZE=2><I>bons de souscription d'actions</I></FONT><FONT SIZE=2>) to be granted, the number of shares issuable upon exercise and
certain other terms and conditions of the share warrants (</FONT><FONT SIZE=2><I>bons de souscription d'actions</I></FONT><FONT SIZE=2>), including the period of their exercisability and their vesting
schedule. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Free Shares (actions gratuites)  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under our 2018-2, 2018-3, 2019-1 and 2019-2 Free Share Plans, which were adopted by our board of directors on January 26, 2018 for the 2018-2 Free Share Plan,
December&nbsp;14, 2018 for the 2018-3 and on June&nbsp;28, 2019 for the 2019-1 and 2019-2 Free Share Plans, we have granted free shares (</FONT><FONT SIZE=2><I>actions
gratuites</I></FONT><FONT SIZE=2>) to certain of our employees and officers. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Free
shares (</FONT><FONT SIZE=2><I>actions gratuites</I></FONT><FONT SIZE=2>) may be granted to any individual employed by us or by any affiliated company. Free shares may also be granted to our
Chairman, our Chief Executive Officer and our Deputy Chief Executive Officer. However, no free share may be granted to a beneficiary holding more than 10% of our share capital or to a beneficiary who
would hold more than 10% of our share capital as a result of such grant. The maximum number of shares that may be issued under the 2018-2, 2018-3, 2019-1 and 2019-2 Free Share Plans is 484,350 as of
March&nbsp;31, 2020. In addition, under French law, the maximum number of shares that may be granted shall not exceed 10% of the share capital as at the date of grant of the free shares (30% if the
allocation benefits all employees). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
board of directors has the authority to administer the 2018-2, 2018-3, 2019-1 and 2019-2 Free Share Plans. Subject to the terms of the 2018-2, 2018-3, 2019-1 and 2019-2 Free Share Plans, our board
of directors determines the recipients, the dates of grant, the number of free shares (</FONT><FONT SIZE=2><I>actions gratuites</I></FONT><FONT SIZE=2>) to be granted and the terms and conditions of
the free shares, including the length of their vesting period (starting on the grant date, during which the beneficiary holds a right to acquire shares for free but has not yet acquired any shares)
and holding period (starting when the shares are issued and definitively acquired but may not be transferred by the recipient) within the limits determined by the shareholders. Our shareholders have
determined that the vesting period should be set by the board of directors and should not be less than one year from the date of grant and that the optimal holding period should be set by the board of
directors. From the beginning of the vesting period, the cumulated vesting and holding period should not be less than two years. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>147</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=151,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=1033958,FOLIO='147',FILE='DISK116:[20ZBV1.20ZBV74901]DG74901A.;25',USER='SCAVALI',CD='10-APR-2020;08:24' -->
<A NAME="page_dg74901_1_148"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
board of directors has the authority to modify awards outstanding under our 2018-2, 2018-3, 2019-1 and 2019-2 Free Share Plans, subject to the consent of the beneficiary for any modification
adverse to such beneficiary. For example, the board has the authority to release a beneficiary from the continued service condition during the vesting period after the termination of the employment. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
free shares granted under our 2018-2, 2018-3, 2019-1 and 2019-2 Free Share Plans will be definitively acquired at the end of the vesting period as set by our board of directors subject to
continued service during the vesting period, except if the board releases a given beneficiary from this condition upon termination of his or her employment contract. At the end of the vesting period,
the beneficiary will be the owner of the shares. However, the shares may not be sold or transferred during the holding period. In the event of disability before the end of the vesting period, the free
shares shall be definitively acquired by the beneficiary on the date of disability. In the event the beneficiary dies during the vesting period, the free shares shall be definitively acquired at the
date of the request of allocation made by his or her beneficiaries in the framework of the inheritance provided that such request is made within six months from the date of death. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
January&nbsp;26, 2018 the board approved the grant of an aggregate of 65,700 free shares (</FONT><FONT SIZE=2><I>actions gratuites</I></FONT><FONT SIZE=2>) under the 2018-2 Free Share Plans which
will vest as follows: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="51pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="47pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="96pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Number of<BR>
free shares </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Vesting<BR>
period </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Holding<BR>
period </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Date exercisable<BR>
(subject to<BR>
service conditions) </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2018-2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>63,300</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><SUP>(1)</SUP></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Two years</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>One year</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>January&nbsp;26, 2021</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Excludes
2,400 free shares (</FONT><FONT  style="font-size:8pt;line-height:9pt;"><I>actions gratuites</I></FONT><FONT  style="font-size:8pt;line-height:9pt;">) initially allocated to an employee which where forfeited
following his resignation. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>As of March&nbsp;31, 2020, 63,300 shares had been issued upon vesting of free shares (</FONT><FONT SIZE=2><I>actions gratuites</I></FONT><FONT SIZE=2>) granted
under the 2018-2 Free Share Plan and are under the one year holding period until January&nbsp;26, 2021. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
December&nbsp;14, 2018, the board approved the grant of an aggregate of 265,700 free shares (</FONT><FONT SIZE=2><I>actions gratuites</I></FONT><FONT SIZE=2>) under the 2018-3 Free Share Plan
which will vest as follows: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="51pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="47pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="107pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Number of<BR>
free shares </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Vesting<BR>
period </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Holding<BR>
period </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Date exercisable<BR>
(subject to<BR>
service conditions) </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2018-3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>227,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><SUP>(1)</SUP></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Two years</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>One year</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>December&nbsp;14, 2021</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Excludes
38,450 free shares (</FONT><FONT  style="font-size:8pt;line-height:9pt;"><I>actions gratuites</I></FONT><FONT  style="font-size:8pt;line-height:9pt;">) initially allocated to an employee which where forfeited
following his resignation. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>As of March&nbsp;31, 2020, no shares had been issued upon vesting of free shares granted under the 2018-2 Free Share Plan. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>148</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=152,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=431279,FOLIO='148',FILE='DISK116:[20ZBV1.20ZBV74901]DG74901A.;25',USER='SCAVALI',CD='10-APR-2020;08:24' -->
<A NAME="page_dg74901_1_149"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
June&nbsp;28, 2019, the board approved the grant of an aggregate of 283,500 free shares (</FONT><FONT SIZE=2><I>actions gratuites</I></FONT><FONT SIZE=2>) under the 2019-1 and 2019-2 Free Share
Plans which will vest as follows: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="51pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="47pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="87pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Number of<BR>
free shares </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Vesting<BR>
period </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Holding<BR>
period </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Date exercisable<BR>
(subject to<BR>
service conditions) </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2019-1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>29,100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><SUP>(1)</SUP></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Two years</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>One year</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>June&nbsp;28, 2022</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2019-2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>228,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><SUP>(2)</SUP></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>One year</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>One year</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>June&nbsp;28, 2021</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Excludes
8,400 free shares (</FONT><FONT  style="font-size:8pt;line-height:9pt;"><I>actions gratuites</I></FONT><FONT  style="font-size:8pt;line-height:9pt;">) initially allocated to two employees which where forfeited
following their resignation.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Excludes
18,000 free shares (</FONT><FONT  style="font-size:8pt;line-height:9pt;"><I>actions gratuites</I></FONT><FONT  style="font-size:8pt;line-height:9pt;">) initially allocated to an employee which where forfeited
following his resignation. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>As of March&nbsp;31, 2020, no shares had been issued upon vesting of free shares granted under the 2019-1 Free Share Plan or the 2019-2 Free Share Plan. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>149</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=153,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=880262,FOLIO='149',FILE='DISK116:[20ZBV1.20ZBV74901]DG74901A.;25',USER='SCAVALI',CD='10-APR-2020;08:24' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_di74901_1_150"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A NAME="di74901_certain_relationships___di702238"> </A>
<A NAME="toc_di74901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Since January&nbsp;1, 2017, we have engaged in the following transactions with our directors, executive officers and holders of more than 5% of our
outstanding voting securities and their affiliates, which we refer to as our related parties. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Transactions with Our Principal Shareholders  </B></FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Issuances of Securities  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We issued 5,706,577 ordinary shares in February and March 2017 in connection with our initial public offering on Euronext Paris, we issued 5,572,500 ordinary
shares in a private placement on April&nbsp;17, 2018, we issued 4,473,935 ordinary shares in two private placements on September&nbsp;20, 2019 and October&nbsp;2, 2019 and we issued 3,778,338
ordinary shares in an offering on February&nbsp;11, 2020. The following table summarizes the ordinary shares acquired in connection with our initial public offering on Euronext Paris and these
offerings by our executive officers, directors and holders of more than 5% of our outstanding voting securities. </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="22%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="22%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="60pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="59pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="61pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="74pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>BVF<BR>
Partners&nbsp;L.P. </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>NEA </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Novo<BR>
Holdings A/S </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Sofinnova<BR>
Crossover I SLP </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 IPO on Euronext Paris in 2017</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Number of ordinary shares purchased (#)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,643,835</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,095,890</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Purchase price per share (&euro;)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>8.50</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>8.50</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Private placement in 2018</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Number of ordinary shares purchased (#)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,569,858</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>775,500</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,569,858</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Purchase price per share (&euro;)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>6.37</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>6.37</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>6.37</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Private placements in 2019</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Number of ordinary shares purchased (#)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>666,838</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3,102,811</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>390,350</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>313,936</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Purchase price per share (&euro;)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1.99</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1.99</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1.99</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1.99</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Offering in February 2020</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Number of ordinary shares purchased (#)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,317,382</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,007,556</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>125,944</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>327,456</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Purchase price per share (&euro;)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3.97</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3.97</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3.97</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3.97</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Arrangements with Our Directors and Executive Officers  </B></FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Consultant Agreement with ISLS Consulting  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Jean-Louis Junien is the principal shareholder of ISLS Consulting. On July&nbsp;8, 2014, ISLS Consulting entered into a consultant agreement with us which
has since been renewed several times and for the last time by an amendment agreement dated June&nbsp;25, 2018 renewing the consultant agreement until June&nbsp;30, 2019. Under this agreement, ISLS
Consulting assists our management and teams of the company in the scientific conduct of its clinical and pre-clinical programs. ISLS Consulting charges us for these services on a monthly basis
according to the number of days worked during each month. Under this agreement, we paid </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>150</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=154,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=96285,FOLIO='150',FILE='DISK116:[20ZBV1.20ZBV74901]DI74901A.;15',USER='SCAVALI',CD='10-APR-2020;08:45' -->
<A NAME="page_di74901_1_151"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>ISLS
Consulting &euro;162,000 and &euro;169,000 for the year ending December&nbsp;31, 2018 and for the year ended December&nbsp;31, 2019, respectively. In addition, in May
2015, we granted 1,500 share warrants (</FONT><FONT SIZE=2><I>bons de souscription d'actions</I></FONT><FONT SIZE=2>) to ISLS Consulting which were exercised in 2017. Following this exercise, ISLS
Consulting obtained 150,000 ordinary shares. In December 2018, we granted 80,000 share warrants (</FONT><FONT SIZE=2><I>bons de souscription d'actions</I></FONT><FONT SIZE=2>) to ISLS Consulting which
have not been exercised. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Director and Executive Officer Compensation  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are parties to employment agreements and other compensation arrangements, including equity compensation arrangements, with our directors and executive
officers in the ordinary course of business. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Share Warrants (bons de souscription d'actions)  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have granted share warrants (</FONT><FONT SIZE=2><I>bons de souscription d'actions</I></FONT><FONT SIZE=2>) to purchase ordinary shares to our directors as
of December&nbsp;31, 2019 as follows: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="65pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="58pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="64pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="55pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="139pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="65pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Grant date </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Type of<BR>
instruments<BR>
granted<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font> </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Number of<BR>
ordinary<BR>
shares<BR>
underlying<BR>
awards (#)<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font> </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Maximum<BR>
number of<BR>
new shares<BR>
that can be<BR>
issued (#) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Exercise<BR>
price<BR>
per share (&euro;) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Expiration<BR>
date </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pienter-Jan BVBA</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>05/29/2017</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>BSA 2017</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>20,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>30,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>6.675</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>05/29/2027</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jean-Louis Junien<SUP>(3)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>05/29/2017</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>BSA 2017</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>50,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>50,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>6.675</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>05/29/2027</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chris Newton<SUP>(4)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>05/29/2017</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>BSA 2017</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>20,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>20,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>6.675</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>05/29/2027</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CELL+</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>05/29/2017</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>BSA 2017</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>20,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>30,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>6.675</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>05/29/2027</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Karen Aiach</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>05/29/2017</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>BSA 2017</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>6.675</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>05/29/2027 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>120,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>140,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">BSA
2017 refers to share warrants (</FONT><FONT  style="font-size:8pt;line-height:9pt;"><I>bons de souscription d'actions</I></FONT><FONT  style="font-size:8pt;line-height:9pt;">).
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Each
BSA 2017 entitles its holder to subscribe to one ordinary share, with a nominal value of &euro;0.01, at an exercise price of
&euro;&nbsp;6.675. BSA 2017 will vest in three tranches at the end of the following vesting periods: (1)&nbsp;one third on May&nbsp;29, 2018, (2)&nbsp;one third on
May&nbsp;29, 2019 and (3)&nbsp;the balance on May&nbsp;29, 2020.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Jean-Louis
Junien's term on our board of directors ended on May&nbsp;29, 2018.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(4)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Chris
Newton's term on our board of directors ended on May&nbsp;29, 2018.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(5)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Karen
Aiach's term on our board of directors ended on November&nbsp;25, 2018. </FONT></DD></DL>
 </DIV>
 <P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Related Person Transaction Policy  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We comply with French law regarding approval of transactions with related parties. Prior to the closing of this offering, we expect to adopt a related person
transaction policy that sets forth our procedures for the identification, review, consideration and approval or ratification of related person transactions. The policy will become effective
immediately upon the execution of the underwriting agreement for this offering. For purposes of our policy only, a related person transaction is defined as (1)&nbsp;any transaction, arrangement or
relationship (or any series of similar transactions, arrangements or relationships) in which we and any related person are, were or will be participants and the amount involved exceeds $120,000 or
(2)&nbsp;any agreement or similar transaction under French law which falls within the scope of Article&nbsp;L. 225-38 of the French Commercial Code. A related person is any executive officer,
director or beneficial owner of more than 5% of any class of our voting securities, including any of their immediate family members and any entity owned or controlled by such persons. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Under
the policy, if a transaction is identified as a related person transaction, including any transaction that was not a related person transaction when originally consummated or any transaction
that was not initially </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>151</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=155,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=502350,FOLIO='151',FILE='DISK116:[20ZBV1.20ZBV74901]DI74901A.;15',USER='SCAVALI',CD='10-APR-2020;08:45' -->
<A NAME="page_di74901_1_152"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>identified
as a related person transaction prior to consummation, our management must present information regarding the related person transaction to our audit committee, or, if audit committee
approval would be inappropriate, to another independent body of our board of directors, for review, consideration and approval or ratification. The presentation must include a description of, among
other things, the material facts, the interests, direct and indirect, of the related persons, the benefits to us of the transaction and whether the transaction is on terms that are comparable to the
terms available to or from, as the case may be, an unrelated third party or to or from employees generally. Under the policy, we will collect information that we deem reasonably necessary from each
director, executive officer and, to the extent feasible, significant shareholder to enable us to identify any existing or potential related-person transactions and to effectuate the terms of the
policy. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, under our Code of Business Conduct and Ethics, which we will adopt in connection with this offering, our employees and directors will have an affirmative responsibility to disclose any
transaction or relationship that reasonably could be expected to give rise to a conflict of interest. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
considering related person transactions, our audit committee, or other independent body of our board of directors, will take into account the relevant available facts and circumstances including,
but not limited to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the risks, costs and benefits to us; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the impact on a director's independence in the event that the related person is a
director, immediate family member of a director or an entity with which a director is affiliated; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the availability of other sources for comparable services or products; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the terms available to or from, as the case may be, unrelated third parties or to or from
employees generally. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>The
policy will require that, in determining whether to approve, ratify or reject a related person transaction, our board of directors, must consider, in light of known circumstances, whether the
transaction is in, or is not inconsistent with, our best interests and those of our shareholders, as our board of directors, determines in the good faith exercise of its discretion. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>All
of the transactions described above were entered into prior to the adoption of the written policy, but all were approved by our board of directors to the extent required by, and in compliance
with, French law. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>152</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=156,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=773561,FOLIO='152',FILE='DISK116:[20ZBV1.20ZBV74901]DI74901A.;15',USER='SCAVALI',CD='10-APR-2020;08:45' -->
<A NAME="page_di74901_1_153"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A NAME="di74901_principal_shareholders"> </A>
<A NAME="toc_di74901_2"> </A>
<BR></FONT><FONT SIZE=2><B>  PRINCIPAL SHAREHOLDERS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following table and accompanying footnotes sets forth, as of March&nbsp;31, 2020, information regarding beneficial ownership of our ordinary shares
by:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> each person, or group of affiliated persons, known by us to beneficially own more than 5%
of our ordinary shares; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> each of our executive officers; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> each of our directors; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> all of our executive officers and directors as a group. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Beneficial
ownership is determined according to the rules of the SEC and generally means that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or
investment power of that security, including free shares that vest within 60&nbsp;days of March&nbsp;31, 2020 and options and warrants that are currently exercisable or exercisable within
60&nbsp;days of March&nbsp;31, 2020. Shares subject to free shares that vest within 60&nbsp;days of March&nbsp;31, 2020 and shares subject to warrants currently exercisable or exercisable
within 60&nbsp;days of March&nbsp;31, 2020 are deemed to be outstanding for computing the percentage ownership of the person
holding these free shares and warrants and the percentage ownership of any group of which the holder is a member, but are not deemed outstanding for computing the percentage of any other person. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Except
as indicated by the footnotes below, we believe, based on the information furnished to us, that the persons named in the table below have sole voting and investment power with respect to all
shares shown that they beneficially own, subject to community property laws where applicable. The information does not necessarily indicate beneficial ownership for any other purpose, including for
purposes of Sections&nbsp;13(d) and 13(g) of the Securities Act. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
calculation of the percentage of beneficial ownership prior to this offering is based on 30,687,750 of our ordinary shares outstanding as of March&nbsp;31, 2020. We have based our calculation of
the percentage of beneficial ownership of our ordinary shares outstanding immediately after the closing of this offering
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares (including ordinary shares in the form of
ADSs), assuming no exercise of the underwriters' option to purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional ordinary shares (which may be in the form of ADSs)
in this offering. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Unless
otherwise indicated, the address of each beneficial owner listed in the table below is c/o Inventiva&nbsp;S.A., 50 rue de Dijon, 21121 Daix, France. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>153</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=157,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=481658,FOLIO='153',FILE='DISK116:[20ZBV1.20ZBV74901]DI74901A.;15',USER='SCAVALI',CD='10-APR-2020;08:45' -->
<A NAME="page_di74901_1_154"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="55pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="45pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="45pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="45pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="45pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=3 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Percentage of shares beneficially owned </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=3 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Percentage of voting power </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Number of<BR>
shares<BR>
beneficially<BR>
owned </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Name of beneficial owner

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Before<BR>
offering </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>After<BR>
offering </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Before<BR>
offering </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>After<BR>
offering </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><I>5% Shareholders:</I></B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fr&eacute;d&eacute;ric Cren</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pierre Broqua</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>BVF Partners&nbsp;L.P.&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Novo Holdings A/S</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Sofinnova Crossover I SLP</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>New Enterprise Associates</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><I>Directors and Executive Officers:</I></B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fr&eacute;d&eacute;ric Cren</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pierre Broqua</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jean Volatier</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Marie-Paule Richard</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pienter-Jan BVBA, represented by Chris Buyse</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Sofinnova Partners represented by Lucy Lu</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CELL+ represented by Annick Schwebig</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Heinz Maeusli</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nawal Ouzren</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All directors and executive officers as a group (11&nbsp;persons)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">*</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Represents
beneficial ownership of less than 1%. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>154</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=158,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=614942,FOLIO='154',FILE='DISK116:[20ZBV1.20ZBV74901]DI74901A.;15',USER='SCAVALI',CD='10-APR-2020;08:45' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_dk74901_1_155"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A NAME="dk74901_description_of_share_capital"> </A>
<A NAME="toc_dk74901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF SHARE CAPITAL    <BR>    </B></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


General  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following description of our share capital summarizes certain provisions of our bylaws. Such summaries do not purport to be complete and are subject to,
and are qualified in their entirety by reference to, all of the provisions of our bylaws as they will be in effect upon the completion of this offering, a copy of which have been filed as an exhibit
to the registration statement of which this prospectus forms&nbsp;a part. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
of March&nbsp;31, 2020, our outstanding share capital consisted of a total of 30,687,750 ordinary shares, with a nominal value of &euro;0.01 per share. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
of March&nbsp;31, 2020, to our knowledge, approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding ordinary shares as of such date were held
by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shareholders of record in the United
States. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under
French law, our bylaws set forth only our issued and outstanding share capital as of the date of the bylaws. Our fully diluted share capital represents all issued and outstanding shares, as well
as all potential shares which may be issued upon exercise of outstanding founder's share warrants (</FONT><FONT SIZE=2><I>bons de souscription de parts de cr&eacute;ateur
d'entreprise</I></FONT><FONT SIZE=2>) and share warrants (</FONT><FONT SIZE=2><I>bons de souscription d'actions</I></FONT><FONT SIZE=2>), as approved by our shareholders and granted by our board of
directors. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Upon
closing of this offering, based on the number of ordinary shares outstanding as of March&nbsp;31, 2020, our outstanding share capital will consist
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares (including
ordinary shares in the form of ADSs), nominal value &euro;0.01 per share (or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares if the
underwriters exercise their option to purchase additional ordinary shares
(which may be in the form of ADSs) in this offering in full). </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>155</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=159,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=669315,FOLIO='155',FILE='DISK116:[20ZBV1.20ZBV74901]DK74901A.;13',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dk74901_1_156"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Reconciliation of the ordinary shares outstanding prior to this offering  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="67pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ordinary shares outstanding at December&nbsp;31, 2016</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10,030,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Number of ordinary shares issued in connection with the exercise of founder's share warrants and share warrants</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>707,900</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Number of ordinary shares issued on February&nbsp;16, 2017 in connection with the share capital increase authorized on February&nbsp;14, 2017</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5,651,240</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Number of ordinary shares issued on March&nbsp;20, 2017 (greenshoe) in connection with the share capital increase authorized on March&nbsp;16,
2017</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>55,337 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ordinary shares outstanding at December&nbsp;31, 2017</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>16,444,477</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Number of ordinary shares issued in connection with the exercise of founder's share warrants and share warrants</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>180,300</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Number of ordinary shares issued in connection with the vesting of free shares that have no exercise price</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>60,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Number of ordinary shares issued on April&nbsp;17, 2018 in connection with the share capital increase authorized on April&nbsp;12, 2017</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5,572,500</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Number of ordinary shares issued in connection with the exercise of founder's share warrants and share warrants</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>27,400</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Number of ordinary shares issued in connection with the vesting of free shares that have no exercise price</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Number of ordinary shares issued in connection with the vesting of free shares that have no exercise price</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>77,500</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Number of ordinary shares issued on September&nbsp;20, 2019 in connection with the share capital increase authorized on September&nbsp;18, 2019</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,159,999</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Number of ordinary shares issued on October&nbsp;2, 2019 in connection with the share capital increase authorized on September&nbsp;30, 2019</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>313,936</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Number of ordinary shares issued in connection with the vesting of free shares that have no exercise price</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>63,300</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Number of ordinary shares issued on February&nbsp;11, 2020 in connection with the share capital increase authorized on February&nbsp;6, 2020</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3,778,338</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ordinary shares outstanding at February&nbsp;11, 2020</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>30,687,750</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


History of Securities Issuances  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>From January&nbsp;1, 2017 through March&nbsp;31, 2020, the following events have changed the number and classes of our issued and outstanding shares. </FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> In February and March 2017, in connection with our initial public offering in France, we
issued an aggregate of 5,706,577 ordinary shares at a purchase price of &euro;8.50 per share. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> On April&nbsp;17, 2018, we issued an aggregate of 5,572,500 ordinary shares in
connection with a private placement at a purchase price of &euro;6.37 per share. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> On September&nbsp;20, 2019 and October&nbsp;2, 2019, we issued an aggregate of
4,473,935 ordinary shares in connection with a private placement at a purchase price of &euro;1.99 per share. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> On February&nbsp;11, 2020, we issued an aggregate of 3,778,338 ordinary shares in
connection with a private placement at a purchase price of &euro;3.97 per share. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> During this period, founder's share warrants (</FONT><FONT SIZE=2><I>bons de souscription
de parts de cr&eacute;ateur d'entreprise</I></FONT><FONT SIZE=2>) and share warrants (</FONT><FONT SIZE=2><I>bons de souscription d'actions</I></FONT><FONT SIZE=2>) were exercised at prices of
(1)&nbsp;with respect to BCE 2013-1 (2013), &euro;0.585 per ordinary share, (2)&nbsp;with respect to BCE 2013-1 (2015) and BSA&nbsp;2013-1, &euro;0.67 per ordinary share.
Pursuant to these exercises, we issued an aggregate of 915,600 ordinary shares. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>156</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=160,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=292708,FOLIO='156',FILE='DISK116:[20ZBV1.20ZBV74901]DK74901A.;13',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dk74901_1_157"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> During this period, we issued an aggregate of 210,800 ordinary shares upon the vesting of
outstanding free shares (</FONT><FONT SIZE=2><I>actions gratuites</I></FONT><FONT SIZE=2>) that had no exercise price. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Key Provisions of Our Bylaws and French Law Affecting our Ordinary Shares  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The description below reflects the terms of our bylaws and summarizes the material rights of holders of our ordinary shares under French law. Please note that
this is only a summary and is not intended to be exhaustive. For further information, please refer to the full text of our bylaws and French law. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Corporate Purpose (Article&nbsp;3 of the bylaws)  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our corporate purpose in France and abroad includes the research and development, production, distribution and marketing, at different stages of development,
with respect to all products, principally pharmaceutical, cosmetic and chemical products, including in the area of animal health. Our company is also engaged in the provision of study, advisory or
commercial services and, more generally, any ancillary services, similar or connected to the activities described hereof, including the leasing of laboratories or offices. Our company may participate,
by any means, directly or indirectly in any operations that may be related to its purpose through the creation of new companies, contribution, subscription or purchase of company securities or rights,
merger or otherwise, creation, acquisition, leasing, management lease of any businesses or establishments. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>More
generally, we are authorized to engage in any financial, commercial, industrial, civil immovable or movable operations related directly or indirectly to the company's purpose or any similar or
related purpose which may facilitate its expansion or growth. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Directors (Articles&nbsp;15 to 22 of the Bylaws)  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Duties of the Board (Article&nbsp;18 of the Bylaws).</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Except for powers given to our shareholders by law and within the limit of the corporate purpose, our board
of directors is responsible for all matters relating to the successful operations of our company and, through its resolutions, governs matters involving the company. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Appointment and Term (Article&nbsp;15 of the Bylaws).</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors must be composed of at least three members, but may not exceed eighteen members,
subject to the dispensation established by law in the event of merger. Directors are appointed, renewed or dismissed by the ordinary general meeting. The term of a director is three years, and
directors may be re-elected at our annual ordinary share meetings; however, a director over the age of 70 may not be appointed if such appointment would result in the number of directors over the age
of 70 constituting more than one-third of the board. An employee can only be appointed as a director if his or her employment contract corresponds to an actual job. The number of directors who are
also our employees cannot exceed one-third of the board. Directors need not to be shareholders of our company and may be natural persons or legal entities except for the chairman of the board who must
be a natural person. Legal entities appointed to the board must designate a permanent representative. If a director dies or resigns between annual meetings, the
board may appoint a temporary director to fill the vacancy, subject to ratification at the next ordinary general meeting, or, if such vacancy results in a number of directors below three, the board
must call an ordinary general meeting to fill the vacancy. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Organization (Article&nbsp;16 of the Bylaws).</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The board must elect a chairman from among the board members. The chairman must be a natural person, age 65 or
younger, and may be removed by the board at any time. The board may also elect a natural person as vice president to preside in the chairman's absence and may designate up to two non-voting board
observers. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Deliberations (Article&nbsp;17 of the Bylaws).</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;At least half of the number of directors in office must be present to constitute a quorum. Decisions are made by a
majority of the directors present or represented and, if there is a tie, the vote of the chairman will carry the decision. Meetings may be held as often as required; however, the chairman is required
to call a meeting with a determined agenda upon the request of at least one-third of the directors if the board has not met for more than three months. French law and our charter </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>157</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=161,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=86884,FOLIO='157',FILE='DISK116:[20ZBV1.20ZBV74901]DK74901A.;13',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dk74901_1_158"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>and
bylaws allow directors to attend meetings in person or, to the extent permitted by applicable law and with specified exceptions in our bylaws, by videoconference or other telecommunications
arrangements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Directors' Voting Powers on Proposal, Arrangement or Contract in Which Any Director is Materially Interested (Article&nbsp;22 of the Bylaws).</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Under French law,
any agreement entered into, directly or through an intermediary, between us and any director that is not entered into in the ordinary course of our business and upon standard market terms is subject
to the prior authorization of the board of directors (it being specified that the interested director cannot vote on such decision). The same provision applies to agreements between us and another
company, except where such company is one of our wholly owned subsidiaries, if one of our directors is the owner or a general partner, manager, director, general manager or member of the executive or
supervisory board of the other company, as well as to agreements in which one of our directors has an indirect interest. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Directors' Compensation (Article&nbsp;20 of the Bylaws).</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Directors' compensation for their functions is determined at the annual ordinary general meeting. The
board of directors may also grant exceptional compensation for missions or offices conferred upon directors subject to the circumstances and conditions provided for by law. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><I> Board of Directors' Borrowing Powers (Article&nbsp;18 of the Bylaws).</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;There are currently no limits imposed by our bylaws on the amounts of loans or borrowings
that the board of directors may approve. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Rights, Preferences and Restrictions Attaching to Ordinary Shares (Articles&nbsp;11, 14, 28, 31 and 32
of the Bylaws)  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Dividends.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We may only distribute dividends out of our distributable profits, plus any amounts held in our reserves that the shareholders decide to make available
for distribution, other than those reserves that are specifically required by law. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>"Distributable Profits"</I></FONT><FONT SIZE=2> consist of our statutory net profit in each fiscal year, calculated in accordance with accounting standards applicable in France,
as increased or reduced by any profit or loss carried forward from prior years, less any contributions to the reserve accounts pursuant to French law. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Legal Reserve.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to French law, we must allocate 5% of our statutory net profit for each year to our legal reserve fund before dividends may be paid with
respect to that year. Funds must be allocated until the amount in the legal reserve is equal to 10% of the aggregate par value of the issued and outstanding share capital. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><I> Approval of Dividends.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to French law, our board of directors may propose a dividend for approval by the shareholders at the annual ordinary general
meeting. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Upon
recommendation of our board of directors, our shareholders may decide to allocate all or part of any distributable profits to special or general reserves, to carry them forward to the next fiscal
year as retained earnings or to allocate them to the shareholders as dividends. However, dividends may not be distributed when our net assets are or would become as a result of such distribution lower
than the amount of the share capital plus the amount of the legal reserves which, under French law, may not be distributed to shareholders. The
amount of our share capital plus the amount of our legal reserves which may not be distributed was equal to &euro;307,481.12 at December&nbsp;31, 2019. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Our
board of directors may distribute interim dividends after the end of the fiscal year but before the approval of the financial statements for the relevant fiscal year when the interim statement of
financial position, established during such year and certified by an auditor, reflects that we have earned distributable profits since the close of the last financial year, after recognizing the
necessary depreciation and provisions and after deducting prior losses, if any, and the sums to be allocated to reserves, as required by law or the bylaws, and including any retained earnings. The
amount of such interim dividends may not exceed the amount of the profit so defined. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>158</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=162,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=270272,FOLIO='158',FILE='DISK116:[20ZBV1.20ZBV74901]DK74901A.;13',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dk74901_1_159"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Distribution of Dividends.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Dividends are distributed to shareholders pro rata according to their respective holdings of shares. In the case of interim dividends,
distributions are made to shareholders on the date set by our board of directors during the meeting in which the distribution of interim dividends is approved. The actual dividend payment date is
decided by the shareholders at an ordinary general shareholders' meeting or by our board of directors in the absence of such a decision by the shareholders. Shareholders that own shares on the actual
payment date are entitled to the dividend. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Shareholders
may be granted an option to receive dividends in cash or in shares, in accordance with legal conditions. The conditions for payment of dividends in cash shall be set at the shareholders'
meeting or, failing this, by the board of directors. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Timing of Payment.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to French law, dividends must be paid within a maximum of nine months after the close of the relevant fiscal year, unless extended by
court order. Dividends not claimed within five years after the payment date shall be deemed to expire and revert to the French state. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><I> Voting Rights.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Upon the closing of the offering, we will only have ordinary shares outstanding. Each share shall entitle its holder to vote and be represented in
the shareholders' meetings in accordance with the provisions of French law and of our bylaws. Ownership of one share implies, ipso jure, adherence to our bylaws and the decisions of the shareholders'
meeting. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
general, each shareholder is entitled to one vote per share at any general shareholders' meeting. Pursuant to our bylaws, however, a double voting right is attached to each registered ordinary
share which is held in the name of the same shareholder for at least two years. However, under French law, ordinary bearer shares in the form of ADSs are not eligible for double voting rights.
Purchasers of ADSs or ordinary shares in this offering, in the open market following the completion of this offering or in subsequent offerings will be unlikely to meet the requirements to have double
voting rights attach to any ordinary shares held by them. To our knowledge, double voting rights only attach to the 5,704,816 ordinary shares held by the Cren Family (composed of
Fr&eacute;d&eacute;ric Cren, our Chief Executive Officer and Roberta Becherucci, married name Cren and their minor child), and to the 3,882,500 ordinary shares held by Pierre Broqua,
our Deputy Chief Executive Officer and Chief Scientific Officer, as of March&nbsp;31, 2020. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under
French law, treasury shares or shares held by entities controlled by us are not entitled to voting rights and do not count for quorum purposes. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><I> Rights to Share in Our Profit.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Each share entitles its holder to a portion of the corporate profits and assets proportional to the amount of share capital
represented thereby. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Rights to Share in the Surplus in the Event of Liquidation.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If we are liquidated, any assets remaining after payment of the debts, liquidation expenses and all of
the remaining obligations will first be used to repay in full the par value of our shares. Any surplus will be distributed pro rata among shareholders in proportion to the number of shares
respectively held by them, taking into account, where applicable, of the rights attached to shares of different classes. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><I> Repurchase and Redemption of Shares.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Under French law, we may acquire our own shares. Such acquisition may be challenged on the ground of market abuse regulations.
However, Market Abuse Regulation (EU) No.&nbsp;596/2014 of April&nbsp;16, 2014, or MAR, provides for safe harbor exemptions when the acquisition is made for one of the following
purposes:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> to decrease our share capital, provided that such a decision is not driven by losses and
that a purchase offer is made to all shareholders on a pro rata basis, with the approval of the shareholders at an extraordinary general meeting; in this case, the shares repurchased must be cancelled
within one month from the expiry of the purchase offer; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> to meet obligations arising from debt securities that are exchangeable into equity
instruments; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>159</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=163,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=874106,FOLIO='159',FILE='DISK116:[20ZBV1.20ZBV74901]DK74901A.;13',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dk74901_1_160"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> to provide shares for distribution to employees or managers under a profit-sharing, free
share or share option plan; in this case the shares repurchased must be distributed within 12&nbsp;months from their repurchase failing which they must be cancelled; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we benefit from a simple exemption when the acquisition is made under a liquidity
contract complying with the general regulations of, and market practices accepted by the French Financial Markets Authority, or the AMF. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>All
other purposes, and especially share buy-backs made for external growth operations in pursuance of Article&nbsp;L. 225-209 of the French Commercial Code, while not forbidden, must be pursued in
strict compliance of market manipulation and insider dealing rules. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under
MAR and in accordance with the general regulations (</FONT><FONT SIZE=2><I>r&eacute;glement g&eacute;n&eacute;ral</I></FONT><FONT SIZE=2>) of the AMF, or the General
Regulations, a corporation shall report to the competent authority of the trading value on which the shares have been admitted to trading or are traded, no later than by the end of the seventh daily
market session following the date of the execution of the transaction, all the transactions relating to the buy-back program, in a detailed form and in an aggregated form. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>No
such repurchase of shares may result in us holding, directly or through a person acting on our behalf, more than 10% of our issued share capital. Shares repurchased by us continue to be deemed
"issued" under French law but are not entitled to dividends or voting rights so long as we hold them directly or indirectly, and we may not exercise the pre-emptive rights attached to them. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Sinking Fund Provisions.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our bylaws do not provide for any sinking fund provisions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Liability to Further Capital Calls.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Shareholders are liable for corporate liabilities only up to the par value of the shares they hold; they are not liable to
further capital calls. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Requirements for Holdings Exceeding certain percentages.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;None, except as described below under the section of this prospectus titled "Form, holding and transfer of
shares (Articles&nbsp;10 and 13 of the bylaws)&nbsp;&#151; ownership of ordinary shares and ADSs by non-French persons." </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Actions Necessary to Modify Shareholders' Rights.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Shareholders' rights may be modified as allowed by French law. Only the extraordinary shareholders' meeting is
authorized to amend any and all provisions of our bylaws. It may not, however, increase shareholder commitments without the prior approval of each shareholder. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Special Voting Rights of Warrant Holders.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Under French law, the holders of warrants of the same class (i.e.,&nbsp;warrants that were issued at the same time and
with the same rights), including founder's share warrants (</FONT><FONT SIZE=2><I>bons de souscription de parts de cr&eacute;ateur d'entreprise</I></FONT><FONT SIZE=2>) and share warrants
(</FONT><FONT SIZE=2><I>bons de souscription d'actions</I></FONT><FONT SIZE=2>), are entitled to vote as a separate class at a general meeting of that class of warrant holders under certain
circumstances, principally in connection with any proposed modification of the terms and conditions of the class of warrants or any proposed issuance of preferred shares or any modification of the
rights of any outstanding class or series of preferred shares. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Rules for Admission to and Calling Annual Shareholders' Meetings and Extraordinary Shareholders' Meetings
(Section&nbsp;IV of the Bylaws)  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Access to, participation in and voting rights at shareholders' meetings.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Shareholders' meetings are composed of all shareholders, regardless of the number of shares
they hold. Each shareholder has the right to attend the meetings and participate in the discussions (1)&nbsp;personally; (2)&nbsp;by granting proxy to any individual or legal entity of his
choosing; (3)&nbsp;by sending a proxy to the company without indication of the mandate; (4)&nbsp;by voting by correspondence; or (5)&nbsp;at the option of the board of directors at the time the
meeting is called, by videoconference or another means of telecommunication, including internet, in accordance with applicable laws that allow identification. The board of directors organizes, in
accordance with legal and regulatory requirements, the participation and vote of these shareholders at the meeting, assuring, in particular, the effectiveness of the means of identification. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>160</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=164,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=925474,FOLIO='160',FILE='DISK116:[20ZBV1.20ZBV74901]DK74901A.;13',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dk74901_1_161"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Participation
in shareholders' general meetings, in any form whatsoever, is subject to registration or registration of shares two trading days prior to the date of the relevant general meeting under
the conditions provided by applicable laws. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
final date for returning voting ballots by correspondence is set by the board of directors and disclosed in the notice of meeting published in the French Journal of Mandatory Statutory Notices, or
BALO </FONT><FONT SIZE=2><I>(Bulletin des Annonces L&eacute;gales Obligatoires)</I></FONT><FONT SIZE=2>. This date cannot be earlier than three days prior to the meeting. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>A
shareholder who has voted by correspondence will no longer be able to participate directly in the meeting or to be represented. In the case of returning the proxy form and the voting by
correspondence form, the proxy form is taken into account, subject to the votes cast in the voting by correspondence form. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A
shareholder may be represented at meetings by any individual or legal entity by means of a proxy form which we send to such shareholder either at the shareholder's request or at our initiative. A
shareholder's request for a proxy form must be received at the registered office at least five days before the date of the meeting. The proxy is only valid for a single meeting or for successive
meetings convened with the same agenda. It can also be granted for two meetings, one ordinary, and the other extraordinary, held on the same day or within a period of 15&nbsp;days. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>A
shareholder may vote by correspondence by means of a voting form, which we send to such shareholder either at the shareholder's request or at our initiative, or which we include in an appendix to a
proxy voting form under the conditions provided for by current laws and requirements. A shareholder's request for a voting form must be received at the registered office at least six days before the
date of the meeting. The voting form is also available on our website at least 21&nbsp;days before the date of the meeting. The voting form must be recorded by us three days prior to the
shareholders' meeting, in order to be taken into consideration. The voting by correspondence form addressed by a shareholder is only valid for a single meeting or for successive meetings convened with
the same agenda. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To
better understand the voting rights of the ADSs, you should carefully read the section in this prospectus titled "Description of American Depositary Shares&nbsp;&#151; Voting rights." </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Notice of Annual Shareholders' Meetings.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Shareholders' meetings are convened by our board of directors, or, failing that, by the statutory auditors, or by a court
appointed agent or liquidator in certain circumstances. Meetings are held at our registered offices or at any other location indicated in the meeting announcement (</FONT><FONT SIZE=2><I>avis de
r&eacute;union</I></FONT><FONT SIZE=2>). A meeting announcement is published in the BALO at least 35&nbsp;days prior to a meeting, as well as on our website at least 21&nbsp;days prior to
the meeting. In addition to the particulars relative to the company, it indicates, notably, the meeting's agenda and the draft resolutions that will be presented. The requests for recording of issues
or draft resolutions on the agenda must be addressed to the company under the conditions provided for in the current legislation. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Subject
to special legal provisions, the convening notice (</FONT><FONT SIZE=2><I>avis de convocation</I></FONT><FONT SIZE=2>) is sent out at least 15&nbsp;days prior to the date of the meeting, by
means of a notice inserted both in a legal announcement bulletin of the registered office department and in the BALO. Further, the holders of registered shares for at least a month at the time of the
latest of the insertions of the convening notice shall be summoned individually, by regular letter (or by registered letter if they request it and include an advance of expenses) sent to their last
known address. This notice may also be transmitted by electronic means of telecommunication, in lieu of any such mailing, to any shareholder requesting it beforehand by registered letter with
acknowledgment of receipt in accordance with legal and regulatory requirements, specifying his e-mail address. The latter may at any time expressly request by registered letter to the company with
acknowledgment of receipt that the aforementioned means of telecommunication should be replaced in the future by a mailing. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
convening notice must also indicate the conditions under which the shareholders may vote by correspondence and the places and conditions in which they can obtain voting forms by mail. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>161</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=165,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=458384,FOLIO='161',FILE='DISK116:[20ZBV1.20ZBV74901]DK74901A.;13',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dk74901_1_162"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
convening notice may be addressed, where appropriate, with a proxy form and a voting by correspondence form, under the conditions specified in our bylaws, or with a voting by correspondence form
alone, under the conditions specified in our bylaws. When the shareholders' meeting cannot deliberate due to the lack of the required quorum, the second meeting must be called at least ten days in
advance in the same manner as used for the first notice. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Agenda and Conduct of Annual Shareholders' Meetings.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The agenda of the shareholders' meeting shall appear in the convening notice of the meeting and is set by the
author of the notice. The shareholders' meeting may only deliberate on the items on the agenda except for the removal of directors and the appointment of their successors which may be put to vote by
any shareholder during any shareholders' meeting. Pursuant to French law and our current share capital, one or more shareholders representing 5% of our share capital, acting in accordance with legal
requirements and within applicable time limits, may request the inclusion of items or proposed resolutions on the agenda. Such request must be received at the latest on the
25<SUP>th</SUP>&nbsp;day preceding the date of the shareholders' meeting, and in any event no later than the 20<SUP>th</SUP>&nbsp;day following the date of the shareholders' meeting
announcement. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Shareholders'
meetings shall be chaired by the Chairman of the board of directors or, in his or her absence, by a Deputy Chairman or by a director elected for this purpose. Failing that, the meeting
itself shall elect a Chairman. Vote counting shall be performed by the two members of the meeting who are present and accept such duties, who represent, either on their own behalf or as proxies, the
greatest number of votes. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Ordinary Shareholders' Meeting.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Ordinary shareholders' meetings are those meetings called to make any and all decisions that do not amend our bylaws. An ordinary
meeting shall be convened at least once a year within six months of the end of each fiscal year in order to approve the annual accounts for the relevant fiscal year or, in case of postponement, within
the period established by court order. Upon first notice, the meeting may validly deliberate only if the shareholders present or represented by proxy or voting by mail represent at least one-fifth of
the shares entitled to vote. Upon second notice, no quorum is required. Decisions are made by a majority of the votes held (of the votes cast, as from our general shareholders' meeting convened to
vote on the financial statements for the year ended December&nbsp;31, 2019) by the shareholders present, or represented by proxy, or voting by mail. Abstentions will not be taken into account in the
votes cast. In addition, pursuant to an AMF recommendation dated 15&nbsp;June 2015, French listed companies may be required to conduct a consultation of the ordinary shareholders meeting prior to
the disposal of the majority of their assets, under certain circumstances. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Extraordinary shareholders' meeting.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our bylaws may only be amended by approval at an extraordinary shareholders' meeting. Our bylaws may not, however, be amended
to increase shareholder commitments without the approval of each shareholder. Subject to the legal provisions governing share capital increases from reserves, profits or share premiums, the
resolutions of the extraordinary meeting shall be valid only if the shareholders present, represented by proxy or voting by mail represent at least one-fourth of all shares entitled to vote upon first
notice, or one-fifth upon second notice. If the latter quorum is not reached, the second meeting may be postponed to a date no later than two months after the date for which it was initially called.
Decisions are made by a two-thirds majority of the votes held (of the votes cast, as from our general shareholders' meeting convened to vote on the financial statements for the year ended
December&nbsp;31, 2019) by the shareholders present, represented by proxy, or voting by mail. Abstentions will not be taken into account in the votes cast. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Temporary measures for Annual Shareholders Meetings and Board of Directors due to COVID-19 crisis  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On March&nbsp;25, 2020, the French government adopted the ordinance No.&nbsp;2021-321 adapting the rules governing meetings and deliberations of assemblies
and governing bodies of legal entities held until July&nbsp;31, 2020 due to the COVID-19 pandemic. The ordinance provides the possibility of convening board of directors remotely for all decisions,
including the closing of accounts, which previously required a physical meeting. In addition, the ordinance provides two options for holding general meetings of shareholders: behind closed doors or by
means of a teleconference or audio-visual conference call. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>162</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=166,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=761214,FOLIO='162',FILE='DISK116:[20ZBV1.20ZBV74901]DK74901A.;13',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dk74901_1_163"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>By
decision of the board of directors, the general meeting of shareholders may be held behind closed doors ie., without the shareholders or their proxies (and any other person having the right to
attend the meeting such as the statutory auditors and the employee representatives) being physically present. The possibility of holding a meeting behind closed doors requires that the meeting be
convened in a place that, on the date of the meeting announcement, the convening notice or on the date of the meeting, is subject to an administrative measure restricting or prohibiting collective
gatherings for health reasons, even if this measure is ultimately no longer in effect on the date of the meeting. As of the day of this filing, measures restricting gatherings (decree
No.&nbsp;2020-293 of March&nbsp;23, 2020, amended by decree No.&nbsp;2020-344 of March&nbsp;27, 2020, prohibits all travel except in exceptional circumstances and any meeting attended by more
than 100 people at the same time in a closed or open environment on the territory of the French Republic) are applicable until April&nbsp;15, 2020. Shareholders will only be able to vote remotely
and prior to the general meeting of shareholders by the usual means available to date, ie., vote by correspondence, blank proxy or Internet voting. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
ordinance provides that shareholders (and all the persons who may attend the general meeting of shareholders) may participate in the meeting by means of a teleconference or audio-visual conference
call if this conference allows for the identification of the participants, transmits at least the voice of the participants and allows the continuous and simultaneous retransmission of the debates. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Provisions having the effect of delaying, deferring or preventing a change in control of our company  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Provisions contained in our bylaws and French corporate law, could make it more difficult for a third party to acquire us, even if doing so might be beneficial
to our shareholders. These provisions include the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> under French law, the owner of 90% of the share capital and voting rights of a public
company listed on a regulated market in a Member State of the European Union or in a state party to the EEA Agreement, including from the main French Stock Exchange, has the right to force out
minority shareholders following a tender offer made to all shareholders; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> under French law, a non-French resident must file&nbsp;a declaration for statistical
purposes with the Bank of France (</FONT><FONT SIZE=2><I>Banque de France</I></FONT><FONT SIZE=2>) within twenty working days following the date of certain direct foreign investments in us, including
any purchase of our ADSs. In particular, such filings are required in connection with investments exceeding &euro;15,000,000 that lead to the acquisition of at least 10% of our company's
share capital or voting rights or cross such 10% threshold; see "Limitations affecting shareholders of a French company"; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> under French law, certain investments in a French company relating to certain strategic
industries by individuals or entities are subject to prior authorization of the Ministry of Economy pursuant to Law n&deg;2019-486 (and as from April&nbsp;1<SUP>st</SUP>, 2020 pursuant to
the decree n&deg;2019-1590); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a merger (i.e.,&nbsp;in a French law context, a share for share exchange following
which our company would be dissolved into the acquiring entity and our shareholders would become shareholders of the acquiring entity) of our company into a company incorporated in the European Union
would require the approval of our board of directors as well as a two-thirds majority of the votes held (of the votes cast, as from our general shareholders' meeting convened to vote on the financial
statements for the year ended December&nbsp;31, 2019) by the shareholders present, represented by proxy or voting by mail at the relevant meeting; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a merger of our company into a company incorporated outside of the European Union would
require 100% of our shareholders to approve it; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> under French law, a cash merger is treated as a share purchase and would require the
consent of each participating shareholder; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>163</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=167,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=27072,FOLIO='163',FILE='DISK116:[20ZBV1.20ZBV74901]DK74901A.;13',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dk74901_1_164"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our shareholders have granted and may grant in the future our board of directors broad
authorizations to increase our share capital or to issue additional ordinary shares or other securities, such as warrants, to our shareholders, the public or qualified investors, including as a
possible defense following the launching of a tender offer for our shares; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our shareholders have preferential subscription rights on a pro rata basis on the
issuance by us of any additional securities for cash or a set-off of cash debts, which rights may only be waived by the extraordinary general meeting (by a two-thirds majority vote) of our
shareholders or on an individual basis by each shareholder; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our board of directors has the right to appoint directors to fill a vacancy created by
the resignation or death of a director, subject to the approval by the shareholders of such appointment at the next shareholders' meeting, which prevents shareholders from having the sole right to
fill vacancies on our board of directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our board of directors can be convened by our chairman or our managing director, if any,
or, when no board meeting has been held for more than two consecutive months, by directors representing at least one third of the total number of directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our board of directors meetings can only be regularly held if at least half of the
directors attend either physically or by way of videoconference or teleconference enabling the directors' identification and ensuring their effective participation in the board's decisions; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our shares are nominative or bearer, if the legislation so permits, according to the
shareholder's choice; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> approval of at least a majority of the votes held (of the votes cast, as from our general
shareholders' meeting convened to vote on the financial statements for the year ended December&nbsp;31, 2019) by shareholders present, represented by a proxy, or voting by mail at the relevant
ordinary shareholders' general meeting is required to remove directors with or without cause; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> advance notice is required for nominations to the board of directors or for proposing
matters to be acted upon at a shareholders' meeting, except that a vote to remove and replace a director can be proposed at any shareholders' meeting without notice; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our bylaws can be amended in accordance with applicable laws; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the crossing of certain thresholds has to be disclosed and can impose certain
obligations; see "Declaration of crossing of ownership thresholds (Article&nbsp;11 of the bylaws)"; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> transfers of shares shall comply with applicable insider trading rules and regulations,
and in particular with MAR; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> pursuant to French law, the sections of the bylaws relating to the number of directors
and election and removal of a director from office may only be modified by a resolution adopted by at least a two-third majority vote of our shareholders present, represented by a proxy or voting by
mail at the meeting. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Declaration of Crossing of Ownership Thresholds (Article&nbsp;11 of the Bylaws)  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Set forth below is a summary of certain provisions of the French Commercial Code applicable to us. This summary is not intended to be a complete description of
applicable rules under French law. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Any
individual or legal entity referred to in Articles&nbsp;L. 233-7, L. 233-9 and L. 223-10 of the French Commercial Code coming to directly or indirectly own, or cease to own, alone or in concert,
a number of shares representing a fraction of the company's capital or voting rights greater or equal to 5%, 10%, 15%, 20%, 25%, 30%, 33.33%, 50%, 66.66%, 90% and 95% shall inform the company as well
as the AMF of the total number of shares and voting rights and of securities giving access to the capital or voting rights that it owns immediately or over time within a period of four trading days
from the crossing of the said holding thresholds. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>164</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=168,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=800201,FOLIO='164',FILE='DISK116:[20ZBV1.20ZBV74901]DK74901A.;13',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dk74901_1_165"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This
obligation applies when crossing each of the above-mentioned thresholds in a downward direction. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
case of failure to declare shares or voting rights exceeding the fraction that should have been declared, such shares shall be deprived of voting rights at General Meetings of Shareholders for any
meeting that would be held until the expiry of a period of two years from the date of regularization of the notification in accordance with
Article&nbsp;L. 233-14 of the French Commercial Code. Additional sanctions may apply in particular pursuant to Article&nbsp;L.621-15 of the French Monetary and Financial Code. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, any shareholder crossing, alone or acting in concert, the 10%, 15%, 20% or 25% threshold shall file&nbsp;a declaration with the AMF pursuant to which it shall expose its intention over
the following six months, including notably whether it intends to continue acquiring shares of the company, it intends to acquire control over the company, its intended strategy for the company. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Further,
and subject to certain exemptions, any shareholder crossing, alone or acting in concert, the 30% threshold shall file&nbsp;a mandatory public tender offer with the AMF. Also, any
shareholder holding directly or indirectly a number between 30% and 50% of the capital or voting rights and who, in less than 12 consecutive months, increases his/her/its holding of capital or voting
rights by at least 1% of a company's capital or voting rights, shall file&nbsp;a mandatory public tender offer. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition to the thresholds provided for by applicable laws and regulations, any person who comes to hold or ceases to hold, acting alone or in concert within the meaning of Article&nbsp;L.233-10
of the French Commercial Code, directly or indirectly, a number of shares representing at least 2% of the share capital or voting rights, including beyond the reporting thresholds provided for by laws
and regulations, must inform the company of the total number of shares and voting rights of the company that such person holds, by registered letter with return receipt requested sent to the company's
registered office within four trading days after crossing such threshold(s). Such person shall also indicate the number of securities giving access to the capital and the voting right potentially
attached thereto, as well as any other information provided for by law. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
notification shall be repeated in the conditions stated above each time an additional fraction of 2% of the share capital or voting rights is crossed upward or downward. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
the event of failure to comply with the notification requirements described above, shares exceeding the fraction that should have been notified will be deprived of voting rights at shareholders'
meetings if, at such meetings, the notification failure has been recorded and if one or more shareholders jointly holding at least 5% of the share capital so request. Loss of voting rights shall be
applicable in all shareholders' meetings that would be held up until two years following proper notification. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Changes in Share Capital (Article&nbsp;7 of the Bylaws)  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Increases in share capital.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;As the bylaws do not provide any specific stipulations, the share capital may be increased, decreased or amortized by any methods or
means authorized by law. Pursuant to French law, our share capital may be increased only with shareholders' approval at an extraordinary general shareholders' meeting following the recommendation of
our board of directors. The shareholders may delegate to our board of directors either the authority (</FONT><FONT SIZE=2><I>d&eacute;l&eacute;gation de
comp&eacute;tence</I></FONT><FONT SIZE=2>) or the power (</FONT><FONT SIZE=2><I>d&eacute;l&eacute;gation de pouvoir</I></FONT><FONT SIZE=2>) to carry out any increase in share
capital. If shareholders delegate authority to the board of directors at an extraordinary general meeting to decide a capital increase (</FONT><FONT SIZE=2><I>d&eacute;l&eacute;gation
de comp&eacute;tence</I></FONT><FONT SIZE=2>), the delegation determines the period (26&nbsp;months maximum) during which the board of directors may decide to carry out the capital increase
and the overall threshold of the capital increase. If shareholders delegate power to the board of directors at an extraordinary general meeting to carry out a capital increase
(</FONT><FONT SIZE=2><I>d&eacute;l&eacute;gation de pouvoir</I></FONT><FONT SIZE=2>) already decided by the extraordinary general meeting, the board of directors is granted the power to
determine the terms and conditions of the capital increase within the limits set forth by the extraordinary general meeting. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>165</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=169,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=205565,FOLIO='165',FILE='DISK116:[20ZBV1.20ZBV74901]DK74901A.;13',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dk74901_1_166"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Increases
in our share capital may be effected by:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> issuing additional shares; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> increasing the par value of existing shares; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> creating a new class of equity securities; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> exercising the rights attached to securities giving access to the share capital. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Increases
in share capital by issuing additional securities may be effected through one or a combination of the
following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> in consideration for cash; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> in consideration for assets contributed in kind; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> through an exchange offer; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> by conversion of previously issued debt instruments; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> by capitalization of profits, reserves or share premium; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> subject to certain conditions, by way of offset against debt incurred by us. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Decisions
to increase the share capital through the capitalization of reserves, profits and/or share premium require shareholders' approval at an extraordinary general shareholders' meeting, acting
under the quorum and majority requirements applicable to ordinary shareholders' meetings. Increases effected by an increase in the par value of shares require unanimous approval of the shareholders,
unless effected by capitalization of reserves, profits or
share premium. All other capital increases require shareholders' approval at an extraordinary general shareholders' meeting acting under the regular quorum and majority requirements for such meetings. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Reduction in Share Capital.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to French law, any reduction in our share capital requires shareholders' approval at an extraordinary general shareholders'
meeting following the recommendation of our board of directors. The share capital may be reduced either by decreasing the par value of the outstanding shares or by reducing the number of outstanding
shares. The number of outstanding shares may be reduced by the repurchase and cancellation of shares. Holders of each class of shares must be treated equally unless each affected shareholder agrees
otherwise. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Preferential Subscription Right.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;According to French law, if we issue additional securities for cash, current shareholders will have preferential subscription
rights to these securities on a pro rata basis. Preferential subscription rights entitle the individual or entity that holds them to subscribe pro rata based on the number of shares held by them to
the issuance of any securities increasing, or that may result in an increase of, our share capital by means of a cash payment or a set-off of cash debts. The preferential subscription rights are
transferable during the subscription period relating to a particular offering, such period starting two days prior to the opening of the subscription period and ending two days prior to the closing of
the subscription period. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
preferential subscription rights with respect to any particular offering may be waived at an extraordinary general meeting by a two-thirds vote of our shareholders or individually by each
shareholder. Our board of directors and our independent auditors are required by French law to present reports to the shareholders' meeting that specifically address any proposal to waive the
preferential subscription rights. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
current shareholders have waived their preferential subscription rights with respect to this offering. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
the future, to the extent permitted under French law, we may seek shareholder approval to waive preferential subscription rights at an extraordinary general shareholders' meeting in order to
authorize the board of directors to issue additional shares and/or other securities convertible or exchangeable into shares. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>166</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=170,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=842653,FOLIO='166',FILE='DISK116:[20ZBV1.20ZBV74901]DK74901A.;13',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dk74901_1_167"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Form, Holding and Transfer of Shares (Articles&nbsp;10 and 13 of the Bylaws)  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Form of shares.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The shares are held in registered form, until their full payment. When they are fully paid up, they may be in registered form or bearer, at the
option of the shareholders. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Further,
in accordance with applicable laws, we may request at any time from the central depository responsible for holding our shares, or directly to one or several intermediaries listed in
Article&nbsp;L. 211-3 of the French Monetary and Financial Code, information regarding the owners of our ordinary shares in accordance with Article&nbsp;L. 228-2 of the French Commercial Code. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Holding of shares.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In accordance with French law concerning the "dematerialization" of securities, the ownership rights of shareholders are represented by book
entries instead of share certificates. Shares issued are registered in individual accounts opened and maintained by us or any authorized intermediary, in the name of each shareholder and kept
according to the terms and conditions laid down by the legal and regulatory provisions. Each shareholder's account shows the name of the relevant shareholder and number of shares held. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><I> Ownership of ordinary shares and ADSs by non-French persons.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Neither French law nor our bylaws limit the right of non-residents of France or non-French persons to
own or, where applicable, to vote our securities. However, non-French residents must file&nbsp;a declaration for statistical purposes with the Bank of France (</FONT><FONT SIZE=2><I>Banque de
France</I></FONT><FONT SIZE=2>) within twenty working days following the date of certain direct foreign investments in us, including any purchase of our ADSs. In particular, such filings are required
in connection with investments exceeding &euro;15,000,000 that lead to the acquisition of at least 10% of our company's share capital or voting rights or cross such 10% threshold. Violation
of this filing requirement may be sanctioned by five years of imprisonment and a fine up to twice the amount of the relevant investment. This amount may be increased fivefold if the violation is made
by a legal entity. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Assignment and transfer of shares.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Shares are freely negotiable, subject to applicable legal and regulatory provisions. French law notably provides for standstill
obligations and prohibition of insider trading. They are registered in a share account and transferred by means of a transfer order from account to account. We must receive notice of any transfer for
it to be validly registered in our accounts. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Registration Rights Agreement  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Certain holders of our ordinary shares who hold their shares in the form of ADSs will initially be entitled to certain rights with respect to registration of
such ADSs under the Securities Act. These ADSs are referred to as registrable securities. The holders of these registrable securities possess demand registration rights pursuant to the terms of our
registration rights agreement, dated September&nbsp;18, 2019. The registration of ADSs pursuant to the exercise of the demand registration rights would enable the holders to trade these ADSs without
restriction under the Securities Act when the applicable registration statement is declared effective. At any time beginning 90&nbsp;days after the completion of this offering the holders of at
least 50% of the registrable securities may request that we register all or a portion of their ADSs. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
of the completion of this offering, there would have been an aggregate of 4,473,935 registrable securities that were entitled to these demand registration rights. We will pay the registration
expenses, other than underwriting discounts and selling commissions, of the ADSs registered pursuant to the demand registration rights. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Generally,
in an underwritten offering, the managing underwriter, if any, has the right, subject to specified conditions, to limit the number of shares the holders may include. The demand rights
described below will expire no later than five years after the completion of this offering, the date New Enterprise Associates no longer owns any registrable securities or with respect to any
particular holder, at such time that such holder can sell its shares under Rule&nbsp;144, or another exemption, of the Securities Act during any three-month period. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Securities Exercisable for Ordinary Shares  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Equity Incentives  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>See the section of this prospectus titled "Management&nbsp;&#151; Equity Incentives" for a description of securities granted by our board of directors
to our founders, directors, executive officers, employees and other service providers. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>167</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=171,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=559341,FOLIO='167',FILE='DISK116:[20ZBV1.20ZBV74901]DK74901A.;13',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_dm74901_1_168"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Differences in Corporate Law  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are a </FONT><FONT SIZE=2><I>soci&eacute;t&eacute; anonyme</I></FONT><FONT SIZE=2>, or&nbsp;S.A., incorporated under the laws of France.
The laws applicable to French </FONT><FONT SIZE=2><I>soci&eacute;t&eacute;s anonymes</I></FONT><FONT SIZE=2> differ from laws applicable to U.S. corporations and their shareholders. The
following discussion summarizes material differences between the provisions of the rights of holders of our ordinary shares and the rights of holders of the common shares of a typical corporation
incorporated under the laws of the state of Delaware, which result from differences in governing documents and the laws of France and Delaware. For a more complete discussion, please refer to the
Delaware General Corporation Law, French law (including the French Commercial Code) and our bylaws. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="126pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="38%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="38%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>France </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Delaware </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Number of Directors</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Under French law, a </FONT><FONT SIZE=2><I>soci&eacute;t&eacute; anonyme</I></FONT><FONT SIZE=2> must have at least three and may have up to 18 directors. The number of directors is fixed by or in the
manner provided in the bylaws. The number of directors of each gender may not be less than 40%. Any appointment made in violation of this limit that is not remedied will be null and void.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Under Delaware law, a corporation must have at least one director and the number of directors shall be fixed by or in the manner provided in the bylaws.</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Director Qualifications</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Under French law, a corporation may prescribe qualifications for directors under its bylaws. In addition, under French law,
members of a board of directors of a corporation may be legal entities, and such legal entities may designate an individual to represent them and to act on their behalf at meetings of the board of directors.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Under Delaware law, a corporation may prescribe qualifications for directors under its certificate of incorporation or
bylaws.</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Removal of Directors</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Under French law, directors may be removed from office, with or without cause, at any shareholders' meeting without notice
or justification, by a simple majority vote.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Under Delaware law, unless otherwise provided in the certificate of incorporation, directors may be removed from office,
with or without cause, by a majority stockholder vote, though in the case of a corporation whose board is classified, stockholders may effect such removal only for cause.</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vacancies on the Board of Directors</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Under French law, vacancies on the board of directors resulting from death or a resignation, provided that at least three
directors remain in office, may be filled by a majority of the remaining directors pending ratification by the shareholders by the next shareholders' meeting.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Under Delaware law, vacancies on a corporation's board of directors, including those caused by newly created directorships,
may be filled by a majority of the remaining directors (even though less than a quorum).</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Annual General Meeting</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Under French law, the annual general meeting of shareholders shall be held at such place, on such date and at such time as
decided each year by the board of directors and notified to the shareholders in the convening notice of the annual meeting, within six months after the close of the relevant fiscal year unless such period is extended by court order.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Under Delaware law, the annual meeting of stockholders shall be held at such place, on such date and at such time as may be
designated from time to time by the board of directors or as provided in the certificate of incorporation or by the bylaws.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>168</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=172,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=344929,FOLIO='168',FILE='DISK116:[20ZBV1.20ZBV74901]DM74901A.;19',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dm74901_1_169"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="126pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="38%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="38%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>France </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Delaware </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General or Special Meetings</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Under French law, general meetings of the shareholders may be called by the board of directors or, failing that, by the statutory auditors,
or by a court appointed agent or liquidator in certain circumstances, or by the majority shareholder in capital or voting rights following a public tender offer or exchange offer or the transfer of a controlling block on the date decided by the board
of directors or the relevant person.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Under Delaware law, special meetings of the stockholders may be called by the board of directors or by such person or persons as may be
authorized by the certificate of incorporation or by the bylaws.</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Notice of General Meetings</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;text-align:left;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 Under French law, a meeting announcement is published in the Bulletin des Annonces L&eacute;gales Obligatoires (BALO) at least 35&nbsp;days prior to a meeting and made available on the website of the company at least 21&nbsp;days prior to the
 meeting. Subject to limited exceptions provided by French law an additional convening notice is sent out at least 15&nbsp;days prior to the date of the meeting, by means of a notice inserted both in a legal announcement bulletin of the registered
 office department and in the BALO. Further, shareholders holding registered shares for at least a month at the time of the notices shall be summoned individually, by regular letter (or by registered letter if they request it and include an advance of
 expenses) sent to their last known address. This notice to registered shareholders may also be transmitted by electronic means of telecommunication, in lieu of any such mailing, to any shareholder requesting it beforehand by registered letter with
 acknowledgment of receipt in accordance with legal and regulatory requirements, specifying his email address. When the shareholders' meeting cannot deliberate due to lack of required quorum, the second meeting must be called at least 10 calendar days
 in advance in the same manner as used for the first notice.</font> <p align=left style="font-family:arial;margin-top:12pt;margin-left:0pt;"> <font size=2> The convening notice shall specify the name of the company, its acronym, legal form, share capital, registered
 office address, registration number with the French Trade and Companies Register (</FONT><FONT SIZE=2><I>Registre du commerce et des soci&eacute;t&eacute;s</I></FONT><FONT SIZE=2>), the place, date, hour and agenda of the meeting and its nature
 (ordinary or extraordinary meeting). This notice must also indicate the conditions under which the shareholders may vote by correspondence and the places and conditions in which they can obtain voting forms by mail and, as the case may be, the e-mail
 address to which they may send written questions.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Under Delaware law, unless otherwise provided in the certificate of incorporation or bylaws, written notice of any meeting
of the stockholders must be given to each stockholder entitled to vote at the meeting not less than ten nor more than 60&nbsp;days before the date of the meeting and shall specify the place, date, hour, and purpose or purposes of the
meeting.</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>169</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=173,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=11968,FOLIO='169',FILE='DISK116:[20ZBV1.20ZBV74901]DM74901A.;19',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dm74901_1_170"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="126pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="38%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="38%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>France </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Delaware </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proxy</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Each shareholder has the right to attend the meetings and participate in the discussions (1)&nbsp;personally, or (2)&nbsp;by granting proxy
to his/her spouse, his/her partner with whom he/she has entered into a civil union or to another shareholder or to any individual or legal entity of his choosing; or (3)&nbsp;by sending a proxy to the company without indication of the mandate, or
(4)&nbsp;by voting by correspondence, or (5)&nbsp;by videoconference or another means of telecommunication in accordance with applicable laws that allow identification. The proxy is only valid for a single meeting or for successive meetings convened
with the same agenda. It can also be granted for two meetings, one ordinary, and the other extraordinary, held on the same day or within a period of 15&nbsp;days.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Under Delaware law, at any meeting of stockholders, a stockholder may designate another person to act for such stockholder by proxy, but no
such proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a longer period. A director of a Delaware corporation may not issue a proxy representing the director's voting rights as a director.</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shareholder action by written consent</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Under French law, shareholders' action by written consent is not permitted in a </FONT><FONT SIZE=2><I>soci&eacute;t&eacute;
anonyme.</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Under Delaware law, a corporation's certificate of incorporation (1)&nbsp;may permit stockholders to act by written consent
if such action is signed by all stockholders, (2)&nbsp;may permit stockholders to act by written consent signed by stockholders having the minimum number of votes that would be necessary to take such action at a meeting or (3)&nbsp;may prohibit
actions by written consent.</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Preemptive Rights</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Under French law, in case of issuance of additional shares or other securities for cash or set-off against cash debts, the
existing shareholders have preferential subscription rights to these securities on a pro rata basis unless such rights are waived by a two-thirds majority of the votes held (of the votes cast, as from our general shareholders' meeting convened to
vote on the financial statements for the year ended December&nbsp;31, 2019) by the shareholders present at the extraordinary general meeting deciding or authorizing the capital increase, voting in person or represented by proxy or voting by mail. In
case such rights are not waived by the extraordinary general meeting, each shareholder may individually either exercise, assign or not exercise its preferential rights. Preferential subscription rights may only be exercised during the subscription
period. In accordance with French law, the exercise period shall not be less than five trading days. Preferential subscription rights are transferable during a period equivalent to the subscription period but starting two business days prior to the
opening of the subscription period and ending two business days prior to the closing of the subscription period.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Under Delaware law, unless otherwise provided in a corporation's certificate of incorporation, a stockholder does not, by
operation of law, possess preemptive rights to subscribe to additional issuances of the corporation's stock or to any security convertible into such stock.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>170</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=174,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=209602,FOLIO='170',FILE='DISK116:[20ZBV1.20ZBV74901]DM74901A.;19',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dm74901_1_171"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="126pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="38%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="38%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>France </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Delaware </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Sources of Dividends</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;text-align:left;"><p style="font-family:arial;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 Under French law, dividends may only be paid by a French </FONT><FONT SIZE=2><I>soci&eacute;t&eacute; anonyme</I></FONT><FONT SIZE=2> out of "</FONT><FONT SIZE=2><I>distributable profits</I></FONT><FONT SIZE=2>," plus any distributable reserves and
 "</FONT><FONT SIZE=2><I>distributable premium</I></FONT><FONT SIZE=2>" that the shareholders decide to make available for distribution, other than those reserves that are specifically required by law. </font> <p align=left
 style="font-family:arial;margin-top:12pt;margin-left:0pt;"> <font size=2> "</FONT><FONT SIZE=2><I>Distributable profits</I></FONT><FONT SIZE=2>" consist of the unconsolidated net profits of the relevant corporation for each fiscal year, as increased or reduced by any
 profit or loss carried forward from prior years. </font> <p align=left style="font-family:arial;margin-top:12pt;margin-left:0pt;"> <font size=2> </FONT><FONT SIZE=2><I>"Distributable premium</I></FONT><FONT SIZE=2>" refers to the contribution paid by the shareholders
 in addition to the nominal value of their shares for their subscription that the shareholders decide to make available for distribution. </font> <p align=left style="font-family:arial;margin-top:12pt;margin-left:0pt;"> <font size=2> Except in case of a share capital
 reduction, no distribution can be made to the shareholders when the net equity is, or would become, lower than the amount of the share capital plus the reserves which cannot be distributed in accordance with the law or the bylaws.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Under Delaware law, dividends may be paid by a Delaware corporation either out of (1)&nbsp;surplus or (2)&nbsp;in case there is no surplus,
out of its net profits for the fiscal year in which the dividend is declared and/or the preceding fiscal year, except when the capital is diminished by depreciation in the value of its property, or by losses, or otherwise, to an amount less than the
aggregate amount of capital represented by issued and outstanding stock having a preference on the distribution of assets.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>171</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=175,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=207068,FOLIO='171',FILE='DISK116:[20ZBV1.20ZBV74901]DM74901A.;19',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dm74901_1_172"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="126pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="38%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="38%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>France </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Delaware </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Repurchase of Shares</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;text-align:left;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 Under French law, a private corporation may acquire its own shares. Such acquisition may be challenged on the ground of market abuse regulations. However, MAR provides for safe harbor exemptions when the acquisition is made for the following
 purposes: </font> <p align=left style="font-family:arial;margin-top:12pt;margin-left:0pt;"> <font size=2> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> </font> <p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-10pt;margin-left:0pt;"><font  style="font-size:8pt;line-height:9pt;"> </FONT><FONT FACE="WINGDINGS"
  style="font-size:8pt;line-height:9pt;">&sect;</FONT><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;"></font></p> <p align=left style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font  style="font-size:8pt;line-height:9pt;"></FONT><FONT SIZE=2>to decrease its share capital, provided that such decision is not driven by losses and that a purchase
 offer is made to all shareholders on a pro rata basis, with the approval of the shareholders at the extraordinary general meeting deciding the capital reduction, in which case, the shares repurchased must be cancelled within one month from the expiry
 of the purchase offer; </font> <p align=left style="font-family:arial;margin-top:12pt;margin-left:0pt;"> <font size=2> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> </font> <p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-10pt;margin-left:0pt;"><font  style="font-size:8pt;line-height:9pt;"> </FONT><FONT FACE="WINGDINGS"
  style="font-size:8pt;line-height:9pt;">&sect;</FONT><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;"></font></p> <p align=left style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font  style="font-size:8pt;line-height:9pt;"></FONT><FONT SIZE=2>with a view to distributing within one year of their repurchase the relevant shares to employees or
 managers under a profit-sharing, free share or share option plan; not to exceed 10% of the share capital, in which case the shares repurchased must be distributed within 12&nbsp;months from their repurchase failing which they must be cancelled; or
 </font> <p align=left style="font-family:arial;margin-top:12pt;margin-left:0pt;"> <font size=2> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> </font> <p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-10pt;margin-left:0pt;"><font  style="font-size:8pt;line-height:9pt;"> </FONT><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT><FONT
 FACE="arial"  style="font-size:8pt;line-height:9pt;"></font></p> <p align=left style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font  style="font-size:8pt;line-height:9pt;"></FONT><FONT SIZE=2>to meet obligations arising from debt securities, that are exchangeable into equity instruments. </font> <p align=left
 style="font-family:arial;margin-top:12pt;margin-left:0pt;"> <font size=2> A simple exemption is provided when the acquisition is made under a buy-back program to be authorized by the shareholders in accordance with the provisions of Article&nbsp;L. 225-209 of the
 French Commercial Code and in accordance with the General Regulations. </font> <p align=left style="font-family:arial;margin-top:12pt;margin-left:0pt;"> <font size=2> All other purposes, and especially share buy-backs for external growth operations by virtue of
 Article&nbsp;L. 225-209 of the French Commercial Code, while not forbidden, must be pursued in strict compliance of market manipulations and insider dealing rules. </font> <p align=left style="font-family:arial;margin-top:12pt;margin-left:0pt;"> <font size=2> Under
 MAR and in accordance with the General Regulations, a corporation shall report to the competent authority of the trading venue on which the shares have been admitted to trading or are traded, no later than by the end of the seventh daily market
 session following the date of the execution of the transaction, all the transactions relating to the buy-back program, in a detailed form and in an aggregated form.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Under Delaware law, a corporation may generally redeem or repurchase shares of its stock unless the capital of the corporation is impaired
or such redemption or repurchase would impair the capital of the corporation.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>172</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=176,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=1768,FOLIO='172',FILE='DISK116:[20ZBV1.20ZBV74901]DM74901A.;19',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dm74901_1_173"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="126pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="38%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="38%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>France </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Delaware </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Liability of Directors</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Under French law, the bylaws may not include any provisions limiting the liability of directors.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;text-align:left;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 Under Delaware law, a corporation's certificate of incorporation may include a provision eliminating or limiting the personal liability of a director to the corporation and its stockholders for damages arising from a breach of fiduciary duty as a
 director. However, no provision can limit the liability of a director for: </font> <p align=left style="font-family:arial;margin-top:12pt;margin-left:0pt;"> <font size=2> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> </font> <p align=left
 style="font-family:arial;margin-top:0pt;margin-bottom:-10pt;margin-left:0pt;"><font  style="font-size:8pt;line-height:9pt;"> </FONT><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;"></font></p> <p align=left style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font  style="font-size:8pt;line-height:9pt;"></FONT><FONT
 SIZE=2>any breach of the director's duty of loyalty to the corporation or its stockholders; </font> <p align=left style="font-family:arial;margin-top:12pt;margin-left:0pt;"> <font size=2> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> </font> <p align=left
 style="font-family:arial;margin-top:0pt;margin-bottom:-10pt;margin-left:0pt;"><font  style="font-size:8pt;line-height:9pt;"> </FONT><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;"></font></p> <p align=left style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font  style="font-size:8pt;line-height:9pt;"></FONT><FONT
 SIZE=2>acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; </font> <p align=left style="font-family:arial;margin-top:12pt;margin-left:0pt;"> <font size=2> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> </font> <p align=left
 style="font-family:arial;margin-top:0pt;margin-bottom:-10pt;margin-left:0pt;"><font  style="font-size:8pt;line-height:9pt;"> </FONT><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;"></font></p> <p align=left style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font  style="font-size:8pt;line-height:9pt;"></FONT><FONT
 SIZE=2>intentional or negligent payment of unlawful dividends or stock purchases or redemptions; or </font> <p align=left style="font-family:arial;margin-top:12pt;margin-left:0pt;"> <font size=2> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> </font> <p align=left
 style="font-family:arial;margin-top:0pt;margin-bottom:-10pt;margin-left:0pt;"><font  style="font-size:8pt;line-height:9pt;"> </FONT><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;"></font></p> <p align=left style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font  style="font-size:8pt;line-height:9pt;"></FONT><FONT
 SIZE=2>any transaction from which the director derives an improper personal benefit.</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Voting Rights</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>French law provides that, double voting rights are automatically granted to ordinary shares being held of record for more
than two years, unless the bylaws of the Company provide otherwise.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Delaware law provides that, unless otherwise provided in the certificate of incorporation, each stockholder is entitled to
one vote for each share of capital stock held by such stockholder.</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shareholder Vote on Certain Transactions</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;text-align:left;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 Generally, under French law, completion of a merger, dissolution, sale, lease or exchange of all or substantially all of a corporation's assets requires: </font> <p align=left style="font-family:arial;margin-top:12pt;margin-left:0pt;"> <font size=2> </FONT><FONT
  style="font-size:8pt;line-height:9pt;"> </font> <p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-10pt;margin-left:0pt;"><font  style="font-size:8pt;line-height:9pt;"> </FONT><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;"></font></p> <p align=left
 style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font  style="font-size:8pt;line-height:9pt;"></FONT><FONT SIZE=2>the approval of the board of directors; and </font> <p align=left style="font-family:arial;margin-top:12pt;margin-left:0pt;"> <font size=2> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> </font> <p align=left
 style="font-family:arial;margin-top:0pt;margin-bottom:-10pt;margin-left:0pt;"><font  style="font-size:8pt;line-height:9pt;"> </FONT><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;"></font></p> <p align=left style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font  style="font-size:8pt;line-height:9pt;"></FONT><FONT
 SIZE=2>approval by a two-thirds majority of the votes held (of the votes cast, as from our general shareholders' meeting convened to vote on the financial statements for the year ended December&nbsp;31, 2019) by the shareholders present, represented
 by proxy or voting by mail at the relevant meeting or, in the case of a merger with a non-EU company, approval of all shareholders of the corporation.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;text-align:left;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 Generally, under Delaware law, unless the certificate of incorporation provides for the vote of a larger portion of the stock, completion of a merger, consolidation, sale, lease or exchange of all or substantially all of a corporation's assets or
 dissolution requires: </font> <p align=left style="font-family:arial;margin-top:12pt;margin-left:0pt;"> <font size=2> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> </font> <p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-10pt;margin-left:0pt;"><font  style="font-size:8pt;line-height:9pt;"> </FONT><FONT FACE="WINGDINGS"
  style="font-size:8pt;line-height:9pt;">&sect;</FONT><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;"></font></p> <p align=left style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font  style="font-size:8pt;line-height:9pt;"></FONT><FONT SIZE=2>the approval of the board of directors; and </font> <p align=left
 style="font-family:arial;margin-top:12pt;margin-left:0pt;"> <font size=2> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> </font> <p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-10pt;margin-left:0pt;"><font  style="font-size:8pt;line-height:9pt;"> </FONT><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT><FONT FACE="arial"
  style="font-size:8pt;line-height:9pt;"></font></p> <p align=left style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font  style="font-size:8pt;line-height:9pt;"></FONT><FONT SIZE=2>approval by the vote of the holders of a majority of the outstanding stock or, if the certificate of incorporation provides for more or less
 than one vote per share, a majority of the votes of the outstanding stock of a corporation entitled to vote on the matter.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>173</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=177,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=440508,FOLIO='173',FILE='DISK116:[20ZBV1.20ZBV74901]DM74901A.;19',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dm74901_1_174"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="126pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="38%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="38%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>France </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Delaware </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dissenters' Appraisal Rights</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>French law does not provide for any such right but provides that a merger is subject to shareholders' approval by a two-thirds majority vote
as stated above.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;text-align:left;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 Under Delaware law, a holder of shares of any class or series has the right, in specified circumstances, to dissent from a merger or consolidation by demanding payment in cash for the stockholder's shares equal to the fair value of those shares, as
 determined by the Delaware Chancery Court in an action timely brought by the corporation or a dissenting stockholder. Delaware law grants these appraisal rights only in the case of mergers or consolidations and not in the case of a sale or transfer
 of assets or a purchase of assets for stock. Further, no appraisal rights are available for shares of any class or series that is listed on a national securities exchange or held of record by more than 2,000 stockholders, unless the agreement of
 merger or consolidation requires the holders to accept for their shares anything other than: </font> <p align=left style="font-family:arial;margin-top:12pt;margin-left:0pt;"> <font size=2> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> </font> <p align=left
 style="font-family:arial;margin-top:0pt;margin-bottom:-10pt;margin-left:0pt;"><font  style="font-size:8pt;line-height:9pt;"> </FONT><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;"></font></p> <p align=left style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font  style="font-size:8pt;line-height:9pt;"></FONT><FONT
 SIZE=2>shares of stock of the surviving corporation; </font> <p align=left style="font-family:arial;margin-top:12pt;margin-left:0pt;"> <font size=2> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> </font> <p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-10pt;margin-left:0pt;"><font  style="font-size:8pt;line-height:9pt;">
 </FONT><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;"></font></p> <p align=left style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font  style="font-size:8pt;line-height:9pt;"></FONT><FONT SIZE=2>shares of stock of another corporation that are either listed on a
 national securities exchange or held of record by more than 2,000 stockholders; </font> <p align=left style="font-family:arial;margin-top:12pt;margin-left:0pt;"> <font size=2> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> </font> <p align=left
 style="font-family:arial;margin-top:0pt;margin-bottom:-10pt;margin-left:0pt;"><font  style="font-size:8pt;line-height:9pt;"> </FONT><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;"></font></p> <p align=left style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font  style="font-size:8pt;line-height:9pt;"></FONT><FONT
 SIZE=2>cash in lieu of fractional shares of the stock described in the two preceding bullet points; or </font> <p align=left style="font-family:arial;margin-top:12pt;margin-left:0pt;"> <font size=2> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> </font> <p align=left
 style="font-family:arial;margin-top:0pt;margin-bottom:-10pt;margin-left:0pt;"><font  style="font-size:8pt;line-height:9pt;"> </FONT><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;"></font></p> <p align=left style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font  style="font-size:8pt;line-height:9pt;"></FONT><FONT
 SIZE=2>any combination of the above. </font> <p align=left style="font-family:arial;margin-top:12pt;margin-left:0pt;"> <font size=2> In addition, appraisal rights are not available to holders of shares of the surviving corporation in specified mergers that do not
 require the vote of the stockholders of the surviving corporation.</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Standard of Conduct for Directors</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>French law does not contain specific provisions setting forth the standard of conduct of a director. However, directors have
a duty to act without self-interest, on a well-informed basis and they cannot make any decision against a corporation's corporate interest (</FONT><FONT SIZE=2><I>int&eacute;r&ecirc;t social</I></FONT><FONT SIZE=2>).</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Delaware law does not contain specific provisions setting forth the standard of conduct of a director. The scope of the
fiduciary duties of directors is generally determined by the courts of the State of Delaware. In general, directors have a duty to act without self-interest, on a well-informed basis and in a manner they reasonably believe to be in the best interest
of the stockholders.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>174</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=178,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=1036607,FOLIO='174',FILE='DISK116:[20ZBV1.20ZBV74901]DM74901A.;19',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dm74901_1_175"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="126pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="38%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="38%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>France </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Delaware </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shareholder Suits</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;text-align:left;"><p style="font-family:arial;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 French law provides that a shareholder, or a group of shareholders, may initiate a legal action to seek indemnification from the directors of a corporation in the corporation's interest if it fails to bring such legal action itself. If so, any
 damages awarded by the court are paid to the corporation and legal fees relating to such action may be borne by the relevant shareholder or the group of shareholders. </font> <p align=left style="font-family:arial;margin-top:12pt;margin-left:0pt;"> <font size=2> The
 plaintiff must remain a shareholder through the duration of the legal action. </font> <p align=left style="font-family:arial;margin-top:12pt;margin-left:0pt;"> <font size=2> There is no other case where shareholders may initiate a derivative action to enforce a right
 of a corporation. </font> <p align=left style="font-family:arial;margin-top:12pt;margin-left:0pt;"> <font size=2> A shareholder may alternatively or cumulatively bring individual legal action against the directors, provided he has suffered distinct damages from those
 suffered by the corporation. In this case, any damages awarded by the court are paid to the relevant shareholder.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;text-align:left;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 Under Delaware law, a stockholder may initiate a derivative action to enforce a right of a corporation if the corporation fails to enforce the right itself. The complaint must: </font> <p align=left style="font-family:arial;margin-top:12pt;margin-left:0pt;"> <font
 size=2> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> </font> <p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-10pt;margin-left:0pt;"><font  style="font-size:8pt;line-height:9pt;"> </FONT><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;"></font></p> <p align=left
 style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font  style="font-size:8pt;line-height:9pt;"></FONT><FONT SIZE=2>state that the plaintiff was a stockholder at the time of the transaction of which the plaintiff complains or that the plaintiff's shares thereafter devolved on the plaintiff
 by operation of law; and </font> <p align=left style="font-family:arial;margin-top:12pt;margin-left:0pt;"> <font size=2> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> </font> <p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-10pt;margin-left:0pt;"><font  style="font-size:8pt;line-height:9pt;"> </FONT><FONT FACE="WINGDINGS"
  style="font-size:8pt;line-height:9pt;">&sect;</FONT><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;"></font></p> <p align=left style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font  style="font-size:8pt;line-height:9pt;"></FONT><FONT SIZE=2>allege with particularity the efforts made by the plaintiff to obtain the action the plaintiff desires
 from the directors and the reasons for the plaintiff's failure to obtain the action; or </font> <p align=left style="font-family:arial;margin-top:12pt;margin-left:0pt;"> <font size=2> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> </font> <p align=left
 style="font-family:arial;margin-top:0pt;margin-bottom:-10pt;margin-left:0pt;"><font  style="font-size:8pt;line-height:9pt;"> </FONT><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;"></font></p> <p align=left style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font  style="font-size:8pt;line-height:9pt;"></FONT><FONT
 SIZE=2>state the reasons for not making the effort. </font> <p align=left style="font-family:arial;margin-top:12pt;margin-left:0pt;"> <font size=2> Additionally, the plaintiff must remain a stockholder through the duration of the derivative suit. The action will not
 be dismissed or compromised without the approval of the Delaware Court of Chancery.</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Amendment of Certificate of Incorporation</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;text-align:left;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 Unlike companies incorporated under Delaware law, the organizational documents of which comprise both a certificate of incorporation and bylaws, companies incorporated under French law only have bylaws as organizational documents. </font> <p
 align=left style="font-family:arial;margin-top:12pt;margin-left:0pt;"> <font size=2> As indicated in the paragraph below, only the extraordinary shareholders' meeting is authorized to adopt or amend the bylaws under French law.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;text-align:left;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 Under Delaware law, generally a corporation may amend its certificate of incorporation if: </font> <p align=left style="font-family:arial;margin-top:12pt;margin-left:0pt;"> <font size=2> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> </font> <p align=left
 style="font-family:arial;margin-top:0pt;margin-bottom:-10pt;margin-left:0pt;"><font  style="font-size:8pt;line-height:9pt;"> </FONT><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;"></font></p> <p align=left style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font  style="font-size:8pt;line-height:9pt;"></FONT><FONT
 SIZE=2>its board of directors has adopted a resolution setting forth the amendment proposed and declared its advisability; and </font> <p align=left style="font-family:arial;margin-top:12pt;margin-left:0pt;"> <font size=2> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> </font> <p align=left
 style="font-family:arial;margin-top:0pt;margin-bottom:-10pt;margin-left:0pt;"><font  style="font-size:8pt;line-height:9pt;"> </FONT><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;"></font></p> <p align=left style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font  style="font-size:8pt;line-height:9pt;"></FONT><FONT
 SIZE=2>the amendment is adopted by the affirmative votes of a majority (or greater percentage as may be specified by the corporation) of the outstanding shares entitled to vote on the amendment and a majority (or greater percentage as may be
 specified by the corporation) of the outstanding shares of each class or series of stock, if any, entitled to vote on the amendment as a class or series.</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Amendment of Bylaws</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Under French law, only the extraordinary shareholders' meeting is authorized to adopt or amend the bylaws.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Under Delaware law, the stockholders entitled to vote have the power to adopt, amend or repeal bylaws. A corporation may
also confer, in its certificate of incorporation, that power upon the board of directors.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Listing  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We intend to apply to list our ADSs on the Nasdaq Global Market under the symbol "IVA." Our ordinary shares are currently listed on Euronext Paris under the
symbol "IVA." </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>175</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=179,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=172868,FOLIO='175',FILE='DISK116:[20ZBV1.20ZBV74901]DM74901A.;19',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dm74901_1_176"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Transfer agent and registrar  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Upon the closing of this offering, the transfer agent and registrar for the ADSs will be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Our ordinary share
register is maintained by
Soci&eacute;t&eacute; G&eacute;n&eacute;rale. The share register reflects only record owners of our ordinary shares. Holders of our ADSs will not be treated as one of
our shareholders and their names will therefore not be entered in our share register. The depositary, the custodian or their nominees will be the holder of the shares underlying our ADSs. Holders of
our ADSs have a right to receive the ordinary shares underlying their ADSs. For discussion on our ADSs and ADS holder rights, see "Description of American Depositary Shares" in this prospectus. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>176</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=180,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=653480,FOLIO='176',FILE='DISK116:[20ZBV1.20ZBV74901]DM74901A.;19',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_do74901_1_177"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A NAME="do74901_limitations_affecting___do702222"> </A>
<A NAME="toc_do74901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  LIMITATIONS AFFECTING SHAREHOLDERS OF A FRENCH COMPANY    <BR>    </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Ownership of ADSs or Shares by Non-French Residents  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Neither the French Commercial Code nor our bylaws presently impose any restrictions on the right of non-French residents or non-French shareholders to own and
vote shares. However, non-French residents must file&nbsp;a declaration for statistical purposes with the Bank of France (</FONT><FONT SIZE=2><I>Banque de France</I></FONT><FONT SIZE=2>) within
twenty working days following the date of certain direct foreign investments in us, including any purchase of our ADSs. In
particular such filings are required in connection with investments exceeding &euro;&nbsp;15,000,000 that lead to the acquisition of at least 10% of our company's share capital or
voting rights or cross such 10% threshold. Violation of this filing requirement may be sanctioned by five years of imprisonment and a fine up to twice the amount of the relevant investment. This
amount may be increased fivefold if the violation is made by a legal entity. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Moreover,
certain foreign investments which (1)&nbsp;fall under the definition of control pursuant to Article&nbsp;L.&nbsp;233-3 of the French Commercial Code, or (2)&nbsp;result in the
acquisition of all or part of the branche of activity or (3)&nbsp;which result in the acquisition of more than one third of the share capital or voting rights of companies incorporated under French
laws are subject to the price authorization from the French Minister of the Economy, where all part of the target's business and activity relate to a strategic sector, such as public health, energy,
transportation, etc. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Foreign Exchange Controls  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under current French foreign exchange control regulations there are no limitations on the amount of cash payments that we may remit to residents of foreign
countries. Laws and regulations concerning foreign exchange controls do, however, require that all payments or transfers of funds made by a French resident to a non-resident such as dividend payments
be handled by an accredited intermediary. All registered banks and substantially all credit institutions in France are accredited intermediaries. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Availability of Preferential Subscription Rights  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our existing shareholders have waived their preferential subscription rights with respect to this offering. In the future our shareholders will have the
preferential subscription rights described under the section of this prospectus titled "Description of Share Capital&nbsp;&#151; Key provisions of our bylaws and French law affecting our
ordinary shares&nbsp;&#151; Changes in share capital (Article&nbsp;7 of the bylaws)&nbsp;&#151; Preferential subscription right." Under French law, shareholders have preferential
rights to subscribe for cash issues of new shares or other securities giving rights to acquire additional shares on a pro rata basis. Holders of our securities in the United States, which may be in
the form of shares or ADSs, may not be able to exercise preferential subscription rights for their securities unless a registration statement under the Securities Act is effective with respect to such
rights or an exemption from the registration requirements imposed by the Securities Act is available. We may, from time to time, issue new shares or other securities giving rights to acquire
additional shares (such as warrants) at a time when no registration statement is in effect and no Securities Act exemption is available. If so, holders of our securities in the United States will be
unable to exercise any preferential subscription rights and their interests will be diluted. We are under no obligation to file any registration statement in connection with any issuance of new shares
or other securities. We intend to evaluate at the time of any rights offering the costs and potential liabilities associated with registering the rights, as well as the indirect benefits to us of
enabling the exercise by holders of shares and holders of ADSs in the
United States of the subscription rights, and any other factors we consider appropriate at the time, and then to make a decision as to whether to register the rights. We cannot assure you that we will
file&nbsp;a registration statement. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For
holders of our ordinary shares in the form of ADSs, the depositary may make these rights or other distributions available to ADS holders. If the depositary does not make the rights available to
ADS holders </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>177</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=181,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=134918,FOLIO='177',FILE='DISK116:[20ZBV1.20ZBV74901]DO74901A.;10',USER='JFUSS',CD='10-APR-2020;12:58' -->
<A NAME="page_do74901_1_178"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>and
determines that it is impractical to sell the rights, it may allow these rights to lapse. In that case ADS holders will receive no value for them. The section of this prospectus titled
"Description of American Depositary Shares&nbsp;&#151; Dividends and Other Distributions" explains in detail the depositary's responsibility in connection with a rights offering. See also
"Risk Factors&nbsp;&#151; The right as a holder of ADSs to participate in any future preferential subscription rights or to elect to receive dividends in shares may be limited, which may
cause dilution to the holdings of purchasers of ADSs in the U.S. offering." </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>178</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=182,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=197894,FOLIO='178',FILE='DISK116:[20ZBV1.20ZBV74901]DO74901A.;10',USER='JFUSS',CD='10-APR-2020;12:58' -->
<A NAME="page_do74901_1_179"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A NAME="do74901_description_of_american_depositary_shares"> </A>
<A NAME="toc_do74901_2"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF AMERICAN DEPOSITARY SHARES    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT
SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;has agreed to act as the depositary for the American Depositary Shares.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;depositary offices are located
at&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.
American Depositary Shares are frequently referred to as ADSs and represent ownership interests in securities that are on deposit with the depositary. ADSs may be represented by certificates that are
commonly known as American Depositary Receipts, or ADRs. The depositary typically appoints a custodian to safekeep the securities on deposit. In this case, the custodian
is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
have appointed&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;as depositary pursuant to a deposit agreement. A copy of the deposit agreement is on file with the SEC under cover
of a Registration Statement on Form&nbsp;F-6. You
may obtain a copy of the deposit agreement from the SEC's website (www.sec.gov). Please refer to Registration Number&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;when retrieving such copy.
</FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>You
may hold ADSs either (1)&nbsp;directly (a)&nbsp;by having an ADR, which is a certificate evidencing a specific number of ADSs, registered in your name, or (b)&nbsp;by having uncertificated
ADSs registered in your name in the Direct Registration System, or DRS, or (2)&nbsp;indirectly by holding a security entitlement in ADSs through your broker or other financial institution that is a
direct or indirect participant in the Depository Trust Company, or DTC. If you hold ADSs directly, you are a registered ADS holder, also referred to as an ADS holder. This description assumes you are
an ADS holder. If you hold the ADSs indirectly, you must rely on the procedures of your broker or other financial institution to assert the rights of ADS holders described in this section. You should
consult with your broker or financial institution to find out what those procedures are. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>DRS
is a system administered by DTC pursuant to which the depositary may register the ownership of uncertificated ADSs, which ownership is confirmed by periodic statements sent by the depositary to
the registered holders of uncertificated ADSs. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
an ADS holder, you will not be treated as one of our shareholders and you will not have shareholder rights. French law governs shareholder rights. The depositary will be the holder of the ordinary
shares underlying your ADSs. As a holder of ADSs, you will have ADS holder rights. A deposit agreement among us, the depositary and you, as an ADS holder, and all other persons directly and indirectly
holding ADSs sets out ADS holder rights as well as the rights and obligations of the depositary. New York law governs the deposit agreement and the ADRs. In the event of any discrepancy between the
ADRs and the deposit agreement, the deposit agreement governs. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
following is a summary of the material provisions of the deposit agreement. For more complete information, you should read the entire deposit agreement and the form of ADR. For directions on how
to obtain copies of those documents, see the section of this prospectus titled "Where you can find more information." Unless otherwise indicated or the context otherwise requires, references to "you"
in this section refer to purchasers of ADSs in the U.S. offering. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Dividends and Other Distributions  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


How will you receive dividends and other distributions on the ordinary shares?  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The depositary has agreed to pay or distribute to you the cash dividends or other distributions it or the custodian receives on ordinary shares or other
deposited securities, after deducting its fees
and expenses. You will receive these distributions in proportion to the number of ordinary shares your ADSs represent. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><I> Cash.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;After completion of the global offering, we do not expect to declare or pay any cash dividends or cash distributions on our ordinary shares for the
foreseeable future. The depositary will convert any cash dividend or other cash distribution we pay on the ordinary shares or any net proceeds from the sale of any ordinary shares, rights, securities
or other entitlements into U.S. dollars if it can do so on a reasonable </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>179</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=183,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=61843,FOLIO='179',FILE='DISK116:[20ZBV1.20ZBV74901]DO74901A.;10',USER='JFUSS',CD='10-APR-2020;12:58' -->
<A NAME="page_do74901_1_180"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>basis
and at the then prevailing market rate, and can transfer the U.S. dollars to the United States. If that is not possible or if any government approval is needed and cannot be obtained, the
deposit agreement allows the depositary to distribute the foreign currency only to those ADS holders to whom it is possible to do so. It will hold the foreign currency it cannot convert for the
account of the ADS holders who have not been paid. It will not invest the foreign currency and it will not be liable for any interest. Before making a distribution, any withholding taxes or other
governmental charges, together with fees and expenses of the depositary that must be paid, will be deducted. See "Material U.S. federal income and French tax considerations." It will distribute only
whole U.S. dollars and cents and will round fractional cents to the nearest whole cent.</FONT><FONT SIZE=2><I> If the exchange rates fluctuate during a time when the depositary cannot convert the
foreign currency, you may lose some or all of the value of the distribution.</I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Ordinary Shares.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The depositary may distribute additional ADSs representing any ordinary shares we distribute as a dividend or free distribution. The depositary
will only distribute whole ADSs. It will sell ordinary shares which would require it to deliver a fractional ADS, or ADSs representing those ordinary shares, and distribute the net proceeds in the
same way as it does with cash. If the depositary does not distribute additional ADSs, the outstanding ADSs will also represent the new ordinary shares. The depositary may sell a portion of the
distributed ordinary shares, or ADSs representing those shares, sufficient to pay its fees and expenses in connection with that distribution. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Rights to Purchase Additional Ordinary Shares.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If we offer holders of our securities any rights to subscribe for additional ordinary shares or any other rights, the
depositary may (1)&nbsp;exercise those rights on behalf of ADS holders, (2)&nbsp;distribute those rights to ADS holders or (3)&nbsp;sell those rights and distribute the net proceeds to ADS
holders, in each case after deduction or upon payment of its fees and expenses. To the extent the depositary does not do any of those things, it will allow the rights to lapse
unexercised.</FONT><FONT SIZE=2><I> In that case, you will receive no value for them</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
depositary will exercise or distribute rights only if we ask it to and provide satisfactory assurances to the depositary that it is legal to do so. If the depositary makes rights available to you,
it will exercise the rights and purchase the ordinary shares on your behalf and in accordance with your instructions. The depositary will then deposit the ordinary shares and deliver ADSs to you. It
will only exercise rights if you pay it the exercise price and any other charges the rights require you to pay and comply with other applicable instructions. U.S. securities laws may restrict the
ability of the depositary to distribute rights or ADSs or other securities issued on exercise of rights to all or certain ADS holders, and the securities distributed may be subject to restrictions on
transfer. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Other Distributions.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The depositary will send to you anything else we distribute on deposited securities by any means it determines is legal, fair and practical. If
it cannot make the distribution in that way, the depositary may adopt another method. It may decide to sell what we distributed and distribute the net proceeds, in the same way as it does with cash.
Or, it may decide to hold what we distributed, in which case ADSs will also represent the newly distributed property. However, the depositary is not required to distribute any securities (other than
ADSs) to ADS holders unless it receives satisfactory evidence from us that it is legal to make that distribution. In addition, the depositary may sell a portion of the distributed securities or
property sufficient to pay its fees and expenses in connection with that distribution. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Neither
we nor the depositary are responsible for any failure to determine that it may be lawful or feasible to make a distribution available to any ADS holders. We have no obligation to register
ADSs, ordinary shares, rights or other securities under the Securities Act. We also have no obligation to take any other action to permit the distribution of ADSs, shares, rights or anything else to
ADS holders. </FONT><FONT SIZE=2><I>This means that you may not receive the distributions we make on our ordinary shares or any value for them if it is illegal or impractical for us to make them
available to you.</I></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>180</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=184,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=585721,FOLIO='180',FILE='DISK116:[20ZBV1.20ZBV74901]DO74901A.;10',USER='JFUSS',CD='10-APR-2020;12:58' -->
<A NAME="page_do74901_1_181"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Deposit, Withdrawal and Cancellation  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


How are ADSs issued?  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The depositary will deliver ADSs if you or your broker deposits ordinary shares or evidence of rights to receive ordinary shares with the custodian. Upon
payment of its fees and expenses and of any taxes or charges, such as stamp taxes or share transfer taxes or fees, the depositary will register the appropriate number of ADSs in the names you request
and will deliver the ADSs to or upon the order of the person or persons that made the deposit. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


How can ADS holders withdraw the deposited securities?  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>You may surrender your ADSs at the depositary's office. Upon payment of its fees and expenses and of any taxes or governmental charges payable in connection
with such surrender or withdrawal, the depositary will deliver the ordinary shares and any other deposited securities underlying the ADSs to you or a person designated by you at the office of the
custodian or through a book-entry delivery. Alternatively, at your request, risk and expense, the depositary will, if feasible, deliver the amount of deposited securities represented by the
surrendered ADSs for delivery at the depositary's office or to another address you may specify. The depositary may charge you a fee and its expenses for instructing the custodian regarding delivery of
deposited securities. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


How can ADS holders interchange between certificated ADSs and uncertificated ADSs?  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>You may surrender your ADRs to the depositary for the purpose of exchanging your ADRs for uncertificated ADSs. The depositary will cancel the ADRs and will
send you a statement confirming that you are the owner of uncertificated ADSs. Alternatively, upon receipt by the depositary of a proper instruction from a registered holder of uncertificated ADSs
requesting the exchange of uncertificated ADSs for certificated ADSs, the depositary will execute and deliver to you an ADR evidencing those ADSs. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Voting rights  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


How do you vote?  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>You may instruct the depositary to vote the number of whole deposited ordinary shares your ADSs represent. If we request the depositary to solicit your voting
instructions (and we are not required to do so), the depositary will notify you of shareholders' meetings or other solicitations of consents and arrange to deliver our voting materials to you. Those
materials will describe the matters to be voted on and explain how you may instruct the depositary how to vote. For instructions to be valid, they must reach the depositary by a date set by the
depositary. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
depositary will endeavor, in so far as practicable, to vote or cause to be voted the amount of deposited ordinary shares represented by those ADSs in accordance with the instructions set forth in
your request. The depositary will only vote, or attempt to vote, according to the instruction given by you and received by the depositary. If we do not request the depositary to solicit your voting
instructions, you can still send voting instructions, and, in that case, the depositary may try to vote as you instruct, but it is not required to do so. In any event, the depositary will not exercise
any discretion in voting deposited securities and it will only vote or attempt to vote as instructed. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
cannot assure you that you will receive the voting materials in time to ensure that you can instruct the depositary to vote your ordinary shares. In addition, the depositary and its agents are not
responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions. </FONT><FONT SIZE=2><I>This means that you may not be able to exercise your right to
vote and there may be nothing you can do if your ordinary shares are not voted as you requested.</I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
order to give you a reasonable opportunity to instruct the depositary as to the exercise of voting rights relating to deposited securities, if we request the depositary to act, we will give the
depositary notice of any such meeting and details concerning the matters to be voted upon at least 30&nbsp;days in advance of the meeting date except where under French law the notice period for
such meeting is less than 30&nbsp;days. If we </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>181</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=185,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=135606,FOLIO='181',FILE='DISK116:[20ZBV1.20ZBV74901]DO74901A.;10',USER='JFUSS',CD='10-APR-2020;12:58' -->
<A NAME="page_do74901_1_182"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>request
that the depositary act less than 30&nbsp;days in advance of a meeting date, the depositary shall use commercially reasonable efforts to distribute the information and otherwise comply with
the voting provisions described above. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>Except as described above, you will not be able to exercise your right to vote unless you withdraw the ordinary shares. However, you may not know about the shareholder meeting
enough in advance to withdraw the ordinary shares.</I></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Fees and Expenses  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


What fees and expenses will you be responsible for paying?  </I></B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Pursuant to the terms of the deposit agreement, the holders of ADSs will be required to pay the following fees: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="48%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2><I>Persons depositing or withdrawing ordinary shares or ADSs must pay:</I></FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2><I> For:</I></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(or less) per 100 ADSs (or portion of 100 ADSs)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:12pt;margin-bottom:-10pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT  style="font-size:8pt;line-height:9pt;"> </font> <font  style="font-size:8pt;line-height:9pt;"> </FONT><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;"></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font  style="font-size:8pt;line-height:9pt;"></FONT><FONT SIZE=2>Issue of ADSs, including issues resulting from a distribution of ordinary shares or rights</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:12pt;margin-bottom:-10pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT  style="font-size:8pt;line-height:9pt;"> </font> <font  style="font-size:8pt;line-height:9pt;"> </FONT><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;"></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font  style="font-size:8pt;line-height:9pt;"></FONT><FONT SIZE=2>Cancellation of ADSs for the purpose of withdrawal, including if the deposit agreement terminates</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(or less) per ADS</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:12pt;margin-bottom:-10pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT  style="font-size:8pt;line-height:9pt;"> </font> <font  style="font-size:8pt;line-height:9pt;"> </FONT><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;"></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font  style="font-size:8pt;line-height:9pt;"></FONT><FONT SIZE=2>Any cash distribution to you</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>A fee equivalent to the fee that would be payable if securities distributed to you had been ordinary shares and the shares had been deposited for issue of
ADSs</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:12pt;margin-bottom:-10pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT  style="font-size:8pt;line-height:9pt;"> </font> <font  style="font-size:8pt;line-height:9pt;"> </FONT><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;"></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font  style="font-size:8pt;line-height:9pt;"></FONT><FONT SIZE=2>Distribution of securities distributed to holders of deposited securities which are distributed by the depositary to you</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(or less) per ADS per calendar year</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:12pt;margin-bottom:-10pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT  style="font-size:8pt;line-height:9pt;"> </font> <font  style="font-size:8pt;line-height:9pt;"> </FONT><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;"></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font  style="font-size:8pt;line-height:9pt;"></FONT><FONT SIZE=2>Depositary services</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Registration or transfer fees</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:12pt;margin-bottom:-10pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT  style="font-size:8pt;line-height:9pt;"> </font> <font  style="font-size:8pt;line-height:9pt;"> </FONT><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;"></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font  style="font-size:8pt;line-height:9pt;"></FONT><FONT SIZE=2>Transfer and registration of ordinary shares on our share register to or from the name of the depositary or its agent when you deposit or withdraw shares</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expenses of the depositary</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:12pt;margin-bottom:-10pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT  style="font-size:8pt;line-height:9pt;"> </font> <font  style="font-size:8pt;line-height:9pt;"> </FONT><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;"></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font  style="font-size:8pt;line-height:9pt;"></FONT><FONT SIZE=2>Cable (including SWIFT) and facsimile transmissions as expressly provided in the deposit agreement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:12pt;margin-bottom:-10pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT  style="font-size:8pt;line-height:9pt;"> </font> <font  style="font-size:8pt;line-height:9pt;"> </FONT><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;"></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font  style="font-size:8pt;line-height:9pt;"></FONT><FONT SIZE=2>Converting foreign currency to U.S. dollars</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Taxes and other governmental charges the depositary or the custodian have to pay on any ADS or share underlying an ADS, for example, share
transfer taxes, stamp duty or withholding taxes</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:12pt;margin-bottom:-10pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT  style="font-size:8pt;line-height:9pt;"> </font> <font  style="font-size:8pt;line-height:9pt;"> </FONT><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;"></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font  style="font-size:8pt;line-height:9pt;"></FONT><FONT SIZE=2>As necessary</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Any charges payable by the depositary, custodian or their agents in connection with the servicing of deposited securities</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:12pt;margin-bottom:-10pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT  style="font-size:8pt;line-height:9pt;"> </font> <font  style="font-size:8pt;line-height:9pt;"> </FONT><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT><FONT FACE="arial"  style="font-size:8pt;line-height:9pt;"></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font  style="font-size:8pt;line-height:9pt;"></FONT><FONT SIZE=2>As necessary</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>The
depositary collects its fees for delivery and surrender of ADSs directly from investors depositing ordinary shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting
for them. The </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>182</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=186,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=507772,FOLIO='182',FILE='DISK116:[20ZBV1.20ZBV74901]DO74901A.;10',USER='JFUSS',CD='10-APR-2020;12:58' -->
<A NAME="page_do74901_1_183"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>depositary
collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The depositary
may collect its annual fee for depositary services by deduction from cash distributions or by directly billing investors or by charging the book-entry system accounts of participants acting for them.
The depositary may collect any of its fees by deduction from any cash distribution payable to ADS holders that are obligated to pay those fees. The depositary may generally refuse to provide for-fee
services until its fees for those services are paid. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>From
time to time, the depositary may make payments to us to reimburse or share revenue from the fees collected from ADS holders, or waive fees and expenses for services provided, generally relating
to costs and expenses arising out of establishment and maintenance of the ADS program. In performing its duties under the deposit agreement, the depositary may use brokers, dealers, foreign currency
or other service providers that are affiliates of the depositary and that may earn or share fees, spreads or commissions. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
depositary may convert foreign currency itself or through any of its affiliates and, in those cases, acts as principal for its own account and not as an agent, fiduciary or broker on behalf of any
other person and earns revenue, including, without limitation, fees and spreads that it will retain for its own account. The spread is the difference between the exchange rate assigned to the currency
conversion made under the deposit agreement and the rate that the depositary or its affiliate receives in an offsetting foreign currency trade. The depositary makes no representation that the exchange
rate used or obtained in any currency conversion under the deposit agreement will be the most favorable rate that could be obtained at the time or as to the method by which that rate will be
determined, subject to its obligations under the deposit agreement. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Payment of Taxes  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>You will be responsible for any taxes or other governmental charges payable on your ADSs or on the deposited securities represented by any of your ADSs. The
depositary may refuse to register any transfer of your ADSs or allow you to withdraw the deposited securities represented by your ADSs until such taxes or other charges are paid. It may apply payments
owed to you or sell deposited securities represented by your ADSs to pay any taxes owed and you will remain liable for any deficiency. If the depositary sells deposited securities, it will, if
appropriate, reduce the number of ADSs registered in your name to reflect the sale and pay you any net proceeds, or send you any property, remaining after it has paid the taxes. Your obligation to pay
taxes and indemnify us and the depository against any tax claims will survive the transfer or surrender of your ADSs, the withdrawal of the deposited ordinary shares as well as the termination of the
deposit agreement. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>183</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=187,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=104775,FOLIO='183',FILE='DISK116:[20ZBV1.20ZBV74901]DO74901A.;10',USER='JFUSS',CD='10-APR-2020;12:58' -->
<A NAME="page_do74901_1_184"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Reclassifications, Recapitalizations and Mergers  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="48%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2><I>If we:</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><I> Then:</I></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><BR><FONT SIZE=2>Change the nominal value of our ordinary shares</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2>The cash, ordinary shares or other securities received by the depositary will become deposited securities.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><BR><FONT SIZE=2>Reclassify, split up or consolidate any of the deposited securities</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2>Each ADS will automatically represent its equal share of the new deposited securities.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><BR><FONT SIZE=2>Distribute securities on the ordinary shares that are not distributed to you</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2>The depositary may also deliver new ADSs or ask you to surrender your outstanding ADRs in exchange for new ADRs identifying the new deposited securities. The depositary may also sell the new deposited securities and
distribute the net proceeds if we are unable to assure the depositary that the distribution (a)&nbsp;does not require registration under the Securities Act or (b)&nbsp;is exempt from registration under the Securities Act.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><BR><FONT SIZE=2>Recapitalize, reorganize, merge, liquidate, sell all or substantially all of our assets, or take any similar action</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2>Any replacement securities received by the depositary shall be treated as newly deposited securities and either the existing ADSs or, if necessary, replacement ADSs distributed by the depositary will represent the
replacement securities. The depositary may also sell the replacement securities and distribute the net proceeds if the replacement securities may not be lawfully distributed to all ADS holders.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Amendment and Termination  </B></FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


How may the deposit agreement be amended?  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We may agree with the depositary to amend the deposit agreement and the ADRs without your consent for any reason. If an amendment adds or increases fees or
charges, except for taxes and other governmental charges, registration fees, facsimile costs, delivery costs or other such expenses, or that would otherwise prejudice a substantial right of ADS
holders, it will not become effective for outstanding ADSs until 30&nbsp;days after the depositary notifies ADS holders of the amendment. </FONT><FONT SIZE=2><I>At the time an amendment becomes
effective, you are considered, by continuing to hold your ADSs, to agree to the amendment and to be bound by the ADRs and the deposit agreement as amended</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


How may the deposit agreement be terminated?  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The depositary will terminate the deposit agreement if we ask it to do so, in which case the depositary will give notice to you at least 90&nbsp;days prior
to termination. The depositary may also terminate the deposit agreement if the depositary has told us that it would like to resign and we have not appointed a new depositary within 60&nbsp;days. In
such case, the depositary must notify you at least 90&nbsp;days before termination. In addition, the depositary may initiate termination of the deposit agreement if (1)&nbsp;we delist our shares
from an exchange on which they were listed and do not list the shares on another exchange; (2)&nbsp;we appear to be insolvent or enter insolvency proceedings; (3)&nbsp;all or substantially all the
value of the deposited securities has been distributed either in cash or in the form of securities; (4)&nbsp;there are no deposited securities </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>184</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=188,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=541290,FOLIO='184',FILE='DISK116:[20ZBV1.20ZBV74901]DO74901A.;10',USER='JFUSS',CD='10-APR-2020;12:58' -->
<A NAME="page_do74901_1_185"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>underlying
the ADSs or the underlying deposited securities have become apparently worthless; or (5)&nbsp;there has been a replacement of deposited securities. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>After
termination, the depositary and its agents will do the following under the deposit agreement but nothing else: collect dividends and other distributions on the deposited securities, sell rights
and other property, and deliver ordinary shares and other deposited securities upon cancellation of ADSs. At any time after the termination date, the depositary may sell the deposited securities.
After that, the depositary will hold the money it received on the sale, as well as any other cash it is holding under the deposit agreement, unsegregated and without liability for interest, for the
pro rata benefit of the ADS holders that have not surrendered their ADSs. Normally, the depositary will sell as soon as practicable after the termination date. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>After
the termination date and before the depositary sells, ADS holders can still surrender their ADSs and receive delivery of deposited securities, except that the depositary may refuse to accept a
surrender for the purpose of withdrawing deposited securities if it would interfere with the selling process. The depositary may refuse to accept a surrender for the purpose of withdrawing sale
proceeds until all the deposited securities have been sold. The depositary will continue to collect distributions on deposited securities, but, after the termination date, the depositary is not
required to register any transfer of ADSs or distribute any dividends or other distributions on deposited securities to the ADS holder (until they surrender their ADSs) or give any notices or perform
any other duties under the deposit agreement except as described in this paragraph. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Limitations on Obligations and Liability  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The deposit agreement expressly limits our obligations and the obligations of the depositary. It also limits our liability and the liability of the depositary
to ADS holders. We and the depositary:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> are only obligated to take the actions specifically set forth in the deposit agreement
without negligence or bad faith; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> are not liable if either of us is prevented or delayed by law or circumstances beyond our
control from performing our obligations under the deposit agreement; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> are not liable if either of us exercises, or fails to exercise, discretion permitted
under the deposit agreement; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> are not liable for the inability of any holder of ADSs to benefit from any distribution
on deposited securities that is not made available to holders of ADSs under the terms of the deposit agreement, or for any special, consequential or punitive damages for any breach of the terms of the
deposit agreement; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> are not liable for any tax consequences to any holders of ADSs on account of their
ownership of ADSs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> have no obligation to become involved in a lawsuit or other proceeding related to the
ADSs or the deposit agreement on your behalf or on behalf of any other person; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> are not liable for the acts or omissions of any securities depository, clearing agency or
settlement system; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> may rely upon any documents we believe in good faith to be genuine and to have been
signed or presented by the proper person. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>In
the deposit agreement, we and the depositary agree to indemnify each other under certain circumstances. Additionally, we, the depositary and each owner and holder waives the right to a jury trial
in an action against us or the depositary arising out of or relating to the deposit agreement. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>185</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=189,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=424995,FOLIO='185',FILE='DISK116:[20ZBV1.20ZBV74901]DO74901A.;10',USER='JFUSS',CD='10-APR-2020;12:58' -->
<A NAME="page_do74901_1_186"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Requirements for Depositary Actions  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Before the depositary will deliver or register a transfer of an ADS, make a distribution on an ADS, or permit withdrawal of ordinary shares, the depositary may
require:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> payment of any tax or other governmental charges and any stock transfer or registration
fees charged by third parties for the transfer of any ordinary shares or other deposited securities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> satisfactory proof of the identity and genuineness of any signature or other information
it deems necessary; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> compliance with regulations it may establish, from time to time, consistent with the
deposit agreement, including presentation of transfer documents. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>The
depositary may refuse to deliver ADSs or register transfers of ADSs generally when the transfer books of the depositary or our transfer books are closed or at any time if the depositary or we
think it advisable to do so. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Your Right to Receive the Ordinary Shares Underlying Your ADSs  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>ADS holders have the right to cancel their ADSs and withdraw the underlying ordinary shares at any time
except:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> when temporary delays arise because: (1)&nbsp;the depositary has closed its transfer
books or we have closed our transfer books; (2)&nbsp;the transfer of ordinary shares is blocked to permit voting at a shareholders' meeting; or (3)&nbsp;we are paying a dividend on our ordinary
shares; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> when you owe money to pay fees, taxes and similar charges; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> when it is necessary to prohibit withdrawals in order to comply with any U.S. or foreign
laws or governmental regulations that apply to ADSs or to the withdrawal of ordinary shares or other deposited securities. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>This
right of withdrawal is not limited by any other provision of the deposit agreement. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Pre-Release of ADSs  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The deposit agreement permits the depositary to deliver ADSs before deposit of the underlying ordinary shares. This is called a pre-release of the ADSs. The
depositary may also deliver ordinary shares upon surrender of pre-released ADSs (even if the ADSs are surrendered before the pre-release transaction has been closed out). A pre-release is closed out
as soon as the underlying ordinary shares are delivered to the depositary. The depositary may receive ADSs instead of ordinary shares to close out a pre-release. The depositary may pre-release ADSs
only under the following conditions: (1)&nbsp;before or at the time of the pre-release, the person to whom the pre-release is being made represents to the depositary in writing that it or its
customer owns the ordinary shares or ADSs to be deposited; (2)&nbsp;the pre-release is at all times fully collateralized with cash or other collateral that the depositary considers appropriate;
(3)&nbsp;the depositary must be able to close out the pre-release on not more than five business days' notice; and (4)&nbsp;subject to all indemnities and credit regulations that the depositary
deems appropriate. The number of ADSs outstanding at any time as a result of pre-release will not normally exceed 30% of all ADSs outstanding, although the depositary may change or disregard this
limit from time to time, if it thinks it is appropriate to do so. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Direct Registration System  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In the deposit agreement, all parties to the deposit agreement acknowledge that the DRS and Profile Modification System, or Profile, will apply to ADSs upon
acceptance thereof to DRS by DTC. DRS is the system administered by DTC under which the depositary may register the ownership of uncertificated ADSs and such ownership will be evidenced by periodic
statements sent by the depositary to the registered </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>186</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=190,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=542669,FOLIO='186',FILE='DISK116:[20ZBV1.20ZBV74901]DO74901A.;10',USER='JFUSS',CD='10-APR-2020;12:58' -->
<A NAME="page_do74901_1_187"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>holders
of uncertificated ADSs. Profile is a required feature of DRS that allows a DTC participant, claiming to act on behalf of a registered holder of ADSs, to direct the depositary to register a
transfer of those ADSs to DTC or its nominee and to deliver those ADSs to the DTC account of that DTC participant without receipt by the depositary of prior authorization from the ADS holder to
register that transfer. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
connection with and in accordance with the arrangements and procedures relating to DRS/Profile, the parties to the deposit agreement understand that the depositary will not determine whether the
DTC participant that is claiming to be acting on behalf of an ADS holder in requesting registration of transfer and delivery as described above has the actual authority to act on behalf of the ADS
holder (notwithstanding any requirements under the Uniform Commercial Code). In the deposit agreement, the parties agree that the depositary's reliance on and compliance with instructions received by
the depositary through the DRS/Profile System and in accordance with the deposit agreement will not constitute negligence or bad faith on the part of the depositary. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Shareholder Communications; Inspection of Register of Holders of ADSs; ADS Holder Information  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The depositary will make available for your inspection at its office all communications that it receives from us as a holder of deposited securities that we
make generally available to holders of deposited securities. The depositary will send you copies of those communications or otherwise make those communications available to you if we ask it to. You
have a right to inspect the register of holders of ADSs, but not for the purpose of contacting those holders about a matter unrelated to our business or the ADSs. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Each
holder of ADSs will be required to provide certain information, including proof of taxpayer status, residence and beneficial ownership (as applicable), from time to time and in a timely manner as
we, the depositary or the custodian may deem necessary or proper to fulfill obligations under applicable law. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>187</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=191,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=134275,FOLIO='187',FILE='DISK116:[20ZBV1.20ZBV74901]DO74901A.;10',USER='JFUSS',CD='10-APR-2020;12:58' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_dq74901_1_188"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A NAME="dq74901_shares_and_adss_eligible_for_future_sale"> </A>
<A NAME="toc_dq74901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SHARES AND ADSs ELIGIBLE FOR FUTURE SALE    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Prior to this offering, while our ordinary shares have been traded on Euronext Paris since February 2017, there has been no public market on a U.S. national
securities exchange for our ordinary shares or ADSs in the United States. Future sales of ADSs in the U.S. public market after this offering, and the availability of ADSs for future sale, could
adversely affect the market price of our ADSs prevailing from time to time. As described below, a significant number of currently outstanding ordinary shares will not be available for sale immediately
after this offering due to contractual restrictions on transfers of ordinary shares and ADSs. However, sales of substantial amounts of our ordindary shares or ADSs, or the perception that these sales
could occur, could adversely affect prevailing market prices for our ordinary shares or ADSs and could impair our future ability to raise equity capital. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Based
on the number of ordinary shares outstanding on March&nbsp;31, 2020, upon completion of this global offering, ordinary shares (including ordinary shares in the form of ADSs) will be
outstanding. All of the ordinary shares and
ADSs sold in this offering will be freely tradable without restrictions or further registration under the Securities Act, except for any ordinary shares or ADSs sold to our "affiliates," as that term
is defined under Rule&nbsp;144 under the Securities Act. The ordinary shares held by existing shareholders are "restricted securities," as that term is defined in Rule&nbsp;144 under the
Securities Act. Restricted securities may be sold in the United States only if registered or if their resale qualifies for exemption from registration, including under Rules&nbsp;144 or 701
promulgated under the Securities Act. Restricted securities may also be sold outside the United States to non-U.S. persons in accordance with Rule&nbsp;904 of Regulation&nbsp;S under the
Securities Act. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Subject
to the lock-up agreements described below and the provisions of Rule&nbsp;144, Rule&nbsp;701 and Regulation&nbsp;S under the Securities Act and French law, these restricted securities
will be available for sale in the public market at various times beginning 90&nbsp;days after the date of this prospectus. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Rule&nbsp;144  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In general, a person who has beneficially owned restricted ordinary shares for at least six months would be entitled to sell their securities pursuant to
Rule&nbsp;144 under the Securities Act provided that (1)&nbsp;such person is not deemed to have been one of our affiliates at the time of, or at any time during the 90&nbsp;days preceding, a
sale and (2)&nbsp;we have been subject to the Exchange Act periodic reporting requirements for at least 90&nbsp;days before the sale. Persons who have beneficially owned restricted ordinary shares
for at least six months, but who are our affiliates at the time of, or at any time during the 90&nbsp;days preceding a sale, would be subject to additional restrictions, by which such person would
be entitled to sell within any three-month period only a number of securities that does not exceed the greater of either of the
following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 1.0% of the number of ordinary shares then outstanding, which will equal approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares immediately after the completion of this offering based on the number of ordinary shares outstanding as of December&nbsp;31, 3019; and </FONT>
<FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the average weekly trading volume of the ADSs on the Nasdaq Global Market during the four
calendar weeks preceding the filing of a notice on Form&nbsp;144 with respect to the sale; </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>provided,
in each case, that we have been subject to the Exchange Act periodic reporting requirements for at least 90&nbsp;days before the sale. Such sales both by affiliates and by non-affiliates
must also comply with the manner of sale, current public information and notice provisions of Rule&nbsp;144. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Rule&nbsp;701  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Rule&nbsp;701 under the Securities Act, as in effect on the date of this prospectus, permits resales of shares in reliance upon Rule&nbsp;144 but without
compliance with certain restrictions of Rule&nbsp;144, including the holding period requirement. Most of our employees, executive officers or directors who purchased shares under a </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>188</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=192,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=675957,FOLIO='188',FILE='DISK116:[20ZBV1.20ZBV74901]DQ74901A.;12',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dq74901_1_189"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>written
compensatory plan or contract may be entitled to rely on the resale provisions of Rule&nbsp;701, but all holders of Rule&nbsp;701 shares are required to wait until 90&nbsp;days after the
date of this prospectus before selling their shares subject also to French law. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Regulation&nbsp;S  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Regulation&nbsp;S provides generally that sales made in offshore transactions are not subject to the registration or prospectus-delivery requirements of the
Securities Act. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Lock-up Agreements  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We, our executive officers, directors and certain holders of our ordinary shares representing approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our ordinary shares outstanding
on the date of this prospectus have entered into lock-up agreements or otherwise agreed that we and they will not, subject to limited exceptions, (1)&nbsp;offer, pledge, sell, contract to sell, sell
any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, or file with
the Securities and Exchange Commission a registration statement relating to, any ordinary shares or ADSs or any securities convertible into or exchangeable or exercisable for ordinary shares or ADSs,
or publicly disclose the intention to make any offer, sale, pledge, disposition or filing, or (2)&nbsp;enter into any swap or other agreement that transfers all or a portion of the economic
consequences of ownership of any ordinary shares or ADSs or such other securities (regardless of whether any of these transactions are to be settled by the delivery of ordinary shares, ADSs or such
other securities, in cash or otherwise), in each case without the prior written consent of Jefferies&nbsp;LLC, Stifel, Nicolaus&nbsp;&amp; Company, Incorporated and Guggenheim Securities,&nbsp;LLC
for a period of 90&nbsp;days after the date of this prospectus. See "Underwriting" for certain exceptions. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


French Law  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under French law, and in particular under the General Regulations, as well as under MAR, any person that holds insider information shall, until such
information is made public, refrain from (1)&nbsp;using that information by acquiring or disposing of, for its own account or for the account of a third party, directly or indirectly, financial
instruments to which that information relates, (2)&nbsp;recommending that another person engage in insider dealing, or inducing another person to engage in insider dealing, or (3)&nbsp;unlawfully
disclosing inside information outside of the normal exercise of their employment, profession or duties. The use of inside information by cancelling or amending an order concerning a financial
instrument to which the information relates where the order was placed before the person concerned possessed the inside information, shall also be considered to be insider dealing. These rules apply
to all persons who hold insider information as a result of (1)&nbsp;their status as board member, executive officer, manager, employee of the company, third parties acting on behalf of the company
and having access to privileged information as party of their professional relations with the company during the preparation or the completion of a particular transaction, such as investor services
providers, lawyers or public relations agencies, (2)&nbsp;their holding of securities in the share capital of the issuer, (3)&nbsp;their access to information because of their employment,
profession or duties or their participation in the preparation of a financial transaction, and/or (4)&nbsp;being involved in criminal activities. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under
MAR and the General Regulations, it is also prohibited for a person to engage or attempt to engage in market manipulation. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Prohibited
transactions include all transactions related to securities (stocks, bonds, securities convertible, options and warrants), and in particular, the (1)&nbsp;transfer of securities,
(2)&nbsp;exercise of options and warrants (including founder's share warrants (</FONT><FONT SIZE=2><I>bons de souscription de parts de cr&eacute;ateur d'entreprise)</I></FONT><FONT SIZE=2>
and share warrants (</FONT><FONT SIZE=2><I>bons de souscription d'actions</I></FONT><FONT SIZE=2>)) and exercise of any securities giving access to the capital, (3)&nbsp;transfer of free shares
(</FONT><FONT SIZE=2><I>actions gratuites</I></FONT><FONT SIZE=2>) and (4)&nbsp;acquisition of securities. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>189</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=193,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=934479,FOLIO='189',FILE='DISK116:[20ZBV1.20ZBV74901]DQ74901A.;12',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dq74901_1_190"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A NAME="dq74901_material_u.s._federal___dq702252"> </A>
<A NAME="toc_dq74901_2"> </A>
<BR></FONT><FONT SIZE=2><B>  MATERIAL U.S. FEDERAL INCOME AND FRENCH TAX CONSIDERATIONS    <BR>    </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Material U.S. Federal Income Tax Considerations for U.S. Holders  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following is a summary of certain material U.S. federal income tax considerations relating to the acquisition, ownership and disposition of ADSs by a U.S.
holder (as defined below). This summary addresses only the U.S. federal income tax considerations for U.S. holders that are initial purchasers of the ADSs pursuant to the offering and that will hold
such ADSs as capital assets within the meaning of Section&nbsp;1221 of the U.S. Internal Revenue Code of 1986, as amended, or the Code. This summary does not address all U.S. federal income tax
matters that may be relevant to a particular U.S. holder. This summary does not address tax considerations applicable to a holder of ADSs that may be subject to special tax rules including, without
limitation, the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> banks, financial institutions or insurance companies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> brokers, dealers or traders in securities, currencies, commodities, or notional principal
contracts; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> tax-exempt entities or organizations, including an "individual retirement account" or
"Roth IRA" as defined in Section&nbsp;408 or 408A of the Code, respectively; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> real estate investment trusts, regulated investment companies or grantor trusts; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> persons that hold the ADSs as part of a "hedging," "integrated" or "conversion"
transaction or as a position in a "straddle" for U.S. federal income tax purposes; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> S corporations, partnerships (including entities or arrangements treated as partnerships
for U.S. federal income tax purposes) or other pass-through entities, or persons that will hold the ADSs through such an entity; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> certain former citizens or long term residents of the United States; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> persons that are subject to Section&nbsp;451(b) of the Code; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> persons that received ADSs as compensation for the performance of services; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> holders that own directly, indirectly, or through attribution 10% or more of our ADSs and
shares by vote or value; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> holders that have a "functional currency" other than the U.S. dollar. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Further,
this summary does not address the U.S. federal estate, gift, or alternative minimum tax considerations, or any U.S. state, local, or non-U.S. tax considerations of the acquisition, ownership
and disposition of the ADSs. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This
description is based on the Code, existing, proposed and temporary U.S. Treasury Regulations promulgated thereunder and administrative and judicial interpretations thereof, in each case as in
effect and available on the date hereof. All the foregoing is subject to change, which change could apply retroactively, and to differing interpretations, all of which could affect the tax
considerations described below. There can be no assurances that the U.S. Internal Revenue Service, or the IRS, will not take a position concerning the tax consequences of the acquisition, ownership
and disposition of the ADSs or that such a position would not be sustained. Holders should consult their own tax advisers concerning the U.S. federal, state, local and non-U.S. tax consequences of
acquiring, owning, and disposing of the ADSs in their particular circumstances. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For
the purposes of this summary, a "U.S. holder" is a beneficial owner of ADSs that is (or is treated as), for U.S. federal income tax
purposes:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an individual who is a citizen or resident of the United States; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>190</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=194,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=289271,FOLIO='190',FILE='DISK116:[20ZBV1.20ZBV74901]DQ74901A.;12',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dq74901_1_191"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a corporation, or other entity that is treated as a corporation for U.S. federal income
tax purposes, created or organized in or under the laws of the United States, any state thereof, or the District of Columbia; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an estate, the income of which is subject to U.S. federal income taxation regardless of
its source; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a trust, if a court within the United States is able to exercise primary supervision over
its administration and one or more U.S. persons have the authority to control all of the substantial decisions of such trust or has a valid election in effect under applicable U.S. Treasury
Regulations to be treated as a United States person. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>If
a partnership (or any other entity or arrangement treated as a partnership for U.S. federal income tax purposes) holds ADSs, the U.S. federal income tax consequences relating to an investment in
the ADSs will depend in part upon the status of the partner and the activities of the partnership. Such a partner or partnership should consult its tax advisor regarding the U.S. federal income tax
considerations of acquiring, owning and disposing of the ADSs in its particular circumstances. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>Persons considering an investment in the ADSs should consult their own tax advisors as to the particular tax consequences applicable to them relating to the acquisition,
ownership and disposition of the ADSs, including the applicability of U.S. federal, state and local tax laws and non-U.S. tax laws.</B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
discussion below assumes that the representations contained in the deposit agreement are true and that the obligations in the deposit agreement and any related agreement will be complied with in
accordance with their terms. Generally, a holder of an ADS should be treated for U.S. federal income tax purposes as holding the ordinary shares represented by the ADS. Accordingly, no gain or loss
will be recognized upon an exchange of ADSs for ordinary shares. The U.S. Treasury has expressed concerns that intermediaries in the chain of ownership between the holder of an ADS and the issuer of
the security underlying the ADS may be taking actions that are inconsistent with the beneficial ownership of the underlying security. Accordingly, the creditability of foreign taxes, if any, as
described below, could be affected by actions taken by intermediaries in the chain of ownership between the holders of ADSs and our company if as a result of such actions the holders of ADSs are not
properly treated as beneficial owners of the underlying ordinary shares. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Passive Foreign Investment Company Considerations.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In general, a corporation organized outside the United States generally will be classified as a PFIC for U.S.
federal income tax purposes in any taxable year in which, after applying certain look-through rules with respect to the income and assets of its subsidiaries, either: (1)&nbsp;at least 75% of its
gross income is "passive income" or (2)&nbsp;at least 50% of the average quarterly value of its total gross assets (which, assuming we are not a controlled foreign corporation for the year being
tested, would be measured by fair market value of our assets, and for which purpose the total value of our assets may be determined in part by the market value of the ADSs and our ordinary shares,
which are subject to change) is attributable to assets that produce "passive income" or are held for the production of "passive income." </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Passive
income for this purpose generally includes dividends, interest, royalties, rents, gains from commodities and securities transactions, the excess of gains over losses from the disposition of
assets which produce passive income, and includes amounts derived by reason of the temporary investment of funds raised in offerings of the ADSs. Assets that produce or are held for the production of
passive income generally include cash, even if held as working capital or raised in a public offering, marketable securities, and other assets that may produce passive income. Generally, in
determining whether a non-U.S. corporation is a PFIC, a proportionate share of the income
and assets of each corporation in which it owns, directly or indirectly, at least a 25% interest (by value) is taken into account. For purposes of the PFIC test, the market value of our assets may be
determined in large part by reference to the market price of the ADSs and our ordinary shares, which is likely to fluctuate after the offering. In addition, the composition of our income and assets
will be affected by how, and how quickly, we use the cash proceeds from this offering in </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>191</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=195,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=956800,FOLIO='191',FILE='DISK116:[20ZBV1.20ZBV74901]DQ74901A.;12',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dq74901_1_192"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>our
business. Whether we are a PFIC for any taxable year will depend on our assets and income in each year, and because this is a factual determination made annually after the end of each taxable
year, there can be no assurance that we will not be considered a PFIC in any taxable year. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Based
on our current estimates of the composition of our income and valuation of our assets for the year ending December&nbsp;31, 2019, we believe that we were a PFIC for the year ending
December&nbsp;31, 2019 and it is possible that we will be a PFIC for the current taxable year. Our status as a PFIC is a fact-intensive determination made on an annual basis after the end of each
taxable year. Accordingly, our U.S. counsel expresses no opinion with respect to our PFIC status for any prior taxable year, and also expresses no opinion with regard to our expectations regarding our
PFIC status in the future. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
we are a PFIC, and you are a U.S. holder, then unless you make one of the elections described below, a special tax regime will apply to both (a)&nbsp;any "excess distribution" by us to you
(generally, your ratable portion of distributions in any year which is greater than 125% of the average annual distribution received by you in the shorter of the three preceding years or your holding
period for the ADSs) and (b)&nbsp;any gain realized on the sale or other disposition of the ADSs. Under this regime, any excess distribution and realized gain will be treated as ordinary income and
will be subject to tax as if (a)&nbsp;the excess distribution or gain had been realized ratably over your holding period, (b)&nbsp;the amount deemed realized in each year had been subject to tax
in each year of that holding period at the highest marginal rate for such year (other than income allocated to the current period or any taxable period before we became a PFIC, which would be subject
to tax at the U.S. holder's regular ordinary income rate for the current year and would not be subject to the interest charge discussed below), and (c)&nbsp;the interest charge generally applicable
to underpayments of tax had been imposed on the taxes deemed to have been payable in those years. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
we are a PFIC for any year during which a U.S. holder holds ADSs, we must generally continue to be treated as a PFIC by that holder for all succeeding years during which the U.S. holder holds the
ADSs, unless we cease to meet the requirements for PFIC status and the U.S. holder makes a "deemed sale" election with respect to the common shares. If the election is made, the U.S. holder will be
deemed to sell the ADSs it holds at their fair market value on the last day of the last taxable year in which we qualified as a PFIC, and any gain recognized from such deemed sale would be taxed under
the PFIC excess distribution regime. After the deemed sale election, the U.S. holder's common shares would not be treated as shares of a PFIC unless we subsequently become a PFIC. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Certain
elections may alleviate some of the adverse consequences of PFIC status and would result in an alternative treatment of the ADSs. A U.S. holder can make an election, if we provide the
necessary information, to treat us as a "qualified electing fund" or QEF in the first taxable year in which we are treated as a PFIC with respect to the U.S. holder. Generally, a U.S. holder must make
the QEF election by attaching a separate properly completed IRS Form 8621 to the U.S. holder's timely filed U.S. federal income tax return for the first taxable year in which the U.S. holder held our
ADSs that includes the close of our taxable year for which we met the PFIC gross income test or gross asset test. If we determine that we are a PFIC for any taxable year, we will use commercially
reasonable efforts to, and currently expect to, provide the information necessary for U.S. holders to make a QEF election. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
a U.S. holder makes a QEF election with respect to a PFIC, the U.S. holder will be currently taxable on its pro rata share of the PFIC's ordinary earnings and net capital gain (at ordinary income
and capital gain rates, respectively) for each taxable year that the entity is classified as a PFIC. If a U.S. holder makes a QEF election with respect to us, any distributions paid by us out of our
earnings and profits that were previously included in the U.S. holder's income under the QEF election would not be taxable to the holder. A U.S. holder will increase its tax basis in its ADSs by an
amount equal to any income included under the QEF election and will decrease its tax basis by any amount distributed on the ADSs that is not included in the holder's income. If a U.S. holder has made
a QEF election with respect to its ADSs, any gain or loss recognized by the U.S. holder on a sale or other disposition of such ADSs will constitute capital gain or </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>192</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=196,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=713819,FOLIO='192',FILE='DISK116:[20ZBV1.20ZBV74901]DQ74901A.;12',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dq74901_1_193"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>loss.
U.S. holders should consult their tax advisors regarding making QEF elections in their particular circumstances. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Alternatively,
if a U.S. holder makes a mark-to-market election, the U.S. holder generally will recognize as ordinary income any excess of the fair market value of the ADSs at the end of each taxable
year over its adjusted tax basis, and will recognize an ordinary loss in respect of any excess of the adjusted tax basis of the ADSs over its fair market value at the end of the taxable year (but only
to the extent of the net amount of income previously included as a result of the mark-to-market election). If a U.S. holder makes the election, the U.S. holder's tax basis in the ADSs will be adjusted
to reflect these income or loss amounts. Any gain recognized on the sale or other disposition of ADSs in a year when we are a PFIC will be treated as ordinary income and any loss will be treated as an
ordinary loss (but only to the extent of the net amount of income previously included as a result of the mark-to-market election) and thereafter as capital loss. The mark-to-market election is
available only if we are a PFIC and the ADSs are "regularly traded" on a "qualified exchange." The ADSs will be treated as "regularly traded" in any calendar year in which more than a de minimis
quantity of the ADSs are traded on a qualified exchange on at least 15&nbsp;days during each calendar quarter (subject to the rule that trades that have as one of their principal purposes the
meeting of the trading requirement as disregarded). The Nasdaq Global Market is a qualified exchange for this purpose and, consequently, if the ADSs are regularly traded, the mark-to-market election
will be available to a U.S. holder. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
we are determined to be a PFIC, the general tax treatment for U.S. holders described in this section would apply to indirect distributions and gains deemed to be realized by U.S. holders in respect
of any of our future subsidiaries that also may be determined to be PFICs. Moreover, a mark-to-market election generally would not be available with respect to any such subsidiaries. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
we were a PFIC (or with respect to a particular U.S. holder were treated as a PFIC) for a taxable year in which we paid a dividend or for the prior taxable year, the favorable tax rate described in
"&#151; Distributions" below with respect to dividends paid to certain non- corporate U.S. holders would not apply. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
a U.S. holder owns ADSs during any taxable year in which we are a PFIC, the U.S. holder generally will be required to file an IRS Form&nbsp;8621 (Information Return by a Shareholder of a Passive
Foreign Investment Company or Qualified Electing Fund) with respect to the company, generally with the U.S. holder's federal income tax return for that year. If our company were a PFIC for a given
taxable year, then you should consult your tax advisor concerning your annual filing requirements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>The U.S. federal income tax rules relating to PFICs are complex. Prospective U.S. investors are urged to consult their own tax advisers with respect to the acquisition,
ownership and disposition of the ADSs, the consequences to them of an investment in a PFIC, any elections available with respect to the ADSs and the IRS information reporting obligations with respect
to the acquisition, ownership and disposition of the ADSs.</B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
indicated below, the remainder of this discussion is subject to U.S. federal income tax rules applicable to a "passive foreign investment company," or a PFIC. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Distributions.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Subject to the discussion under "</FONT><FONT SIZE=2><I>Passive Foreign Investment Company Considerations,</I></FONT><FONT SIZE=2>" above, the gross
amount of any distribution (before reduction for any amounts withheld in respect of French withholding tax) actually or constructively received by a U.S. holder with respect to ADSs will be taxable to
the U.S. holder as a dividend to the extent of the U.S. holder's pro rata share of our current and accumulated earnings and profits as determined under U.S. federal income tax principles.
Distributions in excess of earnings and profits will be non-taxable to the U.S. holder to the extent of, and will be applied against and reduce (but not below zero), the U.S. holder's adjusted tax
basis in the ADSs. Distributions in excess of earnings and profits and such adjusted tax basis will generally be taxable to the U.S. holder as described below under "</FONT><FONT SIZE=2><I>Sale,
exchange or other taxable disposition of the ADSs</I></FONT><FONT SIZE=2>." However, since we do not </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>193</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=197,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=986533,FOLIO='193',FILE='DISK116:[20ZBV1.20ZBV74901]DQ74901A.;12',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dq74901_1_194"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>calculate
our earnings and profits under U.S. federal income tax principles, it is expected that any distribution will be reported as a dividend, even if that distribution would otherwise be treated
as a non-taxable return of capital or as capital gain under the rules described above. Non-corporate U.S. holders may qualify for the preferential rates of taxation applicable to long-term capital
gains (i.e.,&nbsp;gains from the sale of capital assets held for more than one year) with respect to dividends on ADSs if we are a "qualified foreign corporation." A non-United States corporation
(other than a corporation that is classified as a PFIC for the taxable year in which the dividend is paid or the preceding taxable year) generally will be considered to be a qualified foreign
corporation (a)&nbsp;if it is eligible for the benefits of a comprehensive tax treaty with the United States which the Secretary of Treasury of the United States determines is satisfactory for
purposes of these rules and which includes an exchange of information provision, or (b)&nbsp;with respect to any dividend it pays on ADSs which are readily tradable on an established securities
market in the United States. The ADSs are listed on the Nasdaq Global Market, which is an established securities market in the United States, and we expect the ADSs to be readily tradable on the
Nasdaq Global Market. There can be no assurance that the ADSs will be considered readily tradable on an established securities market in the United States in later years. Moreover, the Company, which
is incorporated under the laws of France, believes that it qualifies as a resident of France for purposes of, and is eligible for the benefits of, the Convention between the Government of the United
States of America and the Government of the French Republic for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Income and Capital, signed on
August&nbsp;31, 1994, as amended and currently in force, or the Treaty, although there can be no assurance in this regard. Further, the IRS has determined that the Treaty is satisfactory for
purposes of the qualified dividend rules and that it includes an exchange-of-information program. Therefore, subject to the discussion under "</FONT><FONT SIZE=2><I>Passive Foreign Investment Company
Considerations</I></FONT><FONT SIZE=2>," above, if the Treaty is applicable, or if the ADSs are readily tradable on an established securities market in the United States, such dividends will generally
be "qualified dividend income" in the hands of individual U.S. holders eligible for the preferential tax rates, provided that certain conditions are met, including conditions relating to holding
period and the absence of certain risk reduction transactions. The dividends will not be eligible for the dividends-received deduction generally allowed to corporate U.S. holders. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A
U.S. holder generally may claim the amount of any French withholding tax as either a deduction from gross income or a credit against its U.S. federal income tax liability. However, the foreign tax
credit is subject to numerous complex limitations that must be determined and applied on an individual basis. Each U.S. holder should consult its own tax advisors regarding the foreign tax credit
rules. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
general, the amount of a distribution paid to a U.S. holder in a foreign currency will be the dollar value of the foreign currency calculated by reference to the spot exchange rate on the day the
U.S. holder receives the distribution, (actually or constructively), regardless of whether the foreign currency is converted into U.S. dollars at that time. Any foreign currency gain or loss a U.S.
holder realizes on a subsequent conversion of foreign currency into U.S. dollars will be U.S. source ordinary income or loss. If dividends received in a foreign currency are converted into U.S.
dollars on the day they are received, a U.S. holder should not be required to recognize foreign currency gain or loss in respect of the dividend. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Sale, Exchange or Other Taxable Disposition of the ADSs.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;A U.S. holder will generally recognize gain or loss for
U.S. federal income tax purposes upon the sale, exchange or other taxable disposition of ADSs in an amount equal to the difference between the U.S. dollar value of the amount realized from such sale
or exchange and the U.S. holder's adjusted tax basis for those ADSs. Subject to the discussion under "</FONT><FONT SIZE=2><I>Passive Foreign Investment Company Considerations</I></FONT><FONT SIZE=2>"
above, this gain or loss will generally be a capital gain or loss. A U.S. holder's adjusted tax basis in the ADSs generally will be equal to the cost of such ADSs. Capital gain from the sale, exchange
or other taxable disposition of ADSs of a non-corporate U.S. holder is generally eligible for a preferential rate of taxation applicable to capital gains, if the non-corporate U.S. holder's holding
period determined at the time of such sale, exchange or other taxable disposition for such ADSs exceeds one year (i.e.,&nbsp;such gain is long-term taxable gain). The deductibility of capital losses
for U.S. federal income tax purposes is subject to limitations under the Code. Any such gain or loss that a U.S. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>194</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=198,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=996282,FOLIO='194',FILE='DISK116:[20ZBV1.20ZBV74901]DQ74901A.;12',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dq74901_1_195"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>holder
recognizes generally will be treated as U.S. source income or loss for foreign tax credit limitation purposes. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For
a cash basis taxpayer, units of foreign currency paid or received are translated into U.S. dollars at the spot rate on the settlement date of the sale, exchange or other taxable disposition. In
that case, no foreign currency exchange gain or loss will result from currency fluctuations between the trade date and the settlement date of such a purchase or sale. An accrual basis taxpayer,
however, may elect the same treatment required of cash basis taxpayers with respect to sales, exchanges or other taxable dispositions of the ADSs that are traded on an established securities market,
provided the election is applied consistently from year to year. Such election may not be changed without the consent of the IRS. For an accrual basis taxpayer who does not make such election, units
of foreign currency paid or received are translated into U.S. dollars at the spot rate on the trade date of the sale, exchange or other taxable disposition. Such an accrual basis taxpayer may
recognize exchange gain or loss based on currency fluctuations between the trade date and the settlement date. Any foreign currency gain or loss a U.S. Holder realizes will be U.S. source ordinary
income or loss. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Medicare tax.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Certain U.S. holders that are individuals, estates or trusts are subject to a 3.8% tax on all or a portion of their "net investment income," which may
include all or a portion of their dividend income and net gains from the disposition of ADSs. Each U.S. holder that is an individual, estate or trust is urged to consult its tax advisors regarding the
applicability of the Medicare tax to its income and gains in respect of its investment in the ADSs. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Backup Withholding and Information Reporting.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;U.S. holders generally will be subject to information reporting requirements with respect to dividends on ADSs and on
the proceeds from the sale, exchange or disposition of ADSs that are paid within the United States or through U.S.-related financial intermediaries, unless the U.S. holder is an "exempt recipient." In
addition, U.S. holders may be subject to backup withholding on such payments, unless the U.S. holder provides a taxpayer identification number and a duly executed IRS Form&nbsp;W-9 or
otherwise establishes an exemption. Backup withholding is not an additional tax, and the amount of any backup withholding will be allowed as a credit against a U.S. holder's U.S. federal income tax
liability and may entitle such holder to a refund, provided that the required information is timely furnished to the IRS. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Foreign Asset Reporting.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Certain U.S. holders who are individuals are required to report information relating to an interest in the ADSs, subject to certain
exceptions (including an exception for shares held in accounts maintained by U.S. financial institutions) by filing IRS Form&nbsp;8938 (Statement of Specified Foreign Financial Assets) with their
federal income tax return. U.S. holders are urged to consult their tax advisors regarding their information reporting obligations, if any, with respect to their ownership and disposition of the ADSs. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Material French Income Tax Considerations for U.S. Holders  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following describes the material French income tax considerations for U.S. holders of purchasing, owning and disposing of the ADSs. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>This
discussion does not purport to be a complete analysis or listing of all potential tax effects of the acquisition, ownership or disposition of the ADSs to any particular investor, and does not
discuss tax considerations that arise from rules of general application or that are generally assumed to be known by investors. All of the following is subject to change. Such changes could apply
retroactively and could affect the consequences described below. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>France
has recently introduced a comprehensive set of new tax rules applicable to French assets that are held by or in foreign trusts. These rules provide inter alia for the inclusion of trust assets
in the settlor's net assets for the purpose of applying the French real estate wealth tax, for the application of French gift and death duties to French assets held in trust, for a specific tax on
capital on the French assets of foreign </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>195</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=199,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=428832,FOLIO='195',FILE='DISK116:[20ZBV1.20ZBV74901]DQ74901A.;12',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dq74901_1_196"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>trusts
not already subject to the French real estate wealth tax and for a number of French tax reporting and disclosure obligations. The following discussion does not address the French tax
consequences applicable to securities (including ADSs) held in trusts. If ADSs are held in trust, the grantor, trustee and beneficiary are urged to consult their own tax advisor regarding the specific
tax consequences of acquiring, owning and disposing of securities. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
description of the French income tax and wealth tax consequences set forth below is based on the Treaty, and the tax guidelines issued by the French tax authorities in force as of the date of this
prospectus. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
a partnership (or any other entity treated as partnership for U.S. federal income tax purposes) holds ADSs, the tax treatment of the partnership and a partner in such partnership generally will
depend on the status of the partner and the activities of the partnership. Such partner or partnership is urged to consult its own tax adviser regarding the specific tax consequences of acquiring,
owning and disposing of securities. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This
discussion applies only to investors that hold ADSs as capital assets that have the U.S. dollar as their functional currency, that are entitled to Treaty benefits under the "Limitation on
benefits" provision contained in the Treaty, and whose ownership of the ADSs is not effectively connected to a permanent establishment or a fixed base in France. Certain U.S. holders (including, but
not limited to, U.S. expatriates, partnerships or other entities classified as partnerships for U.S. federal income tax purposes, banks, insurance companies, regulated investment companies, tax-exempt
organizations, financial institutions, persons subject to the alternative minimum tax, persons who acquired the securities pursuant to the exercise of employee share options or otherwise as
compensation, persons that own (directly, indirectly or by attribution) 5% or more of our voting stock or 5% or more of our outstanding share capital, dealers in securities or currencies, persons that
elect to mark their securities to market for U.S. federal income tax purposes and persons holding securities as a position in a synthetic security, straddle or conversion transaction) may be subject
to special rules not discussed below. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>U.S.
holders are urged to consult their own tax advisors regarding the tax consequences of the purchase, ownership and disposition of securities in light of their particular circumstances, especially
with regard to the "Limitations on benefits" provision. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Tax on Sale or Other Disposition  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As a matter of principle, under French tax law, a U.S. holder should not be subject to any French tax on any capital gain from the sale, exchange, repurchase
or redemption by us of ordinary shares or ADSs, provided such U.S. holder is not a French tax resident for French tax purposes and has not held more than 25% of our dividend rights, known as </FONT> <FONT SIZE=2><I>"droits aux benefices sociaux",
</I></FONT><FONT SIZE=2> at any time during the preceding five years, either directly or indirectly, and, as relates to individuals, alone or with
relatives (as an exception, a U.S holder resident, established or incorporated in a non-cooperative State or territory as defined in Article&nbsp;238-0 A of the French </FONT><FONT SIZE=2><I>Code
g&eacute;n&eacute;ral des imp&ocirc;ts</I></FONT><FONT SIZE=2> (French Tax Code, or FTC) other than those States or territories mentioned in 2&deg; of 2 bis of the same
Article&nbsp;238-0 A should be subject to a 75% withholding tax in France on any such capital gain, regardless of the fraction of the dividend rights it holds). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under
application of the Treaty, a U.S. holder who is a U.S. resident for purposes of the Treaty and entitled to Treaty benefit will not be subject to French tax on any such capital gain unless the
ordinary shares or the ADSs
form part of the business property of a permanent establishment or fixed base that the U.S. holder has in France. U.S. holders who own ordinary shares or ADSs through U.S. partnerships that are not
resident for Treaty purposes are advised to consult their own tax advisors regarding their French tax treatment and their eligibility for Treaty benefits in light of their own particular
circumstances. A U.S. holder that is not a U.S. resident for Treaty purposes or is not entitled to Treaty benefit (and in both cases is not resident, established or incorporated in a non-cooperative
State or territory as defined in Article&nbsp;238-0 A of the FTC other than those States or territories mentioned in 2&deg; of 2 bis of the same Article&nbsp;238-0 A)&nbsp;and has held
more than 25% of our dividend rights, known as </FONT><FONT SIZE=2><I>"droits aux benefices sociaux,"</I></FONT><FONT SIZE=2> at any time during the preceding five years, either directly or indirectly,
and, as relates to </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>196</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=200,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=918480,FOLIO='196',FILE='DISK116:[20ZBV1.20ZBV74901]DQ74901A.;12',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dq74901_1_197"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>individuals,
alone or with relatives will be subject to a levy in France at the rate of 12.8% if such U.S. holder is an individual or 28% for corporate bodies or other legal entities (as from
January&nbsp;1, 2020, to be progressively reduced to 25% by 2022). Special rules apply to U.S. holders who are residents of more than one country. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Pursuant
to Article&nbsp;235 ter ZD of the FTC, purchases of shares or ADSs of a French company listed on a regulated market of the European Union or on a foreign regulated market formally
acknowledged by the French Financial Market Authority, or AMF, are subject to a 0.3% French tax on financial transactions provided that the issuer's market capitalization exceeds one billion euros as
of December&nbsp;1 of the year preceding the taxation year. Nasdaq is not currently acknowledged by the French AMF but this may change in the future. A list of French relevant companies whose market
capitalization exceeds 1&nbsp;billion euros as of December&nbsp;1 of the year preceding the taxation year is published annually by the French State. As at December&nbsp;1, 2019, our market
capitalization did not exceed one billion euros. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Following
this offering, purchases of our securities may be subject to such tax provided that its market capitalization exceeds one billion euros and that Nasdaq is acknowledged by the French AMF. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
the case where Article&nbsp;235 ter ZD of the FTC is not applicable, transfers of shares issued by a listed French company are subject to uncapped registration duties at the rate of 0.1% if the
transfer is evidenced by a written statement (</FONT><FONT SIZE=2><I>acte</I></FONT><FONT SIZE=2>) executed either in France or outside France. Although there is no case law or official guidelines
published by the French tax authorities on this point, transfers of ADSs should remain outside of the scope of the aforementioned 0.1% registration duties. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Taxation of Dividends  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Dividends paid by a French corporation to non-residents of France are generally subject to French withholding tax at a rate of 12.8% for individuals or 28% for
corporate bodies or other legal entities (the 28% rate for legal entities will be progressively reduced to 25% by 2022). Dividends paid by a French corporation in a non-cooperative State or territory,
as defined in Article&nbsp;238-0 A of the FTC other than those States or territories mentioned in 2&deg; of 2 bis of the same Article&nbsp;238-0 A, may be subject to French withholding tax
at a rate of 75%. However, eligible U.S. holders entitled to Treaty benefits under the "Limitation on benefits" provision contained in the Treaty who are U.S. residents, as defined pursuant to the
provisions of the Treaty, will not be subject to this 28% or 75% withholding tax rate, but may be subject to the withholding tax at a reduced rate (as described below). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under
the Treaty, the rate of French withholding tax on dividends paid to an eligible U.S. holder who is a resident as defined pursuant to the provisions of the Treaty and whose ownership of the
ordinary shares or ADSs is not effectively connected with a permanent establishment or fixed base that such U.S. holder has in France, is generally reduced to 15%, or to 5% if such U.S. holder is a
corporation and owns directly or indirectly at least 10% of the share capital of the issuer; such U.S. holder may claim a refund from the French tax authorities of the amount withheld in excess of the
Treaty rates of 15% or 5%, if any. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For
U.S. holders that are not individuals but are U.S. residents, as defined pursuant to the provisions of the Treaty, the requirements for eligibility for Treaty benefits, including the reduced 5% or
15% withholding tax rates contained in the "Limitation on benefits" provision of the Treaty, are complex, and certain technical changes were made to these requirements by the protocol of
January&nbsp;13, 2009. U.S. holders are advised to consult their own tax advisors regarding their eligibility for Treaty benefits in light of their own particular circumstances. Dividends paid to an
eligible U.S. holder may immediately be subject to the reduced rates of 5% or 15% provided that:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> such holder establishes before the date of payment that it is a U.S. resident under the
Treaty by completing and providing the depositary with a treaty form (Form&nbsp;5000) in accordance with the French guidelines(BOI-INT-DG-20-20-20-20-20120912); or </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>197</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=201,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=803887,FOLIO='197',FILE='DISK116:[20ZBV1.20ZBV74901]DQ74901A.;12',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_dq74901_1_198"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the depositary or other financial institution managing the securities account in the U.S.
of such holder provides the French paying agent with a document listing certain information about the U.S. holder and its ordinary shares or ADSs and a certificate whereby the financial institution
managing the U.S. holder's securities account in the United States takes full responsibility for the accuracy of the information provided in the document. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Otherwise,
dividends paid to a U.S. holder that are corporate bodies or other legal entity will be subject to French withholding tax at the rate of 30%, or 75% for any U.S. holder if paid in a
non-cooperative State or territory (as defined in Article&nbsp;238-0 A of the FTC, other than those States or territories mentioned in 2&deg; of 2 bis of the same Article&nbsp;238-0 A),
and then reduced at a later date to 5% or 15%, provided that such holder duly completes and provides the French tax authorities with the treaty forms Form&nbsp;5000 and Form&nbsp;5001 before
December&nbsp;31 of the second calendar year following the year during which the dividend is paid. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Estate and Gift Taxes  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In general, a transfer of securities by gift or by reason of death of a U.S. holder that would otherwise be subject to French gift or inheritance tax,
respectively, will not be subject to such French tax by reason of the Convention between the Government of the United States of America and the Government of the French Republic for the Avoidance of
Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Estates, Inheritances and Gifts, dated November&nbsp;24, 1978 (as amended by the protocol of December&nbsp;8, 2004),
unless the donor or the transferor is domiciled in France at the time of making the gift or at the time of his or her death, or the securities were used in, or held for use in, the conduct of a
business through a permanent establishment or a fixed base in France. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Real Estate Wealth Tax  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On January&nbsp;1, 2018, the French wealth tax (</FONT><FONT SIZE=2><I>imp&ocirc;t de solidarit&eacute; sur la
fortune</I></FONT><FONT SIZE=2>) was replaced with a French real estate wealth tax (</FONT><FONT SIZE=2><I>imp&ocirc;t sur la fortune immobili&egrave;re</I></FONT><FONT SIZE=2>) which
applies only to individuals owning French real estate assets or rights, directly or indirectly through one or more legal entities and whose net taxable assets amount to at least
1,300,000&nbsp;euros. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>French
real estate wealth tax may only apply to U.S. holders to the extent the company holds real estate assets that are not allocated to its operational activity, for the fraction of the value of the
financial rights representing
such assets, and does not generally apply to securities held by an eligible U.S. holder who is a U.S. resident, as defined pursuant to the provisions of the Treaty, provided that such U.S. holder does
not own directly or indirectly more than 25% of the issuer's financial rights. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>198</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=202,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=662405,FOLIO='198',FILE='DISK116:[20ZBV1.20ZBV74901]DQ74901A.;12',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_ds74901_1_199"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A NAME="ds74901_enforcement_of_civil_liabilities"> </A>
<A NAME="toc_ds74901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  ENFORCEMENT OF CIVIL LIABILITIES    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are a corporation organized under the laws of France. The majority of our directors are citizens and residents of countries other than the United States,
and the majority of our assets are located outside of the United States. We have appointed an agent for service of process in the United States, however, it may be difficult for
investors:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> to obtain jurisdiction over us or our non-U.S. resident officers and directors in U.S.
courts in actions predicated on the civil liability provisions of the U.S. federal securities laws; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> to enforce in U.S. courts judgments obtained in such actions against us or our non-U.S.
resident officers and directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> to bring an original action in a French court to enforce liabilities based upon the U.S.
federal securities laws against us or our non-U.S. resident officers or directors; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> to enforce against us or our directors in non-U.S. courts, including French courts,
judgments of U.S. courts predicated upon the civil liability provisions of the U.S. federal securities laws. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Nevertheless,
a final judgment for the payment of money rendered by any federal or state court in the United States based on civil liability, whether or not predicated solely upon the U.S. federal
securities laws, would be recognized and enforced in France provided that a French judge considers that this judgment meets the French legal requirements concerning the recognition and the enforcement
of foreign judgments and is capable of being immediately enforced in the United States. A French court is therefore likely to grant the enforcement of a foreign judgment without a review of the merits
of the underlying claim, only if (1)&nbsp;the judgment is enforceable in the United States, (2)&nbsp;that judgment does not contravene international public order and public policy of France both
pertaining to the merits and the procedure, including due process and (3)&nbsp;the judgment was rendered by a federal or state court having jurisdiction over the matter, which means that the dispute
must be sufficiently connected to the United States and not fall under the scope of the French courts' exclusive jurisdiction. The French court would also require that the U.S. judgment is not tainted
with fraud and is not incompatible with a judgment rendered by a French court in the same matter, or with an earlier judgment rendered by a foreign court in the same matter. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, French law guarantees full compensation for the harm suffered but is limited to the actual damages, so that the victim does not suffer or benefit from the situation. Such system excludes
damages such as, but not limited to, punitive and exemplary damages. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
a result, the enforcement, by U.S. investors, of any judgments obtained in U.S. courts in civil and commercial matters, including judgments under the U.S. federal securities law against us or
members of our board of directors, officers or certain experts named herein who are residents of France or countries other than the United States would be subject to the above conditions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Finally,
there may be doubt as to whether a French court would impose civil liability on us, the members of our board of directors, our officers or certain experts named herein in an original action
predicated solely upon the U.S. federal securities laws brought in a court of competent jurisdiction in France against us or such members, officers or experts, respectively. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>199</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=203,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=138097,FOLIO='199',FILE='DISK116:[20ZBV1.20ZBV74901]DS74901A.;17',USER='SCAVALI',CD='10-APR-2020;08:51' -->
<A NAME="page_ds74901_1_200"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A NAME="ds74901_underwriting"> </A>
<A NAME="toc_ds74901_2"> </A>
<BR></FONT><FONT SIZE=2><B>  UNDERWRITING    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are offering the ordinary shares and ordinary shares in the form of ADSs described in this prospectus through a number of underwriters.
Jefferies&nbsp;LLC, Stifel, Nicolaus&nbsp;&amp; Company, Incorporated and Guggenheim Securities,&nbsp;LLC are acting as representatives of the underwriters in the U.S. offering. Jefferies
International Ltd and Stifel Nicolaus Europe Limited are acting as representatives in the European offering. As used herein, with respect to the U.S. offering, the term "underwriters" refers to the
underwriters offering ordinary shares in the form of ADSs in the United States and, with respect to the European offering, the underwriters offering ordinary shares in Europe, as the case may be. The
underwriters in the U.S. offering and the underwriters in the European offering are collectively referred to herein as the "underwriters." We have entered into an underwriting agreement with the
representatives on behalf of the underwriters. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to the underwriters, and each underwriter has severally agreed
to purchase, at the offering price less the underwriting discounts set forth on the cover page of this prospectus, the number of ordinary shares (exclusive of ordinary shares underlying ADSs) and ADSs
(including underlying ordinary shares) listed next to its name in the following table: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="72pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="51pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Underwriter

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Number of<BR>
ordinary shares </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Number of<BR>
ADSs </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jefferies&nbsp;LLC</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stifel, Nicolaus&nbsp;&amp; Company, Incorporated</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Guggeinheim Securities,&nbsp;LLC</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jefferies International&nbsp;Ltd</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stifel Nicolaus Europe Limited</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>KBC Securities USA LLC</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Roth Capital Partners, LLC</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>The
underwriters are committed to purchase all of the ordinary shares and ADSs offered by us if they purchase any ordinary shares and ADSs. The underwriting agreement also provides that if an
underwriter defaults, the purchase commitments of non-defaulting underwriters may also be increased or the offering may be terminated. The total number of ordinary shares (including ordinary shares in
the form of ADSs) to be sold in the U.S. offering and the European offering is subject to reallocation between these offerings as permitted under applicable law and regulations. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
underwriters propose to offer the ordinary shares and ADSs directly to the public at the public offering price set forth on the cover page of this prospectus and to certain dealers at that price
less a concession not in excess of &euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
ADS. Any such dealers may resell ordinary shares and ADSs to certain other brokers or
dealers at a discount of up to &euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS
from the offering price. After the initial offering of the ordinary shares and ADSs, if
all of the ordinary shares and ADSs are not sold at the offering price, the underwriters may change the offering price and the other selling terms. Sales of ordinary shares and ADSs made outside of
the United States may be made by affiliates of the underwriters. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
underwriters have an option to buy up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional ordinary shares
and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADSs from us to cover sales of ordinary shares and ADSs by the underwriters which exceed the
number of ordinary shares and ADSs specified in the table above. The underwriters have 30&nbsp;days from the date of this prospectus to exercise this option to purchase additional ordinary shares
and ADSs. If any ordinary shares and ADSs are purchased with this option to purchase additional ordinary shares and ADSs, the underwriters will purchase </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>200</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=204,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=627655,FOLIO='200',FILE='DISK116:[20ZBV1.20ZBV74901]DS74901A.;17',USER='SCAVALI',CD='10-APR-2020;08:51' -->
<A NAME="page_ds74901_1_201"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>ordinary
shares and ADSs in approximately the same proportion as shown in the table above. If any additional ordinary shares and ADSs are purchased, the underwriters will offer the additional ordinary
shares and ADSs on the same terms as those on which the ordinary shares and ADSs are being offered. The total number of ordinary shares (including ordinary shares in the form of ADSs) to be sold,
including pursuant to the underwriters' option to acquire additional securities, is subject to rellocation between these offerings as permitted under applicable law and regulations. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
underwriting discount is equal to the offering price per ordinary share and per ADS less the amount paid by the underwriters to us per ordinary share and per ADS. The underwriting discount is
&euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS. The following table shows the
per ordinary share and per ADS and total underwriting discounts to be paid to the
underwriters assuming both no exercise and full exercise of the underwriters' option to purchase additional ordinary shares (exclusive of ordinary shares underlying ADSs) and ADSs (including
underlying ordinary shares). </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="92pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="92pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Without option to<BR>
purchase additional<BR>
ordinary shares and<BR>
ADS exercise </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>With full option to<BR>
purchase additional<BR>
ordinary shares and<BR>
ADS exercise </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Per ordinary share</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Per ADS</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>We
estimate that the total expenses of this offering, including registration, filing and listing fees, printing fees and legal and accounting expenses, but excluding the underwriting discounts, will
be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have agreed to reimburse the underwriters for expenses (including fees of their counsel) relating to clearance of this offering with the
Financial Industry
Regulatory Authority up to $50,000. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A
prospectus in electronic format may be made available on the web sites maintained by one or more underwriters, or selling group members, if any, participating in the offering. The underwriters may
agree to allocate a number of ordinary shares and ADSs to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions will be allocated by the
representatives to underwriters and selling group members that may make Internet distributions on the same basis as other allocations. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
have agreed that we will not (i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant
to purchase or otherwise transfer or dispose of, directly or indirectly, or file with, or submit to, the Securities and Exchange Commission a registration statement under the Securities Act relating
to, any ordinary shares or ADSs or any securities convertible into or exchangeable or exercisable for any ordinary shares or ADSs, or publicly disclose the intention to make any offer, sale, pledge,
disposition or filing, or (ii)&nbsp;enter into any swap or other arrangement that transfers all or a portion of the economic consequences associated with the ownership of any ordinary shares or ADSs
or any such other securities (regardless of whether any of these transactions are to be settled by the delivery of ordinary shares or ADSs or such other securities, in cash or otherwise), in each case
without the prior written consent of Jefferies&nbsp;LLC, Stifel, Nicolaus&nbsp;&amp; Company, Incorporated and Guggenheim Securities,&nbsp;LLC for a period of 90&nbsp;days after the date of this
prospectus, subject to certain exceptions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
directors and executive officers, and certain holders of our ordinary shares, representing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our ordinary shares outstanding on the date of this prospectus, have entered into
lock-up agreements with the underwriters prior to the commencement of this offering pursuant to which each of these persons or entities, with limited exceptions, for a period of 90&nbsp;days after
the date of this prospectus, may not, without </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>201</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=205,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=13225,FOLIO='201',FILE='DISK116:[20ZBV1.20ZBV74901]DS74901A.;17',USER='SCAVALI',CD='10-APR-2020;08:51' -->
<A NAME="page_ds74901_1_202"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>the
prior written consent of Jefferies&nbsp;LLC, Stifel, Nicolaus&nbsp;&amp; Company, Incorporated and Guggenheim Securities,&nbsp;LLC, (1)&nbsp;offer, pledge, sell, contract to sell, sell any
option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any ordinary
shares, including in the form of ADSs, or any securities convertible into or exercisable or exchangeable for our ordinary shares or ADSs (including, without limitation, ordinary shares or ADSs or such
other securities which may be deemed to be beneficially owned by such directors and executive officers in accordance
with the rules and regulations of the SEC and securities which may be issued upon exercise of a stock option or warrant) or (2)&nbsp;enter into any swap or other agreement that transfers, in whole
or in part, any of the economic consequences of ownership of any ordinary shares or ADSs or such other securities, whether any such transaction described in clause&nbsp;(1) or (2)&nbsp;above is to
be settled by delivery of ordinary shares or ADSs or such other securities, in cash or otherwise, or (3)&nbsp;make any demand for or exercise any right with respect to the registration of any
ordinary shares or ADSs or any security convertible into or exercisable or exchangeable for our ordinary shares or ADSs, in each case, subject to certain exceptions,
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> transfers or dispositions of the ordinary shares and ADSs acquired in open market
transactions after the consummation of this offering (</FONT><FONT SIZE=2><I>provided that</I></FONT><FONT SIZE=2> (i)&nbsp;no filing or notification under the Exchange Act will be required or
(ii)&nbsp;any other public announcement or filing will be voluntarily made within 90&nbsp;days of the date of the final prospectus); </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> transfers of ordinary shares or ADSs as a bona fide gift or gifts or by will,
testamentary document or intestate succession; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> distributions of ordinary shares or ADSs to partners, members, trust beneficiaries or
shareholders of the lock-up signatory; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> transfers of ordinary shares or ADSs to any trust for the direct or indirect benefit of
the lock-up signatory or the immediate family of the lock-up signatory; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> transfers of ordinary shares or ADSs solely by operation of law, such as pursuant to a
qualified domestic order; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> transfers of ordinary shares or ADSs in connection with a divorce settlement; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> transfers of ordinary shares or ADSs to affiliates (within the meaning set forth in
Rule&nbsp;405 of the Securities Act) of the lock-up signatory or any investment fund or other entity controlled or managed by the lock-up signatory or any investment fund or other entity that
controls the lock-up signatory, if the lock-up signatory is a corporation, partnership, limited liability company, trust or other business entity; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> transfer of ordinary shares or ADSs to us in connection with a repurchase in connection
with the termination of the employment of the lock-up signatory; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> transfers of ordinary shares or ADSs pursuant to a bona-fide third-party tender offer,
merger, consolidation or other similar transaction that is approved by our board of directors and made to all holders of our ordinary shares or ADSs, the result of which is that a person, or group of
persons, other than the Company becomes beneficial owner of more than 50% of our voting stock; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the establishment of a trading plan meeting the requirements of Rule&nbsp;10b5-1 under
the Exchange Act; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the receipt, exercise, vesting or forfeiture of, or removal or lapse of restrictions on
any warrant (including any share warrant (</FONT><FONT SIZE=2><I>bon de souscription d'actions</I></FONT><FONT SIZE=2>) or founder's share warrant (</FONT><FONT SIZE=2><I>bon de souscription de parts
de cr&eacute;ateur d'entreprise</I></FONT><FONT SIZE=2>), options to purchase ordinary shares or ADSs, ordinary shares or ADSs issued upon exercise of any warrant (including any share warrant
(</FONT><FONT SIZE=2><I>bon de souscription d'actions</I></FONT><FONT SIZE=2>) or founder's share warrant (</FONT><FONT SIZE=2><I>bon de souscription de parts de cr&eacute;ateur
d'entreprise</I></FONT><FONT SIZE=2>), option, restricted ordinary share or other award pursuant to any equity incentive plan or agreement in </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>202</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=206,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=11170,FOLIO='202',FILE='DISK116:[20ZBV1.20ZBV74901]DS74901A.;17',USER='SCAVALI',CD='10-APR-2020;08:51' -->
<A NAME="page_ds74901_1_203"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:arial;"><FONT SIZE=2>existence
as of the date of and described in the prospectus, so long as such transaction or event does not involve the sale or transfer of any ordinary shares or ADSs (other than (i)&nbsp;sales or
transfers permitted under the bullets above and (ii)&nbsp;from the lock-up signatory to the Company pursuant to a cashless or net exercise of a security to cover the exercise price or taxes due upon
the exercise or vesting of such security). </FONT></P>

</UL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2><I>provided, however</I></FONT><FONT SIZE=2>, that </FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> in the case of any transfer or distribution pursuant to the third through eigth bullets
above, it will be a condition of such transfer or disposition that the transferee agrees to be bound in writing by the restrictions set forth above; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> in the case of any transfer or distribution made pursuant to the third, sixth, ninth or
twelfth bullets above, any required filing under the Exchange Act or other required public announcement states the nature of such transfer or distribution; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> in the case of any transfer or distribution made pursuant to the fourth, fifth, seventh
or eighth bullets above, any filing under the Exchange Act or other public announcement shall be required or voluntarily made in connection with such transfer or distribution (other than in the case
of a transfer described in the fourth or eighth bullets, which shall state that such transfers have been made for tax purposes); and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> any such transfer, other than pursuant to the third through eighth bullets above, shall
not involve a disposition for value. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>We
have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act of 1933. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
will apply to have our ADSs approved for listing/quotation on the Nasdaq Global Market under the symbol "IVA." </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
connection with this offering, the underwriters may engage in stabilizing transactions, which involves making bids for, purchasing and selling ordinary shares and ADSs in the open market for the
purpose of preventing or retarding a decline in the market price of the ordinary shares and ADSs while this offering is in progress. These stabilizing transactions may include making short sales of
the ordinary shares and ADSs, which involves the sale by the underwriters of a greater number of ordinary shares and ADSs than they are required to purchase in this offering, and purchasing ordinary
shares and ADSs on the open market to cover positions created by short sales. Short sales may be "covered" shorts, which are short positions in an amount not greater than the underwriters' option to
purchase additional ordinary shares and ADSs referred to above, or may be "naked" shorts, which are short positions in excess of that amount to the extent permitted by law. The underwriters may close
out any covered short position either by exercising their option to purchase additional ordinary shares and ADSs, in whole or in part, or by purchasing ordinary shares and ADSs in the open market. In
making this determination, the underwriters will consider, among other things, the price of shares available for purchase in the open market compared to the price at which the underwriters may
purchase shares through the option to purchase additional ordinary shares and ADSs. A naked short position is more likely to be created if the underwriters are concerned that there may be downward
pressure on the price of the ordinary shares and ADSs in the open market that could adversely affect investors who purchase in this offering. To the extent that the underwriters create a naked short
position, they will purchase ordinary shares and ADSs in the open market to cover the position. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
underwriters have advised us that, pursuant to Regulation&nbsp;M of the Securities Act of 1933, they may also engage in other activities that stabilize, maintain or otherwise affect the price of
the ordinary shares and ADSs, including the imposition of penalty bids. This means that if the representatives of the underwriters purchase ordinary shares and ADSs in the open market in stabilizing
transactions or to cover </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>203</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=207,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=720237,FOLIO='203',FILE='DISK116:[20ZBV1.20ZBV74901]DS74901A.;17',USER='SCAVALI',CD='10-APR-2020;08:51' -->
<A NAME="page_ds74901_1_204"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>short
sales, the representatives can require the underwriters that sold those ordinary shares and ADSs as part of this offering to repay the underwriting discount received by them. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>These
activities may have the effect of raising or maintaining the market price of the ordinary shares and ADSs or preventing or retarding a decline in the market price of the ordinary shares and
ADSs, and, as a result, the price of the ordinary shares and ADSs may be higher than the price that otherwise might exist in the open market. If the underwriters commence these activities, they may
discontinue them at any time. The underwriters may carry out these transactions on the Nasdaq Global Market, Euronext Paris or in the over-the-counter market or otherwise. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Prior
to this offering, there has been no public market for our ADSs in the United States. Our ordinary shares are listed on Euronext Paris under the symbol "IVA." The offering price of the ADSs will
be determined by negotiations between us and the representatives of the underwriters. In determining the offering price, we and the representatives of the underwriters expect to consider a number of
factors including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the price of our ordinary shares in connection with our existing listing on Euronext
Paris; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the information set forth in this prospectus and otherwise available to the
representatives; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our prospects and the history and prospects for the industry in which we compete; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an assessment of our management; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our prospects for future earnings; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the general condition of the securities markets at the time of this offering; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the recent market prices of, and demand for, publicly traded ordinary shares and ADSs of
generally comparable companies; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> other factors deemed relevant by the underwriters and us. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Neither
we nor the underwriters can assure investors that an active trading market will develop for our ADSs, or that the ADSs will trade in the public market at or above the initial public offering
price. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Other Relationships  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Certain of the underwriters and their affiliates have provided in the past to us and our affiliates and may provide from time to time in the future certain
commercial banking, financial advisory, investment banking and other services for us and such affiliates in the ordinary course of their business, for which they have received and may continue to
receive customary fees and commissions. In addition, from time to time, certain of the underwriters and their affiliates may effect transactions for their own account or the account of customers, and
hold on behalf of themselves or their customers, long or short positions in our debt or equity securities or loans, and may do so in the future. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Selling Restrictions  </B></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


General  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this
prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any
other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in
compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions
relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>204</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=208,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=700706,FOLIO='204',FILE='DISK116:[20ZBV1.20ZBV74901]DS74901A.;17',USER='SCAVALI',CD='10-APR-2020;08:51' -->
<A NAME="page_ds74901_1_205"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>to
sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


European Economic Area  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>In relation to each Member State of the European Economic Area (each, a "Member State") no offer to the public of ordinary shares and ADSs which are the
subject of the offering contemplated by this prospectus may be made in that Member State other than:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> to any legal entity which is a "qualified investor" as defined in the Prospectus
Regulation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> to fewer than 150 natural or legal persons (other than a qualified investor as defined in
the Prospectus Regulation), subject to obtaining the prior consent of the representatives of the underwriters for any such offer; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> in any other circumstances falling within Article&nbsp;1(4) of the Prospectus
Regulation, provided that no such offer of ordinary shares and ADSs shall require us or any underwriter to publish a prospectus pursuant to Article&nbsp;3 of the Prospectus Regulation or supplement
a prospectus pursuant to Article&nbsp;23 of the Prospectus Regulation and each person who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged
and agreed to and with each of the underwriters and us that it is a "qualified investor" as defined in the Prospectus Regulation. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>For
the purposes of this provision, the expression an "offer to the public" in relation to any ordinary shares and ADSs in any Relevant Member State means the communication in any form and by any
means of sufficient information on the terms of the offer and any ordinary shares and ADSs to be offered so as to enable an investor to decide to purchase any ordinary shares and ADSs, and the
expression "Prospectus Regulation" means Regulation (EU) 2017/1129 (as amended). </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


MiFID II Product Governance  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>With respect to the European offering and solely for the purposes of each manufacturer's product approval process, the target market assessment in respect of
the ordinary shares and ADSs has led to the conclusion that: (i)&nbsp;the target market for the ordinary shares and ADSs is eligible counterparties and professional clients only, each as defined in
Directive 2014/65/EU (as amended, "MiFID II"); and (ii)&nbsp;all channels for distribution of the ordinary shares and ADSs to eligible counterparties and professional clients are appropriate. Any
person subsequently offering, selling or recommending the ordinary shares and ADSs (a "distributor") should take into consideration the manufacturers' target market assessment; however, a distributor
subject to MiFID II is responsible for undertaking its own target market assessment in respect of the ordinary shares and ADSs (by either adopting or refining the manufacturers' target market
assessment) and determining appropriate distribution channels. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


France  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The ADSs and the ordinary shares have not been and will not be offered or sold to the public in the Republic of France, and no offering of this prospectus or
any marketing materials relating to the ADSs and the ordinary shares may be made available or distributed in any way that would constitute, directly or indirectly, an offer to the public in the
Republic of France. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
ordinary shares in the form of ADS may only be offered or sold in France pursuant to article&nbsp;L. 411-2-II of the French </FONT><FONT SIZE=2><I>Code mon&eacute;taire et
financier</I></FONT><FONT SIZE=2> to (i)&nbsp;qualified investors (</FONT><FONT SIZE=2><I>investisseurs qualifi&eacute;s</I></FONT><FONT SIZE=2>) acting for their own account and/or
(ii)&nbsp;a limited group of investors (</FONT><FONT SIZE=2><I>cercle restreint d'investisseurs</I></FONT><FONT SIZE=2>) acting for their own account, all as defined in and in accordance with
articles&nbsp;L. 411-1, L. 411-2 and D. 411-1 to D.411-4, D.744-1 and D. 754-1 and D. 764-1 of the French </FONT><FONT SIZE=2><I>Code mon&eacute;taire et financier.</I></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>205</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=209,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=267011,FOLIO='205',FILE='DISK116:[20ZBV1.20ZBV74901]DS74901A.;17',USER='SCAVALI',CD='10-APR-2020;08:51' -->
<A NAME="page_ds74901_1_206"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Prospective
investors are informed that:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> neither this prospectus nor any other offering materials relating to the ordinary shares
in the form of ADS described in this prospectus has been submitted for clearance to the French financial market authority (Autorit&eacute; des march&eacute;s financiers); </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> neither this prospectus, nor any offering material relating to the ordinary shares in the
form of ADS has been or will be released, issued, distributed or caused to be released, issued or distributed to the public in France or used in connection with any offer for subscription or sale of
the ordinary shares in the form of ADS to the public in France within the meaning of article&nbsp;L. 411-1 of the French Code mon&eacute;taire et financier; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> individuals or entities referred to in article&nbsp;L. 411-2-II of the French Code
mon&eacute;taire et financier may participate in the global offering, as provided under articles&nbsp;D.411-1, D.411-2, D.744-1, D.754-1 and D.764-1 of the French Code mon&#180;
etaire et financier; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the direct and indirect distribution or sale to the public of the ordinary shares in the
form of ADS acquired by them may only be made in compliance with articles&nbsp;L. 411-1, L. 411-2, L. 412-1 and L. 621-8 to L. 621-8-3 of the French Code mon&eacute;taire et financier. </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Hong Kong  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The ordinary shares and ADSs may not be offered or sold by means of any document other than (i)&nbsp;in circumstances that do not constitute an offer to the
public within the meaning of the Companies Ordinance (Cap.32, Laws of Hong Kong), or (ii)&nbsp;to "professional investors" within the meaning of the Securities and Futures Ordinance (Cap.571, Laws
of Hong Kong) and any rules made thereunder, or (iii)&nbsp;in other circumstances that do not result in the document being a "prospectus" within the meaning of the Companies Ordinance (Cap.32, Laws
of Hong Kong), and no advertisement, invitation or document relating to the ordinary shares or ADSs may be issued or may be in the possession of any person for the purpose of issue (in each case
whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the laws of Hong
Kong) other than with respect to ordinary shares or ADSs that are or are intended to be disposed of only to persons outside Hong Kong or only to "professional investors" within the meaning of the
Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) and any rules made thereunder. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Japan  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The securities have not been and will not be registered under the Financial Instruments and Exchange Law of Japan, or the Financial Instruments and Exchange
Law, and each underwriter has agreed that it will not offer or sell any securities, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan (which term, as used in this
prospectus means any person resident in Japan, including any corporation or other entity organized under the laws of Japan) or to others for re-offering or resale, directly or indirectly, in Japan or
to a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Law and any other applicable
laws, regulations and ministerial guidelines of Japan. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Switzerland  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The ordinary shares and ADSs may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock
exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss
Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in
Switzerland. Neither this document, nor any other offering or marketing material relating to the ordinary shares and ADSs or this offering, may be publicly distributed or otherwise made publicly
available in Switzerland. Neither this document nor any other offering or marketing material relating to this offering, the Company, or the ordinary shares or ADSs has been or will be filed with or
approved by any </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>206</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=210,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=770639,FOLIO='206',FILE='DISK116:[20ZBV1.20ZBV74901]DS74901A.;17',USER='SCAVALI',CD='10-APR-2020;08:51' -->
<A NAME="page_ds74901_1_207"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Swiss
regulatory authority. In particular, this document will not be filed with, and the offer of the ordinary shares and ADSs will not be supervised by, the Swiss Financial Market Supervisory
Authority FINMA, or FINMA, and the offer of the ordinary shares and ADSs has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor
protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of ordinary shares or ADSs. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


United Arab Emirates  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>This prospectus relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services Authority, or DFSA. This prospectus
is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no
responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has
no responsibility for this prospectus. The ordinary shares and ADSs to which this prospectus relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the
ordinary shares or ADSs offered should conduct their own due diligence on the ordinary shares and ADSs. If you do not understand the contents of this prospectus, you should consult an authorized
financial advisor. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


United Kingdom  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may only be directed
at persons who are "qualified investors" (as defined in the Prospectus Regulation) (i)&nbsp;who have professional experience in matters relating to investments falling within Article&nbsp;19
(5)&nbsp;of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order") and/or (ii)&nbsp;who are high net worth companies (or persons to whom it may
otherwise be lawfully communicated) falling within Article&nbsp;49(2)(a) to (d)&nbsp;of the Order (all such persons together being referred to as "relevant persons"). </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Any
person in the United Kingdom that is not a relevant person should not act or rely on the information included in this document or use it as basis for taking any action. In the United Kingdom, any
investment or investment activity that this document relates to may be made or taken exclusively by relevant persons. Any person in the United Kingdom that is not a relevant person should not act or
rely on this document or any of its contents. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Canada  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The ordinary shares and ADSs may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in
National Instrument&nbsp;45-106 Prospectus Exemptions or subsection&nbsp;73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument&nbsp;31-103
Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the ordinary shares and ADSs must be made in accordance with an exemption from, or in a transaction not subject
to, the prospectus requirements of applicable securities laws. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Securities
legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a
misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser's province or
territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser's province or territory for particulars of these rights or consult with a legal
advisor. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Pursuant
to section&nbsp;3A.3 of National Instrument&nbsp;33-105 Underwriting Conflicts (NI&nbsp;33-105), the underwriters are not required to comply with the disclosure requirements of
NI&nbsp;33-105 regarding underwriter conflicts of interest in connection with this offering. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>207</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=211,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=930485,FOLIO='207',FILE='DISK116:[20ZBV1.20ZBV74901]DS74901A.;17',USER='SCAVALI',CD='10-APR-2020;08:51' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_du74901_1_208"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A NAME="du74901_expenses_relating_to_this_offering"> </A>
<A NAME="toc_du74901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  EXPENSES RELATING TO THIS OFFERING    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following table sets forth the costs and expenses, other than underwriting commission payable in connection with the sale of ordinary shares and ADSs in
this offering. All amounts are estimated except the SEC registration fee, the Nasdaq initial listing fee and the Financial Industry Regulatory Authority,&nbsp;Inc., or FINRA, filing fee. Except as
otherwise noted, all the expenses below will be paid by us. </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="44pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Item

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Amount </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SEC registration fee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>FINRA filing fee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nasdaq initial listing fee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Legal fees and expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounting fees and expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Printing expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Miscellaneous fees and expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;* </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">*</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">To
be completed by amendment. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><A NAME="du74901_legal_matters"> </A>
<A NAME="toc_du74901_2"> </A>
<BR></FONT><FONT SIZE=2><B>  LEGAL MATTERS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Cooley&nbsp;LLP, New York, New York, is representing us in connection with this offering. The validity of the ordinary shares and certain other matters of
French law will be passed upon for us by Gide Loyrette Nouel A.A.R.P.I. Legal counsel to the underwriters in connection with this offering is Davis Polk&nbsp;&amp; Wardwell&nbsp;LLP. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A NAME="du74901_experts"> </A>
<A NAME="toc_du74901_3"> </A>
<BR></FONT><FONT SIZE=2><B>  EXPERTS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The financial statements of Inventiva&nbsp;S.A. as of December&nbsp;31, 2018 and 2019 and for the years then ended have been included herein in reliance
upon the report of KPMG&nbsp;S.A., an independent registered public accounting firm, appearing elsewhere herein, and upon the authority of said firm as experts in accounting and auditing. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
offices of KPMG&nbsp;S.A. are located at Tour Eqho, 2 avenue Gambetta, CS 60055, 92066 Paris la D&eacute;fense Cedex. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A NAME="du74901_where_you_can_find_more_information"> </A>
<A NAME="toc_du74901_4"> </A>
<BR></FONT><FONT SIZE=2><B>  Where You can Find More Information    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have filed with the Securities and Exchange Commission a registration statement on Form&nbsp;F-1 under the Securities Act with respect to the ordinary
shares and ADSs offered in this prospectus. A related registration statement on Form&nbsp;F-6 has been filed with the Securities and Exchange Commission to register the ADSs. This prospectus, which
forms&nbsp;a part of the registration statement, does not contain all of the information included in the registration statement. Certain information is omitted and you should refer to the
registration statement and its exhibits for that information. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Upon
completion of this offering, we will be subject to the information reporting requirements of the Exchange Act applicable to foreign private issuers and under those requirements will file reports
with the SEC. Those reports may be inspected without charge at the locations described above. As a foreign private issuer, we will be exempt from the rules under the Exchange Act related to the
furnishing and content of </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>208</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=212,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=847111,FOLIO='208',FILE='DISK116:[20ZBV1.20ZBV74901]DU74901A.;10',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<A NAME="page_du74901_1_209"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>proxy
statements, and our officers, directors and principal shareholders will be exempt from the reporting and short-swing profit recovery provisions contained in Section&nbsp;16 of the Exchange
Act. In addition, we will not be required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are
registered under the Exchange Act. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
maintain a corporate website at www.inventivapharma.com. The reference to our website is an inactive textual reference only and information contained in, or that can be accessed through, our
website or any other website cited in this prospectus is not part of this prospectus. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>209</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=213,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=925889,FOLIO='209',FILE='DISK116:[20ZBV1.20ZBV74901]DU74901A.;10',USER='VRIVERA',CD=';9-APR-2020;23:32' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_fa74901_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Inventiva&nbsp;S.A.  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


<A NAME="Index"></A>Index to Financial Statements  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A NAME="FA74901_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="30pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Page </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Financial Statements as of and for the Years Ended December&nbsp;31, 2019 and 2018</B></FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#A1"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Report of Independent Registered Public Accounting Firm</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#A1"><FONT SIZE=2>F-2</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#A2"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Statements of Financial Position as of December&nbsp;31, 2019 and 2018</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#A2"><FONT SIZE=2>F-3</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#A3"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Statements of Income (Loss) for the Years Ended December&nbsp;31, 2019 and 2018</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#A3"><FONT SIZE=2>F-4</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#A4"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Statements of Comprehensive Income (Loss) for the Years Ended December&nbsp;31, 2019 and 2018</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#A4"><FONT SIZE=2>F-5</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#A5"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Statements of Cash Flows for the Years Ended December&nbsp;31, 2019 and 2018</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#A5"><FONT SIZE=2>F-6</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#A6"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Statements of Changes in Shareholders' Equity for the Years Ended December&nbsp;31, 2019 and 2018</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#A6"><FONT SIZE=2>F-7</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#A7"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Notes to the Financial Statements</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#A7"><FONT SIZE=2>F-8</FONT></A></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-1</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=214,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=611199,FOLIO='F-1',FILE='DISK116:[20ZBV1.20ZBV74901]FA74901A.;8',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_fc74901_1_2"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


<A NAME="A1"></A>Report of Independent Registered Public Accounting Firm  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>To
the Shareholders and Board of Directors<BR>
Inventiva&nbsp;S.A.: </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Opinion on the Financial Statements  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have audited the accompanying statements of financial position of Inventiva&nbsp;S.A. (the Company) as of December&nbsp;31, 2019 and 2018, the related
statements of income (loss), comprehensive income (loss), changes in shareholders' equity, and cash flows for each of the years in the two year period ended December&nbsp;31, 2019, and the related
notes (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&nbsp;31, 2019
and 2018, and the results of its operations and its cash flows for each of the years in the two year period ended December&nbsp;31, 2019, in conformity with International Financial Reporting
Standards as issued by the International Accounting Standards Board. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Change in Accounting Principle  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As discussed in Note&nbsp;2.1 to the financial statements, the Company has changed its method of accounting for leases as of January&nbsp;1, 2019 due to
the adoption of IFRS&nbsp;16 "Leases". </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Basis for Opinion  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based
on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in
accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements
are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to
error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe
that our audits provide a reasonable basis for our opinion. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
have served as the Company's auditor since 2012. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Paris
La D&eacute;fense, France<BR>
April&nbsp;10, 2020 </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>KPMG&nbsp;S.A. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;text-align:left;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="50%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="50%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><FONT SIZE=2>/s/&nbsp;C&Eacute;DRIC ADENS<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2><I>Partner</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-2</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=215,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=54324,FOLIO='F-2',FILE='DISK116:[20ZBV1.20ZBV74901]FC74901A.;12',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_fe74901_1_3"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<P style="font-family:arial;"><FONT SIZE=2><A NAME="A2"></A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
STATEMENTS OF FINANCIAL POSITION<BR>
(IN THOUSANDS OF EUROS)  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Notes </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>ASSETS</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Non-current assets</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Intangible assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 4</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> 1,228</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> 1,543</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Property, plant and equipment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 5</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> 3,721</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> 4,261</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other non-current assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 6</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> 3,135</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> 2,374 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B> </b></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total non-current assets</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 8,084</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 8,178</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B> </b></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Current assets</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Inventories</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 7</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> 387</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> 410</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Trade receivables</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 8.1</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> 4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> 6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tax receivables</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 8.2</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> 9,833</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> 9,434</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other current assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 8.2</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> 2,811</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> 5,093</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 9</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> 35,840</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> 56,692 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B> </b></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total current assets</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 48,875</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 71,634</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B> </b></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>TOTAL ASSETS</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 56,960</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 79,812</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B> </b></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>LIABILITIES AND SHAREHOLDERS' EQUITY</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Shareholders' equity</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Share capital</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 10.1</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> 268</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> 223</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Premiums related to share capital</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> 86,012</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> 77,460</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Reserves</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> (14,670</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> 16,927</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss for the period</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> (30,218</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> (33,014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B> </b></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total Shareholders' equity</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 10</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 41,392</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 61,596</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B> </b></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Non-current liabilities</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Long-term debt</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 11</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> 2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> 74</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Long-term provisions</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 12</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> 574</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> 358</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Provisions for retirement benefit obligations</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 13</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> 1,127</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> 1,029</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Long-term contract liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 15</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> &#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> 1,673 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B> </b></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total non-current liabilities</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 1,703</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 3,134</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B> </b></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Current liabilities</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Short-term debt</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 11</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> 113</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> 151</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Trade payables</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 14.1</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> 7,491</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> 8,372</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Short-term provisions</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 12</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> 1,264</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> 1,140</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Short-term contract liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 15</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> &#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> 548</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other current liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 14.2</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> 4,998</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> 4,871 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B> </b></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total current liabilities</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 13,865</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 15,082</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B> </b></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 56,960</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 79,812</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >
 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:arial;"> <FONT SIZE=2>
The accompanying notes form an integral part of these financial statements </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-3</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=216,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=574123,FOLIO='F-3',FILE='DISK116:[20ZBV1.20ZBV74901]FE74901A.;13',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_fg74901_1_4"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<P style="font-family:arial;"><FONT SIZE=2><A NAME="A3"></A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
STATEMENTS OF INCOME (LOSS)<BR>
(IN THOUSANDS OF EUROS, EXCEPT SHARE AND PER SHARE AMOUNTS)  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="67pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="67pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Year ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Notes </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Revenues and other income</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Revenues</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 17</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>6,998</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3,197</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 17</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,293</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,182 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total revenues and other income </B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>11,291</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>7,379</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development expenses</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 18</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(33,791</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(31,758</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Marketing&nbsp;&#151; Business development expenses</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 18</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(249</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(225</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative expenses</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 18</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(6,088</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(6,045</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other operating income (expenses)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 19</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(1,475</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2,255</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Operating profit (loss) </B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>(30,312</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>(32,903</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Financial income</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>175</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>142</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Financial expenses</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(81</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(253</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Financial income (loss) </B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>20</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>93</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>(111</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Income tax</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 21</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net loss for the period </B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>(30,218</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>(33,014</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Basic / diluted loss per share (euros/share) </B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>24</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>(1.28</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>(1.61</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted average number of outstanding shares used for computing basic/diluted loss per share</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>23,519,897</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>20,540,979</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >
 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:arial;"> <FONT SIZE=2>
The accompanying notes form an integral part of these financial statements </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-4</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=217,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=1032039,FOLIO='F-4',FILE='DISK116:[20ZBV1.20ZBV74901]FG74901A.;7',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_fi74901_1_5"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2><A NAME="A4"></A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
STATEMENTS OF COMPREHENSIVE INCOME (LOSS)<BR>
(IN THOUSANDS OF EUROS)  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Year ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net loss for the period</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(30,218</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(33,014</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Actuarial gains (losses) on retirement benefit obligations (IAS&nbsp;19)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(96</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>31 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Items that will not be reclassified subsequently to profit or loss</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(96</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>31 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other items in the total profit (loss) to be recycled subsequently to the net profit (loss)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total comprehensive loss</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(30,315</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(32,983</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:arial;"><font> </FONT> <FONT SIZE=2>
The accompanying notes form an integral part of these financial statements </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-5</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=218,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=550789,FOLIO='F-5',FILE='DISK116:[20ZBV1.20ZBV74901]FI74901A.;9',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_fk74901_1_6"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<P style="font-family:arial;"><FONT SIZE=2><A NAME="A5"></A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
STATEMENTS OF CASH FLOWS<BR>
(IN THOUSANDS OF EUROS)  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="39pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Year ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Notes </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash flows provided by (used in) operating activities</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss for the period</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (30,218</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (33,014</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Elimination of other non-cash, non-operating income and expenses</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Depreciation, amortization and provisions</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> 4,5,12</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 1,579</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 1,295</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred and current taxes</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> 21</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> &#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> &#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tax credits</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> 8.2</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (4,297</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (4,299</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cost of net debt</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> 11</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (5</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 5</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Share-based compensation expense</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> 18.1</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 1,407</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 833 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B> </b></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash flows used in operations before tax, interest and changes in working capital</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> (31,534</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> (35,180</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B> </b></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Decrease / (Increase) in operating and other receivables</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> 8</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 1,780</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (1,156</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Increase / (Decrease) in operating and other payables</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> 14</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (2,974</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 2,884</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Decrease in inventories</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> 7</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 22</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 30</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tax credit received</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> 8.2</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 3,897</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> &#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 403</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (785</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B> </b></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Tax, interest and changes in operating working capital</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 3,130</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 973</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B> </b></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net cash flows used in operating activities</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> (28,404</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> (34,207</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B> </b></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash flows provided by (used in) investing activities</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Purchases of property, plant and equipment and intangible assets</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> 4, 5</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (136</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (549</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Disposals of property, plant and equipment and intangible assets</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 3</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> &#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net change in other non-current financial assets</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> 6</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (693</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 129 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B> </b></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net cash flows used in investing activities</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> (826</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> (420</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B> </b></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash flows provided by (used in) financing activities</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Capital increase, net of transaction costs</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> 10.1</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 8,654</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 32,526</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Repayment of debt</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> 11</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (146</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (259</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Repayment of lease debt</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> 11</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (130</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> &#151; </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B> </b></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net cash flows provided by financing activities</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 8,378</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 32,268</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B> </b></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net decrease in cash and cash equivalents</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> (20,852</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> (2,358</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B> </b></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash and cash equivalents at beginning of period</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 56,692</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 59,051 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B> </b></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net cash and cash equivalents at end of period</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> 9</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 35,840</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 56,692</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >
 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:arial;"> <FONT SIZE=2>
The accompanying notes form an integral part of these financial statements </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-6</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=219,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=182023,FOLIO='F-6',FILE='DISK116:[20ZBV1.20ZBV74901]FK74901A.;12',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_fm74901_1_7"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<P style="font-family:arial;"><FONT SIZE=2><A NAME="A6"></A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
Statements of Changes in Shareholders' Equity<BR>
(in thousands of euros, except share amounts)  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="60pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="67pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="39pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="49pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="64pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Share capital </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Premiums<BR>
related to<BR>
share<BR>
capital </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Notes </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Number<BR>
of<BR>
shares </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Amount </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Reserves </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Net<BR>
profit<BR>
(loss) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Shareholders'<BR>
equity </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>At January&nbsp;1, 2018</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 16,444,477</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>164</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>44,992</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>35,599</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>(19,463</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>61,292</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss for the period</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(33,014</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(33,014</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other comprehensive income (loss)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>&#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>&#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>31</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>&#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>31</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total comprehensive income (loss)</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>31</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(33,014</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(32,983</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Appropriation of 2017 net loss</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(19,463</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>19,463</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Issue of ordinary shares</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> 10.1</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5,572,500</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>56</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>35,441</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>35,497</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Transaction costs</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> 10.1</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(3,079</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(3,079</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercise of BSAs/BSPCEs and AGAs</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> 10.3, 10.4</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>240,300</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>106</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>108</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Share-based compensation expense</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> 10.3, 10.4</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>833</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>833</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Treasury shares</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> 10.2</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(72</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(72</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>At December&nbsp;31, 2018</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 22,257,277</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>223</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>77,460</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>16,927</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>(33,014</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>61,596</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss for the period</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(30,218</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(30,218</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other comprehensive income (loss)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>&#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>&#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>(96</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>&#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>(96</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total comprehensive income (loss)</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(96</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(30,218</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(30,315</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Appropriation of 2018 net loss</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(33,014</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>33,014</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Issue of ordinary shares</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> 10.1</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,473,935</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>45</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>8,858</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>8,903</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Transaction costs</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> 10.1</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(324</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(324</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercise of BSAs/BSPCEs and AGAs</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> 10.3, 10.4</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>114,900</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>18</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>18</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>BSA share warrants subscription premium</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>57</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>57</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Share-based compensation expense</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> 10.3, 10.4</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,407</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,407</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Treasury shares</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> 10.2</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>50</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>50 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>At December&nbsp;31, 2019</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 26,846,112</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>268</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>86,012</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>(14,670</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>(30,218</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>41,392</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >
 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:arial;"> <FONT SIZE=2>
The accompanying notes form an integral part of these financial statements </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-7</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=220,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=403392,FOLIO='F-7',FILE='DISK116:[20ZBV1.20ZBV74901]FM74901A.;9',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_fo74901_1_8"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A NAME="A7"></A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;1. Company Information  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I>1.1.&nbsp;Company information</I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Inventiva&nbsp;S.A.
(Inventiva or the Company) is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of diseases with
significant unmet medical need in the areas of non alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company is developing its lead product candidate, lanifibranor, for the treatment of patients with NASH, a disease for which there are currently no approved therapies. The Company is currently
conducting Phase&nbsp;IIb clinical trials of lanifibranor in patients with NASH and plans to report data in June 2020. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company is also developing a second clinical-stage asset, odiparcil, for the treatment of patients with subtypes of MPS. In December 2019, the Company announced positive results from a
Phase&nbsp;IIa clinical trial of odiparcil for the treatment of adult patients with the MPS VI subtype. The Company plans to initiate an open label Phase&nbsp;IIa extension study in 2021 to
investigate the long-term safety and efficacy of odiparcil in patients 16&nbsp;years and above with MPS VI who completed the prior Phase&nbsp;IIa trial. In addition, the Company plans to commence
a Phase Ib/II clinical trial of odiparcil in a pediatric population with MPS VI by the end of 2020.Other preclinical programs are also in development, including for the treatment of certain autoimmune
diseases in collaboration with AbbVie&nbsp;Inc. (AbbVie). AbbVie is currently evaluating ABBV-157, a drug candidate that Inventiva and AbbVie jointly discovered, in a Phase&nbsp;I clinical trial
for the treatment of autoimmune diseases under the terms of the multi-year drug discovery collaboration. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Inventiva's
ordinary shares have been listed on the Euronext Paris regulated market since February 2017. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I>1.2.&nbsp;Significant events</I></B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Capital increase  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Capital increase of &euro;32.4&nbsp;million by way of a private placement for a category of
investors in April 2018  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On April&nbsp;17, 2018, Inventiva completed a capital increase without pre-emptive subscription rights for a category of beneficiaries. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>A
total of 5,572,500 new ordinary shares were issued at a per share price of &euro;6.37 (par value of &euro;0.01 plus an issue premium of &euro;6.36), resulting in net
proceeds to the Company of &euro;32.4&nbsp;million. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
settlement-delivery of the new shares took place on April&nbsp;17, 2018 in a total gross amount of &euro;35.5&nbsp;million. The new shares were admitted to trading on Euronext Paris
on the same date. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
part of the capital increase, the Company incurred transaction costs of &euro;3.1&nbsp;million in 2018, comprising compensation to financial intermediaries and legal and administrative
fees. The costs are recognized as a deduction from additional paid-in capital within equity (see Note&nbsp;10.1 "Share capital"). </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Capital increase of &euro;8.2&nbsp;million subscribed by investors in September 2019  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On September&nbsp;20, 2019, Inventiva completed a capital increase subscribed by New Enterprise Associates (NEA), as well as BVF Partners&nbsp;L.P. and
Novo Holdings A/S, two of the Company's existing shareholders. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A
total of 4,159,999 new ordinary shares were issued at a per share price of &euro;1.99 (par value of &euro;0.01 plus an issue premium of &euro;1.98), which was equal
to the closing price of the Company's ordinary shares on Euronext on September&nbsp;18, 2019, resulting in net proceeds to the Company of &euro;8.0&nbsp;million. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-8</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=221,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=479090,FOLIO='F-8',FILE='DISK116:[20ZBV1.20ZBV74901]FO74901A.;13',USER='SCAVALI',CD='10-APR-2020;09:46' -->
<A NAME="page_fo74901_1_9"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;1. Company Information (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
settlement-delivery of the new shares took place on September&nbsp;20, 2019 in a total gross amount of &euro;8.3&nbsp;million. The new shares were admitted to trading on Euronext
Paris on the same date. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
part of the capital increase, the Company incurred transaction costs of &euro;0.3&nbsp;million in 2019, comprising compensation to financial intermediaries and legal and administrative
fees. The costs are recognized as a deduction from additional paid-in capital within equity (see Note&nbsp;10.1 "Share capital"). </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Capital increase of &euro;625,000 subscribed by Sofinnova Crossover I Fund in October 2019  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On October&nbsp;2, 2019, Inventiva completed a capital increase subscribed by Sofinnova Partners, current Inventiva shareholder and board member, through
Sofinnova Crossover I SLP. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A
total of 313,936 new ordinary shares were issued at a per share price of &euro;1.99 (par value of &euro;0.01 plus an issue premium of &euro;1.98), which was equal to
the closing price of the Company's ordinary shares on Euronext on September&nbsp;30, 2019, resulting in net proceeds to the Company of &euro;613&nbsp;thousand. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
settlement-delivery of the new shares took place on October&nbsp;2, 2019 in a total gross amount of &euro;625&nbsp;thousand. The new shares were admitted to trading on Euronext
Paris on the same date. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
part of the capital increase, the Company incurred transaction costs of &euro;12.0&nbsp;thousand in 2019, comprising compensation to financial intermediaries and legal and
administrative fees. The costs are recognized as a deduction from additional paid-in capital within equity (see Note&nbsp;10.1 "Share capital"). </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Research collaboration with AbbVie  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In August 2012, the Company entered into a master research service agreement (MRSA) with AbbVie specifying the conditions under which the Company would perform
services on behalf of AbbVie in accordance with statements of work agreed upon between the parties. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
MRSA was signed concurrently in conjunction with the Asset Purchase Agreement (APA) between Abbott and the Company. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>However:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> they are the subject of two separate agreements; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> they have been signed with two legally separate counterparties (Abbott and AbbVie); and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the MRSA has been entered into at arm's length. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>As
a result, the APA and the MRSA have not been considered as a single transaction but have been accounted for separately. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
research term of the MRSA with respect to the ROR<FONT FACE="SYMBOL">g</FONT> program was initially five years and was extended in August 2017. As of April 2019, the Company no longer
provides research services under the ROR<FONT FACE="SYMBOL">g</FONT> program or the MRSA, but remains eligible for milestone payments and royalties in the event of a product being approved
and marketed. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
of December&nbsp;31, 2019, the Company had received &euro;16.3&nbsp;million in research funding and &euro;9.0&nbsp;million in milestone payments under the MRSA,
including a &euro;3.5&nbsp;million milestone payment in December 2019 following the enrollment of the first patient with psoriasis in the ongoing clinical trial of ABBV-157. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-9</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=222,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=353980,FOLIO='F-9',FILE='DISK116:[20ZBV1.20ZBV74901]FO74901A.;13',USER='SCAVALI',CD='10-APR-2020;09:46' -->
<A NAME="page_fo74901_1_10"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;1. Company Information (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For
the year ended December&nbsp;31, 2019, the AbbVie collaboration generated &euro;3.6&nbsp;million of revenue, or 51.4% of the Company's revenue, compared to
&euro;0.9&nbsp;million, or 26.8% of the Company's revenue, for the year ended December&nbsp;31, 2018. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Research and development collaboration with Boehringer Ingelheim  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In May 2016, the Company and Boehringer Ingelheim (BI) entered into a license agreement and a multi-year Research and License Agreement (the BI Collaboration).
The BI Collaboration was focused on the identification of new treatments for idiopathic pulmonary fibrosis and fibrotic diseases and was ended in November 2019 following the BI's decision to
prioritized other products in its portfolio., BI informed Inventiva of its decision to end the BI Collaboration as of November&nbsp;12, 2019 and ownership of all intellectual property, molecules and
data from the BI Collaboration reverted to Inventiva. All amounts received by the Company under the BI Collaboration prior to termination were non-refundable.. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
revenue from the BI Collaboration recognized during 2018 in an amount of &euro;1.0&nbsp;million corresponds to the following: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I> Compensation for
FTEs:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;Revenue of &euro;0.8&nbsp;million, corresponding to compensation for full-time employees (FTEs) assigned to the research
program for the year.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I> Milestone
payment:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&euro;0.2&nbsp;million of this amount was recognized in 2018 revenue based on the stage of completion of the BI
Collaboration. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>The
revenue from the BI Collaboration recognized during 2019 in an amount of &euro;2.6&nbsp;million corresponds to the following: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I> Compensation for
FTEs:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;Revenue of &euro;0.5&nbsp;million, corresponding to compensation for FTEs assigned to the research program for the year. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I> Reversal of contract liabilities recognized under IFRS&nbsp;15 at
December&nbsp;31, 2018:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&euro;2.1&nbsp;million corresponding mainly to the &euro;2.5&nbsp;million milestone payment
received in September 2017, which was recognized on a percentage-of-completion basis. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>The
BI Collaboration represented 36.9% of the Company's revenue for the year ended December&nbsp;31, 2019 and 31.8% of its revenue for the year ended December&nbsp;31, 2018. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


New bonus share award plans ("AGA") in 2018 and 2019  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>On January&nbsp;26, 2018, the Company's Board of Directors approved two AGA free share award plans for certain Company
employees:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 10,000 bonus shares (AGA 2018-1), fully vested on January&nbsp;26, 2019; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 65,700 bonus shares (AGA 2018-2) of which 2,400 lapsed in 2019 following an employee
departure and 63,300 vested on January&nbsp;26, 2020 (see note&nbsp;26 "Events after the reporting date"). </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>The
plan has the following characteristics:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a one-year vesting period for AGA 2018-1 shares (until January&nbsp;26, 2019); </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a two-year vesting period for AGA 2018-2 shares (until January&nbsp;26, 2020); </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a one-year lock-up period; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-10</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=223,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=679686,FOLIO='F-10',FILE='DISK116:[20ZBV1.20ZBV74901]FO74901A.;13',USER='SCAVALI',CD='10-APR-2020;09:46' -->
<A NAME="page_fo74901_1_11"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;1. Company Information (Continued) </B></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a service condition; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> no performance conditions. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>The
fair value of Inventiva bonus shares corresponds to the Company's share price. At the award date, the fair value for AGA 2018-1 and AGA 2018-2 bonus shares was estimated at &euro;5.54. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On
December&nbsp;14, 2018, the Company's Board of Directors approved a third AGA bonus share award plan comprising 265,700 bonus shares (AGA 2018-3) for eighty-eight Company employees, of which
38,450 lapsed in 2019 following employees departures. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
plan has the following characteristics:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a two-year vesting period (until December&nbsp;14, 2020); </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a one-year lock-up period; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a service condition; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> no performance conditions. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>The
fair value of Inventiva bonus shares corresponds to the Inventiva share price. At the award date, the fair value for AGA 2018-3 bonus shares was estimated at &euro;6.05. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On
June&nbsp;28, 2019, the Company's Board of Directors approved two AGA free share award plans:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 29,100 bonus shares (AGA 2019-1) to six new employees; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 246,000 bonus shares (AGA 2019-2) to 81 new employees, of which 18,000 lapsed in 2019
following employees departures. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>The
plans have the following characteristics:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a two-year vesting period for AGA 2019-1 shares (until June&nbsp;28, 2021); </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a one-year vesting period for AGA 2019-2 shares (until June&nbsp;28, 2020); </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a one-year lock-up period; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a service condition; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> no performance conditions. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>The
fair value of Inventiva bonus shares corresponds to the Inventiva share price. At the award date, the fair value of each AGA 2019-1 and AGA 2019-2 bonus share was estimated at
&euro;1.92. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Movements
in awarded AGA bonus shares as well as the accounting impact of share-based payments are described in Note&nbsp;10.4 "Bonus share award plans". </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


New share warrant plans ("BSA") in 2018 and 2019  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On December&nbsp;14, 2018, the Company's Board of Directors granted 126,000 share warrants (BSA 2018) to Company consultants as
follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 36,000 share warrants to David Nikodem, a member of Sapidus Consulting Group&nbsp;LLC,
a service provider to the Company; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-11</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=224,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=383923,FOLIO='F-11',FILE='DISK116:[20ZBV1.20ZBV74901]FO74901A.;13',USER='SCAVALI',CD='10-APR-2020;09:46' -->
<A NAME="page_fo74901_1_12"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;1. Company Information (Continued) </B></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 10,000 share warrants to JPG Healthcare&nbsp;LLC, lapsed in December 2019 after
expiration of the exercise period; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 80,000 share warrants to ISLS Consulting, a company owned by Jean-Louis Junien, a
director of the Company (mandate ended in May 2019). </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>BSA
2018 share warrants are share subscription options with no performance conditions attached. The plan concerns three beneficiaries. For two of these, it comprises tranches with vesting periods of
between one and three years, and for the third beneficiary, the BSA warrants fully vested on November&nbsp;8, 2019. Once they vest, the share warrants may be exercised through December&nbsp;14,
2028. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
fair value of BSA 2018 share warrants is estimated at &euro;1.98. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On
June&nbsp;28, 2019, the Company's Board of Directors granted 10,000 BSAs (BSA 2019), at a subscription price of &euro;0.18 each, to David Nikodem. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>BSA
2019 share warrants are share subscription options with no performance conditions attached. The plan provides for an exercise period beginning on the date of the first anniversary of the warrants'
issue, i.e.,&nbsp;June&nbsp;28, 2020, and expiring on the date of the tenth anniversary of their issue, i.e.,&nbsp;June&nbsp;28, 2029. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On
June&nbsp;28, 2019, the fair value of the BSA share warrants was estimated using the Black-Scholes model based on the following
assumptions:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> value of the underlying asset at June&nbsp;28, 2019; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> volatility observed in a sample of comparable listed companies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> economic life of 5.5&nbsp;years (middle of exercise period). </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>At
the award date, the fair value of each BSA 2019 share warrant was estimated at &euro;0.48. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Movements
in granted BSA share warrants as well as the accounting impact of share-based payments are described in Note&nbsp;10.3 "Share warrants plans". </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Tax audit  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In 2019, our payroll taxes for the 2016, 2017 and 2018 taxable years were audited by the French tax authorities and the Company received a proposed tax
adjustment of &euro;1.7&nbsp;million (including penalties and late payment interest) in December 2019. This proposed tax adjustment gives rise to a potential risk of
&euro;0.5&nbsp;million (including penalties and late payment interest) for the 2018 taxable year, which the Company is challenging. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>At
the date of approval of these financial statements, the dispute procedures related to the tax audit in respect of the period from January&nbsp;1, 2013 to December&nbsp;31, 2015 are still
ongoing with French tax authorities. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A
description of the audits performed and their impacts on the financial statements is provided in Note&nbsp;12 "Provisions". </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-12</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=225,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=390908,FOLIO='F-12',FILE='DISK116:[20ZBV1.20ZBV74901]FO74901A.;13',USER='SCAVALI',CD='10-APR-2020;09:46' -->
<A NAME="page_fo74901_1_13"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;1. Company Information (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Surety provided to the French tax authorities  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On February&nbsp;1, 2019, as part of its application for a suspension of payment on the CIR and payroll taxes, the Company offered the French tax authorities
a surety in the form of a &euro;3.4&nbsp;million bank guarantee with Cr&eacute;dit Agricole bank. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
part of the process of setting up the surety, a pledge over cash, equivalent to 50% of the sum not covered by the indemnity to be received from the Abbott group under the Additional Agreement
(&euro;2.0&nbsp;million; see Note&nbsp;12 "Provisions"), in an amount of &euro;0.7&nbsp;million, which recorded in the first half of 2019 in other non-current assets.
Should the dispute to which the surety pertains remain unresolved at June&nbsp;30, 2020, or should any disputed sums remain outstanding, the Company has undertaken to provide an additional surety of
&euro;1.0&nbsp;million. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2017 research tax credit (</B></FONT><FONT SIZE=2><B><I>credit d'imp&ocirc;t
recherche</I></B></FONT><FONT SIZE=2><B>, or "CIR") received in September 2019  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In September 2019, the Company received payment of 81% of the total amount of the 2017 CIR, in an amount of &euro;3.6&nbsp;million relative to the
&euro;4.5&nbsp;million requested. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>At
the date of approval of these financial statements, the Company is contesting the rationale for the 19% withheld from the 2017 CIR, in the amount of &euro;0.9&nbsp;million, and called
upon the tax conciliator to challenge the audit procedure on February 2020. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company estimates its maximum risk linked to the payment of the 2017 CIR at &euro;0.2&nbsp;million, and this amount was covered by a provision recorded in the financial statements for
the year ended December&nbsp;31, 2019 (see Note&nbsp;12 "Provisions"). </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Approval and implementation of a redundancy plan  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Following the termination of the systemic sclerosis (SSc) program in February 2019, the Company implemented a redundancy plan in the second quarter, which was
subject to a company agreement signed on June&nbsp;11, 2019 and which included the non-renewal of fixed-term contracts. The Company's total workforce was therefore reduced from 113 employees at
December&nbsp;31, 2018 to 88 at December&nbsp;31, 2019. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Following
the signing of the company agreement and its implementation, the Company recorded an expense in a total amount of &euro;1.1&nbsp;million representing the costs incurred by
Inventiva over the period. This expense is reflected on the "Other operating expenses" line in the income statement (see Note&nbsp;19 "Other operating expenses") and a residual accrued expense of
&euro;0.1&nbsp;million is accounted for as at December&nbsp;31, 2019. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;2. Statement of Compliance  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>
These financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standard Board ("IASB"). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>They
were approved by the Company's Board of Directors on March&nbsp;9, 2020. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Standards, amendments to existing standards and interpretations published by the IASB whose application has
been mandatory since January&nbsp;1, 2019  </B></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> IFRS&nbsp;16&nbsp;&#151; Leases replaces IAS&nbsp;17&nbsp;&#151;
Leases for periods beginning on or after January&nbsp;1, 2019. It sets out the principles for the recognition and measurement of leases as well as the disclosures to be provided in the notes for
both parties to a contract, i.e.,&nbsp;the customer (lessee) and the supplier (lessor). IFRS&nbsp;16 eliminates the requirement to classify leases as either operating leases or finance </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-13</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=226,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=558745,FOLIO='F-13',FILE='DISK116:[20ZBV1.20ZBV74901]FO74901A.;13',USER='SCAVALI',CD='10-APR-2020;09:46' -->
<A NAME="page_fo74901_1_14"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;2. Statement of Compliance (Continued) </B></FONT></P>

<UL>
<UL>

<P style="font-family:arial;"><FONT SIZE=2>leases
and, instead, introduces a single lessee accounting model. Applying that model, a lessee is required to recognize (i)&nbsp;assets and liabilities for all leases, and (ii)&nbsp;depreciation
of lease assets separately from interest on lease liabilities in the income statement. The standard nonetheless provides for exemptions for short-term leases with a term of 12&nbsp;months or less
and leases of low-value assets. At December&nbsp;31, 2019, the Company only leased the following assets: a nitrogen tank, several photocopiers, two vehicles, 12 fibroscan machines and an office in
Paris. </FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The
detailed impacts of first-time adoption of this standard are presented in Note&nbsp;2.1 "Impact of the first-time adoption of IFRS&nbsp;16". </FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> IFRIC&nbsp;23&nbsp;&#151; Uncertainty over Income Tax Treatments, the
provisions of which have no impact on the Company's financial statements. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Standards, amendments to existing standards and interpretations published by the IASB whose application is
not yet mandatory  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>No standards, amendments to existing standards or interpretations had been published but were not yet applicable as of December&nbsp;31, 2019. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><I>2.1.&nbsp;Impact of the first-time adoption of IFRS&nbsp;16</I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>IFRS&nbsp;16&nbsp;&#151;
Leases has been mandatory since January&nbsp;1, 2019. In accordance with the standard, the Company
recognizes:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an asset, representing its right to use the leased asset during the lease term
(right-of-use asset); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a liability, representing the value of the outstanding lease payments (lease liability). </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>For
the first-time adoption of IFRS&nbsp;16, the Company used the simplified retrospective method by applying the practical expedients provided in the standard. Consequently and in accordance with
IFRS&nbsp;16, comparative data have not been restated. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>At
December&nbsp;31, 2019, the Company only leased the following assets: a nitrogen tank, several photocopiers, two vehicles, 12 fibroscan machines and an office in Paris. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Following
an analysis, the Company identified two types of leases that meet the IFRS&nbsp;16 criteria and whose accounting treatment must be restated in accordance with the new standard: two
vehicles and research equipment (10 fibroscan machines). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For
each asset, the discount rate used to calculate the lease liability is determined based on the incremental borrowing rate at the date of signature of the lease. The incremental borrowing rate is
the rate of interest that a lessee would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in
a similar economic environment. The incremental borrowing rate applied to leases at January&nbsp;1, 2019 is 1.57%. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company has not restated its other leases because they are covered by the exemptions permitted under the standard (short-time leases and low-value leases). They
include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> leases that expire within 12&nbsp;months of the date of first-time adoption
(January&nbsp;1, 2019); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 12-month leases with automatic renewal, where it is not reasonably certain at the date of
first-time application that the leases will be renewed; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> leases for which the underlying asset is less than &euro;5,000. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-14</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=227,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=115626,FOLIO='F-14',FILE='DISK116:[20ZBV1.20ZBV74901]FO74901A.;13',USER='SCAVALI',CD='10-APR-2020;09:46' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_fq74901_1_15"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued)  </B></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;2. Statement of Compliance (Continued)  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Rental
expenses for short-term and low-value leases continue to be recognized in operating expenses in the Company's income statement. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Impact on the Company's financial statements  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The impact of the first-time adoption of IFRS&nbsp;16 at January&nbsp;1, 2019 included a &euro;0.2&nbsp;million increase in debt and a
&euro;0.3&nbsp;million increase in net property, plant and equipment (including the reclassification of a prepaid expense in the amount of &euro;0.1&nbsp;million). </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
carrying amount of net property, plant and equipment and of debt at December&nbsp;31, 2019 increased by &euro;49&nbsp;thousand and &euro;37&nbsp;thousand respectively. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
2019, the net impact on the Company's income statement was &euro;12&nbsp;thousand. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;3. Accounting Principles  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>
The principal accounting policies applied in the preparation of the financial statements are described below. Unless otherwise stated, the same policies have been consistently applied for all periods
presented. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I>3.1.&nbsp;&nbsp;&nbsp;Intangible assets  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In accordance with </FONT><FONT SIZE=2><I>IAS&nbsp;38&nbsp;&#151; Intangible Assets</I></FONT><FONT SIZE=2>, research costs are recognized in the statement of income
(loss) in the period during which they are incurred. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>An
internally generated intangible asset arising from a research program is recognized if, and only if, the Company can demonstrate all of the
following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The technical feasibility necessary to complete the research program. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Its intention to complete the intangible asset and use or sell it. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Its ability to use or sell the intangible asset. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> How the intangible asset will generate probable future economic benefits. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The availability of adequate technical, financial and other resources to complete the
research program. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The ability to measure reliably the expenditure attributable to the intangible asset
during its development. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Given
the risks and uncertainties involved in regulatory approval and in the process of research and development, the Company considers that the six criteria set out in IAS&nbsp;38 are met only upon
obtaining market authorization for a product candidate. Consequently, all research and development costs are charged directly to expenses. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Intangible
assets comprise:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The cost of acquiring software licenses, which are written down over a period of between
one and five years based on their expected useful life. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The library of compounds acquired pursuant the APA together with additional chemical
components, which are written down over a 13-year period corresponding to their estimated useful lives. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-15</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=228,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=889717,FOLIO='F-15',FILE='DISK116:[20ZBV1.20ZBV74901]FQ74901A.;10',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<A NAME="page_fq74901_1_16"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;3. Accounting Principles (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I>3.2.&nbsp;&nbsp;&nbsp;Property, plant and equipment  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Property, plant and equipment are stated at cost. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Depreciation
and amortization are calculated based on the estimated useful life of assets using the straight-line method. A complete review of the useful lives of acquired non-current assets is
performed on an annual basis. Any material adjustments are reflected prospectively in the depreciation schedule. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
principal useful lives applied are as follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Buildings: 20 to 25&nbsp;years </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Fixtures and fittings: 10&nbsp;years </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Technical facilities: 6 to 10&nbsp;years </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Equipment and tooling: 6 to 10&nbsp;years </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> General facilities, miscellaneous fixtures and fittings: 10&nbsp;years </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Office equipment: 5&nbsp;years </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> IT equipment: 5&nbsp;years </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Furniture: 10&nbsp;years </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2><B><I>3.3.&nbsp;&nbsp;&nbsp;Other non-current assets  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Other non-current assets include long-term deposit accounts that do not qualify as cash equivalents within the meaning of </FONT> <FONT SIZE=2><I>IAS&nbsp;7&nbsp;&#151; Statement of Cash Flows</I></FONT><FONT SIZE=2>. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><I>3.4.&nbsp;&nbsp;&nbsp;Impairment of non-financial assets</I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>IAS&nbsp;36&nbsp;&#151; Impairment of Assets</I></FONT><FONT SIZE=2> requires that depreciated and amortized assets be tested for impairment whenever specific events
or circumstances indicate that their carrying amount may exceed their recoverable amount. The excess of the carrying amount of the asset over the recoverable amount is recognized as an impairment. The
recoverable amount of an asset is the higher of its value in use and its fair value less costs to sell. Impaired non-financial assets are examined at each year-end or half-year closing date for a
possible impairment reversal. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I>3.5.&nbsp;&nbsp;&nbsp;Inventories</I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
accordance with </FONT><FONT SIZE=2><I>IAS&nbsp;2&nbsp;&#151; Inventories</I></FONT><FONT SIZE=2>, inventories are measured at the lower of cost (determined using the weighted average
cost method) and net realizable value. In case of impairment, any write-down is recognized as an expense in other operating income (loss). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I>3.6.&nbsp;&nbsp;&nbsp;Trade receivables</I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Trade
receivables are measured at nominal value, which generally equate with the fair value of the consideration to be received, net of impairment where applicable. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-16</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=229,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=573414,FOLIO='F-16',FILE='DISK116:[20ZBV1.20ZBV74901]FQ74901A.;10',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<A NAME="page_fq74901_1_17"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;3. Accounting Principles (Continued) </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><I>3.7.&nbsp;&nbsp;&nbsp;Cash and cash equivalents</I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Cash
and cash equivalents include cash on hand and demand deposits, as well as other short-term highly liquid investments with maturities of three months or less and subject to an insignificant risk
of changes in value. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Monetary
Undertakings for Collective Investments in Transferable Securities (UCITS) may be recognized as cash equivalents when
they:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> have an original maturity of three months or less; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> are readily convertible to a known cash amount; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> are subject to an insignificant risk of decrease in value. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Bank
overdrafts are recorded in liabilities in the statement of financial position under short-term debt. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I>3.8.&nbsp;&nbsp;&nbsp;Share capital</I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Ordinary
shares are classified in shareholders' equity. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I>3.9.&nbsp;&nbsp;&nbsp;Share-based payments</I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>At
the Company's inception, the Company put in place a compensation plan settled in equity instruments in the form of share warrants awarded to employees (</FONT><FONT SIZE=2><I>Bons de souscription
de parts de cr&eacute;ateur d'entreprise</I></FONT><FONT SIZE=2>, BSPCE or BSPCE share warrants) and to a non-employee (</FONT><FONT SIZE=2><I>Bons de souscription
d'actions</I></FONT><FONT SIZE=2>, BSA or BSA share warrants), and bonus share award to employees (</FONT><FONT SIZE=2><I>Attribution gratuite d'actions</I></FONT><FONT SIZE=2>, AGA or AGA bonus share
award). In 2018, three bonus share award plans and one BSA share warrant plan were also set up. Details of these plans are provided in Note&nbsp;10, "Shareholders' equity". </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
accordance with </FONT><FONT SIZE=2><I>IFRS&nbsp;2&nbsp;&#151; Share-based Payment</I></FONT><FONT SIZE=2>, the cost of transactions settled in equity instruments is recognized in
expenses, offset by increases in equity, in the period in which the benefit is granted to the employee or non-employee. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Before
the admission of the Company on the Euronext listing, the value of the share warrants has been determined with the assistance of an independent expert using a combination of the following
valuation methods:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The market approach which indicates the value of a business by comparing it to companies
whose market price is available and/or recent market transactions involving comparable companies or assets. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The income approach which indicates the value of a business by discounting the expected
future cash flows of the business to present value. This approach necessitates the use of the discounted cash flow method. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Since
the Company is a listed company, the value of the share warrants has been determined with the assistance of an independent expert using the Black&nbsp;&amp; Scholes model based on the value of the
underlying asset at grant date (stock price), the volatility observed in a sample of comparable listed companies and the economic life of the related share warrant. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
measurement of the fair value of options incorporates the vesting conditions as described in Notes&nbsp;1.2. "Significant events", 10.3 "Share award plans" and 10.4 "Bonus share award plans". </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-17</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=230,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=548024,FOLIO='F-17',FILE='DISK116:[20ZBV1.20ZBV74901]FQ74901A.;10',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<A NAME="page_fq74901_1_18"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;3. Accounting Principles (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
the event of sale or subsequent reissue of these equity instruments, any consideration received, net of any directly attributable incremental transaction costs and the related income tax effects,
is included in equity attributable to the Company's shareholders. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><I>3.10.&nbsp;&nbsp;&nbsp;&nbsp;Loans and borrowings</I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Bank
loans are initially recognized at fair value, i.e.,&nbsp;the issue proceeds (fair value of the consideration received) net of transaction costs incurred. Borrowings are subsequently measured at
amortized cost, calculated using the effective interest rate method. Any difference between initial fair value and repayment value is recognized in the statement of income (loss) over the life of the
loan using the effective interest rate method. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
effective interest rate is the discount rate at which the present value of all future cash flows (including transaction costs) over the expected life of the loan, or where appropriate, over a
shorter period of time, is equal to the loan's initial carrying amount. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I>3.11.&nbsp;&nbsp;&nbsp;&nbsp;Trade payables</I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Trade
payables are initially recognized at nominal value, with the exception of suppliers with longer than normal settlement periods where the payable is initially recognized at fair value and
subsequently measured at amortized cost, calculated using the effective interest rate method. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I>3.12.&nbsp;&nbsp;&nbsp;&nbsp;Current and deferred tax</I></B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Tax
assets and liabilities for the current and prior periods are measured at the amount expected to be recovered from or paid to the French tax authorities, using tax rates and tax laws enacted or
substantively enacted at the end of the reporting period. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
income tax charge for the period comprises current tax due and the deferred tax charge. The tax expense is recognized in the statement of income (loss) unless it relates to items recorded in other
comprehensive income and expense or directly in equity, in which case the tax is also recorded in other comprehensive income and expense or directly in equity. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Current taxes  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The current tax expense is calculated based on taxable profit for the period, using tax rates enacted or substantively enacted at the statement of financial
position date. The Company regularly evaluates the policies it adopts where applicable tax laws for the preparation of its tax returns are open to interpretation. Provisions are made when appropriate
on the basis of amounts expected to be payable to the French tax authorities. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Research tax credit  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The research tax credit (</FONT><FONT SIZE=2><I>cr&eacute;dit d'imp&ocirc;t recherche</I></FONT><FONT SIZE=2>, or "CIR") granted by the French
tax authorities to encourage technical and scientific research by French companies is recorded in the "Tax receivables" line of the statement of financial position. Companies demonstrating that they
have expenses that meet the required criteria, including research expenses located in France or certain other European countries, receive a tax credit that can be used against the payment of the
corporate tax due the fiscal year in which the expenses were incurred and during the next three fiscal years; provided, that companies may receive cash reimbursement for any excess portion. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-18</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=231,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=148383,FOLIO='F-18',FILE='DISK116:[20ZBV1.20ZBV74901]FQ74901A.;10',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<A NAME="page_fq74901_1_19"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;3. Accounting Principles (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Only
those companies meeting the EU definition of a small or medium-sized entity ("SME") are eligible for payment in cash of their CIR (to the extent not used to offset corporate taxes payable) in the
year following the request for reimbursement. Inventiva believes that it meets the EU definition of an SME and therefore should continue to be eligible for prepayment. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
CIR receivable is recorded in the "Tax receivables" line in the statement of financial position. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Deferred taxes  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Deferred taxes are recognized when there are temporary differences between the carrying amount of assets and liabilities in the Company's financial statements
and the corresponding tax basis used to calculate taxable profit. Deferred taxes are not recognized if they arise from the initial recognition of an asset or liability in a transaction other than a
business combination which, at the time of the transaction, does not affect either the accounting or the taxable profit (tax loss). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Deferred
tax assets and liabilities are measured at the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, based on tax rates and tax laws
enacted or substantively enacted by the end of the reporting period. Deferred tax assets and liabilities are not discounted. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Deferred
tax assets and liabilities are offset when a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred taxes concern the same entity and
the same tax authority. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Deferred tax assets  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Deferred tax assets are recognized for all deductible temporary differences, unused tax losses and unused tax credits to the extent that it is probable that
the temporary difference will reverse in the foreseeable future and that taxable profit will be available against which the deductible temporary difference, unused tax losses or unused tax credits can
be utilized. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
recoverable amount of deferred tax assets is reviewed at the end of each reporting period and their carrying amount is reduced to the extent that it is no longer probable that sufficient taxable
profit will be available to allow the benefit of part or all of the deferred tax assets to be utilized. Unrecognized deferred tax assets are reassessed at the end of each reporting period and are
recognized when it becomes probable that future taxable profit will be available to offset the temporary differences. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Deferred tax liabilities  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Deferred tax liabilities are recognized for all taxable temporary differences, except when the Company is able to control the timing of the reversal of the
difference and it is probable that the reversal will not occur in the foreseeable future. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I>3.13.&nbsp;&nbsp;&nbsp;&nbsp;Provisions for retirement benefit obligations</I></B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Retirement benefit obligations  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company operates a defined benefit pension plan. Its obligations in respect of the plan are limited to the lump sum payments upon retirements, which are
expensed in the period in which the employees provide the corresponding service. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
liability recorded in the statement of financial position in respect of defined benefit pension plans and other post-retirement benefits is the present value of the defined benefit obligation net
of plan assets at the statement of financial position date. The defined benefit obligation is calculated annually by independent actuaries using the projected unit credit method. The present value of
the defined benefit obligation is </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-19</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=232,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=622581,FOLIO='F-19',FILE='DISK116:[20ZBV1.20ZBV74901]FQ74901A.;10',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<A NAME="page_fq74901_1_20"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;3. Accounting Principles (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>determined
by discounting estimated future cash outflows, using the interest rate of high-quality corporate bonds of a currency and term consistent with the currency and term of the pension obligation
concerned. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Actuarial
gains and losses arise from the effect of changes in assumptions and experience adjustments (i.e.,&nbsp;differences between the assumptions used and actual data). These actuarial gains and
losses are recognized
wholly and immediately in other comprehensive income and expense and are not subsequently reclassified to the statement of income (loss). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
net expense in respect of defined benefit obligations recognized in the statement of income (loss) for the period corresponds
to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The service cost for the period (acquisition of additional rights). </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The interest cost. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The past service cost. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The impact of any plan settlements. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>The
effect of unwinding the obligation is recognized in net financial income and expenses. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Termination benefits  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Termination benefits are payable when a company terminates an employee's employment contract before the normal retirement age or when an employee accepts
compensation as part of a voluntary redundancy. In the case of termination benefits, the event that gives rise to an obligation is the termination of
employment. In the case of an offer made to encourage voluntary redundancy, termination benefits are measured based on the number of employees expected to accept the offer. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Profit-sharing and bonus plans  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company recognizes a liability and an expense for profit-sharing and bonus plans based on a formula that takes into account the Company's performance. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I>3.14.&nbsp;&nbsp;&nbsp;&nbsp;Other provisions</I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
accordance with </FONT><FONT SIZE=2><I>IAS&nbsp;37&nbsp;&#151; Provisions, Contingent Liabilities and Contingent Assets</I></FONT><FONT SIZE=2>, a provision should be recognized when:
(i)&nbsp;an entity has a present legal or constructive obligation as a result of a past event; (ii)&nbsp;it is probable that an outflow of resources embodying economic benefits will be required to
settle the obligation; and (iii)&nbsp;a reliable estimate can be made of the amount of the obligation. Provisions for restructuring include termination benefits. No provisions are recognized for
future operating losses. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Where
there are a number of similar obligations, the probability that an outflow will be required in settlement is determined by considering the class of obligations as a whole. Although the
likelihood of outflow for any one item may be small, it may well be probable that some outflow of resources will be needed to settle the class of obligations as a whole. If that is the case, a
provision is recognized. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
provision represents the best estimate of the amount required to settle the present obligation at the end of the reporting period. Where the effect of the time value of money is material, the
amount of a provision corresponds to the present value of the expected costs that the Company considers necessary to settle the obligation. The pre-tax discount rate used reflects current market
assessments of the time value of money and specific risks related to the liability. The effect of unwinding discounts on provisions due to the time value of money is recognized in net financial income
and expenses. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-20</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=233,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=762104,FOLIO='F-20',FILE='DISK116:[20ZBV1.20ZBV74901]FQ74901A.;10',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<A NAME="page_fq74901_1_21"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;3. Accounting Principles (Continued) </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><I>3.15.&nbsp;&nbsp;&nbsp;&nbsp;Revenue</I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Revenue
is recognized in accordance with IFRS&nbsp;15&nbsp;&#151; Revenue from Contracts with Customers, which is mandatorily applicable for reporting periods beginning on or after
January&nbsp;1, 2018. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
2018 and 2019, the vast majority of the Company was generated under its agreements with AbbVie and BI. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Collaboration agreements and licenses  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The contracts are analyzed as research and development services contracts. Any licenses that result from the collaborations are therefore not deemed to be
separate performance obligations. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
performance obligations contained in the contracts are deemed to be satisfied as and when the Company expends efforts (e.g.,&nbsp;incurs costs or spends time). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
return for the efforts expended, the Company receives fixed payments (such as lump-sum payments) and variable payments (such as milestone payments or royalties on sales of any future approved
products). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Fixed
payments for research and development expenditures, which primarily consist of rebilled payroll expenditure, are recognized over time based on the Company's efforts or inputs to the satisfaction
of a performance obligation (costs incurred or hours expended). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Milestone
payments obtained following the achievement of specific milestones (e.g.,&nbsp;scientific results or regulatory or commercial approvals) are deemed to be variable payments and are included
in the contract price as soon as their receipt is highly probable, resulting in an upward revision of the contract price and a cumulative adjustment to income in the statement of income (loss). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Revenue
from royalties corresponds to Inventiva's contractual entitlement to receive a percentage of the future product sales achieved by its counterparties. Such royalties will be recognized if and
when sales are made. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Rendering of services  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company provides short term research services to various clients. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Such
services are recognized to revenue over time based on time incurred. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I>3.16.&nbsp;&nbsp;&nbsp;&nbsp;Other income</I></B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


CIR  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Inventiva has been eligible for CIR since inception (see Note&nbsp;3.12 "Current and deferred tax" for additional details about the eligibility requirements
for CIRs). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
CIR is recognized in "Other income" during the reporting period in which the eligible expenditure is incurred. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Subsidies  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company receives subsidies from several public bodies. The subsidies are related to net income and granted to compensate for incurred expenses. They are
therefore recognized in net income as other income for the period in which it becomes reasonably certain that they will be received. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-21</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=234,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=92565,FOLIO='F-21',FILE='DISK116:[20ZBV1.20ZBV74901]FQ74901A.;10',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<A NAME="page_fq74901_1_22"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;3. Accounting Principles (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I>3.17.&nbsp;&nbsp;&nbsp;&nbsp;Net financial income</I></B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Financial income  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Financial income includes:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The "Income from cash and cash equivalents", which includes income from short-term
investments remeasured at fair value at the end of each reporting period. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Foreign exchange gains. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Gains from unwinding discounting. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Other financial income. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Financial expenses  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Financial expenses primarily include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Interest cost. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Foreign exchange losses. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Losses from unwinding discounting. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Other financial expenses. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2><B><I>3.18.&nbsp;&nbsp;&nbsp;&nbsp;Other operating income and expenses  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Other operating income and expenses are disclosed separately on the face of the statement of income (loss). This line item is set aside for extraordinary events that may arise
during the period whose presentation within other items (relating to ordinary activities) could be misleading for users of the financial statements in their understanding of the Company's performance.
This item therefore includes income and expenses that are rare that represent material amounts and that the Company discloses separately on the face of the statement of income (loss) to facilitate
understanding of operating performance (see Note&nbsp;19, "Other operating income (expenses)"). </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Disposals of non-current assets  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Income from the disposal of non-current assets during the period is recognized in "Other operating income (expenses)". </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><I>3.19.&nbsp;&nbsp;&nbsp;&nbsp;Fair value measurement</I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
the table below, financial instruments are measured at fair value according to a hierarchy comprising three levels of valuation
inputs:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Level&nbsp;1: Quoted prices (unadjusted) in active markets for identical assets or
liabilities that the entity can access at the measurement date. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Level&nbsp;2: Inputs other than quoted market prices included within Level&nbsp;1
that are observable for the asset or liability, either directly or indirectly. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Level&nbsp;3: Unobservable inputs for the asset or liability. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-22</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=235,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=504002,FOLIO='F-22',FILE='DISK116:[20ZBV1.20ZBV74901]FQ74901A.;10',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<A NAME="page_fq74901_1_23"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;3. Accounting Principles (Continued) </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
tables below presents the financial assets and liabilities of the Company measured at fair value at December&nbsp;31, 2019 and 2018: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="36pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="36pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="36pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>At December&nbsp;31, 2019 (in thousands of euros)


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Level&nbsp;1 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Level&nbsp;2 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Level&nbsp;3 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Assets</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><I>Financial assets at fair value through profit or loss</I></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Monetary UCITS</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><I>Financial assets carried at amortized cost</I></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Long-term deposit accounts</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>792</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total assets</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>792</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total liabilities</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2><BR></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="36pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="36pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="36pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>At December&nbsp;31, 2018 (in thousands of euros)


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Level&nbsp;1 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Level&nbsp;2 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Level&nbsp;3 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Assets</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><I>Financial assets at fair value through profit or loss</I></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Monetary UCITS</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><I>Financial assets carried at amortized cost</I></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Long-term deposit accounts</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>108</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total assets</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 108</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>&#151;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>&#151;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total liabilities</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2><B><I>3.20.&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency transactions  </I></B></FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Functional and presentation currency  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company's financial statements are presented in euros, which is also the Company's functional currency. All amounts presented in these notes to the
financial statements are denominated in euros unless otherwise stated. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Translation of foreign currency transactions  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Certain limited purchases are carried out in foreign currencies. These transactions are translated and recorded at their value in euros at the date of the
transaction and recognized in operating income or expenses as they relate to the Company's ordinary course of business. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I>3.21.&nbsp;&nbsp;&nbsp;&nbsp;Segment information</I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
assessment of the entity's performance and the decisions about resources to be allocated are made by the chief operating decision maker, based on the management reporting system of the entity. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Only
one operating segment arises from the management reporting system: service delivery and clinical stage research, notably into potential therapies in the areas of fibrosis, lysosomal storage
disorders and oncology. Thus, the entity's performance is assessed at the Company level. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-23</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=236,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=809490,FOLIO='F-23',FILE='DISK116:[20ZBV1.20ZBV74901]FQ74901A.;10',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<A NAME="page_fq74901_1_24"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;3. Accounting Principles (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>All
the Company's operations, assets, liabilities and losses are located in France. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I>3.22.&nbsp;&nbsp;Use of estimates and judgment</I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
preparation of financial statements in accordance with IFRS requires:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Management to make judgments when selecting appropriate assumptions for accounting
estimates, which consequently involve a certain degree of uncertainty. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Management to make estimates and apply assumptions that affect the reported amounts of
assets, liabilities, revenues and expenses, as well as information presented for the period. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>The
estimates and judgments, which are updated on an ongoing basis, are based on past experience and other factors, in particular assumptions of future events, deemed reasonable in light of
circumstances. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company makes estimates and assumptions concerning the future. The resulting accounting estimates, by definition, often differ from actual reported values. Estimates and assumptions that could
lead to a significant risk of a material adjustment in the carrying amount of assets and liabilities in the subsequent period are analyzed below. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Revenue  </I></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Allocation of transaction price to performance
obligations</I></FONT><FONT SIZE=2>&nbsp;&#151; A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance
obligation is satisfied. To determine the proper revenue recognition method, the Company evaluates whether the contract should be accounted for as more than one performance obligation. This evaluation
requires significant judgment; some of the Company's contracts have a single performance obligation as the promise to transfer the individual goods or services is not separately identifiable from
other promises in the contracts and, therefore, not distinct. For contracts with multiple performance obligations, the Company allocates the contract's transaction price to each performance obligation
using our best estimate of the standalone selling price of each distinct good or service in the contract. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Variable consideration</I></FONT><FONT SIZE=2>&nbsp;&#151;
Due to the nature of the work required to be performed on many of the Company's performance obligations, the estimation of total revenue and cost at completion is complex, subject to many variables
and requires significant judgment. It is common for the collaboration agreements to contain variable consideration that can increase the transaction price. Variability in the transaction price arises
primarily due to milestone payments obtained following the achievement of specific milestones (e.g.,&nbsp;scientific results or regulatory or commercial approvals). The Company includes the related
amounts in the transaction price as soon as their receipt is highly probable. The effect of the increase of the transaction price due to milestones payments is recognized as an adjustment to revenue
on a cumulative catch-up basis. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Revenue recognized over time and input
method</I></FONT><FONT SIZE=2>&nbsp;&#151; The Company's performance obligations are satisfied over time as work progresses or at a point in time. For the collaboration agreements, because
services are rendered over time, revenue is recognized based on the extent of progress towards completion of the performance obligation, using an input measure of progress as it best depicts the
transfer of control to the customers. Under the Company's input measure of progress, the extent of progress towards completion is measured based on the ratio of days expended to date to the total
estimated days at completion of the performance obligation. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-24</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=237,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=651501,FOLIO='F-24',FILE='DISK116:[20ZBV1.20ZBV74901]FQ74901A.;10',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_fs74901_1_25"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued)  </B></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;3. Accounting Principles (Continued)  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Provision for tax audit  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company calculated the provision for the tax audits to which the Company has been subject based on an estimate of the related risk. The provision
represents the best estimate of the amount required to settle any amounts owed to the French tax authorities at the end of the reporting period (see Note&nbsp;12 "Provisions"). </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


CIR  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The amount of the CIR is determined based on the Company's internal and external expenditure in the reporting period. Only eligible research costs may be
included when calculating the CIR. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Valuation of share warrants and bonus share award  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Fair value measurements of share warrants and bonus share award granted to employees are based on actuarial models which require the Company to factor certain
assumptions into its calculations. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Measurement of retirement benefit obligations  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company operates a defined benefit pension plan. Its defined benefit plan obligations are measured in accordance with actuarial calculations based on
assumptions such as discount rates, the rate of future salary increases, employee turnover, mortality tables and expected increases in medical costs. The assumptions used are generally reviewed and
updated annually. The main assumptions used and the methods chosen to determine them are set out in Note&nbsp;13, "</FONT><FONT SIZE=2><I>Provisions for retirement benefit
obligations"</I></FONT><FONT SIZE=2>. The Company considers that the actuarial assumptions used are appropriate and justified in light of current circumstances. Nevertheless, retirement benefit
obligations are likely to change in the event that actuarial assumptions are revised. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;4. Intangible Assets  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="79pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="45pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="45pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="96pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands of euros)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>January&nbsp;1, 2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Increases </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Disposals </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>December&nbsp;31, 2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Library of compounds</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 2,142</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> &#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 2,142</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Software</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 1,504</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 29</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 1,533 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B> </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Intangible assets, gross</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 3,646</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 29</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 3&nbsp;674</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B> </b></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Amortization and impairment of library of compounds</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (993</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (165</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (1,157</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Amortization and impairment of software</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (1,110</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (179</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (1,289</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B> </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Amortization and impairment</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> (2,103</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> (343</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> (2,446</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B> </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Intangible assets, net</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 1,543</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> (314</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 1,228</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>Changes
during the period mainly correspond to amortization charges of &euro;0.3&nbsp;million. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-25</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=238,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=10879,FOLIO='F-25',FILE='DISK116:[20ZBV1.20ZBV74901]FS74901A.;10',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<A NAME="page_fs74901_1_26"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued) </B></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;4. Intangible Assets (Continued) </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="79pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="45pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="45pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="96pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands of euros)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>January&nbsp;1, 2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Increases </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Disposals </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>December&nbsp;31, 2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Library of compounds</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 2,142</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> &#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 2,142</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Software</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 1,398</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 106</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 1,504 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B> </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Intangible assets, gross</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 3,540</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 106</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 3,646</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B> </b></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Amortization and impairment of library of compounds</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (828</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (165</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (993</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Amortization and impairment of software</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (906</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (204</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (1,110</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B> </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Amortization and impairment</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> (1,733</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> (369</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> (2,103</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B> </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Intangible assets, net</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 1,806</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> (264</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 1,543</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>In
the absence of any indication of a loss of value, no impairment tests have been performed on amortizable intangible assets in the years ended December&nbsp;31, 2019 and 2018. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;5. Property, Plant and Equipment  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:67%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"120%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="120%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="50pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="45pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="45pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="78pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="68pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands of euros)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>January&nbsp;1,<BR>
2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Increases </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Disposals </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Reclassifications </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>December&nbsp;31,<BR>
2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Land</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>172</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>172</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Buildings</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3,407</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3,407</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Technical facilities, equipment and tooling</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,677</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>74</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,748</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other property, plant and equipment</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,081</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>33</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>43</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,157</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Property, plant and equipment in progress</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>43</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(43</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Right of use<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>252</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>252 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Property, plant and equipment, gross</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 9,632</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>107</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>(2</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>&#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>9,736</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Depreciation and impairment of buildings</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(1,346</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(196</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(1,542</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Depreciation and impairment of technical facilities, equipment and tooling</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2,999</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(398</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(3,396</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Depreciation and impairment of other property, plant and equipment</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(774</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(100</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(874</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Depreciation and impairment of right of use</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(203</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(203</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Depreciation and impairment</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> (5,119</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>(897</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>1</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>&#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>(6,015</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Property, plant and equipment, net</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 4,513</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>(790</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>(2</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>&#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>3,721</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">At
January&nbsp;1, 2019, in application of IFRS&nbsp;16&nbsp;&#151; Leases, an asset representing the right to use the leased assets (see
Note&nbsp;2.1 "Impact of the first-time application of IFRS&nbsp;16"). </FONT></DD></DL>
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>Changes
during the period mainly correspond to depreciation charges of &euro;0.9&nbsp;million. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-26</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=239,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=964344,FOLIO='F-26',FILE='DISK116:[20ZBV1.20ZBV74901]FS74901A.;10',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<A NAME="page_fs74901_1_27"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued) </B></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;5. Property, Plant and Equipment (Continued) </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:67%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"120%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="120%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="50pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="45pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="45pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="78pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="68pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands of euros)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>January&nbsp;1,<BR>
2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Increases </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Disposals </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Reclassifications </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>December&nbsp;31,<BR>
2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Land</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 172</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 172</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Buildings</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 3,407</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 3,407</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Technical facilities, equipment and tooling</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 4,267</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 334</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 75</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 4,677</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other property, plant and equipment</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 1,023</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 58</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 1,081</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Property, plant and equipment in progress</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 67</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 51</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (75</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 43 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B> </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Property, plant and equipment, gross</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 8,937</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 443</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 9,380</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B> </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Depreciation and impairment of buildings</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (1,144</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (202</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (1,346</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Depreciation and impairment of technical facilities, equipment and tooling</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (2,608</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (391</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (2,999</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Depreciation and impairment of other property, plant and equipment</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (668</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (105</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (774</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B> </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Depreciation and impairment</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> (4,421</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> (698</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> (5,119</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B> </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Property, plant and equipment, net</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 4,516</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> (255</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 4,261</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B> </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;6. Other Non-Current Assets  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="35pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="35pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands of euros)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued income</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,932</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Long-term deposit accounts</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>792</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>108</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Security deposits</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tax loss carry back</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>333</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>333 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Other non-current assets</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 3,135</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>2,374</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>Accrued
non-current income is entirely attributable to the recognition of accrued income from the Abbott group following the tax audit of the 2013, 2014 and 2015 fiscal years (see Note&nbsp;12
"Provisions"). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Long-term
deposit accounts correspond to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">&#150;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a pledge over cash granted by the Company on February&nbsp;1, 2019 in connection with the surety provided to the French
tax authorities in the form of a &euro;3.4&nbsp;million bank guarantee with Cr&eacute;dit Agricole bank. The amount of the pledge is equal to 50% of the sum not covered by the
indemnity to be received from the Abbott group under the Additional Agreement, amounting to &euro;0.7&nbsp;million (see Notes&nbsp;1.2 "Significant events", 12 "Provisions" and 22
"Commitments"); and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">&#150;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the pledge of a gradual rate deposit account with a balance of &euro;101&nbsp;thousand as collateral for the
&euro;254&nbsp;thousand loan from Soci&eacute;t&eacute; G&eacute;n&eacute;rale agreed in July 2015. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>The
tax loss carry back corresponds to the tax credit resulting from the tax loss carry back recognized by the Company at December&nbsp;31, 2017 and recoverable after five years if not used by the
Company to pay income tax within that period. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-27</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=240,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=748201,FOLIO='F-27',FILE='DISK116:[20ZBV1.20ZBV74901]FS74901A.;10',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_fu74901_1_28"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued)  </B></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;7. Inventories  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands of euros)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Laboratory inventories</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>420</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>443</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Inventories write-down</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(33</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(33</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total inventories </B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>387</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>410</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<P style="font-family:arial;"><FONT SIZE=2>The
write-down presented for the year ended December&nbsp;31, 2019 is unchanged. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;8. Trade Receivables and Other Current Assets and Receivables  </B></FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2><B><I>8.1.</I></B></FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I>Trade receivables</I></B></FONT></DD></DL>


<P style="font-family:arial;"><FONT SIZE=2>Trade
receivables break down as follows: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands of euros)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>3&nbsp;months or less</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Between 3 and 6&nbsp;months</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Between 6 and 12&nbsp;months</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>More than 12&nbsp;months</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Trade receivables </B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>4</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>6</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>The
average payment period is 30&nbsp;days. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-28</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=241,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=98677,FOLIO='F-28',FILE='DISK116:[20ZBV1.20ZBV74901]FU74901A.;13',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<A NAME="page_fu74901_1_29"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;8. Trade Receivables and Other Current Assets and Receivables (Continued) </B></FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2><B><I>8.2.</I></B></FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I>Other current assets and receivables</I></B></FONT><FONT SIZE=2>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


</FONT></DD></DL>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands of euros)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CIR</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>9,818</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>9,158</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CICE tax credit</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>264</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>12 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Tax receivables </B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>9,833</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>9,434</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepaid expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>495</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,184</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Sales tax receivable</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,416</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3,033</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other receivables</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>900</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>874 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Other current assets </B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>2,811</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>5,092</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Other current assets and receivables </B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>12,644</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>14,526</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>Tax
receivables in a total amount of &euro;9,833&nbsp;thousand correspond mainly to CIR receivables, comprised of the &euro;4,293&nbsp;thousand receivable for the current
year and receivables from previous years not yet received (&euro;4,171&nbsp;thousand for 2018, &euro;880&nbsp;thousand for 2017 and &euro;478&nbsp;thousand in
corrective claims). The CIR receivable relating to 2017 initially amounted to &euro;4,513&nbsp;thousand (corrective claim included), of which &euro;3,633&nbsp;thousand (81%)
was received in September 2019; the Company is currently disputing the residual amount of &euro;880&nbsp;thousand withheld by the tax authorities (see Notes&nbsp;1.2 "Significant
events" and 12&nbsp;"Provisions"). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
the course of 2020, Inventiva plans to request payment of the CIR due in respect of 2019 for an amount of &euro;4.3&nbsp;million under current EU guidelines on aid for SMEs. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
majority of prepaid expenses amounting to &euro;495&nbsp;thousand at December&nbsp;31, 2019 correspond to IT maintenance costs, patent maintenance fees and insurance contributions
paid in respect of first quarter 2020. At December&nbsp;31, 2018, prepaid expenses also included rents relating to fibroscans and certain ad hoc scientific work billed in advance. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;9. Cash and Cash Equivalents  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands of euros)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other cash equivalents<SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>14,004</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>41,767</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash at bank and at hand</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>21,837</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>14,925 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash and cash equivalents </B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>35,840</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>56,692</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Other
cash equivalents correspond to short-term bank deposits at Soci&eacute;t&eacute; G&eacute;n&eacute;rale and
Cr&eacute;dit Agricole. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-29</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=242,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=521318,FOLIO='F-29',FILE='DISK116:[20ZBV1.20ZBV74901]FU74901A.;13',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<A NAME="page_fu74901_1_30"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;10. Shareholders' Equity  </B></FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2><B><I>10.1.</I></B></FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I>Share capital</I></B></FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>The
share capital is set at &euro;268&nbsp;thousand at December&nbsp;31, 2019 divided into 26,846,112 fully authorized, subscribed and paid-up shares with a nominal value of
&euro;0.01. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Changes
in share capital during the years ended December&nbsp;31, 2019 and 2018 are as follows: </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>in
euros, except number of shares<BR></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:67%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"120%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="120%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="65pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="49pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="67pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="67pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="41pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Date


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Nature of the transactions </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Share<BR>
capital </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Premiums<BR>
related to<BR>
share capital </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Number of<BR>
shares </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Nominal<BR>
value </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD COLSPAN=3 VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> Balance as of January&nbsp;1<SUP>st</SUP>, 2018</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 164,445</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 44,991,815</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 16,444,477</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 0.01</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>01/26/2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Capital increase by issuance of ordinary shares&nbsp;&#151; Exercice of 1,803 BSPCE by Company employees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,803</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>106,384</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>180,300</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.01 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>04/17/2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Capital increase by issuance of ordinary shares&nbsp;&#151; Company's private placement</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>55,725</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>35,441,100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>5,572,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.01 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>04/17/2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Transaction costs related to the Company's private placement</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(3,079,174</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>04/18/2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Capital increase by issuance of ordinary shares&nbsp;&#151; Vesting of AGA by Company employees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>600</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>60,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.01 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD COLSPAN=3 VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> Balance as of December&nbsp;31, 2018</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 222,573</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 77,460,125</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 22,257,277</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 0.01</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>01/23/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Capital increase by issuance of ordinary shares&nbsp;&#151; Exercice of 274 BSPCE by Company employees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>274</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>17,693</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>27,400</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.01 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>01/26/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Capital increase by issuance of ordinary shares&nbsp;&#151; Vesting of AGA by Company employees (AGA 2018-1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>10,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.01 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>04/18/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Capital increase by issuance of ordinary shares&nbsp;&#151; Vesting of AGA by Company employees (AGA 2017-1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>775</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>77,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.01 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>09/20/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Capital increase by issuance of ordinary shares&nbsp;&#151; Company's private placement</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>41,600</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>8,236,798</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4,159,999</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.01 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>09/20/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Transaction costs related to the Company's private placement</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(312,294</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>10/02/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Capital increase by issuance of ordinary shares&nbsp;&#151; Company's private placement</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3,139</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>621,593</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>313,936</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.01 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>10/02/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Transaction costs related to the Company's private placement</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(12,023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD COLSPAN=3 VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> Balance as of December&nbsp;31, 2019</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 268,461</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 86,011,893</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 26,846,112</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 0.01</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>The
main impacts on the share capital during the two periods presented relate to private placements of securities (see Note&nbsp;1.2 "Significant events"). </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Movements
related to BSA share warrants plans and AGA bonus shares award plans are described in Notes&nbsp;10.3, "Share warrants plans" and 10.4, "Bonus share award plans". </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-30</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=243,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=855322,FOLIO='F-30',FILE='DISK116:[20ZBV1.20ZBV74901]FU74901A.;13',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_fw74901_1_31"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued)  </B></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;10. Shareholders' Equity (Continued)  </B></FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2><B><I>10.2.</I></B></FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I>Liquidity agreement</I></B></FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>On
January&nbsp;19, 2018, the Company entered into a new liquidity agreement with Kepler Cheuvreux, replacing the previous liquidity agreement with Oddo BHF, for a period of 12&nbsp;months
renewable by tacit agreement. Under the terms of the agreement, the investment services provider (ISP) is authorized to buy and sell Inventiva treasury shares without interference from the Company in
order to ensure the liquidity of the shares on the Euronext market. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>At
the date of approval of these financial statements, the liquidity agreement with Kepler Chevreux was extended for a new period of 12&nbsp;months from January&nbsp;1, 2020. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>At
December&nbsp;31, 2019 and 2018, treasury shares purchased and sold by Inventiva through its ISP, as well as the gains or losses resulting from share purchase, sale, issue and cancellation
transactions during the period, were accounted for as a deduction from equity. Consequently, these transactions had no impact on the Company's results.  </FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2><B><I>10.3.</I></B></FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I>Share warrants plans</I></B></FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>Share
warrants correspond to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> BSPCE founder share warrants granted to the Company's employees in 2013 and 2015; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> BSA share warrants granted to Company directors in 2017, with a subscription price set at
&euro;0.534; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> BSA share warrants granted to Company service providers in 2018, with a subscription
price set at &euro;0.48; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> BSA share warrants granted in 2019 to David Nikodem, a member of Sapidus Consulting
Group&nbsp;LLC, a service provider of Inventiva, with a subscription price set at &euro;0.18. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


BSPCE plans  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>At December&nbsp;31, 2019, 8,800 BSPCE share warrants were outstanding. Each BSPCE share warrant corresponds to 100 shares. They are exercisable until
December&nbsp;31, 2023, after which date they will be forfeited. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
exercise price of the BSPCE share warrants is fixed at:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> &euro;0.585, including a &euro;0.575 share premium for BSPCE share
warrants granted in 2013. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> &euro;0.67, including a &euro;0.66 share premium for BSPCE share
warrants granted in 2015. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>This
price may not be changed during the plan's lifetime except in the event that adjustments are required as part of financial transactions having an impact on the Company's share capital. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
new shares will be assimilated into existing ordinary shares of the same category from the time of their issuance. If the shares are quoted on a regulated market, they will be recorded in the
Company's share register and will not be convertible into bearer shares. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
share warrants will be forfeited if for any reason the beneficiary's salaried position within the Company is terminated. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-31</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=244,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=840248,FOLIO='F-31',FILE='DISK116:[20ZBV1.20ZBV74901]FW74901A.;17',USER='JTAYLORA',CD='10-APR-2020;09:14' -->
<A NAME="page_fw74901_1_32"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;10. Shareholders' Equity (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


BSA plans  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Two BSA share warrant plans were outstanding at January&nbsp;1, 2019: BSA 2017 and BSA 2018. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On
May&nbsp;29, 2017, the Company's Board of Directors granted 195,000 BSA share warrants ("BSA 2017") to Board members, of which 20,000 have been forfeited upon the departure of one member of the
Board of Directors. BSA 2017 share warrants are share subscription options with no performance conditions attached. The plan is divided into three tranches with one-, two- and three-year vesting
periods. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On
May&nbsp;29, 2017, the fair value of the BSA share warrants was estimated using the Black-Scholes model based on the following
assumptions:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> value of the underlying asset at May&nbsp;29, 2017; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> volatility observed in two samples of comparable listed companies; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> economic life (middle of exercise period). </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>At
the award date, the fair value of each BSA share warrant was estimated at &euro;2.47. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>BSA
2017 share warrants are exercisable until May&nbsp;29, 2027, after which they will be forfeited. The exercise price of the BSA share warrants is fixed at &euro;6.675. This price may
not be changed during the
plan's lifetime except in the event that adjustments are required as part of financial transactions having an impact on the Company's share capital. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>On
December&nbsp;14, 2018, the Company's Board of Directors granted 126,000 BSA share warrants ("BSA 2018") to the Company's consultants, and on June&nbsp;28, 2019, a new BSA 2019 plan was set up
for David Nikodem, a member of Sapidus Consulting Group&nbsp;LLC, a service provider of Inventiva. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
2018 and 2019 plans are set out in Note&nbsp;1.2 "Significant events". </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Movements in BSPCE and BSA share warrants (in number of shares issuable upon exercise)  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="84pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="41pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="55pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="34pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="41pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="39pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="70pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Type

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Grant date </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Exercise<BR>
price<BR>
(in euros) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Outstanding<BR>
at January&nbsp;1,<BR>
2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Issued </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Exercised </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Forfeited </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Outstanding<BR>
at December&nbsp;31,<BR>
2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Number of<BR>
shares<BR>
exercisable </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">BSPCE&nbsp;&#151; 2015 plan</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">May&nbsp;25, 2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">0.67</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">22,800</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(22,800</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">BSPCE&nbsp;&#151; 2013 plan</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">December&nbsp;13, 2013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">0.59</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">13,400</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(4,600</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">8,800</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">8,800 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Total BSPCE</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>36,200</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>&#151;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(27,400</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>&#151;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>8,800</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>8,800</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">BSA&nbsp;&#151; 2017 plan</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">May&nbsp;29, 2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">6.67</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">175,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(35,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">140,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">120,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">BSA&nbsp;&#151; 2018 plan</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">December&nbsp;14, 2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">6.067</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">126,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(10,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">116,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">38,667</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">BSA&nbsp;&#151; 2019 plan</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">June&nbsp;28, 2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">2.20</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">10&nbsp;000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">10,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Total BSA</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>301,000</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>10&nbsp;000</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>&#151;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(45,000</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>266,000</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>158,667</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>337,200</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>10,000</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(27,400</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(45,000</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>274,800</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>167,467</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >



<P style="font-family:arial;"><FONT SIZE=2>The
change in BSPCE and BSA share warrants over 2019 can be broken down as follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the exercise of 274 BSPCE share warrants by Company employees on January&nbsp;23, 2019,
whereupon 27,400 new shares were issued; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-32</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=245,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=449170,FOLIO='F-32',FILE='DISK116:[20ZBV1.20ZBV74901]FW74901A.;17',USER='JTAYLORA',CD='10-APR-2020;09:14' -->
<A NAME="page_fw74901_1_33"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;10. Shareholders' Equity (Continued) </B></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the cancellation of 35,000 BSA 2017 share warrants allocated to two corporate officers,
which were forfeited following the end of their offices at the Annual General Meeting of May&nbsp;27, 2019; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the cancellation of 10,000 BSA 2018 share warrants allocated to JPG Healthcare, which
were forfeited; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the issue of 10,000 new 2019 BSAs allocated to David Nikodem, a member of Sapidus
Consulting Group LLC, a service provide to the Company. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>At
December&nbsp;31, 2019, a total of 88 BSPCEs (or 8,800 shares) and 266,000 BSAs were outstanding. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Share-based
payment expense totaled &euro;227&nbsp;thousand at December&nbsp;31, 2019 (compared to &euro;184&nbsp;thousand at December&nbsp;31, 2018) and were recognized
in personnel costs (see Note&nbsp;18.1 "Personnel costs and headcount"). </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="84pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="41pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="55pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="39pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="39pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="70pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Type

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Grant date </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Exercise<BR>
price<BR>
(in euros) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Outstanding<BR>
at January&nbsp;1,<BR>
2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Issued </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Exercised </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Forfeited </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Outstanding<BR>
at December&nbsp;31,<BR>
2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Number of<BR>
shares<BR>
exercisable </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">BSPCE&nbsp;&#151; 2015 plan</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">May&nbsp;25, 2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">0.67</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">54,700</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(31,900</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">22,800</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">22,800</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">BSPCE&nbsp;&#151; 2013 plan</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">December&nbsp;13, 2013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">0.59</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">161,800</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(148,400</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">13,400</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">13,400 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Total BSPCE</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>216,500</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>&#151;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>180,300</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>&#151;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>36,200</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>36,200</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">BSA&nbsp;&#151; 2017 plan</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">May&nbsp;29, 2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">6.67</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">195,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(20,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">175,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">65,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">BSA&nbsp;&#151; 2018 plan</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">December&nbsp;14, 2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">6.067</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">126,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">126,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Total BSA</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>195,000</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>126,000</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>&#151;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(20,000</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>301,000</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>65,000</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>411,500</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>126,000</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(180,300</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(20,000</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>337,200</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>101,200</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>The
change in BSPCE and BSA share warrants over 2018 can be broken down as follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the exercise of 1,803 BSPCE share warrants by Company employees between January&nbsp;5
and January&nbsp;20, 2018, whereupon 180,300 new shares were issued; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the cancellation of 20,000 BSA 2017 share warrants allocated to one of the corporate
officers which were forfeited following their departure; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the issue of 126,000 new BSA 2018 share warrants allocated to three of the Company's
external advisers.
<BR><BR> </I></B></FONT></DD></DL>
</UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2><B><I>10.4.</I></B></FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I>Bonus share award plans</I></B></FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>Four
AGA bonus share award plans were outstanding at January&nbsp;1, 2019: one AGA 2017 plan and three AGA 2018 plans. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>On
April&nbsp;18, 2017, the Company's Board of Directors approved two bonus share award plans for certain Company
employees:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 92,300 bonus shares (AGA 2017-1), of which (i)&nbsp;10,000 were not granted and
(ii)&nbsp;4,800 have been forfeited; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 70,000 bonus shares (AGA 2017-2), of which (i)&nbsp;10,000 were not granted and
(ii)&nbsp;60,000 vested from April&nbsp;18, 2018. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-33</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=246,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=254102,FOLIO='F-33',FILE='DISK116:[20ZBV1.20ZBV74901]FW74901A.;17',USER='JTAYLORA',CD='10-APR-2020;09:14' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_fy74901_1_34"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued)  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;10. Shareholders' Equity (Continued)  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
plans have the following characteristics:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a two-year vesting period for AGA 2017-1 shares (until April&nbsp;18, 2019); </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a one-year vesting period for AGA 2017-2 shares (until April&nbsp;18, 2018); </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a one-year lock-up period; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a service condition; and</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> no performance conditions. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>The
fair value of Inventiva bonus shares corresponds to the Inventiva share price less a discount to reflect the lock-up period. At the award date, the fair value of each free share was estimated at
&euro;7.04. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
plans allocated in 2018 and 2019 are described in Note&nbsp;1.2 "Significant events". </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
new shares will be assimilated into existing ordinary shares of the same category from the time of their issuance. If the shares are quoted on a regulated market, they will be recorded in the
Company's share register and will not be convertible into bearer shares. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Bonus share movements (in number of shares issuable upon exercise)  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="96pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="58pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="59pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="44pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="44pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="41pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="63pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="50pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Type

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Grant date </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Stock price<BR>
at grant date<BR>
(in euros) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Outstanding<BR>
at January&nbsp;1,<BR>
2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Issued </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Exercised </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Forfeited </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Outstanding<BR>
at December&nbsp;31,<BR>
2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Number of<BR>
shares<BR>
exercisable </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">AGA&nbsp;&#151; 2017-1 plan</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">April&nbsp;18, 2017</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">7.35</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">77,500</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(77,500</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">AGA&nbsp;&#151; 2018-1 plan</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">January&nbsp;26, 2018</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">5.76</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">10,000</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(10,000</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">AGA&nbsp;&#151; 2018-2 plan</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">January&nbsp;26, 2018</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">5.76</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">65,700</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(2,400</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">63,300</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">AGA&nbsp;&#151; 2018-3 plan</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">December&nbsp;14, 2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">6.28</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">265,700</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(38,450</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">227,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">AGA&nbsp;&#151; 2019-1 plan</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">June&nbsp;28, 2019</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">2.00</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">37,500</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">37,500</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">AGA&nbsp;&#151; 2019-2 plan</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">June&nbsp;28, 2019</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">2.00</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">246,000</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(18,000</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">228,000</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 418,900</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>283,500</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(87,500</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(58,850</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>556,050</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>&#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>The
change in AGA bonus shares over the period can be broken down as follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Two new share plans for Company employees involving a total of 283,500 potential new
shares. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Final allotment of 10,000 AGA 2018-1 bonus shares on January&nbsp;26, 2019 and 77,500
AGA 2017-1 bonus shares on April&nbsp;18, 2019. whereupon 87,500 new shares were issued. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Cancellation of 58,850 AGA bonus shares which were forfeited during the period: 10,850
AGA 2018-3 warrants as part of the redundancy plan for the period, 2,400 AGA 2018-3 bonus shares refused by an employee, and 45,600 AGA bonus shares bonus (of which 2,400 AGA 2018-2 bonus shares,
25,200 AGA 2018-3 bonus shares and 18,000 AGA 2019-2 bonus shares) as a result of voluntary departures. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>At
December&nbsp;31, 2019, a total of 556,050 AGA free shares were outstanding. AGA 2019-1 bonus shares are exercisable from June&nbsp;28, 2021 to no later than June&nbsp;28, 2022, subject to
continued employment. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-34</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=247,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=485262,FOLIO='F-34',FILE='DISK116:[20ZBV1.20ZBV74901]FY74901A.;15',USER='WWASSER',CD='10-APR-2020;08:36' -->
<A NAME="page_fy74901_1_35"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;10. Shareholders' Equity (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>AGA
2019-2 bonus shares are exercisable from June&nbsp;28, 2020 to no later than June&nbsp;28, 2021, subject to continued employment. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>AGA
2018-2 free shares are exercisable from January&nbsp;26, 2020 to no later than January&nbsp;26, 2021, subject to continued employment. AGA 2018-3 bonus shares can be exercised, on condition of
employment, from December&nbsp;14, 2020 and no later than December&nbsp;14, 2021. Share-based payments expense totaled &euro;1,180&nbsp;thousand at December&nbsp;31, 2019 (compared
to &euro;649&nbsp;thousand at December&nbsp;31, 2018) and were recognized in personnel costs (see Note&nbsp;18.1 "Personnel costs and headcount"). </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="96pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="58pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="59pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="44pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="44pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="41pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="74pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="50pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Type

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Grant date </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Stock price<BR>
at grant date<BR>
(in euros) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Outstanding<BR>
at January&nbsp;1,<BR>
2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Issued </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Exercised </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Forfeited </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Outstanding<BR>
at December&nbsp;31,<BR>
2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Number of<BR>
shares<BR>
exercisable </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">AGA&nbsp;&#151; 2017-1 plan</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">April&nbsp;18, 2017</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">7.35</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">79,900</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(2,400</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">77,500</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">AGA&nbsp;&#151; 2017-2 plan</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">April&nbsp;18, 2017</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">7.35</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">60,000</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(60,000</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">AGA&nbsp;&#151; 2018-1 plan</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">January&nbsp;26, 2018</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">5.76</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">10,000</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">10,000</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">AGA&nbsp;&#151; 2018-2 plan</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">January&nbsp;26, 2018</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">5.76</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">65,700</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">65,700</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">AGA&nbsp;&#151; 2018-3 plan</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">December&nbsp;14, 2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">6.28</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">265,700</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">265,700</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 139,900</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>341,400</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(60,000</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(2,400</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>418,900</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>&#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>At
December&nbsp;31, 2018, a total of 418,900 AGA bonus shares were outstanding. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;11. Debt  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands of euros)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bank borrowings</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>74</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>220</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other loans and similar borrowings<SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lease liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>37</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total debt</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 114</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>225</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">(1)</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Consists
of accrued interests </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>The &euro;0.1&nbsp;million decrease in 2019 is primarily attributable
to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> at December&nbsp;31, 2019, after repayment of borrowings due in 2019 in a total amount
of &euro;0.1&nbsp;million, the debt relating to bank loans amounted to &euro;0.1&nbsp;million; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> lease liabilities amounting to &euro;37&nbsp;thousand at December&nbsp;31,
2019 were recognized from January&nbsp;1, 2019 following the entry into force of IFRS&nbsp;16&nbsp;&#151; Leases in an initial amount of &euro;167&nbsp;thousand (see
Note&nbsp;2.1 "Impact of the first-time adoption of IFRS&nbsp;16" of this document for more details). In 2019, &euro;0.1&nbsp;million in repayments were recorded. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-35</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=248,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=17894,FOLIO='F-35',FILE='DISK116:[20ZBV1.20ZBV74901]FY74901A.;15',USER='WWASSER',CD='10-APR-2020;08:36' -->
<A NAME="page_fy74901_1_36"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;11. Debt (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
breakdown between long-term and short-term debt is as follows: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="65pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="65pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="49pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>December&nbsp;31, 2019<BR>
(in thousands of euros)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Less than<BR>
1&nbsp;year </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Between<BR>
1 and 3&nbsp;years </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Between<BR>
3 and 5&nbsp;years </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>More than<BR>
5&nbsp;years </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bank borrowings</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>74</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other loans and similar borrowings</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lease liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>35</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total long-term debt</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 112</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>2</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>&#151;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>&#151;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>The
maturity of long-term debt and of short-term borrowings and debt is determined according to repayment estimates as at December&nbsp;31, 2019. </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="65pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="65pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="49pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>December&nbsp;31, 2018<BR>
(in thousands of euros)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Less than<BR>
1&nbsp;year </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Between<BR>
1 and 3&nbsp;years </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Between<BR>
3 and 5&nbsp;years </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>More than<BR>
5&nbsp;years </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bank borrowings</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>146</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>74</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other loans and similar borrowings</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total long-term debt</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>151</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>74</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>Change
in the period is only due to repayments of borrowings and accrual of interests, as follow: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands of euros)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>January&nbsp;1, 2018</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 482</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Repayment of bank borrowings</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(259</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued interests</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>December&nbsp;31, 2018</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 225</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>First application of IFRS&nbsp;16 </FONT><FONT SIZE=2><I>Leases</I></FONT><FONT SIZE=2><SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>167 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>January&nbsp;1, 2019</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>392 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Repayment of bank borrowings</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(146</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Repayment of lease liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(130</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued interests</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>December&nbsp;31, 2019</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 114</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">(1)</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">see
Note&nbsp;2.1 "Impact of the first-time application of IFRS&nbsp;16". </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-36</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=249,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=407101,FOLIO='F-36',FILE='DISK116:[20ZBV1.20ZBV74901]FY74901A.;15',USER='WWASSER',CD='10-APR-2020;08:36' -->
<A NAME="page_fy74901_1_37"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued) </B></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;12. Provisions  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="50pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="45pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="45pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="68pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands of euros)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>January&nbsp;1,<BR>
2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Additions </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Reversals </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>December&nbsp;31,<BR>
2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Long-term provisions</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>358</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>216</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>574</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Short-term provisions</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,140</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>123</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,264 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total Provisions</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 1,498</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>339</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>&#151;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>1,837</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>Provisions
booked at December&nbsp;31, 2019 and 2018 are related to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a tax adjustment risk in respect of payroll taxes carried out in September 2019 (see
Note&nbsp;1.2 "Significant events") with regard to the years ended December&nbsp;31, 2016, 2017 and 2018, for an amount of &euro;1.3&nbsp;million (short term), </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The CIR risk related to the tax audit carried out by the French tax authority in 2016 in
respect of the years ended December&nbsp;31, 2013, 2014 and 2015, for an amount of &euro;0.4&nbsp;million (long term), and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The CIR risk for the year ended December&nbsp;31, 2017 in connection with the partial
reimbursement received in December 2019 (see Note&nbsp;1.2 "Significant events"), for an amount of &euro;0.2&nbsp;million (long term).  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B> Payroll
taxes</B></FONT><FONT SIZE=2>&nbsp;&nbsp;</FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Year ended December&nbsp;31, 2018  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Following the tax audit carried out in July 2016 in respect of the 2013, 2014 and 2015 fiscal years, the Company received a proposed tax adjustment for the
three fiscal periods audited relating to the classification of the subsidy granted (subject to conditions) in 2012 by Laboratoire Fournier&nbsp;SA and Fournier Industrie et Sant&eacute; (now
part of the Abbott group) (LFSA and FIS) under the APA. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Despite
the appeal to a higher administrative authority and the appeal to the departmental interlocutor initiated, a collection notice with respect to payroll taxes was received by Inventiva on
August&nbsp;17, 2018 for an amount of &euro;1.9&nbsp;million, including penalties and late payment interest. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under
the terms and conditions of an additional agreement modifying the APA (the Additional Agreement), LFSA and FIS agreed to indemnify the Company up to a maximum amount of
&euro;2.0&nbsp;million in accordance with the conditions described therein, for any amount claimed by the French tax authorities in relation to the tax treatment of the subsidy paid by
LFSA and FIS between 2012 and 2017 (the "Abbott Guarantee"). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company lodged a claim together with an application for a suspension of payment on October&nbsp;17, 2018 and, at December&nbsp;31, 2018, continued to dispute the tax adjustment. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Based
on the ongoing discussions with the French tax authorities on the one hand and the terms of the Additional Agreement on the other, the Abbott Guarantee may not be sufficient to fully cover the
total amount of the tax adjustment and the tax risk. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Accordingly,
at December&nbsp;31, 2018:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> following receipt of the collection notice and in accordance with the Additional
Agreement, accrued expenses and accrued income were recognized in a total amount of &euro;1.9&nbsp;million for the financial years ended December&nbsp;31, 2013, 2014 and 2015, which are
the subject of the audit and are </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-37</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=250,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=182750,FOLIO='F-37',FILE='DISK116:[20ZBV1.20ZBV74901]FY74901A.;15',USER='WWASSER',CD='10-APR-2020;08:36' -->
<A NAME="page_fy74901_1_38"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;12. Provisions (Continued) </B></FONT></P>

<UL>
<UL>

<P style="font-family:arial;"><FONT SIZE=2>subject
to the Abbott Guarantee (see Notes&nbsp;6 "Other non-current assets" and 14.2 "Other current liabilities"); and </FONT></P>

</UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the Company has recognized a provision of &euro;1.1&nbsp;million for the
years ended December&nbsp;31, 2016 and December&nbsp;31, 2017 (which have not been audited by the French tax authorities at that date and for which the subsidies are still valid). </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>This
had no impact on the income statements for the year ended December&nbsp;31, 2018, as these amounts were already recognized at January&nbsp;1, 2018 </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Year ended December&nbsp;31, 2019  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The application for suspension of payment lodged on October&nbsp;17, 2018 was accepted on February&nbsp;11, 2019 by the French tax authorities following
the proposal by the Company to provide a surety in the form of a bank guarantee (see notes&nbsp;1.2 "Significant events" and 22 "Commitments"). </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Following
the tax audit carried out in 2019 of the Company's payroll taxes for fiscal years 2016, 2017 and 2018, the Company received a proposed tax adjustment of &euro;1.7&nbsp;million
(including penalties and late payment interest) in December 2019. This proposed tax adjustment gives rise to a potential adjustment of &euro;0.5&nbsp;million (including penalties and late
payment interest) for 2018, which the Company is challenging under the ongoing contradictory procedure. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Accordingly,
at December&nbsp;31, 2019:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The provision for fiscal years 2016 and 2017 has been increased to
&euro;1.3&nbsp;million (from &euro;1.1&nbsp;million at December&nbsp;31, 2018), with the change for the period corresponding to additional late payment interest. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> No other provision has been booked for fiscal year 2018 following the proposed adjustment
received in December 2019 as the Company assess probable the application of the administrative tolerance for its situation, the subsidy received under the APA having ended in August 2017. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>This
had a &euro;0.1&nbsp;million impact on the income statement for the year ended December&nbsp;31, 2019. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Ongoing procedure  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>At the date of approval of these financial statements, the Company:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> had filed a claim on October&nbsp;17, 2018 disputing the tax adjustments; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> had filed an application instituting proceedings before the Dijon Administrative Court
(</FONT><FONT SIZE=2><I>Tribunal Administratif de Dijon</I></FONT><FONT SIZE=2>) on September&nbsp;2, 2019, for which the Company had not yet received a response from the French tax authorities. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> was preparing its response to the proposed payroll tax adjustment received in December
2019 following the tax audit carried out in respect of the fiscal years 2016 to 2018. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B>CIR</B></FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


CIR for fiscal years 2013 to 2015 (covered by the tax audit)  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Following the tax audit, for fiscal years 2013 to 2015, on August&nbsp;1, 2017, the Company received a proposed tax adjustment from the French tax
authorities disputing the manner in which some CIR items were calculated over the three fiscal periods audited. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Despite
its appeals to the French tax authorities, Inventiva received a collection notice on August&nbsp;17, 2018 for an amount of &euro;1.9&nbsp;million, including penalties and late
payment interest. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company disputed the notice and implementation of the collection procedure pending interlocutory proceedings via a claim lodged on August&nbsp;29, 2018. This was accompanied by an application
for a suspension of payment and an additional claim lodged with the French tax authorities on January&nbsp;7, 2019. The Company has requested a complete discharge of the amounts claimed in respect
of the CIR. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-38</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=251,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=817979,FOLIO='F-38',FILE='DISK116:[20ZBV1.20ZBV74901]FY74901A.;15',USER='WWASSER',CD='10-APR-2020;08:36' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_ga74901_1_39"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued)  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;12. Provisions (Continued)  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>
At December&nbsp;31, 2018, based on the ongoing discussions and the ongoing challenge procedures, the Company maintained its assessment of the maximum tax adjustment risk in respect of the CIR to
&euro;0.4&nbsp;million covered by the provision already recorded in the financial statements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>At
the date of approval of these financial statements, the Company was still awaiting a decision concerning the ongoing challenge procedures with the French tax authorities, and no additional
provision was recorded in 2019. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company began mediation with the French tax authorities on January&nbsp;7, 2020. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


CIR for fiscal year 2017  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>By the final quarter of 2019, the Company had received 81% of the 2017 CIR, in an amount of &euro;3.6&nbsp;million relative to the
&euro;4.5&nbsp;million initially requested (see Note&nbsp;1.2. "Significant events"). As of December&nbsp;31, 2019, based on the ongoing discussions and the challenges lodged, the
Company estimates the maximum risk in respect of the 2017 CIR at &euro;0.2&nbsp;million, fully recognized in the financial statements for the year ended December&nbsp;31, 2019. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>This
had a &euro;0.2&nbsp;million impact on the income statement for the year ended December&nbsp;31, 2019. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;13. Provisions for Retirement Benefit Obligations  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>
Retirement benefit obligations are determined based on the rights set forth in the national collective bargaining agreement for the French pharmaceutical industry (IDCC 176/Brochure 3104) and in
accordance with </FONT><FONT SIZE=2><I>IAS&nbsp;19&nbsp;&#151; Employee Benefits</I></FONT><FONT SIZE=2>. These rights depend on the employee's final salary and seniority within the Company
at his/her retirement date. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Principal actuarial assumptions  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following assumptions were used to measure the obligation: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="68pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="68pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=3 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of December&nbsp;31, </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Variables

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2018 </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Retirement age</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>65&nbsp;years</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>65&nbsp;years</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Payroll taxes</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>41,41%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>41.41%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Salary growth rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Discount rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0,70%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.60%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Mortality table</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>TGH/TGF&nbsp;05</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>TGH/TGF&nbsp;05</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>The
discount rate corresponds to the rates of Eurozone AA-rated corporate bonds with maturities of over ten years. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-39</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=252,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=929166,FOLIO='F-39',FILE='DISK116:[20ZBV1.20ZBV74901]GA74901A.;7',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<A NAME="page_ga74901_1_40"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;13. Provisions for Retirement Benefit Obligations (Continued) </B></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Net provision  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The provision recorded in respect of defined benefit schemes at the end of each reporting period is shown in the table below: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="35pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="35pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands of euros)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Retirement benefit obligations</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,127</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,029 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Obligation</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 1,127</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>1,029</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>Given
the absence of plan assets at December&nbsp;31, 2019 and 2018, the total amount of the provision corresponds to the estimated obligation at those dates. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Change in net provision  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The change in the provision recorded in respect of defined benefit schemes breaks down as follows: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="39pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="39pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Year ended<BR>
December&nbsp;31 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands of euros)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Provision at beginning of period</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> (1,029</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>(866</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expense for the period</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(194</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Actuarial gains or losses recognized in other comprehensive income</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(96</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>31 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Provision at end of period</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> (1,127</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>(1,029</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Breakdown of expense recognized for the period  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The expense recognized in the statement of income (loss) breaks down as follows: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Year ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands of euros)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Service cost for the period</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>195</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>192</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest cost for the period</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>11</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Plan curtailments and modifications</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(157</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Benefits for the period</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(53</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(9</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 1</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>194</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-40</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=253,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=958069,FOLIO='F-40',FILE='DISK116:[20ZBV1.20ZBV74901]GA74901A.;7',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<A NAME="page_ga74901_1_41"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;13. Provisions for Retirement Benefit Obligations (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Breakdown of actuarial gains and losses recognized in comprehensive income  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The actuarial gains (losses) can be analyzed as follows: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Year ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands of euros)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Demographic changes</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>32</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(14</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Changes in actuarial assumptions</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(129</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>45 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> (96</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>31</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>Demographic
differences mainly relate to salary adjustments and staff movements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Changes
in actuarial assumptions relate to movements in the discount rate in 2019 (from 1.30% to 1.60% in 2018 and to 0.70% in 2019). </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Sensitivity analysis  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A 0.25% change in the discount rate would have had an impact of approximately 3.5% on the obligation amount in 2019 and around 3.5% in 2018. </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="61pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>December&nbsp;31, 2019

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>In thousands<BR>
of euros </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Benefit obligation at December&nbsp;31, 2019 at 0,45%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,168</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Benefit obligation at December&nbsp;31, 2019 at 0,70%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,127</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Benefit obligation at December&nbsp;31, 2019 at 0,95%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,088</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2><BR></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="61pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>December&nbsp;31, 2018

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>In thousands<BR>
of euros </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Benefit obligation at December&nbsp;31, 2018 at 1.35%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,067</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Benefit obligation at December&nbsp;31, 2018 at 1.60%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,029</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Benefit obligation at December&nbsp;31, 2018 at 1.85%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>994</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >



<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;14. Trade Payables and Other Current Liabilities  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands of euros)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Trade payables</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>7,491</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>8,372</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other current liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4,998</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4,871 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Trade payables and other current liabilities</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 12,489</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>13,243</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-41</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=254,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=331643,FOLIO='F-41',FILE='DISK116:[20ZBV1.20ZBV74901]GA74901A.;7',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<A NAME="page_ga74901_1_42"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;14. Trade Payables and Other Current Liabilities (Continued) </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >



<P style="font-family:arial;"><FONT SIZE=2><B><I>14.1.&nbsp;&nbsp;Trade payables</I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Trade
payables break down by payment date as follows: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="35pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="35pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands of euros)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Due in 30&nbsp;days</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>7,414</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>7,966</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Due in 30&nbsp;-&nbsp;60&nbsp;days</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>77</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>406</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Due in more than 60&nbsp;days</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Trade payables</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 7,491</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>8,372</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>No
calculations have been made to discount trade and other payables to present value as payment is due within one year of the end of the reporting period. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><I>14.2.&nbsp;&nbsp;Other current liabilities</I></B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="35pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="35pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands of euros)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Employee-related payables</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,124</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,095</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued payroll and other employee-related taxes</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,041</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,052</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Sales tax payables</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>668</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>574</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other accrued taxes and employee-related expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>177</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>172</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other miscellaneous payables</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,988</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,978 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Other current liabilities</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 4,998</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>4,871</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>No
calculations have been made to discount other current liabilities to present value, as payment is due within one year of the end of the reporting period. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>At
December&nbsp;31, 2019, other current liabilities mainly consist of "Other miscellaneous payables" as well as "Employee-related payables" and "Accrued payroll and other employee-related taxes". </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Other
miscellaneous payables correspond to an accrued expense to the French tax authorities recognized in 2018 following receipt of the collection notice with respect to payroll taxes (see
Note&nbsp;12 "Provisions"). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Accrued
payroll and other employee-related taxes mainly relate to payables to social security and employee-benefit organizations such as URSSAF, KLESIA and APGIS for the last quarter of the year. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-42</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=255,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=299125,FOLIO='F-42',FILE='DISK116:[20ZBV1.20ZBV74901]GA74901A.;7',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<A NAME="page_ga74901_1_43"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;14. Trade Payables and Other Current Liabilities (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Other
accrued taxes and employee-related expenses concern provisions for payroll taxes, such as professional training charges, apprenticeship tax and the employer's contribution to construction
investment in France. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;15. Contract Liabilities  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="16pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="35pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="32pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="25pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>December&nbsp;31, 2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands of euros)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>BI </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>AbbVie </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Enyo<BR>
Parma </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Total </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Short-term contract liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Long-term contract liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total contract liabilities</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>&#151;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>&#151;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>&#151;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Revenue to be recognized<SUP>(1)</SUP></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>&#151;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>&#151;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>&#151;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">(1)</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
revenue to be recognized corresponds to the remaining highly probable revenue to be recognized on the existing contracts until their completion. Milestones and
royalties that are not assessed highly probable are not included. </FONT></DD></DL>
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>At
December&nbsp;31, 2019, as all of the services required of the Company in respect of contracts signed with clients had been completed, all liabilities on contracts were reversed in full for the
period. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Since
the Company upheld all its commitments under the collaboration with Boehringer Ingelheim, all the amounts recorded as "contract liabilities" at December&nbsp;31, 2018, under
IFRS&nbsp;15&nbsp;&#151; Revenue from Contracts with Customers were reversed over the period, generating a positive impact of &euro;2.1&nbsp;million on IFRS revenue for fiscal
year 2019. </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="35pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="35pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="32pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="35pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>December&nbsp;31, 2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands of euros)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>BI </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>AbbVie </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Enyo<BR>
Parma </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Total </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Short-term contract liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>436</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>97</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>548</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Long-term contract liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,673</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,673 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total contract liabilities</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 2,109</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>15</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>97</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>2,221</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Revenue to be recognized</B></FONT><FONT SIZE=2><SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 7,718</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>100</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>97</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>7,915</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">(1)</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
revenue to be recognized corresponds to the remaining highly probable revenue to be recognized on the existing contracts until their completion. Milestones and
royalties that are not assessed highly probable are not included. </FONT></DD></DL>
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>At
December&nbsp;31, 2018, contract liabilities related to the BI Agreement resulted mainly from the exercise of the option in August 2017 which triggered a milestone payment of
&euro;2.5&nbsp;million. This amount was
included in transaction price of the BI Agreement, resulting in an upward revision of the contract price. Based on the stage of completion of the BI Agreement, a total amount of
&euro;0.7&nbsp;million of this milestone payment was recognized in revenue, of which &euro;0.2&nbsp;million in 2018, and the &euro;1.8&nbsp;million difference
was booked to contract liabilities. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
remaining contract liabilities related to the BI Agreement (&euro;0.3&nbsp;million), the agreement with EnyoPharma (&euro;0.1&nbsp;million) and the AbbVie Collaboration
(&euro;15&nbsp;thousand) corresponded to the difference between payment received and revenue recognized related to the research fees. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-43</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=256,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=195334,FOLIO='F-43',FILE='DISK116:[20ZBV1.20ZBV74901]GA74901A.;7',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_gc74901_1_44"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued)  </B></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;16. Financial Assets and Liabilities  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="54pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="65pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="60pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="47pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="47pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>At December&nbsp;31, 2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands of euros)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Book value<BR>
on the<BR>
statement<BR>
of financial<BR>
position </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Financial<BR>
assets carried<BR>
at amortized<BR>
cost </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Financial<BR>
assets<BR>
carried at<BR>
fair value<BR>
through<BR>
profit or loss </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Liabilities<BR>
carried at<BR>
amortized<BR>
cost </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Fair value </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Financial assets</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Long-term deposit accounts and security deposits</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>801</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>801</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>801</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued income</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Trade receivables</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other receivables</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>900</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>900</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>900</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>35,840</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>35,840</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>35,840 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total assets</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>39,545</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>39,545</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>39,545 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Financial liabilities</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Long-term debt<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Short-term debt<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>113</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>113</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>113</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Trade payables</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7,491</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7,491</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7,491</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other miscellaneous payables</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,988</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,988</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,988 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total liabilities</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>9,594</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>9, 594</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>9, 594 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">(1)</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">including
lease liabilities relating to leased assets falling into the scope of IFRS&nbsp;16 are included in debt as of December&nbsp;31, 2019 (see
Notes&nbsp;2.1 "Impact of the first-time application of IFRS&nbsp;16" and 11 "Debt"). </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-44</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=257,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=218642,FOLIO='F-44',FILE='DISK116:[20ZBV1.20ZBV74901]GC74901A.;7',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<A NAME="page_gc74901_1_45"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued) </B></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;16. Financial Assets and Liabilities (Continued) </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="54pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="60pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="60pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="47pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="47pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>At December&nbsp;31, 2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands of euros)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Book value<BR>
on the<BR>
statement<BR>
of financial<BR>
position </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Financial<BR>
assets carried<BR>
at amortized<BR>
cost </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Financial<BR>
assets<BR>
carried at<BR>
fair value<BR>
through<BR>
profit or loss </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Liabilities<BR>
carried at<BR>
amortized<BR>
cost </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Fair value </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Financial assets</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Long-term deposit accounts and security deposits</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>108</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>108</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>108</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued income</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,932</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,932</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,932</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Trade receivables</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>6</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>6</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>6</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other receivables</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>874</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>874</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>874</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>56,692</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>56,692</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>56,692 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total assets</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>59,612</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>59,612</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>59,612 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Financial liabilities</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Long-term debt</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>74</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>74</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>74</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Short-term debt</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>151</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>151</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>151</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Trade payables</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>8,372</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>8,372</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>8,372</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other miscellaneous payables</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,978</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,978</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,978 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total liabilities</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10,575</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10,575</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10,575 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;17. Revenues and Other Income  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="35pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Year ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands of euros)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Sales</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,998</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3,197 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total revenues</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,998</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3,197 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CIR</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4,293</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4,166</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Subsidies</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total other income</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4,293</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4,182 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total revenues and other income</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>11,291</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>7,379 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>The
Company's revenue is derived from its research and development agreements with AbbVie and BI and the provision of services (see Note&nbsp;1.2, "Significant events"). </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-45</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=258,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=531696,FOLIO='F-45',FILE='DISK116:[20ZBV1.20ZBV74901]GC74901A.;7',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<A NAME="page_gc74901_1_46"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued) </B></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;17. Revenues and Other Income (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
2019, revenue amounted to &euro;7.0&nbsp;million and primarily included:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the &euro;3.5&nbsp;million milestone payment from AbbVie received in
December 2019 following the enrollment of the first patient with psoriasis in the ongoing clinical trial of ABBV-157; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the reversal of all contract liabilities recognized at December&nbsp;31, 2018 following
the termination of all contracts with BI. The reversal amounted to &euro;2.2&nbsp;million, including &euro;2.1&nbsp;million following termination of the BI Collaboration in
the fourth quarter of 2019 (see Notes&nbsp;1.2 "Significant events" and 15 "Contract liabilities"). </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>In
2018, revenue was primarily composed of fees received from AbbVie, BI and, to a lesser extent, other parties in return for research services rendered by the Company, no milestone payment having
been received in 2018. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;18. Research and Development, Marketing&nbsp;&#151; Business Development and General and Administrative Expenses  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="64pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="103pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="67pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>December&nbsp;31, 2019<BR>
(in thousands of euros)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Research and<BR>
development<BR>
expenses </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Marketing&nbsp;&#151; business<BR>
development<BR>
expenses </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>General and<BR>
administrative<BR>
expenses </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Total </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Disposables</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(1,560</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(1,560</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Energy and liquids</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(505</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(505</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Patents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(506</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(506</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Studies</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(19,353</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(19,353</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Maintenance</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(933</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(933</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(239</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(987</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(1,226</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>IT systems</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(793</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(46</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(847</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Support costs (including taxes)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(568</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(568</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Personnel costs</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(8,076</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(202</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(2,703</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(10,981</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Depreciation, amortization and provisions</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(1,060</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(396</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(1,456</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other operating expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(765</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(40</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(1,387</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(2,192</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total operating expenses</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(33,791</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(249</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(6,088</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(40,128</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-46</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=259,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=287828,FOLIO='F-46',FILE='DISK116:[20ZBV1.20ZBV74901]GC74901A.;7',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<A NAME="page_gc74901_1_47"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;18. Research and Development, Marketing&nbsp;&#151; Business Development and General and Administrative Expenses (Continued) </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><BR></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="64pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="103pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="67pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>December&nbsp;31, 2018<BR>
(in thousands of euros)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Research and<BR>
development<BR>
expenses </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Marketing&nbsp;&#151; business<BR>
development<BR>
expenses </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>General and<BR>
administrative<BR>
expenses </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Total </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Disposables</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(2,210</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(2,210</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Energy and liquids</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(504</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(504</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Patents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(401</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(401</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Studies</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(17,351</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(17,351</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Maintenance</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(934</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(934</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(98</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(1,431</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(1,530</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>IT systems</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(766</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(9</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(49</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(824</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Support costs (including taxes)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(584</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(584</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Personnel costs</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(7,625</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(182</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(2,266</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(10,072</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Depreciation, amortization and provisions</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(890</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(179</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(1,069</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other operating expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(978</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(34</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(1,536</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(2,549</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total operating expenses</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(31,758</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(225</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(6,045</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(38,028</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><B><I>18.1.</I></B></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B><I>Personnel costs and headcount</I></B></FONT><FONT  style="font-size:8pt;line-height:9pt;">

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


</FONT></DD></DL>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="64pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="103pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="67pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>December&nbsp;31, 2019<BR>
(in thousands of euros)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Research and<BR>
development<BR>
expenses </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Marketing&nbsp;&#151; business<BR>
development<BR>
expenses </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>General and<BR>
administrative<BR>
expenses </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Total </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Wages, salaries and similar costs</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(4,908</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(178</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(1,491</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(6,577</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Payroll taxes</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(2,206</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(634</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(2,841</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Provisions for retirement benefit obligations</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(95</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(61</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(156</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Share-based compensation expense</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(868</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(22</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(517</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(1,407</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total personnel costs</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(8,076</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(202</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(2,703</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(10,981</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2><BR></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="64pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="103pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="67pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>December&nbsp;31, 2018<BR>
(in thousands of euros)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Research and<BR>
development<BR>
expenses </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Marketing&nbsp;&#151; business<BR>
development<BR>
expenses </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>General and<BR>
administrative<BR>
expenses </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Total </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Wages, salaries and similar costs</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(5,085</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(178</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(1,349</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(6,613</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Payroll taxes</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(1,981</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(576</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(2,560</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CICE tax credit</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>103</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>20</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>124</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Provisions for retirement benefit obligations</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(145</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(45</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(190</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Share-based compensation expense</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(516</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(316</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(833</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total personnel costs</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(7,625</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(182</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(2,266</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(10,072</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>The
Company had 88 employees at December&nbsp;31, 2019 compared with 113 employees at December&nbsp;31, 2018. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-47</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=260,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=704632,FOLIO='F-47',FILE='DISK116:[20ZBV1.20ZBV74901]GC74901A.;7',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_ge74901_1_48"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued)  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;19. Other Operating Income (expenses)  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>
Other operating income (expenses) break down as follows: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="39pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="39pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Year ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands of euros)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued income from Abbott&nbsp;&#151; payroll taxes</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>68</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total other operating income</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 68</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>&#151;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Provision for risk on payroll taxes</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(123</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>restructuring expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(1,096</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>IPO costs and follow-on offering</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(323</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(2,221</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Write-down of inventory</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(33</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total other operating expenses</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> (1,542</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>(2,255</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Other operating income (expenses)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> (1,475</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>(2,255</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;20. Financial Income and Expenses  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Year ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands of euros)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Income from cash and cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>157</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>120</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign exchange gains</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>21</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total financial income</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 175</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>142</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest cost</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Losses on cash and cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(202</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign exchange losses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(62</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(36</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other financial expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(11</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total financial expenses</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> (81</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>(253</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net financial income (loss)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 93</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>(111</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;21. Income Tax  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>
The income tax rate applicable to the Company is the French corporate income tax rate of 31%. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-48</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=261,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=1028818,FOLIO='F-48',FILE='DISK116:[20ZBV1.20ZBV74901]GE74901A.;9',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<A NAME="page_ge74901_1_49"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued) </B></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;21. Income Tax (Continued) </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Year ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands of euros)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss before tax</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(30,218</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(33,014</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Theoretical tax rate</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>31</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>33.33</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Tax benefit at theoretical rate</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 9,368</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>11,004</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tax credits</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,330</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,435</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Permanent differences</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(21</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>827</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other differences</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(404</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(269</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Non recognition of deferred tax assets related to tax losses and temporary differences</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(10,272</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(12,997</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Actual income tax benefit</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>&#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>of which</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Current taxes</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Deferred taxes</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Effective tax rate</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> &#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>&#151;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>Tax
credits mainly include the CIR, non-taxable income, classified in other operating income (see Note&nbsp;17 "Revenue and other income"). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company faced a tax loss in the years ended December&nbsp;31, 2019 and 2018. As the recoverability of these tax losses is not considered probable in subsequent periods due to the uncertainties
inherent in the Company's business, no deferred tax assets were recognized in the financial statements as of December&nbsp;31, 2019 nor as of December&nbsp;31, 2018. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;22. Commitments  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Commitments given  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Financial instruments pledged as collateral  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>At December&nbsp;31, 2019, two pledges of term accounts were in
place:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> As collateral for the loan from Soci&eacute;t&eacute;
G&eacute;n&eacute;rale agreed and signed by the Company on July&nbsp;7, 2015 for &euro;254&nbsp;thousand at a fixed annual rate of 0.90% repayable in regular
installments over a 60-month term, a deposit account was pledged with a balance of &euro;100&nbsp;thousand as of the pledge date, which was July&nbsp;7, 2015. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> As part of the guarantee given to the tax authorities in the form of a bank guarantee
from Cr&eacute;dit Agricole in the amount of &euro;3.4&nbsp;million, the Company pledged a term account with a balance of &euro;692&nbsp;thousand on
February&nbsp;1, 2019, equivalent to 50% of the sum not covered by the indemnity to be received from the Abbott group under the Additional Agreement (see Notes&nbsp;1.2 "Significant events" and 12
"Provisions"). </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-49</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=262,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=494441,FOLIO='F-49',FILE='DISK116:[20ZBV1.20ZBV74901]GE74901A.;9',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<A NAME="page_ge74901_1_50"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;22. Commitments (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Should
the dispute to which this guarantee pertains remain unresolved at June&nbsp;30, 2020, or should any disputed sums remain outstanding, the Company has undertaken to provide an additional
surety of &euro;1.0&nbsp;million. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Commitments received  </B></FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Agreements concerning the provision of facilities  </I></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I>Agreement with Novolyze</I></B></FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>On
October&nbsp;13, 2015, the Company signed a contract to make its premises and facilities available to Novolyze for a 36-month period beginning October&nbsp;19, 2015. Pursuant to an amendment
signed on October&nbsp;19, 2016, the monthly rent was increased to &euro;5&nbsp;thousand as from November&nbsp;1, 2017, with an annual rate of increase of 2%. Therefore, at
December&nbsp;31, 2019, the total commitment received amounted to
&euro;70&nbsp;thousand and commitments relating to future payments amounted to &euro;145&nbsp;thousand. </FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I>Agreement with Genoway</I></B></FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>On
November&nbsp;4, 2015, the Company signed a contract to make its premises and facilities available to Genoway for a three-year period beginning December&nbsp;1, 2015. On July&nbsp;1, 2017,
the contract was amended and extended through June&nbsp;30, 2019 and then renewable by tacit agreement for a period of three years, putting the next expiry date at June&nbsp;30, 2022. The monthly
rent was increased to &euro;15&nbsp;thousand as from December&nbsp;1, 2017. Therefore, at December&nbsp;31, 2019, the total commitment received amounted to
&euro;185&nbsp;thousand and commitments relating to future payments amounted to &euro;461&nbsp;thousand. </FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I>Agreement with Synthecob</I></B></FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>On
March&nbsp;21, 2016, the Company signed a contract to make its research equipment and services available to the company Synthecob for a two-year period beginning April&nbsp;1, 2016. Pursuant to
an amendment signed on January&nbsp;1, 2017, the monthly rent was increased to &euro;2.4&nbsp;thousand until March&nbsp;30, 2018 and then to &euro;2.5&nbsp;thousand. It
was increased again to &euro;2.7&nbsp;thousand as from September&nbsp;1, 2018. Therefore, at December&nbsp;31, 2019, the total commitment received amounted to
&euro;32&nbsp;thousand and commitments relating to future payments amounted to &euro;65&nbsp;thousand. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;23. Related-Party Transactions  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>
The table below sets out the compensation awarded to the members of the executive team (including the executive and corporate officers) that was recognized in expenses for the years ended
December&nbsp;31, 2019 and 2018. </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="35pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="35pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Year ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands of euros)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Wages and salaries</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,113</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>944</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Benefits in kind</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>47</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>46</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pension plan expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>66</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>41</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Share-based compensation expense</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>280</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>354</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Attendance fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>206</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>200 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net total</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 1,712</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>1,585</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-50</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=263,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=451435,FOLIO='F-50',FILE='DISK116:[20ZBV1.20ZBV74901]GE74901A.;9',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<A NAME="page_ge74901_1_51"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;23. Related-Party Transactions (Continued) </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>During
2019, ISLS Consulting, whose Chairman Jean-Louis Junien was a Company director until May&nbsp;27, 2019, received &euro;169&nbsp;thousand, compared to
&euro;162&nbsp;thousand in 2018 within the scope of a consulting service contract. Additionally, on December&nbsp;14, 2018, the Company's Board of Directors granted 80,000 share
warrants to ISLS Consulting, </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;24. Basic and Diluted Loss Per Share  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>
Basic earnings (loss) per share are calculated by dividing net income (loss) attributable to owners of the Company by the weighted average number of ordinary shares outstanding during the period. </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="67pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="67pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Year ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands of euros)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2019 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss for the period</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(30,218</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(33,014</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted average number of outstanding shares used for computing basic/diluted loss per share</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>23,519,897</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>20,540,979 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Basic/diluted loss per share (in &euro;)</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> (1.28</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>(1.61</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B>)</B></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>As
the Company recorded a loss in 2019 and 2018, diluted earnings (loss) per share are identical to basic earnings (loss) per share. Share-based payment plans (BSAs, BSPCEs and AGAs) are not included
as their effects would be anti-dilutive. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;25. Financial Risk Management  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>
The Company's activities expose it to various types of financial risk: foreign exchange risk, credit risk and liquidity risk. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Foreign exchange risk  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company's activities expose it to foreign exchange risk on purchases made in foreign currencies. Foreign currency purchases are mainly made in US dollars
or pounds sterling and, to a lesser extent, Swiss francs Australian dollars, Canadian dollars or Swedish crown. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Credit risk  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Credit risk arises from cash and cash equivalents and deposits with banks and financial institutions, as well as from client exposures. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company's exposure to credit risk chiefly relates to trade receivables. The Company has put in place a system to monitor its receivables and their payment and clearance. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Generally,
the Company is not exposed to a concentration of credit risk given the outstanding trade receivables balance at each reporting date. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-51</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=264,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=599047,FOLIO='F-51',FILE='DISK116:[20ZBV1.20ZBV74901]GE74901A.;9',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<A NAME="page_ge74901_1_52"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
NOTES TO THE FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;25. Financial Risk Management (Continued) </B></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Liquidity risk  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Liquidity risk management aims to ensure that the Company disposes of sufficient liquidity and financial resources to be able to meet present and future
obligations. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company prepares short-term cash forecasts and annual operating cash flow forecasts as part of its budget procedures. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Prudent
liquidity risk management involves maintaining sufficient liquidity, having access to financial resources through appropriate credit facilities and being able to unwind market positions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company's operations have consumed substantial amounts of cash since inception. Developing pharmaceutical product candidates, including conducting clinical trials, is expensive, lengthy and risky,
and the Company expects its research and development expenses to increase substantially in connection with its ongoing activities. Accordingly, the Company will continue to require substantial
additional capital to continue its clinical development activities and potentially engage in commercialization activities. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Note&nbsp;26. Events After the Reporting Date  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Full payment of 2018 CIR received  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company received the entire amount of the 2018 CIR, totaling &euro;4.2&nbsp;million, in January 2020. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Vesting of 63,300 AGA free shares  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On January&nbsp;26, 2020, the Chairman and Chief Executive Officer recorded a capital increase arising from the vesting of AGA 2018-2 free shares in an
amount of &euro;633 through the issue of 63,300 new ordinary shares with a par value of &euro;0.01 each. On that date, the number of shares outstanding was therefore increased to
26,909,412 and the share capital to &euro;269,094.12. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Capital increase reserved for a category of investors  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On February&nbsp;7, 2020, Inventiva completed a capital increase with cancellation of shareholders' preferential subscription rights subscribed by BVF
Partners&nbsp;L.P., Novo A/S, New Enterprise Associates 17,&nbsp;L.P. and Sofinnova Partners, existing shareholders of the Company. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A
total of 3,778,338 new shares were issued as a per share price of &euro;3.97 (par value of &euro;0.01 plus an issue premium of &euro;3.96), resulting in net proceeds
to the Company of &euro;14.6&nbsp;million. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
settlement-delivery of the new shares took place on February&nbsp;7, 2020 in a total gross amount of &euro;15.0&nbsp;million. The new shares were admitted to trading on Euronext
Paris on the same date. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-52</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=265,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=365881,FOLIO='F-52',FILE='DISK116:[20ZBV1.20ZBV74901]GE74901A.;9',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>(including ordinary shares in the form of American<BR>
Depositary Shares) </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g580373.jpg" ALT="LOGO" WIDTH="220" HEIGHT="84">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>Ordinary Shares  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="28%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="28%" ALIGN="CENTER" >


  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B>PRELIMINARY PROSPECTUS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="28%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="28%" ALIGN="CENTER" >


 </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="23%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="23%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="47%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=4><B>Jefferies</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B> Stifel</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=4><B> Guggenheim Securities</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="48%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=4><B>KBC Securities</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=4><B>Roth Capital Partners</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:arial;"><font> </FONT> <FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;, 2020 </FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=266,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=356842,FOLIO='blank',FILE='DISK116:[20ZBV1.20ZBV74901]HO74901A.;7',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_ja74901_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A NAME="ja74901_part_ii_information_not_required_in_prospectus"> </A>
<A NAME="toc_ja74901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PART II<BR>  INFORMATION NOT REQUIRED IN PROSPECTUS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A NAME="ja74901_item_6._indemnification_of_directors_and_officers"> </A>
<A NAME="toc_ja74901_2"> </A></FONT> <FONT SIZE=2><B>  ITEM 6.&nbsp;&nbsp;&nbsp;&nbsp;Indemnification of Directors and Officers    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under French law, provisions of bylaws that limit the liability of directors are prohibited. However, French law allows </FONT> <FONT SIZE=2><I>soci&eacute;t&eacute;s anonymes</I></FONT><FONT SIZE=2> to contract for and maintain
liability insurance against civil liabilities incurred by any of their
directors and officers involved in a third-party action, provided that they acted in good
faith and within their capacities as directors or officers of the company. Criminal liability cannot be indemnified under French law, whether directly by the company or through liability insurance. We
intend to maintain liability insurance for our directors and officers, including insurance against liability under the Securities Act. These arrangements may discourage shareholders from bringing a
lawsuit against our directors and executive officers for breach of their duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against directors and
executive officers, even though such an action, if successful, might otherwise benefit us and our shareholders. Furthermore, a shareholder's investment may be adversely affected to the extent we pay
any costs of settlement and damage awards against directors and officers pursuant to these insurance arrangements.  </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A NAME="ja74901_item_7._recent_sales_of_unregistered_securities."> </A>
<A NAME="toc_ja74901_3"> </A></FONT> <FONT SIZE=2><B>  ITEM 7.&nbsp;&nbsp;&nbsp;&nbsp;Recent sales of Unregistered Securities.    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following sets forth information regarding all unregistered securities sold since January&nbsp;1, 2017. </FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> In February and March 2017, in connection with our initial public offering in France, we
issued an aggregate of 5,706,577 ordinary shares at a purchase price of &euro;8.50 per share. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> On April&nbsp;17, 2018, we issued an aggregate of 5,572,500 ordinary shares in
connection with a private placement at a purchase price of &euro;&nbsp;6.37 per share. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> On September&nbsp;20, 2019 and October&nbsp;2, 2019, we issued an aggregate of
4,473,935 ordinary shares in connection with a private placement at a purchase price of &euro;1.99 per share. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> On February&nbsp;11, 2020, we issued an aggregate of 3,778,338 ordinary shares in
connection with a private placement at a purchase price of &euro;3.97 per share. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> During this period, founder's share warrants (</FONT><FONT SIZE=2><I>bons de souscription
de parts de cr&eacute;ateur d'entreprise</I></FONT><FONT SIZE=2>) and share warrants (</FONT><FONT SIZE=2><I>bons de souscription d'actions</I></FONT><FONT SIZE=2>) were exercised at prices of
(1)&nbsp;with respect to BCE 2013-1 (2013), &euro;0.585 per ordinary share, (2)&nbsp;with respect to BCE 2013-1 (2015) and BSA&nbsp;2013-1, &euro;0.67 per ordinary share.
Pursuant to these exercises, we issued an aggregate of 915,600 ordinary shares. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT FACE="WINGDINGS"  style="font-size:8pt;line-height:9pt;">&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> During this period, we issued an aggregate of 210,800 ordinary shares upon the vesting of
outstanding free shares (</FONT><FONT SIZE=2><I>actions gratuites</I></FONT><FONT SIZE=2>) that had no exercise price. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>The
offers, sales and issuances of the securities described in the preceding paragraphs were exempt from registration either (a)&nbsp;under Section&nbsp;4(a)(2) of the Securities Act and the rules
and regulations promulgated thereunder (including Regulation&nbsp;D and Rule&nbsp;506) in that the transactions were between an issuer and sophisticated investors or members of its senior
executive management and did not involve any public offering within the meaning of Section&nbsp;4(a)(2), (b)&nbsp;under Regulation&nbsp;S promulgated under the Securities Act in that offers,
sales and issuances were not made to persons in the United States and no directed selling efforts were made in the United States, (c)&nbsp;under Rule&nbsp;144A under the Securities Act in that the
shares were offered and sold by the initial purchasers to qualified institutional buyers or (d)&nbsp;under Rule&nbsp;701 promulgated under the Securities Act in that the transactions were under
compensatory benefit plans and contracts relating to compensation. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>II-1</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=267,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=400961,FOLIO='II-1',FILE='DISK116:[20ZBV1.20ZBV74901]JA74901A.;8',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<A NAME="page_ja74901_1_2"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><A NAME="ja74901_item_8._exhibits_and_financial_statement_schedules."> </A>
<A NAME="toc_ja74901_4"> </A></FONT> <FONT SIZE=2><B>  ITEM 8.&nbsp;&nbsp;&nbsp;&nbsp;Exhibits and Financial Statement Schedules.    <BR>    </B></FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>Exhibits

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


 </FONT></DD></DL>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="54pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Exhibit No. </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Description of Exhibit </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1.1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><SUP>#</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Form of Underwriting Agreement.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><BR><FONT SIZE=2>3.1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR><SUP>#</SUP></FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2>Bylaws of the registrant (English translation).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><BR><FONT SIZE=2>4.1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR><SUP>#</SUP></FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2>Form of Deposit Agreement (incorporated by reference to the Form&nbsp;F-6 Registration Statement (File No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;), filed
with the Commission on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><BR><FONT SIZE=2>4.2</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR><SUP>#</SUP></FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2>Form of American Depositary Receipt (incorporated by reference to the Form&nbsp;F-6 Registration Statement).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><BR><FONT SIZE=2>5.1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR><SUP>#</SUP></FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2>Opinion of Gide Loyrette Nouel A.A.R.P.I.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><BR><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR><SUP>#+</SUP></FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2>Summary of BSA 2017, BSA 2018 and BSA 2019 Plans.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><BR><FONT SIZE=2>10.2</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR><SUP>#+</SUP></FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2>Summary of BSPCE Plan.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><BR><FONT SIZE=2>10.3</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR><SUP>#+</SUP></FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2>2018-2 and 2018-3 Free Share Plans (English Translation).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><BR><FONT SIZE=2>23.1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR><SUP>#</SUP></FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2>Consent of KPMG&nbsp;S.A.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><BR><FONT SIZE=2>23.2</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR><SUP>#</SUP></FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2>Consent of Gide Loyrette Nouel A.A.R.P.I. (included in Exhibit&nbsp;5.1).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><BR><FONT SIZE=2>24.1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR><SUP>#</SUP></FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2>Power of Attorney (included on signature page to the filing of this Registration Statement on Form&nbsp;F-1).</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">#</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">To be filed by amendment.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">+</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Indicates
management contract or compensatory plan.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">(b)</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Financial
Statement Schedules </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>All schedules have been omitted because the information required to be set forth therein is not applicable or has been included in the financial statements and
notes thereto.  </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A NAME="ja74901_item_9._undertakings."> </A>
<A NAME="toc_ja74901_5"> </A></FONT> <FONT SIZE=2><B>  ITEM 9.&nbsp;&nbsp;&nbsp;&nbsp;Undertakings.    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The undersigned registrant hereby undertakes to provide to the underwriter at the closing specified in the underwriting agreements certificates in such
denominations and registered in such names as required by the underwriter to permit prompt delivery to each purchaser. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing
provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act
of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director,
officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the
securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question
whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>II-2</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=268,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=834018,FOLIO='II-2',FILE='DISK116:[20ZBV1.20ZBV74901]JA74901A.;8',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<A NAME="page_ja74901_1_3"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
undersigned registrant hereby undertakes that: </FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>For
purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration
statement in reliance upon Rule&nbsp;430A and contained in a form of prospectus filed by the registrant pursuant to Rule&nbsp;424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be
deemed to be part of this registration statement as of the time it was declared effective.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>For
the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be
a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>II-3</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=269,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=657997,FOLIO='II-3',FILE='DISK116:[20ZBV1.20ZBV74901]JA74901A.;8',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A NAME="page_je74901_1_4"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A NAME="je74901_signatures"> </A>
<A NAME="toc_je74901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SIGNATURES    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form&nbsp;F-1 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Daix, France, on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="49%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="20pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="46%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:arial;"><FONT SIZE=2><B>INVENTIVA&nbsp;S.A.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2>  By:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><BR><FONT SIZE=2>&nbsp;&nbsp;<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Fr&eacute;d&eacute;ric Cren<BR></FONT> <FONT SIZE=2><I>Chief Executive Officer</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>II-4</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=270,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=1035023,FOLIO='II-4',FILE='DISK116:[20ZBV1.20ZBV74901]JE74901A.;19',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<A NAME="page_je74901_1_5"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A NAME="je74901_power_of_attorney"> </A>
<A NAME="toc_je74901_2"> </A>
<BR></FONT><FONT SIZE=2><B>  POWER OF ATTORNEY    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Fr&eacute;d&eacute;ric Cren, Jean
Volatier and Pierre Broqua, and each of them, his or her true and lawful agent, proxy and attorney-in-fact, with full power of substitution and resubstitution, for him or her and in his or her name,
place and stead, in any and all capacities, to (1)&nbsp;act on, sign and file with the Securities and Exchange Commission any and all amendments (including post-effective amendments) to this
registration statement together with all schedules and exhibits thereto and any subsequent registration statement filed pursuant to Rule&nbsp;462(b) under the Securities Act of 1933, as amended,
together with all schedules and exhibits thereto, (2)&nbsp;act on, sign and file such certificates, instruments, agreements and other documents as may be necessary or appropriate in connection
therewith, (3)&nbsp;act on and file any supplement to any prospectus included in this registration statement or any such amendment or any subsequent registration statement filed pursuant to
Rule&nbsp;462(b) under the Securities Act of 1933, as amended, and (4)&nbsp;take any and all actions which may be necessary or appropriate to be done, as fully for all intents and purposes as he
or she might or could do in
person, hereby approving, ratifying and confirming all that such agent, proxy and attorney-in-fact or any of his substitutes may lawfully do or cause to be done by virtue thereof. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Pursuant
to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="258pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="89pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="CENTER" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Signature

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Title

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Date


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:arial;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Fr&eacute;d&eacute;ric Cren</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2>Chief Executive Officer and Chairman of the Board of Directors </FONT><FONT SIZE=2><I>(Principal Executive Officer)</I></FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:arial;"><BR><FONT SIZE=2>&nbsp;&nbsp;<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Jean Volatier</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><BR><FONT SIZE=2>Chief Financial Officer </FONT><FONT SIZE=2><I>(Principal Financial and Accounting Officer)</I></FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:arial;"><BR><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:arial;"><BR><FONT SIZE=2>&nbsp;&nbsp;<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Pierre Broqua</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><BR><FONT SIZE=2>Deputy Chief Executive Officer, Chief Scientific Officer and Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:arial;"><BR><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:arial;"><BR><FONT SIZE=2>&nbsp;&nbsp;<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Pienter-Jan BVBA represented by Chris Buyse</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:arial;"><BR><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:arial;"><BR><FONT SIZE=2>&nbsp;<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Sofinnova Partners represented by Lucy Lu</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:arial;"><BR><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:arial;"><BR><FONT SIZE=2>&nbsp;<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Heinz Maeusli</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:arial;"><BR><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:arial;"><BR><FONT SIZE=2>&nbsp;&nbsp;<BR>



<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Nawal Ouzrezn</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:arial;"><BR><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:arial;"><BR><FONT SIZE=2>&nbsp;&nbsp;<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> CELL+ represented by Annick Schwebig</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:arial;"><BR><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>II-5</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=271,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=50606,FOLIO='II-5',FILE='DISK116:[20ZBV1.20ZBV74901]JE74901A.;19',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<A NAME="page_je74901_1_6"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A NAME="je74901_signature_of_authorize__je702335"> </A>
<A NAME="toc_je74901_3"> </A>
<BR></FONT><FONT SIZE=2><B>  Signature of Authorized U.S. Representative of Registrant    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Pursuant to the requirements of the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of
Inventiva&nbsp;S.A. has signed this registration statement on the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;day
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="49%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="22pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="46%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:arial;"><FONT SIZE=2> Cogency Global&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2>  By:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><BR><FONT SIZE=2>&nbsp;&nbsp;<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Name:<BR>
Title:<BR></FONT>
</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>II-6</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=272,EFW="2241310",CP="INVENTIVA S.A.",DN="1",CHK=725071,FOLIO='II-6',FILE='DISK116:[20ZBV1.20ZBV74901]JE74901A.;19',USER='VRIVERA',CD=';9-APR-2020;23:33' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g89970.jpg
<TEXT>
begin 644 g89970.jpg
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MD;$50E)A@<'1)#-3<I+PH;+""!87)4."-&)T@\/2X?_:  P# 0 "$0,1 #\
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MD2ARIR-F6V92Y$MT5:$ZUC85#2TK#S038QOB-Q=AYL9-BE"U+&]PNT)!=,0
MQPIC:R8O:\J9C8]([ CR=$F)3LTI>F,\YJ<G5O*3G*D)QI!G4!@];]T"E*=
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MP"T(.]AWK>0K*P!5@P(5@5((*OR58$<CA@#U/P>#QSP= RDD @E2RD @D,O
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M[_4T:N06]ON-Z.SV)]Z,>7Y(' 30,CA%#S,2C]1W3Z9%GC]6X[ 01%6(!XF
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M4:WFEJ!ZU[$OL\N*I5Z+>0@(&[ZFJV8O%F[8A3V=&56DMZ0,YL?>[G;J>,D
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MZ\O+_>C<M>OZM?B0Z[_3K73'KJ4=UZ>B7U_-&Y;=/G_$?T_;F+(GCY2*E**
ME)U'#2;[ILK@%:+1&7D#D%3['VX/!&6C1I-YM5 **5)#J" WP1[D<^W(!!4\
M<,K#D&)^%\;>;_'VPZ>Y2T'Q.AJZ0,G&.>\0Y7Q<L_F*IFT@C+%JV%-NUW;#
M1R4DD:<Q2].M?5BYNFL0>&XIZ3-!B +0YJ3$!9)?@N6'9^<V.0[[4DE>Z5XT
M&\F7:N>/;*\\Y*IMNR*ID?&64UW;[K.ITDB=8KESOJ9Q,,5<MM$/_!L]L7R)
M_4/!LQ3IF0YM2HYG?74H[S_O2^O+_P#2-RU_9^XAY_JZX]=2CM?\$OKV=?\
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MT(?=V,738NZ'J+7>%TUO?=#UWTUO?3IKKGZ9!-VI[UQ[77/4L"D\Y,AEZ/\
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MX?<@[Z=.0W("IV6])<LJ!LI%FCEN)F^=5W"(:A?G&1KU$"A;TWG-\4E$D<G
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MXU' _(?A^'Y?'\/PUUO0D>MZWI*FUO1A9NMZ(*\C"0>&49K\C_'+!^06/_&
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M\FWFA5D[7:LT;MRB9.7N=F!5RQD#^K[3#<C-&X?,5QU3+G +G34'EOIE6O/
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M-YEM\LN.0S&M&IIH1=6]9.+1&T;'6VY5'9*K?-,B]M:$C^M&Z*639R\3Z[O
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M CV94]M+XTDJ_&;R0:$N:5Y&RAFA$0+8@B#Y&X^%5074W<:&F0B=V=KXNWI
MK^A;='"(TB;Y%+Z^BDAB+4W3)"KCZU(X,*UOD:I0YD-I+4XFK4R$Q*XI2B=D
MCM5VM5_6CQ:[.+EUR"I5[)C=J574J^40E\4,K?(BFQZ*>65$6J$R.Q)[<YB
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M?*S!E1N;N*;F[8G]&UC$K<G);(7R2,.C<J9KP[L7Z]0CS/(]ZHO/.?)9@#0
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M(2%AVADC'L(PW8QEN3P!R>%I.H'X"L6[RH/RI)_OFX^Y&^Y2#[ZC_P#K1/\
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MLTKTE+L_1Y.C2A&%A :6(0>XY'N.O;D>XZ]BG;D>W7NK+S\=@5^01J"0#P2
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M,;]((ZI=XS%S0,:]8ID+PVHVTD3D>DR"!UYHWIIKY#D--T6;"YIPMB3""IF
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MA_\ QZRK\C]W^2:_/=OVSXF]?C0L3ITWY?AM)>GM_P"T\X_&_;/0/[J%B?\
MWM)?S=_YSQC+K\#]P_EJ!\G_ )C_ .9-5"MZV>YO?XT+$Z]WV_AK)?S^G_.?
MP>6<[MZV>_O7XT+$Z=!^7X:R7WO9_P 9^]C&57Y'[O\ )-#^V?\ [?YKK@5O
M6SU#^ZA8GO?OUDOYN_\ .><:M^V?$WK\:%B=.YUZ?AM)>G7NZWU_V3^'&,D?
MU?\ E/\ Z=&_:'_-_DNJ?QOVS^5^ZA8GLW^_:2_"+_.>5;M^V>NOW4+$]O\
MTVDOP;_SGC&!^T?\?Y)JJ_/\/_,NJQV];.N_TM"Q-= ^7^&LE\O9_G/* V_;
M.][ZVA8GLW^_:2_"/_.?R:^;&,@?'^*?R75F_;7_  _F=!V_;.M[Z6A8FO,7
M[]I+\ O\YYZJ#VM:*N<PQ(KLF?*DBJ6Q5,J2J)C(CDZE.H?4!*A.>28XB+.)
M/*&,HXHP(BS2QB ,(@BWK;&/P7]P_FFH'R/WI_+4V6O^_?\ 3O&,9MZW=?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g114393.jpg
<TEXT>
begin 644 g114393.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@ ^1$E32S$Q-CI;,C!:0E8Q+C(P6D)6
M-S0Y,#$N3U544%5473$U,S0Y7S%?4U1%051/4U\T0U]"05(N15!3_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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M;_V_7*U\X!+?["@E@[>'];'\*WZZ=O#^MC^%;]=1/^Q-M_[?KE:^< EO]A5
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M':J:JP]/'XV/X[4'M9\*'U)+CG^1]!OYED*E#J+SA0^I)<<_R/H-_,LA4H=
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M<SF9)=7%4T\(%/Y$YH3]M7M__M82_=C7VWJ)W0JU[7MM7M_UM>U_=(2^M_\
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E2N[%5PNY0*B&"MC-SCJ<KD<)LT.:-*JZHF1\A:4H)7:4I0?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g146425.jpg
<TEXT>
begin 644 g146425.jpg
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M!A2!D:&Q\",S0E)RT0<5P18D0V*RX?$T8Y(E1%-SPO_:  P# 0 "$0,1 #\
M^X7-N!:YG>/@(NRVO*E5;5Z1=R35?%>4;?C!^\6>,Q9J(R[VH/X]U*LDR#YC
M=F\5.BBYZG)"@?C2\CX=^*1[_A?W>@/\H-VF;>0#X@ _2?T'MR'H/'II^=&H
MH<_;W]O[##!F H&AZ;80?ZO'%7Y7MWGY@W9YM /T %G  [ '8 T?5XXK_*_N
M]_:TS;^\_P >>-/P// \>O';\^M!$0#G\W//P^?I_7^C2DJMV.!?-[6!Z^H&
MWM]F)UOQ9^6W]L(1]7ABK\L&[T?S[M<VCQ^;FS_UX#6GU>&*ORO[O?VM,V_O
M/^C_ %]]/J8Q@Y$.!#D./F(?XWQ]0'\WR[ZW )N?0..1[_=_B_']?]'R/+8
M!WU4=Z&D@$'?8WQ\O;!K;^;\O;V_580GZO#%7Y7]WOYOX6F;?WG_ %#]XZ/J
M\,5?E?W>?M:9M_>?3\:--I'Z)[5[^P^[!K?^8_AA!OJ\,5?E?W>_M:9L_>?_
M %_(?7G7ZO#%7Y7]WO[6F;?YO]L_;^H^O.GXT:-(_1/M[^P^[ 7<\L3\ZP@W
MU>&*ORO[O?E_A:9M_>?X_/U^0Z/J\,5?E?W>_M:9M_>?O\N_]/?3\Z-%#\NY
M[5_88-;_ ,QVXP@_U>&*A_X7]WO[6F;?WGT?5X8J_*_N\_:TS;^\^GXT:-(_
M1/:O?V'W8C6WK^6$'^KPQ5^5_=[^UIFW]Z-'U>&*ORO[O?VM,V_O/I^-&BA^
MB?;^PQ/4?^8X08/#OQ4'_"_N]'\^[3-O[SZU^KPQ5^5_=[^UKF[\_P#QH].?
MAZ:?C1HTC]$]J]_8?=B-;>OY?VP@WU>&*ORO[O?VM,V_/G_C/\/Z.P\Z/J\,
M5?E?W>_M:9M^?_Q/I^=&C2/T3[>_L/NQ.M_YCZ?9Z80;ZO#%7Y7]WOKS_A:9
MM_>?^;TT?5X8J_*_N]_:TS;\ONL_Z>WQ^[3\Z-&D?HGV]_8?=@UO_,?PP@_U
M>&*ORO[O/VM,V_O/H^KPQ5^5_=[^UIFW^GZ3\_SZ?C1HTC]$^WO[#[L1K;U_
M+^V(5PK@VN8-@9>OURS9-L[68FAG%GF4,EVW)TNV<"P:L/9HZ6M\A(/8^+*F
MU!4L6W5*S*\4<.P3!5<XC$>0ME./\E72P7F:R9N4AI*Q.TG;J+I>X[*M.J[,
MZ+-LS*G#UF G6<3$MS$;$4409H$(HX.LX/RHJ8=.-HT4-MN-\ 9@202">^$&
M^KQQ7Z#EW=V!0[B7^%IFP2F$?41 ;/S]X\"'(C^;6H^'CBH>><O[O>__ #M,
MV]@^[BS]OT:?C1HTC]$]J]_8?=@UL.#7W80?ZO#%7Y7]WO[6F;?WHUI]7ABK
MO_NO[O>__.US=^]'\_KW'OI^>?3[QX_F$?\ -H[\_=W_ ,W'^?2^46-]B =S
MRU =^./E@UMZ_EA!OJ\,5?E?W>_M:9M_>?G^?[O3MK7ZO#%7?_=?W>CS_P [
M3-O\W^V?_7I^-&FH?EW/:O[#!K;U_ ?VP@WU>&*ORO[O?VM,V_O/Q_FUK]7A
MBK\K^[WX?^MIFWX?_,_Z_GI^-;!$P%,/ =7 ](<"/(\=N>!$>!'M\.-1I'O]
MY]O?V'RK 7;U)Y/ _5G"%?5X8J_*_N\_:TS;^\_].CZO#%7Y7]WO[6F;?YP^
MD_']>VG3LMNKE,A'UBMU@@*O!QC=1U(35FF(^O0K!NEQYB[^5EG+9FS;IB8A
M55UE (F)BB;\8 UCDEEO'$2M5T)&^T5@I=VSA[2R/KA7FAK<R:,1E'CRL@O(
M)C.-&L6!Y%9W&>U-DF1?:552)&Z@4E1V-!@E[T&-  F^YH#W]R+.HY_B-G>N
M^V_'L-SZ 7P,*?\ 5X8J_*_N\_:TS;^\^CZO#%7Y7]WG[6F;?\]G'^OW:;&N
MY8QW;0KJM8OM'L+6W)RJE3<0=K@I=*U$@S&+-*5I2/D')9U*( AQE#Q@NBQH
M!_;PH" @$B@;GG\P#S^?N'Q']?\ 4972P)6R 2M[@6M @>NDBCZ,"#N,3U'L
MC4;%6/F+'WC?Y4>^$++X>>*R_P#"]N[-]QMV>;! ?AP(?2?CCCL/W??K:/AX
M8HYY#+>[DAO01)NSS?W /0H@-I$. Y'@0 !^8B';3\:V',)0Y .?7X"/I^;4
MT#7.]5N?GV/M^CB-;#N=M_?_ ,G\<(3]7ABK\K^[W]K3-H_TV?\ U_H[:U^K
MPQ5^5_=Y^UIFW]Y].#8\ATRHNXMC:+=5JR\GY1G"5]M8YZ*@UIV9?%44:1$.
ME)OFJDI*/4T7 LV#(BSESY"HH)JE25,3')K.&*:V[LC"QY*QU /:;'M)>VLI
MN\5F)>5F(D5RM8^5GVKZ41<0T:]<G3;M'DFBU2=KJH(H=:BZ0'*'%$<5N0#P
M-M]ZV'SK# R'RBSLIH"[U,%6A6Y+D( +MR%%LP!6#ZO#%7Y7]WO[6F;?WGY_
MS_?QVUK]7CBL/^%_=[\_\+3-O[SZ9E3..+0+.&3R;C4P55M#/;84;W50-665
M@*B:$>6 /?(#"MYKVA(L0K(>0G(F61%F9<%2 >7"&,8H"8  >1 W'H''/WC]
MW/R[A\.=5K(C.R!7M-()H@;MI%&^?+?](![X"S@ ZK# $$;@C8@@U1%<$;>F
M$*^KPQ5^5_=[^UIFT/Z+/\/AH^KPQ5^5_=[^UIFW]Y_]?WZ?C1JW2/T3VKW]
MA]V(UO\ S'"#_5X8J_*_N]^'_K:9M^'_ ,S_ *]'U>&*ORO[O!_Z6F;?WGXT
M_&C1I'Z)]O?V'W8.H_\ ,<(&KX=N*E2')^&'=^7K*)>HF[;-I3EY ?M$-])C
M"!P$0$#<>H<#R B N\R@D6,(V@4UWZK1I$H0R;IU(NW$F=HW9IL4U7$BJH9V
MO(&23!5:1.K[4LY,=P90%1$X^]HT  <?KC^PPI8MR;_7MA!OJ\<5CW-E_=Z(
MCR(_^%IFSU$>1]+, >OH  !>.P  < &OU>&*ORO[O/VM,V_O/I^-&C2/T3[>
M_L/NPW4?^8X0?ZO#%7Y7]WG?_G:9M_>?6GU>&*O3\+^[T/\ I:9M^/WC9Q_I
M[?JU73XGGB^9OV0;C;7A;&F(Z;>HRH;/7FZ8SR7IN:+K)3CR-OZM0>U&5>XJ
M9OHS%-70CD5IV1RK>FQZG -FCL\GRFD82>E3_%8RC<<\9 H:B^*(RAQN[SPY
M\$X[F*/6)#*Z<_7-XFUU+-5L0>VU#)5/AG#=O:%#MJIE&%C'<:RK#=!RM0[,
MH_(Z1G+QG,0R9B)6,<0=C9(9NGGQX:512?,QS6E% Y4AM@1AY!)#((V<!BBR
M$@VJ*^3BSX+L!2@9>:-F)V#6O(Q8)]7ABK\K^[W]K3-@?T6</S:U^KPQ5^5_
M=Y^UIFW]Y_Z_'2=D\<[ $5))2&0<*;A,7XIE<=;KLC53,UM@**YI=S:;-Y.2
MC<OPL"RK5\G+0E)&"+67JB\U"13.? Y$R&;"584H?KOC>ST'DC<*MG';M=<8
M4"LPFR%A@'%LN%'1SG=[[O#:VYU -+9.M,G2N,8" 6;5\)05Y22@EZ;%QTX-
MI.=^1NQ*D9271TR'#M$J$.!J::1(H@"6%EY&50!=&R: ) PF4.S!EZ9</8W!
MB=8Y.+L1L].;H:6WVQ9']7ABK\K^[W]K7-P^GY[1_7\VCZO#%7Y7]WOY_P"%
MIFW^CZ3\?S?SZ0G)?C?P1L13Z^#]NV8+EN,:X7W0Y2?8NDXRH-X?%D9MF=?1
MRT7:\VR0O5<K-TQPYMSJ-3K$CC.?FGN08-0[ZL%*<P@BW]@\0ACB/9IM"W$9
M-I,]?,D;KHW;73*!BO$$8S)*7W.^X"B-;3'5"L&M]@CX>NPGFI3CT9:UV%!E
M#0T:)I*167$#J*C(RRL 0(#E UFB3G6S*P!5U%F%Y.742 JD* 2U@!64&)>3
M*V95*((O*"!I23P!69CT&Z>V(V!.,X^KPQ5^5_=[Z\_X6F;/U?W3^FCZO#%7
MY7]WG[6F;?WGTK64O&8H6'9:W0U[VQ;D(IUA"B8\R+NU.@TQ7)H[6:SE6VKU
M6C.;LHPR6JG>W,LB@-N79XH4MZ\=2U$9=T4'9C1A.Q9O&AQ#5J'NBRF\V[;H
M7N,MJ>038JN&0H^H4(*C=<A#DJC8U0JF-)%]D=FZL$JY=7R+L($D8Z$:MH%!
MV#MXC+^S1KB8SU76.*-Y'8D(J#4SE<S%DZ15)9B<Q)%$HKS,Z=F!,$S!2YU!
M%(5G:@@+029H L:&^7ADE&]%%L<BV=^KPQ5^5_=Y^UIFW]Y]'U>&*_RO[O?G
MWW:YN_>C^OIZ<!I.'_CAXCC"S=1DMOV<(7/T)N(R%MM<8!M$AB.MV!"W8RQ;
M$9ILUA?WU[D53&36I*8VL$#*PSI.S.)*5EY=C7FL<H\4.HG[%M\;G M/A-OM
M]?XFRZ.,<],,/.5)YPZQI$WW%KK-5W''U7;9(P9+7EGEZ)8,;)T-YFQH5=>!
M]G4!W#/9A)-?RFH6BZ6!DZ?3%-^T$L4<T1C_ )P\3QNNF[4@X@M)3DD_LC()
M+JTZ<LD,A8<JHDBD0L:4E3O6&O\ J\<5#W_"_N\'_I:9M[__ ,G_ )_76GU>
M&*ORO[O?VM,V_+_XG_3\^=1UMAWW66Z[2MT>YK.%91.CMOS-O%JKN P_5IZ9
MG)NA;:;I9HB-)#5I24F)*?NTQ!U\0408N&K.3F%2BU:QK4XE33]_XV=FLTAL
MR/AW:C+76(W0[G"X$F6R6;<!6.;KD>XQ:?)321C5J+E"<@XNVILC ,I5,C/J
M>O'MXR6*!G#@T8#T%%TC56:1Q 0B[L/K!A6(,+V+-+$*]36",R265-!6G0L?
M* V729Y;-;#3!(0>#I'J,6#?5X8J_*_N\_:TS;^\_P#1^G1]7ABKO_NO[O>_
M_.TS;_-_MGTK9/&?QJ^8W1Q!;8MT,JK"[D0V?X[=*U_'<57,X;E%+^XH">-L
M;V-]D,&R9&SAH]GYNU6YM6ZS"0#!\LXD5GB)&BF$SOCM8:BX)52,VU;F[1D*
MO,]UPY.Q+!1&,?I9B><V6.:<&>H&W24CDIE67IXB+O,+.UJ3JLM/1]HCA738
M*ED""S!$>.16>*Y%1=;E;(1!D<KXD7:R-*+D<YE,T6.PBF0GA@)!F(#4P!D6
M(%AI(E>>3*I'340[YB&6%5Y:2-E&XW=GZO#%7Y7]WH_]+3-ORX_XS]OT<<?#
MMVUK]7ABK\K^[W]K3-O[S]_T\Z7"H^,=BN[Q.7'47@S,-=F,<8CV]9WK4)DZ
M=POC)+)^*=S#ARQQK::_:+3D]M48%1Q(LGC9Y 6V;B;&<J)3145)N%V[126,
M5^)MCC+FRS-.]"LXES O#X D,R0F1<0,XRL3.523V"7!OIY%UEM&69:LV<WN
ML FX-PQGR(R\:8@H@F[.1H:QET=36K)T@3)K!70J&,.230I"\8<@G266ZU"U
M#NP1E)8.8@A6FU&;680NF[,O3<QCE]#%;TG&;_5X8J_*_N]_:TS;_FL_Z?S_
M *- ^'ABH?\ A?W>_HW:9M_>?4,OO%JP]*US(]IQ7CZVY1@L?/,!1"$^A=L,
MT*KW:R;@,9M<LPE2I-AR'D6OMI^UU*HRD&:XUUDDM,,I>::Q,>SD'#24%C@>
M(/&<QEN/>XG@MM^W/<5FBXY!Q=(YEN5,@H_&=>D\*T"&RE+8=D'5_E+AD:$@
MI"?7NU?GT(.M4M]9)"<C(ES(-#$*9))2" KB.B7(!" VU=&;,7INR/J^6GGV
M!_90L_&G4US=.2:GZ42ZY9-)T1KULOE@SM5+>8S66@6]S-*D8\U@-%]7ABK\
MK^[S]K3-O[SZ/J\,5?E?W>_M:9L^7'_&?]/Y]0^[\7+;M"5VI7*U061JW4+5
M>-X]+5GG\'#*-JR39"RM,CEFPSB+&QO'RT;,-*I(#26,.SD9N3<&00D(Z-,*
MPHI7F3QT'R./&A,;8&N>(<R2DILIR/5JSN+BH"4B+YM8W89WJ^)V^4*^.,+_
M "JL;.MF\VH52LS[MG-5B5=Q:LI#R2(N&8-E4.;ER\.75G?,2110\Z6:<Q=(
M:K( <2(ZV?@MN <.Z9B/5U0T80SARY "G*R]', T3^YFJ-ZNF(!YQ9G]7ABK
M\K^[W]K3-H?T6<-'U>&*ORO[O?VM,VC_ $V<=)UN$\:&M89L>XK&L3@6UV/)
M&+,4[GK_ (L<-<A8CL=%RE-;7H16?N]8FY&C7BPS>,7S>"37LB\7=(R,L2</
M'23,\2A8P9PKKP''C'M<>4O$^:-P= LF,:M=MB=9W12F&HBIPERO<M:+MD^C
M8VI3"DW^+RD>#<-;K+7:-3JE2FJNSD@B'B4_;;-5W3)Y701:<(45F5Y(8T(_
MB:9,W)&0"064ID,RVH J!&=[.*B[+(T9:I% )6P6WS.5RE&KHB?.9=""174!
M.P.'E^KPQ5V_W7]WO'KQ_"TS;WY^?^V?G]'^C1]7ABK\K^[S]K3-O[S_ -?N
MTLB?C(41M*&Q[-[8MQ\=N"8[EZQM5G]OC=#$TA=H3(UZQE)98HTJ:RER<WQU
M*42S56*>*)6F-M2I(UV@Y1E&39-LHL,\53Q*L36G858/$#"@Y<C\=U*OY E+
M1C(M20G<QQ$WC*WR]"N%0+7*W*RT7(S$;:H5XR.\CYA>%(S34E%Y!)B@NJ17
M=4BDFT.T4;Q1LZ#4MRP+F(R"#NIB*'4-@2H)MA<@R=2.+4!),+C2Q;_MG@%5
M>YEC=5!HD FJWQD?U>&*ORO[O?VM,V?K_NG_ -7S#1]7ABK\K^[S]K3-O[SZ
M6ZK^+_5+^SQ)"8RVUY8RQF',Q\ER=4Q%B_).VJZNV]&Q-#P$M<+S/9!BLS'Q
MO!-FZUFAJ\SJ<K8VE[<V9T,8K6FR)"O#]YUXQ6&&68S8Y=X>S@SH+;<E#;-9
M;/+R-HZ>/(/=9,T$+\EAZ0ATKJI?CJ,TCIU20NK&KNZ6WN9'40684:M%) S$
M :?*]L450%<DF1E1  MDEF*J*NS0YP:I-]S0#,?0*@+LWI2J"Q/  ))K#!_5
MXXJ_*_N\_:SS;^\^CZO#%7Y7]WG[6F;?WGTDM+\8QEFF1V=6VC8<S?B#%&X^
MZ7J-BGN:L259=UENO4W#ENR9+.L;3<!G)J>J,(!S5#QCFVSU8LC&>=O&K&)A
MB-3.)QISP'COX"?T*0R-:< ;F,>0#_;'3MU&*T;17<>.Y7--'O&5:[A. @J4
MRK.1)U.*M;_)EPJD"W8W9U6VRK6;;S!' QQ%%@G3Y]&E@X(&DW8/3$M<UJ"
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M-UNXU^RU>*C)683D6+\B,A(Q*B*B@VY)&.=),ZA 34,0ICIE."@)G$H"8@*
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M,/HK)Y'MV/\ -L'4K=B*&D9 9>O5Z9M,%"/'D#F*W&BV<&QQ##I2$U/&L#:
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M@[\<!H((#P \@(F^ \?=\N_IZ"///<   Y!?U^N<7XM8\+4>;7ET>W]SE.^
M!_Y_*?I_0(!Z=N?75S.J9_"U_NJR\/P&NT[Y\]G\J'?_ #?+GC5S&K(]E._\
M1_/C'&Y@5*WR7CCX0-O;;%5&]"0(AE5!E[RJ[=)2@0\Q)1[X7R;95I"V!RHG
M9LJRR1A)&XQK+HZ+EG7HT[:4NEC4;,B)OD4!334IQ//$$Y)XO9Q:G2*QN$@]
ML\3(F!!T^*"<?D3)\,V(!B*O@419X5PG%%2$%/=LG+QRAS*@JVV\Y[[/E"/Y
MGO9$8RI5J;<IGJJ;^OU-RG//6D==+DX.!%+\^2<K%CL?8S0*^14L2I)APS*D
MD?I4LSMRU,JJ61M<2XCY@7YU7D.G/3E4L4PF(,Y:Q-Q\Q/(^X*]I+D0KT"0'
MD?BN,?-U01BED$U4<A^-_=SR/E[>O>A7>A=:8O@7OL!W[$>V_I1O[=@>HBHE
M!S$PZ:/'4%)JVF+D)]Z:"-*V-E9YN/9P,9*W9$J*J5\W+VV,:MXFJ1J!W$'B
MN#2:MWC5%2$22:^DVD9%%>/:-I>?:K(RTE3VK2O+.GTQ&RDBFW5D,:5)RX*M
M])LUS90%QD[)L@)H2I-E';=$C$IP)KI(B^:O6A&I+='FCI.3@6[*"(60EZY.
M2RKQ26QU5Y@72B=HR7:4!64RCFQX=^6BM32+./F6Y" 0FUJ"ZJ<<V(TEI$JT
M6[KC&-KZJ<4A,QK(C=:5Q9098SXQ86C5]7K5RCG<SEJYN3U!9HVFEO.<)J2M
M,P!JN"#Q8%CT[ 75GT],.>+YK;L03MM9K^QW]R;7-E"HJX!JQ/:(%0&[R9;
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MSKN;;'D7K9R<&N;)IN+(S1)7A&/,G'"$>R5\[J=((_9<"FF=8HBD4NC4E7K
M''H/4421R+/;@X-]K%$\#[O]36WMZX:@5$P]3E_6&M/-3_EE_7I7AVSH+ Z'
M\.>YPHNI=O+F!+-DT3V=1(RQP9-1*Q("$.8RH@O&I?VHL4B1#)F(D0H=@^VM
M(2&*.;MRWVI].>^QF:8*8#IB<P1@'!@42P)C#RI#@/LJ@=)# *8 4)VYOG;@
M\V!R!QWO?>QB-_:MN_K]GIQOOAF?-3_EE_7H\U/^67]>EG+ML3^P;\-FY0ID
MIY>>(4<S3!BG44 @%BU -'FZX$@)@"4.J M4Q,H82&,<QAX6VV1)NHR.&<]S
M2@,I164 KG-<VN1R<_D@#%Z4\<;VJ**"'";%013(*BIND3+G-J=O6N.Q[T/]
M3\ZVP6;X[\WV]<,]YR7\LOZ]'FI_RR_KTLC3;.FU]@*&<=S"P1JL@J07>:9A
MQ[::1(1,Q'YC1YC/4&8$ZH\B_P#Y$H8YTB\F$0VLMLB3(\<8N=-S+D(U.123
M*\S7..0>!) J0YY(JD=R]49 L(QIUS&,S%-(Z0E,D4=&WK^!]O[G[L&_I^/Z
M_/MAFSJ)B''63L8ANX_ IBF_7P';X<\<]M4QG\)N"D4\R7&6O?7E.]Y5SI>J
MFJW6ED,<1[/*68$,B52?N-//YBD[E/'5;5GZ37;8FY*E%1]EE6[%J"*C<4+!
M6^VM)!)DE^&_<LK[OC)>,(=QF6954>$EQ<F%Z].,?U.Y./\ :1+%/EP!:-\A
ML" F! AAX4=M!")-D?PW[FC@VBGD0"BN:I@RJR;XRHG?N5!CP,O,-2K"5I('
M$56O0D""@BDF<%"J)$E4U+$P>-@ =+#2;\P*V.VW:\.LDBI)$#4<JZ9 #\:]
MU)%'202"!S]V$WK/AF5V)@<Q2]S?P&:\@6G(FY.YXSJ>6Y:US6 Z3'[@+)*/
M):*0Q^S,U4A9.9J\HK7+-9(L9&4:+KN9"!.@!@:#/&R;;UD_;Y$Y :9"LL,C
M%VN4KKVIXGJV2\OYCI6,BPT8JRG'T)D?.RZF1Y!>\NU&C^2@5&[&M5\T.V+"
M-!7>23IS)JNV-%8I2?AQW/)E3AC0P&3S?/)G.50XF-(&$&0BI+E#@I9,YA7(
M ]*8<!UZY#[9TE$UDS9PW-%!:'0A!.3-4TFJ1-NHDH$DD9./**4RL9(".)-,
M0<JI&5)U&!4X"^LO09VT])(UO^!(_@"KV L^A)-\LQ,%W(84H+R-,YT[F1R"
MQ.^^HV>*'  &V$4:^'1D6G/-V\E4KS1)]K<,?Y6H&S>H70MD:0&#83<$_<6_
M,D9:9.'924@>.E+ZYZH M59N#L*I'Q4.X;@9%14SS8ZP2NZVK8XP'G$8]^^A
M\8T"CW@V+[A>ZO%OG]+8Q#4KBJ6R,=4Z_1#)TXA6KA-5NYB7Y2*J-%%#(=0&
MYW&VE)S[> YPW,(^WQK.+/Y&:)I 6R3(41(\8>7'\,Y1S[. /'Z E=.2JK><
MIPLIK:[VRHN4Y%,V<MS:02#*,:&.US7.-U&WNP4>A>/.DP [)V\!N4LHY1X.
M_P#.6%;K,J<VL_0C <-<AD2))'8DLZP-G'B!' T/XAG& 519S#W8":1G=WB<
MDAX>J(R+!0S#+"335$EOJF6);D=):(U->%[+]D^,-E^.U*10IJX3KV0=R3N?
MF[/>+U8T9$[RSS]B9E80-LMEFB:T+$DZHQ=&KI(\)=5 TA(E5=KG$%29^']E
M9"G4C:TZR+1F^TW&.9WN;ZM:XM>U(;CWL@3(]JRU6:%* +-*F1[" NUKY=WZ
M*G3V2<@(9FS5@8]Y)O7Y7?4VR)KIR"8YRW-(A(KL5SF2S;.$4:BQYZ4F!RQ_
M4Q0<B/+U)OTD>%X\X1Z0*&YYMH(\]Y<YNW,MQD)!K("#3-<RU*W]G(8A6<>*
M3 3,6"G5R[:(E*5<P%.<QS%#5HW<N26<](,S;FHB6B&X_@+&@.QIK 4!@[AV
MDL%VU62!5R4'(!VLUL:.GD41>*R<=^&'FJ-GL92=VN.!&9,25S:11H^3HE?M
MI;!DJ(VNYGG<A!?,@+2<>Q(.0KU79)NT<HIN9UC#V,\FNG+/F3OJ->H4Y.G\
M<OJ8?Q@'L(B(?>/;T^>EE3VVD$SKG-6Y0@.;"E8N!S1,G!%1,5#C$-NIAU-Z
M^<5A(>%*;V,Y4DRB!2D+SM-MG2%8ROX<=S/VI@LUY89IF2I%4#J_BT$RL  L
M/P;O& (MQ$ Y#[)1U8\DDA)=BQ+,QNAYG(+D4!R=_8\4.$9B2-J"JB*H&P1%
M5% W.RJ -]Z'SMG/-3_EE_7H\U/^67]>EE)MJ32414#-VY54&\VXFR$4S1,F
M(JJNF0ON]P3W>'FPB0I@+>)4,=FD8RAO*X4. \3?;(BW-'"&<MSBONYX]>%%
M?-DVN5V9X0A1;R)5&(@]:-@('L354IDFYS*'*'4<PF7;U_ ]JO\ ,_=MSB-_
M3\?E_P!_N]\,^*B8A^.'Z!^7?^;6P3)<"'F@ #\>0^ \AQVX[#_KTMK3;>FS
M+%%+FK<BY&*4E5"B\S),+B]]YIBF)94YF C(IL?_ !D41<# Q/P9/O\ 9UP-
M]M":"<4G^&[<L<8AI)-4U%<USCD[\LDHHH=>6%2/$)%VR\T21KAP0RC(A4R(
M#_8RB5"JM8.X8 '8\'>K'86>_P!VV 7W%?;\J]./PK;G"?1^R_.-7S;+VROV
MW$S_ !=3\V9IW18?CYU6Y,[F[S-F.H*U<]0R,$;%J12.,JQ(3%BG&LS R$E9
MYI-W$QKF(9E8G>N.7&6Q.WU+?%(;FG#/ 5/@6\WE:T/+5B:"LU:S#G5QE6MP
M< UJ.X)N[0"N3D1CA6,/+P=A0G)=W/R#6O. KU6<,7RCYMR;8TDRL2AG+<Z<
M&<8_C %3-TZ8ZY'Y5P%X]'V 1=2;072AF#Y03+M!0;= \() 3<3;*F0I"!G#
M<T8R<,O"=9\VS9A41<*F5-(J"9@(#-I"<Q&\H! =))E(F14I"$Z42-(W5TU!
MA&\0YKIRKEQ(M$53#+9<$G<=)=)!)NUI&92"!O1)KS6"[62#S<DA/8ZVO:J9
MU,2%(!>2  ";L!@$/QA'OS\1 0$W/?D1Y$1[ZW>:G_++^O2R&VSI"<YOPX;F
M.%( L$8I,TS(%*0@C_&1"^P!Y<\?J^U+IB#DW3^,7COR+;:TE$G9 S=N5*+R
M&908G3S+,)G;IL5$% E&I@8"+:9<^S]#R4(473HBJQ%0 JQQ"P "^W>AZG]?
M]L5;[=_P]/\ N?LPR_FI_P LOZ]:@HF(@ '+R/IWTKBFV1-8KX#9SW/)^VQ\
M;&B"6;)E,S8(PC=$KUD8L> M7[P$ 5DGI#>:_.JX.L F5. <S[;.F^+)D'..
MY=N23)'%.+/-,TS.S]@X$HQAD8[K8F==QD#(G(9X/!50$O'3.Q WW.]5Z?WV
M!V[[X+/I^/R_N?N]\,]U%_E%[^G</].MVE</MC07+(E-G+<XE[RD&<@<4\V3
MJ1FIV0*D!I'&(Q*+!@Y _4\9MNE!T)4C'[IAIG6Z7D-T$!455\E%-+S5U/-7
M5\L@$\Q=40#S%C\=2JG =9Q,;@.=1OZ?C_VQ..;1HT:G!@UI\0_,/])=:Z/Z
M_P!?U:,&*C-]9Y63S!4*K$TB4M-JL]$MU;<1U&L.0CV";P9)R58^F;6T1=:Q
M?>XF"AGEHZ(].7,Y@IHQT&B$3.%.Y=(M+5*XS:14!#L6;0(]@PB8YHT8\KB+
M%HS8(((,S*.Q%=06:"!6YCN1]H$$0]H_LH'YK5W1>$[@#==GW^$-?,C;EJM;
M!I+2ANH/%&;)3'52>0C9^Q?J&48Q,6I)-9"0.P:MY%W'RC55=NB15!9JZ(!S
M6/G@$1KGT90=RK!@$,G")/64BY3FFC8K L>@[9RYQ5>IRC9(I5D)+S3.RNRE
M=B85N^J5!CA<.Q-S%ZNP%.A11V !"UQ:CEFH'%DA5S%IVTQ:6)!'FL$]S?>N
M+[5=#WO:2&,0A0 3'Z# )3E.42@L1,P@)>1$"B(_:Z0*''282G$"Z4'89_@\
M)?Y:]U !^;^$_EW_ $!W^/KJJ#!WAY[R<<[A\$3JMI=5NL4+$LI36&9%<LFR
M';L5,TYG/2<I1$*+;V\HQR2YRM(9!Q??YFV64DTR2E*&#:8(DZCXLA[0/#G8
MR\7M9K<7-S:]FEHW*.Y6/E[*]8QT8^L,JSW)960?SCF,AFK.&CG$NZ(L^78Q
M;9M',SJBV8MR-TR"%QH'9@1KE1=B&(C8+K[C2YLK3$U1( ()@@ 4#J\D+L0-
ME:1"QCN[U)95K"^8&@:Q2?GGD<XYG]!XRMD#CGY!:I3Y?:'@0]./3OSQZQ,'
M(]N._'?GCOWX$>.!^'RYX^_CM+6>A ,X9E^'.5L@@''J(A:I0?7GD.?0/0 ]
M?AQJ)C<!P _$![E !$3>@<B \\!QU"';Y<"';62/@_,_Z8Y-?A7^E3QZJ/E_
M;T]<;O4  !Z?N]1#L'?CGOVX'GT_1Z\:AA$A^H!_$4$.P<B'28! /\8.?4>W
MIR'P[Z\]N1'N(<\B'/?@.X>@C]D0[_ /4-:&#["O/J)5 ]!  X*;@._<?N#N
M( (:?#7CZAMMO]X'#?\ DVJ'_8S;4NR1Q(Q?&%442D:.3BJ5(5S)]#=4_7Y'
M ^>)..L$0 P+=/EF*(&XU$6VW^\#AO\ R;5#_L9MJ7Y+J%B\ @N"G]D<])FI
M0,X(86ZO2=N0W8ZY3<>27MRJ) $>.>+8_P!VG]"_D,<0WQ'YG\_;% :[A9$7
MCEP\F&!TG,59Y"2M+1.16B'SHK-.+RAD6':+*A,WN5X*QQ7A!N1XUK)#MY-]
M&IB G+XDV*C%-DHX,[@"5Z[1,@\=3H#9T:#-OR/^)*T,$W3D<EYKMPD*]=0;
M$7L=C]BZCH\YV8EY9^T4KIF8W2UG85>.G&PJNFZA;'/5*R2B#,JR[9 B)F^0
M-TUK3/[,_5067A,<1:GF W8.&@)ML<EO.:!73-6;N*/&VYM$Q#BK+)6AS2GP
M^VN5ZQB8%2*$R#D&355,?(.2WAE(UM-R[*.CEVR;$Z9\K@^7^@"MAWWY][%G
M;<\$;<D/M&^U@$U0KU!(!JMQZ6#39*F*K!83F+/PBT9/ L/6FA8)NJV&Q-W
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M7IG3L7C--NX%TX%3S!D34>XO P42E]8Q8*!2ZF51.$!L,.B8(".#RXD[4ZB
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MA8%]@":L#'/HUP&4#GI _ B('$>P@!0X$2B;@0 3  \!\N_IK:J)S@0R*@
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M.JH+@&@-]$?84(X[O2#B$_%0_P![<)?'^,KYV[]_XNKWWA_/\]4\',/48?\
ME&YX[@4 $0#@0'D!#MR(?XO8 [:N'\4\.8["7K_OE?/3X?Q=7QY'N'8>/C\M
M4\G !,(E#@>1[]A 1'D!$1Y[=NX#Z?IYU6WQ'[/R&-^7_=#YG\\;0X'D!'OS
M\>W(=P$O(#VY$ 'MQSQ\1'C6X.!/P/ @ AT@/(!R(_,>>1X#T^(@'<>.YV$
MZ2AR8"@(]^/F/W@ <<";_%^''KK0!Y. AW . ^(\\" CP'(<"(\#R CZ]A#C
MNN+\6L>%MQ]+,O=N!^CE.Y[=N[^5'L/'\W]/KJYG5,WA:B/TKR\ @(<5VG
MCSW_ +?E?G_FY#[_ (!<SJR/@_U']?KC'&3_ +P_)?\ I7G%6N\UBY-E:IN?
M=EA<&4K;&)BW[2722D1>R+]\1U5\2QQU2EC+K8VQ#GM-_>$3;U:J-'G]F*HX
M*?2;H1_M9&+=K#-%R/&LY78Z.@+(#!G(MHY-RK)8^QG(BX+[EQ[%![2KF;*R
MQ4U+<NE)MT'KQ-46SIP=YS0%LO5Q+W,Q<J3%.)%IE7LIF-@M35L[=OG]3BUD
MU")X\H8%23D,F9 <&2<.HU-K7X[VLKIV0B<D*Q<M$Q!.D2Z<K"R*AC+OUZ_
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M!EZ;)!U23J"(A0ACP9.LDI9MR%"HUA-UFD7,2R21Q"-9B\\<2<ZI7&XVW4,
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MZK!%CY"W9 -D2SY*NN3'[LCQ8J:MJG;0[ D.9-99@V0;(&D7::"/0VB+J2
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M&I=N;TE;'8FC1!&$6Q#X=>:L&/)Y]CS?=DIDYLC=BUE3RF MMLB15&.576;
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M+HE/]CI859HQ$W-[SL]&948MCL+^1LU.V\23&1N4HRE/?6:\D.IJ@+)W/,;
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M:#Q (<LQ4MK5F$B%T90\0),BJ%;30RE6C2B3(YC&A7:F57<@A5) TQN=7P[
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M#@ 8GXH"7U$. $.X\=0AQ\1X[B'R^[6O00.1Z0#GU'@._!>GO\_L@ =_@&E
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M%N?HV)=.$RBJZ;BE5IU9*L2:T?$.#G5D6Y472"Y6SEJJO +AYD=:,,IB;3;
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M(O@F1E8*+LG@56* I8@*+)ZE ;DB$*\QVW C1@S'@#<[ TY)13Y$"@7JY#D
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M$#:^3,270&SVS-GVF0M3MD^_E]OC&F3];2OEVEWBN.TJ[-5"1FS,$[=9G:A
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MW5GS*6YVT+4:XBQ83WMT<Q?1J<TW0)**K.3Y]3_#VVJ4B)N45!8^? 6_0;6
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MBB8@.+*LC/U%8Z3+/%)!T_)THA&Z/"Q!MQ(P1FL@*0U:M1.$\W8;RK+MCO\
M"1CFHQ,K0G>,+S:DGC9TO,W"VY#KT/+2U>Q=#P40N9[3W%B1C%5XZYV*%FZS
M*JINH;S89ZW(Y<J'">)[G29@J&O*8JQ)C-;(3O(:M>NV7+PO5Z)(15)P/#YG
M,T;L(F9L4RWF$9.15H[D\Q)Q99% B=RBHWV8AH)2X)_2J9*VR(NLC3ZJ^NL&
MV?14'<7M=AG=JA8U\3H?L(FQ+LCS,<Q?IJJ)O&;)\@W<D.8BZ:A3&*,2SVT'
M;1/S%$E9'"N. 2H4S=[-7J^SIE:8U$;'>8-E!6*PS%3;11("<G7,=%LDV\Q)
M,%Y%HHB15%P AQJ820Y#LSK^U;>CL\LF@#@C0H4#L /7&C7'TU'24%E1PX))
M_=(E $D*"Z,YV-ESL* %7]E\8:=:QS^<J6,JW-I'V]VC)@5B5=6FN/*5DJGU
M#'=ID<=7&WO62K24,JI??=SQ6OU-,()O$A+A(319(6#&0\T^(CE?'^0QP5#-
M,83V47^.+\A-NJ]"W1S!XTRQ%;:<B[B*J1X_EWC4MKC9&+I;2/0JL;%J/W2,
MNVEUY]LH1:N:M+=XKQ@M)2=O5QO0%;-/12,9-V!:EUE:=F(A-%)%*)E9E6+-
M(R,>D@@@@DT=KJM2)(IIE0!-,A"[R8ZH"UN1O*U&IJUX;LV\2WNB]5@%K8A&
M*HNDPCT;(I'FFTF":3ATBFR2?D:E1=.4P2Z5C@*61*J2^:-TE6,JQ63ZPUD%
MC3!HE@)"H:.M0VK^$A=%2(B*BLY9R2&$D>B(",@\ ,=1)V.KX;W%6>-?$6S)
M:LN89PVWQ#&7\)JF;<Y7(^1JLY2BZW,.,TT/Z535WH<E*3J4>-<QZY3!E+02
M+&?DIU^+UG'+Q*K(S8TE9HW]6G'%PW!-6-;Q42'P39J!CMM7[G>W]?O]CL.1
M4ZB+;*3IFV9N&D'AJJDMWG3K]9DY67BH28F@GHM)JJS3?=MAO$C21J4HTQ;C
M9K)T%!RUHTBVH530?4QF[<JNG36I/$H@CFMHN'2[ARNG"JLDEG#E==9)194R
M@^O*8ZQ[.3KNS3-"I4M8Y"#7IKV?DZI R$X[JDEYA7M9=R[R/6D'5== 90'4
M&NX4C'(*&*LV, CRZ,LKVH*E3H/_ #'I)1W8@7S?/F._80S("\A0$$JX2Z50
M)(_*!556P].U5BB#-V\W,ULGYYG%VU"G.L=S-1H4G.XFLCQ]CK(3J/WD;685
M[>:4Z<^:X!G+52^3U!EXQW(R)8UR6QPBTR\3.<R6?V+Q>7D5+9 BH&#Q]*5]
MA9L9,*%DI>/OK.J.(G(<[E:$.Y>U]('-GM(13_&96+:3CTZ>A(/)E4%8N/;Q
M!E']RS/'6/(.#BX2&H5+BX."CTHZ$A(^J5YE$0\>WE6TPW8Q4:TC4&4<S1F&
M[:62:,D$&R<FV0D$TB/$B+EAC)>TK ^1F#,'=)CZA)(W5"_EL..&4/29YU;B
M(24<,S-NHN)]DLZZK2<E$U26=A,)*'=JN!)[4/G:K-.86&P6&- JED)D&:RL
MK2$@GSM#EI\O9OR9F7L:P_4B(D+165FD=38-(V5=5A((^ 3+#(*-+TR &\M5
MJ*^*GGYD_OC61VQQY%<78Q>66_\ L]J02@V,XTVYNLZ.)V,MJTBX+*X_:RYX
MK'8EAZS*S3UXM*6:,>.V4,\C"L"[W19MN&W/?":18T*F9<P5B1A9ZM8Z;(3T
MC7 +DK!+?*M:=+-I5!*42F:J,BI$+O&ZRC2:<L6TTR:Q97)HQJYU)VR8"QE5
MJ;"U+$]'12QU2!Q_49:6K4+/6F)IYT79G5?2M4PP>3GNE^=^],\BP>%C5@=N
M$?8P:J>0$M1\% A%R #!0@IS35LRF40BF!4I=HT9%CVC:33!N))!NVC^AB@@
M\!=%%F0&R1$T.$RC-%&^;B0.#/E@8RSN6CF1W$LXMF4+(BJJQ @1Z36Y+/3&
MY3,99P R02AY$95/54#+E4<D;J?/JL,3U-R0#CYZWFZ?->%<NXKH\9D:*4:8
MKK^1CVLF;<O6,].R ^;[-Z%F5DD[E))DI8BR S<K*!#-Y"3EU&;B0/+F$Y&:
M<2I+\AXON87,5E>WUO:I(-:MCN@2\\JRO4X-8D(J;88OQ[?HI]8951R9VZKU
MEF[ZE3VL? 4AQ*135@G<G4FZ9/'</$7,36+\8VP3-K/C>A6) '+9\"4_3JW-
M$!VQ2:,63GHDHMR47#-NU:H-'' *MFS1LV1.1)!,"ZR&+<7RUE<763QK0)"X
M.HE6LNK4_IE:>V5U7$NG^(7$^ZBU95:%$"$#W4J[.P+T$X;])"E 1U"MY0 $
MS"K0TZ6_9Z'\I!\@) 44*8C<  N!&O34144CC5B"+DT#268_Q.PI2[$M2#<[
M4KM W,Y(4W+0^W?+['&5?EYG'*%HK;BD+V&>)=IMM&EFK8WB7ZS\YJFE46CE
MBV4A;I",)&Q-3*6*&D_9UDHI)\P3)SR <<A\!$.P_F'6'-*'2FUJ=WQK4:LU
MO,E%-H61N;>NPZ-KD(5F8%&<.]L:3,DTZC&IQZD&#A^HS2,(BF@3GMFFKU1?
MB(!8MKL@7973=^NG:_3;%1-G85M57L?[?+ULX #C^ORT:-&K* X%8C&PZ95
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%&IP8_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g152837.jpg
<TEXT>
begin 644 g152837.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@!!1$E32S$Q-CI;,C!:0E8Q+C(P6D)6
M-S0Y,#$N3U544%5473$U,S0Y7S%?0T]23D5!7T903U\T0U]02%0N15!3_]L
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M84)2@9'1\!05(V)QH;$6X?_:  P# 0 "$0,1 #\ O\:-&C2Z71HT:X) !)(
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MTD6!8Z%+ZB_3?3LR#+Q\U(/\'DX6:9$F!".WH[HHVVLI!;(6(H[$JDB *-S
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M'B&KB,#">]:!M\_P\YT.O/U/:UV):D^H2UU"JVY46E+M.[T-Y5[KK0*7[>E
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MA"4H7-0"A);4[Q4H<0.U?UTUNO!'CLQ666&&TLLLMI;;9;'%M"$@!*4I2 ,
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*ST:-&C2Z77__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g175228.jpg
<TEXT>
begin 644 g175228.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@!!1$E32S$Q-CI;,C!:0E8Q+C(P6D)6
M-S0Y,#$N3U544%5473$U,S0Y7S%?5$]824-/7T903U\T0U]40DPN15!3_]L
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MN15TS#EUQ,UC5ZQQB@7'(.]9'/<:,^H=37_FZ/<'H41<X1C,!>99E#MEI=*
MLCJ\.54&[U5TXF%G,AJO$I$%;)*BE(5JJM(V<0R)1T5+PB62%5= TG$)3Q>G
M;W5BH0I5H952E$E1"M?(\L&*1[=2:2G@O)\/WBICXC4---4+&Z)3"/ATR12Q
MYK+E3N%_F"(=VCS!\/?_ +"F$/O !#_?U3S!W[=C?5_5-V^_MV_V_#K37X*9
M5:N??B$Y^KX@\;>)NVM/"4XG;)H67N[A?<\BYC6TM6EVE5NMTJ=0LL"56;:P
MOIV,8B0 K$DU.KO'<650B+-HTG2L:BGOAM^+)S(&\ZXQWSC]XH.R,L#N$1LV
MG0S3'2MN0><1<@K3:S&6EG5V3R<):'II=X\B7SEP1M%MDCMVL:U;EFJ.)&F+
MYP!@AXJS8RL&VN%<7@X1(V#PH1++),9TB8@)&H1Y [$)+#6O40B>*G[$C4B1
M"64(S-5<#DXYV\$E542)4IPRO)G*S-BL2!I-]\! ?=[_ /: A]W< [_[.J]:
MT.$Y%#\3O&PX]9ODUMU!&L\BO#BOFK;S&V_5M!T%#5-;K5WKK-OI]C0O-AGD
MPM[DSAXX7?Q:<<BD=Z]19M6;-RJU-LO=7*:?WB)G*8/'45E+(@;-1+15E11R
M%'LI>-WIS)&S)&Y1USC1@1JS!,93(&0(8S 19LLDJ:*EKHR>RN+".J1)%&2K
M(C8NZXL3HZ.CJQJ?1T='1TTT='1T=--'1T='331U&5ST\4G(N -XQ?.+QC7)
M+:;MNT;>I2CUGCEG,7I4^JVSSY&/80=P2MI@YI0Z;>;0>)_)4?)IILFKYR].
MT20 QY->M:'Q>,TV/7_%-\)[/<!WV0XQZO.T/FD>L[3%4V$T!_5"1E*J\E+M
MT:E87#6*E$[#%-7=?<G<K 9@A('?-RG<()D-0KIIXC2)3AB\]4(F5$C=V39F
MD(02R1(&.V.;..5[7) ->LD:&BJ9D($D?NJQDBXRGKZ2E/+N)*3L%#%4S*EW
M106$C7"3Q9N/7-[4KGA5?S_D+@NWTJHM- =9-R<RQ7*+G-T5V^0C!M5:8*R\
MNG*QC1ZZ9I/BBJW=H$>MG)&ZK4RBR4H0& ?=[_\ :40#[Q  _9[_ ']::?#&
M4W',.2?B4#RGNVE[/XU7'CBC>H3C]*V=Y4_Y*]#X]!'#::C9>/U1@ZI5#/9!
MQ8PBW]I:3+62=+F=IMF;8CHEI320CPWR;M<+WX:.[8_9<FI&G7C08Z4Y6ZE<
M_%(/HNK<U:5/+KLM8KESXD7"&;GAK]21<NWL'4H$SJ6H#EDVB6Q_S4G9*]-Q
M3=:EA,3222PT\LLB*RJJUG$*ZD@M&P)62FCI"W$XI'CDIYLXH$J7["T5K9H8
MV-0H=S55T*QVQGC'#X>'-/'-'3BI03S35W\@584U13A)9*B$.K/O1^8/_KO\
M)O\ ?[O=_MZ!, >[WC]/N*)OO[ /;[._Q^CKST\X#CP7PN^=O(>5Y+:!"\\^
M.W*S8W'&!J/(:^0-NS2PN-?C7.?P.49BC<V\=96.KR;V93L9PK,\$ZY&1B%E
M46U<(BWE4K:U*Y>\\=5SGQ>]"DZ+&9?P4XBZ)AV1W38++QRHB=DOF>H37)39
MX=K5[?0HZ;T&JZ#[5"O72[R35H:+<\6V9HIQI!;[Q<1,L<+".%6F@HJD%JFT
M"Q5O#JKB2HU1LX"IACI)$GIRH*%HY,S"7=-_XC=]L0DEIYZ>*T@)#T_$?X<S
MU"A"T$4DA5X) )1,#M ":R';8$P![_?]?N*8?O[![OV#V'IOU?Y08]:N2&@<
M4Z[85Y;8\KSFI:?H<,TCW QM4KUZE7D74VLG+J>1L$[- P=2:$0W!=9"(33?
M.SMP=-$UM*'CDUO/-?D-X.&6<D] UK1,DN(>)+2X"QS&@7VLV;D#Q:S6VO"9
M*[N-E@9R%L5IB;+#13:,6L:SMO(6BOQA$UWB[=RX<.UST'%LQXD>(GXO,OQE
MI;6F[;@7 *FZ=Q"AVUQMK^TQ>AVO.[C'W^T4>"L-JD'E\E6=3"6ETXQ\SLK.
M)7BROXMA'NDO7ZK-QG%:>I,!6ED3BTC(S6J67AW"JGB 3!@J0RMM("C/)>57
M@)1;5&MQ5RREDACC!2KX5322/*63^?DI@[0[<;;L:B8B*;)%D0QSJIS$8W;0
M, _6'[2F#_B >_[/CTT_FKS$S7@IQ_LG(W6(2ZV&E5B?H]=?QE C8B4LRSV_
M6^(I<.JS9SLW78U1LVE)EJO(J*RJ)TF)%E&Z;I<J;=34M\-\O(56_P#A_;9Q
MKD\9JMAO-4EI'E'.V7Q01WW2N<=9FJCZLM+V?C1<(MJ_K^FTJZ)$?-VL"Y<S
M-,5=*U1P]*W:G<JM&U:-XZWGP59'DWJ6ZV.<\234^3D=#[C'V;>KD[O=EM$%
MR;6;262V[$GMM4@6=3HU*CF-IB(U2E,TJ@O%QTQ&R+(ABMEYJCB$JQN$C2.6
M/Z9=FLUJJEI[TR211R3QL:BSNZ4[Q$ &,L\2O G%1+!N1PE=RFGJ(7D<I$JI
M1&J DD,>/O NN,"YQ3!9&CJ3$C./0T9N2/6K9VD!RINFZ#E,IP #E(ND14@'
M !, & IP P 80 P" "(>_KL=6F _]AP__P#*H[__ $D.KMUV6 #,!W!B!]@.
MNG$Q>*-CWM&C'[64$_F='1T='6NI-'1T='335#? ?V#_ ,.HS\@S&@:%8N34
M]HE*HEZG%>2^VU$LQ,1[.T2)::9G06)*F]>2%.K"K5D1E#1;5W7R_.-FW0C8
MY(MJG"HD%I)@;X#^P?\ ATPWCK#R,,[Y)A(-5F@RG+/:9ECZRSE;VB.?EJHM
M':7M5OMXIHK^DKY$6YJRU(!1]&FP/<WM?+KHUDJN'H\8DCRJ2RNH=+B'LEE8
M$7!)Q/*Q)ZZJS*KU%*KH'0F:ZL R7P&)8%6%^?(]XN;=^LR<\?\ "':;%-UC
MF:.4XI)TA&D6I\,HFQ1?34I9'J3,IFX@@FZL,[,SCDJ8 565EI!Z<!7=+&-U
M67'+C]&-EF<=B66L6B\(^K"[9I2X5N@M7)**90,C!*ID:@4\2^A(V.AW3$P>
MSKQS%JT.444" "U?=W[!W[?'O]?;MW]WT"/^WKB;ZOK#W>[W=_I[]_AV ._V
M>\?CUO[G27!]UIKBUCL17%@  #C>P   O8 6'+EJ84]/<?R\-Q:WPDY 8VMV
M;\@/L'> +:1;^;=Q[%X,A_(AE8/Q,!A>_,B#!T)PFE[(!A6]F]03!87+F= >
M_<)5PL]]RZAS=<&W&KCPQ;JM&>'92U:KQ#F 7;-Z/!IH*P3R"^:[R'53*U I
MXQS6Q& 7:&#T5(<18&(+?\SI;!_V^\.W<0$1^/?M[_B'T=NW<?M#OVKV'X?[
M^_O[]OB/U_L'W>[]G6/<J/D?=*:X)(/N\-Q?OYX7%_+6/=J>X(@A^^*,=UKV
M./7I<];WTB@\;N/9G0/38?EAGA5DU@=#28,7 +(S1+&DJ"WLWF!5*PIDFTS@
M/F)+$(]*/K@!NNHZP3CQ5H"4=(XCF3:)AZ]-KN&,?28),IX=O4IN$DX]!OZ*
M21B/*C(S=<%N<Q$5HN5>1RIBM7:P"NWV>_MV_P!O?ZNP>[MV]_80^GMV^@,6
MO0_^(UW[^[M2;D(_'Z*Q+?2(?1]??X_7U!4TU+#35$L=)2!XH970FGAL&12Z
M_P"T=S 'O&I8:6F>:%33PV:2-3:*,'%F138X\CW\_ ^>F)<(;MPTYS8/4^4V
M.<>(*KU>R6>Y1<0A?<[ID3<V<S1[PW+*OG"5?D;#'H XML!&S\>X0E55U'<?
M'OUTF[MNF0KND..6'@+%PVQ#/.\9'%AHU=O18PWL$22(FZZ$6T4(S$$&*<%9
M+%"^RI""98V<E6?E]%ZN0VOAX!7,_A_C?AC9+0]<Y4<=LLN\7HF[/)*G:#LM
M I]GCF<KI$D]BW3R$G9UC(M6\BR,1ZQ<+-BI.6IRKHG.D;SC';XJVQXMKDKX
MCFN9!!#&:?QVME>I37D1MW/>]TF\U30*Y%PCJ+BN#G%BE/DEEX&726"28OYY
MTC6K"9!_/M6Z:::ZH15[\-H1&Z4E+*ONZ5#B..+(!8J9I60K$T=UEG0 221"
MY1%<N54\6CJ(9.&P5,D5&]0[!#&$5/BD3R@%8X9I%.W3.P.T5LI=V149AN*I
M\8^/QET72."9@=PB11-NX2H$0=5-,7D9)*D1539F$"A(PT,]4*4P #J+8+F_
M/;)&!+-"J.-9C;\/JD=PZF;^&CVEQF"=HS'(ZW-U?$(3Y#LZPV+6)!V^BG-,
MSETWN%N@TG\>SEU%'MKFV8QX(RCI0^NQD.0P?-KQ7=2I7(FRWZX4F:\)'B)I
MEMJD#J=^I\#=+W,YWG0H62?"CV2#/,$BYB=E;-'M3KA'.; LTEGS=Z=FV(5O
MG$30+[I6 > M&Z+?[G>BCXH')7)W+^R6R<D)24H$#$6&%B:Q+2QY$)*5CXZ,
M5.QCTI!VZ.R;>DBV.F5NW!/0BG$RPCA](LIJTCBLD6$B1^T2\ EW']WRAO,%
ME&"2D0L65EE0*<"LIVADF2CC2(0N1*$A:9)1PJDXLHV3'@RF&I"*QEY2Q,"F
M#*YFP:<N.'%IOO(JE8[X;W(+?OYJUEF,RN-QQWB]29^GS.@PDO2:U;,UH4G(
MVZ'>2MC@D!@9228/&$4@M6JDK)ME5F\8Q*X<QDE^X<;MR;Y'\3:_QMCVVD<3
M*]F 7Q_9,TIZ=6=16G1<[9("&J+EA)24LX"(^=UJ+-M).'B$&<A/3H-#/"OW
M"JFK1+X7E.3>&CXWN@9Q7751N%,\0F2X_5JP1-PO /8?(JUMN/2T)343.[,Y
M14(RD#G74G72*]J?D4.UDYUZS$&X.N99]PYU/Q7_ !<JMS%T\*57F.$\?[C4
M(>1V^QXS$OINN8Q5W$I?D%Z_::J-LN6:(N6$E5XZ1<S)8@\N_EV\"]55.JCS
MJ>>(QT<CT=$YDX=#75 ,,$(DW^$-Q1<&V28RJ;8$;&0%E$1F*@U#;%K5$D34
M](K-Q-J6)1'%M)&O%*_A8620PB1B7H[F8@ED(=8%<B!=I@O%WCNJ0C<G'_*U
M$V[8T>5$F?PRA4&BK*)BU&0$(R-Z:*D=7X./,@(%*9I"QS<Q?(R1 MW/QTQ1
MR0B2F(Y\X1;=D2)C1HY1-N!)B>G_ $BE]B,"8ISUJLDR)![>23L$N[[>M(+F
M4TXN,J&A\T@\!&D<KKAJ-RKFD,?$)A;"[DKW>:O9MCQ*B+HGH+6WV&O3,)99
MZ*G8R+:QZ\HI($?3<"P32/(&1<K**Y]XE\AQL?W?F[F.59;\FV?@_@E SIIH
MV]\^=%R.L8@^B*$$M2&O#GCM"RSVZ:!<GB'R<W<6.3EODZV71.+/).'!I%PZ
M?6YIZ&"&2?\ A]-BKU 6/:19Y(J:G%1,S(*<K&RJT$8CDE""1G5Y4PC,TD,T
M$R;J4=,BE:1 SXXM/5QQ2QQ+M02M)'@)GW5#%TCC<1X/(8=L=/BYQW,1-%'C
M_E1DDDCLD4TL_ACD30-#,J^=J0A&)@(F-?BXZ%.C[NT4P:LQ+Z""90N"G'/"
M5%&2*N)9L=6.677CTCT>*%5FX=SCZUN5F:0M/.BJYLDE(V%8Z90,I+O7<B;N
MNNHH.KQB%+)S9YT>%I3N1=PT"[U73/!1A[OKL)%ZC>:JWUF7;6E9! +S*TBR
M04M.MU)-9G-32?RDF,S+Q34959VBDLW59[2]EU:K< \OQ:U;QK%,XH%\:G3.
M+V\ZLWO]F:6*A<8XE>"=UW.W^HE?GLU/HTW,.)9"0D1ET")>4S;V@K50[):7
M*D6H]V_A]$LDE35TT+%85A9J3VCI_9QGJ9# -B)JB:&IR"SXQ+(""Z)N1)64
MII'KQ0+[K'!2R28QQM49U/LU'[3)&L 2SVIMR!G,H43(K%0C$IN@H<9>/\>F
M#%O@^8,DCQ#V *T)0HAN!X&1A6]9D8<B'L91/&OZ\U:03IH4ID5XML@Q.444
MRI]=M;CIAA2-/:,2S@I6SJ1?,O6I$44J+V5FT++*NVHJ-"@1Q(6)LWG'RJ8B
M9Q+(HOUA%<@'#52VN0K.&;AXE'&K@OH,W8^$[;PFM>U/7*56]5M&O9;B/(<(
MR1;4]:H7R7L]M<4RT72O@U?2M<BK4962^47<FLS(HW(HRG$\)+C;EV.\.<#U
M*ML)V0U;>^/&&VS9-$M%WO%SL%YF@J"$G''=?.JQ3$=#LX=.76CXQA7(^':)
M1Z#1LLFX!HW,26E2CJ6D1*&F1(H8W<M#$&+O7<4HL401!7A,G"))4FS7..6%
MA&KJZI91H6G6G%'3%MRI61D,<D2K3T_"*@&.007D=AQ:!&B9(MJ2GG5F)1,G
MN1W''C]#H^SQ>(Y9&M_D:0KOH,J5"H(_($K"NJW*0GD3:E#Y+D*\]>P;UGV]
M!Q$NG#)0ID%3D'[GX]X,H+,5,9S(XQRKQ=B)J=#&]B7D9J.LL@LV'V8?25?6
M&)BIUT<G85Y6.9/E!%=LF<JQ![_B/N'O[OI#O\.X_1\?<'N_V]N_5.P=P[=^
MX#V'N/Q]W^WZ  ?H 0_W7!148%A24P'0016\/##Y5_".@U>$%. 1L0CESM#&
M!_M(Y8^-@#<$7 MRTC+;CEQ^:)(H-<2RULW0AUZ^@BA2H1-)&"=Q4W!.H9(A
M6P 2,<0MDL40LR* (J1T[+-#$])ZN!Q/CCQ]15,LEB66)K'1]G.J2E0A5#H#
M)Q$WZ F]E 12&9K\%*^01$ORA#QKKL"K-$Q%F[CW[ (#[N_</C^SX]N_?W=
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MO>X>^4+&G=)+ED>D@GCB201R(SN&*1R]NE)!73T\Z4[20R-2I$DLL]4"E8E
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M&NHZA$;LHE1!3URB50I99$KY$>46(5T@X143!G:YBAR0D)R"IA:9HK',S5E
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MK(\^AM"DGJP* X>/;A&0#:P.';DJJH.'2C\5UP55]4Y_4/YM;KE'XGNYZ?\
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M2P<9G+ N:=BE*_9^$U5@5*M9;].5T%H"=<R]I=0DW*+G?R\D^!1Q(+;<)0$
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M^D1'M[OJ^/U>_P"D1#H]_P ?K#]G;ZQ_X=P]_P!7<0]_48O\^[EA\/R-G/\
M^WOHW!X>_P#_ ')=^_P]X_\ WJ#SMY8#_P#!LY_?[=%X/?[_ /SDO?TVGZ#\
M:>7S>8U@2IRN2/M1STMWKY^7('S&I.NWP]X]OH$??\/?W[]^P=_H$?M#X=@
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M_P"?^?N'HZ::X>FG_9D_PE_#H]-/^S)_A+^'7/HZ::X>FG_9D_PE_#H]-/\
MLR?X2_AUSZ.FFN'II_V9/\)?PZ/33_LR?X2_AUSZ.FFN'II_V9/\)?PZ/33_
M +,G^$OX=<^CIIKAZ:?]F3_"7\.CTT_[,G^$OX=<^CIIKAZ:?]F3_"7\.CTT
M_P"S)_A+^'7/HZ::X>FG_9D_PE_#K6=\8Y6(2Y0TTKVMU>65_D,JHE<S-CX_
M0[HB?SXT@"HIM=3BWEA.W((&,1=HJ6',=11-LF5XD_,;9EZU\?%7S?3[?R+J
MDG3*_N\K%(XY6V2[G,C[D$ 5^E<+\LJBZ#-<PN<#\KE0<-CN/:I1"6]D48^T
M,$6OL*[GR/MM&TO W5,[^]4Q[ !:P9K\BC\NO9^_7#]H49^',JY$F:'Z(R/>
M? AN77EK8._Y^_J)+F7IAYW5,MIS!0BT;'1-\T'V-4W9-[/0TD^HE<2<I]_>
MBU>P\ZJF/G @_*2IP\AP,(2VC_S_ +/AU SXA$4[S?3\SO+0CA.$9/[EG,PZ
M]X@U7M\B?5*6Z74, =DY1P^OT2R./E0%>O+LB>9P4P=>EJPS1,JW%P02.\&X
MM:WVF_E?7HH #):]KA@#TN"+CS'AYG5C\*^52/Q1@;#,)LT] O6@:O:M4<HJ
M@NY?:"YT*?:2Q'[GS'44/%-V;*,:ME53E8M&R3='RD#\YW>AX'BFHZOD>WWB
MHM)G1\16F'5 FU5?*5H>8:E0$LNT$AT)I**<%+)U\CWS!!RP?*#(2J=PZ@^B
M-5NW%6YV71:/'/+W@>B3A;+I.?0P'5G<QM#[REGM&H\4@F!7\--"";^W01>R
MB2R"LFR**AU?-)/ <GJE;*PQM-;L\9.5Z38@_83$>^37CUFOI^H94' ?FHF2
M* ^TI+"FJU.4Y')$CD,4/*<.> TL?"JRG3?X>D >&5 4E]W9##709\I8Y'02
MYK=HY69)K."#SZ*&)X(^&U,:F>B2'.*5 RR"!DV:Z&XQD1Y$642#MPS$QR82
MJ1IX.B2->F(&6@K(W92L#,L'4;.QTF1)TQ?13Q$Z,@B^2< HBLD=L=4QQ5*8
M4Q %2B50A3!$3P*T9>-HG&I!=RL_ARV>;S"+56<*.5Y#*['>)[/H9LLX4%51
M< K#UBJV4. &(:/9G(0ADT_*AV]<G+/RDD9C',8LKZMY4U.5KJF[0S@Q22:1
M2%.ZSW-':9TROY!]Y_9+-.)*%;,V0KM&:QCK'.95>-D?'3VW8IG]5:%CJ9GD
MI$VF1;LBA[-!47+4TK"\75-[BE!48QA&$.<P'=R,H@EYQ<N2B:6G;W_B:5L(
M_E:>":E%3R"U<DLU/(1'XO!3F VFYQO)*ZQ$A'8S4^-56&KB6]-!334_O'()
M52RR0.PA_P!SPTX@*B4?#DEF81%MN0ZV<<NFE)RD03I=47#E!K\G.7 E$@N%
MXTYV"JXD-^<7U5&YU  WYW8WO[CW'I0>DPQY@NQH4*9RB#=9^D>340*42%1/
M(*G>*)E(/]0I5%C !?@'T?3TI_7K(_H)?OP6_H.O/UU*>\_:?^='41OBV:KH
MN01_A\6/-8G1;7+2/B68'7)?.\OL$)7K/IM<DLZVQ:1HP.+39Z=47L?(+LV<
MD[C;79(J!<#$I*N71%T&P]2Y=-YW[C71^13_  .0NDI9XU;CMR$I?)*EEK3V
M-9IR5WHM?N%<B8NR%D8J4,\K#AE=915^SCC1<DJZ;L3H2K=-)=)QE@2T![@E
M71RO_P#QPU<,LO+F"=M&LMCD>SXZU;G'.H^D]-4QI>]LY*>2..Y!! S9;L""
MOTAW:@\Y#>(UI./\S:3MFR\=.2G'[*L)\-OGQMEAS'0KGD+IIL<K1[MQC"#^
M0X_)-4TZ"+/0R\B>!:3%Q1C%8DES46C4W3(\H;I0<G\9.^V:T7#.9*D\;=4N
MRW&70^0E%FL5VNX5S(:E9,W6KA+'C6_ZEMF>U."SLC>-LQ;+&["F8]?G8*KW
M#M3H>490[&:DXY#\#\*Y1: PO>OH66=;H<<-_P"+<G2VLHTCZG8,TY'/<\?W
MI63]",&Q-K-'N,T@%*I-PL_%&@UU'CX&[F0+'NF+>K7X5E8UBAWK/>07+3F#
MO4):,AC\3K)+K?<_@F5 JT-;ZK>X:S-*KGF95"C:%JK:S4JL.WND[%5]"FI9
MA%JP3U(T+.65E,Z1AUC".  L54 %)+&26HXI(CABUC(#/02A6QC.V\6Y$@99
M9#@92PO9YZ8DMW"..#A<3J54 X6@KT8J<_BI(%D<J\+!)'QQ="J[/D;!Q55X
MM\H[IDN/X'L-&FN,VKZ&EE=N-KO)VF<;9/-I2X7VE%;%F&$A<F-AK=[J+RRU
MJ49"=*P15;71(@[==@VL^(3)^)_+9#R&=\>8;.XSA-3M)G<[R&Y:E98*(E;%
MN&JUN(L]?=7&CU8\M='P5V)@K2I*(,XEI7F")Z^!WB[Q)10;?X3.?ZO:K;H6
MX\D.2FMZ!=\RS/)9N>EW^/U:)94_).0]"Y*TUK5:30\CK51J[A.^T)NUFGC"
M+4=V&#G9I&66<2"->D()W\MQ;A'O+FN<P8C1M&K%P88V?"[E0HD]*=YOIM%9
M6:>N=4+:F<]39>VQ4U3;599B6AY:BVZI*O@=!&V-.:BTRM!MQM&II69;N#7B
MI[R@5Z:LBH\%)L2'DI]PE6*LI<%F4NT#B1A5J" K"@--R 8-'/02U@+=ZYB*
ML$?, [BHV,;8(Z+HZ.CJ'4FCHZ.CIIHZ.CHZ::.N)O@'_P#$3_\ R#KEU00[
M_> _<(#_ -W336F/G7BR<C^(^^Z]3';Q/7L7C=MU% F<W!XJG)P3%6_SI1;T
M2Y>F[D8("&$PLX210F8#U5#)-H]B*OJEVV,$V!MO.55/5&=(O^>M;7'I/T*O
MI=>/6;6R3.FF8%'$:==?SLG G%2.?D,5*0:>F[23(FJ4.FE8#X87&/#M$M&R
M/:Y_*CKUFN]INZ=SOK=K(-ZH\LTY(37L=)K(%-!P81PO2H(3*S>0LASI&7++
MH%5]G3D6  #X=>&]A>"^T7!>&1P<=XF*D""%(*#E.U#BB H:XD-)8 IL)G3Q
M6O#*RG7GN#T'%:2HKI*RNW*2:IJ9*6B(W3"DD[O&V^UFC&!M[NF<:WN"K775
M!^ _L'K38YJ\U+55?$T\0[)-1Y[\Z./-)R[.,4EN,]"XKTIQH\<[T&PY1&2\
MY&SM?89/H9$8Y_,J1KQ!&:D:PQDWDI)I!-I@D<K;<H$.X"'UAVZ8UD'!ZLY%
MS8Y9<U(^^V69LG*^LX[6IZC/HR&;5VH(X_!&@HYU!R30I9=^M,I&%P_)*&,1
MNJ(D:""8@ >JJZ66IE@"RF&)8JP22#,E7D@QA*JDT1W _.-R76)[.R,+@]NI
M61X56*V8JJ9SD6"F)&<RAL&C9T(*Y1B1"X[F! UK"WKG#RS86OPV(+Q"N5'+
M'AL&H<$M.T?9FW&&F.%K_/:+$:XYB,FL5KS^!R[2WL+.67/!8R5S8MZNS9P\
MHM[$Z3@#G%HBH$;X@'."3X-9K@S;<-%K>S\U>?%YX]\..5F[5"/R;9&?#6F*
MQ%BG.0]^@'$37V3*6BT <U>.DGD(Q=3#:14,D3V]NR64V4[5PVKMIYTY5SE6
MN]@9V;+./V@X RH*,=%*5N7B;_:8VTNK"]E50^6D)2.<1I&S9HW,+%9)0RBP
M H4.Z4[EX8N \H^6<9R9Y-,(_>*Y4L/6QO.\ T:H5N>RJEO):UIVBT:.BV>(
MKO9BZ3WL[.']>3*9I%QC5$&*8."%5+6EHJJ0L1(4%345@FC2:2(1TK<4DKX_
MB(TA,DM-3P\.B:"*(TU/72AE8Q$KS4HZV%9 E2\CPI2PT\DK%I)__A%'PZ>>
M5FD*(L50U5Q 1-$\LM9312[I$I5H/]M\2+=[CX)>1:ZSVO0,[Y%YIS"R?B+R
M<T#(58]_H#R8I&GO*#I,O6DF4=--9N0T6G)15SAT(^*<)3,E,MD(UNNF=-)3
MCQ*YR[S_ #LK&_XA:#XC'B(\8\QS"QPO)C-N2%"S^I:/5-WGK#'QV,UG-GER
MK&,R\%.N6Q9B3O+:T)-:[$UF->R+YP1TLR12D(LW@.8,:TZ^&3:=;,.QO6]J
MXL[\; *%3J8GG%'TGC!.HS#&3HR"Z:;B#9W](KEC:V""9440<$<QH)G9M$DG
MO6?@E66O.>M\_P#,KM:\ZT@,RELMW"@UF/@5Z9R5J#<!>TMO?4) 6R[*V4>1
M21^:]MCW!7Q&Z32,D!5C$#I'Q'!7M/'4SN8BQM/@0<''"TIY*A(4=XGII*Y9
M)DI559462.:Y>-J=QI:W%$$G9IDHHHR)G9YHH.*U4Q(E<QVG]P:D6J>I1UJL
M)Z<%,DG&?<7^8],Y93>C)9M4[:WIN=P^0+.+[/!$MXB;M>J9U&:B]HL6S8OG
MKXL_G-9L541O1G@(-&4]/$AV*CU:/?*)/ Z8)X8^+V/"^&F75B]9FUR+2;*_
MOVH:70V[IK(+5^Z:?H-GNCZ*>R#*0E6SMS"QDM$0"0(2;YLPCXAC%,W!F;!N
M4K^^NG3F4PQF:VZR!I HLJLW:*+R!Q2^ )&1"@M=B3KJ1%FC1F^DP#&ZXD9<
MP"I ((! (/.]]'1T='4VI-'1T='331T='1TTTVWE=QGJG+;'I+%+Q.3U?JLY
M/5>6FGE:]B3FEV=<F$)8\<R=OT';9@:0% &RC\S1THU2.=1!$5O(8N1X)QRQ
MCC+1FV>8G18BDUM(X.7A60*NI6<D13(FM+V*<?*.):>E5P('J/))VN8A0!)N
M5!N1-$C-/%YOEUS+A'>+SG=KGZ3<:_;LX>0MEK,FXBI>-<!;6)#&0=-S )DU
M4CG1<MER+-7;=11NZ;KH*'2-&UP&\;^V72S5;%.3](E;78YY=O#5O3\IJLE,
MSTH^46311"WYC7&CMVL42F.H^L=*:F0;E(51U5VZ'KOD_"2>T/LUP_VPJ^'U
M=*M)QBHIN'HO%7C$BU22J^S2;HR>EP((L0D$A(+R9XKKB\1XCPSA_$:!:Y0E
M1/1GW:K:,.L,9JIXS"7YO%G)DY=5Q(8B1E5%OLO]=&3CT):.?Q;H5 ;2+)VP
M<"B8"*@@\;JMEA3.)3 50$U3>0PE,!3=A$H]NP]PI@.4I@ P 8 , &*8A@ 0
M 0\Q#@4Y1[#[RF*!BCW P (" )_K=Y',<KTK20CEI@<^H%SN_P D-P.+B5^:
M5:D[!\FH D4Z@K/AC@:I@F4R@F5#R%$_8.O;RE%BE:07C6-S(+970*2PMXW6
MXMX]VN]$':6-8C\1I$$9!MVRP"$'P[1'/P[]8CQ[P.B<:,%RWCIG:\\O0,AH
M4)F]5<6631EK$I 0##Y-8GF)9NQCD'LF9 /Z0Z28-"*K#YBMTP_-Z8Y%>$=@
M]0A<FA\OU[D[D1LNPAUQED)?.M0@HN;U/#'%SE[^C1-(D).AS/OB[/8;"\A;
M?04*'>XA">EV+&S(MGAB$;SQSXG[=R,X>XCR\EN=O)6C\R-MRW..1;?1HO5+
M7)<;Z#*Z%$0^BMLN:\1RV&$P:QXC P\FE2'D5-5\+S,Q*#J=7T5K;%RSR'+F
M3XO5TX<Z?:FUTRWCX&29S?\ (J).P5BY85:N\P-0B-.F:M7'FMXCQBB*W;T7
MN=P4S:T@B&NB:+3+/<8ZO6>29,8QFTB%YJ:16:H,$UC4SSB.17(*22G.#MRF
MT94FKGA?<*HRRS?3A+MJ%&&T)XKF&*$R1NH(D6,&.;)8P-Q3>F@FC*7=6CBN
M(Y@B%S<#X27%"NY3+X_'GU0M:?8AQ6PR%E/G\9M;:/&<,+!:[9QZOU'LL;#L
M7\'J-*M%L<3OSJ-[8WDWD9%(OH=2/^4V4FK_ !JX*T'C7L&[;\UU+<=@V/DA
M!Y7 :M>-GME:G7,JSQUO:F5*&&A*?2:/6:H1K'VV09.HZO0S"$53;M'*48WD
M591[)L>EO%0WJ.>\D)]'B54WF99GRCG^"F#R1M[49WSD%RR7V"L9908(]3/F
MJT-G.3R9;,K+W'0I>U2DQ62UFQ)Q5-LJ!8MQ(-)@>7?+6'YZ<E*-RDA+/33P
MNU^#/FU2R_&>2MHD,?B'F\:!O4)9-+I5A?9]6)J>H%V-!QK?2\QL=*K#RYKU
M<]?F90&+2.F'>J.7='4G*IDA#->Q,E=L.N=[$3S1U=-,Z-C*8)H)9<8<779X
MPJ3JRV%)&^26(&%"VU9?!H8'IY(D<91"6GFBC+3*R&8ZW>'EQVO>3\C<:M32
MZR=3Y-;L^Y)7)VC<'D+::IL"J]#D8.VYC::^WBI>DOJ=.YO5+#4UVR[QU'2S
M-<[IS(,G:S(4ZG/##S"\9YMU-U/=^4VJVW=&.0QDSM%RTZN):;26."7-GHV1
M)9BSJU KF64U6GW]H:YK/$LT?O;?/NW2]Y<61I[*R:-DC/%NN4=RNRG%M+RK
M *13=EW^T\>H6E1O+>GWWF9FLK$5:Z6>LZ)MG'VFUN6I=,I5M:T=VY<Q;#89
MFTTZ&L%7D9IDL_=R<+%KMQ6YO<I>2,YC6G!PZCHKAIR5:VN9R37J_LS:?U>D
MTR/CW,MFU^W[(I6G5N(J]<VF*:"YKS?.;]I,W37<G7XZW1Z82+]Y#ZQ,)$C:
M,G#&+ WQV2D$:P W(-/,:=(HXK[<SQH(A<1,B;2@QO(L@!D5F=Q8.TF4\C2,
M  =^):A)))",XED^*><D;/>)CPL,:E;)?G[;8^3M=HVT7ZJ:OR!QFJ:G%UO+
MMUU"M(5U*1O-R9Q5+;VVJ2>A+U2!>ZI$X[;\RJN@O&)CSL =%_)H/5%M_AU8
M%=LDUC&)E]HI*CLO*MCS#MJS&TL6\TEK,?JU+V%NVAGYX!9)A3_G90X-(\&J
MS>.1AS/F(2I57!':#,.2_)KF;EGB'[35..6:P.Y5*E^'CEFXSE"U#<I/(,UK
M#N&V7?$; [KA8J@:.ZD]7TJ$@HZN0RBT/#UUNSK)'-JL[%JUCV;VZUGQFL\F
M,4VC<YK-7U6KE=X:\;N:& P<E8@7L^XT[DM"/JU5*+[&SB%FM?O<7R-CR81(
M-(YU8F2TA8J?84%P0GTF***7*-:E PVF<*%!,B>ZU=1'"L:*"S+EP5I::.-6
M")2!451&!I)%C*U*P4B7:8DD"*1ZFDI9',CDX)(5XXD4SRLKR/5,S%MPMITD
M%X:N#0NB/+^K8]6GVBO)W6.649GEDL]?E,\KVF;IF%[RO78R)C!IZ$ZK0[Y%
M:-9Y^5JDU8Y=%G9W2;J$>1<2"\*X3VM>$M@T+'4ZJSFJ\DM"S/(\_P!+S?CW
ME-^TJ%F*3QYK^HYY/9'++YP=C28JU3<W6LLL\[GV?36MV?2WM'J\D[90IDUU
MU79T!F/$_P"4];B^1NMS_#W/FW'3A=KS++.2]J:<@I-WIKM%E5<SLNG6S$J'
M_)42 N,;CB&@J*6!G;KK2G-O2@WS:H'6?E%$<#DO'6HQ=<N"T'!X0[XV9SR6
M1XM6B0E.244QY<62R)7F,S"PZ[F?%MG3I(UDQJK7^:8,55)&_1%]L=3C[3>H
M&JJQ\$WCY<D:RXQ(JOOQ0# %2'A:&GIJ5W%[;1BF@AII'[(5F$; +,5,S)N3
M,60PR3!GL5<3":>>JC2P#&7=2>6IA2[,><JG.,-*52N%6/4%SPZ=0;JZ&4X.
MX[8,/QD'\^T<)NJ99:)0\[D5;N4D.A\X)LL#G< =K(,QAD49$\@Y%DHFZ(W;
MN[ZUC>8/B6^(_/9'>KQQQX^X]EV;43Q#Z+P]C]4M'(M]\^=(EZCS.B\)M,<R
MH+;![1&UC/\ 2@2;U>7MR]J^=M5CG]IEX&O2ZD?!J2CJ9#Q4N14.\Y)69[P]
MJ4AD^$<@Y7AK5I:%Y +*W[;>6LQ:,SI.84NFU&1R^/BX',K!;M,81-LTJU6.
M.>U5A$3<XTI\X1DDP>9$K3Y3'-FE)ENP)DD,RT<X<IS<-.W$J54C8":268*(
M[LI88MH*G95$)B%C9$,3U$;)D;+C$*2H=W4F-(HG<N K6G)Z.H/-+\4/DUQ[
M=6G(=PXAY^^Y3-I;C-(9;0L@Y"2%ER_9,_Y(;Q&\=B2L1HURR>E3=/M.:Z1(
MMV5T@+-231RD(_A;)#3+]L]>L8MOG,?Q >8%:<YOB4OE<=G'+K,N<W 5Z_SS
M"]WDY?+>0V#\D;!I4#6X!+4;50*)-0L+*7.@V:C:U"VBA&;Q*-?:V2)"RQLN
MP:IKDB(@%EFJX:-6',&:2>FA=4M<R/ :E6ECC#.H25;91N%RJ9&8%E#04=16
MN";8PPTU14H7)L(A4"G*0O(55FDBYV=;[(W1U"]1_%%TZ(U4^%\BN/\ 3Z'H
MF=\OL>XL;],9MJ\SH><5!ARERJ4N_%O5*;8)O.J3,3\-?KTC"9';*_9H"I2=
M-LT_'/T7$VQ<HE,^KB1RB_G7Q>V7:"IXP.8T/D-IV'9?;E)51^IK45CKUG2[
MMHK1G\G-6\3 *:M'WJH5U-!]*_*T;4RSYG+<),C%OMBU[8MRB68FW9$;QT4J
MG+Z.31\0I'"7S*R,0OPI<(R0+7Y7?; /(ELJM!8=Y4M0U/: *VC5KVEA,CM^
MCHZ.L:SJ@_ ?V#TSCAXU2:CRE])I'M/:.8VWNE/8)&J2/M*JWS7\[M[\U9J9
M]AD%A*'M,=8_DJU-?*G\L0K#SMO5>./P']@]-(XEQTQ'CR8^5VDZU]NY;;/(
M1?RX6R%]HAW(UKV)U#_..JU;O!+>FK\G&@?G'6Q JOR7:I?]/[/1J!>MX>>?
M+WO[.<2]_(_=S'CWZK2#^8IO(3?_ (*.G_N/OT[CHZ.CJ]JSHZ.CHZ::.K%:
M%%$JW8%$5#I*IPDL=)5,PD.FH2/<F(<ABB!BF(8 ,4Q1 2F ! 0$ ZOO74D&
M24BQ>QZYE"(OFCEFJ9(2E4*FZ0404,F8Q3E Y2*&$@F*8 , ")3!W :M;%)-
M1U<,5MV6FFCCNV(W'C94[7^WM$<_#OUO&P62-F^BKJS<K\@P)Y'OY>&M02N\
MN-]SWP\])S'6=%MIYC9LTC]RXLZV6S3/SG<M8G7H.MZIER]E5<$DB3U=,V-/
MQC5-T<RT#*R"")CLQ;))S-6?G1NS4=^?XOB-*T',N'$37V.RS=TTJ6JUXNDZ
MSHD7>;E'9E$,JM,QBBE<K[OU?;[5*,D9J2!1%L5)/LH*GW?PO>..@\6LUXH6
M1Y?7%0R24-+T:ZHRM?2TB)=.'L@ZD2%F1K)X8[671DEV$FT^02H.6B;0_D(]
M9MW2=PT;PX<MOMET"8CM2W;-Z_L[" C]VS_.;K$PE,V)*OPK:N)N;.U>5J3E
M(J2EX%JE#V.0J$I7G$TP\Q' @N<ZX_,J3V>]M.&+,E+7K(#P[A5'2R^\0BH6
M2DHN)-"*IJB"HC>DH.(5RP3K"BSUE%3TTJ,T@J()/'4G#>-4J0 SLZI24L<@
M6=#4 XUCU4,4DZ/&2M;)3S12N"!2!Z;F8D$C?.,G*7>=S\1#281"4A7''%;C
M9D>GT^K.)=VU=UZJZ3%M+%5;*A%MZ^!)/0)U\^+&71A*RXQE<C6WIUZ5D0[H
M.7';%RFVX.0-BXX\9<DHN@7+.<HBM=T>8U"^RM%@46%ED)&.J5,JWR)6[$\?
MV>=-%NW!Y"1*R@XM+T"N%5#G/Z>?5/A7FM Y'->1U LE[IDD&7U?(YC-X62A
M?Y,[!4*-#GA*4SD(M_!/)U U99^SJ, C+ P3.[8M%W!%0]J3==;<.%5.V'2!
MUZ"U#9L-TF1I 9G;;5BMJBJZ[O% (\7?M:]96L[7K&P54BW3ITI"SL>W83T6
M+A0K>0\@)%2[XH/:>GX0U/!4S/6_QSB\\THJ:45$W#:B7B4M![K/4P5$, 2:
M;ALDT4L>4<$-7!$N!AA;JPP<3CIIQ+*SU#UD4K-')&2].13&HBHS*I2 66:.
M))@<>=G0LDJQJU[EYMG(SEMQAT#CK66Y5=&X>ZB\F<LTW0YJO9Y4+A4M:D*M
M9).R*5N&FU+$\B):&5@(-[%09';]&39.U5XUHF\(CG%J\6NP1N7X?<1S.EYF
M[T&:V6F:'<-:L5Y7Q_/M$QBQ$JKZD%M&>4BQRSES<Y$QWU;F)B+AHYE%)J+2
M/JJ(.?1=.Y\,[%HR3RF=RZ^;3B<[BF32F29Y+9I<(EH[CXJ>L#RRS\],FL-:
ML 6BPS\G)2:LRI.@[BWBK]5\6,0DV[!ZTO;;P]L]K6<YWGF8:SNF6MZ UNC9
MQ+5VWPTZ;1%=&?*2MVE=0JU[K-JH-QL$S*KN)%"?=51"5AG"OHP[EHQ(1H7D
MIPKVXIX*A(*Q$FDEJZFH:.2DD@J*BHXE3U$;4,4L<4U-&(/?EJ$GJE(6:EV6
M;9:GU2CI..(U4YG DG6FE9PT4L;2QT/!Z:4)$13E9&DI:WFLD$#1R740S2+)
M"W71O$WFZ^KB50@HSC;"WW1L;F-GM-AO?(,%<0B8R-GG59B:I2]'J-6DU+K9
M+;)L7BC$Y8N.:0K5JO\ *@*N454B=.I>)5L&ZW[!,\X\X72'LQMW'YSL[M?4
M=#G*VQH3RLZ%,T:\0LBK U687GVD>M"J_(#N.:M'$TJ]9N%TH]F"PIKE$^&/
MB]&@LO8XQ?\ 9<2M&75&Y4-EH=$LM=6M]JJ6@SRUIMD5<OG34[!7Y0[VQN%Y
MJ->LH.,=5]^H PRC1N1-N18J/PNS6A[%FVVQ]ITZ:N&888ZP.)-;[:6U$FZP
M^GE+$\G[3)S$<XLDS;W,DJH8\B:;0CR-S%;(12**2)$[]/0^VTM6@K>)"&D>
MKC:I%*U&2M((:FR4LKTP=F5C31U)>D@,LP::!50$:D6#CS$"2I6-6CH581[#
M%2).$^^$2,G^L4CXL3\';(GAP<L$6!J]7\2:;L45E%35S:"CMWGN26GX9K]%
M5L,DI#YI 8A&S-MT[0D'H1Q)65CVU$9PTQ7V[IFQ0DI";3CUGJ7LYE#IGB/B
M]1^E73,W%DJ><P^9;/-WN$JL95=(>6K<,["IQDO+04WL-$"NLX>(A[RT@W:<
M<>$G'BL0\=1B+L7:;LRI'XU[@[A5;Y0Z'RS91TPOHVE51:K3T.^>,7%);&D&
M<3&3]@BH0L:FZ:V*S14)'1D\]5DW*#QH1<I6J*CI<Y\1QW@#G>)SM?"J:ENC
MK+:4XN3NC8++WIJKD]94OA')+ U58Q\''6:UPI?;'9X:OW2R6"&AU7*RS9H9
M84SIQI1>WHFHV?B=-B)"DX6.G:+&F_A],LTRLB2;?$(::OKBD)D>FJ>(B Q8
M00S02-!QS.,+51[:53QDA8W>2D5X6IIY581#<9&J8ZU(W!8I3-3@%I66/NV<
MM.1^[H>'IK+FB0N58MN/,G/EJ:\IVI3TC<GM,*I:H]G5]8KPUR&B%T;@R:J3
M8(PTU*1C)2/+'2+(ZRK=R,^G4;%7\,3(JI*Y(HTUCD"^IV!ZJSU7%<OE+S"O
M<_SQ\U?O9,]<C8Q2J!)25?4<R#E% TY+2,Y%1PC'0TO'MW#[VR2?KM>R]#Q>
MCCXE)QAW>IK:NEG5I)X)Y"(N#\,HYRS4T,,**U935+1(B"T+1EK.6 M</AKD
M>22M<O(T%-&QS1D::,SF9XEC2,)"[2!HE==P(0'(L$0Z.CHZ]3KJ:.CHZ.FF
MCK6R\8&#82?)NGN',!4)10F(U=('$_<\"KSPA"W;1C@BFRU+2Z=85&Q14,<C
MEI%K0ZBAUDFSY5XB_0;;)O6O!XL5-TBP\CZF]J$!JLI&)8S6FJSBD);6>)*]
M)<M 5527-G. ZE!_*!4%FYU@<V%I*>SG:BO#MFHLGC_R7MJ@?@;J59OYJFY(
M 3])N=BKCR^CX^&N'[0KEPYA9C\:+Z-KV!-^]6'=Y?>-;#_35>4V"1&STR5;
MO8!Q:$G4&M!6.K,7S**EK+!$=DEHI>M3$B)&,+?J38$4K-0)=\JC'DD32<'*
MK(P]BD%DU4M&RTRH3:]?F"V@9!N6.,H,;2[5,,NTHQE)!KY)",BG3)0?9X=X
M#@"+B+5;V9NX!-9XV(K95>0>>I*+)&)<_,@H@DIY<\NIR^9PU@G:?D,6%$JA
M?1L4=YS)B8J2@/D5!*I&OBH>I8HP*E@/#O'(C[?V>8ZZ[ZAU((!ORMR-N=K<
M_O'.]QR-P;:U>M*P[:L04EW#>-G=)SR%7.V6OM=@I [ROD*/E+$ZM36Y7E@S
M&T()G(1ZSG6HUV1\WMU;GIB*727",VSP4VC(RM>S&ZITK*]&>$7T^LLI(B01
M0I. =2ZU09F.(1Y[J@=:)GF[<J*)"K'<B!"^X=V>\S.$V&T!./&.@0-\:.AJ
MZ%UJ%4T2 L)"H2<ZR+'KST#'-3R<$1]7Y)4C:15>P1TCM70(&;RK51RV^4S;
M$)N;/-.'KJ7<E<(KNG-HXF4B>E7JSU@QD_5?3K_'QF'ZZK21;@NZ6>'63<^L
MU44*Y:KD)R*WAM)6!!.N>VY9&1\& 8!9(\@ROM3H=N6(DI(O9>]E(5,-/7(B
M54+DQMDCQL\4@# +)'G&"VU.EXYX^2RQL05N$(U],BS;1M109T?!<UD'<%#(
M@E_T&U2A:16&1CB8[F=MDD+*MPK8!-ZRSB0DRNW!A,<B+I8Y2#/7PSXF-LU@
M%X4BS&S3EE=Q[[5M(;MG1(Z02BU2/XS/J*L[2;O%*7%/BE>2$LZ0;KW"; D@
M+5O%,HU([@6J61LCM8*TS&BV!E#SH1#"OH9Y:8NJ1THE-RL$11C#0-?95]-N
MA(1CP$)5%D"1& M7Y77LCMNNJN3#<<OAX1JI'LK<TBRBNB@@CG=U]4OLE>C;
M(IYFH0HN2@,9)M"IG.3LL_!Q&)B9^U<-T[D,2* .RB * MU!"C$! %[*K_MY
M'F+ 6%]6))#BL<<>" !5519; +B ++V1;D J@>8 LO"""39!)NB4"(H)D22(
M'P*FF4"E*'["@ =?7I%W>\T)E(N8Q<EO]J:S*D$KZ5!N2Z'MR<R$"84W2,,=
MNJT]O'N5^FH9F9G_ $\JPL_TW7S2W_/U8PTL1.Y>R$276$#9]=".?(WK"MN4
M[,S0H.1-\D)& A03\RDEY8@A321RMAN9IW9+ZC\O_P!=WCJMBWU6]#I;.CI%
MW^]4&.D'$8Y);_:FK_Y.5%&@W)RW]I&790GZ-TA#*-U4/;I!N(N4U#( T]9\
M*@-&ZRI/A_."S[Y/<R8DN?LK4Z*:O_D\NOKB9Q7Y*S)BFU^1/:%2A&13L%#)
MIF*F_P#9XQ02OW;9!1FE[9+?[?WUY]-,6^JWH?TTM_1TA:O(C.D15 Y+KW1>
MF8'\N=7@X>T%D8R+'R"6$$#H^U2S007)W1%N#ET!_9VCA1/NAO-"&-=2ODM_
MLK1VV9+!\P;B#@5W<9.RR7I-?D?VA9+V2NR0*+I)F12<BR:*'*YDF*:^<T[L
ME]1_SW:8M]4^A\OU'KI9^CI%&>^T!\^3CT"7$'"DL2%+ZV?W-!'VU20@XPHF
M<*PQ4"M?:K%'>9Z8X-2H ]=&5!O'/5$/HIO-"32=+&);_(TD4(Q;RT&Y'-[4
MX&R GZ9"PPF60[U65\[I(#-T_-'"HH4):.]IQN)WY+ZCH#_P1RUC%OJGT.EG
MZ.D31W[/UQ3!,ER[JR'R:7S9]<T_Z3VKP]S>>%#R(=K/%C[2?LA[GX>?O%R
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MB7^D/K ZK*'I^:&#UD?E-HL*SE+S(-V'IR:QR,%DES-5XUZK6:1'[Q*6%*]
MUNO(W9-$KX'H=W>N#55\C'.&A_929M4W#(3)P<A[-&*IV-R)_133M$V=V@5*
ME.0:R@8&ZJ*HL0>0#1HHRZ78@"_CRU7DC<STS!'(437(!L+HH%_M)%NIU(CT
M=(\3<J,<JIP);?*B=,BG>BV\H^92RMJH7R ,1W.'RJ[2$PD P%CO4EC"$:DH
MY+:D>16<K(K+D)=O30CAE#@?.+P0_L@0+VQ_F)G@P.=Q\FL' >R%*+D7WHQH
M)>W.$4#W=Q/K+ZCQM^O[L=3XM]4^ATNW1TBZ&]4)P9R5,EO[M$$G"OGH-R3#
MTU9J&@2>F*D,4%C^WSK 3)IB8Y&?M;\P S8/%D;<;D;G!4W"HIW?R-FB3U7M
MF]Y$WHK1,E-$],H00F55]BB78'03 RI'7L[$Y"NW;9%1N)]9>?F/W_\ KGW:
MSBWU3Z'[O7PZ^&EYZ.D><[E1FJ\HW5);/4B$TE'?IT6W+$$JSZN1Y!;*)1!B
M/!]HM,5YBMA4,1$)!P8 1BI$[>UFY$YT45RB2Z]VS=-RKVSB\B'I*H3#@GIB
M$'V54].#? 9)/S*%.+1,Q0.^:%6;B<NTO/S'['?XZ8M]5O0_IYC2Z]'2-N=V
MH;56815);O/!MUW3[R4.X*D])N6MF4]D.E#F(^4[6J*\B305E%!"0*0HC%2(
M-^B?D-GB:JB)B77SIF(4_;.KN8G<Z\VV+V.$()#!ZE?D1$Q1$"IBR4,($D&1
ME\YI]9?4:!6/<I]#I<NCI%7^^4".3.JY)</*F5(YO1H%R<CV6C:U*D\I4(90
M3#[):XGS  ")' 2+0W9S$R*;;X?SA<\]4Z'DN@*$$X&[YW=_*(IR4I%&\I_D
M3R&_I<.\$O8P^9L+9V41;/&RBN-Q/K+T[Q^_'3%N79//NY'GI<>CI#GO(3/6
M"?JKDN@E^3&\MV0SRZN#>R.8.)L*0>1&%.;VGY.FF0':=O:4WH.H\Z8/63I!
M+MI[O0E!>%(2W]V*S)!?S4*XE 5)"=D:\W]+S0X>N3Y1BW0K'1$Y&[(6\BN8
MC)TW74SFE[9+ZC]_L]#I@WU3S\CY?J-+-T=(8[Y#YVR:%>K$NOH'AF4\4$LZ
MNRZWL#^(0FT %!&$.J#P&3A,%F D!XW=^=BLB1VFHD6Y(;E1G!) Z:=M[1BL
M<BY ]%MR9A/)V$:PU] IX@#.B_*@"*YVX*$:L ^5' IQX@X%FGUE]1^_WY'3
M%OJGT/C_ -Z6'HZ0UWR%SQDW]I6)=!2"'93@^EG=V74]A?P3BQ-P])*$.I[9
M\G-5068>7VQN]]..71(^530-WS[I12*2"8DMPFC5FB#GRT2WF#U'LW&U]'T#
M%B!*Z($A*M164;B<B#,',@L8C)HX639I]9?4?KIBWU3Z'R_4>NECZ.D+_G$9
MT#5R[$EU]%JFW55_\G5W]3RN825L"0)HA!BJJ8(^'> H5,IA2>BVCU *]>M4
M5>XWWFA.O:_2);_Z$5,R_GH-R2]RDI7X@OI I#%]<?:[-&"((^<2M@?O#=FT
M8_4;XS3ZR^NF+#_:?0^7ZC2T='2$%Y&9R<@' EW["B@N'?-[R4?3<,IF03 0
M&" ?/[/!/P.G_737%HW.4%W[,BW<;[]0')5S)$N/9O'GDU//G]S3'V4BU=0-
MY /#%%1<3V>+\K5/S.#$+(* F)(N0%N$B'N=?4?\Z8M]5O0_IYC2U]'2'*\A
M,]1[^=.Z>YDD_'RYW=C_ *!;Y=$@!Y80>ZW_ (NR/F;AW6((L?,0/E)CZ]R-
MN%&*:2()+9YHJ'4G'?:C6X0%BFQK<B8&XA$"#MW[/:HKRL&PJ/#KA(MBHBO$
MR)&^<T^LOJ-,6^JWH?TTK_6M9XPDB+3D[3TP.8/-B%7/V!WFB >^[Z,']2X[
MAF\H/]7^LA!.6 _!*5<+@Y:LIX3<A<\*X5;"2Z>JB0JAQ#.[L*?E,^E(\/*J
M$)Z9Q!Q$/!$I#&," MG AZ+QL=6$7Q-ZG:-:Y 5BQ4=K>58EICM,CUS,H6T,
M40=O)6TV=(IDPXS:N4S@(JQ1GM0?.-HHV<"JP<PC%VS77>>5]L8VJ."O'"'D
M<U-.<8>;V#&Y YFPN+V\=<7CT,LO#V6..1FWHC9$+-8$^%N[F+^1\];%?;]O
MWC^/1V#[?O'\>J]=1Z\28H^LJ/Q,!$R )2BHH)3& OF.8J9"E(0ZBBBABII)
M$454,4A#&#UFNQKL',FF4QU#E3(4.YCG/Y"%#ZQ,(@4 _:(!U;E)9DG_ /5:
MH?0+=B_<%, AW 2G1;G(<!#N("4P@( (A\!Z9K/[%9M+D'C#-GK>'JS955FM
MH )^O(R*Z)Q3<#26CL@MF,<0Q3H)V%ZW</9(?.Y8(LFPME#V<F:0S@WM$T_G
M[$].7NJ]FYN1D'!SF_.,?SN'!P+YA]XE(4I #X%#JLU1S(1<@#8DFP\.8[[V
MOTL? ZD$?UC;RM<_?S%O6X\0-/@3FHM10J1G0MU3CV(F]2<,#J&[@'9(KQ-#
MU![B'N3\WQ#JZ]@^W[Q_'IA9JG+5TH.:78[%"@01.:/.NK,UUZ'<?,C(0DD5
MW'.$3^\#>1))<H"(D73.'F#/LXW A9)S6K$DA%2D>BL]?0R:KEPU6B$#D*ZL
M=/7<J*.#14:!P7L-8>G7?P+83R,<Z>Q2:I&^4G!-G&/.P/>#]GW7/<+6/(\[
M"G*X-QTMSMX<O^>GIIVW;]OWC^/1V_;]X_CU0AR*$*HF8IR'*4Y#E$#%.0P
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MZ.W[?O'\>J]P[=^X=OK^C[^@! ?> ]P^L.FFJ=@^W[Q_'H[?M^\?QZKU03%
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M3AD\4%,E'C6F<;D#O[W4,$, (=Y3$5LZ-$P3%3,HL-2#E,4Y2G(8#$.4#%,
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M>7WSEG;8N>REE)X.]T#,ZSM%EH+&F3%K86#6+YBF46^OW388BEI)MX%!^$#
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M V@ZF3(0%F69HSD5<,@C]V+@7C=6-UJ TQ8)MLS&6**3&B^,Q0YV";VV_P"
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M8OHK3GRY85/SOE*Q2?9#T*%1?WWA_?;^:OW6_P!)>_\ ]K:AD_\ ,4WV3?\
MX+^_V-/!Z.CHZO:L:.CHZ.FFCJSV%RX90$V\:G])RUB)-RW4[%-Z:Z#%PJB?
MRG Q1\BA"F[& 2CV[" AW#J\=6^79&DHJ2CBJ B9_'O6151*)P2,Z;*MP4$@
M&*)@(*GF$H&*)@#L!@$>X5:U9GHZM*?+?:FF6'!L'W3&PCQ>ZXME:S9"QYW'
M?K>/$21E[8AURN+C'(97'B+7N/'6L10?$[Y/GX+[V;2+<,#R-A:35MKP;3%(
M"JHAH&2S^GQ%*GU&$*6,&NO9.D2:<E$RQ0C3.$HZ3:KND4W+$[I64W0?$AC,
MZF;W#0V#[1LU<P. J3WD=J.>MJB:M9H^G:ZPL;]F9A+3T;+VB3@H-V6=L;&O
M,5!B6AQ(<3'3.4B):?X0\9IO"O#N-S[2HIAJ>$K22=9V!O47_L3N%L4V]D+3
M6WU9+8"/U868;.&:@-3SB@-IF*921?,F+ALJI.B>'SL#JQ;2PQ?D@PS+*.5#
M6&+R'J<GFR%LL9I1&IL*+:)O*+,K-,DZD\M]79 U>H3;">;1[TPO610*!$"?
M,:2E]O\ AR2QAJBK9>'\)@IIVFHZF26HAHN)SJM3%652Q11)655+0<8JH+U=
M2E'!54[.)93#XVEB]H8(X-TU$@%)2B5UEIYJE&D][EJ8Q'42""2H@J331"5V
M*/P\XB1IXLAV<2YPZ9L/B!:-A$91EW6 P^.4J[TRW1R,$ J,+7'HV.#T^=DU
MIM22=UC063I"&I</%QJ4C'+ HXLD<V.)ET%NY <VD<AT_P#D:SS#-7Y%Z3$T
M VJ7FO96%72^8E".]<1\=)3+NS3,2BYEYQTS>%@JY' XDY)-J=1,I0.D53$<
MOX.36(<MF>XY;H</'9*]P;/<,M.7SE5<2MD7A\H@5(6DN("Z(R[)M'"15",D
M)DSR&>KOSH/4 $A7:*C3N;SQ'V.;V^3Y"\8=VA\4T.\YO&Y+J"5OSU/2:]/5
MF!?O9&LV&!8_*\*Y@KK7%I%ZFT>*.GL4\0.BF[8>9-0ZW=Q]JZ?@SK&:N;B/
M\>XMO26X=/4_PMIN(R<.DH4J98J1H9)#PU7CG:*6"D>KCBCA,-.$ZD7\56FJ
M3-NFH:MB;X7NK%*5Q3&=* 26C81 S+%[YVRRNS"0X!VN3GB*W.T<F..TA@%4
MT;;,CV;BG<M!C\;J413(NRKW^%O;J$>.K1.VI]&HU-2GI14M!3B*L^9@:71;
MLF322=O6AU5;D?%5S5Y4<-EL^RR]76Z[>TTI=EG,C9,WSB6J;W()5* T"OV*
M?T&U0=86M4;.JA'Q==AI*0DISL"[-$J:B)5,6B_#0OV06;&;AQFY"-:%/8G@
MULRQ@O>\^3O:%]M-ZOSR]6ZS7ANVFX-+Y*F)*5D'R,7" S?1<JWB%FTBLP:.
M6#SA/>&59&F$9ADE6TO,;NK7)32+-IL5R'PJO:EGFDWC5Y-Q/V2],(IH\@;C
M0[#"S+I4*N%:N*$<2+*DTEFCUR47IN4I]OH(*H)%.9WDJJB10>&3Q+++Q*!H
M(N%35,\DJTQI6KA,*VGD--%'1K2TI9W=:4(X^K53.),I4II /Y62)'%#P:.=
M:97F+13&H3B-T;*E6[U"K4S%(ZA:;QX@J%<2R6!K''+;;AKNH9O/:V]Q=?YC
M4JZY]0:R^^29.6N;BW6B/@$';R5 S.MQD9)OW-B$OK,O*D=+U,(>>*12YZR8
MY4L5PW8-SG]RQUCL=-C:<-0C5V40%MD:C98JU#8)QBA /Z8^B9 + X.LY8D<
M(ILF:KE5=(XHNY\(M:JU##0SK2L_M6AY5G=MS">>\CL;CMGSVRU^W6:0N:+Z
M#I,A,-5JA+46>DW:5',UEGC9I!K'B9!-R51555RN/\"G&2<@\7V9GH$'(1>6
M<8YC").O1^=0%+4LMCG[DYN4M>&K.E_(E0KC1T^>+D^;\;6?4$1!PXDW+LSE
MPO?@?VZJ*M8J@>X4\E9 LTT4?"ZA:>D-/4L6I79F>5LUIUJ]^"0BJ8FEQI@T
M;2HW'W)5TV T-  P-)*49I>%"L8G% 9T1N+%P$>%E2$Q1HRI[QWZ_P"(MG-C
MH&+6EC2+<G;-@WZ>X\JYFY>0*=HH-MI3J>-H4G<%@>&CD(*CP$"I:9MPS577
M^1'T>LW1.HX H8]DOB<YAJ5WI,8MG.A4?*M<F;Y7<6W*V.:<E3-(FL[:/I";
M:)0T?8GEOJZ,A'Q,J]K3NR0S-"<28+II"BOY4NNY5/#JJ-=YG:CR@<V@\G3[
M[!6AS$9(9@Y085;2](@8:IZC?6TD$@=LJYN%8A_D]5)"-:NVYI)^8[U=(44B
M(]Q\\*Y#$[U6VCZV9):,8S]>ZN*FS'CS0FN[V%&VMW;6/A]&VQZWDY*084Y*
M1?%@9.J,*S8E2"U;N9,C1 R!]4E_\0-^B,L-,(VE>*=46B:+^6/#Z5YJHETG
M2FXAM<4XE2FD=IJ85--!.C&#W>HE<\=5X@!&R+5M"[+L92T\;1M#5N&L%6HC
MDF2KACPEA>GB:GL)'4X?:_$@OVHV7AZ[R;,-<RO*MMY8U&F0VHVV)HKZI;/E
MA7$_%6!@R20E)F?J+B8=M6LG"EDHR,D)*(9O'<?)@+9RV";7J'JG>&ULU9_F
MXTE_R;BYK#^)V[U_3,?HBF6HM+ ZJ,.^FGJ4!>;>VL!3S%BB6TNI#U^7CXV/
MBD6:CMW*Q4B\,R]BF%Z[/LJG&Q#Q&7C@JA/45E+) *MJ3,1KP?AD50$BH9IJ
M6&$<0CK!&D90NMII%,LKN]GAPX@7E>NW 3#3K9C (A.K3FH%.L+L=@%D$+S!
M9WB""7)EN3HZ.CKU6NKHZ.CHZ::.M>#Q8KUHU9Y'U)A4I3;64:KC-:=K)9Q)
MZDR@Q>J7+0$E3N4J5R+R2)&5%%!N5P=>MO) 6I615IMT@5JRCMA_K7%\72,@
M'G)>HJRBEB*X+BE83*$3&XV\;>B6Z:&8HG5T''-!FBK^<Q_,FWFFT8! 3,A&
M(.3/'3SR?MHS+P1RI8'WJF'8(!L6-Q<D"W77$X^6'#F*D@[T/=8'Z1ZD>-M;
M'73:^3>1)ZK1W34(8MD D5.0%@JHNRQJMOI-D;(IS\''RISD1A[(R>L(6STV
M:=>9K%VFOQIW/IM'#I9-8Y;1*# 2"D5.7:I0THB#458Z4L42P?)@];NW;,5&
MCIVDN0';6/?.6PF3 %T&3I9/S)MU3$Z!]7RT@J$4T:BE,F9,BI#VN" 2&62C
METB'*9\ E%5"7BEDRF !.E),%"@)': J>I;%@5+ ?>.1!%N7VVY?KKNC($$
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MHZ3HVP9.5,ZIM-H!4DDS*J*#<*^!$TB-&D@=0YAD/*1,C&08/#',(%*U>M'
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M,LW#&.HL!"%"6C1,( ^;>KUS:UEA#F3-I%$*H42E,F:VP('*8RC]$H&*+_S
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M0=52(CCJ'7]5%?UC',V$YE?6;MUO4,(G]5!%3S>=(@EOW1TL.@]!I<]3^_\
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MR2GH67FK(C:9JJPFE BXL%DO>3F?>SL9*O1U@KA$-(G6>(RQ %1424O:&/\
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M(5=HV9E,;R0LLVMDH*M6.RA0KT%Y5#)F5 (B.['.D9R=,5 ]F[&,F=Z\.03
M)B&=.3%["NJ)Q:JUAQYO7KL$OYDTT3>M#QROF221;MDDC>=L;NFFW9M$$R#^
M:1%JW2* )H)%+')X<DS>(JT<[\'LVG:!JU4XV\OEL\RB=U6R+7;08>@6G!,2
MULE0G;N_+\NVQI7;-H-B;U^4LZ\C8T()5C&/Y>138-E2R==:V4I"X QGIZ:I
M2X (2JIXZB,,.8#JDJAP"0&# ,PL3FYRE7G>*>HIVYFQ:FGD@9E[CBS1%D)
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M#TU9N>I_?_0]-6$M6K1!.):]!E%0H$4$L1' )RE70= 4X@V#S%!RU;.  W<
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M;N<4W2"+D@G$PE<))+%[*ID,6^='2PZ#T&ESU/[_ .AZ:Q[YHU7R'3^;5?\
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M#K9NZ13=-3:Y52I&>.@5\]*#5G%1/KG;'FYV7<"R@H0JR93*HI/5R.GD@X2
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MAW[?7VZUD<XWGG ]0?\ **>Y@W66K\-XWMNX21/'P,YQ]KEKSC+*<W)7C8>
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MY/IX#3ITWR+R0OQW.H+.GU4IU&?H3IUB/G-[2(0[.5:%#UT8^O&D+(<0 &K
M>_F#;MXL9?LN0Y'!TS=-Q?[]>6)4Q<7.0K\?!J-FP-6Z185-PW 92Q(LEDUC
MDL=D55GY,%?4?"00*D3PWL7[2\5]H*9FXCPB2F6-?A\2C&W1UA! (2*9A,).
M\EH-^ D,"\)QC;SW"^+5M97\2I)N'R+3TE=6T\-?'V8'2GJ)(HXW65@SRA4
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MJ/#DS"1B9.UQ[5K4)*#;M[2>/JC "P-I;64\@*LG(L'7KLG8"F^V<^NO[/\
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M.">IDW:B:%L,HI9Y?B32(5>63MN6;GK+4\#VS@A>THG&4:-:90 LPNIM*H
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MDG1S=@/^;BW\D_'YJ=1-/-*V"J@H"HBFS: Y.9JQ91:("R/)E>&.BPC634A
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M/*_C]MONTH"]ZI+50Z3FX59!1,Y$E$UK#$)'(HJ=JFFF<BCPIB'44?,2$(8
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M,NY5:&,K(/DYUE9B.7)O5#SJEGXYE*@8 +_2VR2G;L7RB8.^9<(Q>P?(ELP
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M_FR6=4U[J%E87[0'45/QZ:]KLS&GPM!86285<RS@SAXE3\^AX%-T04R'8UD
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M'N4DQ!Q$@4/=_28]L?X$$!Z!N.>'F(ND;,JJ*;EJFR7)["?LJU1BY"%20/\
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MY/N-TIP"N4;76@,U:F>N2C/10"W9E18.#.UP]K[I-BH2D:L9PIY402D&*HG
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M';E.N)@  \WJF RGG^ ^<3>81#OW[]^F'\.DUVFO<AWS>;\]?;/X^!:UX[9
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M&^8KF&Z3<=)X+8+&ZBC.\B,TJ%AX\Z6U\.W/..#O,;]0K0="WZK59]Y0D97
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M)-18JUVOF!QAI%,I&AV?<\XC:9I+1R_H5@"Q-GS*VL&*95)%_ A&@]<2#&+
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M_P!W?Y$VOKU3J=Q?J\ @W:23IJ>#:F350H]3K<!0\Z1<IB(E>C2ZM',(I_(
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MYNGAUQ\_F_+3?^3^K_'7KY=P^W[A_#H[A]OW#^'7D&_E'/$,_7QYF_O0[?\
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M_P#CGH_*.>(9^OCS-_>AV_\ CGIM?-T\.N/G\WY:;_R?U?XZ]? 2IC\2 /8
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32F,$QDR1G)2218]W+'_G[M?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g209163.jpg
<TEXT>
begin 644 g209163.jpg
M_]C_X  02D9)1@ ! 0$!KP&O  #__@ ^1$E32S$Q-CI;,C!:0E8Q+C(P6D)6
M-S0Y,#$N3U544%5473$U,S0Y7S%?0D%,3$]/3E\T0U]"05(N15!3_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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M%S558W24H;$V5I6SM>4(&"(D)31$5&9S=7:DI;+3U-7D_]H # ,!  (1 Q$
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MUX)7HU(0SJ!ZF'4$ AU.7D9*413:<.TH%+S5:?#,]*6DR.S4$X9&DXYEXCD
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MARSSRRRR$1$1X$F<<<<#Q#5Z$@S(HY8E*-Q[#D68I(+SQ#( RQ'+#,S'(/*
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M9;'VMLS.(5R)KP+18*,E1^)V>91>6!)HXV]\!QQQP'''' <<<<!QQQP''''
M<<<<!QQQP'''' <<<<!QQQP-;/U18S['S:&:KUAKX]63*5<X>]DO.6M=$W(B
MJ:\;GF#!0KHX4U-H\VY/<9>+6KC7JS3&>Q;<K1D>RSW)B4-CPM;G%"SFBES[
MZ243VECU'74^[.Q.S*Q)L_;*[;6U]I6Y9\TV5:5*:\S@V..46K^929E='M 0
MJ&:A8$K9HD6\.OM#C4G9H>"LHIH+;T>)G7/BT-ME[T,H9GIBW;SVIL6Z[2D.
MK\6K/:AQTX:XTLKBH'%YMNR9A=K0TOKRU$1" . ELS(P-><A?U+LN0MBHG')
M4G6SYT4).QK]9K8KH8K?$ M*AMH[4IG8&O-@-D'G;*00>XH\R05Y<6B&WJ]E
MICYC6J^'R"&R.+B0@;2FT]Z=D*A'YQ*6JE87#CD " =_$?0 =Q'M\H@'?L'Q
M=Q[  ^'?QYTRR#'MW\H>_P#S<<LA_8Q 1#[8\I.ZIS+-&7:/I!V/';?N!D97
M?J,5O44HIYBDZ1LI^4,[U2NQ\R/E4LC[>R$R!^E")9&&MJ;LW25GQ1$U"?VB
MV;L=B[%UG==39BB+><*@41?9VF&6+ZP2W>2O+3K^[VO=*.U79>T%8U57#@V:
M_+9UK;(J:/16JWMKPIS@[<XV@.#\OER=T@L2L]<U*F0H-AGJ,#WZ?.](_+IQ
ML\/B @/O'SKT@/B'VA\>3O2/O,5-^IK7OT39.5"[:VGL@?T?UCE6&HK&V1FP
M.F'/7BUHA9FPCY!YMK<2YZN">9"/-,AJ^P)':;_#VU>\M[D9(9%$GM4ZQHI,
M]J07O*M<WV^4H&(4W5 89#G@%;U^&&0X^2.6(11E\G(<>^7DB(=A''RLNPCV
M[CV[\#@G;=]].R/N^FGTG=N1WR1+=]].R/N^FGTG=N1WP'''' VN_4</PM4D
M^:!=7TRI_G*>\XL+U'#\+5)/F@75],J?YRGO <<<<!QQQP'''' <<<<!QQQP
M'''' <<<<!QQQP'''' <<<<#7QZ[$EUT72?IQ4?L_'ZCB]4W!M0_+I+M-<-F
MV#1S;KBQ5A7*V5/^$"NFN)/"72O[>MEK4&Q. GR64IJ_<S6YR3RMN78E(%35
M('J?N9UL^Z965!*LK>G(C&J-VTO6H3+(U]EDYL*GMFG)I.C,H/V*A]BV:[22
M?SS.8))8ACDCD<EEDK-.DT/=$K.\EQQ*S,S3\#ZH NS9BIZIHIEI2H,K>@D_
M?K@:II&<]7H]M:V3*X4=7G)M4:BE4+D[1(&N'0RP;??!>GVR<&G%>S'5\W,"
M1V;@DQQ+AD)T3WR^3M8;.KR[9(=/VZB-E[*HVGK1SH^*:\)K&KNOX[ TLE<6
MFM(2PQB+IX]#[T5W'5\:E#0P-">9L,&02+)*:>M.6* N$S*+,$L3"\,Q*S T
ML<\,<Q+, ,L0SP'(!\C,,<LL0SQ[9 &0@ ]A'O\ GDD39@(9$$Y!D;Z_D E%
MCCD=X?[[ECY/;(T.P=C1 3 [>&0<\CC@8:=1@.W3YWI#_P"SC9_^)"=?^>_)
MWI'WF*F_4UKWZ)LG((ZC/P?.]7S.-G_XCYUR=Z1]YBIOU-:]^B;)P."?MWWT
M[(^[Z:?2=VY'?)$MWWT[(^[Z:?2=VY'? <<<<#:[]1P_"U23YH%U?3*G^<I[
MSBPO4</PM4D^:!=7TRI_G*>\!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''
M' <<<<!QQQP*N.HENS?VLL_U I+5R@J^V*O+;>P[,B,9A%@W*=2;:VL%55HJ
MLF72[*49163(CT+,W)RB5Z S#!S4G+FY,R-[PM5"G(Q'Z=W6$OG9S8W+7/:#
M46(:]/+]*-J*TALBKC8!ONU'A=&E\BAS5?=839MQB<:4,IB!CG\4EL1F3$MD
M,3D;6XDHRE9+B;FG1^JZ^A\"FK-I=K?,-5M>M@7:^;MGN$(G6S>P,ZU=K.EI
M%6-6.D[.4%775BMHLF/2^P&E,N8XTTQQ]1II":U*D3HB=!+0EIIQZ1NGE/5?
M5\7M W6K3&I;>KIKG=#0IWU"N29[#0YIIYUE2&R')N4V9/3C7U9/I3-W=S=+
M"<G/V=*'A,BBZ=XD*UM2-K8W!='QS!#9_?*(ZPWUJ/0#]5ENRAXVXM]GJ.-V
M R1)8FJ"%NKNQ3=^(*E5DKR<8]G*CT<&=%+;7C8<HE;@TXJ'X2$C0CR4'_)[
MW=07\AP]4O7L,U]LG9NZ;R:+IFD2JVMW^#11816NNL.:IM<4S<I'/W=J92\V
M-MD,<;(]'21.=I?(WQ"SM@$F#F: 2AU&?@^=ZOF<;/\ \1\ZY.](^\Q4WZFM
M>_1-DY@[LO?U=;*](C838&MG!29 KUZ=UW6G!P?""FI\SCLTUQED@;R'-KR4
M'9)'9"F78I79&4<J+2+B5!."@XO#$[/.*DO>8J;]36O?HFR<#@G[=]].R/N^
MFGTG=N1WR1+=]].R/N^FGTG=N1WP'''' VN_4</PM4D^:!=7TRI_G*>\XL+U
M'#\+5)/F@75],J?YRGO <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''
M' <<<<#6:ZY;XC@[:PN6V%J]- FHY1=+:1JU"MM]'K_VOEC:F0TTG)M-*GB5
M-.<@?WZ4*9D N_MN:8PT1V.054U,#X:<\J49RG-#H82"KI)I:[.%1.&K3E%<
M;QL%,8HU"U4N33RJ0=R&:%>S25%3WDVM4T42XHK-(#W+2DPLCNE%J;T!QBAE
M7>3 W76S<6>0Z#3.G+7V#@6YD:N:WT^KT4U6UNJW9"\+#&24NY,EPI$;'<LG
MBE=QRN(Q CL7ZQGN3+'%L+(\R*1:#5[<@<6O++H[7C/+UU8DSQ;6PER7];T)
MO2QZWM,C837FL]8[II.9Q=+&164?/ZPJ-<Z0G!RC:->BE#?)FUT<?;,QS-M7
M">67@4C2ADGMIJ9^2@E6F\F]O00O\B9MY#MJ/8?M;]L SH(G6-LUS[2 4>>V
M?VM^SQM '?VP^LO8)O,GL'S*<+@"M%ACLQTU]GM@9['+E;]Z6:%W/5M@[8M-
M%RI3J\Q2&-U[J?MG6T(@<CH)[B+?:D1-G4Y@CK"&^<0N\US^VKC7D"6Z2PAZ
M9B3DJJY?C@4K[C=/#4JNND[8%3O=+5U;@:<=/"ZJYI"=V]!(C.I]$R(7K^])
MB)&SO[RSJ3H](W5UC35)7!5' :B"GQ(C5-Y"/%O08IK5J4RRSIJJ,\\ARSSK
M>OLLLLA$<LLLHHR#EED(]Q$1$1$1'Q$1[CR!NHS\'SO5\SC9_P#B/G7)WI'W
MF*F_4UKWZ)LG X)^W??3LC[OII])W;D=\D2W??3LC[OII])W;D=\!QQQP-KO
MU'#\+5)/F@75],J?YRGO.+"]1P_"U23YH%U?3*G^<I[P'''' <<<<!QQQP''
M'' <<<<!QQQP'''' <<<<!QQQP'''' H.ZXQ47=%&D\<KV([42??IXMZRS=(
MS]/K,K>G;39CVJK5:S8%3(;&N5N>ZI9*F65G[$;YVDEC(X^>#CV%$DQ3$BXG
MA+G1 &I2=7;7:H;&=B(M=[#M1;K-NTCVPF,=L38%9MZG;88?.W2=SR&%(X-+
MD:R#*:X""OD%;&B+*( 5&BDC:0N)<,SJX>MC=SW8=X-5#N&M].+EVO#M&+,H
M[9Z*];77SIX;5UO*YW R$\M,C$<E49>YY"FQW9W)=%7'![(<62<L6"&0($Y)
MI+6J0V4=#QDB[+IF[!'JGBM7.3G>5DO,Y7,6[T*ZA,EMB>N:2+JI%;]J;+P5
M&WM<FLV5F&$(7ID5HTKA'6EC8D_L5(WJ$"4H+B^.=HY 'I[_ "^&.0_L]@'M
M^O\ 9^0>=1$ ]/?]8!'_ # / PUZC/P?.]7S.-G_ .(^=<G>D?>8J;]36O?H
MFR<@CJ,?!\[T_,XV>_B/G7)WI'WF*F_4UKWZ)LG X)^W??3LC[OII])W;D=\
MD2W??3LC[OII])W;D=\!QQQP-KOU'#\+5)/F@75],J?YRGO.+"]1P_"U23YH
M%U?3*G^<I[P'''/42 '[)B>0BYC25)1:7((^8_DK3V,M\%$>#1F\$-IR=P.:
ML''V-DXE(3R5AB(#\$IQ1^19F(>WXY4F8DZY"=)D>?-.E+EF0ER./ JK=Q<<
M,C"4XFG 5ZY;W<,,L\,P*#,<LPQ'$!\K+TP#J9??6DVZUHHO9V).?2_B,:O>
ML8I:#)%Y#7&VS@]L#;+&_!Q2-3HN;+<Q0*UR0K/$M0H2EE$&&=Q*P\CR<L@O
MJXY#%!%;!DUFSE[/KZ<<[A!:]B_*Z'9YRQ5MFW"[*ACF+0VV*]R&5$K2V/V%
M@]9K70X@YV!4:@+(1Y%$X3/P'''' <<A2_G+89IKU0KUBAM/SJT@=V@M*P7C
M8LRJZ"&,9A^8/JH^502M[4?RG1*F O-K0EQ,Y(N.RS+5KD.&&)F=3VR>XG5O
MU9J_&VK#U/Z>SM&\K(I2K@11#<_8Q>]>V"^+C@M'P]7['=]+F1%YH;I;8+(O
MD1_L_P!F)8^G<E3<A=%Y*=M5!>9QRJ\)UUI/7!Q'6/IGY%XFCAD9ANWM!^6P
MP,\C/,O$S1?#+QQ#+(L#,<,A_*AGC@(CY-I9(G"24*C O \2RQ.P),R-*P-'
M#$3<2C,RRLS"\3/*QPSR*+RSP ,LL,!$< #]>... XXXX#CCC@....!JM^J)
M8FTUPKHZPJ@TCTBLVX[M.NU+-+UV$T=@6T4G?'JAZ#73^H:'0J'J-KCB)7;Z
M6-O\9@[E(5V2=OQB!;4WB2FS4%99C^I]+)CEC:C71[3#-='J%0W;RU8=#; U
M/UC8M3Z&M*,I(15#NUSJ&UHQ-;2"A>HP><V*:/3LF.=DLT8GN)"Y/+5%FEX7
M4<]8CJ&SJN.I!?E.S'J1;"ZC1*$3OIY4W&JKII4>P,CEJAL2P*9)N]>IBYIK
MZ4.*6WZN3+&=? [(:G=OF4+0%J&J--;N*XK%#>WT!;U.O#42YR&6[)=L73U-
M;K;'TCK9=%A>6IL"?:[1%=%7FLGF;OREAC#I+))DCE2\A;*7MB;7EW+*3YKT
MI9A6.&(5@]?!.O5;<3$B8XWAG)<^F^R^Y<X5CE:N.674@PVB=#',*Z&O1!N^
MK#[6L:<%;Y_$,?J8!(1[@Q ^"'D]:N[J5O\ 34$Z/5HQ(PK4]WW-K2T(->6H
MVV=HT'9>YD0IJL/85&.J^H9)31">9*\WM>15TG1/DDB<@5R-R<JY]N+K&U#-
MS;\'$!'N/?\ 6RR#[/B " #^OW^,/0(\Z#@ ^/Y;OX^C+(/3]H0\/D#T!\7;
M@4>;5S+:<SH]KU<!U;J*"LTFZ85@+;LK6S+PG];RW710JU9,S5UU#HRCHZUC
M)^X05*H?&3-%+Y9 5GG&.MK4XN1>;FX/+1;G2@8A3=4!@.66 5O7X8998ACE
MEC[5&7R1RQ#+,,<A#L(XAED #W ,A[=Q@;J,>'3YWI^9QL]_$?.N3O2/O,5-
M^IK7OT39.!P3]N^^G9'W?33Z3NW([Y(EN^^G9'W?33Z3NW([X#CCC@;7?J.'
MX6J2?- NKZ94_P Y3WG%A>HX?A:I)\T"ZOIE3_.4]X#CF#/4EV:GVGFEUS;#
MU>RPZ03Z"!7:.,-4_(?%,..<)W;,#K@3W]-&G-F?5")O32]0X^L-CHB4&GI"
M2P.##+/'*A$[K&=3$HXXKS+H2/K1II7?ZF^R8=_6\\L._8;J\._D]_U^5K;V
M^&[>[&);86W=IT;/KO*,7$MJ:[>\Q^+1@U44XLQ-K;X\4Z)Q*(RKFF9S_<Q.
M4Y5_;6].P-W:[?#VSM&BQKNJ<2NWIJP+K&XE.%513B3$VV!C13IG$ISUS3,Y
M]V>4Y;8KI_Q:O_P)7_\ S&\K+Z*/P2W3O^:13'T52\IE4=8GJ7J"#D^;+H5C
M@>2:3EEC7&R/E!B:7D7D./E72(>4 9"(=P](!R!-5.H-U!M2-;Z2UE@PZ526
M'T56L6K"-O\ +*WO\)*\,\3;\&U$XO@,UP(6H'-227CFK! D(2^N"/K)6&';
M *_\+/D]_&/!_)^U_P#K_?*?5GXGPF;C?+^%]2VGZO8O7]D^ANL<<U)_=D.I
MC_>30G[W&R?XZN7$=*+=*[-TZNOA^OIBJEFFE.;#KZ?3G4\VS-HBCRQXU!4-
MFHG,UOG4DE+T0[8*+(6-BL<7,$1A+>F-(3%YYFY&>UL+??=;>6[Q+'8>UJ+^
M[PK>N[Q,&FUOL&:;>C$PL*O$FNYM<##F(Q,?"HTQ7-<S5G%,TQ,QZVQM\-V]
MX+FNSV/M.B]N</ JN:\*FWO,&:<"BO"PZL35<6^#1,17C8=.4535G5G$91,Q
M:AR'K7V&H*A_,7U<+PJ"F_;0+B$:^JK9D*KOVPBS@C%V!C]N#XS>=A:P<6\7
M$&_V1[!!<C%5ZU[*(]<F'FE1ZK81HUUE=.LE<B1+B0B.XAF)2Y&E6E8F8N6L
M>(&8%JBCL,3 QRRQ#/'$,@QRR#OV$>6"_NXL;.XNYHG$C PYQ)PXJTS5E,1E
MJF*LO'QRGH]R[N(M+;&N9HUQ@T37HBK3JRF(RU959>/CE+:5]T,T%_1OZ@_O
MEZ4_#?E:/5KW?TNFNG13'#MN]8)8]AM?T^7D6>-7_4S\Z SQG?76^22-U%O:
MI<K5@VQ^/-3F^O:X2?8S4S-R]T7&D(4:D\KCN/:]'OK>CW^(&?\ H/.[%A8<
M!\K!A8<,NPX^5@QM.&7DY ..6/E8H@'R<L1''(._;+$1QR <1$!IOGSA_)U?
MUJ/^/[Y3ZLZSYUT_S&KZS'^QU]Y[N5QQZA>@V/E .[^H("!AH" [+TJ _P!L
MR^(9N A^N #SN]T,T%#N([OZ@@  (B/Y)BE/  \1$?\ VW] !XCSBBO:]'OK
M>CW^(&?^@\_%1'X][&5#[7H]X)5(_P#$#/\ $08(?\BY,;\X<Y?P;5G/M4>K
MV?WRZ9S&]=,S$<C/?[3'J^8Z^\]W,2QZ0L$N866511\9Y-&)(U-[['I''W-$
M],3\R.R4I<UO#,\-IZEN=&IR1'DK$#BA4GHUB4XI0F.-),PS'W', NE+\&+T
M\O1_[DVK_H   /[#$.\  .P  ?$ !V / .9^\OD=\1/I6Z.^(GTG''' <<<<
M!QQQP/#-;T)YF1IR-*:9EY(Y&&IB#,\AP#M@(YYEY9#Y >&/<1\D/ .P<_8E
M.0FP$M.241@.0YC@27@5B.>7;RLAQ+QQQ'(>P=\A#N/8.X^ <_;C@....!AI
MU&?@^=ZOF<;/_P 1\ZY.](^\Q4WZFM>_1-DY!'49^#YWJ^9QL_\ Q'SKD[TC
M[S%3?J:U[]$V3@<$_;OOIV1]WTT^D[MR.^2);OOIV1]WTT^D[MR.^ XXXX&U
MWZCA^%JDGS0+J^F5/\Y3WG%A>HX?A:I)\T"ZOIE3_.4]X%277/\ @O-D/^U]
M>?\ 6CI+FLJM_NU9_A:G_3F<V:NN?\%YLA_VOKS_ *T=)<UE5O\ =JS_  M3
M_IS.<O?LA/C'=?Z%M7\_8N=/+E_'MW?HFT?SUH\;CCCG/#"CE\WJ?_WK-XOG
MQ*/]4W5?E#/+YO4__O6;Q?/B4?ZINJ_-O\@?X8;2_NY=_I+9+8/(I^%-_P#V
M#=?I#9B_KFEAZK/]\[IU_<=N+_XGK%S=/YI8>JS_ 'SNG7]QVXO_ (GK%SJ'
M>#XFVC]'J_U4NCML?%E[_4S]]+4NXXXYB[,3GXJ?[F5?X*I_T!G/VY^*G^YE
M7^"J?] 9R:?&.L?>FGQCK'WN4IZ4OP8O3Q^9-J__ !,0[F?O, NE+\&+T\?F
M3:O_ ,3$.YG[Z.;]3X1TC[FO4^$=(^XYA5LPEZB!\NC^6GL@TQ:()C&\L901
MLG#;VD<L-EWG14.!K KJN;Q=F(CGF7V%ADG<D:AT%TQ5&@I!)F25A\S/.HI4
M,)M.S:A;JLVTM*3T](&2)V$X4EJ7>5OP^/RA_@T4LA#'C9E!XFZ1Y2\8PV;Q
M9Y6(4JTTY"2\)2E0%G#E@'S_ +I5 ?T+G45_@^MH?P"Y*6%;SL#UHV;;&N]2
M#G'I@'RRQM?K>V%02XNN=M<(^V,-/6'4-=.T<6-^=NBY'N[RON)G<FY83F6D
M3I&=Q(4%9G*4>8YR4<CZJI5H1DS9"4=/QQIG$'?VX(Z2@.RC+9IPBRN ,7M;
M<Y_8S[$TP82$6LQV\ZM2KUUFQ7DHO65YB8XO 25;8'NO4IHW9=%J5U!C*G@^
MD^SM)R-XRT3V1*<DE@V=>&K\XA[82PF0?%V6(UT=JR7*U+LD3'-K><C2HUJH
MA4XI2LLZ_=*H#^A<ZBO\'UM#^ 7 L;^WQRN9OZFE+Y2JOHK*:?W-K'ZIEBPJ
MJ8S)[8TSV!K>#>WFQ'Q/&X8S.\RE,-0L+&+\_*TK4C5N:M.E%:I()S-PR-P[
MV, /< $/0( /[/ Z\<<<"G??WJT%Z1VR]5JQ:SSJ_&^HM;T.X6T4IB\[B4-&
MF-;W&TU-5)I9'F*1HU2BU9@#BQS*1'05O7Q82HQ$7!8,@R7*T+>;*&]'43=]
M5W2@('2VN\CVMN'8J*W;9D)@+%8$<JEOPJ?7F!,<_LV7+)=+FEW3XNWL*5Q)
MEAL3\T%J9-(7\A(J<F)&F5+\(VWUZ3:;=>WW>S6G9&<T6TVYK>CT]VDB$8A$
M4EHW5K>WV@KM-+$X[(9"J3JJHF .C[,& Z=-S?*LCHO+7%$$?+<$R!S(]1L)
MTMKIO!_BUA->^$OK^UZEGFRC9K],T% 5<[M]1ZG[.UG!:VE>L(Q<'-F(G*B)
M8P-JE4$NR4.9LX120<#)$WR1N(!"8$L[%["0#9WH_7WL17QZQ-"KZZ<]U6M#
MD4@+(;G].R376^62!*WNJ'$\XLIW:RUOL%V*1GK$A2U.?[&5J4PE*#,V:3>&
MG&G*D)R<V_$W*M:Z\DL5R4#!]=B3%D7VP$[RA\O'+$<.P#Y898CCW 0$<>(_
MTT](TE&Z]4#/-<JDO*&:QU1'Z=JI;>]=PNU)$SQ-C9F5G4CYSE#$LQ)6R06%
M Y206U.@1.3B5@:"(DDA,01^ =++II!V - --      -;*B   /    B?8
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MUQ/T\]*$YG8<?7$^L--$&>2/;OCZX3#\,_)'L'?'OV$0#N ]@YY'N6733_0
M::_O;*C_  4X&.W7)=VI1TOMD2R')O.S!UUZS' I:E,R#'':.D@'(0P.$0Q
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MV[^@   ] !VX]REZ8OZ7CI-^]?IC\#N3&XT1,3VGX>Q]/:NOO/<C=3++]_\
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MHY:.N6S%46DUZ=Z;M]20^EKS@TTK@*!KPDJ43V?S&BWJNYB8RD0X8ZO,A3%
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M,NXM>#78Z8UPY.&"W)0E?GR/QB:S*"&E)5#5+8;#G61MR\&UPCAKT&97'''
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M,XX$K6#K+M+NK;3M>%NZH%4U&UDKZ6L!74A:L[I:>N\BB&KNV4ZV4V+GSJ9
MYG.H,X5^GSGJ.,UO'5[O[<IJFBKR\NL-CN3NULQ_SK[TT+&BIDWE5=02OZ1D
MR[?OJ#WTW6_#TD132. U-?N@^PE(5]8J(N*D9296H06;,(*O60ID)424K%OP
M=LF8TQOQ,Q<<#!#4*+MU^6#6%7ZWZ\UM66)?2/K75.YI[45FT%8#1*(--]FJ
M$CDVL!1)Z>F;ZH31Q34[)><PJ(NVU<1OZ:.KI+Q=ZDBKDR2!0;FO8O3OVIBF
MQFT&TD&?#"$]JVALU7,1CCD\11>S:Y4S>6H%.5PR[IT,VH,"'N-797MH5@+'
M9#(6N6SJ<T/DY1B#M:52U,4?ESC@1WTBW2N93M_KX=55 UC5;?4O2$8ZCGTU
MJ>P:0L]DL%[(NNG_ &H/BF04A))8<CBTD"+V%*:Q/NP^$7/)\%]@J9-5T1<6
4%[%;M#\<<!QQQP'''' <<<<#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g252607.jpg
<TEXT>
begin 644 g252607.jpg
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MRN218??KC.0O_">45&75*!7*!6'E42WI E)11)4(&24=4:DG>W'AT#_V?_H
M^&_OXWJ/Z;PMYA]QVX5DV H_.=T9,NH_D&6RU,ULU:E^/UW_ !:OI@E&)0I$
MAXDYBD5S59FYTTI6//XC'PQ^F3XHNV.#;2=40^?$8EM[GZ;DX\W;_,%PRR;D
MB8U=XHCC3VU=JXD'Y5?GHHB10JI"PR^+VQK&^V?PW/@X=''PK;3=JXZ5Q=T!
MC-Z ,.KLT_O#W DS6)XV#$Y 51?*HWTU4E?(V7)K/S;T6=26K U48D*=V5C3
MG_?"Z4K$9\1WX*'13\4O.=N-PNJ43=8G(=K<2M<+Q9=OMQ'X6$REN+EEZ8E@
M*RDM5,*4YC5C(\6%&PHD:QOX:YL@?AY_#FZ<_AC[*W^PG3)!G ^!9)N-=;HV
M4>?9:_,KA<IOJ+&\>/</9OKJSP*]:[%:KP@FCKV$(3.Z5[R'<3QY_?[>R_\
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MEL$L,IM%F,\PWQ85'B6%/ 1[LT6FE*AWT+=#FQWP\.GB@Z8NGB++8=L<;O\
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M1W=B+!AN.<JO"2J;D'@$S0HO#E2 5RN9_A=RJ<W P[8K:W Y7&TF(5LML_\
M//?W2R9!D$\GU?);W'FRT<Y?558^-.7.X1J+J[??"U/5S6M:B>BJB-:B)PB<
M?X4X3V_RU&)& RZI@=@"V>W=G '?OA3WY[XIE!V!/;DG _09]?\ [?I47#0N
MIR^A(L+;*]MMIZ2**0HN&FKCLKO10A8WS$2S6)L@U4DC(&R/<L43F-5B<.5.
M=0\Z0#K?JJ%W.DWDW SZSL\3S^PCQJDJ\DEH*>QVRLD=^$+<ZNKX8ITM3&0&
M07"Q%-%6>.+RS&-1SEEIUH9_)AFQ.2C59;8;C-IQ<'K9(GHDT#;MLOS4J)4<
MG"BT\!DG?Z>&YS5145R+K&MT89R)MOOIC0[Y(Q:;/@9<"M5F<J1#D\(?B_:J
MJC&<68R@PR/_ ,2'R(U$5Z<\[[5E1&)<'&[<Q(P>%)&<  #).!WQSP1O1=T;
MN %8?AP!P%P3[MSVY/? 'M662JZ8MBJA[)HMM<=/):BJIEY$1?%N=Z*BOFMB
M"E<Y53E7<<JOVU=BLQ/&J9C(JC'**JCC1$C2OJ:\7PT3T_*L,#')QZ_7G7=,
M*'[?S$0HO<J?FE8B\I].%=]/MZ_UUKYP7UX(B7CWXD:OUX^^ND)&,8P..PVC
M\C@ UH)8\$D_4D_S]Z^J1JBI^=W"?]OHB<?;A/IK?PGZ_P!5_P#>OGX\*KPD
MC%_5'-5/\EUJDL2IRDC./_\ )/\ WK,%1P"/U_O]?WBHY/I_#]_*MW:W[?ZZ
MU1J)ZHG'T_W_ ._?6WQ(U]GL7]G(O^BKK>B\IRGLOJFIX^6<=O4#Z>GI44TT
MTU-*::::4K1R(YJM7V<BHO'OPJ<:AQL%T2[8]._4=UD=36'7^;VF<=;66[79
MAN=4Y$?2DXQC]CM-A$N"8^-A E=1UMD"$9632EVS;NSO2)K!W>*0(*U@K9C/
M56L>J>Z-<J?NB*J:Q)]#?5[O5OM\03XMW3UN#:4)FV?2'NATU8MLL!6XZ%56
MM74[F[.F9CE<=[<C.\SD,I%X.R8.8YOB@PJ\>)ZPN:R-2LMVFFM%]E_9=#P"
M?:E=;<MMWU5@R@E!@NG"3-K)K..::OB-5BH.\V(=S9Y!FOX65D+FR.;Z-5%]
M=1XEP;J4M)'K8;WXK11N5/\ A\7VZC>D:<JKFM*N+$J57>O"2.;SZ(JL]TU)
M=KD[$<J^GW7]5]-?!\L3$<YTL:(BK_W)S_-/=%_3Z\>FM+C=CEN<' 9@/3'X
M2.Y]_P JR!([ ?4@'V]P>W]:C<S9'<@GUMNI'<R15_QMIP\<IX_5$](_#KYG
MMX7GU55]./3GW^B=.B3HGS/>G?&R<O*/[\UC%C?S[_PPZV%&\IPGHOM^OKJ0
M4EI7QHG>3$SA/7N<UOV]>>?77$=D%*Q.7V0K$]>.Z5J<\>_'[?76LHO;&?JS
M-W R.6/Y_/-3N?T^O"@>@]A[8_9JPO\ ]+F!/X\YDNZ5EZIRAFX5TJ?1.>(G
MQ^WZ*B_JOMKZKTJ;0/<CIA,K+=PO<XG.,H>JIQZ\_P#,4157U5?1/75ZURW&
MFHY7W(+>WU=S/%Z)]U_/RG\TUQGYUA\:\.R.H8[T1K9#86<JO"(B\NX1%541
M5Y]$7GCZ:C;%@#:GI[$\8'J3CWR?7FFZ3CEA[>@[_D._O6*'KSP_$=FL8VY
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M/7_QQSZZ^\42L=QXCG(WZ.]O1>/3[?YZXMS=U&/5I%Q>V8%/5">#YJQM"X0
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MWR2QO>; UTL<V$:U/9./V543^G.B-1.?=>4X7E555_=576@1 $$$X'./4<8
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MJ["WDC-ODP6M=AU?E8U8U92P351G?W@&Z9]%9EY-6;X8[7(1M28)B5I/NIE
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M* 0:ZR>PC6"L;<6K88*JD2T*%I:Y[3+0V:H"8 ,BRFQC_P"%-MIOMMG56L%
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MY1&DWQ?30*A<;PLIVPAY9E!AV0) -@*,< <+,*8&9!$4(6(5"Z D8D>=LD)
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M$''+C!C,8D$*=K9?,>,YW,CY'R*KUBKFOP;?AYYJ^:>?I_JL<(F?XKYL1O\
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M5VQQ!MB#G;E@Q' &!DG Y_$!W!-2UTUUU1:!7E5675;/YFNMZ\*T )\*:#S
M5@-$6+-X!#(IX?%@FCD\*:..6/N[)&,>US4['5>"#V_?K_6IIIIIJ:4TTTTI
M33332E----*4TTTTI33332E-8.?C-?#_ +GJ8V^K-]-HZ-]MO3M+7D#'8^"C
M?/9_MNBSGGTX,:HB39'CYJK;4D'#GV [[&K8CYIQ6IG&UM<G/'LO"\^O/O\
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M>]R]J(G"JG.G>R.)\DKFLB8U7R/>O:QC&_F<]SE5$:UB)W.<Y4:UJ*JKPFJ
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ME>ZRLI+R14&51G5-P5V+,Q PJH"Q*@EW('E0,>6VJUV8LQ&)G/;15)%I*-)
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MU8!-Q[^2[?"UT\C(HX)E#@!CB#;X[W*L$OC1^8EC\%JM0IA/>V7B16JWE-2
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M^-\)]M/A#Y=6VS(<RW^??8+"1$XBGVOQ>SJ[N[&\9'3!?.LM? %2-,B1T!!
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MY:65CQ'#'_\ )(<A<CCOCNL[%KH2RM)%!;V\;232ROM "X\JCN2<\GLH()]
M<@\Y<F4%#/CC?'C SVD_QXU9+?F1/Y'<D$B=S*85Z-(8]Z(X\EL?Y/+Q\R0W
MZY"]PJ[;?(#,!,J1;$O#[BHB;:UAMM-.)8R1Q9 /C\03F/'R=]=(V>JGED9$
MU(92'O3R_"Q?Z1?B36F^&[%;M=EE92QF68Y(WFJVWK3%AN:N3P+!H# F11S
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M4VSWG6RAN<Q)5K1R7Q@#2JBO?! DW'+VIJ25-C4,<@MK;R/M+GM;,DY#W.%
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M6:'U5$5XP<<+G.1.6+.YGJKM5ZST3VX]5^W]?3Z+_/5KI<;?ZBY<[FF98PQ
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M*1M*J!(,97CV[\>E:7LK*3?U+2U?J;3)OMXGWE&W+N+(=VUAN7.<'D<U:_\
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M#"9!,88C*H($O33J#/?#A0PSZX//K5O]U\AL\1VOW%RFF?#';XU@>8W]7(3
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M@>99VB1IE78LC*"RKG.!GMSZ]\<9Q6P32K&81(XB9MS(&(5FP!E@/Q<*, Y
MQD#-:(U$]DXUKIIK:!@8Y_,Y/ZUKJELU@RXK%[@;!+*CI\L)%?!36N1UQ=M4
M5Q4JHQ#2:P(D.<YPS%=+ -YF**6=D;9U6%7M=9''<>W.NK6NQ/(LLEL<3P.
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MQW%N)=O)!KK!LIH"@;F_Q^)F-VV39F5;V]V=A!'BOM8:V:K,!IXLC)-:-/\
M,B:J>.5D4HLB1L[.R\">R<^_"<ZHY^"TC ,6JZQ3J$##[ $^E%HC9Z^%K 8I
MH5K36-=(A]29#.^,X(KQ&S\I*KVSL;*E9:A=W.<>G;'?'/\ ']>_RH3G')..
M!GVSP.Y^OYD>U-%_3]/]?7_+336516SM_-W<)Q_/GV]_MS^OVU2-OE5<BY-3
M4UWC[\MQ^ADN)ZLPY9?E3"!R751N0!U[I+(2J)F'>]RMB822/!/Y-'/:CDJ]
MS>Y$3GCA47VY]EY_W_3VY345\FVMQ*_SI^&UVVV2U6.6MN[</<_.\<R.? ZN
M_P BB:DF/UE^8!)%DNX,DTD<LTP 9D%/C\+(F%S<DQ@KCA<;6+8)P".3G(/.
M?3N>,8 &2!FI SGY#Y=L\]R/R [DU<4#=AIU-@-E2TEEGD666$-/:W^(1"@8
MQCT\$3&V=Y839?9TQL-"TU5&KXA([.W,<^.,8,EW>]MY4]?]_P"_]^^K-9/9
M[99MM=;EYZ"]NVQ:/ MX<QJK:D8HH%LRO@.(&,B%M@AFV0\)-=;*T5R,2"SA
MGCA<R=UW VQ,'A9 Y'0,BB9"Y)%E1T38F)$Y)7/>Z5%C1JI(KW*__&KG*[N4
M",[?EGDY./0_0X./H>*$<=L<GO\ EZYY(SR !COZ\<G33365133332E----*
M4TTTTI33332E----*4TTTTI5J=]?,_W*;O>3\QYO^Z_<+RWE/%\UYC\'W7@>
M7\#^/X_B]G@^#_%\3M\/\_;K\OS9)_47_<QM%WOWH[_[L,![^]V?]_=^%*GN
M[_7_ !<\]WZ\Z_5/.."K B[&R+&KZ\ 4@TXXV>(40,,2%Y!191,SV0CC#01R
M3SSRO9'#%&^21S6-<J1FK^MWHRM@ ;6JZM.FFRK+,,:PK;$#?7;0L$\ V%A(
M9H9<&320%"%#R1SCD0R/BGAD9)&]S'-<JE2CTTTTI33332E----*4TTTTI33
MWTTTI7%+"$L!)P3AAS BHGP$B%P1$C$P2(K9()QYV20S1/:JM?'(QS'MY1R*
MB\:^\<<<,<<43&QQ1,;''&QJ-8QC$1K&,:U$:UK6HC6M:B(U$1$1$1$UOTU&
M!G/KVI33334TIIIII2FFFFE*::::4IIIII2FFB^B+^VHR[;;YV&7Y+U)UN2#
MTV.T6Q.Y#L3'MAY"'N)Q\; J+,3KF]\RY\<4\"V9:JT!K8F P0JK'SK)KGFN
M88)+>*5MKW4CQ0C'#/'#)<,"?]H$<3G)XR O=@#:6&C:AJ=KJEY90B:'1[>U
MNKT!T$JQ7NI6>E6XAA)ZEQ))>WUM'TX5=P'+D!5)J36FH%8S\0+:/(+/&*TR
MHW#QB7,UH;#&5R?%(ZV.UPO* +\K&]QQGQV!*LPZZ*QP^KB>0V*Y!M)@(3ZL
M> V.9MT=F.J_;??<@(; W9%)(1MQ1;I&I<T3JSY+CF1W=Y1U(5PCB)'#9$7+
MCUH>VJ9WN9510FOD8PB%).6#6--N61(+R&1Y,[$5O.V!"3Y3AN.O"#D<&09P
M 2/0ZM]G'CO0[:[O=6\*ZU8V5@L#7EY-9R?"6ZW4EQ%;&2X3=".O+:W$<8#D
MM+$T0'5PAE)IK%Q3=<6Y%R3M]N(\'8S'ME]S-P[+%<1Q;,,V(Q;>>TPNER(G
M#;/<J ^U/'PB2.*\%=:,PI!4O):.<82$F:WF8Q;FUG6223U09UL]85^+!;:X
M_7Y%28WF,5C,5E=YNAMUCM7FNY>+DX]&0JBUU5BEJL]0<HL"''TMR.V>=8HF
M+S1>(=+F9569QON8+9&:)PC-=0M<6TO4 *""XC4F*0L-S-&NT&2/=>7?V.>/
M+0WZG3+>=]+T;5]:U*.UU"TG>SBT"]BL-<L9%64=74]*N)3\5:6QGS%;WLUO
M)/'8WC03ZTUC$P3K1W1R>XV<RRX!V,H-L=][^.+","M,Q,H]\0\%N#3:G&L[
M-(NK*##;T@H\0<BPPJC$2]\K:0AU<AE@&0UV3 29TR2=SVO['HQ58U6M1R-1
M51.??W1WNO'=VJO**B=MAJ%MJ,32VS$HI3\6T,4FACN()=H8LL<\$J2Q;PKE
M2<JI%>:\6^"]<\%7=O8Z[':Q7%PMV MM=PW0CN=/O;C3M1LY&B)'Q%A?6TUM
M.T?4MG==UM<3QY<<O3337=7DZ::::4IIIII2FFFFE*VR(JL>B>JJQR(GW547
M6%/X>>P.\NV/Q,?C7;LY_MSDF*;<;^[N]*%ULUF=N)%!2[C5.&;&'X_E)V-$
M-F?(8/17<T=:>]\438BW^&WO<C^W-:JHB*J^B(BJJ_HGJNH\;5=56Q.]6\/4
M3L/MKF;\@W3Z5;_!\9WVQMV-Y14-PRZW%QE^7X>+'<W--7T>2MM<?CD,4K%[
M&Y%!>QX=A.*:U1T4J1&FFFE*::V.<K>]?=&HG\O1?7]?7Z:LZN^NVPQ65#7>
M4UN+?A++3,).FRB<:E@-O@:$#)"HZ=Y,_P#S(>"IL(B99841T;6$*^-&0N?K
M-(Y9=_2AEF,>TN(D9RJLP4,0H)"@G)/H >#ZZI9X(-O7FBA#DA#+(L89@"Q4
M%R 3M!.,]@:O+IJ@B=S,!"*H02\VQ: W*((R<='DNJ]C[L>:/Q(2*Q%F_P"*
M@(8BN&EC58R$14A=(K7(G4_WT;5J&%8-W'PQ0+*S?35YK;^N44VUC2-9 A2/
M'\*>:/Q8DD<QSHHW21MDD:Y[465@N& *VUP<D#B&0D$Y\IPO?AN!G\+8[&H-
MS; D-<VZX&?-/$.!C)Y;L-PR>PR/4C-T]-4$_<S X\EGPV3,\8CRL8:8LG'7
M7(#;@<<8;SA,TH;IO$8@X?)9#7-1T(O_ !#VMB_/KK6[R[6241F3Q[BX:N/5
MYK*TVY2_KOEPUA(G=$%,2LW:TN>/^*/#PDA$7\:%KXD5^HZ4QVX@G.[:5Q!*
M<A^$(PIR'/X<9)P>,4^(M\D=>#()4CK1Y#+C<N-WXER-P_3)(JY^M'-1WW3[
M*G'*?JB\*J+^VJ<.RK'ZVADR@^]J@L;B"BL9;XLX:"IC G:U837'O>@WEY4D
MC\"1)5;,KV-9W.>U%MQ+OSM_)F>!8+2VT>3W.X=3:9!22T$]>97QT%3X32;D
MPN0R!/+.FE6""$%II<CX2%</&R![M9103S[^E!*XC$ID94)5!!&99B[?A7I1
M@M(&(9<<CD9B6ZMH>F)9XD,IB6,,Z[G,[B.':H)9A([ (0I!Y.< FKPDAC&#
MS"%PQ%BDQ20$CE11$0$02HK989X9F/BEBD8JM?&]JQN:JHYJ\KS]8((AXHX(
M6,BAB8R***-K61Q11M1D<<;&HC&,C8B-8QJ-:UJ(UJ(B(B40;N/A%=>D8P=F
M&-BY(%42WIM 3;@P6HM1#"XJ6RF"?*A#1(!44B63L_(,BDN:D*+(E-99OCMU
MA=MAU+=Y)7ML,YR"KQVC@$)&+7S=R!/95A)BQ2IY>O-%@[QRE[DE2:%T;7QO
M[TB*WGF=5BMIY'>,RJ%B<EHU0NT@&/PJBEF(' !S42W=M"I::XAB576-F>5%
M59'=8U1B6P'9V5 "<EB *O#IJTR[X[1QBA6$NYN#,K[$R:N!-?DE9&(6:,K$
M)''G=-X<KH%DC29['K%"Y[62/:Y4;JI9]P,,&OYL7GR_&H<A'K5N)Z2:V"BM
M(:IL?COL)A)"&RQB,@19WS*U$:.J$.XA5)%-!<+WMK@?BR##(#A6"N<%02$8
M@,0" 3@D&@N[5@&6YMV4E0&6:-@=X+)R&(\Z@LH/)7D"JTTU'[)>I';''JBM
MO1\ABRBHMY<H'#L,.;!D(K"L/Q^7)+H4F84CLAG;71IY>%SO$EFDA9PC962+
M6!&\&!#8U+DZY%7S!PC6$JA#%"SVTAU70.R4^@@ 9.KYL@$J6.)GJ6N\U$C7
M=[6HBJFSX.\VH_PMQLE9EC;I-AV5BC*/7*L"&R!@@@\@UK&H6+/(@N[<O$BO
M(O47*HP#*W)P0P((VDY%71TU:>GWKVSNGU D&:XZ-<W=$+D8>.V%H$)?Q5A5
M6EUW&5;YW$#3P5:N-('=S+$-&\AS?!3OU6F-9=C695K;G$[ZJR2H>3,*RSIC
M8; !Y$"L2:*,H9SX9'1=[5<K'N:K7(J*J*BZUR1319ZL$T8#;26BD R2RCDK
MCDJWK_M/J"*W1W-M,5$5Q!*67<HCE1F*[48G:&S@!U!XX)'N,U)IIIK76ZFF
MFFE*::::4IIIII2K9[T5-E?;0[ITE.%/96UQMQG5565XS6O(.L;'%+<,$.!C
MG-:Z8HJ>*")KG-:Z21J*Y$553\Y7:'X37Q'J?:?;"HM>C[>0"TJMO,*K;( J
MB!B)"/!QNL%,$(C?9(Z.<8B*2&5CD1S)&.:Y$5%U^D]D%]58O0W62WA/DJ7'
MZFRO+<OP9R/*UE0%/8V!/@#1S$3> &--+X4$4DTG9V11OD<UBXFZ#X[/PM<G
MHJ7)*7J1D*I\AJ*V\J27[.[VB/(K+8.$\"=XI>W<!0SIA2(I'#DPPD0JY8YH
MHY&N8BE9?----*4U';+>I/$<9O\ *:,'%]Q\XCP)P46X-W@&*?B.EP@HP> ]
M0KJ=E@,:98@U)0]S:UN/@7)M95RL(,AB>]D2R(5.45$^J*FH#;A[#[J]F]F,
MXE5TF0TNZ^8$;BX9DR[CY9MK=;:YK<X\!CUJ3>?A-D5CE%36$",OZ,< UBD.
M:ZILQ.UL!B:Y"X V^_/!)^7 SP3WX[<<9R,D"D^8X''KCU //TR?X^F#)6^W
MTP'&]R]N]JK$VP=D^YE?:66/2BUSYZ88>O&\R*R]M/$8RG)R!&$PXT.3'XER
M2$<- GBCN:E'Y!U0831WF0UP^-[CY10X=>BXWF^>8CB3KW#<-O)I(HRZVU-'
M-;;'34JD#+D2T%/<LHD(8T]\3V3LACU<]+.\5U6YOEQ6XAD6ZM,1M9!M7$#D
M:LP^^$V/& ,Q6SSOS^/F6P=KF&0EY<5D4->9,P(6]9'XM@Z%RN^&8]/&]9&'
MY_MMC N/LAS?/LFW.PG<<'<S,,)MMJ,CW%L)KG+(+>HQF$<K/(<9M#K/\+K$
M9 !< 2!16X A SY'ZR\F"-I'J,9)QCL>Y&2.YQC(!P#FM@6/CS9[ Y8#U&2,
MX[ XQSG!.<\5.[-=P,.V\I'9!FF34F,52/2&(R[LP:R(LMT,A$0(+C2(&%V!
M#(G>6#A<Z:9?1&<>J4CBN_.U>5@;?DCYC2U-EN?0AY'A>+Y%9UM-EUU6'-<X
M9XN/$&*;-+(K'L;&,DZ221R,A=*L;D2UF^.T.;9/8;-9;BXN/YC8;9C9G56N
M,93:.IZ^\BSG R<.DR$>PEK;9D=K2ERL-6$H?DVKGL1(B(2Y(G.BWC'1ONC4
M$8>)?25I]6_&NG6"\3'L_)QVIPN^V6$($L3ZH9F'FY->N&=(RXPI*NZQT8@[
MQ0<CA8&^28@7D#<+D#ODG!X7!SR.<X/L>3QP8"H5R6P?;(]\=L?1N^".,YK(
M(N^6R[9;^%V[&W#9L5;/)DL3LUQQKZ",4J  F6X1UBWY?$/8$CU\\A/AQQ'S
MQ!/<TJ1L2\NOWCVHM;^HQ6LW(P<_)[^OBM*/'1,II9[NVKYA)+"$NOK&&*85
M!*!#,=&Z*)RO#AE):U88WO3$14;"9[NBMGMWCN*XU*-A&TGX&GSZT"OZ6HR^
MQ?U(8]N/&^S_ !!B-6>RW,H:>RL[&OA$MQ$O722+9^7-%E63VXW3KOKG&\3+
ME"\6K,$"W="S*K*I[>LI4&Q5V$'8LI+L>#PSYW9;C@6%D2>3=6>725IU7"+7
M!CB.:J) F<@$*&'&< ^N=V#D]B,9P1R#VJ3&@."V."<DCV!''SSG'!P".]2D
MAZG-D"<OO<2@W"QJ9V,8N_*<AR**[IY,0I1X\DEQ1U39Y$RQ<&'D7SJ&4=M-
M,C"G)#(K$>]JL3I[KJRV0J[ROQX/-:?(K"XPD[/Z:;'KK'2JBTHJ[( <=)C%
MO2;D2H^9L.-5[ 9RXED%#->CEGA0=\-:KIBZAZ),4FJ,>VKI9=O]N-L-LG&U
M%Z 1D.<5^#9U-<W&2U!5]A9U3AV4V%0D)6/6]H'='T]@1:#N)9,1%8LZ;_Z-
M=[XL5+I)!L#M#;W']V:(XTW*7/>&_,=ZL1W2H;$LA<3A99ODJJ4NGNHP0P&P
M6TGFA&2A3(C,=\W/D/)[@'N=N.^?_ [<XJ0D>>7X_P"H ]LY/\OS[Y%9-9]V
M]K1;3(Z,K<?!Q[G#Z\FVRNL(RFD@/QNL"9&\VQO19#62U083)H7F$&,BB%;-
M$Z=T:2,[NWQ+/L(SX(JQP;+L:S$ $Q]<:9C%W77@P9\<;)7AE35Q!$<!*0R1
MS>#*K)%BD9*C5C<URXV-Q^D/=[, <WQBOK]O8!/.=3U[2YB9>&,N,TEWV#=%
M18W? QTDDU2+5O(<S)S"R;,8J.GIUK195[T'F#L=M)=[<9ANW<'04(E/FDNU
M4E(+2R^L<F';6T.'7CS16!"0BR2VU9-Y58G3*0$V&:58GKX+=JO(6P4V@>N#
MWQG^&,$YYR"",U@RH!D/D^WY@?Q!SC.1@YJ2>FFFMU:Z::::4IIIII2FFFFE
M*:@T[IKRFHW$W7R"LWL^7[?[X9DS(]Q-L+/;K&C_ )Q$9B86'7&/U>;%W8MO
M5Q6]+6HV B  @P"5\\L$<K>6+.76!+J"W3S2YZEZRCNMP+AVXVWG63A,6U/3
MNQ!V45EMR)M=>6^,[@^0$ AM[5]]DTSX"+V>WGKXRB_PZHX\SHE9Y[Q#<6EM
M'I\EU;W$^;^)(.A<36PCDE1XF,K0RQ&1'ADEC%NW4$S, (S@LGV/[&_#WB/Q
M-J/B?3M UG3=&A7PQ<7>L2:CHUGKAFL[.]LKFU%O:WEA?1V4D&K16$[ZX6T]
M-&1#=OJ,)V0W$JH_AUUQ^#Y-B^4[T9ED]S-@F ;6[=9@_&\;J++;/ =N,M_%
ME #7A5\\<%UD/CRR 666FSB&'!JQB"1JUZ/D[L9TT8;L+9[MVV-&SF_WIYC#
MDKQS @X&8U3ATH=57874S0.<^;':][#"Q8I6P]LUB3&D2-_,[$)M[U2]1%SB
M/G+O?D=F 6]EL2W>;/ ,GQK+=PM@?Q7EAU=N!9POJ=N:O&MO*8QD05"3B^5/
MOLBP-46UG:@I2&.J?:OJ/W?R27*[>WZ@]U+S#ML-ENHO<0&UQ+&<-L[/,GX/
MNO9X?B=K9UDF/1A6[Q<8<,2)6MFK!)B(AK&Q5T$4_?YRPUC0(Y[%[32+J.=X
MI98&EEC#HBL(Y99?B;PRS(L<[!IT2=5*R6JMU8N@OV[Q1]FOVVZCIOB/3-=^
MT+P_>:4-0AL]4L;&ROO@;J[GM=.OK6V5=%\*Q6UK<RW7AK2\:87M;L3K%K"V
MCV^JW6HWDU+#H(JS01-O)-V<FBZ?:S<&'<JGVA7'L<)L:2[CN'9?#256YQK9
M<D$PM,Q<MQ!C<8*K".]:1A[:Y5US*WH2VP9C.#GU5^&_=S'-R'[E7V_X^*XZ
M3G>X-D?>W!>78]DQ0Q*M.QG**6X/Q"QI&V<X@=4D38VK) C4Q^[?=6NZ=RRQ
MJLAW^R6@VC_OGV K<DW>7*L#SFXPO#LXVQR2\LH?[QJ?"JW$AA,GS^HJZ.QG
M;1$CX>>4=C'G))G-E;9NAZGLZVWVDVFQK;K=G.ZBTJZ6CR,$8TO#L:HLO!R[
MJ)R:KNLIJ\?N<<O,IW@=88TCWY -5D8[0X",V*Q26212$CKCK?A9'2Y_R=WB
MZ5XZR2S1F:)]/OK.UA2PMY;CJ11K).3:36B)';+"R0B,M*%]/%]F'^("96TY
M/M(TZ"\77/#8Z%EI[1Z5?MXMT+5;ZZU#Q-JUCH4=KJ&HW(:RMO$=GJPU:[UM
M;NTO=::_:#1&O,J]7T4TT1FV>&F[TW-MLQM+N"%N=MKL]+2XDZ^H+;$+I]QC
M-#/N4V>;*;+"<+O#G>7HEK62QB>1J;*S<T6%SLC@21MB_*L?"\+S'PC5[N7>
MB(O;QRY7(C>$1'<(G":\RX>YVYVTQN>5FW687-C<X[:]91.1GVE13Y7DVW T
M/4=MQ5V6:!N(HW6(!=3A-E9YC+4R$24]@3"/=+62CP0LCNB[J$W_ ,MS6UPG
M".I;<<_::CH>JS(]NMW:FJQ62XW,K-J\,Q#),;D+OB,6EJK^OQS*+"RH)K:K
M!$;<!-(#E?+-&LK+"P\3:+8)LM-,N(YISI^^*&:*;F=!!;0H9[HRK%:0JR-&
MD4<-J-D2JIN(ED\MXN^P3[0_%=U%=ZG]H'AW4M+L8O$UU!J6H:9>Z.SI8RS:
MAJ^HW-KHV@S1W&L:ZPM[U)[JYOM:U\+>:C/<SVVE75VOH4,.@%E'BEGCB<5(
MD4+7R11NEE[7O\.))7M=*]6L<[PXD>_AJKV\(Y4Y4$G>QSE=SP]R*J_3U]D]
MO1%]$]_WUB#WZW&W"R/9/H$W:KH%O]T;:PJL]&"' *06SS@KIPS>\B8ZK%;$
MYT)=M(DD%6[MC>]8X$8BN?VQIPCJWW:7:N^M<MW^L#:._P AZ>,??;8UN!ML
M9D^#YWFXE^9G./99N$9M[6X?LGB%JE2QQ(=G795EV!$PQT;(&NL4*2[G\66-
MK,(I8K@(\0F2<(>B4;3XM1!WM@'*3+#A,A9-F["R*:^7:1_A\\1ZYH<6M:?K
M.BLZ:E-I-YI\LD[7:WL7BR\\+?Z%+6"Y:XMF-FVHBYN5LXVA$\0/5MF#>@$Z
MP8$V:<B6$86%JN?.01"/&C4[455EF>R*-.YS41SW-15<B*O*^H.Q&.8^0<R
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MCWK;"L&J#'RQ1%LE''^4B"!1-KG"CA"PPH*R!&HY>@N-A-F,G-$N+3%:L^5
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MQH]L*B.=VKJL].AG2SGE\0_#R.P6$-.H>V$MBMU,Q!O5DC59B]J^(U$LRGS
M,*VWVHS027EO#X;-Q$JEY7,64N.E>_#01A5MI"[&%4N0<$1PG()(R<BL.V6U
M@@[)X:.B8)%=%6[9W%JZ)UD=6.H2X)YI#',( FJE2K6DG>^I:''$,P!C8(49
MTF.[$[+XG:TUE3XS7CWM+9S7%$:9=VUE8@F$T\M&Y I+2W+G:#'23R@"5K>Z
MN$$D5!1XE7O2(^;;09G5/RC&,:VQ0G;T[=.JMZ6NCQL#,JFH%?M8. 3:U6#6
M.38_4S1V>5L<-:6MH2YU-8+)?1 $$S2%,HN@VKR/"]O-Q=P]SJF;&<QPO =I
M3L&RK*;"&4D;),# +(+IPC&G$L9%9V$0V/DQ(U_S&"QB@8TN-K&JCT\/;M*/
M$#[IOAU$"2%I)S<]-%5P+L9$1E?X@8.Q1V(892:@8YT0^'8@D!G)N7C"I EH
M'DD9#\'D=1(0;7##JR%5)7!(G<G3UL[*/DH:8@+*%E(\@-N$MK>3!PBR6[+Z
M8.E&2U4?&AWW<<5J\>A96QH=''/V<L8U.S'V.VO%OB\FAQ05UL;"6PI23+8N
MKFDL:UM19'OHB3Y*7YM:5L;0K2W: VPL(5D0HF1TLKW_ $V3H[&GVYQR>^&<
M)DV1C39EE0[E>JP9+F$SKZX$1SGR<LKB#?ED+$5&1P!PM8QB-[4NVB<(B?9.
M-44UQ=QRW$ O;B15=XS(L\NR55"QLR^<Y1Q&N">64*2../16]I9316]PVGVT
M3M''*$>WAZD3/]Z%;$>-ZL[%@. Y;&<Y-JMO=GMN=JUMI,#QJ.CEO6U45O.E
MA;6,YL5'#*+3PRSVYYTK8:L2>04**-S&0C=L+&HQD:-NKIIKGDEEFD:6>62:
M5\;I)7:21MHVKN=V8G"@ >P&!Q7;%#%!&L4,<<,2YVQQ(L:+DY.U$  !))QC
MN2:::::PK933332E----*4TTTTI5&[B8M+F^ YOAD!D=?-EF(9/C,)\T+R(@
MI;^C/J(RY!V21/GC&>8V=\+)8W2MC5C9&*Y')Y$\!_LNFY6'8+A>(D=7>"G3
MXMB6.8Y,;%M'DL41DU'3AUDA4<3\U<^*,AXKI61N57,:]&N5515UZ[-Q,IEP
M? <VS.$-EC-B>(Y-DT0$LSAHS9*"C/MXQ)"&1RO@82\-('S-BD=$V17MC>K4
M:OD7P+^U&[B9C@N%Y=/T?86#-E.)XYD<P46\E]-$'+>4X=G(+'*_!6/EC'>4
ML3)'L:Y[6(YS6JJHBE>QK3332E----*4TTTTI33332E----*4TTTTI33332E
M----*4TTTTI33332E----*4TTTTI33332E----*4TTTTI33332E----*4TTT
MTI33332E:.3N:YJ^SD5/ZIQJ%_3[T0[<].O4IUH]3N*91FMSF/6]EVU68[BT
M>0ST<F-8N?M)@\^!T8N%15M,!:0!V%=/(9;)>V-S.\Y6J),*.G@:F>]5:QSD
M]T:Y4_=$5=8F^B#K#WEWYZ_OBS=.N?$8S+MOT>;G=-N*[-0U&/LK+L>JW/V?
M,S/*FY+;M+F=?SONQXWU\T@XK@AE? GBM<WL4K+-IIII2MKG=J.7W5J<\?\
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M8,$"04XP(R$B%ZIWM90)O22/+49@&%FMD':97AV XLMFM2'(P6?$+!;7(SR
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g253994.jpg
<TEXT>
begin 644 g253994.jpg
M_]C_X  02D9)1@ ! 0$!KP&O  #__@ ]1$E32S$Q-CI;,C!:0E8Q+C(P6D)6
M-S0Y,#$N3U544%5473$U,S0Y7S%?24Y&3$%-7S1#7T)!4BY%4%/_VP!#  $!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1
M" #! /H# 2(  A$! Q$!_\0 'P !  (" 04!              D*!P@+ 0(#
M! 8%_\0 8!    4$ 0$!!PD/#PH& P   P0%!@<  0(("1$2"A,4%2$Q.187
M&'%WE[&XUADB-SA!25%66(B1MK?(UR,R-%-9<G1U>(&2E+/2V"='5WF3EJ&R
MT=4:)B@UAO"UN<'_Q  = 0$  @,  P$             !P@!! 4"!@D#_\0
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MG$W4]N ?BT1!0$ %*4H!2E* O^=PW?7*?O2_SAZO^50#[AN^N4_>E_G#U?\
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M@S+#BZ==D;.<PJ@MAWC-=U-5+=I="5#".8<;5 =R0BJ*VSE,^2,CM=V$B@R
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MG9S-%E\C&T4.P_ A5993_: <'-D)MQ<I)AB;W>.\V?&""2:26EQLMHI14&3
M)U3.GNIISL>%ZQZ\FN]]KO?A,)1>/V.UT[78[ZU,NSVNSCVNSTZ]FW7KTM7J
M^PPU!^Y8UP]XJ*ODE688T>5Y$CIAO^Z.:;UWPS&J\/$)XV1/G43U3H*>N>*#
MAU+&,IILVF>'^ F#2>8'(F1@,QR@HA<0+._VU :T>PPU!^Y8UP]XJ*ODE7>'
MIKJ*#GB*#JYKF$)CU[(@<&Q8'GCVL;XY=G/%IVRMVL<LL;]+^7&][7\E[VK#
MG)>\78P]1W Y62YE]H.$":-1$L%<;"L?1%<),<FX,#-EQ)X:@F#ESF))=;BP
MK(*N5P%L"I(ZF?33> Q0X.")\GOUM-*D#"1FSX34&I>17^DRTYBJ ;@>=ME7
MXK)D:$&MB$*@Q5#!II%$YCX.5YMU+D:5Y E%E-QAE55 (I9)SKKH+X(@&RWL
M/M3ON8]>O>2C#Y*5T]A_J;YO8R:]=?+_ )DHP^I_\4_!]GZE0XVY3-L77&>$
M_M9EP*UXYCW47C$VHDF/U])D!SO-Y']Z%9:+/Z+VD]B#S;Z(S"C 2$D4\U'\
MI,UZ#*:MX,GJ[1%3AS!\#6F>MA9E*/E^R-@[G'C&\):T\SSD(1D5EG8]'4UY
M^Q+R8!:V$'88D%N38BJZ>.&SQ2X3()>+U,G#Z$<<C1B@NU$T^WS34SF^-];,
MYOC?6R:UF\;NM+7V!G&:CD1P:MHDNLJ#&FDQX9@F/0TQBFX?QE'!56TXV,GF
MR9HP^<9"3[* 19$212EFJ3Q'-JN X&*?GCV'VIWW,>O7O)1A\E*@GCW?S=&"
M4U^/]Y*4.RIKVM\CW)SJ8QVZJD)26=B&ZYHL?NY$HQT\EU\&GWZBST5MX.&+
M1P)$:,QD,TR(N#2',D2(8LD9-(']N:^4?=B%-9FQ,*N1UZ>$MD=0$;=R0H:B
M;7_9Z1""0RGQDL.%I1T]Y&376$Q(&:Y9F-)W)!;89_.Q6/R _4M<';\ ([59
M!V[H9OC?6QF^-];)OK:?ZGXWME;637NU\;VO:]H3C"U[7M?K:]KV:O6U[7M:
M]KV\MK^6U>K?3'4*][WOJQKC>][WO>]X+BN][WO?K>][W:76][W\M[W\M[^6
MHT5?D1V3:$ENYYNEOPZ=UV:F]T^Z:!,)MME[6F-:08FU@D2?D^5L) /OP9ID
M5_)PQNH,@>/,8Z-)BXDJ)=QA/-OJ&'B2L/N?E$W%C.*TM676KK'(DJSGJ)K=
MMS!:,VL7RUV7'MYUV:@V %"(I0/9OIXKK^24DO/K666G-K:*L(!TG6X]0Q(W
M+%R!$#,VWM;?.&V]K;YR8WV&&H/W+&N'O%15\DJ>PPU!^Y8UP]XJ*ODC69H^
M+/LDQVH4E!;:KDD4L@IH#W7F,VE5GLY6= 1?#!:/M=KKCH>JR@H)@]87-+2U
M1V.%0*%+AAFU8X-;,6^DVN[V=ZSO5R&M%9=#B5FJR\M0,6<VU%74CR"UO5/#
M"\IN+U/)0PPQ%%\>*8(2@L7( %\5 \$$:.W$%QQ$M@P9^"T_U/+AV" UDU[!
M"QOEEB&%"<8!AVRSOUSO;#!JXXVOE?RY7M;KE?RWZWKR>Q%U5^YIU_\ >6C+
MY+5">L<O.P;>/3$X4QLQ?)D?8Z5;_;0PZY$F&]AHXC3-T:?8,Y79#9;,T2<;
M;^&T3!D5MO(KZKI"CJ-8X16RNI@XS15'<W5I&,Y927-NMI@-A&-K=+(T4')!
M([!:MCMA\Q4%,D>,Y*);*:K;JO$NV7LQP)7.F9838T?4!#!B8.)Q)[3D=%6D
M=6/L%HN]JI*H$S?'V[)#-\?;LD;Z['\>&M,[:^3?"B'#T'QLLRY$T@1LDR$E
M0;'IQ38ZB]&PI-\D[4\H32T(V:.-\P>#5"Q<NLI0PPI;# %1)"98&0\P$]/M
M5BI0J6SUN@ ;(L6+E\ALH6C2V0MP  P;BY6R;&=[9"7P[=[7SRZ7RO:U[VM:
MJOD9;#[:LZ)>-)G,&4LCTX2>A\2[P7'_ "7).QCHCY\*^Z*'R?KKLO*[$69A
M7#SC*D%)LH[L<B>V7&SQ),="(U6V(>9[):$<)+!D9BSDBVX>,JYPXZPM5&=?
M6\CO"M;@3$MH\J)4=.M"TJ?,,(.:I#A3U9JZC&R5(Z-,R:([U5Y&Y7M"2DU7
MIX.1E05,34E39OC&;XR7/V(NJOW-.O\ [RT9?):O"/IYJ89QQP,ZQ:\F,,,K
MYX8CPC%XN..=[=F^6.(C4RMCE?'YV^5K6O>WDZ]*A7:_*=N$HJKHCS%GQ:K/
M%;.<=(\8/IZZ\;(:\,ZY7=791YZ^/L+"/I4=P,H/YF1W9J8/".92S)QF+(14
M_P")59AHQDH9/AYS9F\&XTF/EMZMMA0UG;,[$93WV;#PG)V,A^FHL6FAI4K0
MDE)!IOP>5EE*=*(XY-/;%L#!PX#3,Y4QAHC0?2\0LXA5-#34IF^/MV2Z@26>
MPPU!MYM6-</>+BKY)5].5UEUR(EBY(E <*E"9, $J4*%8H8!<L5+%P\0@"Y<
M %NX!   A88!A A88!AAXXX88XXXVM:.W0+>K8;>64;+X;:AV.==T76#5:7E
M=&#*.UWRLX9(V?B<Q(.3>0WB$ZDAEIC!CTPDG,RKD$:"TIR&EKB-8N3:N2>;
M.J,P5 *4I0"E*4 I2E *]0^0)*A$XFJ10L?3U J8(GB)P$,R4.$S8.9<T5,E
MQL<PARY@N*(".")AD&*$)F'GCECE>U_;I0&ISLT7U&><6QK"RU 4>!1G#94V
MGQ,UV^E#L\O&J:I(YQO+*4QE!GG$%::Z0X6^HGT!S)*.IE$YSH9TTD. JIIY
M@4OE]V1U@UW2T52;:7"D9)C=5R\0E%%"36<BIZ,9)P"(C"0D3R3"94 E@3BG
M-NH/J!* @!EVQBD)V"6$7P*!8XYVI0&H;RT'TW?YUIGG;KI%ZN*RSJX=1P,T
M"Q1.,6<DD#3$N)KD24\P32GJWU*6#!B2S#8>I)PMJ[['&=8:2&MBB'<_))6A
MVG\OEDDG(FOD;N0LC*<D*98(9'%3\3=ID>HLCRZCKET<VG9.5J2F_1LGA([+
M<F2LSGPX[!J[E05(X""*'MQ2@/ 6+%B1< F3+@E2A4$(L6+%@@P"Y<N 'B$
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MH2CU<<BM89H!K Q4D=9(H)$"Q<\M%=.I!9Z6P'AK?$:ZTD-L1@S4!%-,XB$
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MV\^7M_\ \M2E =:4I0'BR\PG[_#X Z6_78>V-_STI0'<)^MM^_#_ +3&JA_
MY]-DUOY'&ZO_ .S(U2E 6HIN^@Y*ON;/[\4%JJTW<Y7_ +LY?]7#QC?_ (:>
*:4H"U52E* __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g328266.jpg
<TEXT>
begin 644 g328266.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@! 1$E32S$Q-CI;,C!:0E8Q+C(P6D)6
M-S0Y,#$N3U544%5473$U,S0Y7S%?3U527U!)4$5?-$-?2%1-3"Y%4%/_VP!#
M  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MP  1" &' JP# 2(  A$! Q$!_\0 'P !  (" P$! 0$           <("0H"
M!08!! ,+_\0 ;!    8" 0$!!@P/"PD$!@@' @,$!08'  $($0D2$Q0A,7(5
M%A@:-U%7=G>7MM47,C9!56&1E)6QLK2UU-<9(C,U.%18<8&6MPHC>)BAT=/6
M\"0E4L$G*&1EDI,T.4)#1$9UAD5'5F)F@N'_Q  > 0$  @,! 0$! 0
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M=4O!,8D<I8_ QF: PFRLA]8T&E ]J3AL2E4/0"SRBPSMDL<B2HLD;<R.-U8
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M\>NU5G)520'=SU%8E\69:7(.]:3H-]XWU0IAC9R+BM.L;/*"+>:8);\SC[C
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MN4O;<4<L>4$<2O2"(H ;=) Y)6TM0J(RQM+D2\-;<[)@&EIW- C<""SPA"<
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ML<RNI1ZG>>2]M,:F:SG>/@AKG8!]<1U'/'N'-[\H<D:16=WA&#0"D^Y4;>U
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M(ZZJ'10S;M,6C(0 9A>AV&V^Q'H/8"%!&X&^YZ4';<G=CMW9(3SPGY9VM8%
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MFM:Z[\N_MYN-/EU"06?5"".!DLR+7Z,J1)7 '([ 2R[,3OON1\'GSVI8\W,
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MTG)&7"R>SKR+'(6B=Q"C5X>2*)XXU"\H7E(&>#)6.WV1.P@]X]*D=_;L"%V
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MY&!WKQ;T)BK+6];]K>MV9K>O[=9\]='\#/<UY%_@.L?VFY7EXAX7GDCDEU&
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ME#8\ TFC2U.!*VHV[>R7!J<U'13K&!ZZ/X&>YKR+_ =8_M-QZZ/X&>YKR+_
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MJ?*'A](S97QFM1ZZ/X&>YKR+_ =8_M-QZZ/X&>YKR+_ =8_M-QZZ^'O?2O\
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MKH_@9[FO(O\  =8_M-QZZ/X&>YKR+_ =8_M-S8KQ3PXJJJZG655 55 D 50
M   G8 "  /,.SS;^NL0>ZI\8\/I&;*^,UJ/71W SW-.1>][\6M:8ZQWO>]^+
M6M:U9O7>][\6M:\N\;_RH[@9K>];K3D9K>M[UO6V.LM;UO6^F];UNS>NMZWX
MMZWX];\6\SZZ^'O?2O\ XGA^)X_7<;NL0>ZI\H>'TC-E?&:U'KH_@9[FO(O\
M!UC^TW'KH_@9[FO(O\!UC^TW'KKX>]]*_P#B>'XGC]=QNZQ![JGRAX?2,V5\
M9K4>NC^!GN:\B_P'6/[3<>NC^!GN:\B_P'6/[3<>NOA[WTK_ .)X?B>/UW&[
MK$'NJ?*'A](S97QFM1ZZ/X&>YKR+_ =8_M-QZZ/X&>YKR+_ =8_M-QZZ^'O?
M2O\ XGA^)X_7<;NL0>ZI\H>'TC-E?&:U'KH_@9[FO(O\!UC^TW'KH_@9[FO(
MO\!UC^TW'KKX>]]*_P#B>'XGC]=QNZQ![JGRAX?2,V5\9K4>NC^!GN:\B_P'
M6/[3<>NC^!GN:\B_P'6/[3<>NOA[WTK_ .)X?B>/UW&[K$'NJ?*'A](S97QF
MM1ZZ/X&>YKR+_ =8_M-QZZ/X&>YKR+_ =8_M-QZZ^'O?2O\ XGA^)X_7<;NL
M0>ZI\H>'TC,^QG'JA33##C:4J,PTXTPXXPRM(0,PTXT>S#33!B8MB&88,0AF
M&#WL8Q[V(6]BWO></4[4%[B-0_%E!_F')DQF[ZO![C%\A?H\/G])R78>@?$,
MAOU.U!>XC4/Q90?YAQZG:@O<1J'XLH/\PY,F,=7@]QB^0OT>'S^DXV'H'Q#(
M;]3M07N(U#\64'^8<>IVH+W$:A^+*#_,.3)C'5X/<8OD+]'A\_I.-AZ!\0R&
M_4[4%[B-0_%E!_F''J=J"]Q&H?BR@_S#DR8QU>#W&+Y"_1X?/Z3C8>@?$,AO
MU.U!>XC4/Q90?YAQZG:@O<1J'XLH/\PY,F,=7@]QB^0OT>'S^DXV'H'Q#(;]
M3M07N(U#\64'^8<>IVH+W$:A^+*#_,.3)C'5X/<8OD+]'A\_I.-AZ!\0R&_4
M[4%[B-0_%E!_F''J=J"]Q&H?BR@_S#DR8QU>#W&+Y"_1X?/Z3C8>@?$,AOU.
MU!>XC4/Q90?YAQZG:@O<1J'XLH/\PY,F,=7@]QB^0OT>'S^DXV'H'Q#(;]3M
M07N(U#\64'^8<>IVH+W$:A^+*#_,.3)C'5X/<8OD+]'A\_I.-AZ!\0R&_4[4
M%[B-0_%E!_F''J=J"]Q&H?BR@_S#DR8QU>#W&+Y"_1X?/Z3C8>@?$,AOU.U!
M>XC4/Q90?YAQZG:@O<1J'XLH/\PY,F,=7@]QB^0OT>'S^DXV'H'Q#(;]3M07
MN(U#\64'^8<XCX[4%W O_0C4.OWHO']#*#>UO_W#DS9Q'](+S1?BWCJ\'N,7
MR%^CP^?TG&P] ^(92*AJ&H]>7;^UM.54J\&ORTTR?PFNH:?WA,4XMX24Y/?F
M0?>B"@^(LL'<A#K>^FLGOU.U!>XC4/Q90?YASSG'K^"N;_2#M?\ 23?EA\@K
M00F%-XHSW_S%]/P9@ ;#L'</,,AOU.U!>XC4/Q90?YAQZG:@O<1J'XLH/\PY
M,F,GZO![C%\A?H\/G])S.P] ^(9#?J=J"]Q&H?BR@_S#CU.U!>XC4/Q90?YA
MR9,8ZO![C%\A?H\/G])QL/0/B&0WZG:@O<1J'XLH/\PY\WQXH,.PBU250ZV$
M9>];U6<'UOKH8=^73#K>OZ];UOVMZR9<XB\FO.!^6''5X/<8OD+]'A\_I.-A
MZ!\0RF_'J@J,7TM7:I;3-3JE)L? (U0HK>%'G&B\-6_OC#36,8Q"^MO>]^/I
MUWX^N]S-ZG:@O<1J'XLH/\PY^3C=[!U;^]X'YZMR;\@JP0FK6)BC)->$DE%[
M3T:>'U[?2<;#T#XAD-^IVH+W$:A^+*#_ ##CU.U!>XC4/Q90?YAR9,9/U>#W
M&+Y"_1X?/Z3C8>@?$,AOU.U!>XC4/Q90?YAQZG:@O<1J'XLH/\PY,F,=7@]Q
MB^0OT>'S^DXV'H'Q#(;]3M07N(U#\64'^8<@WDK0=&M]%68K0TU5"-43&S!$
MJ4M<0M.>2+PY#^_*-)8P# +7DUO0OK^WTWJZV0)RA]@*T/>T9^?(<@M00BK9
M(BC!%>;8\B[C[&W;W=_9W_2<;#T#XAG;>IXH,6Q"%251;V(9F][W6<(WO>]C
M%O?7>V'>]_U[WO>_K[WO/OJ=J"]Q&H?BR@_S#DQ!\F_.'^6+.63B"#8?88NX
M?S%\/#Z]OI.-AZ!\0R&_4[4%[B-0_%E!_F''J=J"]Q&H?BR@_P PY,F,=7@]
MQB^0OT>'S^DXV'H'Q#(;]3M07N(U#\64'^8<>IVH+W$:A^+*#_,.3)C'5X/<
M8OD+]'A\_I.-AZ!\0R&1\=J"[D7_ *$:A^EW_P#RR@WM;_\ <.1A5-!46L;)
M>)53%3'B*M.T""Q'5M"C1 ((F;H402'9C&+>BR2PA+*#UZ !K0-?O0AUJV8_
MI!>:+\6\B>H/XJF?PL6K\MG;(G@AZ:$=%'L5EW]@O;L$V\WU[?2<;#T#XAGY
M?4[4%[B-0_%E!_F''J=J"]Q&H?BR@_S#DR95RR.65:U'?5<498:D,:46M&5S
MM#Y:N4@+8CI A?B&4$4=#!%A"U*G;PH@QF<51X4"M;H34:-.K/0^%0W;&F:;
M$D]YZU6!YZ]999@B1]/:E2"NC.1RKTLSI&I8A>=U!(YNV.1XHE#2LB*65 S;
M <SL%0$GL!9B%&^VY('><]_ZG:@O<1J'XLH/\PX]3M07N(U#\64'^8<F36];
M\>O^O]V]?7UY=;QEOJ\'N,7R%^CP^?TG)-AZ!\0R&_4[4%[B-0_%E!_F''J=
MJ"]Q&H?BR@_S#DR8QU>#W&+Y"_1X?/Z3C8>@?$,AKU/%!AV$0:2J+0@C+%K>
MJS@^MZWH8=ZZ;TPZWK^O6];U];>M^/*[<3Z&I!TH* K'&G:J7*S 2@)BE97,
M,4GF:+G$H #NS3V0PP7<%A" .MBZ! $.M:UTR]@O)KS@?EARM?$'^3S7WFRK
MY=2G*[00];@'11[=6M';D7O$M/;S?#\9])QRKZ!\0SV7J=J"]Q&H?BR@_P P
MX]3M07N(U#\64'^8<F3&6.KP>XQ?(7Z/#Y_2<;#T#XAD-^IVH+W$:A^+*#_,
M./4[4%[B-0_%E!_F')DQCJ\'N,7R%^CP^?TG&P] ^(9#?J=J"]Q&H?BR@_S#
MCU.U!>XC4/Q90?YAR9,8ZO![C%\A?H\/G])QL/0/B&4UO.@J,116*&)*9J=,
M8;=%")C!D5O"R1F)E=RPA*K3#$4Q@V(A4F.-3J"][V$TDP90]; ,813-ZG:@
MO<1J'XLH/\PY^2_?J2B/PW\?/\;8'DWY"D$/3S?8H^Q(=AR+M_ZGFV\_G/G\
M^-AZ!\0R&_4[4%[B-0_%E!_F''J=J"]Q&H?BR@_S#DR8R;J\'N,7R%^CP^?T
MG&P] ^(9#?J=J"]Q&H?BR@_S#CU.U!>XC4/Q90?YAR9,8ZO![C%\A?H\/G])
MQL/0/B&0WZG:@O<1J'XLH/\ ,./4[4%[B-0_%E!_F')DQCJ\'N,7R%^CP^?T
MG&P] ^(9#?J=J"]Q&H?BR@_S#CU.U!>XC4/Q90?YAR9,8ZO![C%\A?H\/G])
MQL/0/B&5PG?'RAT\)F!Y%*U(4<5%9(,LPNM82686,+(OV$8!@8@B"(.^@@[U
MO6];UK.LJKC]1*NL:Y4J:6J4]0? X::<<=6L)----'&FL1AAAAC$(8QC%O8A
M"$+>]BWO>3E87U"3/WIR7]!K\ZNHO8JK3X/X5\F6K(>@AZR!T4>W0$[<B]_2
M+X>';Z?/F>5=AV#O/F'A].>?]3M07N(U#\64'^8<>IVH+W$:A^+*#_,.3)C)
MNKP>XQ?(7Z/#Y_2<QL/0/B&0WZG:@O<1J'XLH/\ ,./4[4%[B-0_%E!_F')D
MQCJ\'N,7R%^CP^?TG&P] ^(9#?J=J"]Q&H?BR@_S#CU.U!>XC4/Q90?YAR9,
M8ZO![C%\A?H\/G])QL/0/B&0WZG:@O<1J'XLH/\ ,./4[4%[B-0_%E!_F')D
MQCJ\'N,7R%^CP^?TG&P] ^(9#?J=J"]Q&H?BR@_S#CU.U!>XC4/Q90?YAR9,
M8ZO![C%\A?H\/G])QL/0/B&0WZG:@O<1J'XLH/\ ,./4[4%[B-0_%E!_F')D
MQCJ\'N,7R%^CP^?TG&P] ^(8QD(VK>3!4TNI.'O#,].:V\;%,K=A5->V_21F
M="XV[R;;@\^&+$Q^V_:5G.3Z]#REBKPDTKJG[UW9@95?)$P1AL->I*]M$>:"
M.XTH='QS0M#<1LSQ T<N<#TR4K8M^(.AFAV+>N@=;WD:7:DDER)9X^>@Z1W
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MY^:6)6!4;';D+;D$<HW;<;;C.#$IA%)['VV5PF1LDLC+PG"J:WZ.N:-X:%Y
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MQ.NFA([+F7O.P# !+W?0O_%>>V DLQP9>.;I7=/6IR^XIRYEHYP+BK>M:(1
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MB6G "C:E0-A[ZB3I#%#X>,&AMR X0-B!M"9P"66$0Q!  (C!:&8((=:V8/0
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MM<'O!&RDQ2U:DW&.-O&VM>+M:MM<5PV][)+[A9(I$M 2*03&0") 4K?W]64
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M?4>\C%1\'^*E(!3FP"DH2D=D_>!ADKZVZE\I\(3].X5 D,I$[.250(6N[&)
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M]!K\ZNHO8JK3X/X7\F6K.TL+ZA)G[TY+^@U^=747L55I\'\*^3+5FP_UD?\
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M3R(MK:@31)3AMO*5IL@2O05>EB6%'QI4>YJ&Y,L*(4:/.7GMAB\TT8LYNO\
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M/%UUU\>NGBZ]-[WK6M_V=?+GW*\<@[.M.J$,'DE?U [W#&S)>2@L]JB QK+
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MV35!.W.M[ GT*!&X+92*M"U"B8&Q)R&ZJG7NFQN1K7<)+ZS,QRAI1*59(-Z
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M9.G'"@[;Y*6Y%ZMI9J5+IJX*R7(+L!0K;FV&-K<I).435_?$8!',#4PG:(4
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M 42C0=@($'OF@%_PAA816_5_5=8XH37;5==1U.U;$KUJ5:*J;,A4H(XHJD!
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M,>HRA7)NH; <JV:HP^.*Q;;#/,GV% /CKVA X-L"<3FN2'*35:,HML&D6$&
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MZWT$'>P[UX];WK>MX_<=NT4_H_A\O3V2*T_YI\GV_)F]>'6NF_%KZ8?UM?\
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M$ WO8"4B%&40E3%!Z_O2R2@!U];6=EC&=TJJBA44*J@*JJ JJH&P  V  '8
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M8GIQ#-8[$Y8%/Z!;@3YM*)M$ZC0[-]%%&E820*-%I]C$5D*^NXC_ .@MK_6
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MI-]#$_9&NAV@=QL\[?4.Q=WT%H(?:^NXC_Z"VO\ 6 #^RS(:_DE\H$<$$;:
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M(PK2.5C1G8)&>>1R%!(5$5G=NY54LQ !.>9)(XD5I9$C4N$#.RH"\A1$0%B
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M0M;UK6_)O>^OBUOZV>YJUBNQ6Q!- P=HRLT3Q,'18W9"'52'5)8G9>\+)&Q
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M_7SVY26!,ZT2Y :::@A$C>79_B"?O@01IZ<U[HR^!+5B@\R-WS@=PHDD0;8
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M'$Z-"5WT"0\XE(L,3JSBR!7AL>X0TUSEY%OBMR4HFEV;I"U&D%-93T0JDR>
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M14B50R95&@52!.E4^ R-"H:&N()TJUG4GB$W*0A(<%&E#8N G"JV$H13BD&
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M$XZF40>9I=<(J5@0SI;%W^$)R$0ZELN:5>Z-]EP../#W(V1QCHEK8_2F,R]
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MPF=)P[&KM*M\>)8@XRW6^Z+HR>/6@0:2NRO84E1S=W/WK:4]0<+O:* 3)>:
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M'("41(/+*I8S(T<6#/D$/E;.HE"+TFI;3ACK74X)6M*)Y":Y-[]"GIPCRY<
MP]:A1JC5B1&!6 "HG)Q>-)L%Y19+'7IR<68]L<@NS2ZMNB31I5FDYR,S2A&H
M_P PM3')5!I8R1")&$?>S2CRQ WH52$_9W,01ZVJM)]-!U%U"FC34G%T\?<=
M##5ZG6A:\6Q[V6+0O('0/+GY7\K<'\)L^433M0\E\=&?@_3Z50Q49+VA04]0
MLN>;4X]=K:I9K79B[<L4+4W0055CDIS07'L.;,1@">S)#[GM'-N/,-BH[/\
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G\8]/,8^R>OO-Q_4L>GF,?9/7WFX_J6,9Z74)B=BL7=]Z_A^/C/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g343056.jpg
<TEXT>
begin 644 g343056.jpg
M_]C_X  02D9)1@ ! 0$!1 %$  #__@ _1$E32S$Q-CI;,C!:0E8Q+C(P6D)6
M-S0Y,#$N3U544%5473$U,S0Y7S%?24Y(24))5%-?-$-?0D%2+D504__; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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M@9'_V@ , P$  A$#$0 _ -_CCCG'7R]/+UZ=?,/3X>G3K]SKU^KTZ<1.>.<
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M1(>^O0D?VE6[GQ5UW_&;GQ)+MD[2F.OT9<=+=Y2V^1,KJQ+C$=8UVG5X(W=
MH;E6:4\+ER$E1B0I,R(.#'(2C0PS[H]WH,_/!E_6\/P<?U<>#+^MX?@X_JXB
M:Y6ONHVM&M4VU@GM=Z<=J(J>]2&*W&&K<)<7"I&@7%76[2)ZFSG.4JFURAE3
MWDKD&.#.Y'F)36U,S,Y(8G^!5Y++5 W0D0!T#2K=SH'D#_PKKO\ C-R</@R_
MK>'X./ZN/!E_6\/P<?U<1(/>O0D?VE6[GQ5UW_&;G7I=O[C 8I)YU,]0MTH[
M#X7'GJ6RN0+JI@>:)BC4<;5+P_/*O!'<"E7FE:VI$K7*,$B92JS)3YXIDYYP
MX%9V!>#+^MX?@X_JYZB]L;G1"M;') B<&YQ2*4#@@7)$ZM$N0K2#$RM&L2*"
MS4ZI*J3FF$*4QY9A)Y)F91N&9>>6(HG[)%1*Y*F6ILAS3JTY*DC,0'$<R5!6
M!Q67='RX]XO/$1 0 0$>@\]CGCAA@7CC@7CCAAACCCAAAB&....(!CCCCCB
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M1E$DQKWPKZOYQVA%G&S> 0*;&MNK&K!3:=,X3%9<:W%*K%VX,5$MYLD:'0Q
M4I,(),4E),B2U!A)69V.>1> XX$)H2AA/3@-$T<( <3B #358" 8B;B(X@ Q
M,0#$1'(1Q#H CED/3J(B*)M0M#NU/S<D=V-S;WAJ7EB<B<VM<E<F]85W\\/"
MI5J(T]*H*#/#/#ODFYX!EAECUZXB ?1Y6WV23>@:M#ZO:VI @:FQNL'9Y"W-
MC6B2MK:WHDNUUX$)42!O0DIT2%&F)PP)3)$A!*9.3A@42467ACB$\;#L"+59
M#7V?35:K;HO&TQ2MW6H&1_D:M.0>L3(2\R62+M3V_.&0J59& E-K6L-PPRR.
MS+Q(*--+1.Y\<@<F[2W3A8YN#*DLV0JGAHQ:\W=J3TK?YSDTX/A:@YD,=4)=
M59*6TIX(1K#VHU:406XD)%1Z/(XI,?F7._#/'/''/$1''/''+$1 <1''( R
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M78[VP^7@_+=H''''.A24CCCCB(XXXXB4&[Y]L%L+J'LQ**)@/9[V%>L58(E
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M1OCT<G\5,<\%-PVC%ZWP>B$J)2YGK"8V$DSD"Q 0FQ-6HVU0GP4H^_DK(E$
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M5-][5TJ$J1K'4L5K4!5!.@!H3$RN&XK-M-^7@8V1<0JFVVL,Y51I06/DA0-
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7(XXXXB....(CCCCB(XXXXB....(G_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g374512.jpg
<TEXT>
begin 644 g374512.jpg
M_]C_X  02D9)1@ ! 0$!10%%  #__@ _1$E32S$Q-CI;,C!:0E8Q+C(P6D)6
M-S0Y,#$N3U544%5473$U,S0Y7S%?4D5615)315-?-$-?0D%2+D504__; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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K3BDMUAY,;R38]CW8Q^QCG[QP!QQQP!QQQP!QQQP!QQQP!QQQP!QQQP#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g394328.jpg
<TEXT>
begin 644 g394328.jpg
M_]C_X  02D9)1@ ! 0$!F@&:  #__@!!1$E32S$Q-CI;,C!:0E8Q+C(P6D)6
M-S0Y,#$N3U544%5473$U,S0Y7S%?4%)/5$5/7T903U\T0U]02%0N15!3_]L
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M 0$  04! 0               0(#! 4&!PC_Q  \$0 ! P,# @0#!@4# P4
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M3T"@\14(!H&R$\/8ER?P=04?EG;6,\X,8I2F,<Q2E* B8QA "@4 $3"81\
M  "(B/L  (C[<PY\"+<HKD.8T'671R,E*T+'*'6EC"FW6S\R'$$*21D'J#U>
MBM;:D\/M10-4:5N"X%U@K(&4AZ)-C.8$BWW&(O+,ZWRT#RY,5Y*D+3A:2AYM
MIU'R/XO:=@QJXVG/F,RAF\JUL"[B6CM<;E_+C.?,1%VXI=\^;%S<>Q)(R)&[
MVD7&;A AY!ZBJW_$6SYZ'U4EG?8VPW7L3UOT#LWGLEF6:Y.[D)-K9XV!<,*)
M<I^),_-#.*W(&3+$S)4+$#9V[<L%F\8Y:(-DFA06]:9;7NU/4FL]D(R/TW,Y
MV/J6V5YCZZ;HD0NDK%V1FB(J)5FVK,/FDEH%P<ORFKXAEWD,H;YS45$2JM5-
M$8CW*C56E@Z_]TH)E6K[5&:T?.M;A&)24;8&3=!0Z!W"#AN\83C.7:I :"FV
MAG*4TN<&KA)!Z**KSS9-E5:'$VV3<WX\%Y]I^US7?X]HD2692)K+%QC^:RB-
M(0M&$-LNQX\Q&Y:5%22PU]YR/%>V>)%LEZ_T_P"'4*_:H8M=PLWB#8[/*7:_
M$;2\&]6%[2]RONF)";=<#J&SRFI)4;G<HUPN%CF*;ARV(9>8N<S?^X=UL/J^
M$V6^P%GKMY3>1+B.:U])R1999649G2%&9BSF2=)MSIN!2!JH"0R2ZA&39;RH
M91/=G5]U;'O7O'U[Q O:U9_R' (R<+).2.I!H+9F1NS.[,F0@(+NV"39V9B?
MUK1P+E9.%%%T%#C2-B77H_9K1]&U3(Z? 9OCF3VI6V9[558SZJJW_5((J,A#
M5:2CW;@R:589-FZ(V+Z(!;,):8/^'HIJE723^@BCV=&Z4ZKVUN@9JC9(&+FB
MM3F]1VHR+-)RHU,?P '%LJ<Z'K  *?T 8OL/.JT].N=T=<GS2TW%+*V+>W';
M(8EI;?Q(N"5.YD)2XI+2&6EE*2U_% 7O2I/SCXUZ/T3X<V>VZ-TU\=<=0?;"
M;SJ^9>)+?VOIAR7:&G+%HV5$MKR[,9C,63.F769&5)69C:(.^(Y#DQUY5ST9
M&291+-5_(N"-FJ/H ZIP,/\ ;54*DDF0A ,=1554Y$TDDRF.HH8I2E$1 .>]
MSJ9N';SK [!RJX0#YS9T@Y:G*FY:NV;A-RV<('.10@'262*(E.0Y#E]1#E$I
MAYNKNNYMVNXKLK45^[HA2E6QF:I:(CL\,K,1$E2%(6&%/[ [M<;.PD!QO[Z?
MG6.&2^R)*EICEU ?4V 7$M%0\PHR%#<$Y*<I5S_*KH8V:I RF\UJU9DWG)"(
M@+:8T4$A&02AR,8=F#=Y^,FE'7RDS.%)-LK&NHXXH+)G 6Z9$G")E3^EE_3K
M):="YN:[56K:5?LQ1F4*]H%A@$7,NW),/3O#_+*^5?!X;")#,2.U'OX6X^:X
MBSM%5U3&D_"0R$&R%F@LY='4<.'CIX\.11T[=NE!57<+"F1)(!,(@0A$DDTR
M)D(0"_V1$>WYI='P-21=).6365T1?EW.^G54FW2H[,J%9[H\PR!"MSDE4N1\
M+;W4+^$3\2J.P2!%;0&TN+P+K9M.RM2-ZCBVU+=QC6E-B:F*=>*GK>W*^+27
M(P4B('5/A+OG_#"43G>\=Q2.     #V    #^ ?;G/''.KK)ISTW\>RE&3V.
MD&R;IE(,W#!ZW4 ?0X9NT5&[ENH)1*;Y:J*JB9@ P#X./@0'WY[G'(4E*DJ2
MI(4E0*5)4 4J21@I4#D$$$@@C!'!I@'J,U6Y6/A7=4Z/HCW1Z="VR'?!"2T?
M7:^%LDEZ]49>39*QY;)7S*#^/H2C%HNX18D>S;]BU%PHNDV!8B!DH8=M.B'9
M>M8/FM P*RVK1B,= GKK?8J*FDZN\0F74&6/AI"#]4Q'J.(Q,#/BOF*SAR[6
MF7A9?YB:8J(EORYP( /W_4!#^ A[@/\ ,!YSDO2]M7HV^Z&M:!8+'J*7%GW%
MJT,QV%KF0W6W&7D%;+J4##26EM("6E,@-E(2E..;EZ2L,NY1;NN$&KG"BRX<
M67&<<CK:8G+97)1Y;:@PYO+" DO-.>4DK#6S>K/SY=-$.XE@PV%K-&U>-?6S
M-NP4ZTO=7FYUW/7:B1[@L?%MXRYJRCA\C)5Q.086&1+$1[I0@HJBDUD%%D5D
M6O5;1\(#4IG5-CUBL:7$NHU^]E=/I\+&PZA+C+W1[)JSR]5 9-W^"QR39X10
M(J=<.7HO3+,6JL:S^4NYY<UC763.<-NFK7>EJ3QI'695A(2C*5DB/(J :1SJ
M9DD(2L-2-D#,(D9BQSLJ=-RJ]<BXD3I X!N@@D21/-2[HFV7W1FD=)ZF@LOC
M1YN"(4V*ZXU.EMR7W-BI\QO8Y)2IH,.(8(2W'*4LH :;V'JY6G-%Z;UX]?M(
M3=0:GL:7M(W2+ URIN3%$ZT6NWKN4%^T,;()@/W1,N)*:2DMW"&TV5_*X=T=
M>JA-)5PG/Y+9(96'U.2ASJW DC%P\3872R,@]3B7=H:0:*,8C8UX?Z)>809E
M^F1D%7!42)%$4RR*XXYVD=I3$>.PM]Z2IAAEE4B0OS'WRRVEOS7EG[[KFW<M
M6!E1) %9=YGM76\7:ZL6VWV9JZ7.X7)NTVE@1;7;$SY;TL0+=&!5Y$&)YWD1
M6MRBVRA"2I1!)<<<<O5K:<<<<4IQQQQ2G'*O-Z^(FOD7:V%Z],J91DJTQE\
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M'=671"9%CL<FZ0792T(%R,>\OW%AQ$.T+$N/]KQ-/0FH0EQ9L2'=9=T>>;5
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M0-2H<G<2X%2K_(+]67<O6<Q&TZ%UX1MVNU62" DX.5+(YE<=5F9^&M-YF&E
MF*[+Q$S3:H]I1E;!LB)U[O==-@P)G/,-J:-U-@GT=RK<+AN@42F9,VB-[ZZQ
M+.AIZ,S30IVRTB2S0]RL@W]-"P1IXN1MZ,?<W+$DK$UZ? X)7@ 2A=]?](";
MP7]J=M]/N/DP^/K_  'J'W-X#^T/N/GGC^P2O!Z0_.VO^ #T '[4K;X H 80
M* ?7^ *'D?!?L'D? !Y'E)D@X^57!!^\.Q!YP!Z8YSQ[GAY0_J]ON^N.>O\
M<./;.2>#.KR'\?Z#_JYI+LE4[G>\!V*HYS-VJNZ!.YU;&=)EJ78$JE9T+6,0
MZ5KZ,39G!?EP2SZ53:L590JK19FV<K*H/V"P$>H:!' :V ^/SGKGW$/_ &H6
MO]!_Y]_#G 8%7!\B-TUSW\?^]"U_O !_^._7E1D@C[AZ9X5SUQZ4#0'S;NA!
MP4_0_P!7OS4![]@/>F2OO8J>0+NDK'6&[Y?8LYKT3I5+_(3B?JJ%F;P$>@SE
MM@AI<V0O$']=<;*Z29YU;860CVD94JQIK&(7G7%F_67)[1GTOO-JMZ$]$R&D
M;'/R,#6G>B6V]5Z'H=:22K]1D*^SL=BGFE<6N0)RMTFV<4A#&.YG6C&1C&IX
M=JU;8 & UL0#_=IKG]KT@/\ OH6OV\B'V\O?W?</OX'G(8%6_(_[M-<]A_Y4
M+7^@#Y_]>^_N/*1(2D_</0?S#O@_TC/[^HG;N& 0.@.$XR,I'/SG., ].U3K
M\A_'^@_ZN/(?Q_H/^KD$_P!@5<'Q_NTUSW#R/^^A:_W>/^??;W_T?ISD,"KG
MC_AIKGCW#Q^U"U_K_P#7<J$H$@;#SC^;O^54^4,XW'M_+ZX_N]ZSY?Q_=C![
M"'^\I!CY$/;Q^:+:'M_#]PC^H>/'GWY*[D:<AR&KTVQN[$Q>V:6F5V!8\TA9
MK$_L+HC),YU"-4G,D=9PFW(HHJ<B!502*=50Y2 90XC);EUD[DJ5C&]94!G.
M.$CK@>E4+Z@ D[0!SQ[],GUIQQQR]5%....*4XXXXI3CCCBE....*4XXXXI3
MCCCBE....*4XXXXI3CCCBE....*4XXXXI3CCCBE....*4XXXXI3CCCBE....
$*5__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g424598.jpg
<TEXT>
begin 644 g424598.jpg
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M)R@U0D=256*"E9>9U-CQ)"8I2,%#1DEFDO_$ !T! 0 " @,! 0
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M+;P.I0%1K6L41]P5+H^9Y+Q],I]0B ;ZZ)TX8QN&MA8TO)J=[W.-')P:\T9
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M ]^P0XP$.,!QC&-F7/H_A#]_'-:?6']C5W?7P]0?\MB\^4_RU$C2U!@D?O\
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M<_-W7SG#7>M<.=UMU'XS^.*SSJ@[RXB[W7B?"5=[5+_A]LK^/R<W_P#-[?\
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M7]SL4P^C'SL?>Y;NCJNIK++'/5SRU$QGG:99GN>\M:6[07.).!G '0!T*^=
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M0Z15OD6<-!;EJN^=W.IG8--SV,V3"1O.GT>#*(BY%NS*-\8:+?27EL+6E8"
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M'[GJ.)P#@><J.<JT<DEDMXC8]Y^ZK,AC2XC]R50R< X&?&N<\<X8&R*Y'G.
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MH6<B%J1JV(0L]Q"%KK30A"SGWQ"%"<B%GX<YSGE4_APMOX@KOSRG\W_"^/\
MN\ZP?WQQ?R63^L;_ /7X_L>&PXUVO6+XX)6EFL2".SHN,\2C;FR8QMP7JS?!
M$/Q:9&C=#E*@SP B%X!)0Q^"$0NW;&<XY_S50F>N6N]8W/H?*ZTH"C:YE1'4
M'UN;R)/ :?KF%R,EO<FFU"G% 2_1F,M;L4B<"BRRUR0"P*=666 "@LP(0XQM
M5D_T(KZ6#_%QRR]):FAU9:G76"EEHV-JYJ0PS2,E?NACA>7[F-:-KN>  QD;
M3D\5F:&L%= 9VQF,"1T>TN#CEK6.SD <"'CYEJ+[H^Z;;M_V)Z:?BFGG,1\R
MYNC[IMNW_8GII^*:><Q'S\]N7+X5M8=JMWZ$MBH[5W6.Z_*P>QTZ<YQK;[H3
MTY?KA+;_ "*]G^<'YSC6WW0GIR_7"6W^17L_SQ\C?PH:+],,]1.NO2_A^V=I
M;]!6X>'T8^=C[W.OPZW/NLNRWU)=3?P$G/.P/#Z,?.Q][G7X=;GW679;ZDNI
MOX"3GGZ(:WZN5ORE)[5"K(Y1^J5Q^5H?;8%5_P <<<HM:T*?G24]U<T"^J5=
MOY(U_<[%,/HQ\['WN==9TE/=7- OJE7;^2-?W.Q3#Z,?.Q][EWZ%\ 1=IJ/I
M:MD>33JM!VNK^NU>>...3%3]....$3FOUUP81&W5[T]EUM7#!('4S5:4\1,Z
M"ZZBUQF6OD<L]#KK?<D+F%OR_9(TZ%)4\NB;:MJV!Q90W>JS+!>X_)&5S1JF
ME>2JV!>50]2>_P#8.CY!0#96V-='>O+7>YK#'V#VC1FU>QEF3.>,D*?K C">
MOJMU:K^R9*Y,D>:(H[RB6NRZ.X)94K5A6:O2$9!D1%,?3&0MTNU"U;E;.SJH
M\T2;7BF9"UL"V#1RLEC*WO5>1YR1M*JNH?G,1@JAO3JBTAL2BHAQM@$5EM8A
MB:TZ469+\PC6DGL)3KO IA($(9]::FH8Q('EM:8?(Z2+E\[41-$N7HFV"6WA
M%+*K+>WT9I".,60%&_PX"@MME@$R] N "H5!UJ'Y='*-F8]6B&^,R*MZHMC9
M *V\6_,BI:(W1N$Z:8Q$FNF='72I/>#\R3YC>Y3.$BASK%K00YN &+.TKDCJ
MUL:@BEUK![H;U-?XD_XAY'RR[E/O3[NNL]@=U.I=9%1R8,MABEUTZ9"7H+/(
M6()CHST.]8<DV&^4-#&[APG$J(Q@\QO 0=@>,D&&>"9@%P7")QQQPB<<<]!^
MC'T9?^$P.,_X.$3PP_('_<S,_>#RK'K(9QG24KM@>?\ =@]-[S9 9[W4.UAS
MGS9QZ,8QGO[WH]_..4\4'0<'N:#R.R;)D=]2*9R.^]M"W9V*VRVRCJ<TB/;9
MWA%6)&C88I>#%&V= T1QB9V9N;F5G;D"1 W)BB4P/!$(639#H=K3+VSR++&2
MWY2S>4&=W\D27;+<!_:_*T==D3_'G3R<[7XL1>4F%^;6Y\9%_B/5;0\MZ%U;
MSDR]&F4%51<.5_3MNKZVWS4%Z?-0U=31RNC@H3&^2FF="]T9=<&N+'.8XL+F
MM<6XW-:3@8.6_4L4LD3HJ@F-[V$M;'@ECBTD9D!P2#C(!QCAQX;0H!!QC/F'
MWP8;_P  S./Z(/T=@YQG'SO-\CGZ8%@7HP+S?)"(/^-C'?\ @YK)YTUH\6<B
M$IOX0A9R(0A;F[IY$(0LYR(0LYV&SG(A9SG(LYSG.<YSG.<YSS/O3>B"*JM\
MM@JXB,@LLV#*M/-?)T*-3BYKCMIN32]POC8^..#^V>RY/ITH95R]C8&5L7>1
MCT!"Q.UH_5))IA(3.9/3G*79-3W2.TT-'=8:B2*:9LE7%2,A#8&![@XPUDS]
MQ&0T!A&1Q('%=U)>*>LF;!'',USFN=EX8&X:,GWKW'RXX*^TWXW'TPG^5!S1
M)UN_:;CO]E%S_C^M?F]L;\;CZ83_ "H.:).MW[3<=_LHN?\ ']:_*E]U1U,T
M]_.B/]$7117E$\%47I!OLU0LY<<<<T55/JPGHO?NP=Z?K?-(?PXW(YL>B]&/
MH@?XX>:X71>_=@[T_6^:0_AQN1S8]%Z,?1 _QP\_3_D>^#'17H2G^O(M@M+]
M7[5V5OUG+J@*^_8:R?1O_P"%D@YS'G#J^_8:R?1O_P"%D@YS'E:W+PC7]MJO
M7R+5^\^&+KZ2KO:I4YLZ_$O_ .S/J)_3=0/P1NWFL5S9U^)?_P!F?43^FZ@?
M@C=O)1H'P^>P5/K*=3/DNZT'T96>LIEMM\<<<NM;%IQQQPB<9]&>WFS[V?3V
MXYXSW[9[=N_;/;OZ._O=^WG[=_3VX1:L6SQ3+7?6,0RNVY5KS8D\D<LZ?$?J
MB&6EJ=4\FMPN 6-L-=L;C1.I[S/KS,L14_T>L*72?86VJOBR8AI95L;F X+A
MXKQ5Y4V8+.J^OKIKZ959:L08YU7MA1=]ADRB<@1A6M+_ !B2(36UZ:5A?<LX
M*=<C-$6(Q,<G4ECP6H3G$J"232ZC;)V6VO;NH2HH0I?K8MAS-+M?W^+*8OJ9
MN[?EO5[3=IR!Z9Y0785FUC73U0M,26R2X7*V=@?Y[/XM&&)H0*)B])U#,S*P
MGW8?Z_Z_Z^?A% AGZ86B[&Z5,^HZ#9SWZE9 XRN$O[S+[*D3^LDCG.FZSS7N
MQWR035S=;H<D5D-#3/F)3<JR?#C<S:FR31[R6\-Z165PC6#W0WJ:]\YSG_<3
M]\BSD6<Y]@>1^?.<YSG.<^G.<YSG.>^<]\YSRRWP@^;]<'S^CSX\_G[>;Y/G
M\WF]_E:6L'NAO4U_B3_B'D?"*R[CCCA$XXXX1.1#VRUD7[1$51&5<L;(U!X9
M-I',I<D/A\;F+K(3%]6SNM61"UI9@V/4:;CFK-AN\C3/"UI7JVM]:(^X-J<1
MZ4?)><<(JYTW3A@K+Y!2QJZ;_)9F\ (ZZLLRGA5GI5]8B=( ]J*V9%,Z:W-?
M"FDYRJZ#X\KQM20^!0-JM&-4<:K(6(/CV7TWVBU/7(.477-%P7M[4RQ*SKH5
M63I%$TLE0(8*S%[I'ET<'B3-$R<8#&WYNCSNXY2PM^297,:DTHM"D0V8<<(N
M,0J+)H/#HI#$2]S=4<2C3#&4KF\G$*'=Q3,#2C:"%SHH3)TB<]Q6%(P*5QQ"
M5,2:K-.&4G)+$$H')^..$7\ZM6E0)5*Y<I(1HT9!RI6K4F@(3IDR8H9RA0><
M8()91)!)8S33!B" LL ABS@(<YQ19U">H_T_)Q0\%:H9NYJA*W-+N!H'*%#=
M';_J]Y7$1J(;M4'+I7(#4C?)E!Y;+&HLS.TC?G,1>$30QMJYT7G$(DIQP;/M
MH-HXCJ[&8V^R2,R:9JY6Z2= V1V)K(8@<<(877$RM*6/BM5.Y5$&4ML:8M"7
M$H))3F>Z.+ZYL#.WMZ@QR$<FB_+-]:[,E4 ;JKA4?D,6>)*%LES_ #CP:]<S
MDA%K4_3#ZQ5W%G=J]<3Y-HU*[C;ECNAD;9&FD2*-KVUL6N)C^TNR4BDG4V\^
MEU\3,BNJ2VRURMV?*F]T=TL+K6YZ^FTH4M+-@HQV<R&*./[BXG(&T"A.-<K+
M3B3I0'E"., $P&12JY4C86^\CB$OFK1":OK!V;F28/[*VNR*:MBN51R%UC(3
M66WIU.8>E&Q'#(RW%>NJNHQ&Y$H?I1%RCG 1!JK!+:;:VRNZ%_9VI\;#PJFY
MX;4#J@4A*/("H1.*0E:D/"2J*(4E!.3GE&A+4$E'EX'@!Q19H1@"1?3_ -?L
M>CD?EFI^KS@K5KU^N-#+5RY4H6K5BNG*V4JUBQ8<8I5JU2D^,&'*%*E0:8>H
M/.&,T\XP9IHQF#$+,@>?Q.3DW,S>O=W=>B:FIK1JG%S<W)40A;VYO0D&*EJY
M<M5&%)DB-&E)-4JE2@TLA.048<<8 L A8)DCH.%3]U$]8=;6&"ZSFLNOU(M!
MJ[J"Z$M*TQLJ6OFXQ8U.NRT(0.C6J&BCI E#>Y(5!R->C.R-.K2FF)SRQDF&
M %8&#4/5/P0_[FC7[XW'_$K67R,?_P!6Y6!U"=\M'9;!=:BHKN7JE)36S?G1
M&4.1;!L33[R8WQE@V/A#P_2)<!MF2D21B9&A,H='=V/P6@;6XDU<L/)3%&&A
MM"JW;K5*[9'ZRZ9V;U[MN8EM*M[,B=9736L^DH&9N-2)W!W&PQ23.SJ%L0GK
MT)"Q?E)A(F.6I"SS@#4DA&R?*N<GRGYRLB0*H:IJO#IBLJTK^N\/>4>7G$%A
M48B&';+?A1A!ESQ'&IL]7Y185JL),J_'9384J/$>+\<;X>1...%PM;#J%T-7
M >I974F>:!C#PGNNMZE<WJQW_6';O;,R?6'6%QX;FR"$1ZI-F*7JZMP0Z&B8
MY9E]>H?9:;QI@)#+V!M;V1O+F.R:'';&?>_7#SZ,X](LY]&<Y]/?OW] OCL8
MQC.,8U6^M-#J1?-_-:I+8K_8T8E<7JFH26&+19?4I<EV=;I7N5%H4LHW6]-.
MX$_S@JW8F@DK_:5F>Q7(VM[=X:CKM&K1MRE$S6'!MJ,'QOO_ !P^_?Y/AB[Y
MQ_T<Y[Y#_P!'.//PB]^5H[/^Z&],K^.Q^(>.<LNY6CL_[H;TROX['XAXYPBL
MNYXR(./-D6,9^1G.,<\\AC<.E41N*?N-B.]Z;CPM8Z$LB,^,5'M[>]30!,4T
MI2&\)C;!H)+V:/MBE>47X]V5H$J=2YKAFKE1PE1F3>$4S/#!_P H/_\ K'\_
M/;E"_3UU#QL+J+3UPV;MAU!G6<RH$Y&^KT.]VR;.B6#C]K3J--F<-+=.2FXC
M!;*QMB0X"9.26IR0,\\L:@]0<=?, &"P !C(A8 $(<"&(0QBP'& XR,8LY$(
M6>W<0LYSD6>^<YSG.>$7MRA?8+W4.^_K'=,OQW[M<OHY0OL%[J'??UCNF7X[
M]VN5_P J746^?^V_I:A6+O7@RI_]'VB)<@XXXYI^H&H^W7^V1HI_;$M8?\F6
MOS9&)_H17TL'^+CFMS=?[9&BG]L2UA_R9:_-D8G^A%?2P?XN.;4\C74^3TS7
M>ST2FU@_@![1)ZJ!:B^Z/NFV[?\ 8GII^*:><Q'S+FZ/NFV[?]B>FGXIIYS$
M?-)N7+X5M8=JMWZ$MBIS5W6.Z_*P>QTZ<YQK;[H3TY?KA+;_ "*]G^<'YSC6
MWW0GIR_7"6W^17L_SQ\C?PH:+],,]1.NO2_A^V=I;]!6X>'T8^=C[W.OPZW/
MNLNRWU)=3?P$G/.P/#Z,?.Q][G7X=;GW679;ZDNIOX"3GGZ(:WZN5ORE)[5"
MK(Y1^J5Q^5H?;8%5_P <<<HM:T*?G24]U<T"^J5=OY(U_<[%,/HQ\['WN==9
MTE/=7- OJE7;^2-?W.Q3#Z,?.Q][EWZ%\ 1=IJ/I:MD>33JM!VNK^NU>>...
M3%3]....$3E$O7L#/B*#UX>8'6IMCJ6'9EG=7(B/RIZ8K,9VI%6-D+GM15S8
MS[!:Y&N\B<8JBD[8^N89;(E$)@A\JF (<H1-;E(XW>URDWK5/K=!X7J;82MY
M>X@MC^R+K&VB<0&W-?*HM^/KK7H2WJHRWU2+:!ME5/31_EY$O,BKY%GR!R5P
M2P]R?9:R+XDXQHJ0IR*R[4O$C%JSK?F8M+0Q2P5$U&;)F1AF#C8+&T2 <$83
MG9N9YT[2::N<P;4:\1Q*&2KIG,%+TG 6X&RN1B/\LK>!J- ]-E3[2DF4ZZUF
M>_:[*UJVFG,YD,-4P<];+O9 _P#@<C5Y+<24$]\&<L:5^+=TL=F91$JCY#8_
M)R7 '-M0H]!XEJEK3%ZS9CX[7,=H.H66 L*F8L%B'L\,;("PHXPW&SZ*N;U&
M)L8D9B490Y9''AT89"(.75H7JF]4G.%(KA%6CK!CMU#.IKCOG/[B?SB%D0L_
M[0TBQWR(6<BSG/;OG.<YSG/?.>^<YSFRLPP)18S!^%X)8!#%X(1#%X( Y$+P
M0 P(8L]L9[!"'(A9[!#C.<XQFM36#W0WJ:_Q)_Q#R/EEO?'R<?9QPBJ6E'6X
MT A#0ND$S?\ :"(Q]L4(TKC()/T^]^H^PH5#DZI&)L*5O;OK6C:TXW-[<&]H
M;,&JP>47-P0($7CU:U*4;G"E^I9J[?EFQZHJ])V3*FDG$\ :PV!I)N;4,6+&
MQ-#@]N('>?VO0\,@D>&%"V*PI0/TC;1.+AA.T-V%3JL1HS\+=;G <=-BZ^PA
M?M@ZGXSW,'GS?JQM?^_I%GM\_';/P\M<*P'&,Y\+/?QIWFR,6<><TS_@Y%X/
M\';S>]VX1?OST,^-Q]&7_*!Y[=\9]&<9_AYZF?&X^C+_ )0/"+63TT_:./\
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M=]7F5J6_R6;"TOO^9;'4BJKJTR)I'EM3K%,VG#NU6 L'&)JI=HTG;@1$R%2
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M7*&PTT=<WQVJ?>_=&,))LD:D2O,3<')=%M@4A$A3-S<]+\L"H\U64F1NJK*
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MH9KQ(ZRBML7+OFP.UMNI[5#Q(-Z^I?)FLO*62P.&J765OD9O!W9X-'$\KL^
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=)SB3@&$I&QO3%B"2B3 *LP#Y@AQCT=L?>X1?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g501832.jpg
<TEXT>
begin 644 g501832.jpg
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M 0_#T#H/VC[?GQW_ 'W^=*]G'. []/4.P_K=?>/_ %>O =]>H]C^7[?3_+F
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M1\+M 4/N7?O \<+SVPZTR64C"#)P\\"3R0Q]]I-S(J6Q*X=582\GS5D3!?\
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MHB9!$YC!]DHB'/--9) $4W#I,%7!P21(JL0JBJI2"8Z:13"4RB@ 4YC$(!C
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M2 .6R2C8@-U%"N$Y,E 0*4#" F H 80 0 1 /40 1$0 1]>A$1#\1]^<\<R
M!VS^))_N36/WV _L!3GYW9')VK@K-1!%V9!8&RKE%1PW3<&2.5 ZZ"2S=59$
MBHD,JDFX0443 Q"+)&,"A?T<<S2H:%I^^Y2E <Z:I&-Y2 <PZQY3+YU *!3G
M H;/CY0,( ($$QO('10,(  \Y^J.^_Z\]4?W9,J?Q/?MY,KCD=H]V_,WZUG)
M^7Y5_3]Y^[$-?JAOOYO-^G/5+O[_ .C)E/O_ !_E.]_Y\^9)8WW<EE8]Q*99
MT^DG42Y,\B7,AJSDEXM%O3IF2,[CU'.RJRC1R9,PD,NV.BL8G9!/Y3"')N\X
M$ 'W !Z]NP >O\>8"^^>#QAG[#MG)[^_^]8/(P0K#CAE4@X([C;\OY_A4,DZ
M;OP0@%_3GJ@/0B/8:R93#T$>_;^4[UV =!^?0#V'W>SZH[\?KSU1]/;^C+E3
M^)[TY,H  /0 Z#\ XY+:/G^9OUID_(?(*N!VX'E[?K]V(:_5'?C]>>J/Y?T9
M,J>G_I/\?5'?CT_Y<]41_P#-ERIZ?AU_2>'_ *N3*XYC:/=OS-^M9R?E^5?T
M_>3\L0U^J.^_Z\]4?W9<J?Q/<Y^J._'Z\]4?W9<J?Q/<F3QQM'^K\S?K\O[^
MYID_+\J_I^\GY8AK]4=]_P!>>J/[LF5/XGN<_5'?C]>>J7[LN5/XGN3)XXV@
M?YOQ9C_<TR?E^5?E_I^7]34-?JCOO^O/5']V3*G\3W'U1WW_ %YZH_E_1DRI
M_$]R97/SJN")D4,8Q"%(4PB=0WD*'0"(B8PAT4 Z_K#T'Y]\;1[M^9OUIDY
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MZ\NRPX((.<$%5!7'?(('J,$=^?Y0X^J._'Z\]4?W9<J??[_\Y[[^<?5'??\
M7GJC^[)E3^)[DR#B($,( (B!1] ]_;[OS_#D?,P;*8JPNB<ENL!U9CX7QTZW
M!D&4G11\Z2155F;<W;) ZJJ28.'AD4_B*%* B8P!S&%# >;NN<,YQN;:O&22
M68A5 R2Q  -;=E8WVI7$=II]K->74I CA@B#NQR!DX7"@=R[%5&220.1CKZH
M[[_KSU1_=ERI_$]Q]4=]_P!>>J/[LF5/XGN14G/%*B"_+FJ&)++,L7*C@$9*
M1L<<R3620#U.5NDW<N1*58#(*"GYU$U \IP\G9N<4KQ6JC/NDD9_&5A8-%"'
M'Y^N332Q!TFN+98X,S(,'!O@+%,50"*")/*)A]! 1T1J-MUWMB722.=;1F=L
M1B\=I5%F7+EEN5,$^Z.1$*B&3)\IKT7_ .C/TG?")>_]TM1,$L33Q,HM6::&
M,+OEB192TD:DX9D! '/ [2L^J&^_Z\M4?W9,J?Q/<?5#??\ 7EJC^[)E3^)[
MF:<59IQYF2+)+T2QIRI&X@60CE>VDO&*J)=E0E(U0070,(F 2*#YD3F*(IK'
M !YEXI@'L [$2CT/?7??8^G^(=?AS;B99064DJ&*@B1F!*X#>N.'#+ZA@H8$
MJPKS>ZMKFRN)+6\@EMKF)BLL$\)BE1E[AD=0P_ESDX[<0X^J&^_Z\M4?W9,J
M?Q/<?5#??]>6J/[LF5/XGN3*XY9M'^K\S?K5&3\ORK^G[R?EB&OU0WW_ %Y:
MH_NR94_B>X^J&^_Z\M4?W9,J?Q/<F5QQM'NWYF_7_P"?6F3\ORK^G[R?EB&O
MU0WW_7EJC^[)E3^)[CZH;["/1LY:I"7L/, :R93 1+WZ@ CL\( (AZ /0]=]
M]#UR97'&T>[?F;]:QD_+\J_+Y?+^OW8Z=1&-V8U*%:Y)FZS8[PB@L%AFZ97)
M2H5F0=&=N#HK1-;E[-;Y**1*S,V251=625.HY37<$6326(W1<[CQR5*<<<<4
MIQQS@P )1 ?80Z'\P^\.^PZ[#L.^PZ]^*5SS'.3<JT3#M6D[WDZW5BA4B%,R
M++VRX336 @8T9)\UBHTCR2?&(V24D9=ZUC&20G%5R]<(-T$U552DY1'EW8/?
M:@;/H:R*;2.R62]6"$)6<CP&J&,5M;\9,LA2,^O4*;E+($_<CV"O9!CXIDS8
MU6H/D7$[F98II&O%A$1?HL9&>)]X;66_$DUIQABH-C9#$MUH#N(N<HM'T^)D
ML:Y$R;%1\.V:3ULJK\SZ5CHZN2K:9L5.CHQXX&)F)!JH\([^017Y4D@D2&4;
MA&]S;QNRC<PC-Q")V4 $-MA<DD<*&5B0I#5:8PDAC=UR(]X(W!3N4-&"S)D!
MMP.=O;)!X-638KV.PEFNPY,JF+<JX]R!9,.6L:/E&"I=LBK'*X_MQ4 <'KEO
M:1JZQH:7(3X@"U6$P"=%PD"GQVZZ2>;Q[].@[]?7\@_'_?\ PYK7X%\)K8?2
MFH[.9/0W.FZG8X+$MC@<;W?!U QY&7"_U&GW'/VPJ%DS['95HN0J@YOLM><O
M.X:02HL8T:HUVJQ";.PI$DWT8UO%U OMJRGJ9J]DZ[R))JZ9&UWPG>[A,)M&
ML<G*6>WXRK%BGY(D>R1;,V1'\O).W1&;-N@U;%5!!!%)(A"%O*(@41RO,NQ"
M7D38V]E#.A4*F.FQ* [1N !RW)K51Y&,G4B$.)9%C4.'W1)(5CDSDD=1=KE3
MRF[:3D5(SCCCD:MIQQS\YG2)!$#&$O0"/8D/UT!O*/VO+T/0]=@ ^@&((] <
M@FP2!W(& 2<G' [G[AZFE?HXYTJ:R1CVMV*LU"Q7JGP%MNJCU*G5::LL-%62
MV*QHI!(IUJ#?O4).=48?&2^<3BVKH[;XB8+%()R@/7)[/&$:LXMS.S9@Q?7G
ME 0B7-[9S=]JT4[I3:>432@W-M:O95%Q6V\RJLBE$K3*;-.246139F6.J0!;
MEX.X88$J<CD @$CW ) ./4CWK.".X([#MZDX _$\#W/:JPO&+=R+: \/[Y%\
M^9 /BO:* N9@Z<-SNFZULM*2T6Y*V41,NS>!Y?CHG,<BOV2JI*I@4H=B\2:[
M6RIY/\-FL4Z.J)[7E'=2QTFM6JWPTE,CCZQOM7=AY2O7&(8,Y2.07=QLPS9-
MWZ4LE)L7<"XE6H1WS:[9\QE%M)KEKEO-4H+#V8EEK7"5JU8]SW4VU!RE/42X
MP\_6E9,U R%#V+'L[$VE@R3?O'WT/*MWA(U^N0RC=5<[8/+B_'GAB:SX_G:/
M:$FV;KC/8RRI%9JQZXROLEFK+@5#(D12K;CQ&9@R9 NT\FT0<5>\V-G)10 ,
M9(N'#9\X:'=1[,R509&,-O(DZ=+4+J[ZB1YB:%XM(3IER3ER7OF 9<!E8*&*
M^24A4D31!=ZZ8(0K.1ON5N=1>*7;D85TFLU!&Y62 .0-S-)4L?QNLQM\,4S(
MS6AUJ5M.LVF6Q^P'B$T!NV!)[$Y>Q%:'6OM,PI$NB*K'H$A<\W,)2_+*+IOE
MFF+HA1PW:KH/V#E3"\EXJ_B380P3L+D"]5ZR9#=%U&N.PU%OV0M'+CJQ1,%9
M1JKNFN4<6?"L=PEQS9C.S0MI53@+6=>,M[.8CBJRR!HZ98BTV&*5H#JO1)_:
MBQPF'('YS=24":V70F57$]#Y-<A7%:LNW?0DL\?QT7&R,2Y>&DX:&;,8EY)/
M7<LHV^D7"C@<!L_!]TB2J-\HMAI>3KS7[]AIWKBFEDO/>9,C/:/@N0DX^9?X
MRQC*6NY2KW'U?>R,3%N'[F#62FY%"-81[V36C6I&9(QW#/-%)+ T*26T N8T
M!98KIS>RW\,<DB#-M!-)!;V<H;J26UO$SN[22/)F01XG53Y0Q%L6PQ!#::T,
MS@*-SE8=0$J%60/=A0"(8L2VU%AMEH;#L9_*PRACO+.6YB2?6)Q8,7XW=8NJ
M</7YQ-J]A:>V@7UDL[N27K!%%X]2SN'K5:>1!!PM'MERJ>>4'.K(V"IPT4[[
MFHEC$52.+]+.W$BW385]C'L2KB>9?KK_ "\61O'ID<J'D5T!*VZ<*&\@B?F,
M*_L]K]:[+<*C7,MTF:L% B7,]<64?,).$H"$9-6[V0EGLB4OT8:.BVSU@>6>
M-7CA")&2C22)VQY%D5>XE,CE055F SV5$RS=^0J LS'.!EF/<U4H?"JQW281
M20H4LY"]E4  N2"% 'VA@<BL\<<BC7]YM1;4^I\97]@<;R<C?9@\!5&"$WY7
MDG+E=QK!%BHV6026C%)%_,PS*&/+D8(SKN7BVT,J^6D&9%LU8WRWC',4 I:\
M57RK9$JZ5ALM4-8Z;,LK% FL=.EWD!:8=&7BU7,>X>P$Y'O8B430<*%:R#1P
MU.;XJ1RA)?,NY?,O^9>5[9[CCL0>_8Y[5-T>/.]63#F,[U*XD7O&<@><8.5^
MT,<BLB<<<<5&G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQ
MQQ2G'''%*<<<<4KUJG$A!-T AZ^81'KHO0B(_P"0  ?B/X=CR 6P>5GUH5?T
MZJR*S"#8.%V4W(LEC(KR[I !(JP:N">0Z3--;M)=<I^EE"F!/[(^;DOLKV(:
MKCNVSA.P79P[DC00'RB#UZ 1[,_?N ).722INO7RD'KUY6^A%>9%!JJD8 *@
M+9-0Z0N$SNFQ/MK+B'8%!5?S."_%$IC <  WF[\N_8Q([,\@RJ8]\9)&.Q'M
MV^9SZ8]9^BS0[.\O;C6+Y!)'ISQK;)(H:+X@C>7P00\D:8*KAMN[?@$*1%&;
MKL0#\E?%S''F3-7,NWBP A'Q(XZWPE7?P@'XATP6."9G:I@575,(B;H>N1MS
M=0+#'8IR.YIAS,;,PHUI6K[ORJ+K,I%&,>+BZ2!43B+Q+X0JLE!.)B*E3 @%
M*0O=FBU=;.!5,9%('Y4E&1WR#1([A 3$^((D,('4^$0P?$*@8PHB<.C$[#OG
MQGU4;G(0RD<>11.*27E!%+I85NF[A=P1<Z2)FP)'46<(&!4P@)TTTCB($&\:
M=;?Q2QU QI(]G<PW20S()H).F0625) R@21;UW$ Y90#S7UQ8>-4MK&73RTJ
MV\L;1$0SR0DEQA3&T;H0P)W#:58*I8D#)K^?]1MW]G,87Z&E#Y1M=D:PSI\F
MK%3<B>1C)D%/,BLD\0?$42$R:P%51$"G4(JD0W103(([5G@N[SY3SC1K/99D
MC-K;L8VAM!6ME%*%;PM[A)R-4F(AV^B4TQ91<TT2:N&:KU$"&5>?"*=8"JG
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M%%1FXB7"+I$3!!BQ8DG[1R<+V/'8>@X/IQ_6L.V]MQ'.V)?3M&NTYP /-WX
MVG./3$IX^3:3,.SEXY9-VQE&#>0CW"!RJHNFCYN1PR<(J%$2G2<H+)*IF >A
M(H4?3D-X'Q =8KA#1-FJEDR1;*Q, 9U"6BJZZ['6.LSC%%TJS/)0L]#XH>Q$
MS&F<LW:;>3CG;IFX%N<S953R]C#RUY9\2W$.5M:=?TH/0QPKFK](U=JTFT-L
ML2.JK/"F-D[H@61:O99=[)DDV#5*)2*1<JC9<IGSE:1,<Z)I%ZH8@W"P8RQM
MB.;C=0*[KECZ#5KK" Q8KL,^O<?%-&KQ:&:14ID>>E(]<"RJY3/E9E=XL9@9
M5)L<IR-RDBP9E !QG!R5SR"!V..,@G\*B1ZXY(&"3Z \^V<]O8$=C@BJ@\3Z
MR:Y6&&GW^PLYD^$L*EAN%@I26$-8]NH!2/EEL^9.RG6;[E127QW.TS-5N&-N
M36%=1EJISFG)0QG+9.(!XX1?-\SNJ'B-]8[^XE,PY*<U>UTS9/&U>11THVCB
MK$PK6XT[3[%G)_+K1]"9UR0L$:\I$63%R4!$1$#7V3I^E.14L@U8I);$Q2>4
MI2]F'RE .Q.8PCT'78F$>S"/WB/J(^H^O/+H/S_Q'_;R1,O.V0(3&T994&X!
MDV,5.X $C)'! /)!YSL&X8R-(1G=.EQM)'EDC:%D9#M\I5H4*G! P 00"&UB
MH'!^/5LDSE_N><[O).,GSFNSC-\77]$]LHYM+U_4BTXXL6&(K&0/*8_<5*6D
MVV,F,/E!:PC8&,L>:?25<9Q+MJP\ECNL^9==]=*O=:DSF<M2K*U9WSOF5L6,
MU V6@64*AF7),_?4ZPWC&6*%V_5;^FOH@7B?P0?BU,\%JV,L9(MK'0?G_B/^
MWCH/S_Q'_;S #JFP/Y1MQE1QA%3G;MSD#VP,@8P!53N77:XR.KUL+A1U/,N>
M!G'3*Q@$DA47))YJ)4/N]KO-VRCTA.QW>$LN2;*G3J*UNV$<WX]866UK0,[9
MDJY'3]ZQ[7J^,RK UJ>DT6"\HBX<-HA\9 BADA*$LDC_ !" </4#="'H( ("
M " AV(]@(" @/IZ"'8 (" 8VOV)*/D^2QE+W6&-*O\/Y)9Y:Q^M](/FH0EZC
MJM;Z4SF!(T713? G6[Q9&(LGQ5FAOI+XQTC+MD#DR2D0$R 4 Z !'H/R^[V]
M_P!O0"(]B(=B/,C(')R??&*AQQC/;G[_ -_[]Z]G''',TIQQQQ2G'''%*<<<
M<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2L19XB7,UB6YL6A3J.2
MQ[=^FFF &44")D64JLF0HB'F\[=FJ4P=]^41ZZ'H0HPWKVJN.L.,&%WHE7K]
MP=SU@&LLB34@];,F,PY3%TU([&-_G%3'1273*@50AQ72^&8P (B&Q*Y03<HG
M25(!TSD4(<@@ @<BB9TU"& ?<ITSF((?GZ^G?*8O$5TD>93P-;J52P:M5C.F
M]HI3YXDM\E!V>*<*.8]*6%'S&^15%9=J#HH&! #@JH @ ASL7A::P36["/55
M1M.>YB^*ZC.J",NJL6*88!59G;:V<)C!!KUOZ,->LK%KW2KL)UKJ19[$2LJQ
M2RB(HT1D;*QME8V0N"K892IS6M-->.!MOCN7;/+IC;%;NOF6^(M#H-9Z-<J-
M51[(0DH+E14B@$,)2*J%, &\OG$0'EW.DF_^)]WJXH:EJI5^^5A%BYOF.YU?
MJ9AV+DBB*$G$G*<HR42Z=$2*WD.E2I><$'2:2ITS\U'L^Z4[RH2#N.O> KQ)
M-H!8[%*9J;5*R0KI!#_M#AH]CUU5 *X1.FN4BJ!% (;HQ ,40YSJ%4MQM=<W
MT/+6,]?\UR$[7'P1UEC"55\W;6FG/CH-K%6Y/YH$6ZB;UFD4&2[D_E8O6[=Z
MAT)3 /U+XC^CSP+J?AY[G0K_ $2VU>&'K0FQU"-H)]HXAE5IB@2163ZS_B(^
M,^7*UV.V\6>)1XA-M=>'K]- N.FL5[<:7-!+"[\/+$]K;()E5B"%975HM\D;
MJ=H;;PWVVR'3O7&VY>80;.V6%*1B:_3(1\JYC6#NRS;Q=%J>86;"#A**8HIK
M.WJ9#$5621Z^(7OL=1W;7=+;;8*,B27W(\6\JL3+0]Y1I=.009U^.E8-TE)1
M1GR*)?.Y38O")B/SYW *G#^=*?L Y</XA+C=;>?$3''V/]7W^**/$2[:R2"F
M4[=7D;W:W[!@L$=%0,+$KNFS-@U!=11X=\Y!=VN1(P F7S%&"F+O"6N+B@Q$
M5<;8".2;F];Q\E68XJDH_BVSA0"KQC5-E\5-U*#WY2%(8$$A,10_1"CUP?T>
MKX)\+:&NJ^)[[18?$!U9X([>66'4)Q;]-0HB6,NMNW35WW+N)=T7=D8/+^(;
M/Q5K^HW.C:/I>IMH<^B&XN]9AD6SM;'4HYY#&CW+H)98I8UMVN(P([=(4G+L
MV[<=M[PO,MR^R%8QOF65CR1#^5P8QD9YFGT9)"?G)E-HH9'L#"FB^"$<2;5/
MSB(,W"'F^WYN2CV$8_162V%B<*)-8^PUJ+B6RY@-V:6A9%ZD1OUY3 <ZY)9$
MS8@"'8-EA,(%^USLFCFM4=K)A>MTH&J:4V>)B$I,B0$^!&,XF,2C(2";B7TZ
MC8Q! CHQ1\JK\[I4.@-UR3%\I$=>83Z.>$^ Z:F!U$OT@Z<Q[\""0%D3==>5
M5$RC9<@>IT%E"^G8"'S)?WEN^J7]UIZ@6LMW="U1@?+;-<D)QWPJ*"!\AVKS
MJX\70VWCQ]5#BYLX(AI,TR !7C6)(YIX@%;=%UPTJ  AH\;<>7&B]N+LEL76
M-O\ )EAQHGBNB9.QTR7Q@MDQCB^M.<EO*8V2),HP2EXF6[R0<02K9ZBM]'-Q
M!L!C&(40$IRCA3 WCG[!8ZNPPN?8]OF*E)J'2EI*)C8^%N4.V,X336>QRC(C
M6,E5"D/T#-T0@K)E,FB8%1 1M,\5OPM<V9 R,XRGA"XU:I6:69,6ECJMF!]%
MQ%M=D,9FA)05@9)JM&TFX0%!LNSD  3IHB;S^@!S7LLGA*;[1$\=RO@60L3@
M5A^(YKUB@)!HL F\PJ%75?HF\B8E[,<0Z( ]]=^WU?X5C^BSQ#X9CAU>?P[%
M?&PL[5TNNG!>V\T*CJA9Y2CA&)WHT+J &Y8X(/;_ !#K/BDSV-QX,TV6YTLR
MM<WD]E'!-:7,4T0)E:V0RRAXGR'5XU9P"4<D@C91V.UN3\0JRZ2[+8CS@\B\
M;4>?D;>]/"3<E .Y2B2BT'+(-JTVB(Z113M\=-PBT#,C-G8%+%N'K-9ZDY02
M'E:OB4^(!GB#V7N6O&,LO+X:H&.JI!-Y.>;)I#<K[9WL:JL\<OI]5-58K5%
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MU]V@(%+HEI64A3$*&I>MX%(90BIB%##5+ "F5(4I%#%   3E*4IQ#S%*!1
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MY&7./LN8+;#5Z7DK2XQ3#N)9P*%5C5F#>2+,6-H9)I&+_0L@X"R@JV0M)#U
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M?4;*9<@,%GB8A03MR_U,@BFQ&VV9SO! VP27D<QW8((CDTZ]C8C(W6\J@E@
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M<BO$J92!Y2]@7U] 'T]>Q$>OQ$1$1'W$??GEY \H%]>@Z'O[_0>_]_3GEQR
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M\L LK@8OIS]G=::<O14@Q*([9DZJ%<J'N02T_)9V4;_L@MA'8]L@GKYGA0I
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M9>.,_:D2=BP6455:"K\LJH8Z9C#29+^)EN<TEYAJWRNQ(@UF9=JW2^H5*/\
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M7$H)FU]YCQ_[U8F.+,<6'0"L/[_GJ G[!.82MFQ#0JV/<#K0S1VAE+8(\[A
M*_CW'MJKSV2M"K2W 0S7&;1&[3:"$1.P[=YV[P_X \4>++:2_P!#TR&]M[:X
MEMGFDU'2K)HI;>W749CMO[VUE$,$,45Q+<JOP\4@MU>59GA5NN:KX@T;2G6U
MU.X,;3Q+*(OA+NY61'E-L@/0MYD9WDD:-(23*ZF0JA0.1/\ N.#?"ER#<KG;
M;=G/%$\QOKBS33_'SG:NI%QG"7^[U1A1[/ERH5!"[IMJQE66KD<Q;A=8=PE)
M,9$BL[$)Q\\^?R3GNU8JGAP5.FN*8.T&/I\LSF.MYVR-9;CM71K%;\N7^FIQ
MB, ?+$Y(6T#VRO1B%=KC9.L*-V4*5"MQ7_895DW2KG7MROXHVJUYUUV6FHWP
MJM6:CCM:,OF!<,Y:CEJ"5UFW*\]'O*>U1P1 EUMC)NU,:BE(ENMDFVRT>C6(
MCZL-9)1A/VN)CT^[8Y\0? .-FN#M<['X3>I4QD6E8-J<QLS.V":QDS8:W5RL
MQT)7'MGV!G5M<)"/KEAD8A%O:ING)24Q8H:3L,!05AE+K)ECP[&_T,?2,BLD
MGAY5C0W!D1]<\/XC>"SLC=]13JN$,-LFGVEP6 Z<PL=-D*W36]L=*/Q[X65P
M8M5E4@0(IBLM0#,&GE2!8V6U <-(T\T 5B6A^(NT!@626MH34_5C".LT'9CX
M4=S$K#Y-=PEF5F)>S%M23F(BH5**J3""DVQ2,3UR(@E2H1"B(NEG;58BZ\B]
M\J:@2VYJA0_^D;V:)Q+5+E!^'N6,B;Q<8G&>LV-(O-KIC=\YQS9T]AG-AQ9C
M^/P69R&.ZN=A&UOZ:;HC%*VI^A2X(KM_'296&R[@?)DSES#N+LD66FFQ]9+Y
M1*Y:YZB!8&%K-39>8CT'4E6E;'&(MV$RK"/%%8]>1:MT$EUD#C\%(WF(7K7B
M?P+XG\%6]I/XET^'38;J[DTVUQJ>E7C2W=LJ]:".*POKJ7%N?J)'V=**XCDM
M&=;B&2)-_2?$.D:W)+'I=P]RT,*7$N+2[@1(I698R7GMXHPTNTR1Q[NH\16=
M5,+K(V8....=3KFJ<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<]:JH)%$Q
M@$0 /N[$>Q,4@!T "/J)P]?8/41Z !$,0R&?L,1M;NET>99Q8TI6-)J0KV2K
MB]R/4&=6Q[.Q)VR,M"7:P+2H0]5FXMR^8MI&)L#Z-?,E7K4KA%,SA$JD=PSC
MDD*&P 3Y2P4'@>K$#'?Y8H!GMZDJ/3D+N(Y_T\_T[\5F P (=#["(?ZP_9R*
MFY^O1MH=7LY8!CI5M69W)6/)J!IUI=H+NFM1O27PIJAV]9NAVZ4"K7*-A)SI
ML/S @S.5 /.( ;M<?M/KU*9$;8@89MPX[RT[!,S;%S7*U#<Y%6(O#I6)H=&C
MHSI[4X*_KKAM8H\6\.J5Y!.495$3LU"*F^E [(X'M-_EL45G,^(;#E2!5<I3
MF,H/*%'F,AP@L%$"283-+C)QY8HP\7\RB,@F[CDA:_%1^.9+XH=5L5F10CNN
M=C(Z!P5+ ,C X&&PP()P5R"<5D.(RLF%( #^91(CH1N*LI!5D8#SH00PRI%4
M^89\(C(&/-A]%LS7++E=M-?UKP*BGFJMQT9*LW&8]R&*-[9Q6P!?BM_EU$&C
M'+.2V9ADUD9<$WL, %5! QD+'M==:[-A[.^ZV5)N<A92&V9S51,E52.C&\BE
M)5V)J>$:)C!U&SYG1A:KR+F;JKV4;KQX"B9BZ2^8,#COJ3#;(U2>REEAF-EK
M,A+4M1LC=8MA8(QW(TM1['#+L"VQB@X.ZKIW\4!I-J6729BXCR"^1!1J!EB]
M(H&R^OV4K*O3<;9RPQD&W-8-M9W55HV5Z+<+*VKSXK=1C.KP%>FY&51A'23E
MNHWEU6A8U8CAN=%TH18I^9ZXGDWH0C;92@C01PK'<.':.&- (Q&CP$HL8"1E
M&4!1Q4CO43!]Q$SPB8OEY&FM\L)7D8LQDDZP9Y&.9"RLS,Q!K.(&_G/)T/\
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MUBL/0=]^TU(#Z==B(_[@'8!SY ]=] '0]^O[/7T[^X0^_O\ +V$>^?7L ?\
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M"9+R\T;_ #>1)* =72S.5L)8P3=N!;?6"\"W(\>D9-6_<:V5=V.53A6:3%U
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M3,ODAS.QT<\U@VJ<K+1!J_$L2/!4C\)O$2$4<MU$R%,H!_YLWF(4!((V6?\
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M+72O(8307C9H\8F:$=3+-I'0?E6&*C'S:)!_*KXP>>0< <@]R2!@>[<[B/\
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M]XE^P:,JM"H9FSV>$?JV&.P77[:9^WC8AG+QYTTG)JGCMZ^NHWK)37;WW?\
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MDC"^H*HZ@J2R@#:"0%Q4EDW=79.I6#:'49C;(W^5:ONEA;%>K]P:U>.D3L<
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M*>/"HGQYDZHY$,Q?J5ARUGFB<F:K$9D?1BOS+-91-P0IA)V%;K[P^_$.-CR
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M2<I/0+^/4?'78+V!PP?,F6)6Z$[6THV2A2R*2IZRB1X]T14E6'D9R&*L$VY
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M:HB3$69-6,/97Q##88?01Z7CZOR<7/PE?QP2,J,9'.VBAFI6Z4*WC'%=7CE
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g554321.jpg
<TEXT>
begin 644 g554321.jpg
M_]C_X  02D9)1@ ! 0$!F@&:  #__@!"1$E32S$Q-CI;,C!:0E8Q+C(P6D)6
M-S0Y,#$N3U544%5473$U,S0Y7S%?5%)!0TA%05]&4$]?-$-?0D%2+D504__;
M $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M ?_  !$( *P"EP,!(@ "$0$#$0'_Q  ?   " 0,% 0              "0@&
M!PH! @,$!0O_Q !I$   !@$# @,$! 4-"@<,!PD! @,$!08'  @1"2$2$S$4
M%4%1%A<B81E7<8'6&!HD,EB1E9B9H;'7\ HC)B@X.4)WP=$E)S4V1E)R*3,T
M-T=(5F)H>+6V1$F6LKCA\5EGA(67M+?&U?_$ !T!  (#  ,! 0
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M2\1/*2FI6$C)F4CV)B>8*CEG%OEB& G@;J<\:-0(L$'8'8@V#TKY]O7MB:W
MZ6:WVW_\=_3'NK2#=!04CB(J F54Q"B43 D)P3\SP<^,4P/R45 *)?$ E 1-
MVT!(-_&5,QO+,H;P(@H8A!7."/GB1(AC H8Y4>53)@05")E,8Q2@4W"?+ICC
M)]@WR8&N#' UNK-]CGTB7/V6*RRD5L;S]#GL+SE71DJ-N D9H9IC$XZL+AJP
MC, /\=01[E;7J&17K5H>!2E%K?Q&S7)3'"6-#1I,NQ.6<3[G]P37%7OYVK<7
MS6'R%N3EK73LMW6UV%_)3B4'&UJ&C9Z<G4W*LK9ZS).J2Z1:LI\QF]2X4J6L
M*>I"EB"2 !0WZD#^F^QOH!79QS#HT(5I6),VNY"0JT(THD$6X!KJ7GD.50H'
M((&*// @8I@["(#]HHF*/ @(#P(]^WKK=J&6QV9R.[P;$060L1OL.&H[QI3:
MU7)(LNG).:S&5Z!<D>R83J[J2>R;";?3-<E;&HL5A<7\*ZMD.W9QLNV9I3+\
M9.1+XB\AZ@(\"'[^K$J-7G4JIK4&4J?B2"5!]1>W3KMA=$6"-QL?G_;XXW:-
M&C4X,&K59KS=BW;KC&X9ES1<8NA8SH49[WM=JE_:E&D8R%5-ND!&<<V?2DB]
M=NED&<?&13!])R+Q=%HQ9N%U"D&ZNE!]:]U:VFRJ;<QK? B%);9#QHZR9:LZ
M9AR/@_Z!5AE;(UTRN.+[WBVEWNVQV5XZ?)'HU!:(KTM)L7C@LC%P%K>M25U[
M1V*BP-_]^P^O]+PV%%>5%<D*2 2 2:[T!WJZ^.&-X.S[B+<E0F63\(WB(R%1
MG[QW'(3\-[6FD22CQ2!_&O6<@V924=(,P<-SKLG[-NN5)=!<I#H+)*'O#I/W
M1&;51#92DXJ%JQS<X9[EC(1D+!CJ\YDRFDJE'FA8:-CK=E;.M!Q7>LD6^&A8
MR+BW5D+CBG5UO"-8&O0,4JSA1D7K@![_ '^G]/K^;U^_3I%"2,@-T$.]73*#
M?R)NCT-$C:L(0ZEO_,P^@8@;^M5?IB*F>=YV"]M=UH=)RY*V>NJW[Q"UM9*5
M9G^/ZZ"A988TMOO#..5@()S-'@9LD7'F=.9)1.*>/G;-G&$*_/'*D=7S8W?Y
MK']<@LAV=&>R#;(.HH0\QC:\1$C3W-T?TR,QG-9(:/(8BM"JV6'V2L;-<;V*
M?!O'V-:^UQ+QLU%9 D?56]G81&;UIW'K>\9<O=;QG55D'<YCVK0%.]MD)9HO
M)BVLE'R6\BE+WBBS24;,2%0NDG7I!^SMV/73JI.8IDF\>OW,)J%T*L7TV[4^
M]O\ /F5+39$;'BY?+KIY6*3&L<O4+ <_A>QX(QVHT9M3%HC.E2&WW&0V&?K0
MK2MY21M23XD46R$"*K$%(F,SE*D(@" MK019=@S[>4M*^8BHT (4<M4FSW$8
M5-%EN5&7W.TC33A^J@:5B$!I2QU-W.H*]])TDL94J8E.*)Q35 JB1Q3.'82'
M\LYP(<!]2',4X!P(@ #SKLZ4-LFP/AK;9OXWUXOP'C.GX@QXZP_LZO#FDT"'
M2KM86N,\YW -9RS&AF8@Q"<E6\:P0D)%-(KEXDS;%=*K"B4VF\ZCU^!K_?\
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M!HT:-&#"F,UTG;O'[L*1=<B;CXFNY:"6QW#-ZB./X!:3G$$Y>SS]"BYRP13
MSR+@D4%Y-DPDI5TV91)54G;YZ@]GVRC]L* <)AZ@ ";@!["4 '@ 'D1'DH!P
M(B//(#SP/8$/[NV\@OU"<>,6J&VZ/<O*[@^64>W"0K![W8X&+R>S;OJ+9XR4
MF1>1M=>RZS&U,IWW6V?S#VETZKUI:;46EVT:]E(AQ33$IU #S/$(&$P*>$#F
M$04 ?](?50H]_'R _($PKIR\#BS:S$"ST+)0%[V=/< FO,+W:TEA^YN.*QL
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M+7<Q6FLVN=C*?##MI0ED[)(O*C6AEK)+3DTLS<P;16G_ $;0<R"3MY' < '
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M2'0^J'$R;8Z:"\B=L*4"5.O+J.II04V$ DS@47SX//.I'&@J4=]1WK;')GY
MV^;=DC'7M&:;(NN9$,DY.4:H@_>1(."G<.#+MD@>)*! P1@B6\A(*8^W6MKV
M'H!TZU6X\ONGRK;6<;.VW??>SUHUOUO8G5U'GDI0%QU^:K]&:N=U7IYMB5)^
M"V$\&-#F"^[C+B1P++ZPK\FS3%VG N7!103=>25(K0BE>K:2P)/'B]2$-9D[
M982ELT*?-AXCRLIY3*LW)C;:MC]/PLPHU.59\LF]I*S,2!\B*56=M%E/HW"%
M]YK.78"?TF&SVLC:TPSG+)HX7&=L]*"B:C;=Z@9$C0*#C@&I@:!.,(X$(?SX
M-RNX,N56"KQ?:$G;DM.J+5@:G7 &MRR.%TIPGU18E\:OT\W07XCL&9+O>!:I
M"_1KB#DW+HBK4J#5(P5:NBY=*.I-(';X=NG32#O9Z;C;=; 4%C>+;^EV*];!
MHCYW6]UKW9]* ##A]MI*XG@[&2=0E)6;K)*FP+"S$VV(RE91B55T"<@]9IF/
M[*L\$#+^SJ',X1(<A')C. 5'5[E.!(;D -VYX'OR(" A^?GT^_5L<+ELQ<6T
M<MRB8F M!:\S+.0,$@R;0\+(%,L"T5'-H]5=FW:QX>%FF@BNJ"/DF3.H94JA
MAN:L(@D?CGG@ #@!$>1$ ^'?X_FUK.T1-=(SM5GW>E&[^1OT-XX\[L:WMCWZ
M[^HK[C&++UH$HE'?;M^D<3XWD,N;TE]N;QOAM*Y,HEEM_P!N51C,AW&3LNZO
M(]@E%%(M:6QT[.88$MP(RQ]2#LRW6P.960+"0QTK@KC ,<Y68M<S7%OM/^E1
MAWQ;ZSBZ+F[J)YO%4)D=M6VYM8_,EG./%I<ZCY5&6*LV(T,7*F;5" A3(5R[
MSKP)287ZL.,M7]KAK9=]3$..;96CDA6.X'<U<(B_6Z5J&U"@2XJK3KJ*DD/\
M+Y)1_'%QW03O%[K;"S3I2*AU%$(.<G_6;BKG#%0-N^^B*Z&R?9&FHR;X,Z;N
M!V['WPAN"W"-+""L0WR>:(.%R%ODMVTEX9X@?)N843.7-&JQ?:GX:3ZO ?A>
M;F!Q%PY[D7-H5B?(YK,9UN;FLU N2RIX."V>TF&7@_AAY!Q_B:\8\3YW@/"H
M?/?BA-'B7C*%&+-F8OU/(8F1<W&F7%9>"0YB89XJN355D3B?'UOA>3;AW X.
M)YN;H&-;C7;##R4P=7WNX,]>]FZ=O3<(8TCC/9]C1VA[Y7W2;J&LT#9L>U.6
MC+Z?N4\D&CI:T/F:V4,MFB:K7JQ%N*2CBU(\!G5O"9^F_JH?2@GZE74_F.7E
MNSW:I=,TI)[3=H9I($)*SPURD2KB")03=9'%0EWR(,/AMK7&"_I)GICJB9R]
MASC._J;AL!1Z@G4?<N'3W*N^#*+A()Y/:_M=--F2FG=(D)%L9))$I#K3+9#Z
MU,H>R4UA5ZH[]AZ6YA8,!&DL$PZ^9',8!.F[TP8Y,LA2<#4R7:EF$=W&[1%\
M1!*>MD@1)&WJ)Y#"#DKLNP4O]^^C>)XR,KNOMT)Z&HM% !@L!CY+?I,!HN*'
M,+EVRH(XP(>*O(.$+-_C3QV^<X]FN#\!3@U UZBO-#Z_U81I1*KZ>'L$;(K%
MS1,Z_HQO85B?B;QCPUX3&4X5E^(\5EZ4DW1>R.#E+-MY6D908T4>FKTI(EI*
M6)"'K<X0XJ;J]X+=#V21E)"UH,@NL@TG3,+%EX8P'D\I6<2PZ"ZWT XDJ@13
M(%@3;*BRC_&#<I 3*H5JB4X)D1,H0J8* *103.=,J8%\!S$ ##\_IBFNY_5!
M,J?GM-6L+K(M^I#U7;$T=62:OMBESG=&VM;3V1Y*-D)^%LSMJ-53C*Q(HR>7
M4&RD\^?4[%$5&-)+/]A"I##1OE'5\@(R-*0RP%(L!"LVWEBH4HB'F*$ !4$A
MA3 _)"#]D1'SI_Z@6 3PFA9K"\?*0L.(CEK,G",U3+F0%RKS+F_;I4S\LGBC
M.#-_ISQ&T$G%<ED<EV?^&V\O&7!!YB<.)(]F))C?.9<A6AIIDA:$Y2.7*I'P
M*$9=N&<%25.'YK.9JI0] YT:T#C@./3@./R:UUT'CL_!I9W5HN5TH&S2U6C&
MMRM]#R*QR;@9*A3U)F*/ RJEOD,OU*.@X:0D<G62H8V+5K ]<HPMO0OM@851
MW6GLJUF5#-5!3%F.ET=2S,UEPI@23LCC"VVO,6$W;:4C,]([H\W(X<QU 59V
M1@U@2+I.\595;792PS+H\<,'[J;.D5TF9F2<@X<E305+LA^)%]ZHCL 36V_I
MAL!J6/;5YNE@78(-$[7Z?&L1JZ4^_6_;FS9-P=GB+E#YUPV\G9:7L2#C ;VK
MV6J!?['CI)A%_J?L@Y!J$8[K-EJ\E!E]Z230]E8@G.,/-:IOB,]O3ZZ@VZ/=
MEN1R'CK+FTSZAL9UK',S,P$M*5_(\/>$;G4;I!U&=2LBES@X2&/5;7(3$Y%X
M^-%(%DIY;&-QLC,92GNXF2&0O3&R'BK,NVF)R?C'$6VO$<>>5G<?$AMK,^G=
M,?(0U)EWBD9'L;J7%F)G,HJS=3DG(+13>LJ1T5*R;P&C]^[<O%!0OT Y7$4K
MOHW"&J\K>[!D*.QOF"#D)>PVVBV6;:8Y@\P8OC\<U?,$'5'"\UC:U5^ 20;U
MJEV)10@VHV8Y-VHE9E95H@Z/0TY0)L,C*]-^[(G*"O6Q+ DFB:W)-[84!IRT
MSL07&<A0$W864R6HW(JE%BNFD"AOC,-*0O #QW$ ]>>0^R ?'^W/.M?++\0Y
MY]?%WYY#@>>>>>0[#S\-;P] Y^6C55]T?(7\2=R?J=S@PN'"@<=37?, >@;=
M]D? ?+B0W'AZ>@>GI_-ICVEPX6_SFV^;Y?J=]DO;_P#F.X[O^?\ V#ICV@;Z
MOG_0 8D]?HO]!@T:-&IQ&#1HT:,&#5/6[VH:K9@8D;JO1K\T#-)W[+[*HZ]V
M.O9TW/MPE9>0=;P%6]L,#7RQ-[0((^,=5#JEKS[*-*MX/15!G]%[![6*!TTE
M@;>Z'GM HJ+)JI)J@CX_+.HDHF0_A,=,Y0$HP>A^1Q(ZCYC"#?"19K=%9&[&
M51>"@7<+N$1\#PTK[0D()84Q )2()RJ;]-DFS<G:$(E,(L#K+@QI40T*_P#2
M($FI(T=-*CLD)T&JKG . %2D7BJ;$ND!=*YCS(994C=5XN@7Z0JK2RK8TRJE
M[YEO9Z@R9(NNH@#TZM*2;4MM](E&0+8"P&X,DYB:/!+H NKF;+8N3)I/Y%VD
MB23$T\HT][IMD9N1"*K$*P8R7 "D":-N!U+9)/*(L]$N<<XF. V?--H4$CP,
M8XU4=II\UUV]\Q8[@Z0%<MB%LUK1CZ^$##N<;^\0>E+\]@IZDT +#'I74V:&
M.2 _GOOOWKL?^F@>EJFVICV1+%%K]O>N;?(+T-U*F+G+.!! ;;FVU''VDV,L
M5*OR$=*P'GD\M=XH@9F<QRV:T@G$HQ44K48#8T;1! G7(1AE!I C]6&+UU44
M,?;9Z"D0K]7(F0'4AXF:%N51)[Y\Z:4*K'N%B6"S(KOW=?BT^!()P9JL A Q
MJ>56T4*N+\8*G*E1MLV/DT@>_3R^&DBB0EP29BK/@O/F(X9R )S]H05E5(6#
MUY1QJY*[-BI+3C[$2DX!;?<$3KMLA;L,EHK$6+6*\H\35D8^G,7RR2WG^0Y1
M@TG",I-$=V*98Q["M_&J-7]K% ]03Z'2?,1J(&(L].M[COUK[@U0KWJTKI12
M2V;9T6"+A&+]P6>7NS<UEN*C^WS2?DN+).*6!X>=EFR2G[,+&N)4SD(T\EQ(
M+M")N7!$_.(F24*H@!>_''(>H<@''V@$?7_2 -1ZVM!9BX=@D[; P=2E4G\V
MFG3Z^#(C&I102*HPM=519J+&0D(V+%J221D5U9@CTZWO8Q7YETDY!+@!B@ E
MY 1[CR( 7L/ B/IP(\ //8?3U$!#0Y(@L $Z5I=P&)H!3Y9"+)"GRGKO7486
MWD;?;4=P0=NO44-OAL.V,=;^Z#EHU+%6"FF2<L2%#V\.[/>769*!2)&.;YBW
M%.8U"EN\<81QNR5;.)%9"P6<JTE;)PY5JG2V,>RL]B92LNRJL4ZQVE3Y0;Y;
M8+Q]5Q_7MW,/CP2T+'2QTH_;[TE-M4:C[6G:;>]G3KQT-G-A'2BEK,I,*KSE
M*M$^-GEVDWG"Z0%=@LC?KL.9UK(;17.-:/!2&;V#S/,G0<WWR:;L,7;4ZU$U
M^@/,D[@+7&/8]Q&.;!58,6:6/YV4<J%K5@6%Q6Z[:[Z_J$:3%X<CBQ3&2R[E
M3(+C9^KD'QL _9\-N0ZK>YN,E@2]XNRJDE;!6<,UR=DS*-2+M)MOCY"76C47
M%CW 79_]%/:WX+KJ_#S@<00,'DXK&T7*R\XD;-\5SD!1\MEY4$YS RIRO(S,
MT.=XO'D6R>9;A7@_A/&,SQ'SQX^D"^*.('4PD5<@Y;7+$4&7@ADU+/+%+R1E
M^>)!-#$^5X:^:6>"/B'B3B/#H<CQD#&26,6K0J-^DMIBV1O&44"RL5N-ZKVY
MF*E@ B#1J5%U:8'!]9M;\[5JHDWD%*,C(."%5G=T-L5;Q=T6@9-)DZP.GUCH
M%<W70^/"$OV0V0QZ>W/I,;;(XHQB%8HY:\9W&H9X)%/#5:-A:PX>3U9L%A<T
MBOA,;B)V:F(?B*3)3?)4D5>QTJJ;KHRB)(Y4R,V2*QP%TE-M<:"L4ECJAQS!
M1]'MLU%K[D8$&L'(25TK%@EEL<02<]N)G)VTQM,Q;?'9,=4,D7CRX3.VR5O*
M'ZEW;&Y,Y5SGU--P[>24KILQ9N]PHC--L)5^;.O'M(=BFDS*S\W$=)DGF07E
MPR&P[58\P,;,HF)!:TSAS)SBB0^>=8(LXF>BRO-:25<IEN.93)>W9W]$_AWP
MC*Y7BGQJ@(2-)C*!05I\MR.0QB6UB,\N6.4DF,2JK9B7A<V8.4RYXCXQXE/F
MLBY;H>&]GW%4MCC1Z;$&U5;%N77F':9=BK(Y]WJVMI(UF.NN[C)<=&^8DG5(
M50'%6I#F372IL&D\/3Z"::LK/(4L7+L#_?Z?E]?S^NL1#HVB*O43N0W!H3/6
MYI/"]H5W*9RK8+K80VO)$=5:,H6T?#*-; *(D,0V:%:66>8OW<"*E=/1Z)'G
M-6+A9I?+O#_:/QY^/]@X^ :\<?C:!_C8L!9FX3D)VDV8S&=LS+[29GK-YSVD
M,)AG\]%EIN("09W+Y'(<.GR.2R_?GX>6/#V@_P#X\]FH]'NB+EB)#"(T'L^7
M$)!C]DRKS1Y,J<I/F<UG8<WF)==&C1KJ+'W.#7$L;PIF-SX?#P//PX 0$>?_
M %> ^W_ZGB[AZARZX'( *"I3  E,0Q3 /IX3 (" _'@0$2\  B//' \Z@[@C
MU%8D $@'H2 :ZU>%'K]0/)#C?*TVU0$#09RERD_!Q\.:*:6R6L$I5E!43LEX
M;Y!CGZV-DT(X%"O25]0"R#(D6]A'YS3TE%HBW0HE "CR'V@#@1$.1[!Z#ZC\
M_GR/?OK'6)MPP=6.I=&9%KF&*C!ST7N K;*,W60M$O,62GR'T&]B_4A-6,8S
M2QTHO8T'SUT>ZB"46W5G1;22RMQ4AR@TC?QN,R5M?P,YRIC*$Q1-2C"?CXYZ
MWRW:Y^M1*S)ZVD CH2JQM7B9:RW?(=QL+>'IU,J$,BDZ=2DX62<**1\>[2.E
M6TY;*LQU/)*89+Z!I<RD,8!W&A-74@&K+!16'RQ%\Z8(E"*8LN(P2%!;0W,8
MZO,K.RV0W<C388$S@\U+GCS$^>>./&7GGGCCCGUY[<>O/;UTO_I6" ]/3:<(
M" A]4D3W >0_Y3E_EJ%^W/JZ25ZSU8Z!N'Q56=N]$)3,L3L7,/+FM/62A6+;
M_D*HXLRM6,M))1981%=Y>[;['3']4>2"*S6-.E(D%9VU5-,?I0N4'O3MVCO&
MJA56KS#<$[:JDX$BK9U(2Z[=8@@  )%D5$U"C_U1#D 'G34#\N%V0@2Q1R*Q
M*[AT!4U>HZB' (!HQMJJUO,6 >2)K$B2/&5TL03$(S)3UH.E9X21=D2H1=-3
M#=&C1JV)P:-&C1@P:-&C4-T/R/\ 3!B*N\XM</@6P%ML3,V"OC8*.#^ @%$$
MI6=$;=$E:Q#=1=)8"ED7HMVK@$4Q=&;*+$:B1P9,Y5H!]+@MZAT$ZXAG!&O@
M()B*"6-MG^+2)^ A1,H*C-K> 8B=1! WF/8YZLIY@.9N02!NTC=:>P$P[*&J
M]ABZC-A8*?[+:YA=DV85Q(;)'E>S"JSY-4@*LV)G)VA&Z2CY9WY*+ OM9TC%
M4 [7J1JF+<A+ 3!R%@4]WMRBHWR%NRR>DX+YC]Z<H+O4JFR?&$3BFFZ;Q;-4
M&30KR:67.AFE]Z_@IZB_Y7\KW !-62,:X/<(]7(Z6-PH^'7TOS=R$#7VO-I@
M51L7B;=X6:V0XQ\88%4LB;MLJH+CXGCXI"J/"45M(*%;N5"@<L:Q.HQ(HYL*
MZK@GJ+K7!6W23MW(0R>9TX$Q9>:(*9<<;3L:I 4I646JV!5HWM:3,0:-FK 5
MGT<Z7+'-C*VQWPAQ'^E);*L8SN$99?)!B-@EB@1+'^TS&3=,$RL(TB1S,FUP
M)'G*DCY3M649/UACF:+VVKF<(^0V1J05ALY6C9T^&BSX%J55 RZ>0MU&20."
M0R$L8B8.SU5H[6\1/) 8Z%CA/%L32<^X47,D=-O7KN.A&_TNC1-#U8FM'IUW
MV)V-W7IL;V/;419(C !X2A6TJS"IECIA/#H6 JE2IR8*H9%W09%!8Z))^=21
M!5RVJQ'2BP 81438-$PCHX5)ET_6(Y;;&2THX:JZ-V91$79T7-C3E(: 5CE(
M>",2R2H-H*/+%&49MT(9H*$>+,%57#)1 [=ZH=X18PJ>1;V)O;94Z,G"HYH-
M#F4OUZ.)"8YVG8Z,FFE]&:X43>P?2M&. C1 [91T=BZ76BHY(TVL\=IM#V>_
M14=OU+^A*\T[K!75K)%2%A4(:7E4R6V;*XF'290\37WP[*M)HL5C*.&2#M-L
MNJHHF8PM@4!R;W"D;?-=B+/3TZ#OYK.,\]% 1_$/I:W^21;78I0N).:-&C6H
M&P#ZB\9,&C1HU.#!HT:-&#!HT:-&#!HT:-&#!HT:-&#&+'NRW()Y*ZG>)JC4
MWUVD0I>5L781?0)FFWV IK1VZG90,B25U-;(6S9*N59%BO[*>N5V;AIJ7C+.
M>-KD;".H2RN+#E%,FC2.8-V,:U0CV+)!)BP8LVZ35HR:M2%;M&S5LB0B+=L@
MW3211123*FBB0B:9 (4 UC>YWJIJ/U/8&$R(XQM2*]:[I@ZU;>K,Q:YJ?WNU
M'D[#9'M^@Y%N;=;5<?O[0RMJ:#%Q.RV)KE$J5^S,D(R&(X@3,0R34@ R8#V#
MDQA$  !#D3'$>!X+R')NPB4/$'<2@ \ N(,,EE48@3<N74W4!]1:[).H R71
M)-L;ZDX;,R&=A&*C18]((WHJH\QTA;_5T:V(47T QBIYLZZF90W#;@\'8S#%
MF'X>OYEV\XFQ?=L[8ZR(FXJ%7LBFX:/RSF#*,9,2>/88S.QVO$M2@,1UU>PP
M+=6&MR$XXDYMZX4C8CR[1O,GMW'4ZZ!;RS;?LX8EL,;";D<@SETNM!5KN#\@
M2^5=H%3G)"-P5=7DR\?WEO5G!ETK B[BHMS! LT054>F$RHY/EOP[B[(#:?9
M7K'E#N;.U,H:.LS.VTNLV5I8F%<=/7U=8SS>:C'J<RSK[R2DG4&VD@<I1#B1
M?+QY6ZKQR=5-W4$9-8OJR=!..8H(MF36^;]FS5JW12;MFK=OMEK23=!N@B4B
M2**"294D4DRE333 "$*!2E K%8!%5HR) L&J6U*LRQ:)J2S1DF_6]*44H8]!
M4%=8(#!=4Q"$@GSNC1>;2#42!HP.C%BY (%L7WX?Y+61O3]I6?7T_P"<T5]P
M_O<=]8ZR@_;4$.> .?CD!["!A$>_ B''KV#MZ<_+(IWX!_BLY&^XE9^[_I+%
M?V^_T^[6.J?Q>(X<\\B//H'/(_ 0X .1_;>HB'K\])?WC^>PQLRO[-O]9_\
MBN-IC<]^.WQ'P\?[.?7@1X'L/Q . UJ/')A#OZ@("(B "/IP/IR(=P#[0\C\
M^VM/VP_MN1'D!#@?B >O(  #Z_#COV'D.0"]^P=N>W #W^/8?EW[]N.?0![
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M]6L+.1E0RK5920C8>[@Z;>Y+M(-$58^D>%M-*/[(Z8Q85^=]M]V+,Y-Z?O\
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MLKIHXC2QR7!L?3_<\E$SL2K#?6L]S6UE%%FD-8BOU'*38T>9G*M*RA*1;AP
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MSU\W>J*PS!K7('(-=G96*M,,I&(P@14K)R+V4@_O8@4/"/C. %'N!.#B
M/'!. ^R4WA 0$I1XXXJA/LV7;M(LKIN=[*:KOXH-S3==7PER6D -#0B*"!5B
MB19W)HNU ;"]J%7UE)-BD18ZKA-,K;P>TB<Q0!N*@%$A7 \\('.4Y3%(J)#&
M*8@E 0.3Q([ZB @KU;N@XH00$I,A;^_$(_9'D=M-<   IN#&'D>X  \=Q'@
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MUK:;YR/3-[(:%HJ[VANDZ0+XGZG7;8BX%6RY7GEG I)Y1RNX;I).EX[VE 9
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MV0 Y^7[*J?SY#X?$/SAZ@N3W6_UIU_U)_3MC1!^V7_3_ -GY^V%-&$0$>1^
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M4Y6$ZBCY,R<6B^2F+ 1:PR<.R;UP7Z5H64A@"MQN9&$ 86#8#(DQALXQDU,
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M+$@8I!O '=OE<W+.U$?"K'=0!L.QL;=/=7S6<;;&U]SZ]B+_ 'O7WM^M:WH
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M>*8R$8/,[6$W1;94(R/2#<1@TJ)&+$H)K9>QH15)--DB0B2I"6<Q"*)%* '
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MA$ X$2&+R)B&*"Y-E8U^\I^EKAT.TJ$[#2=STK0=[[;[7],+Y'GU$ 'OP "
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M]#ON=ZL EJ0*,<A$84("G"%1?EQJYF"A@_!GF+&MV<K@FHHV3R=E(S8"NO<
MJE45;)G,D@JU1]T1)0CDGSA1OFV@;..':S]-)F$G+25U9"33JMJM%H)L\)99
M4AH:,.P219 VKY )"D3:D\E(6)DBG4$AE#*6\<I[\N*X6U@:Z$9^SYRW ^%,
MU3Q!6/ 1#ZJ<3(M_$T<3H$*2&*I!![2IR9A&%1CT'SX[1]GAJX;;Y1AJ$1-P
M=9%2S^Y&%C<&=3OL'TJF!2>RBQDTRBZE.1DC$2 Z*1'9$DE5"$ XLA_:]/\
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M!^8#W^'R#LZ_/V!0L2UI\Q:0E"2I:5C(S+9.S,Q-=!=   #'I-KLW=BAOL:
MH#;;8 #!HT:-.Q7!HT:-&#"H<:;0]PDQDIME;,#S:]+2$3EJWRD(XO\ MHCL
MC9WC<6,<BS<YCVN,,\)Y/0,R5@H=ZFM4U$JN9"J)/"LAC7"[9PL[:Z <!QV#
MN/I^7^GCU^_0!0#N  'J/8/B(B(C^41$1$?C\=:ZJBB-$C!\J#2H/8?/J=[.
M_KBS,68L:MC9H5OTZ#Y8B!O/V@5W>1CRFU"4OERQ=9L9Y.@<P8UR'120;J<J
MMY@(2RUA!X>*LL=*P,Y&O*[<+#&/8F49G;J^V(NB&3<,T3:BHKT-.E=,-:\-
MYV783R3/P%0J%-4NEZK3B:N,_'TJL152AWECF/>3<LI)%AX9B@=T=J00!(I4
MP(0I2@VK1JP\NL FG9686:+*NE3704/3U)ZG$%B=%D_JPP3_ "AF#L 1V+*&
MH]& (WPH\>@YT?1$!_!Z[:.W?_F0MZ^G?B5 !#@1[" ASP/J :VCT&^CYZ_@
M]-M0CSZ!2G'Q$ '@ E> X]?0 #[@Y'3<M&C$8QE]SNQKH>[5U,K-[GTK\8V1
M_C.EX>N\;%5"AQ;V4R<RR[<KG3"1F/F+ZUL3R$O15Z-,SES:OQ8$:0)FKMBJ
M]76*VU3^2-D/1UJ>/<EY3H71VQ3F&BXHR="8QL<[7"4*M(R3JQUK%<W$V.K)
MW"Y11Y^!-)9:A*L].B9-\SF8BP_L59NQ2.X>[F':?CK,F<\%YRMPSKN4P9&9
M(C8ZJ-UH_P"AUQ2R/$-(4REUCW+15W)+T]%*5>5'V5VU29O;',G=$<E72*E;
MZE;%L>4S:6VV?,;-D%W26\PWG%[G+/H-U?Y)\AE-ME-%22DBQ)8QP=!^PCZX
MB<(P#H5EBS;$4]K0!R*6?H@#\Q198"T=K6E)9*"E.8S%6#!PBV P!?<=1D*"
M/+S;+6$8:7*A6!UHZ(R@C2R2DG>(#$4J9T,^DU8*O#3%HZ8^W6AV!^T!:6I[
MZ%86!W .Q54(9@O-0$ZYAI Y2$(K[1'+JMQ!0"%/XR' *I#H.='P/_J]-M/Q
M]:2L/K^65'\WR^&FUIE,!1\0 43&$P@ @;CQ#XA#G@.>!$>_'/Q^/&MPJ$ >
M!,'/B O'?]L(\ 'I\^WW?'3&=5U%BJ"S5F@!0/5CT%]R3ZG"!ZC;Y?['TWVP
MI/\  .]'W_\ 9Z;:/_L0K_\ ]37"KT(NCZ0R8?@\]M(\F$0XI"X<CX1#@>)3
M@P=^0*?D.>X%\0 (-P.LDF/!S@4>W80$?7GCT ?D/Y/CKC4#S? 8@"8 $IO$
M4>!X(8#>$>1#D#>GIWY$.>^JRARC"-M+FJ:@:\PLT003INK!WQ(:R+8U>^_Y
MZ&K],8CD[B[^Y_J[@6+SL]Z55'40E-S]XVL*T!MCV&5N<59*++69FZODH52X
MDBV6.YF"@6%MA)D7PO'T1:ZVB+$DDZ5;(<<?A;H=J5EE-S?2,PE"2<WCS'&3
MZLP:V'#=IK:M7R9;JY1XQSD7(E=R6[J&%R0,S;(9Q97>3W<,Q1B@E'<(XG'<
M.^9)-[L/1]P)88RS1BM\S''I6BOU.!?!&R]5(W2?U++DCE1&ZLV*U9,S3N<V
MW<PV.YV8.DJ9U0JO!QH$*]0=OW4C6VP[$]-P/#X2P<8^WQS"1U":CD7$E-QM
M7[%;'F/H+Z-LE\GP!JBK1\JQ=AC%Y)*T5J\UR7@)091RN5DT<HLW#:0:YA!=
MPS1E P"%0B,DL?3S!Y LED6101D%@M<1$KH.DW(C ZBFDG+LDE[-8TSII!/E
M<,RLP32K$>G!T7X[;2MN;M/2KPY7JM'RS=M:85O 4ZVNH> ^G#6D2.082QTZ
M]351MV/6*+@MS0G*U,J'D*<FX?DCF\JW=Q*7:;=-_HCO-R">VYMTQ\,+2JUM
ML-#;WPM)8A2W5KJ.(X3,EJB6:IK&$F\/7J[9("*E'"#,Z32Q27NU82*-7?E-
MZP=M&Q]A7 MBP""SBYU:[/,B2EY4D82IUAE/OLI+OEK<A'4N@PE8HM.A797R
MA&M>J-?BHEJIYK\R*\J\?/G%'89V,8^PTAMW&-MN0K-.;?'^7YLMLMTE#2-B
MRG:LWQIHZ\7#)+YO#- ?SK@3@Y9GADH=LU\I!D")V#9)N#04YAULP2I- 47Y
MQ%(8[-$A2XCLD@BJNC1H"NGOJW(NP!8!!&_4$5T-AKVTXCG^ =Z/H<!^#TVT
M?(/\!UN?SC[T$1[ '<?4>1]1U$W<-TVNB+MMR-MAQU<^F=A277W19;>XAK]A
MKM":.(6BRC>LR%@:V*]"\L#1TRJ[UZVCJR,BQ1=G9S4]$@Z1(S6.Y3R(0YX[
M^OQU#W=3L^HN[%"ML+U-W.!1K5=RM!1CZFOHF.D&#K)U22JWTC9NY"+D5F=C
MIZ[=C9Z?(-3$(SL,>V6?(/FA3-]9F=ARR0Y5I(58*A)TNZ*]TI*K1.IOW19L
M58A;) U4.^]4.]60+]!>Y]<8WKO&/0L?9&R;CBE=(K%D\\Q/(9L2L$Y893$.
M(XB=A<&V&M5J<GZ.XR/E*M_2IM:'=C0>5!BDLS5D(IJK(22T8U>-CK7[Q%LX
MZ(F;,Q1F+Z'TI<4NHN06@6*MEEX2EUVRPY;+C>/R7%6Z=P5/Y C\O,\8.8B6
MCH%'*3:JR$4I;7:<>@B>/;OIEFU/'W2MVP4K+JF69JK(95=(T5M2(:LY;J^/
M;O6J\9LQQBR&U02,O5'+]C;7:>+HI1_,E=E6?.I287<$-XF!6M;3FPJ!L6XZ
MKY^G\L9#L,?1LB'RO2L;3L3CB51J%S6B7\6X8U;*[VGKYM@L9KGDG<H;$C"^
MHT8C]06J4:E F4AS/#G]6G,S#+5/J8A%9XSS"J%J361&KD465$!L#>6Y0$KH
M"#YB@()9FUKI!(&]+J8$UYF<V?*H6)>>G/T3J#)9IK\ETR,-.[GAVTX:JD=3
M&%3CS3^5%L_O(^*Q9(8]47N*+5PTG9\UAK[A&658/8]]3K*NN@5D@DLXK"H]
M,KH563;XVW-V#89M@QQC-2-LDL]D+Q764<2-95:=GX%T9TX)9#1CIT^<U]ZO
M&-6SA9V_16;)))'=*>0#8,A;4L?9%W!8?W#S:UC2LF(X^09MZS'.8PE/N;Y/
MVX]"G+NS78JOY"3Q&[L5VD<>*LWS-",?W>PN'C=Z<6 M.S4]IN)(3;LPVQ66
M 1R=C%I%S\0YC\B1T),C*MIZ;G9Q95\@2.2CTWK)S.N0BY!DS;O&(IMW+99!
MX05S)7FD$/)*-3D+4DA&@J-=@GR,Y5@0I$;HQ!0,;,N8PR<M:!C!D-;K)N-"
M'=3&?*PL<Q#J!9E  49>^F7T+:C@R+SU7-A6W+*%7MTC2:]CICC2LMIB8R-=
MLC6"*J]!I57=K7!A#-IBP6698Q3A69F(J)@"B\=61U'LXUX9..MSVL]!7"L7
ME:,W*=-#!^!\M8FJAKT[P_+5EGD"Q7:DNZY9;%#76@3&.YFPL)>FO3U"?KLY
M999.!C:+96(,+FI#MI*%>RV0%;]J&([%@J+P#7X(V,Z94WM-G\>*8V;Q=<D\
M=7+'4]&6NBW*K%]@7B0GJ]:(>-FS'F(R48SRZ3EO8F4HT?OT7$.KCTM([(4_
M:,K6S<SF]YN/ON,+3@*[9];5[";&PR6W6W1IV4IA>(HR&.U,;5: 2DE%;7'V
M"&K9+@E:G3Z2=S3Q!9!BUL@1'4.9BEMY 2R1J'R[%UU$C62)"H4C45MP=,=0
M"#%YE'.$;,#^ZTI-+&2""(RMZF.ZD@"A>)9[-[#AJ4PA4Z[@&C1>-,58X10Q
MY5<?0BD4$=3&$-!0LJE7@9Q*[M"+6BT)Y!FO%JN#N&CA-8RAE"JD4/*_4>=N
M>WJM[;JE+TNJ2M@F(R:MTI<G"]C7CUW3-[)Q$##'8,S1S"/2"/1;UYJJD55-
M1QYSAR<ZQB&333D-JP[ 7IT[6 #6HZ; V!TU8&*$V[UL-6P%T+520"220&)H
MDDGUP:A/NXV+X^W@3.)K39LI;AL/W+"Q[\6DW3;GEN1Q#:DX_)L9!Q%RA968
MC8V26DH:69UR)*HP,5(A5&WF 81-P$V-&IH6#Z=/^.F)!(Z8C%M4VJ4G:-C6
M6QK2+?E.^HV&_P!MR99+IFB\N\D9%LEPNKALYG9.>MKUFP<R1E#-&Z38JK<H
MMFZ1$0,<I2\2< .  /D !^\'&M=&IK>^^E5_Z472H^2J !\!BM=][)9B22;9
MVU,3?4EM[/TZX-0&W(=/O&>Y7.6(LX6BVW. D<<%JL99ZS7QA#064ZGC_+=7
MSY0JG:5):,D)&*C:_F&F5VTN758<1DA/1K9Y6)5=6*?J>"?.C1_MO]L6!(NC
M5@@_(]1^>G;$-U>G?L)6,8RNR7: H<Z[A<YE-L>$U!,=R<QU1,*E(,8QU/&/
MFJ";S%3?:.)N3 .H=.SI_E  #8WL\  Y$.-LF$@]>.>P48 ^ >@=_CJ8^C4V
M?4_?\^@^V(PN'-FT#I^86Q5D/*KGIZ;6+>PQU5)2WR-?K.V; YIZ1C85+VN3
M3C4W],:LC.&\>1P^\"[I$#I-E2@;QB4!BE (]+RW96MF'ZCTY=M\Y9(C.47A
M"H2(;;=N+6NY*=K8RM^1K+>:I)#6%E1HM'<X_NU'L\J^9HN$;?773-FT=-G#
M1PNZR>@X^PQ4S!2C('L9.1C^(D6ZH$,DY8RC%>/>H'*8W!DUFBZB2@&#@2G,
M'?TU!["'3PPA@&PX#MM-<7^4G]NF&+QA2I.[/8&,D>RQN0;,VM=DN]U]GC&!
M)S)#J5]]BE:2 R$K>V6E$S0PRQA3HK O(CNZE@#$ZJ2%\I,FHD,MHR9=8@00
MPS.88EC#&JCZ1"2@N4-T/33:#8#N!S& [E(A=$DQZVMX)V7[BGV5&\[TIMKN
M)&>*<C6G$TF_G</[6[668O5)<LV]F9Q3:IT]RN2':@_;JL)>0!H:1)YH>PMC
M%+YDOOP=NP#GG]0WL][>G^+)A+L//KS]!N>?Z-79PYA> PTIDCZ-N)MT3*V6
M[WFRQ^^G+-R+&UY 5CE)>.C!:M6@IPK<8Q (YNX!V[0*94JKU8GEE)>[5@37
M4]*^?:S\P 2*'I0JL6<)S)>7LG,?EBNB TH!-DB@#9+'>M1K$-OP=/3\_<,;
M.OXL6$?T&T?@ZNG[\-C&SH!^ _J8L(]A^?\ S&U,G1HQ7"E-Q&$^FOMOM6W2
ML6CI[;8IM/</F5IAV-G(/;%M_"&H+^1K\Q,M+9=E7M2;N&E55E(Z,K2[Z.0>
MK-9>Q1*KE!-C[2Y17:]W2]*0+/FB#@NEUMV>QV#;'F.,M$S8,2;+\=GMU?PS
M-5J*EK)BV'O+>'?9!&S%LZ4I4:['&;S<M&()K DFYF(1O(/=W/[6<?;I:TRJ
M^07-L;1[.&OT.V4J<JUAWS8;[47=3<2R#Y=D[7:3-?*Y1GJM(-!24C+''1[]
M0KE) S92PV(.FAMLQ'EB<R\SK+NY3TBP9L(J/R-'4VW0M3681V.8U*>J+=Y6
MROX:P.$\;0;AY*D?J.W3L[]RHH)E6B;2@<:BK&4 35Y5!#1^QS,%-K[OM(RX
M+ V%>0:AI #OU0B) +2#V8E6.E:]HG&8"U18\@0%=_*22-\19P[7>F]F7.EC
MP[7^FCMI9-Z[,W* <6*1P-M3:V*&=49JB\6E[IB%U#L\J4RE6Y-P!<;W%:O2
ML59ECI>VA (R$8J]+Y#],BAURZR3SIO[=)*P4/,&7<2V"DM=LNW9"<(GAC&$
MOF2RY 3,\JJ#12AN,;-8*Q1LF!A=C],JW'.F;9Z[522F["['JI&[CHC<3,9.
MRI=)"GS60K'C:E6]6A2D/CV:RA&2D1;TXJ\)TEKF29J)V$W+H5['=LR1/46K
ME?)A#0"!(FODB.UD;91BO(>3<N9<EANR=IS!@.;V\3S%A.M0K<37K)&NH*Q7
MJN0CIHNA'Y+FZVM#5>1LZJCDKNO5*N1JL>9..$R[%:Y([O0=1<$DV0OD-@@[
MOI5B"M(SL+*J<"" S1AP1$98 ["[$8<":R=6QCUR @']8J*I4$WXE'V*=/2]
M4NIW1EL0VAM65MK,!9F+5[MCP9[6U9V"'93#5LY!&D*)%7;HOB(K@D<Z8*D.
M*9C$$HC!S,A^E9A/(&Z7'EIZ<VWQ22VN[<('<?(OHG:IM[=QV3XZ<&;12QQC
MD1JQ7;_([>18UY@>'D&C-JLI=JRJW>G27=F:NKHU8;4NFU>G,E'2K&JUV$K+
M%9ZHDJ\68P,4TB&:SI1$B21W*C9FD=R=))%-1<5#II)D,4@0[S+T_<+9RR6;
M)UT?WXDZI886R+-H6<CHZ(=N(#'$WC>-C7S48M=9]!(^\XF\C#NG"C0U[IE1
MF_#Y$<X8NZ@ T"\BJ=@Z;.*LJVU;M2Z@:7<VI'EQ1"A.J0&](8*-P7M;4EKI
M0"U'WK H]<*8QYN"Z7-M]AF$^F#@"-BYICF1S7DZQAO9S>\C)R.$\>6+(UCC
M['BJGMU\@5$DQ#5689UB=?QCJ$<3)HEE,/X8D]#*/):8PIFPC)>W[*V=6'3>
MVNKQ>,XJ3GG$)3L7[2,E1E\C8VKM+>]4IUNI,7)03V<C(I5Q'S%9L",!8HRP
M,%8U2-<-'D1*/YAX6V!X$P)AZPXFQ['S$2]LT9:XJ4R['F@:]G Z=J<&>"Z1
MR95X*%G"/8-X#1S!.%#K S4C6)7";U)OY9ZOVX;4J[M]')LJXNEMRK=,P2L-
M)9"N=W@\9UUU/IUN)5@H-HXJ^)J+CNAF62CW+T):>/5CV:SK/#J6.9D4FL:W
M86O3Y4>91I&ZR2IJ(*G4RJP&HA5%5>E0M!0!@<1&R5#V]C4H8A#U4$B^Y\QM
M@>AZXA!&U;IE6/-^-<35+8IMIM*.0F-9"+R7&;<MO_T6C)2XXCM^<X*LO2KU
M5.?]X.<6U=E:'7L; S5JQMM7\U7AZH9&ZBF"NDZ3. [8S;=]C)<U.*B.1#8Q
M# 6!/?JT(20!@=R>,^AQCJ2GF@$@$:9(90T8F>9(A[O2.X"\>(=B>(L+CC0:
MM*WAXKB[+V2LP0CR?EHN2>/Y;(='L.,6=<EG"<.U,K4<=XVF(R@XZC&Q6SN!
MJE0JD6XD'Y&3H[N^BF!,/*9F)G\V-ZN.8DZ<>B%R-[L;!9"U@\HG,&BP> GX
M@\3U,IA?@(2 (<L < Q,9$!WE*J$GS(!4F0^TYA6+"RI4"38BZ)%%@*:]P5Z
M(M3'0FF@(UY:>4@CJ2MT:+4#2F@NPPJ3($-TZ:=/9&GICIJ[=I/ ^%LFPV&L
MM[@%< [8&T#3[I*N*HQD%T*A)P"=UGJ)29:\UV'O=PCV:*,*]=2JS"*FHROS
MDDQ]_ LUTIKWN788TP1M+VP,;S3G+"QU?(\-MNQ=CYP$]'P,E<&LKC=Q)8ZK
MUKECQ+"+0DVERJP#$*,WT9,P4P_9J&7)*7)/3_QUDZ;R*SG[QDQ/"&9K<VR!
MFK;.P>U F*LJ7=!&!27F9B:=U)SE2OQLZ>K5Q]:ZG2\@5JKV25ATGDC&&]Z6
M(LSU,.=/FE8IRU3\RO,MYFR-:,>UH:+1&EX>4%*$JV/FE1=T>NTUNRJ%'K"\
MFUKE?>*D1FIAW(V.5DC*RL[*R+M=8ZD*ZL5Y[3DLLA9B6DMM,*PCS:BHO7S0
M"H_>%L6PSR*C% -=J%4>4 &M3[5J>[V) ._4;A@VC1HT8I@T:-&C!@UP' 0#
MQ  B)OD'/A ! P_'OR4!#MP/< ^&N?6G !Z!Z=P^?R[<_=J&%@CL003WWVV_
MG_+!_/Y_#&/[@C9OO=QSO]W*9V@XZG5..L#+.AX_).0;7(W*E9Z=9.RO6+;A
M-"8H55L$;<(M+ .-HR9H8A)FA2L'S]-"NJR44Y<+ZE?MRV]=03;9@_&F":MD
M_9W8X+&-9;U>.G9_%F;4I>3:MW;YT1P]089039HK@+T41! !()$BG'[1A*5J
M0 '81* #]P!\_GK=J%!6#+P#9,O!# ""=3B",HKN226=M3%C8!L"J1 H]//+
MF"H$DTDDK5[H:7EZPB>XBGE1TJJ%72=(&IM2&<D=.#>_DF]6^_26=MJ47(7"
M<<SKU@PPQEY5HU6<E3(#=!9?+0KJII 4>%%"%.IXN3@ AR- CTJ]Z!. -N(V
MN%,;QB!387RT'B\'A$?"7ZVN3< (F.(!R0/"(\@(B7(C,(@ B <CV[?G[_S:
M7[U$8G,S;$U7RAMWI%DR%F;%&08>2K%.K"_E/[%#W9E(8YM;1PFH\:-58F-C
M[*WM,JHL*JC-E75';5,SE-,AEN) 4$2J[,ZQ!7TJMRNJB1I"!I$5LY)-4/,:
MW&B.5R54N%4 [UZ+06@1U('3<63OT*TE.EYO#;D\UUN0VJ-41( G<.,/Y50;
M]Q*0!*LMEPB? G-X $3!]HR90 #*<:[+7I9;RGJ(+,MQ^U-X@)E"^>TP]E5R
MEXR" >$%$<NG3$P#V4+X@%(P   8>X5CA#9'=4ZONGP#FG&UCOV&<!X=D]ON
MUU:^OY&RGR]7YDC_ "JG:BJR4FJ[FYZ(GUJQ549U\I[R3G(ATBW<)I%*;3-=
MB6((# NTO!5 C<?-<7OV6-J8[M]618F8.TKRZK$3]+'TRV\UR<9][+).%)E=
M9=5==Z5118YSCSJT4=B<M*6$8R4D)=(TDFBSK<1;=5 "OEH\KE^?&%U1'-PI
M-IDLR5;,,&"!F++)-$S!6"%H#$I<$T2LLK2K$PI)(X%E0LLJU '!^PG?7@G(
M#/(<#FW:9/R#.*F(DL=+X>S&U9G2F$4D55CJL\LG7\Q$$BF(4OA*8PB!^0[!
M-<8KJ2?"Y[( ^?&+L\#P/S#G*G?D>_?T^_4Y2'(H'B(;Q!V[]_B'/Q /AK?J
M2@WW87U -#H.PH= -ZW^N%LY?=B":JZ%[?'[_<_"EL9+Q%U <KU5:F6ZX;)W
M5?=R4))/F26,L]I%?#!2K:7:M'!T<L)*>R+.FB(.2$.4RB0&(!@ Q@&,B>R_
M?VM)7BP&W!;3$;S9T2PWTN)A;+R3NGU8K8Z"E;ID.GEHD?6X]9MY3,DFV*F]
M19-CMT#%,NNNH\+2"]UV%=U*VZS=+:<05_*ZM8W0X5QUM3DIN#7,I6Z+&A3[
MC8QS+"-EY!)&/<5MP[L='EI:,0]YJS%JK1#I+>Q-U4$RVB2E%,CIEIIT5S2N
MT)CT0ABI)DF=UC5>HC:6381%EV9./G"93/%!H2'3S"BAVFS^2R['4Q7]E%+)
M-(::HHG)7RAEK5GL;WBBUI=7;Y;V:.ZA17*<R]H:6,,S*-+C:3AR%JO2[?+W
MO&77$QDE6\:Y3&/;MR^QMS)H+JK&YE-FV_I0;Y9?U1FTA>YW)'W(ZR"VP_EP
M\G6JJ@B+-Q3ZDU2R\K&UEM[-PP4>L@"10CO''I>2FJ)RQ3V9=/7<%"4&<R'=
MX1UB]6ML<@FC&-&C;O5M[&2D PDEC6#J=ERO9L@OZ(\AE$UE9.K)J5U(S*T1
MD.NI(LW)7T@$M-@.)YQY5MQ>)Y?%=]K>)K=2JY5%[W;L27';+=;=9Y" EJU<
M/>^,):RS%<=72,9.D).4S1C=&"CK=+"1P_"3EFR$B4DC'*E$#ZI%R8G@+H L
MC&)6B1UH'79 EC0ZT8LE BQEBS#2K$Y+1B;-'+L&1@T2B<QF9A__ %E5$@8^
M5P5-D;CJH[)-YKA*AQ!<H[.#42AF(_CL<'Q'F]*"G+.JF;QVZU.?K;))V"55
M>&3.9%\)V@MDBQH 1L/&I2T:@=2RF5MK N\L;,[6Z1=RKQ>9E,19K8+KGE)1
MW) @DQC\K"S9,6!70,(YDV $6C!LV;I@)4^=0ZK.(]S=S-3[[D6EY,97/#.9
M]M>V^$CU%I!-&R8LP_D9.=R1GII&MY<6\I5\A)N84P620#WDO$5Z11>M?+4!
M%1[0?[1_I'34B4I))YDTYN?+HI**[0KELCFDF&@FXF.<;+(3=MDY 69U>E-F
M&:<P%695RN6S'.T,(S)/+FHWA!90#+$,LCS#J!/'Y0K*6@>:/ZD!%/+&\['O
M&83& HXRSP102 7D_A*7*AC?8$W[8.0 /#X@#GPZ6MNYZ9.\G>YF+%UXS?N:
MVS/<;8U482C7:VRQ;E%IBR]VJ#+)FC[7<W9,J-;9/*-W+]%)Q!J*.(H8EBK#
M-Q9(S<L=25'4 IV?F>X;;!N)P31\B7V5VZUG,4LYJ5/75"$NP9'3KF/7-6L+
M%1XUCY5PQCYIQ?(MFY*"Q34YR9FX37.F516FUCIC[IY:^7>L7LK:K1T)(W5+
MZ^\U5F_V7,S1:T[A<C7R6L>V6WQ%_AX"I/W8.F:Z+RPP\PS4KB]6%"*,U3DF
M:_(\!XMQ3@F=?B?"<^W#<]$F9A$Z0Q',)#FH<ZDS9:657Y$H,4<:9F!4S$:2
MH\$J,2\E<YD<EQ/+-E<_$DN49LN94);3(ZSQ/&LD2.IFB4JLLJ,7C.DHZ$'0
M?4-T,]YCF4S[=5M].%'&X#.S%I5['GA#!5O1NF-,7J,U&;[$N(ZRTR@G7\65
M:<C$XZ &3@46,W%T^*;U:#79,'4BH\VGZ"6=%5<!P3S/&U]Q@C;X1&4J^W1;
M#.2T\;7;)!V/AF\K9<F$<J(63)%JGYE-*8DF4HX2CDH=F2AQ7NJKN7WFS:V?
M8_O5$WG31&.*,ROXZ7'-;S*N4LR8PGZ';819Y-MWE%BWN:(:QFQENHK$HL5X
MA1%W, K<J+ +->)",9-7$2'A9LV^;@YB'W38*BJ/DV3Q?A+'&XS*NWF<C';H
M$\H9!W!5R7&BXXK*J+]-[(N\*.9R\M6+9=9J9I+/:H;S5F1@(3Z\?BAX\:2'
ME^(Y523(R3*R9/A< RW+X>.$0Y> )DD7+RIP\SY?)& Q2Y!9,Q)DA!)GLU)/
MQ"^#?#<DQ@ER, !S4,$DDDN:D659\X,Y+/*[Y@M(ASHAGS(<M'FF$;YIG3+1
M<N':O0@WLNHG/#]SOLPVZS5N0>$:Y+W%*8 NJ.1$\:&;^!YAJ@Q;;*J-?QI0
MY5TDT))&IZ<>^6K+%K16A6-7]J:O*JQ]T/-S6'LI[8LA53<QMR@L;[2I)O:,
M<8,#$>2XRDRF2E6AVLSE2_VTF4R6.W7FRN5$CR,A*$$4(MG&5B$&+A67D.')
M9\I>\N<JNUUOMCO%+Q\M7;]C-_G!K?8!],.Y;'L= J)6.'(5M,1Z@I%=BBG*
M129PDGSCV<[61:D:N 7H3>K4WDID?!5BRWBR\YTVOP-8RC'Y)QGCRGSF0W:F
M69<]'-C"YSN/J^X&2L59B8IA?XUJJ+240K4],1$FX014\F48Q/\ B7XZFR^8
MRS^(G]GS(S>7EA7*<,B3DQ\/_1I"<K)+R(GX<K</R7):/V?+2S9?)B&/,RB2
MB>$_#\;9:=>'P&?5&ZD2YEY(Y!GES0YFN;S.V<(S<NK4)I$CEG+M&I2Y\0QZ
M@S24B36&[;,#UXC^/--)Q>.,VLI8\.D[0-(EB7+W)KABA('8 Y!FX>MW#-)T
M*"JZ*B)3E&:C9Y[1X."<%/XO ;Q@;Q$ !$A^P<"!B@'H(AWY >.-8P[2M]0)
M"CJT>WU/<F]E*G=<[3FWC&:5&CKACYGMJE,=7=W@^+RUD1V#N:?9CC%I2*K,
M[5)Z??*Q4DA%5T64DBW6F#9+5*1D$JO6BRK8[213K<"F];*)D1.W>DB&97C<
MR28F*D=!R"J1DRB)2&*)2B)2@.NO8P0H"'0@CRDBINVTZRL\1U"U,.E XV*$
MJI"C'.R-IE$>EC?M%O1H&',- #=E2)N698S9!CD5E)!&*LT:-&GX,&C1HT8,
M&C1HT8,&J.R';T<?T*ZWMPQ6DV]+J5EMB\<W5307?HUN$?S:K)!94!226=IL
M3-TE5 %--10IS@)"B&JQU3]LK<1<JO8ZC8$#NH*T0,Q7)EJFY69G<Q,['.8J
M2;D=-S$<-CK,G:Z1%T#D61,8%$CE4*4P'Y]< ZB^G?"*,1=9//\ FZFQN0*-
MT\'"E-D,;5S*JM@EMY.#8>.BZM:(5E.Q9)59[!I^Q3"C5^V1]TJ@#E1X<S9#
MSE$U0),385U#I;>?==P&.[-@"5P3;<!)XI>2;5YD^G92C++%9;AIZ9@7\5,4
MQHU:M1;)P#I%VT=E%P)SD$ (   QNKO0NP[3Z#%8HJ.]+J1U?%\ 6.2@Z'"[
MDZTUKT6WA(]&)@FS= V'E7:[>$B6K6-BBOWKM1NW;D$3&7.JNK-W:%L0QQLY
M=Y+FZID?.^6[CE1K0(RTWO/M_:WNTC7,6Q,C#4&K12\56:C%QT)7F<S*BW*2
M+/(.%W:JTA(N@!/RU@,.CJ0#V0J3=5UL=/3>SZ;X83&0:5@VU;V.UW\3N?0=
MNV(\95ZE-KPSE7-%1M^%0.TQRSM;VG8^-*V"KY<RE7JLV9+I9&Q]+7*NPV$[
MY49TSP!6K]0R-(7^GL$7,G98 J;*2;L;RSW4CPG7+^MB=]4,PN<IJM8Y]7\>
M15'92EEMK)\>V-EGT.FSLJC",:1TC2+)&O5+>^K*AEV*+E@F^CI*.>.:QMVS
MO;U=[+;B6L;5,'MH35C/0'F3+2XJ=2M%F:2<3,Y4H5&6F%6]%N[EO-RB+6Y5
M]%L,2[?.%XD&3MRX,K2N/.G?M;QQ?Z[?J^QO3^WU!"6:5-2RY=NUB;P49*/K
M#,R["+AI*949D:.9RXV:P.O-;++C*61XY57%(6:+:(V8R@/6C3J.D@F]J%;$
M7N3VH$K>X Q32=*G50^ )\M]]MO6[OY70B/4]QK:+OAUCBRC7S(F-,IP64I-
MMD=K!J0#%_+8ZK%/G%ZI54+&YBVSJ=82%K+"7 ]N>4^'K4A'R30LL^=1$TC'
MZ0757V\7N*=/,85?,.0)%1J9"#CX;'JI#3-R0J5RO#ZCM%GLPU(XFJ_5L?7*
MP6-XT,M76L9 JHQTY)2\K78^9J1;I?[3#FJ7L4%D&$0QR="2QO'PN7K_ !\1
MCVWIA @ZR)4(A*8-&QF09-:LP[V8M"C1T\D9)HM(N41>2,BLZ[D-TY]JM(I+
MRDUF N55CGEM0N2=J899O;2^1%I=0EGJ<B_@+VXG%)V$/9JK>+E5[*DS>$3G
MH6SR4<] 2+I&0K*R\F*R>894YGD+IRE?5* 5%AF72J[#NQNL23'K?2K! %T6
MWF-U>H@UWO;:QM0.U+9 ZC]-Q_@#%>5I2@V6R7W(N%<0YK=XYJ+"5DD*?6,J
MVBETQA)VNP+1Z"D'#)V6Y!%,G+J,/)/%HB645C&[..DG3/PIWJT;<Z[3[;(,
MT[!>KM3HB<7<4BBQCQ8TW:8&(;VZ0H<'*6)"$/\ 2=I07C>Y.AE(UA"D8D<Q
MB$NO.HA%FOA?MA.WK(U=QI6Y2/O$-7\84VIX]BFM,R?<JLI9\=4>3A+!4Z+?
MY"*DDI"\U6(L->C)MHPG'2YC29Y%15PNA-S+9[2B?3:VK-279HQAKU%0E[J$
M_6+75HK*=SCJ\]DK%!)0#S(1H]H_1*WR>6MMHV)978'!7K!K%Q[EH7VYL5^H
M^X3HHR+)S\S,RDDH^7DF3V> &_(88PPY@LR%MUVQ52C-9L)I72H%MJHZR6OH
MQJA6U==\,&9N/:VC9UY*[;VENBN+=TF"+E 5DB*^2X2 Z@)+I>/RUDP.<"*%
M,4#&XY'LZ\* !FSB(V,:2+R72BV#*-"2?R(S#]X+%NDU%S)2IS&/(2*OE>;(
M/%3><NZ.JLMPHH(:]07C8JQ6XKI X.0RA$!4("QTR& AU")>+QG3(8>#J%*)
M"#V,8!$.8!ZW57MOVH5_._7YXICLZ-=91VW1*H=50J::0"*BAQ B9 *4QC"<
MYQ*4A2%*)CG.)2%#@3& !#6\CA)1/S4CE4(*952F()1 Q#% Y1*(B "!BB @
M//A[AR(:FQZX,<VC74;/FCPJAFKA!P1)95LH=!9%8J;E PIN&QQ24.!%VZ@"
MFNB?PJ)' 2G* @(!RJ.$D4S+*G*FF7U,<Q2% ?&"8 )CF*4!$XE*'(@!C&*
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M(78TZ3(W3,QJ$O,41['*I.ADT'L%-4M_!3,!(-Y GMB3R'?LE_/.H90Z@*J
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M9Y[&N/YRRP;0L="V*8I=;DYV(CDP51)'Q<N^C%Y"/8@D<Y 9M'"+8I%%$RI
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MZ.4>GU[W"Q)'P/N&LPD/[CC_  K)^[X<8YBV&-9 FZ=$!LS%)(".5R^'PJG
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HF4  !4,TFA !L BTH VH#!HT:-,P8-&C1HP8-&C1HP8-&C1HP8__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g580373.jpg
<TEXT>
begin 644 g580373.jpg
M_]C_X  02D9)1@ ! 0$! @$"  #__@ W35),3%]'4D%02$E#4SI;24Y614Y4
M259!7U!(05)-05U)3E9%3E1)5D%?-$-?3$]'3RY%4%/_VP!#  $! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !2 -P#
M 2(  A$! Q$!_\0 'P   @(!!0$!              D("@<! P0&"P(%_\0
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MZE)*0$F85KL5&(-N4&)WQ VE):4LC6O4?9)@;IO$[W)N(.U\=BZH>4^L3G+
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M[3X>K*3R4,=ZI%)RIHMN@+TD<>1?G9E6\0-S.W I\"J;GN65\.XLSI3W6/\
M,>/JCDVD/7L=).ZI=H-C88%R_B')7L6\6C)!)9LHYCW92N6BIB"=!8H*$$#
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),&#1HT:,&/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g669759.jpg
<TEXT>
begin 644 g669759.jpg
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M\?+PY=_3E8_T'1OA/(D8Q]3.W/B_A/HJA^CZ?5+N/X?S?TK>_/\ A'R:EO\
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M"X3\U=[I=K6A &0>')*/13G(QF];1YUUFZJ)2KD2./0,W63:\*OL9EO[6Y=
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M&[/95'L&Z)&[7WH%4'[P1-]Z &'M>'7//&--;;N@K+R<:4_C]!ZSYJ<'^8O
MXU4HPWB(YJ+:QK]YT[!M5$6UZH$_ 2"CBVHKTJO-EF=5-.2LOW)D$V#YHG"M
M6CQS%BT2_'>_<6?+'Z<XD;'UE5*>_P"2VKMF:4HDOLV(UC'V;652AZ_);$-J
M9G8)2+))UV1F:[=4:W P:?8DV*L+%IMRHRT*@YUPU&S54X*JM6JJH=GHJJV0
M55+V>G9[*ATS'#L] [/0P=GI][TSS.FFH)14334$INT05$R*"0WA]\43E-V3
M> ??%Z#X!X^&<O1V:+39;:C+@+)M8^VH:V&J4D.L8_,U<P%K*U:;D5<C>.:L
M5)N(3CBA#K!2LS;,QCQH0)27>Q$]2RCI2 1,K<#H)H@0BP_<='6,+GIDI])3
MK=.D.1%5G]E:1Y@\>OD:'U%1..=:B&N[MN\W=V:U?Z7;0-3=L;3IJX<4JG-.
MH=])F<"1G&0S'7DNYG)%5@[D"C*Q-?77QGQ3L.GXMAY.S<C:XZ?N5!:6:ZV"
MV;!VYS+?ZRK_ !!G[S;)LR.C=.<9HB6J"]B?N%9-.(9/=K0=C<-8E@6;LBT6
MQ*5REI^&10,J5<R"!ER].RN9%(RY>GL[*PD%4O3\79.'3\6<&;MS'%4S=N94
MQ!3,J9!(RIDQ#H*9E!()S)B'@)#&$@AX"'3PS&SV05(JG45G;2QD)J@PD66-
MFAY-E*P)<SUU RL+C*N8)UBJ8XY$@?B7*LV093];!Z)"'%'FZ8+@I+N^E@],
MSWO,E'>3,2,@N>."5,$43L.RL[7[GPG\J-K.'V7K?[KH+RDLWODFOYS<%9JS
MV^:4AK %@L?[GX/9U-E=FMIAXZ8;LHBM+ODK(Z6\S*5S(2#5!W82:UL9CRC=
M"\I57N8.GJUY/>&T)$F>0JN[HUM*P5<8:ID*_(Z&5T&1<'QY]U>UV=A&')#*
M224FB5L@B:R,8R-6TVA11$$P%!$02_\ D@**8@CT]G=!V>B73H'_ ,OL^P/F
M#..X;BKYP+=N+CV^<"@B+@!Z=.H+]CO0'IX=0/[/#V9D+/9DIX60#,DL;:LG
M6=#,77L<5<SC\/0R0IAEGH3:GUF0ZC<Z#.I+7J:NX)00SECX*"B&S$$+ GE8
ME/2U:5LXYG@2_41(#B.0YF)@XGF-L_A9<*AMO1W&./L,;QTV+IW6>V=NS55M
MU;Y327#WDIP)B[OLF3L:R]H@75BBFVR2Q,%*&?1TE6G,8UE(F*0: QENAI-S
M$C]T345<XF<Q(.D\DZW,]/+%:BONO]J;,D&EWLUDI<!8J/(I;QM-2CRQ]BV%
M6V;Q@XG+3)P\(BC8F3*0<(BBJ[$Q=>91NV6,4Z[9LN<@="'7;HK'( #U "'4
M(8Q0 ?$ *(  ^/MS].P03@J)""J4!*542%%0I1'J)2J=.V4HCXB & !'Q$,J
MJ[-:ZKUNU&7L=Q9R-;(!4BJ)+ T95F5.&"^R^M+7,82C95J4J[8DWVZ=RTPW
M3&* P9E#2X)HL@>F.(D6][/[(B'DIF8F1$!G]D8F4R6MM3FDXUO:>.?./96U
M'VH=-7_85(A)"M;FXJ\UE+MKOG):6WFZ-9J\OQG?S<L^BHYTD")7S=Y'R3^*
M9'<OD+:",4K*JZEQOXP^/7Q'Q$>HCX^T1_'U^?/P(W;)J&52;-DE3]KMJI-T
M4U3]H>INTJ0A5#=H?$W:,/:'Q'J.?MFP[1VM&U*=JH.09?&Q84X.M35+K@FI
M7I@E(ON7W0/17$I#RF*ZYF%5*U2N )BO6K^3"00<G!%$QS$Q Q "'3$21SQ[
MGG]ETQSP(@,1&F,8S;-7.F,8QIIC&,::8QC&FF,8QIIC&,::Y+[0_*']N2:J
M_P#)FN_U%$?L]OD92^T/RA_;DFJO_)FN_P!11'[/;YA\Q_@D_P )/\V=2'Z(
M^_\ \IU=KC&,Y_KYE:8QC&FF,8QIIC&,::8QC&FF,8QIIGVJ[7+#;IJ/K=5@
MY:R6"66\WC(2#8.9.4?K 43F(V9M4U%E 33*9593L@BW1*=9PHDB0ZA?BY<O
MP55CM'\<K3OJ U7=-M[0NEEL56BHNH0JST\97Z@5N(-I2;[E1M68%Q)&<2LT
M_/WSR0[#%JQC9!:. B>O[FS98'&3;36BW;?832I5S:"%,M/ZI"7O,A!*%@#&
ML,B&. Z9,.KK'/[:PH9W)Q4=8FI537==NV 4;VKJHD(.$(7!&YS#8M2P 3+J
M/J@#Z9"81R/ SEQ%PIYYQI><6:)MR.3LXZ9JDK. D<O:[)8&.GW,JLNF _PK
M1NV6=%$!*5$YP[.1+=-73%RX9/6SED]9KJM7;-XW6:/&CIN<R2[9VU<$3<-G
M*"A3)K-UTTUDE"F(H0I@$ L/HOE'>2P;B):GBK6[0MJDHZ)#3[1L#2 \W=.R
MMHR-I:Q$G,K&3XJ.2H-I5RM)&F'2B9)AH[2%L1GW3RE%<KDV.HM]15-LNOK#
MLE&PUR[U:WP*M;L19BK(1CB-?2K!4YTG3U%DZ=1:LQ'*/(^29MXI0CY44DRY
MA,?G=QU,S0Q&YJ6*&,LEA4;>(<V1392@WMJ6T66L;/N%L$;*^$$R $9/K*59
MN_@]NV\->R^VKF5(L2U07JF62F";7<]==5NH^LI:O.QH2==DRZ DC* Z1[VK
M8 $P@4I3&,80*4I2B8QC&$ *4I2@)C&,(@!2E 1,(@  (B 9YK(K-U5$'"*S
M==(PD50<(JMUTCA[2*H+$(JD<.H=2*$*8.H=0#.TT#^7M#_/FE_WIB,LEVW1
M-.N+USKW)M6K6NXJ:MW306$+7JU<#4Y.63MC1JU=Q\I(@QDO-V2ZJ:!W#UNR
M5D6Z"9TH\R"JPKDSN2SJ\9<36;6<\7UX8OR>5D\[#,CC<;7K@MQI5$-=D0DF
ML>L5P'GYB>8P6,P9Y.H^RNRE!(L2MGE$,% 5UX[(9*Q8-B0<WE2:!P*EH,F$
M<<3$Q E5;C+/!XW\<V&\Y2,?OU(RES>A:/M[6E*O^PW-'AI"SW;OQ)3K3M1&
M+DG43%LDFIEVAQ3])OU77FJ3IX5BH1;X<CQ<H;?8VY8F3I%QI<-6^*5LW;4X
MI[>XJTQ0VF&4:HH2%8NT LJ%OH(*JJ$;%G4F$P98JR4JS;E*U <<&]<0<Q'=
M70ZJ:;HRQ2%R8NE,2E8%9AK6I[X>_)0'6"1,8L$8],WY[-RH#)0VD?3<=2*%
MM><"2H;/?,8-:5*4V%%*0<Q=ED$!]Q"RZXKE0;N'2I4&K=PZ7/VNP@U06<KG
M[)1.;L(H$45/V2%,<W9(/9(4QS="E$0X,@N5$C@S=P5NHH=)-R9!8K915,.J
MB23@Q 1453#Q43(H91,.@G*4!#K:IQ+UK5:CM/@;>H--Z6<VO1]\S=M67D5G
M;-=]7X>PPT<>-:GZI1R(,E3%62;F$BZG14_WY1$V+M>:UA+WJCB+!V23LKNO
M[ Y87RFS, C-*MHIK&K?P;IW#((I%5C)9X0!*ZD$ESJ' Q^P4@F 2F;NK!8<
M$5V36K\0QLE$-DEMW.FR()B)&>[/;395).&&C8&2[J0Z2F5M*RRNDYL+BR_J
MD%#$RF!8K;#JI&Z2$H[P-R+AT"DNY)!0/?"?4%>^,GSL_4V@7FH=ZV35]5O-
M1LO'O;\-0'TG9KJ%I0OL//V-_ ^?N8TL>S:0#EDX:+"Q;1XJG3:-FYG[V1<O
M7 M^YZ*XYZ2V%J&FOD(=79FRK2E9U;E 1.Y([7NRZ4+!TY2@"ZXUW8V;*MWY
M!RU21=/WTY-H,W(J"FS7./5HWJLW?CDT)OMK9!:PO#0:HU51:EAT@R N<<W(
MJ+05-JFP96H*28"(#RB>ZBDO:60=>&BJS0:;*)7U-6RR:W+&X5 TI7%3RMCQ
MMK8H@&MTP*S=U^3QWLUIXRT?5/%O1,?K+4UAW&O%*2FWEY]S,R%GWS7=,2.L
MX"(L!H%(]9I[]!Z?8%C:"DJO9&3QTBWC7QO1!$P6*DFX^>RT3QCH$5I_[M(:
MV[8<[0WKLG3[6TU'800%:4@X6[)5J!O"#6/;.O2+ILP>QBZ$=%R#*-D'"DBX
M>.UDT&3<] ][XJ&N2FMDK)KL.K+[A%:1LG6&X5DDFRVH1%,T+$2-F:[61"V(
M4U3!9JN.RLIW27-LXVL#:Z++._=8@JP6BHC6%P+J-(C=ZX5YB:\/4O\ 5 >U
M35RO59&?H"*YD3N"H+F;I'(DJY*@L9LDJH BFDJX*04$E5  13344*=0 $2%
M, #TLJUWQKT<WN._ZE87$==K=K[;[F@4*CW;;!]*MIRH-E#"ZGF=I:P[M"Q7
M5(JGF;.!(HR8]^S%Z_3;-GJ1R_%GM9P^LM5\B8^8A=G1E:I')[348YUC8[1$
MQLA)UQ^Q92(H3<E6TYF&<RRK!R*<#;8E9VW&/58216RJPJHY/]6%!MCR6LBR
MQW5C9"&PI$6%9%M)8G7 G=^71Y<D>\<E-8FS(#8F!(AI_4C?6B+%AU8%=&1Z
MY5+G]PW'JN,)=@P3W R?D3I[M3G6!7$'-?W0B5=Z*2KDBBC9)5TFBF9991JD
MHY311*/9,LLH@50B*)3?>F65,1(IA IC@80#/SRXG>M<J;O>W.&.J+&8H9ZA
MQ41D9I*O3R3:&MDHK%U-ZS3>P;>,;MXZ!)&/&;*1@T3JA*/6BTR=VDJ_.BGA
M%3CAIL8!IO$C&S_N'FXJR&S7D>:=D >FW.RFR4C[BTY_J+E-!:V.4NP@;J44
MT5$P3%$P(Y1J;UIM0A]JG:K3:51*NH)78,WWZ%>\BIU0:PFQ8!_ZT&)_50 B
M=Y,<2J*UG9EQ3WHK6ZUGR5MT;#2AB !-&^^B^WTR+#A"#3$VIF.5$P85Y2$P
MV:Z%TE6W=>=)*M?."$5;^=)J-O.$E>O=*-^_*GWZ:O0>Z41[9%>R;NS&[(]/
MSRZBF5ZA0AE0O<+8-D"IY,6%O8&GK:0A(:';&>A8*K5^^A'80!'HJ,C5R;1%
M5W42MGH-TG_I,XMXWZZXV:BOD%HS;/FEA8ZI7H.Y)O?K1O8GSIY"6+430SHK
M9I-+))FBD;,5[$G:(MA*<Z'>"V(4Z@CDJ=[4^E[+=*VA*B%:["Y4]=AQ5+EP
M4+#O%N%K I-4B&+$76"!<$/6,S,W95R2KKJ7*KW.$F,KLAJ&5DC;I4R>PH!J
M32!WEM<2V%*J\$R1GH.!KGQGZ*J)*JJJHH&:H*J**HM3*&6.U15.91%J=8_W
MZQVR1B('6/\ ?JF3%0_WQAS\\W://$3Q,<QZ)XYCPGB9CF/"9CWIG6ESYIF.
M8GB?3'/$^,<Q$\3XQ$^_$:8QC&FF6X^2(_"AN'\P*Q_>=]E1V6X^2(_"AN'\
MP*Q_>=]FE=HO[2L]_ 5?Z1IZW3L[_;I@?](L_P"X6]7WY0#_ *2-_N^(/_F2
MU+^R+]E_V4 _Z2-_N^(/_F2U+^R+]GGOLU_;]M'\.T/_ +HU[)QO^/U/X=?\
MZ-:)N,8SZ(ZWO3&,8TTQC&--,8QC33&,8TTQC.2AVC%+_P"HP!]H],::RCIW
M2&W^0=W8ZWTCKBV[0O,@@J[1KM0BSR#I"/0.1-Q*RKI0[>+@H9LHHFFYFIU_
M&Q2*JB2!W@+K(I*3'VSY)/RBFDZ:^O\ ?.+US"J13==[,2%/F:7L9U"Q[5N+
MIU)2T'0K+89]I&-$ .H\D"Q:S1FFFJJ[5012.J%VG'6V\?N"?D5YV8:[39ZI
MY3\R-"[*VC3;,W<35;NMNMY@G(?7U6HML8LTNS)4>*;L4F$3'S"+YA)2$G8!
M;()2XO5*M_)X>43WA6N:V@I_DKS)W*GHJ+M,^XV*KLW<EYE:$E#GH=O08GLK
M"2EGC!=B6?6AA1!TV413?^9K"!!3*H3D\[OW=E2W-D-O8W&!AMLV;]44Y2GE
MFY+<+,8MLV2Q+:K4UUBUZ&U:T37ME#8"61)$2 QOE5ILV#0M<*KD8Q# ;+;$
MK_9=U(S Q$D)",=)3S'G\\],4\E,4Q2F*8IBG*4Y#%$#%,0P 8IBF 1*8IBB
M!BF*(@8H@("(" YP<Z:8=I11-,O7IVE#D3+U'V!VCB4O4?Q!UZCEJGEC=4:@
MUQS,?VO0I(UOJ;D)K.D\A:K'PT>:&AF*MZ=6&*GE8.$7;,'D1!3TU6'5KBFK
MB-8(G3L"R\6B>)49*CE3R$*;4>8NR73J0A888SB'OV6:6"PPJ%@B:T^CUZ&L
MULCR(<-'Z;Y"#/UD5VQ6CA1RW16:E15!<R1]J=NU(;,G>"*36+C%AD8Q[C*N
MX63 PRFU@H>0,2Z329"AG)!,B!<Q&KB;,14\J@)F.ZAG=E/3,3,1R$SQ/$Q/
M(SP,^>/-$ZI5(L@H(E2705, =1*DLDH8 Z].H@0QA .OAU$.G7PSR*HF<3%(
MHF<Q!Z'*10AS$'Q\#E*81(/@(=#  ]0$.G@.71\G+9N3F?9.+W&UISVT7S2>
M;1V_$0L7&:=XZ,M'KZ^G)N/:UXMQL$L.NZ8[E(EQ!SM@=D8$<NF<>2'</WK8
MAT6BR5A?EB>/[NY\3)JZ5SC[8=.0OD_=_1^AZ5*2E+5KR.TN,%AHNOZBPV-&
MS MT LD6TVRR2(D](F#=&-.K(%,!I$ZCG%3OY5:_MK&Y"BFO9W ^RMG=W+@#
MCUC971Q["1E\/A<A9G(Y!D50#R%$*$&V(8Y01)T_+8$ZZV! F^2B>"..[CJ@
M%S,-4DREC)@..@>GSES,1K53QD]X'BUK^3\G[ \K74S;$M@2G.Z"XPN8A)_%
M$J"5"D]<LK>YETF!X@TH2U)R#A1)-^I,GBR,2E3/$F5 5QG'>O)Z<-].7ORF
M#K:5MY&.-6<&[]QB@:5&T64U\\V%?VF[6760K,O(3]8CZTA+/I=9HTC+05"'
MCZY%IOGCJ)FGPLVY\O:WIAJCFUSB\UZK+J?<HJ2UC+*,IA\.2DQ!Q!D5[.X]
M:_/$$!L.9&%S$U3M*"9&>N2@I'@1YF2AJE<1]\W+B/"9GS1&J)!$ \1$ #V=
M1$ #K^(.H_C'\0?C_%G.;,'&[A;PQUQRZILB$#L;<G'SDSY.O9/)S2-?V0TU
MO)V:BHH0BI;Q"WEE+0+J*EK?"1JD>OJRW0[)GZ"L#MRX?N)M%B#];$G"CR8G
M&;D[KK3LO+PG+"LCR)F]D)4O:5CO^@=<537,3!+S:NO(6%I5X%&\<J9Y[#QK
M,U[M&K8!&MA+^DQAR0D:R6>$PS>TW 5U6;5A.0320FBR+)I4$F=L,J3Z\I:Y
M9@^C.'NJ>ODF.>HDU >R4B^E.02,$1"R & GJF(CF3AG(\3,3!!W1P4>>2F.
M @ID>K7X Q1$Q0.03%Z=LH&*)B=H.I>V4!$Q.T'B7M ':#Q#J&>6;.T#P9IV
M\O)E\,-H;&6M9M2\3Z+SWNVUXG3$? #O':BL1O):)KL#2DIEG(LV;1!&OR<Y
M9+1,-)QK58-J1HFS45D"O&F&^+WDJN/^PM#:#W#N%3;'FW*1U:;+%2M-W_QK
MUQ7^-&J6L^O!U2Q7%CN!Y#VO>4NX*5.4L"E&KR3-M&D7;(0+.:%DVD(1VG;>
M6B\ZUWZCH9F_A6K3 -@K-2UE06(L<549:_'XLLF2N)A86$4ULL76*2UZX(B#
MDN8D&FF8CB?="3(B.2D8Y(%]YQ]:"$8ZCF!G7MQF3]VZV+IS<6TM3$L\+=DM
M;7ZTTMO<JVLDX@+8S@)5PR8V.(616<(F8S+$C:03(DX<)H'74;E<+@CWI\89
MT%#E64)LI+K382IZ3X(>M3@%BRZ2B"'J AGI*(*.>)B)YC5[$P404>@H@HGS
MQS$QS$\3Y_/$_7TQC&5=1TQC&--,8QC33&,8TTQC&--<E]H?E#^W)-5?^3-=
M_J*(_9[?(RE]H?E#^W)-5?\ DS7?ZBB/V>WS#YC_  2?X2?YLZD/T1]__E.K
MM<8SO&LJ,\V;L2D:ZCW[6+?7>S1=99R3U%9PS8.)5?N$W3E!N=-=9%$WWQTT
MCE.8/88OMSG;G+KI;8<4 E"F.:<Q,P"U#)F4P,24P(C,\#$S/'$1,^;7S.2E
MEARJZ1DW/:M*@B8B38TX!8Q)3 QU$41R4Q$<\S,1S.NCXR=MBX+2[;]T:-HF
M\-1[+NVJ(^7D[KKB%4FH>Y,FD"<A9?S1G)$7;O%V('$%$Q7;HG<=RR3<F=.F
MZ9_F5[ALSD]>:GOMDY"ZFUV.YX@TG2(.ZM)YBL]4(N@W49'ED5%&('1.[8@J
MX%%-,#/6Y"IG,<.N!C=FWR4+8OS(DP%",4[\ODV5CMA/DT59L0LZJV6 =*H2
M:EF8LF!GC.SM3/BTE30B"%1N(IN4(3 +L!49'E,VO)I8%IJD&F&RX6L "7$E
M$3"7&2BB.)>RWW) W&637AX:X-EGJK^<,=S(5QK M((]B)9B'3(T=KQ;V-%K
MYLFHFS= [>),W":"Z:I0]22XQ6R(Y,,N,DC.1+>Q2-CC()E:/,WBD&Y:S$($
M]&SB3(JP/3LG+,>[[@''>$<D53%402,8;N,_AY.5C?09QBIS? =9\XJ/_P"8
M,@!"2_KP(S+)C@H"8F)U:S@<Q 0PL>\0G*QA.3Z XRL\<4B@S$A;Y^)(HA43
MS$LB8F(C1C)WO>##YZYO,#KS?FG-D7[7C*>>6/7$6I.PML*%;6\WF&K%"12<
MMW+QDX*=LJ0YT&I'0H-U7B0N$SA SOD@[OJJF45@**1#J$(=0#].SV"&$#F$
M>H!T* CU\.G7PRKCLOCLK#9H6.^E/=2T"2^NU</"301)LJ2V <$22F=$K9 E
M($73/%'(8G(8J5>7U^YA_>PDQ<BPIA). < NK-<J6),A%J^OO%R0P8CU1S^F
M,\0.02B8I@.4O:ZBF('\2^T [(CU,'3IV0\1'P]N20V/QNGM;:[JNP)*VUN0
M"S5^IV<L"V;2[)88>YH"M'.:W//VY("]*0JHHL+JQKKGTI4GCQFL\CW$.X++
MA7LWZE1M5%APJ;=;*:H2)E+61T\C$@)"'[(8ZF2 ]1",%U$,30KT;5M5I]=,
MM535#K)P01"ES,Q!3!$,GSTE/2N#+I$BZ>D2F(XXSCM%[0%[10,("8""8H'$
MH" "8"]>T)0$0 3  @ B'40P!BF #%,4Q1]ABF Q1_%X&*(@/_L.7>K77.6?
M\!^7]5U)"6O2NU9,T%2+6XD).KV\[55VQJL_,, 82K.>3;%4=(P<H*+5\@_1
M(=*/DBNP?%2:/S/6M8&<AUZATZ]>OAT]O7\73^G,1G<)2W#C78R_!]RT@8#%
M3 N0Y1=2G*(A(8,)YC@A(3 B QD2F)R^#S5W;^13DJ,AWRA-9K;!$EZ6CTM2
MX1("D#CB?<F)"8@8%!@,Q:15N&.IM<2]/V9)\U='/(.G3]5MZZ;0C!1>19P,
MM'S M6:36\/GAW#Y-D9!N1!@[7[U0H$:K'#NC8>YW<J(WDML.&1IR;Y+6]!:
MR3&M+2**C-W/R<NLV4FK*JP5 JS!LX38L6$2U=%(^*R;*NGB+99^+1M!0I$^
M\$Q2)@KU'J8I" IU#VB)@#M]?G'KU^?//,92VR:\I7S&7RK\U?I)<C'FVI3I
M*IKLQ N(54UAWKC#E<,8<B(&?2N"*"C)7=R@>,L8?$XM&&H76H?D 5:MW&VV
M5IY2,MML/ND@<"R5K""(P"29,1TS[D=(.HF1CY5BH5)]%2#&49*G3(J1)[&N
MT7S-0R2@"14J;END<R9P$B@%$AP$IA <JV3?.SK:QVK'3DTQ<M-U6.!MFQ$T
M82.:C+3E9$HPSEDHBD!X=)N)2]XVCS)I.>G\,!NINN'L9L+J=2PQ;7UD.:KH
M[MC% 9KZ'ILAT$43(]%BNAP\3'#4K./= ,QKRK=I"V*38<I3>KO%K88 ?6EM
M8^L1F(+JKO>@N8GE3F+GW)E$R*C>5.Y8V;&:/+UR7(XUW7=4RM>L--K\Y49^
MB505C5^%L%:?-CL)4\<HX742DC]U(',NN4[@45U43_NWY8[K:;!;;'9S5?9R
MC*E&ULSKK2H03>@-->'$ICTIM2$VX1"->.J4K@S4G1<7 %4!T!2E($;L993@
M<+,E,XK'\FF:Y_K1/!)(8"5S'1QQ("(<\=70,#STQ$:O8SF9B B,K?X!T6 _
M73N1<)2<,B>OF"@YD_3QUD1\=13,R36Y;;R6MNO[M]T4&C/:M:6F.H8LZ966
M$57XRX(':R\6WA63!O&*1R3(X,8EHJW$D2T212:B!DQ.;I%?WELFKQFO(>&F
M&3>/U9?I#9E)25AH]P>-N,H/5Y(.EEDS'DVR@]>S'/!.T3Z_>D]G9Q'C*@X;
M$@$*#&T07 ], -90C \VYZ>F B.GG(7O-Z/UW9^S,ZI"S.6,^\/(W29)=<F5
METE)<4XZIF3YZN,?1CGT_K2O]A7TY,5V_?5J_LJKJ2K48;;EICKG>VX13$JL
MI88F5=S3%VU<E3!:*22D7KA8S1B9-NH0Q43D[L@%S(M*Y7;AH=;K=9AG-,?)
M4=*11U_.V;7]8LMOUZG*]\+U.DV>3:*2,(0YEU3)$ZNBMP,"2(%;$(@6-V,B
M[#XJPLDOQU-JB:+R ZZB$G#7&I#)B1\Y^2@-:2],UX[F>5^YU!.7RE=D-3D+
MBFBJ4"P+#1,538*U*XF"Y@?*B*S$>B'E+HX9[K4D:#RPW5KJ!8UV&F:Y+L(2
M6E)^JKW6E5RZ2M,GYMT=]+S52EIQFL]AW\A(**2+@>]<M3/U%')6I3*J@ITE
M_O/9TJRHS&4L19$FNKQ.['K#E[',5Y!*XV6=0LLU+R;XR7?3 O9INF\,U?"=
MLD';023(@8$RXDQDHX7$ UCQQM$7-9+6-&LF#)A Y9')0$3U&%BQ!SZ3[]LE
MS+"YB68RQ*6@LE=)*EBI:BLND 4!H8"X&3F($#K5R".. [A/3Q"PB)(0W*S;
MT4[O*SY6D6^/V+<3;"M%;ONOJU<*HK>#%*0+/%P,HV\WA94J1$TBJQRB*781
M0[:)U$4U"]4MN_\ ;%ZCK_%VJS%EVVSKA!WNX'7C(]-V]L5::)L(%5DY013-
M$Q\6Q0;,VL4P*DR(V;()]V($,*F&L87A<0IO?KQM);H[KA@5E"<=P2"3(S Q
M(RLJU<AF.)ZD)F>94'29F<LU4I9DKK%3WO*SLM(9[\7"Z"B2X*&#8L"43S$B
M]T<<-/JD+9>4NY[=)6R9G9V#<2UZUT?5=NDFU/KD<\GZ>HN@X,A(K,&3<5Y?
MM-D$B3IP&11:))M$%$VR::9.G_NU[*_<A/HD;$(ZP/8PM0U\6305BRP.0>]"
M2O=^D"QPOP](#%@MYGY^)G0)@H8W7%6,F5B,4D%K5CJ2P2Y%A(!64(J?5&0K
M.7$!P#*X3(I,>"6,](3$>;4&9?*.)AMR-UAN4]#3.RXB:BR4'84PI/DUO.()
MP%,BPH@CB9\^I#0_*;=,'.P=A8V"&,^K^J&ND6:#^HUV4B76LV2I5T*[+P[]
MDNQEP[TI3KO7B9W3GIV%U#HF.F?ND3O>#I_%"[:9KLY9Y&W[BNC.>NL:YA&D
M74*;"Q[D?/V-<D4GAW,J[MR,5 >D")LVS-BS\X8]DAVX"[B+C+=V Q3I3Q42
MF%6J=PHKJ2J'LH,8^H+YA<D2TO9+A$2">J.F2E1,6==.>RB8=S;<Z6U;E2"L
M-<V4KOK6BV28EL"+'(7"2(A..B>J!AH*8L(]1$1]H^(XQC,SK#Z8QC&FF6X^
M2(_"AN'\P*Q_>=]E1V6X^2(_"AN'\P*Q_>=]FE=HO[2L]_ 5?Z1IZW3L[_;I
M@?\ 2+/^X6]7WY0#_I(W^[X@_P#F2U+^R+]E_P!E /\ I(W^[X@_^9+4O[(O
MV>>^S7]OVT?P[0_^Z->R<;_C]3^'7_.C6B;C.0#J(!\X@'VCEL6OO)<15EXZ
M\>^0^R.;?&_CY%<FD+$76-:V]&6^,6?2M:FWD)(1+FRL72D.F9)1NU=N'QVZ
M#=JWD6P"FLH4P&]]Y;.8O!KKMREDJX6WS5K0%6Y;8Y\(=9)8)I5[+IZ:]=[C
M*5P K49$4<>?=V.6F!EA=/472/ F4D7$EQ$ )3YA$BGS<1$3.JG,9;?3/)!;
M@?[]Y/Z#VIM[56EWG%;5\)N:Y[#FFMBMFOI[6<_Y\Y8V^">Q 14HWB"Q$<\E
M'AI)@F^8G:/8QTP(Z:*''"7)SR?MCX_:2J/)FE;VTCR:X\6^YN]>%V?I63F%
M&]:NC:.7E4H"V0<XV(ZBW3UFR?&1[E\\5;+-TF\FV8&D(XSJPK[QVU:N5J%?
M+);9MQ3FM )MS7=.0J#>HK"[->*4NMU"AR$>40YD<B*Y.)&)!M5R(0%L21]/
M3Q!=,]8081!]/1U&$\B/5U3YXB.?-JOW&64\F_)@[JXM\5M$\J[I9:Q+UW<Y
MZ>A)TR(CI1O9-6O;]3W-SJC*W.W3A9D[6D6#55@MYFV9@SEC)-!!?O0.'?ZQ
MY+BO.-"\=][[5YT<;./K#DW4WEHUM6MLPUSCG+CT>NW;2,>ZL+%TK#D+&*/X
MLTE)G1;M6B4BBH*2A2&$TD[TVQY&B^&5!]6S>LXRNRK4OW";>I@UMJN":M5S
MY)*DM<3.ZA4I"7"PE$!E#RNOTB<-B1(R6,B)G,F,3)#$",E[F!(IGCIZ8YB9
MB8F:E\9)?EUQ4V7POW9*Z,VN[J\E/M8:#M$#8J=*+2=5N=2LK=PXA+)6W+YI
M&R*C1SYF^;.6SM@@Z9/&+I(W?MRH/',9B'(H BFHFH4#&()DSE4*!R#T.01(
M)@ Y!^].41[13=0, #X9GZ5RKD:E:_1>NS3MI6^M85/*VI:/4!C,Q$\3'IB8
M@AF)$H@HF(K"0F(F$P0E$$)1Z)B8YB8_^->6,8RYU-I@!Z#U#VAXAC&--;.G
MDL.>_#S8W%57R;_E#4JJUHD:_D$=36[80':T=W S4B]F6]<DKBEW*VM;I2IN
M2D5:3<%)&(;#$.VT>SG(R3C"-9.1FL.%'D9_)_W:U\E=L<M=>;_C8&:5E=)Z
MWF[;1MA.:B=LD1XQ;%I-"?3,EN&_,WA.Z@9R6AHZ#BT3LW[J"0FD#V5/3_\
MG^80$!#\0@/@("'L$!#P$!\!_'G@FBDB(BD@B@)@Z&%)%-(3!\QA3*43!_0/
M4,Y;D>S$;%_+NQ6ZL]@,9N)Q6<YA\<29KVK#2@K3J;6Q)XYESB?*34#9:)FJ
M?UM,5XQQXZ"-LJLO0M\R3E+F.DRF8ZI"9YE<G_ER//5Z/V/FB9W/OEY-<XN4
M>P>0,E$.*U#318FM4&J.W"+MY5]>U5NJSKD7(.6YCMUYAVHXDK!.G;**M23,
MV^:M%EV;9NNICOC3R<V3Q3NMIOFKT*LXG+?J^\:CEB6V(>S,>6J[ ;L&\ZJR
M;,)B$60F4BQK4\:]4=+MFR@*><,'B2ADLCQC-]5A,6G#IP(TU3B44TT IG$F
MN:J $%K.2F2.> &3,BDS/DS*2F9F]A2Q5"8&.Z$(" GF8Z1B(B)Y\\^:/3,\
MS/GF>=9YXP<BKUQ*V]5MWZOCJA)7JDQ4_&U96]P3BRQ,,YL%>=5E6?:QK>5A
MA^Z&,C'KOT,^4=';LW+A559DZ*;N@[]K?FYR"UW5-ZT=S;%MGU+D3KE]K78D
M!N.3N&PXTL:]>.9 EAK#5_;&J-=N$>^=KNHV:;D71;+"B8T<MYHT!")&,FM8
M7%7FN?;H5K#["Z:FN:N":2\?89;I#!S[H(K66L>KHD9%IR?,SQ.A*6<R1 )$
M4#$S,<SP!28>?TQTG,E''H+S^G4V^/\ STVWQYT]:=&0])T9LR@3M^8;<@(_
M=VKF>R#ZXV]%Q+2$CMGT5%[)L8M"T,6#!IYH6PQE@BD':!7)& )K/FKZ:>I?
M*?LPU]Y2K8N[8+5ETW_RPEN+\E7]6VK4DI;M'[&:ZVFG$3L"#M4 L^?,8:+/
M22-7"2C^RQTH,X8)*LR+63:MB(4HXS%9'9NWLD=EKL>M5B[9IV;=FOPI]B:F
M1QN3[IAS!1"K-C%4XMPL08T *18#B[V*9U4,DIE<01$!$0^:2Z&+9Q,^\1*#
MJXXF8CF)@O=:L6<^5 Y*+\G8+E&6-U"E/5+54AHFG:J#7IS:-JFE9&.<1BVL
MX:BDGD'R5>%%RJJ<ZEB,^<+#W2S@8TJ<:GV?7_E7-YZT3TH]K.FN)HW'CJO:
MX[2VPI;2CJ1MNN-=7&4DI28U#4%/NS;Q==H9?2:D0Q7AX]G<F-<;M81O:2$%
MZZ>UA8R=NSMKN6M3,)1E:JRZ@!"R 8K+7;4*2@"&#"57K@,AG5WPVG0WK[PM
M1FK7F(B4AQ P,1QQ[F(.(&>/3'!G$Q//,%///.K!=?\ E,.2^KW''52F&UY'
M-.,KG?0T:)<522D(FQPG)&PJ6;9]1V0T<V8PVVK/)(R Q+%!2%>1I&$<J:1=
MOV:;T?;UKY239NO:17]>RNBN)>W*UKBPW.S:$0W/I%.^.>.+Z]3CNR3,?IYV
MZLC9>/K*$PZ*ZB*W95+&TC@9L&_?K-F;=%.N_&3LVGMML'#,/3F3.6F0@0&3
M2L7K1,EBR$^LG9/(D1]7407K2BF4O8LDUD3SRH///,SQQ/,D93/,>?F9:SF?
M3/643YBF-?;LMBE[?8Y^V6!RD\GK/-2=@FG:#%A&(.968>K2#]9",BFS*+C6
MYW+A06\?&LVD>Q0[MJR;(-D4DB?$QC-@ 1 1 !$  1  "($0 8@1$1B(@1$8
MB!&(B(B(B(B(U7]'$1YHB(B(]Z(\T1'A$>:-,8QDVFF,8QIIC&,::8QC&FF,
M8QIKDOM#\H?VY)JK_P F:[_441^SV^1E+[0_*']N2:J_\F:[_441^SV^8?,?
MX)/\)/\ -G4A^B/O_P#*=7:Y(+B=_M/: _XL5#_OP_\ O_Z^S(^Y^B2JJ"A%
MD%54%DC =)9!51%9(Y?$ITEDC$43.4?$ITS%.4?$H@.<UO5IN4;E.#[N;=6Q
M6ADCU0$O2:NN1Y'JZ>OJZ>H>>..8YYU\U*-F*=VG;D.\BI;K6>[ZNCK\G<#>
MCJZ2Z>KHZ>KI+CGGIGCC5I^\N4E!U1M_DA$ZST!%P.V;#*W?7EAVW*7V?GO/
M&\J\33GI=G3G;,L=&.I Z*+ENT:/4&K=P@W[XSMJD9HM]^[;!U#KWBIP;<;/
MT<GN14]'GEZT"]]FZ:A7E(AY7U77?MXIHZ0G4Y(YH_O$9!,44BL!(":A':I!
MJ155574.LNJJNLJ83JK+JJ++*G-XF.JLJ8ZBAS#XF.H8QS#XF$1SS4<NEDD$
M%G3I9!J4Q&J"SE=9%J0P@)B-D55#I-B&$ $Q$")E,( )@$0 0U0=D8\%XI8N
MMQ-)JFWGQ>R<6KTIQ-G&J!5N+_E5)*YL2P$(=" 5WE85PMI\[5.];Y,RK"15
MD;BF*HHFEC2JT>^RU7)M8RI-":MUS(K0LWO3WQL[NP3)8H(U;_JK8D7?8+E/
MS&W7/)ZI2VBU8\>*1-P%=?6IQ5TI&$2;2(P,>B5)]+2#6/3AT%9(H-.V[CY9
MZL5HU2!HGWY[!5*\[6X!\@==6=>]P3:RM-&6ZW.8!U6Y&3G:7!SQH.3FX=WV
MW,>_>$:SZ*J;@Y@.4T>=NHHW61$*0A=.A;E9BZ=&9D4%8C,SE<69%C (&6(T
M%06Y%C )@,J5(%# 8P"<0$0']$9"0;)D2;2$@V237!TFDW?.VZ2;H [(.DTD
M5B)IN@*(E!R0I5P*/9!0"^&6;MB\O?8JY,ZLL6^BBJ-91TJ^(9ARQ"J<#,C;
M-B0[NQWI7.Y-P2<UH84LB[3OF82BO:QH6H!E>\^T5IH7+&65F R[;A% E5$'
M'WE?NQI]\"3@(M2L87-W%"N6N[GOKE]2Z1J&%U9M6)I>\Q:[C@[!*62S2\@Q
ML*<?+N$Z]/-%(Z-=3JZZ,@X+#@=5 4S-D#$+W"J>!:+#3$=ICADRTSK^NVV"
MVM/3K+D*Z5I\5:?3,P66C&$Q3]A3[Z+DGU/K\%3G<T[8G\Z@BL$F",XS>F<-
MBKK5@)/GR#@[M!\^;NU.\[QVW>NT':G>B!E>\=(K$<*=Z8 ,KVU3=Z8 ,IVC
M!USWF%BL,4QDHN+L$]%QDR0$YF,C)N5CHV83*'9!.6CV3Q!G)I@7[SL/T'!!
M)]X("3[W)XV3*8(:]_K67D$DBZ-JXMAU,9>QY$QCK9O)8.MKOTD0T55'UX%(
MK(X<N2=Z0[IFQ0Z6#Y=$.I%5J, +62H9 86M-,*XL-51E"W8E1.MHL3+B,5]
MRR<O+32-]F=V;0M]9U*XK&G*@QK;EM*P#:!9P3/64<1*O)7MNFS=@=VQFG,;
M/3:+TC5V]=,D%))PFHR1,ODO+S#A',N3?'^?J,5%\4]?Z C]@Z-L:,"9:/86
MP6<4ZK5@@[V9#_\ $=IO%JF)=-XV))N';MTV%DT3(S>/4GE2U?VY;JW6;K76
M+@'#B]5IA1Y&Q2CV:DIJ,H3,QC.:97TW4H:'BXB5$&Z+I7T6N_9Q[=2,A7,6
MSD)$CCIRUILKN'CZV_L5B?U>+<@Z85AW8)E:O,E>T J'80QWQHV/54+VB><,
M6J"Z0&$R*A#_ 'V#VOE+2<=5LW:HHPP(KTFK18AQ=S&,:.4"&77=WDTG3LU5
M.(XZE7;,D  1!8!N?&579"U6I6B=F#?8NJ8]$)#O9R2BQA]W25WF,<%JM::@
M ]RZE6@3(Q$ZT[=$:^?L+#+\0M[:YB*/);";M]HLK=8&K=Q9J^[J3&*M4>BD
M]CUWB):S(5:J7F+?M4'(N1>2[I!T1L=LNBI$3=E[B=F[:V#?*_#M("O6:RO'
MM>AV3-NP090"":,=" 9FU(1N@Y<Q;)J]?$1(4@/7+CP$>IC9.K?)Z<C=OI;8
MGJM$S!8[6\]K"MU&/?R,9$5>MOZC(U2%:QCZ04GI9V2&3DG3QZO,.Y"3GEGT
MJJ[D47;U)TUBZD3NTDD^O7NDDTNO3IU[LA2=>G4>G7L]>G4>GLZC[1RV(QMQ
M64M9&\N%-?CJG4*72=3UPLF<Y4D*-SFJY71Q(2)&2AE1=P9];2G$Y;)4VXRM
MCJ+)8I&0M]).2(V_(*P+C%"YH*2MO2R[EC@A 6E#([\ Z4B/GEEO!7B?KW9T
M%:MZ[W?-F>HZ._7C6T;)200D+-R4<V0=S$E9945VJB-;A2.VK4&C=R@$M**+
M(NG -F*C)_6EET' ^(T[OOCA:=)[ A4;+8M;V:UW6,JR\U,LR2+.RM$G$78D
MHB+E6"<RI%3*;B+ SIN^"(=&:*)"V5E2BM9;_O6Z&WF.JOMU0.W41>N4 %ER
MI1<<BUM?K:@089]TB&2T)7#I,9@HB8O=A4:E_<*TVDU+1KJ6K%*I>82ZEN\D
M0)*7]"G$:Q7WSY5"CALIA9#(E,3V6%Y">3DO-]?ZCD-'4*O4=R1O#P.TI&E0
M4%!R[\ANY$BKIDT96>J1ZIRHA%6:0<MBN3B9:1-#IB@NX@GS?XN,>-E^A5JB
M\=26L]A,GTM3UWBX/'42XCU6X2M=7D ,8THBT2?Q[^*DU/X=W&O2I.3N'+)9
MXZQ[KCC+NQ]?=?M+5HK:@5M[<J>ULPR-"M31AZ!=3T8C.^D'7F"'FK/T:H[\
M\<=\CYNAWJO>I=CMEEUY2UYJ^ECJ/CUK)H5BWUL6R6:6BDY>3FF]8"U(1K:%
MK[=>8?R;J.*JS9NI885NY19LFB\:LFS2!VB.:_CT(P>[,+C\#ELED:N2IVBR
MM5]P,G4!=6O,C?)_?R56V5CN!D03W3(;*UDH2%4[!?L/S>U,S?SN)QN.LXZW
M4'%6D4RQMPV6K 0= 40@0MU1K=^8D3^]5W4,9#I@FC6-7HHL[8:_!F7,V+-S
MT'"F<D("IVQ9B69QAG!$S&(50R!70K%3,<I5#$ @F*!A,$RX?AP$IRWG.-)[
M7/MX2(":[O8(U0!,Y]%4UK:4^K$S@D47SA=P:-$229NG=BJ0!5$4BQ IKYK&
M7"H2;Y8K9C&VVK2+UP<#F(W91]@C7CQP8J93J"5!L@JJ8$R'.8""!"&.(%&V
MF$YPD#FO9)&6WK(GXQJEL!8E%5-R>J""M$9HQ8(L4X,9P.MI\Y%$5$^@.Q.H
M<?-Q*([#NBYN&LQ\859& [?S#YGNS+HNJ90BJ=?HIVH?=@3?%>FR5K?$L(BY
M7'&O;8J;?L F<TP5F6X<.B([P!ZZ35W)MB^3N5)12D@3Y1<7#6(GNX&([R>8
M>UOCUIIMI&A;EVSN:X49M?K9<:HPCJ[K0MS0:.*E)/VRSETNWEFSTB*S)B+L
MX@T4$JAS-T2+&*03_?2X5.$-C7^FO[^DZKT#Q\EN0]!NT'"=XSO]5;IM3Q"9
MHY^^(K#&>&67;R(E</CLU4"*-Q70<IF#[+%YI;:'%73NKK)O^G:JM%'V-LRR
MS+.Q5JWSJYHRS2TNG'F:D@F MA7,S=)/TRK/.[.0Q4511.)Q)F^M<C]$RFY[
M- FOGW):CK?#M]QHHE\L\),&6GI RT4FI8',*R:*2:*;LXN'#5JY(R46:1AE
M# Q4=IH%P5K)[E5.1*JW+N8I^<AZ&8GFO4K5\DM>*9CVQC0FTY]:9&%!8N]Z
MB6OD!)0%K.U,9MML8X;2\2E;$8.4O#+\6+5JQC29EEY!4Y$QJJ38B"[TT4NZ
M?"DP9BTAU4] PTQ9Y2)@J_%/YJ=G735A$0\4V5>R,E(/!*5NR9-42F5<+JG-
MT*0I?8!CG["93F+D'9>DMM:<4BB;/H%AI83B:IX=>60:G92(H)I*N6[:0CG;
M]@9ZT362,[CS.2/FQ3E,LW(0>UDM-)'X_<9MZZAV$AR!K>W(-.0L<%9#U^B6
MJ%6HS26J,C%Q]Q6)*B^7D$&DB[305;1C<[]!NHNZ1!44Q3S"NZ&U8K%'KM,@
M^1KO=CU6YV6VO8&MEEE=95IO)%7(VFDWM@01DE;Y."X.>8;-CN&;9!1YYP<J
MYD5GVT!G+5G+U*]2LT<8Y"F=_:Q672ZPPCOA8%;&)2JCY%Y-6,HO)B+0W [D
MP_4Y;JQ82M7Q-FQ:LJ/))<P.XJY7$M2@!''F@S6#FLO1<BU9$)HNGR4J;.^
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M7+TE.S-VS2MM'+.:6F4WS=&1:3W8:M3P:2!@%N[>=G6B9/W\8Y(]C'[^,>I
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M(T];IV=_MTP/^D6?]PMZOOR@'_21O]WQ!_\ ,EJ7]D7[+_LH!_TD;_=\0?\
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M$:ID]3Y ?3W8?<"&^(L>I\@/I[L/N!#?$67-XQ[(^]?AQOS3'_HFGL;[*^!
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MN/6YP?T$SOO_  _P[E)!CIE,)#*)@8I@*("H0! P]>R @(@(";I]X @ F_\
M* YR)BE$ ,<A1$#" &.4HB!0ZF$ ,("(%#^,(!T+^,0S%>V0[8/C.CZ!V_\
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MRALUMKC/7<C3#U6"CIL[M[9&,V1\60DE8X&Z:+6+8&0,D9(515.HH4X&[ $
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MSO,J=RV+R2_X3]N_F#6O[SO,Z]V"_NN[)_TZ_P#T+D]<&]4]^X-VB_@[%?\
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M5,<%NKD+-JN=([(2=-E&+E;+6,G8SU<'K8PLS>%T5;!&*Y),MXN#,UXK4UY
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M'>L]>N=^U3]P;*"K=F'+"HR"T#M)[7*/9K9!61PUJ]69M;<^XO+E6UUZZ+.
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M-AQ]%&UJ7Q^\UNSTVO9312<L6@DAE9D=C(* 4XLBV-PU305<%.N"'<%(V4N
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M[2]T9NPYGE"<96=13CO6^@#3K+KIBY$$D\BZ_;388.0NJ;8396TJU@Z42-.
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M"J->J2SM*-=7&T:6,J4B-5@#=0&AC<?5?CWDVE<72K>6(>25R/     ![
M#\?@ = ZB/B(] \1$1$1\1$1$1RV/R2_X3]N_F#6O[SO,J=RV+R2_P"$_;OY
M@UK^\[S-S[!?W7=D_P"G7_Z%R>M ]4]^X-VB_@[%?\2875[V5"^6P_V.XK_C
M9K[]F6[+>LJ%\MA_L=Q7_&S7W[,MV?1SM(_:'NO\"W/YFOAYD/\ $;7\"?\
M)K5!QCVY-;6WD]>5.V]?5'9]%IE7D*C>VSMU4W,CLFE0$C,E9OW<8LBWB)F5
M9O =>>LET2-SE*<W\&<1*FJ4V>#<=B<IF&L1BL?<R+E*ES%4JS;+%I@P7+3!
M(&0AWC%AU3''68#SR41.CK4UTR*EFPHCF8 9*8CF(YF!B9XYF(Y]^8C4*<9*
M^D<(N3%_V1L34</KQ.,V#JJ.8R]ZK]MLE?JHP\9)JBG'2"<C)ORQ<DQ?D ';
M-]'/'+-RP42>HN#MU"G'K^\^)/(#CBP@IK;=$"$KMF<*,H*U0\_7[95W[])!
M1R>.";K<C(-FL@+9!RX1:/RM%72#1XJS!PFT<&3N&;>SRJ;<BW"Y1=!#&J?<
M.A:&NAB'36<#G$J 42;$2AHLD96Z.Z/@_<ZC-=\!+)2V%Q,P1RLH$9$NDHF>
M.(F"]S,3QQ/FGSZCAC,_[$XO;NU5JW6VY[U3O0VO-LD9'I4P$K&O'+L).'4G
MXPLG%-5U'T(I)0Z*K]B2122,X23. =% [ Y>U_Y.[E9LZB4W9%0IM2=U2_Q9
M)BHN)+9M(@I"89*J&12!&)F)5H](Y.J4$P;'("A3G2 _8[P,F3MO<%BR=)&$
MRKK@5E7#JKH63L!4?"Y19)0KDX0Z&J[MLCT'W@=,SU1S$:]@BD!2TC@8.0A9
M24 7'273QSQ/5'$\<3S&H18SOVS=7; TU=9C7>SZM(TZYP(M_24))BU5531>
M(@X9/&SM@X>1TA'OFX@LRD(]VZ9N2 ;NUA.FJ0G0<Q3DNK.;7L):AZ&&IR'+
M-3DM64B:VJ.!-; *)$P,8(2B8F(F.-4B$AF1*)$AF8(2B8F)CS3$Q/GB8GS3
M$^>-,8QE+4-,D?Q!U3"[OY.:3U990$]:MEW:)V1N4YTC/J_"L)&S3$655,!.
MGZ780JT490H *:;TYP,02@8(X9D;4&S)S3.T]?;8K::+B;U[:XFTL6;DYDVL
MCZ/6'SR*=*$ QTFTO'*O(M=4A3'12>&6(4YTRE'(8AM-&5QC\BOOL>G(TFWE
M=/7WM-=E1VE]'^7UH$QZ/\KGI^OJHF0%JB9'4N&!+(]/(0424<?7Y'F-;"7E
M(.>&X^+>S=84/CS,ZW94F1U2C+K,CU.)LC9D[9V24@V3.-69R35M'1S6)CVC
M=M&H) BD1,!2 I1 I<DZAMCORA/D\;XVW^_J$C>YEWM(*ZK$,8NN*PT]0"+R
M-+L$9&G>N%6[V*41*=\[25(#R*6?MW1R,73@#19VWQEX8\[ZXEO'BYM;6>BM
MIRBC)U?]>6V1CJS!*23TZ(RIK+52'0D:Y9FP*+')8ZPU>UFW*-A5417</!FV
M_P G:<AQ!\G9HRXZ\TI9:WN;EOLRHOZ?+[,;C$S\G4(BQLS1D[(@ZCE9")H<
M.C'KO#0%.9/U9^;?*,7E@<R31F9\GZ7;E,ZG.[DS>=R6.M]GMW#V1KUQSXVL
M791;KI6BOB:,!WK\BSR=BYIG5JB@[#.JQ(BLG[)+'B^R][ +'FDH$>_@U$)B
M,#"@XY(YZ2CHD1B)*?=3$1)4,(*G$C=P4035$B#@H@4IRIJ]DBQ1 IP,10I%
M.@@4X&(H4.R<#$,(#9G7^<NCZ]?(C?\ &<1(Z!Y)P<&DS:3U-V?*T_3+JR-H
M0T"UM;_54%"L^T)F9Q5D*ZC)>CI!R7O'+M5V8)-.LPI2D*5-,H]DA2IID* G
M-V2@!$R%  $QS=  I2@ F,/0  1$ R8=^X.;RUQ0;5>Y]?5[I;7E<B[=L_7=
M?VC69O;&L*U- V-%2]YH;90KV+;O"/&Z@%:NI!9),YU#)BF@X.EY^V[9W'4"
MY9P5:; 5)KW+3"QE/)!3=4&PZM<7-NK8BK:KK&VU3T0MPI789SW:CD,!7*R$
M&21ZH#I,Y[L&0!!U2!QU@728Q!S!#Q/3!3Z!GCN=1YS2=2H>D(Y'7J3W:FA-
MW7?<=1V(-M>,("4+LRP.YK8-6L5"9Q)2N&UA:2,C"(OVMB1&(9N"N6;,S@IR
M*9"M/E *HZFZA8:=J7:#)]';CIFV[2WV%R?V9LN),WJ-H86X:'K^!ES)UZL0
M$C*L2 1_+PLVXBFA448^/340;KML:/\ R=/)*.@9N85)JQQ)PVNVNV$Z*PVI
M7W>QIO7BT:64>6>#I8))RCF/B43E:/E'P1I%Y0#1L.I+. ("G;>+?D^K[M^=
MT59K^-;A-5[8FTWC>O!L> K>W[/KE))\60O%-J#])60>03-PDR74>(E5D!BG
M 2B46=@<KG-KJ'VF&^KB J7%,LKIK3-K#U/U)56:F*59.PRBQJ26OR.I9LR4
MV6H&J#2;$5HU=!.3F03 '$E 1'4D(Z8'H3!R4KYCB.@2*9DI'IZNKW.NMK<X
M#F:WA)/5K%RM;^;,)S'21E[&#Z(:FA79G?[F\FP"!3/*M7ANPFM8B+-.[(!A
M]!K")0#O.Z.?\#LVG;LJ<+JW8$>ONC86O]FNYZ_[SEMBJ5R;HUM2M2-7K\ [
MK;&(@=>(@B6*@X. 4CGC%)9P\?.GHE9,F4.ZYI.V;*WA+:6U=&EEIS[L+S#0
MZ4M*LHUHT@Z=)38O9B>G'HH,F,?$P<0H_EI%0O3HF?N&ZJZR#8^5Y?@WOAK;
M]65*K)Z\VH3=3^PQFM;?J78]>O%#L#VH(BYN"2MG9F;(Q)*JU!1S.+R+5%!L
MB@X!!1TY04;%Q]?+[^LU+@U0M6Z;6GBGL1BJE@9;9EU-E=+1IDP6-+,S7(TR
M+(*]65)#+:XS3%U\P. ZC IE12*@*.2Y"1B8"9B9EW3,CQ/+ CF.1U(MUY1^
M)>;3W9;RZ=M\#2N1L)3 VO6ZCO:Q5RZ-;]1N\;0U]UQL.%K\0^J(#%%8Q+VM
M S6:2#9HJ=W)&(\<LU(V['Y5N[!O/6&X]=U>9J"6FW58>TJ*O.R;IM^?D9"O
M2R4T\E;A:KE(.UW;RQNDQ1DF<&TBHMLT-U0;KO1.\-E>C^3MV&_W+I2AWFZ:
MU2UYN*;L,1';3UMLFKW& </*BS.XLU6@'ZB!&[W8#);H@SK"\>8TEYI,&9*K
MFB7A$?A3'#E^VJ3F,@TX>;N*_+\O&Z!V:VVQ6G>K9$\A5PF(2!<1\=$KND)Q
M9==H$M:4GIXF*E3.ZHM&@^:*K%OK?LB7JIS>!BQ7DG6@F<=31<C( :,UTURJ
M4HLJ4]^2#()Z250:]YM@^J8U.<Y PGO(GB&$4?J0"?7$@_W,@OKB")D,&>8
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M!N9R@/\ 44+_ %3'?]FCF*Q7^%9_!Q_.C5 /3_\ '_.-2&S/O%;_ &E=#?\
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M3&,]R.CI"8D6$1$L7<G*RKYG&1<8P0.Z?2,E(.4F;!@R;)@*CAV]=KHMFR)
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M%174E90ZXNE7PKGE) ZXOG &!P^%8SD5?/7 &,"[SM^=+@8P*K' P@/K Z=
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M?.^\\T[/8\T[SONWYIV/O?-.UYMV/O.Z[/AGJXR67.F8F6LF1$ &9,N8!<3
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M3=<N&Y8<FS5R'IX[[VH-6@(-Y68J &V/1BT*Z_C_ $2ZA'#<0_\ BL<:*_\
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M+'Z$[)^E:?\ $N/D-\L?H3LGZ5I_Q+FTCT#Y@^P,= ^8/L#.^>U)V#\/[O\
MG6&\/N+X3\OAKZ/>WK[4OBSL'YAN'_J7[_\ >?-JW?(;Y8_0G9/TK3_B7'R&
M^6/T)V3]*T_XES:1Z!\P?8&.@?,'V!CVI.P?A_=_SK#>'W%\)^7PT]O7VI?%
MG8/S#</_ %+]_P#O/FU;OD-\L?H3LGZ5I_Q+CY#?+'Z$[)^E:?\ $N;2/0/F
M#[ QT#Y@^P,>U)V#\/[O^=8;P^XOA/R^&GMZ^U+XL[!^8;A_ZE^__>?-JW?(
M;Y8_0G9/TK3_ (EQ\AOEC]"=D_2M/^)<VD>@?,'V!CH'S!]@8]J3L'X?W?\
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M>L-3[+8_C+_-:TK?5J<Z/JZ6OW@U]\8X]6ISH^KI:_>#7WQCFZET#Y@^P,=
M^8/L#'M>]I_"^X?QV-\/N;X3\OAIZPU/LMC^,O\ -:TK?5J<Z/JZ6OW@U]\8
MX]6ISH^KI:_>#7WQCFZET#Y@^P,= ^8/L#'M>]I_"^X?QV-\/N;X3\OAIZPU
M/LMC^,O\UK2M]6ISH^KI:_>#7WQCCU:G.CZNEK]X-??&.;J70/F#[ QT#Y@^
MP,>U[VG\+[A_'8WP^YOA/R^&GK#4^RV/XR_S6M*WU:G.CZNEK]X-??&.9;A_
M)Y\SV\1%MU]!V9-9".8HK)C.T41(JDU2(H01+;!*(E.42B)1$!$/ 1#QS;WZ
M!\P?8&.@?,'V!EQ7[!-JUB(@RN?*2B!GJ=C^.(F)\W&.CT\3\OAJ(X*J,\][
M8_C+\/\ _%KG&,9W+6;TQC&--,8QC33&,8TTQC&--,8QC33&,8TTQC&--,8Q
MC33/@VBQQM1@)6R3!ER1D.T.]>F;(&<K@@0Q"F[I @@=4_4Y>A"CU'Q^;/O9
MB'??X'M@_FZY_P"LWS5M\YBYMW96[]P8^$S?P>U\_F*460)M>;>-Q5N[6AZP
M-1,3+DA#0%BR,.H8,9GJC*X*DG)9O#8ZQ)Q7OY7'4GRLH%D)M6TH;*RD2@3@
M&%T%(E$%Q,C,>;71AY8:D 1#SFQ^'_\ +;W_ !X^5CJ3^<V/W;>_X\K'-[1_
M*/\ ;G&?(?V_';I]J["_V>R?A_G#X?EGW]>PH]3]L.8B>^W!Z(__ &%3P^YO
MA^6??U9S\K'4G\YL?NV]_P >/E8ZD_G-C]VWO^/*QL8]OQVZ?:NPO]GLGX?Y
MP^'Y9]_4?:_;#^S;@^D*GA]S?#\L^_JSGY6.I/YS8_=M[_CQ\K'4G\YL?NV]
M_P >5C8Q[?CMT^U=A?[/9/P_SA\/RS[^GM?MA_9MP?2%3P^YOA^6??U9S\K'
M4G\YL?NV]_QX^5CJ3^<V/W;>_P"/*QL8]OQVZ?:NPO\ 9[)^'^</A^6??T]K
M]L/[-N#Z0J>'W-\/RS[^K.?E8ZD_G-C]VWO^/'RL=2?SFQ^[;W_'E8V,>WX[
M=/M787^SV3\/\X?#\L^_I[7[8?V;<'TA4\/N;X?EGW]6<_*QU)_.;'[MO?\
M'CY6.I/YS8_=M[_CRL;&/;\=NGVKL+_9[)^'^</A^6??T]K]L/[-N#Z0J>'W
M-\/RS[^K.?E8ZD_G-C]VWO\ CQ\K'4G\YL?NV]_QY6-C'M^.W3[5V%_L]D_#
M_.'P_+/OZ>U^V']FW!](5/#[F^'Y9]_5G/RL=2?SFQ^[;W_'CY6.I/YS8_=M
M[_CRMII!S+^.E)9C%OW<7"%0/+R#=N=5I&$<F,5N=\L7P;E6,4P)F/\ >F$I
MO'P'"<),*Q#B?3C'QX1H\2CW4L5N88]!\N!#(LU7(]" Y4*HF)4@ZG$#D$0
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MQC&--,8QC33&,8TTQC&--,8QC33&,8TTQC&--,8QC33&,8TTQC&--,Q#OO\
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M44:VS:^XZ.[,'0SV.A@5[JRF4NB(=7<IA)L(; S(R2G 8P8STL#I8/N3C7D
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MSL)^PHW*\<L.X<?R,MGYV$_84;GKOU#W_B!P/X"W-_1;-<=[=OW/+_X0Q?\
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MW@MI2418U;=&0#2%=0;4T82"6?)(+1BD^UEU7(O4@)&.W2B$2K%F-Z0[@QY
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M>)"ZC9-KVO,I5CVQ3\Y;]O\ A$CI* *+IJM_"ME@ .TJBHBNKT, ZB!0]IC
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MAM;;([@1MA@)SMUV:J8D4/Z6L:BHEZ7,LRD:[UL;P$0]1K$"CH8<*\\B>)R
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MX*[<38C$DJR@2M,J);CJF2!,M)KG7&K]VH[H2X#^U$Z<JZYJ-&SM[>P]EO\
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M;B#;J27B174.<S%\0A5NVH5<3E,0$\<&Y^PB_0H4[=;;Z'U\+@0J+M8C?BL
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g760827.jpg
<TEXT>
begin 644 g760827.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@!!1$E32S$Q-CI;,C!:0E8Q+C(P6D)6
M-S0Y,#$N3U544%5473$U,S0Y7S%?4$Q!4TU!7T903U\T0U]"05(N15!3_]L
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MB3DMYJQ.9@ 'AAC/5<H;HJ2=3MS=-Z4;I_%_9[9##$3THWVU3)PY7H5)QL7
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MA,HS#+,T_+ <0#%8HW]\/$]Y:T\GW7;QE<#$Z_>Y>$MU.<?):2,[>*$V\$H
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M7"[=&+<NR(V'E;$X9DD5B)I+(]FQ9VHQK+-@4T?71.XD^\REX/%[CQQ1B5F
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MS) G/<H9E8;0@S!?B<X=RTV1\5(;U =FKIZ,U_[/;OTM&)Y&$UOQ=KA!M8;
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MRS.*QQ*$3,0'&'RY*[C,?L^52)\%DCE/$J5$\>7-N<DR%L3I8^CDQIZ(XQ*
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M;<$";H])[<U>ERR$GNB!MLR2TO9=01EV6-;VXR-*WYYJD?EVI1**_#&QD\T
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M-\&6(7%GMNGM4NM;9)$P5LTN#WFM2 ['K0QS5-9 #@3F*A1C@8B/4Z'1QZS
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M>)0ZF ]NLCN?Y_8\Z0>7]HKA_)]/-K]ET4QO:?LL$+%)6W=%+$%B!LNY<<D
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M[XH$QF2Y0BQQ7QCL34PCCW]U+/G8<L0'_;<Z8X> B 9#W&H^P=@[^(^7F("
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MVS)Y3S<EFMM+UR[NC,0]7G2&1FSJ 36J9&2K-8U9JBS6T]OLTD"UG@WQ)45
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M[?2(_C$1$?X1YYY@M7S+*Q:UKVP,D(M>4Y@\2F(MN68F9-PR=@;WL4.1F6.
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MP[Y?_6,/4#L?ZG']Z'T^SY^:X8?E#NDY]^%//T1]@.;&QRQ'#'(<L>W8/'N
M!W[!W /(._GX?0/-<L(A^R'=)L>X>.X4\]O_ "2+_#[GB(^SOSY6?@_?OQ>!
M?+R.Y9/^K:\[D_W^NOL#^$G^\A[0?T[5C?UK@:G]U^[OV%K-QZ?D HC86VM=
MR+INJXX]/I+3KLQL\H=&6(4(_3AF;O6I"P25M]7*?FL@TS ]K/ 2C#_>_0/$
MD\E TGB^RTTL2KK:E?46WF?;*I4)S\5,R<)Q4ICW!/C*8$T6GGP <7319!/U
M3Q](F:G/UI.K[I2</5O5S?2-%V?NB$0^-#I2>(>.P>QG;Q#Q_H59A_I#\H?/
MQ4W<._F'W/#O_(?#GM_VR^+O$NP>)L##V;>,O;\6NQ8V32..9A'N^X;E)JGK
MFQZFG&2'@\=*#RY\]?G7]J_BCQ!LGB'"Q=IW7)P<>FS8^0\HF85K-G;A-J'J
M1CU,D9H?/CI4#CUYE/TRK]V_;>J-K93EC;L;-[ 5C:=);4R&2PRZY-"WIF+>
MJU:*X419P;B(K!8CF6H2FR9P,,S5F+!'("/>/>,0/Q/L,;W=5C2'IQJH.Q[7
M7)A6,HM1AF+U6;6?7MM3)+),89FU(W;UI?64"F^+&G3.3^R)SC',L@_,E8:I
M1)U9:13[W6FZ>8@/61TD\0\->=Y^_P#_ (*EP'Z0\A\^8I[K),$-LNG0)>8@
M(TUMKCZ6&7CVR?J> ?'$?$/ >X>0]A#G5/9YO&?N'@':=WW/(IGYU)[D][V9
M5I;L;KGQF'94"CIE*<P0GY*CR)UNWA[Q+FX_LT7Q/GFFZ9N'M^[YM16HD^6<
M/.SEG)JK-Q/F<4D'$GZ0 >EB//\ <H]UVR(F8M<6+JG2Q4T.$<<WM582>_MR
M?J)9')O6)TJ>(NN)^A9$P^J1Z*.,<6H6N).D>! E4"YR%M6>\(S[$W3PZS6D
M744>&FI*8N)CE6R#/3B&U+6KB+PN[T47BN")3&(_,_J9GEI536J26L#+,90@
M9VIQ!"W/#RB/(=,F)&6"LI+\V(331'OD:9Z("(B(&9#V\>P9=O2[@/<!R\0[
M^'<0$ #CT_<Q.??K 6*.1@Y!^QSV/XY9CD'<-CZ6$>PY#XAV[CW\O,0\.;+@
M[P<S(6!QQ,,C-UBA?@J.>..A?,^?/GY>7KZZP'@CVNOXPW^.R'8%V\5Q\F_O
M/VDV25]WEW.GLG @"'/*]7=\O7@_.P_L1\NZB'V!T@L?TX"@^;V_B^Z')@^
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M._*H_65V4IQWNFG[)@\Z;FVVM9)7L)KVZ0'8SIU;!;94-(%$GCU7.DV?VI%
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M:\A$?+M\XA_I[<NQ;7_):;+_ '@MR?HW2+@_J/N^_P"O^_1< %>/\GZD_/\
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M!FW'.?B4BQ6<PWQ3Z$BKCBW8B]&1<;$*E<M9<JJ6G,'K[A8)A8LR3?\ *L6
MX<OU--NK'[EUDMZZ<:M=J 8OJ0^ Z.IYG^+YV<'Z!?!58PAN^HE\=O0^%7F(
M>IL1/U-.SG[T6#@XLOJ2Q:!>'K)Q@XXB"WNI( !MWT7NP '?J#341[  =Q'2
M;9WN(_2/8._S]@XX3B?.I+]EUT7OP@LT_0FV=Y4Y/ISY<\\?I( )^_A0.?H
M/D-3  >@'IQ^GCDMZ_>S'[V)]2='1'^Q%L[[_GJ0?ILW1R?>W7V*NRWWO]T_
MQ92GD!.B/]B+9WW_ #U(/TV;HY/O;K[%79;[W^Z?XLI3PTNHV=*/Y)OIS?@_
MM4?T?(1RDOH%X:7:W^?<:Y#R\?*427P'Y^_?Q[_.'AR[1TH_DF^G-^#^U1_1
M\A'*2^@0?T%^MX"(A_M=!X_./U424 '[GF _2/Y'IZ_J_M _GU/CD!SS_D_K
MXZEY^8]1_N^>N]W<[CI[L]X^ 4?/0'N'_P"ZQ\._;OW\N_?MX_1R[%M?\EIL
MO]X+<GZ-TBY2=W;^P\V>\_W$)[X#V ?!JR'OV[>0?1]/+L6U_P EILO]X+<G
MZ-TBX/ZC[O\ ?I<CGJ7GG\GY_P!_3GTU\IZL!_VLZZ#P'^<6)?M?$1'_ &"0
M_B\?Q]@\0#PY[YV(? [3X@/^V%5/;Q_]TZ)>P//P\.X]N_8/H[^BL/W,Z[#Y
MH)$A^[W84(]O ._8.X@(]P[#]//?._\ <=H'P'_;"JGR_NG1+Z.X^(#X]_'E
MIOS9_@'^CJ5OS9_@'^CKZ1_NAWY.%9]]?HY^EI5G)HJA'UQ</?P]?7AYAX=U
M1P"'8>X^(> #Y^WOY\A=[H=^3B6??7Z.?I:59R:"H>ZY>/<?[/7CXCV'OZT?
M[>P^WR[^?M$.< ]L'^,;#_F=P_IXFNH>R_\ (W7ZAL?^9_Y_O^_2Q.J#_O4T
M9\?']ELZ8_L#Q#ZY)G[" A[/H_&/CS._=#/[@>BOX4_4'_%;4Y@O5 [?4IHS
MX=A_9;>F/[/^4DS^ ?0'X_,![^/,Z]T,_N!Z*_A3]0?\5M3EGPS^]5XJ_P"X
M>*/ZFT_/_?6\(_QYX2^G_M?&^G\O]^-0-Q\<<?WH>7EW[!]/-<,/RAW2<'_E
MA3S]$?8#^7]_V<V-A_48_O<?[P<URP_*'=)S[\*>?HC[ <^>?X/W[\?@7T_;
M/)_JO/\ ]?\ QU]1_P )/]Y#V@_Q5C?UK@?V\?\ GJ7/NB']U#I2_?![&?HJ
MS#BIO/\ ]/\ H_EV'C6?=$/[J'2E^^#V,_14F/%2^SOX_P (_P 'G_(?IYZ]
M]OG[K]L_T;Q/ZTW?7YN?;9^ZG;_X@QOZQW36Y^GG\LCI'][SO/\ Y!I;[O,3
M]UECVVRZ= ^/8*:VT[]NP>'P]3O?Q'P#OY=^99T]/ED=(_O>=Z/\A4OS%/=9
M/V6?3H[^7Q-;:CV["/?L^T\/;L AX^'AX]N_GW\A[%[,OWK=H\N?V/O/\GVS
MN?/_ )_+6Y;;^\=F_P 0^)/GQ_\ CMS^?]_IJLB'I"&7GZ/I (XAV''O_P!C
MV 1\ []^XAX ';YPX]CW,1\K_8@?]B'3GL?T?#MY[(4J(_3^,0[]O/B*1[>&
M?8/1Q]$/1'N&0>("(X]@_P"^[B/B/;N(=N/4]S#@(=8"Q/(0'IT6-X^/B'UQ
MU*^(]_'Q\!\?+R#MX!S8=D/.?,^GP4('_P"GQZ^I(^OIP>.3KCGL4_=[A^?/
M^#]R'/U'NQ\Q]%)\P".>03Y<\:L0;#_+O(O#O_2@L?TWRAY,'S[=P]OGW\Q\
MO#R'OX> !X>/EX!R'NQ'R[J+L(]_V(+'MV#_ );Y?\O\W)A#X#V ._@(B/M[
M#[0'[GS=P[^(!SNGA[@[;,>?/<M_J?GYD<_S#])]/1OB/]M*?YJ'_A@_W_L]
M-1HTA^6%WL^\4T'_ (Q=I?N?]7GW'N/$H=3#Y9'<_P"]YT?_ ,A7#QU^D'?]
MF%WL[_:*:#]@]@!\8NTO;S^?S^;N(]N)0ZF'RR.Y_P![SI![._\ VBN'^7?V
M<S/LV_?5VK_O&\>GI^TNY>FJGC?][/<O3_%=I/Z.?M7;3Y?3C_CSJ.(^67F
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M_C[1_A'E)C/+MCD/?'TO1,[AW'OV .^/81#+R\NW?OV\!]H\NS>Y+_L(]O\
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MI/,*8@3O:#+$&* 1R-+[E>BG=N%%F[12K)?)DM;O;Z0DQS7S5,Z-+,B<A89
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MQ'V<]>>WS]U^V?Z-XG]:;OK\W/ML_=3M_P#$&-_6.Z:W/T]/ED=(_O>=Y_\
M(-+<Q3W65V^NSZ=/?R^)G;7_ "[3O?Y@[]N_;OX?/S*^GI\LCI'][SO/_D&E
M^8G[K+[_ %V?3H[!W'XFMM?\NT]X_B\_Q>0\['[,OWK=H\^/V/O/GZ?]=;G\
M_P"_Z];CMIX]AV:?7_ /B3_;MS_7JLGEWQ[AW#L(@/8.XX]O/$!$/+P[9>'?
MOW#OV[<>K[F'#MU@+%\0$/V.>QNPAY>&Q]*^7@ B'M\?'Q\?'B*A'L(@'?MV
M !\L1S$>XAD(=^X>/B >8!V'P$>_'J^YANP=8"Q@ 1'^ET6-W$>W;[(ZE/ !
M#S /+N/B/S<V#8_\?GY?^CJ2>!ZE!Z^7EY<<<'TX'W<=]BG'_+W"X_\ R&YC
M]0QSQQY\$?3@?4^7/G8?V)[?L[J+Q$/Z4%CY?-]>^7W_ ,WY>3"\1[B/;P]H
MB #X=NWCV ?'Q^;R[>'8>\/=B._[.\B[>?[$%C^F^5^3DPQ[^8^'<  1 >W8
M1'[OL[=A^?P#P\>=T\/^6V3^O<M^KX_+T(_2?GP0->C?$9'VI3S_ /0P]>/\
M@#^3GTU&?2$.W6%WL#P^P4T'$>WTV+M*/XQ[#_(/#B3^IA\LCN?][SH__D*X
M?Y?=[<=AI"(?LPN]GWBF@X#Y^?QB[2_. >SMY=P^8>W$G]3#Y9#<_P"]ZT?_
M ,A7#_G_ ,_ES,^S;]]7:O\ O.\??^TNY?+57QQ^]IN//D?==IYY^OVKMQY_
MM^[[N=1RR'P'V#V$/F^?Y@#C^?<T?V)6W_X3/;+_ !"K.(%R\A^X/^?^7M^[
MQ_?N:3[$O;_Q[_TS+;'_ "?5?A^+G4_P@/VAV+^-Z_[%;^37//8C^W.]_P 5
M1^GE^RY$^GU)/GZ'U'EZV+N5RNOW:=^5LAUPRA57O<@HMV5SEJN.?0W4]NVT
MEOO#^XP.-N%,JV-4A=%U806U*S=;&,DLW;6U4?(%D9:(1@H;CG8D_.QIEY#W
M$0#L/B'F'AYA]/S<H_\ 50VHU*@6^$=B['U >JY '4K:UP9MV835<FV005O6
M-4EUB^J<\:73QVME3&65A/"H,G()ARZ4FBB<GDXM)D0!JDGR3D**WPXE@%:P
M=YL04K,O/%9;H.'.-,Y:Y%:!UG)HS]X6^.],>OIF'*3R; E3.%2KJ.'5EE2_
M3%V5T&158/",RAK7NLN,\,GM9,+./2D^,/#037I)9=3-])O;:P2%J9*_;ZUP
MID4-?-LSD2.M'EUJ+$Y1E6LBE<")CTGD4-/4'*V9Z=EI"S,%0FX8L0Y"?IV2
MNGYOIW3<GH6TKPNBJ7-M?\XI9>QZF8++EDY),K?$Z]1-%4\8XY*CE*1T*6M[
M=FZLR/,6E*A!.!J4"CC)L<R>7_C61RK(>Z_*NI5P>H\]:L%(?GS?X5'5SPBC
MA1C\;CL2(*$% 1VB#( \GIEP6_%ISTS!=V" !J.P+L<J6=8+[)/K$?\ FXT<
M_2.VKY;3Y4LZP7V2?6(_\W&CGZ1VU?*^I]64M3OL7M<?[@U.?Q;1CB^>O]\C
MAU!/[@#M_P!)8QQ@VIWV+VN/]P:G/XMHQQ?/7^^1PZ@G]P!V_P"DL8X:-8/[
MH<^15W/]O\YE/^'_ ,?E/<0"K\5:OMV#^:U(]N_M]^S[=NW8 #Q\^X?-XCV[
MO_\ =#GR*VY__,VGOX_*>X@!7W%6L#MX>M*A^GM[^9^4>X?=^D \>2)\_P!7
M]NK6-_TQ\B4Y_43^KCS^8(UH^YP_FS7+R[CO+HN/@/?_ (T5<#]P/ ?/V]O#
MOW\'Q^ZG/DO47G]EUJUY>?[H2SR^GYN(<N?P5ZXA[?KY=%N_G]M#6_S^7AV^
M;\G'Q^ZG/DO47WW6K7\82SB'\O\ 6/[-,M^='Z0I\_7U/K_?S]?GJ@]EYY]N
MX>(C[!$1 1]OT#V[]A'L >/81'C6>@I\M5I+Y?[QMP/XAU/\ ^8?YQ[CQ4P@
M'?+Q\1'+S$!]H_-[!\1'N';P\?+Q:ST%?#K5:2AY]H-N#[.W_ 0I_'Y]_P#-
MRS7\VWZOZ0U+7\VWZOZ0U<BZK_V1_1V_" 2S]#/93DI\! 2R^P"'?#$1#V=_
M1 / /F^Z(CR+'5?^R/Z.OM_I@$L_0SV4Y*<OL&&(>ST,>WC[0Q\/G]H^WV?3
MSSA[6_V]V_\ BI/]JRM=@]F'[5;AY>?V@?\ 9L?GY_=I<#2';KX:J>?CTQ]K
M1'N';_C#5+Y?.';MX\PGKG_9I=(C^V6_7Z/\(^?P_+S-FGQZ^&JGGW_8R-K>
MXC[?Z(:I0\/#\7M\>83US_LT>D3_ &RWZ_1_A',OO7[PGBC_ $#\5_[#N>CP
M7^_]X,_^8GA;^M=OU&WFS.E$']-\V5\_'IQT#Y_?-7('^;Z?'OS6?T?B\?9_
MHYLSI1C_ $WW97Z.G)0(!V\._P#1-7)X^'A^3PYXJ_!._?<Q^/3_ ).[U_+T
MXO\ Q_OZ_0#\,K]YC)_TDV'_ ,:VM6=;KY5?5[\']>GZ1E6<@]R</6Z^57U?
M_!_7K^D95GT#R#P?-\WASN_MO_=U;^*]N_HUU^>3VO\ [LJ_Q=@?T::9S[GC
M^R@ZM7]N]%?XB)SRMOUK?#K/=141\ "2ZQB ]@'N/UIE3^'81#N'@/W/'EDC
MW/%]D_U:O[=Z*_Q$3GE;CK6=AZS_ %%?HDNL?81\@$-3:G'V^ !\_?Z?'QYZ
M,V'R]GGAG]'A_8.>?^Z8G/\ ?U^GGK>O&PY]B>#R.?\ !?A3Z^OO&V\>0\SY
M\?3[QZA;60AV[@ "'H^CB(AW#^I$.PX@';+OY#Y#W[#^UY=G]R8?82;@?A#+
M6]G;_@,UW]@^7*2PY> B ^CX99> >0@ CW'P#N(>8"/< [CVQ .P#=I]R8#W
MTDW 'L =^H7:W@'E^X7KO_+V?<#RYD?#_/O5O+TQR/\ ^2?'R_F/!]>!SK1/
MP?C_ ,Y-[X//^ 3^CG_"&W\GU))YX'H#P/4^8&=]/WPF/5 []^W[+_N^/W>W
MQ5>';V_3Y 'S\8^B$/74'D "M1B ^?B"HD #Z.P>?X_QKAZ?O89AU0.X_P#L
MO^[_ / -4^??V=Q\@\Q$?Q,<1!W7(NP^'KR/Q^ZI*\>WD/CX#]P/ .W.[;2.
M=MP?\Q/S_4/J>#Z^G&NP;OY[GF_Y]_[/EZ?W_2=1L]S[>&HFP?X1_??^/YTY
M5LKOQD&RGS_7P;P^7F/]$[8_;\7W?F'EI/W/MW^M$V$[CW']D?WW_C^=/^OE
M6JN_]\.RGC_QW]X>_A_RGK(]OY/9X=_/Q'FR^PSS\<;AY_\ 46X'[_\ "&V?
M^>J'M@_<?@\^GVM@DCZ_L+-'G]/7R/R/Z.=;52?V6D[^'\U)_9X_U[#_ *OH
MY9L]SG_(QZ0_\UK6_2#MWE9-)_9:3_RI/\W;N)V'W?\ T?-X<LV>YT/D8](O
M^:UK>WO_ ,8.W>;5^$+^:\)_YS>_Z.U:UWV&_E^)?X&T?ZSN1Y/Z?/S_ $Z=
MGPX<.>9]>@='#APX:-('ZVVRUAT5.^GK#&+<UUT7JR[KKNR,75>#8IJ!LP:F
M"(:^R:<P]$L?+MC<EA+24XSMK96<HU:G(,5G.^*%.;DM/1!BM_'9VMQRP ?=
M1,@#TAP 1^-+IF]@#(0 1$?BH[!V#N(AEV /:/8._+4=YUCK79S6P(-DJ\H^
MPV9K<U2V,([OB=?2QL;G@Y%DG6*V%/8"!>D2.1K<.1"D]NP+59HAR*-S$@1Q
MY&[ZTWI9?:S:!_\ S-:V_P#Y.\NXV3""%:X4<DERP>CT5@"% 0!"!T@AFY/G
MRQ'/''%'*Q;WHKSSKXJA IG)(LK,&)ZR:(QY/(7@'CX5^?K&_H<;!6=L=J19
M,MLZ_'+9LZ)[B;6U3 KN<\8-DHGU45M9AT<K:0%JZX96&&.29UC1*5T3NC"W
M8-S@6O!2CS,1F)_1]-_V3=-+[C6Z[J-BKK?*8JK365[G'T/&X]3^>#XX06>J
M&156[8\JZ^42O&+OK(V&I@Q,>,GA.Y+,UA;WB67@E!I%.0>E*]A9,<H*'U=!
MJ]*<W-8G8:@C\0C4-+>%AX&O*HEKA"1$Q8.2M2&)CF?@0"H\\ S5Y9&  \[M
M4EK=1)SW1:DA)\R4LV<)4N2HF/FR51'U"OU\R)'JS@R=368]<9Z[FPF9Y(C5
M>?K&23(W+TQQ] [4%),)NJ9812.M ]L2\H,9MU(ZX^53'R.EU8'L]/\ TCSD
M8LB(4LILA.**>?;=EEEX]K@44=<FOCROCEIE2!<GGX=(+C_6VM92[1ENENM\
M&B34D=(BLLB9*+44O#(SQ.P/J'-C2E+'XNQR&P8]ZJ5,LT3E+Y3$0A2IX0-:
M5*L3I)+@O:)7:V]455>6W=@:W+JXCY$:25S<]I5G/8?)GYWR?8]2-LIZE?VU
MY0OT7CV"EU=W-3@X)UD=]996M02L8<%KV8FQ=CIRMVEVGK0BB#<U:KZY-B"O
MY4X3F"HF^E*W1I(=-'4Y$I<Y7%TR>.%DL<C<%+8V*%CPVX)UZD]L;#CC\S&]
M%D1FT.UXH"O)E(;%@-(U%";!EBAX5RF=1*N(?'9C(E$@6)G!_.?9,T,Z1Z=<
MWM>C2K7<5RTX'%8G)4JP-/+Q,"7E>H'I 7L;BG +$]Z^&DMOJ26 ;W+,YR2
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M>Z(?W4.E+]\'L9^BK,.*F]OY/N^W^0?CXX?:/HV]1[<)XI1^NWJLTZYN6O\
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M;P_ZOHX_GW-']B5M_P!_/]DSVQ\O_(*LY&#_ %.QN;V$!ZIM:#W_ />]6/\
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M[]@[3M.)D(M%9!?$ACSN%J"%8!IOTN#PPX(]=;3XE\*[QNGLTQ?"^)*#;M+
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M'=S\1^'L7;MLG*F5+/Q<AUM9(H)2Q\F;D.Y"DAZ(.D>9!)\P"-0W2?V8D_\
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M3'"YR%?0Z.N3-(*Q6'.:$J&N\R9'ELP(<'.3.LE3N1N#X.P?-_+_ #A] ^'
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M7\]9112<HLD@HLD@DO HHDG#$LHHHO$,"RRB\ #'# O#''####$,<<0#'$
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M;4#F;#95A.8J2*1*444C;V&8X8R=N:6_!&U$/H?"8(A5=S!FECB&(!CB
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MFYK]@#=KVRRJ&5@GV.9X7-4LYD1)$GG&NC)&7)]:7Q2$)S96](L<'Q0SNY+
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MU'6(]2]4SD'',NE6JVN<WRGV<MIBO'\RT<ZW-L YRC:$]1*SZ?, VKE3J>.
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MP-P.](?>@.'$4=+(R^33I6J'_)I>#XM6^]H4>?GR%!ZE 8!@?*J_*TY1J/\
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M2440CCA(03\F,@CS^--FI\3'$W!&)\NI;8]WJK\<=8=VHYZN>'M=APU[%VI
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M88-&HHXK?JX9&Y;5S@YQIJE:L4J-#*F\2S8TV+BF8X[([A<VK43A4BZ06O\
M/$#-9\J:-HI'9MDV9F6=$\["L:$TG:UF3"6/#"E)>LGA)-+<<T4Y"(O+N<TH
M%32U89JU&32@'$X<2("^[3'Y$\K;^V#R3/W:F/BQZ&/+)TX^'BS/21W/=Y-3
MK=%8-L2QR6/!+X&X*YX ZP\*Y3]7 '43?,RJ<GD\V< A> 'E8_U(?< 1^Z/B
M(_C'Q'GGAPXNG:.1?V\U\<=E:?\ J 8I4CATF9Y_6-F15Y=F@V01\))5<Z99
MTT-\E8R%S8H=(^Z*68$#FF3."53@2>"@@WWTC#'(X<AR)K2+JX) XH.&92'D
MPK-@RD,"M$5AP?4?3RU%>27A>%5ZY7A:%4Y(ZY7FTJIU*0R]4W9>I2&'/*D$
M B+>O6AEAUM>DWMJV++K.?1Z=6-8]Y.,$B]3FQ@LJY;1C,;K]Q<%3RXR5\%\
MC,3@$=S8(HF<6X'C(^1R-Q=' \Y9CAC%/7K1-/>NO&S#VRRI)5SI?TGOB(QH
MQL2+Y-]1YS3M#)G,\QW4K%C.<^1=_9(!7D*<88E+;4"6'L:UC(6J2%^6>)PY
M@3M>"+XLNQRD]LWB:]5;,_0S[;B]+5:AJX3'"REUNQBJ2[7093*X3W+%-,21
MEU3R+9674,]&)R*2FST5F<M,NU:LRS9$+TH_3U.Q+0M2-<E^ND4L=*]O<?=)
M/;5P3*YY2AA+*LC%>QQZEY#2C-8(+'%KBY'-C(G3LJ=6I-./]:='E:Y.*G'#
M(_'#&5W#AS8(S2,8QFO3.4IRFO)/3.:*B+R22>E5 Y))/'))/)UF,64XPFDU
MZ5;JJ1RS$TN[6JY+$DEZT=SR?5B!P. #G@0[@(?. A^7APY)JQI'NTW2QNVY
M+:MN=U1?M40J/V1L9KCN A:[+I1?9KPQ7KK!"FR)09D,4XS=@;5M7.ZUA89(
M[I2T*23-ZM(N;6MR^#W96'.,XU0BL"NGH\4]-$;-8LKA-GWI94_LGWM1&%$Y
ML^-4E); >Y:K9$F#B+HC>[?<T,W;XX].YJ1B.960PM8M.9DQ1QPXD0%[2KY!
M+Q=/F4>"K"3(QY9"L<3&0])'4(3+]3*#IMV9A4DDDPM(^9X9+3[E%<>C]3Y&
M0>6!*]^P4@4<%X@!V  ^C_KYYX<.+IVCAPX<-&CAPX<-&CAPX<-&CAPX<-&C
GAPX<-&CAPX<-&CAPX<-&CAPX<-&CAPX<-&CAPX<-&CAPX<-&O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g778779.jpg
<TEXT>
begin 644 g778779.jpg
M_]C_X  02D9)1@ ! 0$ V #8  #__@ W35),3%]'4D%02$E#4SI;24Y614Y4
M259!7U!(05)-05U)3E9%3E1)5D%?-$-?3$]'3RY%4%/_VP!#  $! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !% +@#
M 2(  A$! Q$!_\0 'P   @(" P$! 0            D("@8' 04+! (#_\0
M1Q    8! P,"! 0"!041     0(#! 4&!P ($0D2(1,Q%")!40H5%G%A@1<C
MD;'P)B<RT>$8)2HS-S@Y.D928FEW>)*AL__$ !T!  $$ P$!
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M!PCUFHH"1'38Z@B)03*X1,<3!SR $*<3"(<#R''(<#R'@=?0<Y$R&.<Q2$(
MF,<Y@*4I0\B)C&$"E  ]Q$0 /J.O/BZE-<L_3JZPLAERI@]80(Y4I&[2BHD6
M6*Q>P-JFSR>08-%H"YD!8FLD?D.OF:&331(R>($*B" D[K&77OW2PU'Z:KEA
M2IY!RZW7RU*H=2?,E#@I(4"::IY"M4LQ53#M!L[I<0E&"L50J@%L*!D>XX\:
MWC1'+$^V$_*5%/NF")Z8B+)!;A4AR(,1&TR).P/?H</F1=-G F!!P@L)0 3
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M,J(G'CP743[EU2]CE.37YS;'VIV@82_ 46O6FVK*B @'*+J-AQB3D\_\9^9
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MO-R8#9U*4B$Q/$KF+R^R?86\?(%3$I3F.6LUU*Q3H& INT$GS>-.*H>F?TP
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ME679<F-)%%14]*2!8:BRVA2S825$DFY).+)#;;8AM"$#^5(3^@&.Z  #P
<?8 XUSHT:ML/P:-&C1@P:-&C1@P:-&C1@Q__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g784446.jpg
<TEXT>
begin 644 g784446.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@!"1$E32S$Q-CI;,C!:0E8Q+C(P6D)6
M-S0Y,#$N3U544%5473$U,S0Y7S%?2$5!3%1(65]&4$]?-$-?4$A4+D504__;
M $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M ?_  !$( 40!A@,!(@ "$0$#$0'_Q  ?  $  00# 0$!            !P8(
M"0H!! 4" PO_Q !"$   !@(" 0,"! ,&! 4"!P ! @,$!08 !P@1$A,4(0DQ
M%2)!419A<1<C,H&1H22QT? *)3-"4L'Q-#5#8F-RX?_$ !T! 0 !!0$! 0
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MEIKBMO\ V(?U!22>.Z\2IQ7F510@BJ[D^S)DZ3$XCX#^7[@'P(XS/$/[8/\
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M GB "4/+K[]9VP^FMJR0!,;5MGD':5"@/F,ALY^BFH(CV!A30;B(=!\  *=
M&.<Q_P"#C./,B]OKD?U^'UKZ-8?:M9^H2%S].P+%1GN?EVQ]>VK^%[95VO\
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MXT5(8B1BF(H@L0P"!A >_@1^^=Q6NU]?OUX.'6['L?5C&*G?]?)N/?\ _O\
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MR,ZA:XSIMK])-IL"L5;9KNO+5BU299*2:0ZBT4HL3VY2)5,N&*A<X.,@C)[
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MD&3=M3E6*L!A8IE'I1R4P=#<EW_T^P_TS4&V/JW5<E<MJU])\]@Y6\_5TT+
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M^Y^H.N=EHKN6U[9OW2;=458D$&T;WOE?;86FE56CCM2?M)8U,3<^*1NV"H/
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M]8G[%6GE-GIB"BY*9JD@X0=O:Y*.VB2S^%<NFPBW<JQSDRC8SA$?36]/U"@
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M1B203O9L!- PFYUE'^:4<[EHB=:($6D$6GMF+ATFY SL4 =+$!913)@^GO\
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M *M'NA3;M#I.+*NB90IT43 "K6-(LGXE!PY$ 473 _9$ #S 0.(#6:#=!%%
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M^1[^XY25QJS*WPZ\4Z.H@*@D4;NT (+ALJ4Q1$2>8"42JE***Q#?!TCG#[B
MY*^T/J'J/K3:17DFJTEV[:H-HV+:=IK+2VK:J5;MZ="M'CTI[2D/8F)P9^&
MD:1@2='=:LF]4KNX5D-47C<N+AY6GEE,?.6PTCO).D:QPPQ0<O3BIUXZ\*(
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M<3V+&TW0[40[HBBZ1'+F$ETCSGG&65><2@@R5*L'SJ/<*RBR;9_8)N)(1LB
MF*T8M72:B3(3CT(N!1)_Q)R_D]4QO3 2ADN@    'V   /Z!\90,D0'5GK#4
MP=)) _D3$#H$Q403*1(1*/Y3&()C"4>A,4?DO65_D=TY5$,=J4CD\CQJ\Y;+
MSL ]AWD'R<RVG8G 'Q84 +C7ENYRL\%!#@<HY[ 10 D:O(M1$3Y\5BH1XR2<
M8))8L2QC&=+J'TQC&--,8QC33&,8TTQC&--,8QC33&,8TTQC&--,X$0 !$1
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M.V5Y9]PV[8Z-B*:1*5NM5LWMVDE6%*<EN]-7L25:D4,D]EX:$=:V\K5'2U#
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MID$CB5P:7$@>H<GI)JG((@/JMW+*R6Z,2!0'D<RASRR:)N_0.Z<*D*W652,
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MBMQ2UYO(%>)S,\[4J<2<ZIH2LULSY5.)C6318W2)DH\B'KBDF<JC@#J)B!#
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M4  WCY=VH76DM9B3--1TF[DX<TJ,@R=1$BW?1BJX?*S"170.[1;J(>8&3+Y
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M@+C[.?[1Q[CML_3FXU%>PDX!AMQRUE*N DG<!9E95D#(>)99$^R2#\2ZQMO
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MA)7X1S>BZL2/BC15[D*#@/KS:J@V7DY^41;II)INRPK,2)>F -XTA$UBE[*
MF*#@#% Q1$I@('WZRN<\2N,CL89BDJ4I7*B0.7?@)A SMT/KN#=F #"(J''[
MAW\=9[>3FUP&O0KHPP[J9Y0?(EL,9I!_^K.5 ^04#Y:X*_-ZUN4ABR1\8(B3
MRS% BPH<Y/VE0,<'&6)TQC&2&M/3&,8TTQC&--,8QC33&,8TTQC&--?B#A 5
M#) NB*I! #) H05"B(=@!B ;R 1#Y !#L?TS]LB.:UNY6F)&:AG46"LFX*[5
M;RK-83(/ 3!,SMK)LE$I! PE  *D0Y4R= )1 0^?-4IEI;IE\_=R)R"/B5M=
M;,W2,)Q\CB!';M0Y0[$0 IUS@'71/$@%*'-R[SND,DT;]/VW6.1ECEAF66.6
M,,>,@].-W4,F&*E0RDE648SJ<3;*$T<3Q;O &>-"\4J+"\<A5.:$S31(>+EE
M#*S*P4,"<G%67R3!Q''JT6Y,,W8!3CRE9J%,XCV+@WB\DG($-YMFR;8JQ 6/
MX@*ABE*/D(9J_P#USF>W64U7&-6OLMKR@664BZ5;RMG8((254+&D=M3BV,)2
MJ1_F=PQ<*E[1!\"A%P$Q@[V98IZUK;D22=36K1Y)=-(9<SAH_1?N#AXE(\?(
MF,JD8?@@>Y!-/R, $$3& !PA_6#YZ<&]46FE\8>6&I]EV_\ BN*;6E6Y52*8
M(Q]'CW+Q5BSDBR+\Q?QA8BC=9RXAVIA#VJ)!<"!ET2#@V+:]UZQZIVY]LV2Q
MNV][6QLIL4,!>R*XIV^R1V$B<R\)9K0D$:@F! H 0,9Z@8J,%JC)P@V^Y3=9
M]VEMTX4B9[E$BRT_O(JI726&O5:/WEG03N^2[B/6E-8Y*=<STFS@&4=1Z95H
MAK!Q<<JW9J3]D>/9([-:=:)"8'ZR+Q<1455;I"'2I$P\R  COI_15A]C5_B%
M&J;/4ATWK&3<(,E(=V*[%Q!MXUHJU=O""'3621(58L@B) .54IA6 3CUEG_'
MKZ0O!/D)1ZCO35TI'VNM7-.%F:ALU,%VU\:MZ],D=%9MSMA*QB%D7""T:\8F
M:@9--N4H&\@\S;"%5U] 4BCIT>O-",6*;)VU]4@ 95=9XF<KF0=F\4Q6=.CG
M%=<_C\G'H!$H!W+=9]0MU#=I4I>G/U5/TS/;.X6-PE5MTBW&..%*]."&&2:2
M.10TYL1VS%A3!\)5RRZ7ZOBZ?J[A2EWB/<+&XRP5S7KQ2B*E62P9K$DKO&B/
M)RBA2-8C(5'JME3CGK+?4=^L_L"HWR)U_P 3K%6IEPXG'T=8C1DFV6D*Y#PB
M@D>S$LBX+X,O?G3.DS ! $_15]4WD<N4CPA^M9M'8&[Z51MAL8I:,MH-(UV@
MWG6KYP"_K"BXDB^@H(ED#*D,H+(@>!4Q GD E ,Q.\Z>&6U>.FX-X4=M5Y>)
M<W&R3MJ@KW PJ\@^MU*>-I:3DX2%=*%,3WCY$P*J("0#M@:F*42F. &\?Z9W
M"2Z[#Y"TTLK0=ATI"CQE1L#=I:0E:U=15=.2.57)'K8Z")H5=!4%S,R)%!<J
MI14,*ACB.L^R=%U^@=UW^QN5U-UC0SOO,5LC>Y[,QY/ U RJD0IRM[C#"D?%
MHJZ9!Y',I6L[NN^5=D%*I^H;B>FJ^YQ^G[K$H1;+75@8LTZ(;?JO*&',$D$?
M#O\ NSK(SC:6HZ5A5K$TETT4"LDNP1,@Y3!4RCE00,5,A2]&[,!@,8 )\^66
M#MGJB3TX5UJLV QE'23 Q@%VP=MSD4;/(YTLF)%#M?$WFW$W2@>D %\2>.9#
M+6SL[6K(,:<>%0DD46C8!F@\FB;9NF5-0R(&(<!7  $2^0 7]Q_0;+M@L-CP
MZ;!Q-2E7DFLD_%-W[%DV<*$43*4R(@1O\H 7R4\%^P'[F/T)>\YYW27BDDL,
MDXK ^[2"M#G,3-,5F>PD[<!RD"B%U0JHP3DZ[?V9SU!!9HK^KR]VQ)&([=^S
MSGC5<X-%*[1 ^BK<)$G1Y7QDA1WL[Y4<6.+'. 6#C=])FJ9MB)1)&,MJ4!D=
MG//6Y *)AF&912;R1C&* E5=IN/;#VFD<"E  L1C/H1Z;/,>H[VWN:X022GJ
M'BF,''5L[AO^8JC9>87*F0Z9B>7J*('3, >7B(#T Y?(DJ[^3+$A*/3B]7*$
M8XE#IOF*DD)>Q8'(<B9$R /0(D3,H D !,;OOJ3:37%9VT+4^Z0DNR<K(G63
M<1ZCABDU7+Y?*GI]-54C 4?%$%O(Q3=F*  '?0;-UIUYM=-*&W;G.M#'I&-:
MZ32L@^SRG1YEC,:_8:6*/U0_,!N,C:],GNOTY4F6C?\ <Z-6JUEMJLQU]Q:O
M7!"M)1%Y8K?NZ88F".XRP<8XXT4E$:,]):'D>/='8:YX]:O;Z_J3,I2K+LE"
MR\U+O 1.(/;/-)N55G(E.8QBD,Y5,3UE/("AX%+?C5D["4U'9601<SJ#:1=R
MBB1?)%%,4O32%80,8I#G$Q2D$PB<1 2C^8##GIT#7C'7K-ZT8R#V13?.C.%3
MO%/)0O8&\44D@[33*3R,!3 81.4 \NO$,]N )[ZP3\P J>W0,E"M ,)!3,#4
MB:CI5(2=]@#HRB)_(0,!DC ) #Q$8G</>KMK;H+EV[=N6=XK6W:RT185H(DN
M3M^Q58^$4L7N^1C)(^$EB3X%U%U.-W>]PCK6((!++'NS59(;]Q[$0J1Q3O++
M-*(XDG811LS 15HU5E2,+JML8QG:^-><:8QC&FF,8QIIC&,::8QC&FF,HQS?
M:X@<Y$5W$D)/(#&BVJK\G93"0X ='LIA*<IB& HCT8HA^F>:[M\RN7_RJ%19
M(G2$Q9.PNBLT&P]] HLP(8':I #Y$B9RG[$.^@[R%FZBV:)S&+\$\P)!AK-[
MS(&'R80AQ'W(!,A50?M$8.)*/:-Q<*QK-"CC*O89*ZL",Y7UF0N<=PL89V\*
MI/;7U>%5"R%.23.8IUITP 4!_P :96IO4\@[#R(4#>1@^0^W?Z /%SM;*AP*
M[YV(.#*J%:,VHJ"D9RX6[ A14 IO!(I.S*G\! I0$W>4]!.F;F34?JGE;?--
MD54SRS5D7\): *@'4:11>P13)WT0IR]KJ^  JH;Y$*4VNDM;X$SB$;.G#Z!(
MZ(]A'*"C>10"12*@1^5MT)U3-/$YTB_F*<0,0.A'O.#WW<[SU-VW2M2@BW 0
MBOM:CU'GDI%8UMI:,;&"S(#ZTZ)$7]&,1JQDP^NFV[;X9=PV7;=Q#QT8'Q?F
M_P!R&]>=YX>[\)8(W,D<"23",EG+ )E2.E$;AE16;JR",?['U2HNT4DUDG"9
M%#!XKM51$R:Z9"B ]"!?,O9OR]=9[FX]&U/>4)'IRPF9R<8I[R&GFB2:CENF
ML!14:* ;H5V#P@%*X0[*!@ #=@( .6R5ZL.PDT6T<SD)!=("HH))D>ILBG.8
M04>+"X$Z?8]G45[Z33$Q@*4I0* 7M-I^+@(V,AUWAG\J@T3(=JP3,\=K&3('
MEXD;]E\2CV4!,( /0  =CUG)]';A;W8;M2ZA=[6V111F"2<M&&E9N)B@=CR+
M!<280L\?IG'$N-='U;ML&QW-LL]/J*U]O4+QU@'(BPA626+#!4)9D8RJ%E#X
M*MZ;-J*-4Z!:Z^D#2SR6/+R::9F[4Q6Y446I#%\#G( F$PJ&*4.A$PE*!0 O
M8Y3FY-BO6$DI#M'RL='1B+7W+DGD0KR0=F,)4!5*(F.FV33[73 H""BA.SE
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M (EG;M43++J&'L1\C>!1$03(0O10CGBW3=;!S#^K:=68BMZZ1R2.T?*/WCT
M3SY#D8%=HXHU*2,MAB$CD^>V;?7 ]8[C;M0H;0A:1$19.$WNWKL@XA6""P\:
MRR2LKPJU9%+S4@6JS<\/J3CTD'&K%*H:"@!]%P8YA\P%]+@FDX,H4!\#HMR@
MB ^0 H<.C#6T3"14&A[>+8H,TQ'LXID_O%3CT)CK*F[45.80\C&.81$?G/5R
M"MT\C]3:"/2V>PY]9O.[%LT?4J/5(9@YG+59YJ1<I-BIQ<(P*=THT9^L"\B_
M5!)FS;E.=5;R\2&F:FUTJ?$PP*THS^WD'J3$G)/%VR47R0D?% /"COJ,FO7+
M:K7YD0@Y2M"HCBR !R=4 ]5\ 9EF,DAQW<XU.1RD4**:A"G(8! Q3E Q# /P
M(& 0$H@/[#]_VRFW%0A%C*'116CU50$#JQSA5H8>Q^_B012[Z^._3^ ^/VZ@
M[:DY PFS-=62.J.Q=D76.5?5QO"T.=*,+4HV?.V3DK%>(+\99,?112,4&;N3
M9O54_34*R(F</,?FV6W951WG6'%KV1IZDZ&GT&M8KM<F8V3-LF[;%>LW;D63
M6R.99G7X=HW*CY-&!&$B]D_3.F"B1U"AF>Q3K7$,=JK%.A/821J_88.067*G
M/[IS\\X.K(C9@XM!-+$71GPK,G/B>ZA49B_;!')1\SC"DZF5.@5WTS)O4G<J
M4W7_ .9/7#CQ^1$?'Q.D =]@ ]]_8.NOGOVV]<@&J8)(0\<0@!T "T14'H/@
M \E"',/Q^XCGM8RV.A2B55CJ5E"CBN(8\@><9*D^>Y[]SDGN=)-PORC$ERTZ
MYSQ,\G ' &0@;B#@#P!J%I'SKZMFAV) *F_<LU(U!,1)Z82P^D[(F3_#XI&$
M!(!>@ HF /D #)?8M2,F;5H0.BMFZ* ?/?PD0"]]_J(B B(_'8CG@2E5:RL_
M#3RKMTBI#@J(-$1(5L],;_TA=@8IC'*@(F,0H=?(A\]!E4Y%;/M<E*WND\P&
M)K)2GALA:?\ OE 4=DQ+*\>#WXQ+\L#6YN5^.W7I*A8S!/4N.P(+V!%#77N?
MM_!!ZQ;]^>0><DVXW/CE$[%W-4-M7:Z7.68:Y!%U0=:L)9Q!46*GP( .K//1
M\:LFI;Y@RG8QXRYO:1:(BBDW5_QY)T="7]+8M@GY.[,'>O','&L*W0VM90:/
M8N934%25G9.T&>K.93W90!!I'I,VC=JF(G.=50.S2!C)\ #/WG/DY\Y\Y\9^
M7C!(Q@ZBC([ *2"%7BH*KA1D$X&.S''=OM'ODDDZBUO-[01VR^@']1B7&J7=
M;1D(.ZQTJ'XLPL+<X)R$'88=T*9A1=$,#B+>QH+DZ Z;L4A ,E+&,KWR<GZ8
M[ 8  &.P&?&23DDDY.J,0<84+A0#C/Q$9^(Y)[GYXP.V<>=,8QC5NF,8QIIC
M&,::8QC&FF,8QIJ-;;>'T!,LH=M%$!-TT4<FFI4SMM$ J!RD(S1<MFKDAW70
MB91-P9N  9+TC*"8_ITN\N[WUT$7EE!D*A3"HRA*M,2BR@#\% D@#02(@7X_
M.5,1[[Z-\!DX&(0X>)RE.7X'Q,4#!V'R ]" A\#\A^V?0  ? !T'[!G-WMFW
M&W:EF3?;->!R/3JQQLJ1*$52@:"Q79PS*9.3DGDQ!! &IBMN-*O!$C;8DDZ<
MO4L&6)FD/)F4\+%6RB84A3P /P!@02=0N2+F'TB5S#0"JC@K=$"6BZN14.5(
MQA,*3*.0 [@%TBCY>2Z3<INP QQ$!S]+G5;7(UB0:NYV)D$#-A.Z:N6!8]/M
M$Q52N49 BIS(J(B43$(JGZ9OU,40'N7';MLP;+O':Q$&S=,RJRJA@*4A"AV(
MB(]=B/V*4/DQA H (B 9",G:$;6LFD\]P$,8P'9U5@F#F:GR%4'Q<RJ11$K6
M.-T4R;/S34$/,[A3HH$#FM^H[)M%"2O>EMW+NZ(U9*\%F2D;+2D)))Z4#!$C
M4'+L_K2NO*-!*YXZE]LN[G9L5[-:M"D&W312F=J_O<B-$?51%EFY.KX3(6!J
MT,8'J/Z2@N-=#F!]%M3?VR[)N2,GK:A>KRP4/(2$:VC3UF60BF(MJU$/&;0K
M-5 Y5"HA(/E@,5TW3,X*HHLJ(#7/ /Z4K#B\K!3$^XG+%MM1@^93K],R#N,A
M6K\J'NX:G,FQG'MCF127(N[?.6(IHK&.D)S%],=B9.L2<Z0H3JXQ$5V'A Q"
MQ4SKMR% J:,C()IE4,D)?DS5KZ0$'H@+&*'S6D9#Q<,W!K%,&K!#X\B-TBD%
M00#H#*J="HL?H #U%3G.(?<PY2KLW66X;/7Z?M=0V*O3$<(KM0GK0R7):H"
M0+)A9HTPI >:02@$!HS@%I=^J]MI7)-TAV>A)OKV)+/O<#3>G%8<CC*S.[PR
M2J/*00F(M\2S]RJQ] Q5T1A&<4R1C*DQ8MDFS--992:DO3('B N0 J;1,W0
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M0,K-7>H'UZHSFIY!K'R$NSD55:[%N5$V-@>+MBD08EDFJ1GHM#G,=HB)?6.
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MF-^-%Y :&VVWG4]9;<UML@U:)[B;)3[9!38PI#^0@H_/%NU0CR%#LIW"IT?
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C:6PQD$M!5HRARPDIJM9LP@()CQC&2^N;TQC&--,8QC37_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g841242.jpg
<TEXT>
begin 644 g841242.jpg
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MUSVQ;A<=UV0MUYP[>*M6(HR19*<EHYLG'L>[*E12.X40>KJ)HG5.1,''<A;
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MLE]"VEM)=*%K;=96E)2ZT56YSEF H/Y1*;J%7DO5*@ L)*"2E9";PND P2%
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MI_K#N/\ U]_J--7K,^<]4UE4E.=^<Z4IJ7TI2G+V50E*0ZH  "J      P
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M^4)57"A1X! SS*=JF[/6;)9G:,F>N2<0[*WC(J!K0.V4;-,YA9@L6OQ<8V<
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M7B75>;.A*5WDW5(*P;XT)$K &LH !($R( ). CD%W0OS;I257KP(A,E6(TD
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M))@4@0ME3:+Y6DPI";H*KPOMAQ*C*0 "G")O @@@  F%M*0"24F%!.$S)2%
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MDNXR0 3)QDB =P@Z,'-WS!D2-!*Y(F[.),[)_EW6B734M> L#UJ8^58_<M/
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MRR"*HI*?DBHD0WG*&K!^ L#UJ8^58_<M/ 6!ZU,?*L?N6I&2JP$$<F""""'
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M>T3%U:9TW&]/KM&JL>HNLT@*Q&(1<<FX='!1V[4(D K/'[Q0 4>23]9U(O%
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M!8'K4Q\JQ^Y:=$U>QKW@[M_SV&SFKNQ/:&[O^!V6B734M> L#UJ8^58_<M/
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MB*^SY@XF%K#+5O%#3-U;NM=R%5#-)B>D8*F5&D,;.X'N[J,4A(I\+%X@Q+(
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M3M]MI%6@$&XK#>-W^_@8SHZ_25_WI_XAUZ-0U+R\H25DRED7I2E?NP*4'*P
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M[3N9L_,K(U>P4D-T?;?-M="CW^2K]5+(TDE&9Y#GP;%;X9RXB3,E*G69.(?
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MR;WI+<8RR^[R$HI)ML<3>>6.?'\4]QX:MGF5+NU<H+TML#>QFB5CF1GSNTV
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MU&C8[AN)%3()"82!8G34+>6M)2J()08$X7$<FD"2< G#:=)-H4ZI8(,05!6
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M8@,@LH>4DI*(8VU$KU5R@V*T>2#ATU,8-@W=5N2!.[+<@"B4"=V4Y $$>(D
MO*Y($$>D2 ')$>D0XZXF.<P% QSF @<D@&.8P$+Q$>20#"(%+Q$1Y)> <1$>
M''2\2""9D@G",0/OW_=8IR\""D8@ '21!3H)$Z$QIM^:^OYRWTO-P6"<GO+;
MG.,BK7[(+*XNO>#9.*RE/Q4?MCD9.[4YPED'&B&(ZQB3$T'54&%7LE4R37;7
MD>S3K^::R<U=6:*"C0^5-\C[\L,Y6EPKE\RYO F+53MTBU?>U:2OR>-27.'A
M'UBQ0&1]O^3L(P5=Q"PAY8 J=5/A;,LO%3SANW:3,+)M7)%2?HJ[X<\GD]\N
M>1PY/([X6Y')X<.3R.7R>1PZ.3PY/#HX<->#N'"A>2HX<*$Z/R%%U3DZ/-^0
M<XE_)_5T='ZN&K*<O B !<"1B9$$D&9DC1@21AA$")Y1,CS$QL^0.L@>W$ 2
M=GYV\U-LL//8]L[W2L;D-V.6-Q=IV8STA==OF1L;O[Y"NLP2*;"2?O:?0[7A
M]Q'TR8J$TK)UMECZE*O:Y-0Z""#^#E@;(/3PV#+>/A^P^R&.L3KYV9V?,6]W
M9Y%2=QM<YD\8_'NVB=VT8@)<LDXX<1V-,@A"(L;0TD\4R%FHE.MDOBZ% K1G
M7&9JVW6;_J)%RY$  73H0*("7BY7'DB'F,7BI^28/U&+P$/U#KB"RP<C@LN'
M<Q$R?!94.YF-_*,GP/\ FS&XCRA)P$W$>4(\1X@X09@'5CL!;(!B)CDS'\VP
M00<\Z2G ZA PF8D 8#&)!QW86_/[ 2&]N=Q]EVGN]S4Q3(2JYSH#_',S)*;G
M+)*WBE2<$LYNN"3[JW>W.EY41CD9) DJVRI7<5V6:KAE_!:1>OFBZ0(;"_8[
MK]E:\80LC/,$1EEI9J%EW(5&C[#EB<"WKWFK1LF1]7;12+Z\H&+;3>Z'WA($
MAH:R7R@5V[++1;MI.)2"C5*4>7Y[Y<\H3]\N>6)>2)^^%N6)0Z0()^7RN0 ]
M/)X\GCT\..O6<YU#"=0YU#CPXG4.90X\ X!Q,<3&'@   <1Z Z U"EW@1&E1
M5I4=(C6<?:9))DXQ:I6"(N@;"($:-@&)C$F9^?'3335+4LTTTTLLU]A/T%Q_
M6&_\"VOCU]A/T%Q_6&_\"VK)_:_E/^EI&G[E?(V^/3335;19IIII99IIII99
MIIII99JEOLB"-U?;+MP4-CZM7:U6BQT5Y6&C#';U\RN$>TL2R,5*V6'YM;NW
MS\U8C7#F:=0K5LLK.,FCB* @@Z, W2UY 1 0$!$H@("!BB(& 0Z0$! 0$! >
MD! 0$!Z0'31!V$'A:4FZI*HFZ08.@P9@VTQ; \0QN'=W>9&F,8BOKX>N&UO"
M"\E*8CP/+;9,&US*%)LDO!J-D,8KQ+&'G\IY)KS]6XV6V,EN_(2(C6M<5:IL
MU6H$W.:]BBRRO 5EEEA+QY/=E5%>3Q'B/)[H8W)XCTCPX<1X<>/#7KU*C>,[
MAITX",>_7KQM*U7C.C #5J$:@!\,=)Q)LTTTU%JV::::66::::66::::66^Y
MA_.K?U5S_=CKX=?<P_G5OZJY_NQU\.IU#VGY)LLTTTU%EFFFFEEFFFFEEFFF
MFEEO4N9,J*QEA$J)453+&#NH"5$J9C*F 4 %<!*F!C *("L A^: 5.2&M$^V
MNCX?S#NZI>7<'8*C]F^.<+W;(<;'R9\,7"@Y]WI3DDR?QTW,9+EY"GQS]M@X
MK]4]@KSK)UKLMROTP@E,"A7VJ#8'F]T!$!X@/ 0Z0$/. ^WKW&<.#@)5'+E0
MIOY15'"RA3?^8ISF >'ZN(#PX!P\P:D& =^&G"/9KW;-FRR579@8D$3. D0<
M((.!(QVV] =  '$1Z Z1\X_Z1_TZ\Z::BU;----++----++----++->Q'^=2
M_>$_B#7KU[$?YU+]X3^(-2G2/:/G:4Z1[1\[<W7Z2O\ O3_Q#KT:][K])7_>
MG_B'7HT5I/M/SM%FFFFHLLTTTTLLUK7]EIH$QE#97/T:$IP7YS.9RVI)NZJM
M3GE^C9&%;;C<=.I]2?J+%!PK-5=E#I/'EH;+$39!!(OSOW#5F59<FRC7DIC%
M'B0QB#P$.)#&(/ 0X&#B40'@8!$#!QX&*(E$! 1#4@P01I!!X&;2DP0=,'1X
M^6O1;7SC'814<6;B*?G2D1^#,+LJC4;I4Y7'FUW \9@FN93-:G+!1D^RQS18
M)!M;F]-YO.YI[1:-(O%OY%^Y*_[FN9$9 W4-]YKADS:[:'=#:5ITU3);9*/<
MPK#</#*I/VZA5L2)Y:@K/MUFU7K4JK:3;90:0W>; [M:!=N9X8SN5Q=-),@G
MSCA-[&8V^(^ZTWR2"8,"- T#_77.F;:&,CT2KV/*N3Y[=KB7)^4Z638-1E-L
MR&><5S&3\@4S+\5;,O)9?:LCUZ#LL-3=P\]8U,:S$38ZJM"3PUPE,-69]G$1
M:2+*PMP8;AE/8F344Y\C/-TK/:K3E[/%-R6%QD]V\ 8HUIC22+447KVY/*NG
M)12S=G+&GSO3*D./?)^Z'VRIJJH@((K+(@;AR@1542 W#CPY0)F* \.(\./'
MAQ'AYQUXY1^ !RS\ -RP#EFX ?W8=/0?]?*#@;CT\>.I*B8C""#B9T1ANG&=
MI,VN7-!NB0H*TX8:HC 1IVZ;?GEN&&L:2HY>J.W.C7[ NV^]^QU>!.>)+ NW
M&;:@ME:ZY#JT?%2Q\3N:_56N2,K0=$5N:]QE21\G/)U-Q*IV%]+<M..5L_['
MKBQG@+-66L4XSAJ->\-/<5XYN:N?ZWL[Q3M$FDKT>:L,*CA:0:8@Q?BFM9*B
MHFMM6]]C)%[7W4Y4S65>)>RKH'A4T=OQEUSB4QUUSF(/$ACKJG,0>(#Q(8QQ
M,0>( /$H@/$ ']0:\**JJB K*JK" " "JJHJ)0$>(@ J&,( (](@' !'I'IU
M-\PI.I1!,DDX%)Q.O0>(F8Q@K!!%W5&D:9&.@$Z#&.$[L?7IIIJEL[----++
M----++-29"_Y+9_NS?WA]1GJ3(7_ "6S_=F_O#Z[:']8O^3_ /0M=&D^S_46
M^APP9NC@HX;D5.4O) QN5Q O'CPZ!#HXZ]',T7U-+Z_:TTUZ!;03)0@DZ24@
MD_?%M(&P<+.9HOJ:7U^UIS-%]32^OVM--.3;ZM'93W60-@X"SF:+ZFE]?M:<
MS1?4TOK]K333DV^K1V4]UD#8. LYFB^II?7[6G,T7U-+Z_:TTTY-OJT=E/=9
M V#@+.9HOJ:7U^UIS-%]32^OVM--.3;ZM'93W60-@X"SF:+ZFE]?M:<S1?4T
MOK]K333DV^K1V4]UD#8. LYFB^II?7[6G,T7U-+Z_:TTTY-OJT=E/=9 V#@+
M.9HOJ:7U^UIS-%]32^OVM--.3;ZM'93W60-@X"SF:+ZFE]?M:<S1?4TOK]K3
M33DV^K1V4]UD#8. LYFB^II?7[6G,T7U-+Z_:TTTY-OJT=E/=9 V#@+.9HOJ
M:7U^UKD$3' 02 T3 AA QB_E<!,4! HC^5YP 1 /VCIIIR;?H([*>ZR!L' 6
MX\S1?4TOK]K3F:+ZFE]?M:::<FWU:.RGNL@;!P%G,T7U-+Z_:TYFB^II?7[6
MFFG)M]6CLI[K(&P<!9S-%]32^OVM.9HOJ:7U^UIIIR;?5H[*>ZR!L' 6<S1?
M4TOK]K3F:+ZFE]?M:::<FWU:.RGNL@;!P%G,T7U-+Z_:TYFB^II?7[6FFG)M
M]6CLI[K(&P<!9S-%]32^OVM.9HOJ:7U^UIIIR;?5H[*>ZR!L' 6<S1?4TOK]
MK3F:+ZFE]?M:::<FWU:.RGNL@;!P%G,T7U-+Z_:TYFB^II?7[6FFG)M]6CLI
M[K(&P<!9S-%]32^OVM.9HOJ:7U^UIIIR;?5H[*>ZR!L' 6<S1?4TOK]K3F:+
MZFE]?M:::<FWU:.RGNL@;!P%N9(F.3$1(U3*(E,01 3])3@)3!_*\P@/#_B'
M3KAS-%]32^OVM--.3;]!'93W60-@X"SF:+ZFE]?M:<S1?4TOK]K333DV^K1V
M4]UD#8. LYFB^II?7[6G,T7U-+Z_:TTTY-OJT=E/=9 V#@+.9HOJ:7U^UIS-
M%]32^OVM--.3;ZM'93W60-@X"SF:+ZFE]?M:<S1?4TOK]K333DV^K1V4]UD#
M8. LYFB^II?7[6G,T7U-+Z_:TTTY-OJT=E/=9 V#@+.9HOJ:7U^UIS-%]32^
MOVM--.3;ZM'93W60-@X"SF:+ZFE]?M:<S1?4TOK]K333DV^K1V4]UD#8. LY
MFB^II?7[6G,T7U-+Z_:TTTY-OJT=E/=9 V#@+.9HOJ:7U^UIS-%]32^OVM--
M.3;ZM'93W60-@X"SF:+ZFE]?M:\A#Q@" @S2 0$! ?R^@0Z0'^5IIIR;?5H[
M*>ZR!L' 6&B(TQA,9HD)C"(B(B?B(B/$1_E:\<S1?4TOK]K333DV_01V4]UD
M#8. LYFB^II?7[6G,T7U-+Z_:TTTY-OJT=E/=9 V#@+.9HOJ:7U^UIS-%]32
M^OVM--.3;ZM'93W60-@X"SF:+ZFE]?M:<S1?4TOK]K333DV^K1V4]UD#8. L
MYFB^II?7[6G,T7U-+Z_:TTTY-OJT=E/=9 V#@+.9HOJ:7U^UIS-%]32^OVM-
M-.3;ZM'93W60-@X"SF:+ZFE]?M:<S1?4TOK]K333DV^K1V4]UD#8. LYFB^I
MI?7[6G,T7U-+Z_:TTTY-OJT=E/=9 V#@+.9HOJ:7U^UIS-%]32^OVM--.3;Z
MM'93W60-@X"SF:+ZFE]?M:<S1?4TOK]K333DV^K1V4]UD#8. LYFB^II?7[6
KOO21303*DB0")D#@4@<>  (\>CB(CY]--2$I3]%*4^P ?(60!H 'W6__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g852740.jpg
<TEXT>
begin 644 g852740.jpg
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M_\0 &@$!  (# 0                0% @,& ?_$ "H1  (" 00" @$$ @,
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M:)2_25)-YNVV$^V*"/J+,4SUJ(@B%Z2S)&D#7$14-:A*?/[L3_%_]P+_ ,'
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M./E(MO/Q+_4"_KQI%_F@Y;[Y,O\ BP?1#^KCR9?\6#Z(?U< J"^4BV\_$O\
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M\:8XX&,BQF#@#CCC@'S+%B-N1JG!P5)T*!"F/6+5JLXM,D2)$I0SU*I2H.$
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MHLMN&C*-\\-,4%G&X , $T0AP'';'?\ _(0A9_.+.<_V\UXXX XXXX XXXX
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MWF80H(A$:3G$F!JJ6Y",LXII+,+&'.,9"((PYQG&/Y.::=5)5*W4G5U6KK2
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MJL;;*0>6K;_$!;/(RD[8**)DXX:I<3J=LEUEDY:,.Q %Q_''' '''' ''''
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MC][:9[8[KVG<C"T/,G$O3M#7/*H2RV.WE4SD\. 547<!V)6RL@L-A/*'$KK
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MZ A17UO*Z&AZQSEQ#FQ/=<S HB#8:X>I5()I%I)-TP#V5/Z-PY[XQG[^/?\
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M9TQAL6C3+$XV_-T: XM3B!D/7:\+5==GKEHRWTZ1$XK-?M7MJ(BQMSB3(T$
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EC]I8,8P$.,>S& XQC'Y,8[8X!NXXXX XXXX XXXX XXXX!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g877878.jpg
<TEXT>
begin 644 g877878.jpg
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MQZLM'5Q_&(.&Z<RJY$[9T@=BLS*15)XEI47Z/Q74<532PEX*:HJ9)6?-Y(3
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M>1)7Y1Q( HJ-,2.:&Y6*4*3T>(_OBZ&:U0. II75DC7D"DQXJYJRW+#$N4O
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M3<;MJSQ!0MD:I^?CZBO$O8%U,3,T2(.S<>($BRV/#K*V6AE=''Q56 \:"-&
MJ9 +*  "% #FURX8D[@X>X^7FUB;DBY]KV^X=M[8MOQGEC'>:*HQO&*[I6,@
M4V35=-V5GITVPGX=1TP4\%\S,\CUU 0D(]P!F<E'N"H/H]V4[9V@BH  .?\
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MOU#4<VW'TA#GKICO\99,KTUB^OQLC:YRM3T"LQ(>\UB<YVJ1CF YAZ_O )A
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ML=CP3M?593YL?@QS.Y>Z?%:W.Y ?2==D-N]IK^8[>VE(U/"\:O.0-OR;$/\
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MJ:8SUE.Z&4'2E&7,:2.[!34QB*6)6+F8(A&)TAA+EA'&CDLVM56-BQ4 ZG4
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M#@;GJ,!@Y-["!!+X8 7Z% @%'OU@;D>=LC0A#ATJG,J1,A#'$1 YP .1\0Y
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M47L#J8@#%\I3%'JY Q1 >X" EXZN_80  'GCGGN// "//&N,NFEX1@Y!-+J
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MK5GWDX>F8*6:IN2-Y",D,;9E69NTR.4&[A,BJ8@;I<((JD_=53(?[NK!4_\
M!I_[PO\ S0TN#&O1HT:,&#1HT:,&#1HT:,&#1HT:,&#1HT:,&/AA$ $0#D0
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M[C&NY4KV'I ^27]VLJ;<T(UB,/Y,L5;E(\YX8SZP(7B%JKZG&KM=/9(5.TV
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M_8 _C[CVZN^MS6VF/(B/U$ $>Q@[CS]![!QW[>_U, #QSN:UH;:-B#YI./\
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MR!SU"(]U#F-P1%(@&.LH8$TBG4$I1BA\I)Y!**#QLYAJ4J*:GI[DJB<U;&P
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M[ZX^.KJ"\Q2KJJ9IY$-2]'.\#5-/\TE',R&[4\SK$)H[V9$" <$;-]*A8BR
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M-&C1HP8-&C1HP8-?!$ #D1  #W$1X /XCK[JL;XM\7OEG=H$M!_#W=S[#/\
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MHI%.H66L:L2[<0LB_-<3729&(X373.)RJG!P9 RA5G! 7<I"+?\ 8@#==51
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M (-P=P1BY@TO&33NPS3MX!$3E:A,9+\X(!F 2B'V?.O+@;Y'*;&0"9<2E_\
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M=U/AZ2 R!$9,V8+%E;(ORM5S&G8!DZ+R%+>]5!0ZA>3E H])1X#GD!$3 8!
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M2KM@6:29*/-6][<LIS>3$,T1T\S0*YQ3N R7B5I,M&0L65DAZXM&2T-(HI"
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M$3< 7G@ UHQNB12NA-E*=-6TR$A952J"!CF3D5S%8%,8"$$P)Q:+ A>P<=/
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MI$CMSL3R^'&T;045&GI;]JI=F-D<K,HJD"I>D3J$'Z&24.F8.?K]TP (_AU
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MI._A.[6_AV[0KK:L+;2]V]DW(7FWQ3C-DHS89.8RM?KU=I"%>Q6Z<V"OXD-
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M$[[$[D?7#M3CT&UN!>QX'L!OV[XJUR+(?#1F*6TH.%]^>!-O]6>97#+>0JW
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MRQZ#PE;:V)92N)XDK,=5'CV9<O$62\IZRXF'2S5TT+FYVV%_J1=;;G;B]_\
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MYO882PL00""+$$ @@6V((L>/S<XV$$"-P.!!,('.)QZA ?O#[\< &M_1HTX
M  "]AZDD_B23_'!^=A;^6#1HT:7!@T:-&C!@T:-&C!@T:-&C!@T:-&C!@UCU
ML.*=9L!P7!KT0LJ;S)GS2,!N!8]R/C^HOT'3&/\ !X\3SSQLX:,^CS+I!9ND
MHD?(==3/-W3N%E6S+Q1=N(Y\BW!NX2:+BLJU632!!TN@Z0:KBH8H(N5FSE%N
MKT+JMW!$S(G@J@6IJA5U:C#(!I76URA TII?4U_E72US86/&%7D7XN/YXBS
M+Q1S@W#[P9<MC!SCBF.3S_SE5K\>634K[$YI<U[I<-7Z=<_/ (N362KP,+ S
M@G&1B8UBR71;DF4#&$ $"@(" " ]?N ^P^P^X:5:EOL^56M4*HJX?6F4(B*Q
MQ!3=EGLW5B0GCH.:5-.;K+3"D?C^%93TE5K5&P5<4]-BX-O;QL;FRQC6#90Z
ML2YRB-NF>G!X8DC@&+C4GC>I'F5"9E@WPPJ\K3)^8MK=)-.IH>JA4KDP@*6V
M62,U+9&M@6M+4D:TA5HQYSN7YD*:DIXYHLWU)34J-KR;-F.I((UDL(,GD;46
MOK#\-J5#I4Z7N 2" !=B/*RGN+7N^P_YM@=R<,%R?^P'_'_[M')_[ ?\?_PZ
M7B)N^X!VO'DEMOD5$(./E/U%PGFJ"DACO5:-,S=LZ$4JBW%[\I7AG#T5MX9T
M?F1I,J6]KZ:TBU8IR,KMG]=LR4>[?(IDY7&O>=;$S5!NP8^H8]DI^PB5<M22
M*[^7LA-HW'B($(GZVSDU+L@+-BP4AE[OZXA_P\SX!-LDST\VX_L.Q/-QR.XX
MLRWUW)'*=O7S[#T)V/8G##\G_L!_Q_\ PZ.3_P!@/^/_ .'2X-;UN(53BC.=
MND0U4<DAQE4PSA . BCO,<OK%,D(<M.3"2"%R,@QQND9,K?U1D^/>D@;,&AX
M57?^>-P0G8E';W$@1<8?SZ@9K@N6 .\</;'+]!/E$/.^CY'198V3 @H^J,GA
MKVEY9@U-"JGZXB_P\SV /_@N><?_ ,)S_P HW]AV/QYM^Q__ +X]^/?#$<G_
M + ?\?\ \.OO)_[(?7^M_P"'ZZ79G=]P*JI2/-OD4S2,#(3K!FJ"=&**V,E[
M,]#PR5%,3>2R:FAB\O!@!VP7'(!02CTC0)MDMZW#F(L)]NL20Y46QD2!G" ,
M"JJF,'%G<HB<*< )%;903;XN!02F!=@X-D(I21Z P)S]<1?X69\:C_8N>\;?
M^1[GU7YN=O0M]=S;]CG_ -^P_P"8^7WQ-DS5*[87D4_G:_#3#V"=DD(-U*QD
M;).(5^F8I@?Q"[YFX6BWO[,@>;8';N0Z""54#)IF+TTIC*AS;>S-9BFUB42N
M<>K$V\7D%#J*6F-<-Q:+L["J# JTP@JUZ6YDY!1P4I$TS)]!TRG",_GC<"#7
MQ?[GN)%UW'R@YK@NG_X7?,_ ./E'HX^U'_S6!^S_ /4.<A_^SO[P#\>7?<"B
ML8K/;Y%/$0\[TJFS5!-1-X.,F]E9 "1ZBJ)?.Y-.XQ@?DP^58(!D XJQZX01
M$_7$5Q]EF?%__!<]XVO_ /<=K[?+LQ[#L"UM]^;<IL;VN/M./?CO?OC+:=@G
M$- Q]7L45'&E+A<;U1M&M*]2F]>B5:[&)PR1$8I1"/>-'*:CQBBDDFC(N1<2
M0@0IU':BH"<<L<4&ENXQO".:=5UX9K))S+6(6@896+;RZ1Q52E$(]1@9FC))
M*F,JG()(D>)J&,<BY3&$1BM>Z9[(HY*A@&+732;R"C94<S0:(NG#?&K.QQ[8
MQ!J9Q;ED,DK/,9G7,)RLF+(E].19@[+!I[0W?<#XD@4-O<2*:!ICR!_MK@P%
M^#3'#*Q0XF+\HB++UC(ZSW&R@'%7TQDR)>E1<L'1(1(_7$6WV69\7_\ !,]X
MV]<CY&YTGS>@] CF]^;<H=_N?<>_'OB;6%=A8LK\L="Q;$)5=1S)@S8,&GJ2
MZWB>,M(>6:I>>65\53Q5G7C+*^(IUJ#XA^KI&6-Z+&!&EC*75(PD.G)H1)(Z
MNP;$L:VFP*$VT8%;1J0,VLR!0"6;MO"2DNWG2+\!Q%CV\;@D6CU5EMZBGKM$
M+ +)H.:X)H5Z:/QW&6"O 9R>HJE:!8LAN9/':XF35]$9QB=X7\XQ?IPJ&IY=
M]P"+9\HRV^13URB-A\DV/FJ":%?!'X]C9^O=:YJBJ5I\PY"<R6/%RG(KZ(SC
M$[LN+UB^3AD#]<1;?99GQM_8N>@=O_(]N^Q /H-]BW/.VW['?T\^_P!1L.^)
M8>4*GR$:YA7]4KKV&>+L7+R(=PD.ZBW:\8FW2CE'4<X8*,G)V"31FBQ57045
M9),VA&QTBMD"D^I4.GH*2:R=4KA5IF00EI=8L'#%7E99L@=LVEI-<L>560DV
M[4XMD'[PZ[M- 3)%6 AC :)9:\;@6B\B2)V]14N@W^;?3UU,UP4::2]*HT/-
MU+Q$5:BX%C\VWEY,45P!SK?+32&2M[GU%G)I1+8=7?<"D:<!KM[BG16/SMZ&
M8<U03;UWT6J0DK206*:HG](^>+6]FZFZ\87?RFW@T;&[]4;2R+!HHSB+8]+,
M[$7']BYY[7N#D8(^AL3V& C<['8VV*6^[[3<>XN/4XEM"B4]J^:RC2I5MI*,
MFC)@TDVD'#-I%HQC45V\<S:OT8\CMJUCT7+A%B@W6329I++)MB)$54*;KBXN
MQV1LJR+0*45FO(A+*M JE:!LK(AXX^=51")\-1X*CITJ+U0IW?B.5Q!< 64
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M6I.BL/GJ+D;)+NTE$W U!2MHQKWU=2=;KLD]ROM)S%F[)-RO+ZK[8JDV-,#
MP2>0J+?<G6RQ5ZNM&L5$VZ3G:CEO'L/'!/H-_--:P%?,\K[4J+)])R3@#KCS
M?B*:7,*2.&FRVKK%^($K1SY5G<.DA6#/J-(FJY-E!CC(4D!;%@LJA-N=5A>S
01@=B.6 OMYM[@W OL<?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g938129.jpg
<TEXT>
begin 644 g938129.jpg
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M"K\]]#G;5![82KDL'">/(86,$ 8^?*<]L,KC:/*K1ML46T[=9""-$DE22/\
M[_[!_?JZ/U:8#,9SCE9,(_S7*2JK0HCR*C/#I"^@0FG5/N8+U\DG1(]3=[U]
M"/2ALTI-<M2VK]CRFR9Q$N\PB.P76RIM*&8S86R@*QA*5G'N"#G&D[(?4\W1
MZ:[4O/87:"WHC=1DUH2D7S=E8J]QJH%+D1$QD18L"4\$*<"TI?0XE:0@G\%
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HZC>?9?-V;.%REC$8]798J_2%I7TPW),?^Q5/V!517<*H\NY)/K__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g1002373.jpg
<TEXT>
begin 644 g1002373.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@ _1$E32S$Q-CI;,C!:0E8Q+C(P6D)6
M-S0Y,#$N3U544%5473$U,S0Y7S%?0D].15]&4$]?-$-?4$A4+D504__; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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MQ_"\BV'JHDKB"P2=-JF1=_'_ , W7->[R/,SF>JE TDJ9%X0UBU9_P :-4N
MHENJL&J>[LCYGH]9\S2^B"4@>E0"R[+.3P;CEI \CW='.Y9JLV%*_DU<+$L
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M,W$MMNUM(IZX8LY*<C*AZR9D+.DY1]?84T9CU4.QG#2T];KU1645/$:@U5/
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J9X>^]W6*9&14H2H]GX\_% 3UT222=,8QDPU!=,8QC33&,8TTQC&--?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g1004457.jpg
<TEXT>
begin 644 g1004457.jpg
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M*\'M5U,R@$*)HR8IN(/]AD1F3]E('V.A+W5A3V[W#E,.7YK3LE87^R\$JI+
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MOPYW?3V_4'\M]2=9<ILR"_<=_LN4R/+:+<F52+?I%,IKE1;9UW?9OS9FF7%
M>VO_ *X<$&,HQ8:"?&U]BO5R662N!O0K_P 4M& #Z\"$J!X&P ?WT0\WD+.;
MN0Y.P0;-K%X1[))/FT,106R3Q_3YG60G7YW]$ #@^M%==>OSK*P_@&F/.,O3
M;)BJIY;_ '-/UFJ1U/3D%1[4NQBE):5V_B1O?MQ4^3:S=V'NH>YL>9@O&MUV
M[9!IK=+O&X9JG)E<B0*?'9A1G91 "G(<<(CQT@)'I-)2D#6PZ?ZXV+:MCW,O
M2WUD6^P%1:)49.+;Q="5%3;\]Y%7MB<X4I2AM"1 FPR5N#:U-A V2>)2ZXKQ
M9S1F_#5_II+"JC(OBPHKC+C*%,S2JJTZ'(9>2.[U69$=3K;B5':DK/CSP$>I
M=JQ;[ADPM]Y5A$@-)03[?&9?<$X&^+, T:'].]*Z^ 2.M*>E=2C3[5AS%.**
M6Q-'+\V3BHG66JY1JP?195909"-\2#&Q!\:FZ/?UQI@A@U1R9 =0>P/+4XCM
M4#Y2>X@Z^#H@>!SO; HM4KE17-I<R7!G!W:I<%Y;+AVH>%=ATM()_:H*^=[U
MH6L^H5TA1.E3(MOW%9X<1AS+\EX6_25AQP6)=C,%J74+=:D%"4*I4Q(=ETIM
M9+K25J8*E^GR(.FM49=;<I[Z 5ID-[*B"%(6XG6@1KP1K8]]@$:'!=D<-?P6
M8EQUPO6NTY0$FAD96"D*\-B"92CA9$*O&P*N 1L C0)6*R^-[CQ$&2I!)Z5Z
M(\XIXT< H2DU:Q$X9"\4BM&X/)"5VI9"I,O0K2ORUF?U53J!1JG568BPJ?,A
MJ0Y*24?DJ0&U);==6-E3Q0%[\]VN5:O*Q<(=2U<<H75[A3$+](!D,,UP4Z;'
MNR&T5=JI$&N0TK>CO@A#C8*BEI:4K"21KCUG8-%@6*MV9#8>:$$A7<VWO1:(
MWW$ $C1/SKV/QQ*^=I=%5<4A%)" %R'BIL=NV@'$^-H^"-]O^O;QKE]J^H/=
M7;4=9/E5LQ&Q5RF62S-9*C7Z?F168+)^@=O(Q!!WR!T*7;]->U,O;^7'6FQ-
MF)EX'&21P5RRMS!:HT4D!5M<71!'R!_24.FZMATW=+-G8?HB*!TK]9]>I5F*
M"O\ A\<YF6<A6Q0TZ7_U:7.4U"KD.(%*44-.OK2WL!/XI Y9^B6]U;XMK;F2
M,YQ^E[*&#[5CR*Y+EV-+KE$KLB/ :4\E?V,Z5)8>>6\EMMN.XDM..DA7XJXM
M/#EW633@F)<BOM2I/IID(4&E)!!T0L:_G6_?QO\ UMK%QY$REF"W\$X%ONXZ
MY0;L>8I=R41I]ZHTNH29BPN/3RK_ "(BQJ7VJF5.1M+332#WK![03/VAZW9#
MN6>KB)*-RO;E1T+XZXMF.*.)5Y2S&U'';@K*H56=;,S#F(U5F8#H==W^EO;F
M#AN=P6ZN!N01GG/!/CI*,EF61@B1PFK8:"2[*[;YM$I;B\C !2RM/^GU9L[J
M!R;F7-=Q0EQ;=G(D4BG,H0E#$6?5:K3JRFGL$)*%_94Z*TAWL\(+C8.B= XV
MCIVPG;_3_B>V<<4%IKOIT5$JN3FTA)JMPRVFE56H+(2E2PX\@-L%8*DQFFD'
M7;KAP@1PJ$!<;8[9M[)V2#H[\[\#>R23L[\] .27D[%/T)O2*O@*HUQ 'X
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$77__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
